



EANM 23
WORLD
LEADING
MEETING

FINAL PROGRAMME

36th

Annual Congress of the European Association of Nuclear Medicine

VIENNA SEPTEMBER 9 – 13, 2023
eanm23.eanm.org

TABLE OF CONTENTS

WORDS OF WELCOME 4

GENERAL INFORMATION

Board & Scientific Programme Council	6
Session Coordinators	7
EANM'23 Reviewers	8
EANM'23 Chairpersons	12
EANM National Societies: Delegates / Deputies	14
UEMS/EBNM National Societies: Delegates / Deputies	16
UEMS/EBNM Committees	18
General Information	21
Floorplans	30
Programme Overview	33

SCIENTIFIC & TECHNOLOGISTS' PROGRAMME

Plenary Sessions	43
Continuing Medical Education/CME Sessions	44
Technologists' Track	46
Special Track	48
Joint Symposia	49
Special Sessions	49
Learn & Improve Professional Skills (LIPS) Tracks	50

Clinical Oncology Track	51
Cutting Edge Science Track	52
M2M – The 10th 'From Molecule to Man' Track	53
Further Oral Presentations	54
e-Poster Presentations	56
Case Report Sessions	57
Awards	58

ORAL PRESENTATIONS 60

E-POSTERS 172

INDUSTRY EXHIBITION

Satellite Symposia	260
List of Exhibitors (A-Z)	266
List of Exhibitors (Booth number)	270
Exhibition Halls	274
Company Profiles	276

CORPORATE MEMBERS 332

USEFUL CONTACTS 336

IMPRINT 336

WORDS OF WELCOME

BY THE CONGRESS CHAIR



VALENTINA GARIBOTTO

EANM CONGRESS CHAIR 2023–2025

Dear colleagues,

It is my great honour to invite you to the 36th Annual EANM Congress on behalf of the European Association of Nuclear Medicine. This year's event will be held in Vienna from September, 9–13.

We are able to meet in person again for this edition of the EANM Congress, meaning we will enjoy the fantastic science and face-to-face interchange the occasion offers while also continuing to bolster our growth as a specialist community.

Our present is bright, and our future is even more promising. Our relevance for diagnostics and therapy continues to increase, new tools and tracers have been established, and ongoing research and innovation are consistently providing fresh solutions for validation and testing. The number of joint projects with other disciplines and societies continues to grow with more and more communities recognising the important help that Nuclear Medicine can provide their patients and in answering their questions. This is the main reason for the unusual date of this year's EANM Congress, as we wanted to avoid clashing with a major event with whom we have a big overlap in participants and industry involvements. We plan to return to our usual mid-October dates in 2024.

The number of visitors to the Congress continues to rise year after year with the 2022 edition of the event welcoming an unprecedented 7000 participants. The many innovative features you discovered and liked in Barcelona last year will be present once more, including sessions specifically devoted to exchange and discussion. Please prepare your questions across the year and get ready to challenge our experts during the Congress! We want to make sure that you return home with input and suggestions that allow each and every one of you to contribute to the success of our field in your daily work.

Needless to say, we should not simply sit back and enjoy our success. We must continue to provide convincing evidence of the positive impact our chosen field has in a complex world of limited resources, meaning we should constantly strive for a more efficient, accessible and sustainable Nuclear Medicine. This year's scientific programme will help you deal with such issues thanks to superb material combined with multidisciplinary sessions. And as we know that fun helps foster collaboration and cooperation, some of them will also be uniquely entertaining. On top of this, we hope for your numerous contributions and input via the abstract submission, which is now open. Share your work with the nuclear medicine community!

We have prepared content that will maximise opportunities for exchange and networking for all those who travel to Vienna for EANM'23. On the other hand, we still want to reach as large an audience as possible, just as virtual congresses have done, including anyone that cannot make it to Vienna for this year's congress. For this reason, selected content will also be made available online and will remain accessible afterwards so that everyone can benefit from it in a way which fits around each individual's schedule.

In summary, we are working to provide you all with a special, first-rate congress tailored to your needs and wishes. Join us and savour every moment of it!

Valentina Garibotto
EANM Congress Chair 2023–2025

BOARD & SCIENTIFIC PROGRAMME COUNCIL

EANM BOARD

President 2023–2024
Rudi A.J.O. Dierckx (Netherlands)

President Elect 2023–2024
Paola Anna Erba (Italy)

Committee Coordinator 2023–2024
Felix Mottaghy (Germany)

Congress Chair 2023–2025
Valentina Garibotto (Switzerland)

Education Chair 2023–2025
Sona Balogova (Slovakia)

Secretary/Treasurer 2023
Wolfgang Wadsak (Austria)

Scientific Liaison Officer 2023–2024
Michel Koole (Belgium)

SCIENTIFIC PROGRAMME COUNCIL

Congress Chair 2023–2025
Valentina Garibotto (Switzerland)

Bone & Joint
Salvatore Annunziata (Italy), Tim van den Wyngaert (Belgium)

Cardiovascular
Mark Lubberink (Sweden), Fabien Hyafil (France)

Dosimetry
Silvano Gnesin (Switzerland), Johannes Tran-Gia (Germany)

Inflammation & Infection
Domenico Albano (Italy), Olivier Gheysens (Belgium)

Neuroimaging
Antoine Verger (France), Silvia Morbelli (Italy)

Oncology & Theranostics
Matthias Eiber (Germany), Karolien Goffin (Belgium)

Paediatrics
Pinar Kiratli (Türkiye), Pietro Zucchetto (Italy)

Physics
Mathieu Hatt (France), Dimitris Visvikis (France)

Radiation Protection
Lidia Cunha (Portugal), Uta Eberlein (Germany)

Radiopharmaceutical Sciences
Filippo Lodi (Italy), Johnny Vercoillie (France)

Thyroid
Alfredo Campenni (Italy), Michael Kreissl (Germany)

Translational Molecular Imaging & Therapy
Margret Schottelius (Switzerland), Pedro Fragoso Costa (Germany)

Technologists
Agata Pietrzak (Poland), Luisa Pereira (United Kingdom)

SESSION COORDINATORS

SESSION COORDINATORS

EANM thanks all Session Coordinators for their huge engagement in organising the session details and speakers.

Albano, D. (Italy)

Ambrosini, V. (Italy)

Antunovic, L. (Italy)

Barthel, H. (Germany)

Beheshti, M. (Austria)

Campenni (Italy)

Caobelli, F. (Switzerland)

Carrilho Vaz, S (Portugal)

Cecchin, D. (Italy)

Chiti, A. (Italy)

Costa, G. (Portugal)

Cunha, L. (Portugal)

De Geus-Oei, L. (Netherlands)

Eberlein, U. (Germany)

Evangelista, L. (Italy)

Fragoso Costa, P. (Germany)

Fraioli, F. (United Kingdom)

Garibotto, V. (Switzerland)

Gear, J. (United Kingdom)

Gheysens, O. (Belgium)

Gotthardt, M. (Netherlands)

Graham, R. (United Kingdom)

Grana C. (Italy)

Guedj, E. (France)

Hatt, M. (France)

Herrmann, K. (Germany)

Holm, S. (Denmark)

Humbert, O. (France)

Hyafil, F. (France)

Kedves, A. (Hungary)

Kiratli, P. (Türkiye)

Koebe, C. (Germany)

Kreissl, M. (Germany)

Lubberink, M. (Sweden)

Massalha, S. (Israel)

Minguez Gabiana, P. (Spain)

Morbelli, S. (Italy)

Nanni, C. (Italy)

Noriega, E. Spain

Olianti, C. (Italy)

Pereira, L. (United Kingdom)

Petranovic, P. (Croatia)

Pietrzak, A. (Poland)

Rischpler, C. (Germany)

Salaün, P. (France)

Santos, A. (Portugal)

Schottelius, M. (Switzerland)

Shi, K. (Switzerland)

Stokke, Caroline (Norway)

Strand Olsen, R. (Denmark)

Turco, P. (Italy)

Van Leeuwen, F. (Netherlands)

Verburg, F. (Netherlands)

Verger, A. (France)

Violante, L. (Portugal)

Visvikis, D. (France)

Vrachimis, V. (Cyprus)

Werner, R. (Germany)

Zhang-Yin, J. (Belgium)

EANM'23 REVIEWERS

Abgral, R. (France)
Acampa, W. (Italy)
Adam, J. (Netherlands)
Agostini, D. (France)
Ahmadzadehfar, H. (Germany)
Akdemir, Umit Ö. (Türkiye)
Albano, D. (Italy)
Albert, Nathalie L. (Germany)
Aloj, L. (United Kingdom)
Altini, C. (Italy)
Ambrosini, V. (Italy)
Ametamey, S. (Switzerland)
Annunziata, S. (Italy)
Armstrong, I. (United Kingdom)
Artiko, V. (Serbia)
Balkay, L. (Hungary)
Ballinger, J. (Canada)
Bar-Sever, Z. (Israel)
Barthel, H. (Germany)
Bauckneht, M. (Italy)
Beer, A. (Germany)
Behe, M. (Switzerland)
Beheshti, M. (Germany)
Ben-Haim, S. (Israel)
Bergström, K. (Finland)
Bernhardt, P. (Sweden)
Bernsen, M. (Netherlands)
Berti, V. (Italy)
Biassoni, L. (United Kingdom)
Bilgin, Bedriye E. (Türkiye)
Bogović Crnčić, T. ()
Booij, J. (Netherlands)
Botelho, Maria Filomena R. (Portugal)
Bozkurt, Murat F. (Türkiye)

Brenner, W. (Germany)
Brian, D. (United Kingdom)
Brouwers, Adrienne H. (Netherlands)
Bucerius, J. (Netherlands)
Buchert, R. (Germany)
Burrioni, L. (Italy)
Buvat, I. (France)
Cai, W. (United States Of America)
Camoni, L. (Italy)
Campenni, A. (Italy)
Caobelli, F. (Switzerland)
Carrilho Vaz, S. (Portugal)
Castellucci, P. (Italy)
Ceci, F. (Italy)
Chakravartty, R. (United Kingdom)
Chouin, N. (France)
Cicone, F. (Switzerland)
Cook, Gary J.r. (United Kingdom)
Cornelissen, B. (United Kingdom)
Costa, G. (Portugal)
Covens, P. (Belgium)
Cremonesi, M. (Italy)
Crivellaro, C. (Italy)
Cuocolo, A. (Italy)
Da Pieve, C. (United Kingdom)
Dalm, S. (Netherlands)
Daou, D. (France)
Darcourt, J. (France)
De Geus-Oei, Lioe-F. (Netherlands)
De Keizer, B. (Netherlands)
De Palma, D. (Italy)
De Swart, J. (Netherlands)
Delgado-Bolton, Roberto C. (Spain)
Deroose, C. (Belgium)

Deuther-Conrad, W. (Germany)
Dickson, J. (United Kingdom)
Dierickx, Lawrence O. (France)
Drzezga, A. (Germany)
Eberlein, U. (Germany)
Ertay, T. (Türkiye)
Evangelista, L. (Italy)
Everaert, H. (Belgium)
Ezziddin, S. (Germany)
Farsad, M. (Italy)
Fendler, W. (Germany)
Fernández León, A. (Spain)
Ferrari, C. (Italy)
Fischer, Barbara M. (Denmark)
Flux, G. (United Kingdom)
Forrer, F. (Switzerland)
Forsback, S. (Finland)
Fragoso Costa, P. (Germany)
Fraioli, F. (United Kingdom)
Gaberšček, S. (Slovenia)
Gabriel, M. (Austria)
Gallowitsch, Hans-J. (Austria)
Gear, J. (United Kingdom)
Georgoulas, P. (Greece)
Gheysens, O. (Belgium)
Giammarile, F. (France)
Gillings, N. (Denmark)
Gimelli, A. (Italy)
Giovanella, L. (Switzerland)
Giroto, N. (Croatia)
Glatting, G. (Germany)
Gnanasegaran, G. (United Kingdom)
Goffin, K. (Belgium)
Gourni, E. (Switzerland)

Graf, S. (Austria)
Graham, R. (United Kingdom)
Grana, Chiara M. (Italy)
Grötzing, C. (Germany)
Guedj, E. (France)
Haberkorn, U. (Germany)
Halldin, C. (Sweden)
Handkiewicz-Junak, D. (Poland)
Hartman, N. (United Kingdom)
Hendrikse, H. (Netherlands)
Herrmann, K. (Germany)
Heskamp, S. (Netherlands)
Hess, S. (Denmark)
Hesse, S. (Germany)
Hicks, R. (Australia)
Hindorf, C. (Sweden)
Hoffmann, M. (Austria)
Hofman, M. (Australia)
Holm, S. (Denmark)
Howell, R. (United States Of America)
Hubalewska-Dydejczyk, A. (Poland)
Hyafil, F. (France)
Iagaru, A. (United States Of America)
Jamar, F. (Belgium)
Karabacak, Neşe I. (Türkiye)
Kedves, A. (Hungary)
Kirac, S. (Türkiye)
Kirienko, M. (Italy)
Kirjavainen, A. (Finland)
Kiss, O. (Germany)
Kluge, R. (Germany)
Kobe, C. (Germany)
Kolenc, P. (Slovenia)
Koranda, P. (Czech Republic)

EANM'23 REVIEWERS

Kostkiewicz, M. (Poland)
Kotzerke, J. (Germany)
Koutsikos, J. (Greece)
Kráčmerova, T. (Czech Republic)
Kraeber-Bodéré, F. (France)
Krämer, S. (Switzerland)
Kresnik, E. (Austria)
Kucuk, Nuriye O. (Türkiye)
Kunikowska, J. (Poland)
Kurth, J. (Germany)
Kuwert, T. (Germany)
Langbein, T. (Germany)
Langsteger, W. (Austria)
Lasnon, C. (France)
Lassmann, M. (Germany)
Lavelli, V. (Italy)
Laverman, P. (Netherlands)
Leccisotti, L. (Italy)
Lemos Pereira, E. (Portugal)
Lodi, F. (Italy)
Luporsi, M. (France)
Maes, A. (Belgium)
Maldonado, A. (Spain)
Manevska, N. (North Macedonia)
Mapelli, P. (Italy)
Marengo, M. (Italy)
Massalha, S. (Israel)
Mihailovic, J. (Serbia)
Mikolajczak, R. (Poland)
Milan, E. (Italy)
Mindt, Thomas L. (Austria)
Minguez Gabiña, P. (Spain)
Mitjavila Casanovas, M. (Spain)
Monteiro, M. (Switzerland)

Morigi, Joshua J. (Australia)
Morland, D. (France)
Mu, L. (Switzerland)
Någren, Kjell A. (Denmark)
Nanni, C. (Italy)
Niculae, D. (Romania)
Nonnekens, J. (Netherlands)
Noriega Alvarez, E. (Spain)
Notta, P. (Spain)
Ocak, Emine M. (Türkiye)
Oebro Fosbøl, M. (Denmark)
Olianti, C. (Italy)
Oprea-Lager, Daniela-E. (Netherlands)
Orlhac, F. (France)
Orlova, A. (Sweden)
Orrù, Maria T. (Italy)
Oyen, Wim J.g. (United Kingdom)
Ozgen Kiratli, P. (Türkiye)
Palmedo, H. (Germany)
Palmieri, A. (Italy)
Panagiotidis, E. (Greece)
Papathanasiou, N. (Greece)
Pappata, S. (Italy)
Pascual, T. (Austria)
Payoux, P. (France)
Peñuelas Sánchez, I. (Spain)
Pereira, L. (United Kingdom)
Petranović Ovcariček, P. (Hungary)
Piciu, D. (Romania)
Pietrzak, A. (Poland)
Pilkington, P. (Spain)
Plachcinska, A. (Poland)
Poeppel, T. (Germany)
Prassopoulos, V. (Greece)

Pruim, J. (Netherlands)
Rabiner, I. (United Kingdom)
Rac, S. (Croatia)
Rausch, I. (Austria)
Redondo, F. (Chile)
Resende Geão, A. (Portugal)
Rijpkema, M. (Netherlands)
Rischpler, C. (Germany)
Rodríguez-Fraile, M. (Spain)
Rogasch, J. (Germany)
Roivainen, A. (Finland)
Rominger, A. (Switzerland)
Rossetti, C. (Italy)
Santos, Ana I. (Portugal)
Saraste, A. (Finland)
Sattler, B. (Germany)
Schäfers, M. (Germany)
Schibli, R. (Switzerland)
Schottelius, M. (Switzerland)
Sciagrà, R. (Italy)
Seimbille, Y. (Netherlands)
Semah, F. (France)
Sera, T. (Hungary)
Sestini, S. (Italy)
Siclari, G. (Italy)
Signore, A. (Italy)
Slart, R. (Netherlands)
Smith, G. (United Kingdom)
Sollini, M. (Italy)
Stefanescu, C. (Romania)
Stokke, C. (Norway)
Stokkel, M. (Netherlands)
Strand Olsen, R. (Denmark)

Strigari, L. (Italy)
Strömvall, Anne L. (Sweden)
Sundin, A. (Sweden)
Teräs, M. (Finland)
Terwinghe, C. (Belgium)
Testanera, G. (United Kingdom)
Todde, S. (Italy)
Tolboom, N. (Netherlands)
Tosi, G. (Italy)
Tran-Gia, J. (Germany)
Treglia, G. (Switzerland)
Tuncel, M. (Türkiye)
Turco, P. (Italy)
Türkmen, C. (Türkiye)
Vaccaro, I. (Italy)
Van Den Wyngaert, T. (Belgium)
Van Dongen, G. (Netherlands)
Van Lith, S. (Netherlands)
Van Velden, Floris Hugo P. (Netherlands)
Vanhove, C. (Belgium)
Veit-Haibach, P. (Canada)
Verberne, Hein J. (Netherlands)
Verburg, F. (Netherlands)
Verger, A. (France)
Vidal Sicart, S. (Spain)
Vlajkovic, M. (Serbia)
Vriens, D. (Netherlands)
Walz, J. (France)
Windhorst, Albert D. (Netherlands)
Zanoni, L. (Italy)
Zerizer, I. (United Kingdom)
Zhang-Yin, J. (France)
Ziegler, Sibylle I. (Germany)

EANM'23 CHAIRPERSONS





















(AS PER JULY 24, 2023)

EANM thanks all Session Coordinators for their huge engagement in organising the session details and speakers.

Caobelli, F. (Switzerland)	Dickson, J. (United Kingdom)
Lopci, E. (Italy)	Dimitrakopoulou-Strauss, A. (Germany)
Pietrzak, Agata K. (Poland)	Eberlein, U. (Germany)
Acampa, W. (Italy)	Eder, Ann-C. (Germany)
Adam, J. (Netherlands)	Eiber, M. (Germany)
Albano, D. (Italy)	Elvas, F. (Netherlands)
Albert, N. (Germany)	Fani, M. (Switzerland)
Ambrosini, V. (Italy)	Fendler, W. (Germany)
Annunziata, S. (Italy)	Ferrari, C. (Italy)
Atay, Ö. (Türkiye)	Ferro, P. (Italy)
Backhaus, P. (Germany)	Fischer, Barbara M. (Denmark)
Bailly, C. (France)	Fragoso Costa, P. (Germany)
Bajuk Studen, K. (Slovenia)	Fraioli, F. (United Kingdom)
Behe, M. (France)	Georgoulas, P. (Greece)
Beheshti, M. (Austria)	Giovanella, L. (Switzerland)
Beyder, D. (United States of America)	Glatting, G. (Germany)
Brosch-Lenz, J. (Germany)	Glaudemans, A. (Netherlands)
Burger, I. (Switzerland)	Gnesin, S. (Switzerland)
Carrilho Vaz, S. (Portugal)	Goffin, K. (Belgium)
Castellucci, P. (Italy)	Gourni, E. (Switzerland)
Ceci, F. (Italy)	Graham, R. (United Kingdom)
Chakravartthy, R. (United Kingdom)	Grana, C. (Italy)
Chiti, A. (Italy)	Guedj, E. (France)
Costa, G. (Portugal)	Hatt, M. (France)
Cremonesi, M. (Italy)	Herrmann, K. (Germany)
Dalm, S. (Netherlands)	Hess, S. (Denmark)
De Keizer, B. (Netherlands)	Holm, S. (Denmark)
Deandreis, D. (Italy)	Imbert, L. (France)
Delker, A. (Germany)	Kinggård Federspiel, M. (Denmark)
Deroose, C. (Belgium)	Kiratli, P. (Türkiye)




Kluge, R. (Germany)	Schottelius, M. (Switzerland)
Kobe, C. (Germany)	Seimbille, Y. (Netherlands)
Kopka, K. (Germany)	Shengelia, N. (Georgia)
Kreissl, M. (Germany)	Shi, K. (Switzerland)
Kreissl, Michael C. (Germany)	Slart, R. (Netherlands)
Kunikowska, J. (Poland)	Sollini, M. (Italy)
Lairez, O. (France)	Sorensen, J. (Sweden)
Lan, X. (CHINA)	Taieb, D. (France)
Larsson Stromvall, A. (Sweden)	Testanera, G. (United Kingdom)
Lassmann, M. (Germany)	Tolboom, N. (Netherlands)
Lubberink, M. (Sweden)	Traub Weidinger, T. (Austria)
Lückerath, K. (Germany)	Treglia, G. (Switzerland)
Maccauro, M. (Italy)	Turco, P. (Italy)
Massalha, S. (Israel)	van der Laken, J. (Netherlands)
Mínguez Gabiña, P. (Spain)	van der Meulen, N. (Switzerland)
Nanni, C. (Italy)	Van Velden, F. (Netherlands)
Noriega-Álvarez, E. (Spain)	van Weehaeghe, D. (Belgium)
Papp, L. (Austria)	Vanhove, C. (Belgium)
Petranović Ovčariček, P. (Croatia)	Verger, A. (France)
Prieto Azcárate, E. (Spain)	Vidal-Sicart, S. (Spain)
Resende Geao, A. (Portugal)	Violante, L. (Portugal)
Richetta, E. (Italy)	Virgolini, I. (Austria)
Rogasch, J. (Germany)	Vrachimis, A. Cyprus
Roldao Pereira, L. (United Kingdom)	Vraka, C. (Austria)
Sachpedis, C. (Germany)	Vriens, D. (Netherlands)
Salas Ramirez, M. (Germany)	Watabe, T. (Japan)
Salaün, Pierre-Y. (France)	Werner, R. (Germany)
Santos, A. (Portugal)	Withofs, N. (Belgium)
Santos, Ana I. (Portugal)	Yakushev, I. (Germany)
Saraste, A. (Finland)	











EANM NATIONAL SOCIETIES: DELEGATES / DEPUTIES

SOCIETY	DELEGATE	DEPUTY
 Armenian Society of Nuclear Medicine	V. Barsegian	M. Grigoryan
 Austrian Society of Nuclear Medicine	M. Gabriel	T. Traub-Weidinger
 Azerbaijan Society of Nuclear Medicine	F. Novruzov	A. Aliyev
 Belgian Society of Nuclear Medicine	N. Withofs	V. Shelfhout
 Bosnian Society of Nuclear Medicine	A. Basic	S. Zarac Bobic
 British Nuclear Medicine Society	R. Graham	S. Dizdarevic
 Bulgarian Society of Nuclear Medicine	V. Hadzhyska	Z. Dancheva
 Croatian Society of Nuclear Medicine	D. Snajder Mujkic	A. Baric Zizic
 Cyprus Society of Nuclear Medicine	A. Vrachimis	D. Kyprianou
 Czech Society of Nuclear Medicine	M. Simanek	P. Koranda
 Danish Society of Clinical Physiology and Nuclear Medicine	P. Hovind	M. Reichkender
 Dutch Society of Nuclear Medicine	A. Glaudemans	R. Keijsers
 Estonian Nuclear Medicine Society	I. Muoni	T. Karner
 Finnish Society of Nuclear Medicine	H. Mussalo	K. Timonen
 Macedonian Society of Nuclear Medicine	D. Miladinova	A. Ugrinska
 French Society of Nuclear Medicine	P-Y. Salaun	F. Cachin
 German Society of Nuclear Medicine	M. Luster	M. Schafers
 George de Hevesy Hungarian Society of NM	T. Gyorke	G. Trencsenyi
 Georgian Nuclear Medicine Specialists Association	N. Shengelia	K. Shamatava
 Hellenic Society of Nuclear Medicine & Biology	S. Chatziioannou	V. Valotassiou

SOCIETY	DELEGATE	DEPUTY
 Icelandic Society of Nuclear Medicine	to be nominated	to be nominated
 Irish Nuclear Medicine Association	R. Killeen	K. O'Regan
 Israeli Society of Nuclear Medicine	Z. Bar-Sever	Z. Keidar
 Italian Society of Nuclear Medicine	R. Giubbini	M. Kirienco
 Latvian Society of Nuclear Medicine	M. Kalnina	J. Kedrova
 Lithuanian Society of Nuclear Medicine	S. Sediene	D. Vajauskas
 Luxembourg Society of Nuclear Medicine	C. Als	J. Zhang-Yin
 Maltese Association of Radiologists and Nuclear Medicine Physicians	M.A. Aquilina	A. Mallia
 Norwegian Society of Nuclear Medicine	T.C. Adamsen	R. Sundset
 Polish Society of Nuclear Medicine	A. Sowa-Staszczak	A. Pietrzak
 Portuguese Society of Nuclear Medicine	A.P. Moreira	R. Silva
 Romanian Society of Nuclear Medicine	D. Piciu	C.R. Stolniceanu
 Serbian Nuclear Medicine Society	J. Mihailovic	V. Artiko
 Slovak Society of Nuclear Medicine	L. Kaliska	E. Takacsova
 Slovenian Society of Nuclear Medicine	I. Zagar	K. Zaletel
 Spanish Society of Nuclear Medicine	M. J. Garcia-Velloso.	R. Ruano Perez
 Swedish Society of Nuclear Medicine	E. Tragardh	A. Stromvall Larsson
 Swiss Society of Nuclear Medicine	F. Forrer	M. Wissmeyer
 Turkish Society of Nuclear Medicine	Z. Ozcan	L.O. Atay
 Ukrainian Society of Nuclear Medicine	to be nominated	to be nominated

UEMS/EBNM NATIONAL SOCIETIES: DELEGATES / DEPUTIES



COUNTRY	DELEGATE	DEPUTY
 AUSTRIA	Rainer Lipp	Michael Gabriel
 BELGIUM	Karoline Spaepen	Gerard Moulin-Romsee
 BULGARIA	Elena Piperkova	Antonia Dencheva Tzonevska
 CROATIA	Drazen Huic	Sanja Kusačić Kuna
 CYPRUS	Rena K. Demetriadou	
 CZECH REPUBLIC	Otto Lang	Milan Kaminek
 DENMARK	Peter Hovind	Michala Reichkandler
 ESTONIA	Eve Kelk	Anne Poksi
 FINLAND	Kirsi Timonen	Jukka Kemppainen
 FRANCE	Eric Gremillet	Jean-Louis Pelletier
 GERMANY	Winfried Brenner	Martin Gotthardt
 GREECE	Sophia Koukouraki	Ioannis Iakovou
 HUNGARY	Laszlo Pavics	Istvan Szilvasi
 IRELAND	Stephen Skehan	Ronan McDermott
 ITALY	Giuseppe Rubili	Desirè Deandreis
 LATVIA	Ilga Vevere	Antra Berzina
 LITHUANIA	Donatas Vajauskas	Nemira Jurkienė
 LUXEMBOURG	Patrick Paulus	Christian Picard
 MALTA	Mark Anthony Aquilina	Andrew Mallia

COUNTRY	DELEGATE	DEPUTY
 THE NETHERLANDS	N.J. Wyndaele	Lenka Pereira Arias-Bouda
 NORWAY	Tom Christian Holm Adamsen	Rune Sundset
 POLAND	Mirosław Dziuk	Bożena Birkenfeld
 PORTUGAL	Lucilia Salgado	
 ROMANIA	Gabriel Andries	Raluca Mititelu
 SERBIA	Vera Artiko	Jasna Mihailovic
 SLOVAKIA	Andrej Vondrak	Pavol Povinec
 SLOVENIA	Simona Gaberscek	Damjana Hrastnik
 SPAIN	Angel Sorriano	Francesca Pons
 SWEDEN	Cecilia Wassberg	Elin Trägårdh
 SWITZERLAND	Ariane Boubaker	John Prior
 UNITED KINGDOM	Yong Du	Dr. Sabina Dizdarevic

Nominated from UEMS Associate Member Countries

 TÜRKIYE	Gulay ALTUN	Zehra Ozcan
---	-------------	-------------

Nominated from UEMS Observer Countries

 ISRAEL	Adam Steinmetz	Michael Reuben Quastel
 JORDAN	Akam Al-Ibraheem	

UEMS/EBNM COMMITTEES

EXECUTIVE COMMITTEE

President	S. Mirzaei (Austria)
Secretary & Treasurer	R. Hustinx (Belgium)
Member	A. Boubaker (Switzerland)

FELLOWSHIP EXAMINATION

Chair	Z. Özcan (Türkiye)
Members	A. Boubaker (Switzerland)
	Z. Ozcan (Türkiye)
	J. R. Garcia Garzón (Spain)
	S.Vaz (Portugal)
	I. Kulakiene (Lithuania)

EDUCATION & SYLLABUS

Chair	R. Hustinx (Belgium)
Members	J. Darcourt (France)
	H. B. Sayman (Türkiye)
	D. Huic (Croatia)
	T.V. Bogsrud (Norway)
	P Castellucci (Italy)

CME ACCREDITATION

Chair	M. Farsad (Italy)
Members	E. Lopci (Italy)
	A. Haug (Austria)
	S. Sillanmäki (Finland)

ACCREDITATION OF NUCLEAR MEDICINE DEPARTMENTS & TRAINING CENTRES

Chair	J. Prior (Switzerland)
Committee	
Members	A. García-Burillo (Spain)
	N. Mutlukoca (Norway)
	P.A.L. Van Boxem (Belgium)
	M.L. Hall (United Kingdom)
Corresponding	
Members:	A. Jiménez Heffernan (Spain)
	I. Sippo-Tujunen (Finland)
	N.G. Hartman (United Kingdom)
	S.E. Bouyoucef (Algeria)
	A. Ciarmiello (Italy)
	R. Zakavi (Iran)
	I. Iakovou (Greece)
	L. Torres (Cuba)

LILLY IN ALZHEIMER'S DISEASE:

ADVANCING THE SCIENCE, CARING FOR PEOPLE

At Lilly, patients and loved ones are at the center of everything we do. For over 30 years, we have been committed to the development of both diagnostics and therapeutics in the AD space. Through our innovation, we have advanced the field by helping to shape the standards for Alzheimer's Disease research.

**VISIT LILLY.COM TO
LEARN MORE**





GET THE MOST OUT OF OUR ANNUAL CONGRESS

DOWNLOAD
the EANM'23 Congress App
for an interactive and
immersive experience



GENERAL INFORMATION



Hint: Please note that only cashless payments are accepted at the congress venue.

AUDIO & VIDEO RECORDINGS

Audio and/or video recordings during the congress are strictly prohibited and must not be made without prior written permission of the EANM Executive Office.

CERTIFICATE OF ATTENDANCE

The EANM'23 Certificate of Attendance will be available in your myEANM area after the overall EANM Congress evaluation is submitted.

CLOSING SESSION & FAREWELL COCKTAIL

All registered delegates and accompanying persons are cordially invited to the Closing Ceremony & Farewell Cocktail Wednesday, September 13, 2023 – 11:25-12:15. The Closing Ceremony will be held at the Hall A of the ACV – Austria Center Vienna and the subsequent Farewell Cocktail in Foyers on Level 2.

Austria Center Vienna (ACV)
Bruno-Kreisky-Platz 1
1220 Vienna, Austria

CME CREDITS & CERTIFICATES

The EANM'23 Congress has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 24 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

To acquire CME credits, attendees must scan their congress badge upon first arrival at the congress venue and upon entering each CME session. For CME sessions, an evaluation form for each session attended and the overall congress evaluation must be completed. CME Sessions will be streamed live and are also available

on-demand after the congress until November 13, 2023 (23:59 CEST).

To obtain your CME certificate(s), please visit your myEANM area. In the section EANM'23 > Certificates, the certificate(s) will be available within 24 hours after you have scanned your congress badge.

CONGRESS APP

Enhance your Congress experience to the fullest with the EANM'23 Congress App. Access all the essential information right at your fingertips, ranging from the comprehensive Scientific Programme to the Exhibitors List, the Venue Maps, and much more.

Personalise your Congress schedule effortlessly and evaluate sessions conveniently on your smart device, ensuring a smooth process to receive your CME credits.

[Download the EANM'23 Congress App now.](#)

COVID-19 SAFETY PROTOCOL

The entrance rules will be handled according to the national requirements in Vienna in September 2023. Currently, Austria has no restrictions regarding congress attendance.

CONGRESS BAG

In line with our commitment to reducing unnecessary waste, we are introducing the 'Bring Your Old Bag' (BYOB) Initiative this year. Instead of providing new congress bags, we encourage attendees to bring their bags from previous EANM congresses. Don't miss out on the opportunity to win one of three registrations for EANM'24.

How to Engage: Visit our photo booth located in the Entrance Hall, next to the 'EANM Sustainability Wall'. Capture a photo of yourself with your treasured Congress bag. Pin your

photo with the completed giveaway entry slip and drop it into the designated 'BYOB Box'.

The lucky winners will be drawn after the Congress and will be announced on September 27, 2023, on the EANM's social media channels (Facebook, Twitter, LinkedIn (EANM)).

CONGRESS e-POSTER AREA

As every year, the e-Poster Area gives you the possibility to see all uploaded e-Posters of EANM'23. You can search for authors, topics and keywords. The onsite e-Poster Area is located in the Foyer on Level 1. The e-Poster system can also be accessed online via the virtual congress platform. The online access will remain open until November 13, 2023 (23:59 CEST).

CONGRESS LANGUAGE

The congress language is English. No simultaneous translation will be provided.

CONGRESS OFFICE

The congress office is located on Level 0 at the ACV – Austria Center Vienna and will be open during the following days and times:

Saturday, September 9, 2023:	07:30–18:00
Sunday, September 10, 2023:	07:30–18:00
Monday, September 11, 2023:	07:30–18:00
Tuesday, September 12, 2023:	07:30–18:00
Wednesday, September 13, 2023:	07:30–12:00

CONGRESS SELF CHECK-IN

Our convenient Self-Check-In stations in the Entrance Hall will help you collect your name badge without waiting in queues. Please make sure to bring your QR code and a personal ID.

Saturday, September 9, 2023:	07:30–21:45
Sunday, September 10, 2023:	07:30–18:00
Monday, September 11, 2023:	07:30–18:00
Tuesday, September 12, 2023:	07:30–18:00
Wednesday, September 13, 2023:	07:30–12:00

CONGRESS VENUE

Austria Center Vienna (ACV)
Bruno-Kreisky-Platz 1
1220 Vienna, Austria
URL: www.acv.at

The ACV is within 2 minutes' walking distance from the metro station Kaisermühlen VIC, right behind the Vienna International Center and United Nations headquarters. The Metro U1 (red line) is the only one connecting the city centre with the ACV.

DATES & DEADLINES

August 29, 2023:	Advanced Registration Deadline (August 29, the on-site registration fee applies)
September 9, 2023:	Opening Ceremony & Welcome Reception
September 13, 2023:	Closing Ceremony & Farewell Cocktail
November 13, 2023:	Deadline for on-demand content and evaluation (23:59 CEST)

EANM EXECUTIVE OFFICE

Schmalzhofgasse 26
1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
Email: office@eanm.org
Web: www.eanm.org

EANM LIVE ONLINE TV

Whether you are attending this year's EANM Congress in-person or online - you are invited to join Roy Sheppard and his expert guests for a NEW addition to the Congress experience - two daily fast-moving LIVE ONLINE TV shows each day.

Each morning at 08:30 and each afternoon at 17:15 you will be able to listen to leading experts from all areas of nuclear medicine who will be discussing upcoming sessions you really can't afford to miss - and at the end of each day they'll be commenting on the most fascinating sessions they attended that day.

EANM MEMBERS' ASSEMBLY

The Members' Assembly will be held on Sunday, September 10, 2023 - 08:00-11:00 in the Hall G1 on Level -2.

Please note: Only EANM members in good standing (having paid their membership dues for the year 2023) are eligible to attend the Members' Assembly.

ENVIRONMENTAL AWARENESS

We have implemented numerous sustainability initiatives at EANM'23 reflecting our commitment to reducing our environmental impact and to offering you a greener congress experience.

To give you a comprehensive insight into our sustainability efforts, we invite you to explore our Sustainability Wall, conveniently situated in the Entrance Hall. Here, you can easily view key highlights of our initiatives at a glance.

FOOD & BEVERAGE

At the Austria Center Vienna, we are pleased to offer a variety of food and beverage outlets for your convenience. **Please note that only cashless payments are accepted at the congress venue.**

Here is an overview of the different locations, their opening hours, and what they have to offer:

Leberkas-Pepi

Located at the Main Entrance (outside)
Sunday to Tuesday: 10:00–15:00

Cafe MOTTO

Located in the Entrance Hall, Level 0
Saturday: 13:00–18:00
Sunday to Tuesday: 09:00–16:00

Espressomobil

Located in the Entrance Hall, Level 0
Sunday to Tuesday: 09:00–15:00
Wednesday: 09:00–11:00

Gelatomobil

Located in the Entrance Hall, Level 0
Sunday to Tuesday: 10:00–16:00

Foyer A Outlet

Located in Foyer A, Level 2
Sunday to Tuesday: 11:00–14:30
Warm dishes and beverages

Hall X2 Outlet

Located in Hall X2, Level –2
Sunday to Tuesday: 09:00–16:00
Simple warm dishes, snacks, beverages, and coffee

Halle X3, X4 Outlets

Located in Hall X3 and X4, Level –2 & 0
Sunday to Tuesday: 09:00–16:00
Beverages and Snacks.

Please note that the availability of certain items may be subject to change, and we recommend checking with the respective outlets for any updates.

INSURANCE & LIABILITY

Neither the organisers nor the Conference Bureau will assume any responsibility whatsoever for damage or injury to persons or property during the congress. It is recommended that participants arrange for their personal travel and health insurance.

INTERNATIONAL MEETINGS AND ANNOUNCEMENTS BOARD

Visit the International Meetings and Announcement Board in Hall X2 (opposite the food and beverage outlet) to get information on upcoming events in Nuclear Medicine and more.

INTERNET CORNER

Internet access and limited printing possibilities will be provided at stations located in the Foyer on Level 1. Please limit the viewing time to max. 5 minutes per person.

LIVE STREAM

All ticket holders for the online access will automatically get access to the online content. Onsite congress ticket holders (except Day Ticket holders, Exhibitors and Accompanying Persons) will also be granted full online access.

The following sessions will be live-streamed and will also be available on-demand until November 13, 2023 (23:59 CEST): Opening Ceremony, incl. Highlights Lecture, all 14 CME Sessions (incl. CME credits collection), all 8 CTE Sessions, and the Closing Ceremony. All live streamed Satellite Symposia will also be included (approx. 6 symposia).

The credits for the CME sessions can be collected on-demand (for online and onsite participants).

LOST & FOUND

A lost and found service will be provided at the EANM registration desk for the duration of the congress.

MEDIA

By attending the event, each participant acknowledges and agrees to grant EANM the right at the congress to record, film, photograph or capture the likeness of such participant and its representatives in any media now available and in the future developed and to use, copy, modify, distribute, broadcast or otherwise disseminate at any time and on a global basis such media, without any further approval from or payment to such participant or any of its representatives.

MEDICAL FACILITIES

Medical assistance service will be available throughout the congress.

MOBILE PHONES

Out of respect for other participants, you are requested to refrain from making phone calls in a lecture room. Your mobile device should always be on silent mode when you are in the congress centre.

NAME BADGES

Badges for the congress will be issued on-site between September 9 and September 13, 2023. The badges must be collected in person.

A confirmation email, including a QR code, will be issued upon successful completion of registration. With this QR and a valid photo ID, the name badge can be printed onsite in the registration.

OPENING CEREMONY & WELCOME RECEPTION

All registered delegates and accompanying persons are cordially invited to the Opening Ceremony & Welcome Reception Saturday, September 9, 2023, from 18:00–21:45.

The Opening Ceremony, **including the Highlights Lecture**, will be held at the Hall A of the ACV – Austria Center Vienna, and the subsequent Welcome Reception will be in the Foyers on Level 2.

Austria Center Vienna (ACV)
Bruno-Kreisky-Platz 1
1220 Vienna, Austria

PARKING

Private cars can be parked at an additional cost in the ACV – Austria Centre Vienna parking areas. The costs for a day are € 15,00, € 25,00 for two days, € 35,00 for three days or € 45,00 for a week pass. Further information can be found on the website of the ACV: www.acv.at

PUBLIC TRANSPORT TICKET (PTT)

In Vienna, no complimentary or reduced public transport tickets can be offered. You can buy the tickets either on the “Wiener Linien” homepage online or at ticket machines, which can be found in each metro station in Vienna. Please find further information [here](#).

Please note that this ticket is non-refundable, and neither ENITED nor EANM is responsible for the purchase of public transport tickets. All enquiries should be directed to the municipal public transport provider Wiener Linien.

If you have any questions, please contact the Online-Ticketshop-Team at or call the hotline +43-1-7909-100.

REGISTRATION DESK

The registration desk at the entrance Level 0 of the ACV – Austria Center Vienna will be open:

Saturday, September 9, 2023:	07:30–21:45
Sunday, September 10, 2023:	07:30–18:00
Monday, September 11, 2023:	07:30–18:00
Tuesday, September 12, 2023:	07:30–18:00
Wednesday, September 13, 2023:	07:30–12:00

REVIEW CENTRE

The Review Centre gives you the opportunity to check the PowerPoint presentations which have already been presented during the EANM'23 Congress. So, in case you have missed a session, you can view the slides here afterwards. The Review Centre is located in the Foyer on Level 1. The slides will not be accessible online.

SOCIAL MEDIA AND NEWSLETTER

For up-to-date information, follow us on our social media channels and subscribe to the congress newsletter!

Facebook	@officialEANM
X (formerly Twitter)	@officialEANM
LinkedIn	@officialEANM
YouTube	@officialEANM
Flickr	@officialEANM
Congress Newsletter	subscribe/unsubscribe here

Don't forget to use our hashtag #EANM23 when posting on social media.

VIENNA INFORMATION DESK

The Vienna Information Desk with a guide at the entrance level of the ACV (Congress Centre) will be open:

Sunday, September 10, 2023:	09:00–19:00
Monday, September 11, 2023:	09:00–19:00

VISA

All foreign visitors entering Austria must possess valid passports. A valid identity card is sufficient for citizens from the European Union Member countries.

PLEASE CHECK THE CURRENT VISA REQUIREMENTS WITH THE NEAREST AUSTRIAN CONSULATE/EMBASSY IN YOUR COUNTRY BEFORE YOUR DEPARTURE TO AUSTRIA.

All registered congress participants with a completed/paid registration can download a visa invitation letter within their [myEANM Area!](#)

WI-FI

Free WI-FI will be available at the EANM'23 Congress throughout the congress venue.

The login credentials are:

Network: EANM
Password: eanm2023

YOUNG PROFESSIONALS LOUNGE

We invite all students and junior attendees to the EANM'23 Young Professionals Lounge, a dedicated space to enjoy a refreshment, have a quiet corner to rest, work and network during the Congress (registration type permitting).

Make sure you attend the casual and interactive Lunch Talks featuring high-level nuclear medicine experts and highly motivated EANM volunteers. The speakers will share their experiences within the association and their professional journeys. Find the schedule and more details [here](#).



EANM Young Professionals Lounge Open daily – Hall L1 – Level 1

Join the new EANM'23 Young Professionals Lounge, a dedicated space for students and junior attendees to enjoy refreshments, a quiet corner to rest, work and network during the Annual Congress (registration type permitting).

Be sure to attend the informal and interactive Lunch Talks, featuring high-level nuclear medicine experts and highly motivated EANM volunteers sharing their experiences within the Association and their professional journeys.

Sunday, September 10, 2023
13:15–14:00 CEST:

Family, Nuclear Medicine
career & Volunteer job
Laura Evangelista, Italy

Monday, September 11, 2023
13:15–14:00 CEST:

Harnessing the power of EANM:
My journey – your opportunity
Tim Van den Wyngaert, Belgium

Tuesday, September 12, 2023
13:15–14:00 CEST:

What to do when you are young ...
engage with the EANM?
Michel Koole, Belgium

YPL
YOUNG PROFESSIONALS LOUNGE

▼ PYLCLARI™
Piflufolastat (¹⁸F)



PYLCLARI™ is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings⁽¹⁾

Primary staging of patients with high-risk PCa prior to initial curative therapy.

To localize recurrence of PCa in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent.



Scan or click the QR code to discover more about PYLCLARI™

References

1. PYLCLARI™ SmPC, 2023.

*The Marketing Authorization has been granted for PYLCLARI™ in all EU members. PYLCLARI™ might not be commercially available yet in your country.

LEVEL -2

EANM Arena

Hall D Special Track (Debates, Challenge the Experts, Round Table)

Lecture Halls

Hall G1 Theranostics Track, Special Symposia, Case Report Sessions


Hall G2 e-Poster Sessions

Hall K Technologists' Track

Meeting Rooms -2.16, -2.31, -2.36, -2.47-48, -2.61-62, -2.63, -2.85-86

Industry Hospitality Suite -2.13, -2.14, -2.18-19, -2.33, -2.34, -2.35, -2.45, -2.46, -2.64, -2.65, -2.66, -2.84, -2.91

Exhibition Halls X2, X3, X4, Catering Area



LEVEL 0

Entrance Hall Registration, Self Check-In, Cloakroom, EANM Area, Meeting Point

Lecture Halls

Hall E1 Learn & Improve Professionals Skills (LIPS) Track

Hall E2 M2M Track

Hall F1 TROP / Featured Sessions

Hall F2 TROP / Featured Sessions, Joint Symposia, Special Symposia

Speaker Preview Room 0.94-95

Meeting Rooms 0.11-12, 0.14, 0.96-97

Suite F EANM Congress Office

Offices 0.31 - 0.51




LEVEL 1

Gallery Societies Village, ESMIT Area

Foyer L1 E-Poster Area, Internet Corner, Review Centre

Hall L1 Young Professionals Lounge

EANM Committee Meetings 1.61-1.86



LEVEL 2

Lecture Halls


Hall A Opening Ceremony, CME Sessions, Plenary Sessions, Closing Session

Hall B Cutting Edge Science Track

Hall C Clinical Oncology Track

Foyer ABC Welcome Reception Area

Foyer A Delegates Catering Area, Farewell Drink



One System. More than 7 Million Cumulative Infusions* Worldwide.

More than 7 million times* around the world, MEDRAD® Intego has been trusted for PET infusions. The MEDRAD® Intego PET Infusion System has an installed base of more than 600 units in more than 45 countries.

The MEDRAD® Intego Advantage

The MEDRAD® Intego PET Infusion System enables you to personalize and deliver accurate doses for patients, minimize radiation exposure for technologists, and optimize practice efficiency and economics.

- Radiopharmaceutical Utilization Reduction**
- Weight-Based Dosing**
 - Individualized dosing calculations
 - Precise administration
- Scheduled Compression**
 - Shortened intervals between patient injections
- Staff Radiation Exposure Reduction**
- Hands-off Operation**
 - Built-in shielding
 - Automated dose preparation

MEDRAD® Intego PET Infusion System

Wireless Connectivity

Streamlines workflow and accuracy with automatic record keeping

Simple to Use Touch Screen

Streamlines workflow with fast processing

Patient Friendly

With selectable flow rate and test infusion

Motor Driven

For easy maneuverability

Integrated Dose Calibrator

Accurate and flexible delivery of FDG and NaF

Shielding

Offers a 90% reduction in operator extremity dose compared to manual injection¹

¹ Bayer V&V Testing Results



* Based on Worldwide Patient Administration Set sales data August 2008 – July 2023

Bayer reserves the right to modify the specifications and features described herein or to discontinue any product or service identified in this publication at any time without prior notice or obligation. Please contact your authorized Bayer representative for the most current information.

Bayer, the Bayer Cross, MEDRAD Intego, and MEDRAD are trademarks owned by and/or registered to Bayer in the U.S. and/or other countries. Other trademarks and company names mentioned herein are properties of their respective owners and are used herein solely for informational purposes. No relationship or endorsement should be inferred or implied. MEDRAD Intego is registered as a Medical Device.

© 2023 Bayer. This material may not be reproduced, displayed, modified, or distributed without the express prior written consent of Bayer.

More information on radiology.bayer.com

Scan here:



Manufacturer
Bayer Medical Care Inc.
1 Bayer Drive
Indianola, PA 15051
U.S.A.
Phone: +1-412-767-2400
+1-800-633-7231
Fax: +1-412-676-4120

Authorized European Representative
Bayer Medical Care B.V.
Avenue Céramique 27
6221 KV Maastricht
The Netherlands
Phone: +31 (0) 43-3585602
Fax: +32 (0) 43-3656598



PP-M-INT-AT-0020-1 Aug 2023

PROGRAMME OVERVIEW

SATURDAY, SEPTEMBER 9, 2023

Location/Time	Hall A			Location/Time
08:00-08:30				08:00-08:30
08:30-09:00				08:30-09:00
09:00-09:30				09:00-09:30
09:30-10:00				09:30-10:00
10:00-10:30				10:00-10:30
10:30-11:00				10:30-11:00
11:00-11:30				11:00-11:30
11:30-12:00		Advisory Council Meeting (11:00-13:00) Room 1.86		11:30-12:00
12:00-12:30				12:00-12:30
12:30-13:00				12:30-13:00
13:00-13:30				13:00-13:30
13:30-14:00				13:30-14:00
14:00-14:30			Delegates' Assembly (14:00-16:00) Hall F2	14:00-14:30
14:30-15:00				14:30-15:00
15:00-15:30				15:00-15:30
15:30-16:00				15:30-16:00
16:00-16:30				16:00-16:30
16:30-17:00				16:30-17:00
17:00-17:30				17:00-17:30
17:30-18:00				17:30-18:00
18:00-18:30	Opening Ceremony including Awards Ceremony (18:00-18:35) <i>101</i> Plenary 1 Highlights Lecture (18:35-19:35) Welcome Reception (19:45-21:45)			18:00-18:30
18:30-19:00				19:30-20:30
20:30-21:00				20:30-21:00
21:00-21:30				21:00-21:30
21:30-22:00				21:30-22:00
			Committee Meetings (14:00-17:45)	15:30-16:00
				16:00-16:30
				16:30-17:00
				17:00-17:30

PROGRAMME OVERVIEW

SUNDAY, SEPTEMBER 10, 2023

Location/Time	Hall A	Hall D – Arena	Hall E1	Hall E2	Hall B	Hall C	Hall F1	Hall F2	Hall G2	Hall K	Hall G1	Location/Time
	LIVE STREAM									LIVE STREAM		
08:00–08:30	201 CME 1 Inflammation & Infection Committee	202 Special Track Cardiovascular Committee Debate: Myocardial Perfusion Imaging after ISCHEMIA Trial	203 LIPS Interactive Session Oncology & Theranostics Committee	204 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee	205 Cutting Edge Science Track TROP Session Physics Committee	206 Clinical Oncology Track TROP Session Oncology & Theranostics Committee	207 Featured Session Neuroimaging Committee	208 TROP Session Paediatrics Committee	209 e-Poster Presentations Session 1 Oncology & Theranostics Committee	210 Technologists' Track Opening CTE 1 Technologists Committee / SNMMI	Members' Assembly (08:00–11:00)	08:00–08:30
08:30–09:00	Infection and Inflammation – New Guidelines		Novelties in Radionuclide Therapy	At the Nucleus: Radionuclide Production	Quality Control, Performance, Standardisation	Prostate Cancer Staging	Methods in Neuroimaging: Spotlight on Brain Connectivity	Paediatric PET/CT & PET/MR	Neuroendocrine Tumours and Gynaecological Malignancies	Technologists' Guide Launch – Gastro Intestinal Molecular Imaging Studies		08:30–09:00
09:00–09:30												09:00–09:30
09:30–10:00												09:30–10:00
10:00–10:30	301 CME 2 Translational Molecular Imaging & Therapy + Oncology & Theranostics + Radiopharmaceutical Sciences Committee	302 Special Track Thyroid Committee Challenge the Expert: Integrated Diagnostics of Thyroid Disease	303 LIPS Interactive Session Radiation Protection + Physics Committee / EFOMP	304 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee	305 Cutting Edge Science Track Featured Session Physics Committee	306 Clinical Oncology Track Featured Session Oncology & Theranostics Committee	307 TROP Session Neuroimaging Committee	308 Joint Symposium 1 Cardiovascular + Inflammation & Infection Committee / EACVI	309 e-Poster Presentations Session 2 Paediatrics Committee	310 Technologists' Track CTE 2 Technologists Committee		10:00–10:30
10:30–11:00	FAP – Moving Towards Therapy		Careers in Radiation Protection	Validating Methodology: In Vitro and in Vivo Models	Radiomics	Haematological Disease	Amyloid, Tau and More in Neurodegenerative Disorders	PET in Valvular Diseases – All In!	Paediatric Nuclear Medicine & Adults General Nuclear Medicine	Head and Neck Molecular Imaging – Updates and Perspectives		10:30–11:00
11:00–11:30												11:00–11:30
11:30–12:00	401 Plenary 2 New Imaging Techniques – Jump Aboard or Watch and Wait											11:30–12:00
12:00–12:30												12:00–12:30
12:30–13:00												12:30–13:00
13:00–13:30												13:00–13:30
13:30–14:00	Lunch Break			Satellite Symposium Monrol Nuclear Products			Satellite Symposium TELIX	Satellite Symposium Springer Healthcare IME (supported by an educational grant from Lilly)	Satellite Symposium Pfizer	EANM Lunch Break Session Presentation Skills for Medical Professionals		13:30–14:00
14:00–14:30												14:00–14:30
14:30–15:00												14:30–15:00
15:00–15:30	501 CME 3 Cardiovascular Committee	502 Special Track Oncology & Theranostics Committee	503 LIPS Interactive Session Thyroid Committee	504 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee	505 Cutting Edge Science Track TROP Session Dosimetry Committee	506 Clinical Oncology Track TROP Session Oncology & Theranostics Committee	507 TROP Session Paediatrics Committee	508 Joint Symposium 2 Oncology & Theranostics Committee / EORTC	509 e-Poster Presentations Session 3 Inflammation & Infection Committee	510 Technologists' Track Oral Presentations 1 Technologists Committee	511 Theranostics Track Featured Session Oncology & Theranostics Committee / EARL	15:00–15:30
15:30–16:00	Nuclear Imaging in Cardiac Amyloidosis – What Else?	Challenge the Expert: Risk in Diagnostic and Therapeutic Nuclear Medicine	Rational Use of PET/CT with 18F-FDG in DTC	Radioligand Therapy - New and Old Targets	From Cells to Human via the Fish	Gastrointestinal Malignancies	Adults General Nuclear Medicine	Nuclear Medicine Imaging of the Immune System	More on Infection and Inflammation Imaging	SPECT-CT in Diagnosis and Therapy	Old but Novel Techniques	15:30–16:00
16:00–16:30												16:00–16:30
16:30–17:00												16:30–17:00
17:00–17:30	601 CME 4 Oncology & Theranostics Committee	602 Special Track Dosimetry Committee	603 LIPS Interactive Session Oncology & Theranostics Committee	604 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee	605 Cutting Edge Science Track TROP Session Physics Committee	606 Clinical Oncology Track TROP Session Oncology & Theranostics Committee	607 TROP Session Cardiovascular Committee	608 TROP Session Inflammation & Infection Committee	609 e-Poster Presentations Session 4 Thyroid Committee	610 Technologists' Track CTE 3 Technologists Committee	611 Special Symposium 1 EANM / EARL	17:00–17:30
17:30–18:00	Update in Multiple Myeloma	Challenge the Expert: Dosimetry Live	Residents for Residents	Novel Imaging Targets in Oncology	Segmentation and Denoising	Neuroendocrine tumours Treatment	Functional Imaging, Plaque and Total-Body PET	Infection and Inflammation Imaging: New Frontiers	Thyroid and Parathyroid Disease	Patient Care in Nuclear Medicine	Harmonisation and Accreditation Accelerate Research and Clinical Translation	17:30–18:00
18:00–18:30												18:00–18:30

PROGRAMME OVERVIEW | FINAL PROGRAMME

PROGRAMME OVERVIEW | FINAL PROGRAMME

PROGRAMME OVERVIEW

MONDAY, SEPTEMBER 11, 2023

Location/Time	Hall A	Hall D – Arena	Hall E1	Hall E2	Hall B	Hall C	Hall F1	Hall F2	Hall G2	Hall K	Hall G1	Location/Time
	LIVE STREAM									LIVE STREAM		
08:00–08:30	701 CME 5 Oncology & Theranostics Committee	702 Special Track Neuroimaging Committee Debate: What is the Best Tracer for Molecular Brain Tumour Imaging?	703 LIPS Interactive Session Cardiovascular Committee Challenges in MBF Quantification with PET and SPECT	704 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee Imaging Inflammatory Processes in Cardiovascular Diseases	705 Cutting Edge Science Track Featured Session Physics Committee Imaging Guided Surgery	706 Clinical Oncology Track TROP Session Oncology & Theranostics Committee Neuroendocrine Tumours – Diagnosis	707 TROP Session Paediatrics Committee Neuroblastoma & Non-PET Paediatric Studies	708 Special Symposium 2 Inflammation & Infection Committee Usefulness of PET in the Evaluation of Inflammatory Rheumatisms	709 e-Poster Presentations Session 5 Physics Committee SPECT/CT, PET/CT, PET/MR Quantitating Imaging	710 Technologists' Track Oral Presentations 2 Technologists Committee All about PET-CT!	711 Theranostics Track TROP Session Oncology & Theranostics Committee What's New in Prostate Cancer?	08:00–08:30
08:30–09:00	Will the Microenvironment Become Even More Important in Nuclear Medicine?											08:30–09:00
09:00–09:30												09:00–09:30
09:30–10:00												09:30–10:00
10:00–10:30	801 CME 6 Dosimetry Committee Understanding Radiobiology for Dosimetry-Guided Molecular Radiotherapy	802 Special Track Translational Molecular Imaging & Therapy + Oncology & Theranostics + Radiopharmaceutical Sciences Committee Round Table: Dialogue with the Treating Physician	803 LIPS Interactive Session Neuroimaging + Cardiovascular + Inflammation & Infection Committee Molecular Imaging to Solve the Problem of Long COVID	804 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee TME and Therapy: Direct Targeting and Secondary Effects	805 Cutting Edge Science Track TROP Session Physics Committee Image Reconstruction and Data Corrections	806 Clinical Oncology Track Featured Session Oncology & Theranostics Committee FAP Imaging	807 TROP Session Cardiovascular Committee Clinical Perfusion Imaging with PET	808 Featured Session Thyroid Committee Iodine-131 Therapy and Beyond in differentiated Thyroid Cancer	809 e-Poster Presentations Session 6 Oncology & Theranostics Committee Prostate Cancer	810 Technologists' Track CTE 4 Technologists Committee Prostate Cancer Theranostics	811 Special Symposium 3 EANM / EJMNM You, the EANM and the EJMNM	10:00–10:30
10:30–11:00												10:30–11:00
11:00–11:30												11:00–11:30
11:30–12:00	901 Plenary 3 Radiotheranostics: What's New?											11:30–12:00
12:00–12:30												12:00–12:30
12:30–13:00												12:30–13:00
13:00–13:30												13:00–13:30
13:30–14:00	Lunch Break			Satellite Symposium Spectrum Dynamics		Satellite Symposium GE HealthCare	Satellite Symposium Siemens Healthineers	Satellite Symposium Curium		Satellite Symposium Eckert & Ziegler	EANM Lunch Break Session How to be Upbeat in a Downbeat World	13:30–14:00
14:00–14:30												14:00–14:30
14:30–15:00												14:30–15:00
15:00–15:30	1001 CME 7 Thyroid + Dosimetry Committee New NM Guidelines of Benign Thyroid Disease	1002 Special Track EANM Sanjiv Sam Gambhir Award – Compete and Win!	1003 LIPS Interactive Session Inflammation & Infection Committee Tips and Tricks in the Study of Prosthesis Infection	1004 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee New Roads Towards FAP-Directed Theranostics	1005 Cutting Edge Science Track TROP Session Dosimetry Committee Clinical Dosimetry I ¹⁷⁷Lu / ²²⁵Ac and ¹⁶¹Tb RLT	1006 Clinical Oncology Track Featured Session Oncology & Theranostics Committee Melanoma	1007 TROP Session Neuroimaging Committee Imaging Neurotransmission in Movement Disorders	1008 Joint Symposium 3 Translational Molecular Imaging & Therapy + Oncology & Theranostics + Physics Committee / EAU Metastases Directed Prostate Cancer Surgery - Translational Challenges and Possibilities	1009 e-Poster Presentations Session 7 Cardiovascular Committee Cardiovascular Imaging e-Posters	1010 Technologists' Track Technologists' e-Poster Presentations Session Technologists Committee Tech's e-Posters	1011 TROP Session Case Report Session 1 Learning from Single Cases in Theranostics	15:00–15:30
15:30–16:00												15:30–16:00
16:00–16:30												16:00–16:30
16:30–17:00												16:30–17:00
17:00–17:30	1101 CME 8 Oncology & Theranostics Committee Assessing Response to Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Tumours	1102 Special Track Physics Committee Debate: AI in Nuclear Medicine: Fear or Embrace?	1103 LIPS Interactive Session Cardiovascular Committee Stiff to Sweet - Infiltration and Inflammation	1104 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee Efficient Radiolabelling: Key for Clinical Translation	1105 Cutting Edge Science Track TROP Session Radiation Protection Committee Current Issues of Radiation Protection	1106 Clinical Oncology Track TROP Session Oncology & Theranostics Committee Prostate Cancer Biochemical Recurrence	1107 TROP Session Inflammation & Infection Committee Vasculitis and Endocarditis: Current and New Evidence	1108 TROP Session Thyroid Committee Iodine-131 Therapy in Differentiated Thyroid Cancer: Present and Future Perspective	1109 e-Poster Presentations Session 8 Neuroimaging Committee E-Poster Neurology: It's in the Brain!	1110 Technologists' Track CTE 5 Technologists Committee Cardiac Inflammatory Disease	1111 TROP Session Case Report Session 2 Successful Molecular Targeting in Oncology	17:00–17:30
17:30–18:00												17:30–18:00
18:00–18:30												18:00–18:30

PROGRAMME OVERVIEW | FINAL PROGRAMME

PROGRAMME OVERVIEW | FINAL PROGRAMME

PROGRAMME OVERVIEW

TUESDAY, SEPTEMBER 12, 2023

Location/Time	Hall A	Hall D – Arena	Hall E1	Hall E2	Hall B	Hall C	Hall F1	Hall F2	Hall G2	Hall K	Hall G1	Location/Time
	LIVE STREAM									LIVE STREAM		
08:00-08:30	1201 CME 9 Bone & Joint + Physics Committee	1202 Special Track Radiation Protection Committee	1203 LIPS Interactive Session Paediatrics Committee	1204 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee	1205 Cutting Edge Science Track TROP Session Physics Committee	1206 Clinical Oncology Track TROP Session Oncology & Theranostics Committee	1207 Featured Session Neuroimaging Committee Breadth of Tracers and Approaches in Neuro-Oncology	1208 Joint Symposium 4 Dosimetry Committee / ESTRO Dosimetry in Different Modalities - Where We Are and Where We Want To Be	1209 e-Poster Presentations Session 9 Physics Committee	1210 Technologists' Track CTE 6 Technologists Committee	1211 Special Symposium 4 Lung Scintigraphy for Pulmonary Embolism Diagnosis and long term Management	08:00-08:30
08:30-09:00	Current Bone SPECT/CT (including 360 CZT)	Round Table: Establishing and Running a Theranostics Centre in a Clinical Setting	Paediatric Nephro-Urology – Beyond Hydro-Nephrosis	Imaging the Brain from all Angles	Total Body PET Methods	Gynaecological Malignancies			Artificial Intelligence and Radiomics	Extravasation Incidents Management		08:30-09:00
09:00-09:30												09:00-09:30
09:30-10:00												09:30-10:00
10:00-10:30	1301 CME 10 Radiation Protection + Paediatrics Committee + Women's Empowerment Task Force	1302 Special Track Physics & Oncology & Theranostics Committee	1303 LIPS Interactive Session Neuroimaging Committee	1304 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee	1305 Cutting Edge Science Track TROP Session Physics Committee	1306 Clinical Oncology Track TROP Session Oncology & Theranostics Committee	1307 TROP Session Cardiovascular Committee Plaque, Fibrosis and Cardio-Oncology	1308 TROP Session Thyroid Committee ¹⁸ F-FDG and Novel Tracers in the Diagnostic Management of Patients with Thyroid Cancers	1309 e-Poster Presentations Session 10 Oncology & Theranostics Committee	1310 Technologists' Track Oral Presentations 3 NM Technologists: Competencies and Training	1311 Theranostics' Track Oncology & Theranostics Committee What's New in Neuroendocrine Tumours?	10:00-10:30
10:30-11:00	Radiation Protection in Motherhood and Childhood – What is so Special?	Debate: Whole Body Parametric Imaging	The Sunrise of Alpha-Synuclein in Vivo Brain Imaging	Emerging Theranostic Concepts	Quantitative SPECT/CT Imaging	Lung			Haematological and Abdominal Malignancies / Localised Treatments			10:30-11:00
11:00-11:30												11:00-11:30
11:30-12:00	1401 Plenary 4 Diagnostic Imaging: Proven Beyond Doubt? incl. Marie Curie Lecture											11:30-12:00
12:00-12:30												12:00-12:30
12:30-13:00												12:30-13:00
13:00-13:30												13:00-13:30
13:30-14:00	Lunch Break			Satellite Symposium United Imaging				Satellite Symposium ABX GmbH		Satellite Symposium Novartis		13:30-14:00
14:00-14:30												14:00-14:30
14:30-15:00												14:30-15:00
15:00-15:30	1501 CME 11 Paediatrics Committee	1502 Special Track Neuroimaging Committee	1503 LIPS Interactive Session Bone & Joint Committee	1504 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee	1505 Cutting Edge Science Track TROP Session Physics Committee	1506 Clinical Oncology Track TROP Session Oncology & Theranostics Committee	1507 TROP Session Cardiovascular Committee Perfusion	1508 Joint Symposium 5 Oncology & Theranostics Committee / ESMO Prostate Cancer Theranostics: Where Do We Go?	1509 e-Poster Presentations Session 11 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee	1510 Technologists' Track CTE 7 Technologists & Thyroid Committee	1511 EU Policy Symposium 1 Policy & Regulatory Affairs Committee	15:00-15:30
15:30-16:00	Paediatric Lymphoma and Update on FDG	Challenge the Expert: Amyloid vs Tau PET - Which is First in Suspected Alzheimer Patients? Germany versus Italy	Pitfalls and Common Bony Findings in PET-CT/MRI Using Novel Tracers	Imaging the Components of the TME	AI Methods and Applications	Prostate Cancer Treatment			Novel Therapeutic Approaches	Molecular Thyroid Imaging - Qualitative and Quantitative Approaches	Supply & Shortages of Radiopharmaceuticals	15:30-16:00
16:00-16:30												16:00-16:30
16:30-17:00												16:30-17:00
17:00-17:30	1601 CME 12 Physics & Oncology & Theranostics + Translational Molecular Imaging & Therapy + Technologists Committee	1602 Special Track Bone & Joint + Cardiovascular Committee	1603 LIPS Interactive Session Neuroimaging + Inflammation & Infection Committee	1604 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee	1605 Cutting Edge Science Track TROP Session Physics Committee	1606 Clinical Oncology Track TROP Session Oncology & Theranostics Committee	1607 TROP Session Neuroimaging Committee New PET Tracers for Brain Imaging	1608 TROP Session Thyroid Committee Nuclear Medicine Imaging in Thyroid and Parathyroid Disorders	1609 e-Poster Presentations Session 12 Dosimetry Committee	1610 Technologists' Track CTE 8 Technologists Committee	1611 EU Policy Symposium 2 Policy & Regulatory Affairs Committee	17:00-17:30
17:30-18:00	Long Axial Field-of-View PET Scanners – A Copernican Revolution	Debate: NaF PET in Cardiology and MSK: Pro or Cons?	The Role of FDG PET in the Diagnosis of Auto-Immune Encephalitis	Understanding and Improving RLT	Data Analysis	Head and Neck Imaging			Dosimetry Symphony	Gynaecological Studies	Regulatory Challenges of Radiopharmaceuticals	17:30-18:00
18:00-18:30												18:00-18:30

PROGRAMME OVERVIEW | FINAL PROGRAMME

PROGRAMME OVERVIEW | FINAL PROGRAMME

PROGRAMME OVERVIEW

WEDNESDAY, SEPTEMBER 13, 2023

Location/Time	Hall A	Hall D – Arena	Hall E1	Hall E2	Hall B	Hall C	Hall F1	Hall F2	Hall G2	Hall K	Hall G1	Location/Time
	LIVE STREAM									LIVE STREAM		
08:00-08:30	1701 CME 13 Translational Molecular Imaging & Therapy + Oncology & Theranostics + Radiopharmaceutical Sciences Committee	1702 Special Track Oncology & Theranostics Committee / EHA	1703 LIPS Interactive Session Dosimetry Committee	1704 TROP Session Dosimetry Committee Clinical Dosimetry II - Tutti Frutti	1705 Cutting Edge Science Track Featured Session Physics Committee Dynamic Imaging	1706 Clinical Oncology Track TROP Session Oncology & Theranostics Committee Localised Treatments	1707 TROP Session Cardiovascular Committee Heart Failure, Sarcoidosis and Amyloidosis	1708 Joint Symposium 6 Neuroimaging Committee / EAN Progress in Multimodal Imaging of Parkinson's Disease	1709 e-Poster Presentations Session 13 Oncology & Theranostics Committee Head and Neck Tumours, Lung, Melanoma and Others	1710 Technologists' Track Mini Courses Technologists Committee	1711 TROP Session Case Report Session 3 Every Day a Discovery with FAP and Novel Targets	08:00-08:30
08:30-09:00	Diagnostic Imaging and Theranostics in Breast Cancer – Old Targets, New Tracers	Debate: Staging Lymphoma – Ann Arbour Outdated and Replaced by Metabolic Tumour Volume?	Case Reading – Dosimetry in SIRT							1710a Mini Course 1 (08:00-09:00)		08:30-09:00
09:00-09:30										Radiotherapy Planning Using PET/CT and PET/MR		09:00-09:30
09:30-10:00	1801 CME 14 Neuroimaging Committee Modern Imaging of Paediatric Epilepsy	1802 Special Track Women's Empowerment Task Force Round Table: Women in Science – Special Focus on Nuclear Medicine	1803 LIPS Interactive Session Translational Molecular Imaging & Therapy + Physics + Radiation Protection + Oncology & Theranostics + Ethics Committee Beta Emitters for Radioguided Surgery – Challenges and Opportunities	1804 M2M Track TROP Session Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee New Therapeutic Radiopharmaceutical	1805 Cutting Edge Science Track TROP Session Dosimetry Committee Clinical Dosimetry III Time & Co	1806 Clinical Oncology Track TROP Session Oncology & Theranostics Committee Radiomics	1807 TROP Session Inflammation & Infection Committee COVID-19: Isn't it over yet?	1808 Featured Session Bone & Joint Committee Unconventional Bone & Joint: FAPI and Beyond	1809 e-Poster Presentations Session 14 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee New Imaging Agents	1710b Mini Course 2 (09:05-10:05) AI in the Technologists Practice	1811 TROP Session Case Report Session 4 FDG and Conventional Imaging: Still Surprising!	09:30-10:00
10:00-10:30										1710c Mini Course 3 (10:15-11:15) Phantoms Management		10:00-10:30
10:30-11:00												10:30-11:00
11:00-11:30												11:00-11:30
11:30-12:00	1901 Closing Session											11:30-12:00
12:00-12:30	Farewell Drink											12:00-12:30

- Plenary Sessions
- CME Sessions
- Special Track
- Learn & Improve Professional Skills (LIPS) Track
- Joint Symposia
- M2M Track
- Cutting Edge Science Track
- Clinical Oncology Track
- Special Symposium
- Featured/TROP Session
- e-Poster Presentations
- Technologists' Track Session

SCIENTIFIC PROGRAMME

INVITED SPEAKER SESSIONS

PLENARY SESSIONS

- 1 Saturday, September 9, 2023 | 18:35–19:35 | Hall A
Highlights Lecture
Presenters: Silvia Morbelli (Italy), Sophie Veldhuijzen van Zanten (Netherlands), Hein Verberne (Netherlands), David Kersting (Germany)
- 2 Sunday, September 10, 2023 | 11:30–13:00 | Hall A
New Imaging Techniques – Jump Aboard or Watch and Wait
Chairpersons: Laetitia Imbert (Nancy, France), Dimitris Visvikis (Brest, France)

 - » Francesca M. Buffa (Milan, Italy): **AI Technology: Living up to Expectations?**
 - » Laetitia Imbert (Nancy, France): **SPECT/CT CZT based Systems: Jump Aboard**
 - » John Dickson (London, UK): **SPECT/CT CZT based Systems: Watch and Wait?**
 - » Antonia Dimitrakopoulou-Strauss (Heidelberg, Germany): **Total Body PET: Opportunities and Challenges**
 - » Axel Rominger (Bern, Switzerland): **Total Body PET: Jump Aboard**
 - » Simon Wan (London, UK): **PET/MR: Is it still worth it?**
 - » May Abdel-Wahab (Vienna, AU): **Innovation and Sustainability in Nuclear Medicine: the IAEA Perspective**
- 3 Monday, September 11, 2023 | 11:30–13:00 | Hall A
Radiotheranostics: What's New?
Chairpersons: Cristina Nanni (Bologna, Italy), Ken Herrmann (Essen, Germany)

 - » Jonathan Strosberg (Tampa, USA): **PRRT in Neuroendocrine Tumours as a Paradigm for Progress in Radiopharmaceuticals: Where are we and where will we be?**
 - » Michael Hofman (Melbourne, AUS): **2023: PSMA state of the art**
 - » Sandra Heskamp (Nijmegen, The Netherlands): **PSMA 2.0**
 - » Andreas Buck (Würzburg, Germany): **CXCR4: Ready for Prime Time!**
 - » Katharina Lücknerath (Essen, Germany): **Targeting the tumour microenvironment: next breakthrough?!**
 - » Lena Unterrainer (Munich, Germany / Los Angeles, USA): **Dark Horses of Theranostics**
- 4 Tuesday, September 12, 2023 | 11:30–13:00 | Hall A
Diagnostic Imaging: Proven Beyond Doubt? (incl. Marie Curie Lecture)
Chairpersons: Valentina Garibotto (Geneva, Switzerland), Pedro Fragoso Costa (Essen, Germany)

 - » Josée Zijlstra (Amsterdam, The Netherlands): **FDG PET imaging and lymphomas: a proven certainty?**
 - » Sofia Carrilho Vaz (Lisbon, Portugal): **PET imaging in every oncological guideline: what is still missing?**
 - » Alexander Drzezga (Cologne, Germany): **Marie Curie Lecture: Impact without a cure: prospective evidence for diagnostic neuroimaging**
 - » Danilo Neglia (Pisa, Italy): **Cardiac imaging: prospective studies and the EURECA registry**
 - » Mathieu Gauthé (Grenoble, France): **Cost effectiveness molecular imaging studies**
 - » Jens Kleesiek (Essen, Germany): **Real world data: an answer to all questions?**

CONTINUING MEDICAL EDUCATION (CME) SESSIONS

- | | |
|----------|---|
| 1 | Sunday, September 10, 2023 08:00–09:30 Hall A
Inflammation & Infection Committee
Infection and Inflammation - New Guidelines |
| 2 | Sunday, September 10, 2023 09:45–11:15 Hall A
Translational Molecular Imaging & Therapy + Oncology and Theranostics + Radiopharmaceutical Sciences Committee
FAP - Moving Towards Therapy |
| 3 | Sunday, September 10, 2023 15:00–16:30 Hall A
Cardiovascular Committee
Nuclear Imaging in Cardiac Amyloidosis - What Else? |
| 4 | Sunday, September 10, 2023 16:45–18:15 Hall A
Oncology and Theranostics Committee
Update in Multiple Myeloma |
| 5 | Monday, September 11, 2023 08:00–09:30 Hall A
Oncology & Theranostics Committee
Will the Microenvironment Become Even More Important in Nuclear Medicine? |
| 6 | Monday, September 11, 2023 09:45–11:15 Hall A
Dosimetry Committee
Understanding Radiobiology for Dosimetry-Guided Molecular Radiotherapy |
| 7 | Monday, September 11, 2023 15:00–16:30 Hall A
Thyroid + Dosimetry Committee
New NM Guidelines of Benign Thyroid Disease |

CONTINUING MEDICAL EDUCATION (CME) SESSIONS

- | | |
|-----------|---|
| 8 | Monday, September 11, 2023 16:45–18:15 Hall A
Oncology & Theranostics Committee
Assessing Response to Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Tumours |
| 9 | Tuesday, September 12, 2023 08:00–09:30 Hall A
Bone and Joint + Physics Committee
Current Bone SPECT/CT (including 360 CZT) |
| 10 | Tuesday, September 12, 2023 09:45–11:15 Hall A
Radiation Protection + Paediatrics Committee and Women's Empowerment Task Force
Radiation Protection in Motherhood and Childhood - What is so Special? |
| 11 | Tuesday, September 12, 2023 15:00–16:30 Hall A
Paediatrics Committee
Paediatric Lymphoma and Update on FDG |
| 12 | Tuesday, September 12, 2023 16:45–18:15 Hall A
Translational Molecular Imaging & Therapy + Oncology & Theranostics + Physics + Technologists Committee
Long Axial Field-of-View PET Scanners - A Copernical Revolution |
| 13 | Wednesday, September 13, 2023 08:00–09:30 Hall A
Translational Molecular Imaging & Therapy + Oncology & Theranostics + Radiopharmaceutical Sciences Committee
Diagnostic Imaging and Theranostics in Breast Cancer - Old Targets, New Tracers |
| 14 | Wednesday, September 13, 2023 09:30–11:15 Hall A
Neuroimaging + Paediatrics Committee
Modern Imaging of Paediatric Epilepsy |

TECHNOLOGISTS' TRACK

The Technologists Committee places a massive effort into delivering the most up-to-date and highest-quality educational initiatives. All sessions of this track are aimed specifically at the technologist audience.

PLENARY SESSIONS

- | | |
|---|---|
| 1 | Saturday, September 9, 2023 18:35–19:35 Hall A
Highlights Lecture |
| 2 | Sunday, September 10, 2023 11:30–13:00 Hall A
New Imaging Techniques – Jump Aboard or Watch and Wait |
| 3 | Monday, September 11, 2023 11:30–13:00 Hall A
Radiotheranostics: What's New? |
| 4 | Tuesday, September 12, 2023 11:30–13:00 Hall A
Diagnostic Imaging: Proven Beyond Doubt?
(incl. Marie Curie Lecture) |

CTE SESSIONS

- | | |
|---|--|
| 1 | Sunday, September 10, 2023 08:00–09:30 Hall K
Technologists Committee / SNMMI
Technologists' Guide Launch –
Gastro Intestinal Molecular Imaging Studies |
| 2 | Sunday, September 10, 2023 09:45–11:15 Hall K
Technologists Committee
Head and Neck Molecular Imaging – Updates and Perspectives |
| 3 | Sunday, September 10, 2023 16:45–18:15 Hall K
Technologists Committee
Patient Care in Nuclear Medicine |
| 4 | Monday, September 11, 2023 09:45–11:15 Hall K
Technologists Committee
Prostate Cancer Theranostics |
| 5 | Monday, September 11, 2023 16:45–18:15 Hall K
Technologists & Thyroid Committee
Cardiac Inflammatory Disease |

- | | |
|---|--|
| 6 | Tuesday, September 12, 2023 08:00–09:30 Hall K
Technologists Committee
Extravasation Incidents Management |
| 7 | Tuesday, September 12, 2023 15:00–16:30 Hall K
Technologists Committee
Molecular Thyroid Imaging - Qualitative and Quantitative Approaches |
| 8 | Tuesday, September 12, 2023 16:45–18:15 Hall K
Technologists & Thyroid Committee
Gynaecological Studies |

IN ADDITION TO THE CTE SESSIONS THE TECHNOLOGISTS' TRACK INCLUDES 3 MINI COURSES:

- | | |
|---|--|
| 1 | Wednesday, September 13, 2023 08:00–09:00 Hall K
Technologists Committee
Radiotherapy Planning Using PET/CT and PET/MR |
| 2 | Wednesday, September 13, 2023 09:05–10:05 Hall K
Technologists Committee
AI in the Technologists Practice |
| 3 | Wednesday, September 13, 2023 10:15–11:15 Hall K
Technologists Committee
Phantoms Management |

TECHNOLOGISTS' ORAL PRESENTATIONS

- | | |
|---|--|
| 1 | Sunday, September 10, 2023 15:00–16:30 Hall K
Technologists Committee
SPECT-CT in Diagnosis and Therapy |
| 2 | Monday, September 11, 2023 08:00–09:30 Hall K
Technologists Committee
All about PET-CT! |
| 3 | Tuesday, September 12, 2023 09:45–11:15 Hall K
Technologists Committee
NM Technologists: Competencies and Training |

TECHNOLOGISTS' e-POSTER PRESENTATIONS

- | | |
|---|---|
| 1 | Monday, September 11, 2023 15:00–16:30 Hall K
Technologists Committee
Technologists' e-Poster Presentations Session |
|---|---|

SPECIAL TRACK

- 1 Sunday, September 10, 2023 | 08:00–09:30 | Hall D (Arena)
Cardiovascular Committee
Debate: Myocardial Perfusion Imaging after ISCHEMIA Trial
- 2 Sunday, September 10, 2023 | 09:45–11:15 | Hall D (Arena)
Thyroid Committee
Challenge the Expert: Integrated Diagnostics of Thyroid Disease
- 3 Sunday, September 10, 2023 | 15:00–16:30 | Hall D (Arena)
Oncology & Theranostics Committee
Challenge the Expert: Risk in Diagnostic and Therapeutic Nuclear Medicine
- 4 Sunday, September 10, 2023 | 16:45–18:15 | Hall D (Arena)
Dosimetry Committee
Challenge the Expert: Dosimetry Live
- 5 Monday, September 11, 2023 | 08:00–09:30 | Hall D (Arena)
Neuroimaging Committee
Debate: What is the Best Tracer for Molecular Brain Tumour Imaging?
- 6 Monday, September 11, 2023 | 09:45–11:15 | Hall D (Arena)
Translational Molecular Imaging & Therapy + Radiopharmaceutical Sciences + Oncology & Theranostics Committee
Round Table: Dialogue with the Treating Physician
- 7 Monday, September 11, 2023 | 15:00–16:30 | Hall D (Arena)
EANM Sanjiv Sam Gambhir Award – Compete and Win!
- 8 Monday, September 11, 2023 | 17:15–18:15 | Hall D (Arena)
Physics Committee
Debate: AI in Nuclear Medicine: Fear or Embrace?
- 9 Tuesday, September 12, 2023 | 08:00–09:30 | Hall D (Arena)
Radiation Protection Committee
Round Table: Establishing and Running a Theranostics Centre in a Clinical Setting
- 10 Tuesday, September 12, 2023 | 09:45–11:15 | Hall D (Arena)
Physics + Oncology & Theranostics Committee
Debate: Whole Body Parametric Imaging
- 11 Tuesday, September 12, 2023 | 15:00–16:30 | Hall D (Arena)
Neuroimaging Committee
Challenge the Expert: Amyloid or Tau PET – What First in Alzheimer Dementia Patients? Germany versus Italy
- 12 Tuesday, September 12, 2023 | 16:45–18:15 | Hall D (Arena)
Bone & Joint + Cardiovascular Committee
Debate: NaF PET in Cardiology and MSK: Pro or Cons?
- 13 Wednesday, September 13, 2023 | 08:00–09:30 | Hall D (Arena)
Oncology & Theranostics Committee
Debate: Staging Lymphoma – Ann Arbour Outdated and Replaced by Metabolic Tumour Volume?
- 14 Wednesday, September 13, 2023 | 09:45–11:15 | Hall D (Arena)
EANM Women's Empowerment Initiative
Round Table: Women in Science – Special Focus on Nuclear Medicine

JOINT SYMPOSIA

- 1 Sunday, September 10, 2023 | 09:45–11:15 | Hall F2
Cardiovascular + Inflammation & Infection Committee + EACVI
PET in Valvular Diseases – All In!
- 2 Sunday, September 10, 2023 | 15:00–16:30 | Hall F2
Oncology & Theranostics Committee / EORTC
Nuclear Medicine Imaging of the Immune System
- 3 Monday, September 11, 2023 | 15:00–16:30 | Hall F2
Translational Molecular Imaging & Therapy + Oncology & Theranostics + Physics Committee / EAU
Metastases Directed Prostate Cancer Surgery – Translational Challenges and Possibilities
- 4 Tuesday, September 12, 2023 | 08:00–09:30 | Hall F2
Dosimetry Committee + ESTRO
Dosimetry in Different Modalities – Where We Are and Where We Want to Be
- 5 Tuesday, September 12, 2023 | 15:00–16:30 | Hall F2
Oncology & Theranostics Committee + ESMO
Prostate Cancer Theranostics: Where Do We Go?
- 6 Wednesday, September 13, 2023 | 08:00–09:30 | Hall F2
Neuroimaging Committee + EAN
Progress in Multimodal Imaging of Parkinson's Disease

SPECIAL SYMPOSIA

- 1 Sunday, September 10, 2023 | 16:45–18:15 | Hall G1
EANM/EARL
Harmonisation and Accreditation Accelerate Research and Clinical Translation
- 2 Monday, September 11, 2023 | 08:00–09:30 | Hall F2
Inflammation & Infection Committee
Usefulness of PET in the Evaluation of Inflammatory Rheumatism
- 3 Tuesday, September 12, 2023 | 09:45–11:15 | Hall G1
EANM / EJMNI
You, the EANM and the EJMNI
- 4 Tuesday, September 12, 2023 | 08:00–09:30 | Hall G1
Lung Scintigraphy for Pulmonary Embolism Diagnosis and Long-Term Management

EU POLICY SYMPOSIA

- 1 Tuesday, September 12, 2023 | 15:00–16:30 | Hall G1
Policy & Regulatory Affairs Committee
Supply & Shortages of Radiopharmaceuticals
- 2 Tuesday, September 12, 2023 | 16:45–18:15 | Hall G1
Policy & Regulatory Affairs Committee
Regulatory Challenges of Radiopharmaceuticals

LEARN & IMPROVE PROFESSIONAL SKILLS (LIPS) TRACK

- | | |
|-----------|--|
| 1 | Sunday, September 10, 2023 08:00–09:30 Hall E1
Oncology & Theranostics Committee
Novelties in Radionuclide Therapy |
| 2 | Sunday, September 10, 2023 09:45–11:15 Hall E1
Radiation Protection + Physics Committee / EFOMP
Careers in Radiation Protection |
| 3 | Sunday, September 10, 2023 15:00–16:30 Hall E1
Thyroid Committee
Rational Use of PET/CT with 18F-FDG in DTC |
| 4 | Sunday, September 10, 2023 16:45–18:15 Hall E1
Oncology & Theranostics Committee
Residents for Residents |
| 5 | Monday, September 11, 2023 08:00–09:30 Hall E1
Cardiovascular Committee
Challenges in MBF Quantification with PET and SPECT |
| 6 | Monday, September 11, 2023 09:45–11:15 Hall E1
Neuroimaging + Cardiovascular + Inflammation & Infection Committee
Molecular Imaging to Solve the Problem of Long COVID |
| 7 | Monday, September 11, 2023 15:00–16:30 Hall E1
Inflammation & Infection Committee
Tips and Tricks in the Study of Prosthesis Infection |
| 8 | Monday, September 11, 2023 16:45–18:15 Hall E1
Cardiovascular Committee
Stiff to Sweet – Infiltration and Inflammation |
| 9 | Tuesday, September 12, 2023 08:00–09:30 Hall E1
Paediatrics Committee
Paediatric Nephro-Urology – Beyond Hydro-Nephrosis |
| 10 | Tuesday, September 12, 2023 09:45–11:15 Hall E1
Neuroimaging Committee
The Sunrise of Alpha-Synuclein in Vivo Brain Imaging |
| 11 | Tuesday, September 12, 2023 15:00–16:30 Hall E1
Bone & Joint Committee
Pitfalls and Common Bony Findings in PET-CT/MRI using Novel Tracers |
| 12 | Tuesday, September 12, 2023 16:45–18:15 Hall E1
Neuroimaging + Inflammation & Infection Committee
The Role of FDG PET in the Diagnosis of Auto-Immune Encephalitis |
| 13 | Wednesday, September 13, 2023 08:00–09:30 Hall E1
Case Reading - Dosimetry in SIRT |
| 14 | Wednesday, September 13, 2023 09:45–11:15 Hall E1
Beta Emitters for Radioguided Surgery - Challenges and Opportunities |

CLINICAL ONCOLOGY TRACK – TROP & FEATURED SESSIONS:

- | | |
|-------------|---|
| 206 | Sunday, September 10, 2023 08:00 – 09:30 Hall C
Oncology & Theranostics Committee – TROP Session
Prostate Cancer Staging |
| 306 | Sunday, September 10, 2023 09:45 – 11:15 Hall C
Oncology & Theranostics Committee – FEATURED Session
Haematological Disease |
| 506 | Sunday, September 10, 2023 15:00 – 16:30 Hall C
Oncology & Theranostics Committee – TROP Session
Gastrointestinal Malignancies |
| 606 | Sunday, September 10, 2023 16:45 – 18:15 Hall C
Oncology & Theranostics Committee – TROP Session
Neuroendocrine Tumours Treatment |
| 706 | Monday, September 11, 2023 08:00 – 09:30 Hall C
Oncology & Theranostics Committee – TROP Session
Neuroendocrine Tumours – Diagnosis |
| 806 | Monday, September 11, 2023 09:45 – 11:15 Hall C
Oncology & Theranostics Committee – FEATURED Session
FAP Imaging |
| 1006 | Monday, September 11, 2023 15:00 – 16:30 Hall C
Oncology & Theranostics Committee – FEATURED Session
Melanoma |
| 1106 | Monday, September 11, 2023 16:45 – 18:15 Hall C
Oncology & Theranostics Committee – TROP Session
Prostate Cancer Biochemical Recurrence |
| 1206 | Tuesday, September 12, 2023 08:00 – 09:30 Hall C
Oncology & Theranostics Committee – TROP Session
Gynaecological Malignancies |
| 1306 | Tuesday, September 12, 2023 09:45 – 11:15 Hall C
Oncology & Theranostics Committee – TROP Session
Lung |
| 1506 | Tuesday, September 12, 2023 15:00 – 16:30 Hall C
Oncology & Theranostics Committee – TROP Session
Prostate Cancer Treatment |
| 1606 | Tuesday, September 12, 2023 16:45 – 18:15 Hall C
Oncology & Theranostics Committee – TROP Session
Head and Neck Imaging |
| 1706 | Wednesday, September 13, 2023 08:00 – 09:30 Hall C
Oncology & Theranostics Committee – TROP Session
Localised Treatments |
| 1806 | Wednesday, September 13, 2023 09:45 – 11:15 Hall C
Oncology & Theranostics Committee – TROP Session
Radiomics |

CUTTING EDGE SCIENCE TRACK – TROP & FEATURED SESSIONS

205	Sunday, September 10, 2023 08:00 – 09:30 Hall B Physics Committee – TROP Session Quality Control, Performance, Standardisation
305	Sunday, September 10, 2023 09:45 – 11:15 Hall B Physics Committee – FEATURED Session Radiomics
505	Sunday, September 10, 2023 15:00 – 16:30 Hall B Dosimetry Committee – TROP Session From Cells to Human via the Fish
605	Sunday, September 10, 2023 16:45 – 18:15 Hall B Physics Committee – TROP Session Segmentation and Denoising
705	Monday, September 11, 2023 08:00 – 09:30 Hall B Physics Committee – FEATURED Session Imaging Guided Surgery
805	Monday, September 11, 2023 09:45 – 11:15 Hall B Physics Committee – TROP Session Image Reconstruction and Data Corrections
1005	Monday, September 11, 2023 15:00 – 16:30 Hall B Dosimetry Committee – TROP Session ¹⁷⁷ Lu / ²²⁵ Ac and ¹⁶¹ Tb RLT
1105	Monday, September 11, 2023 16:45 – 18:15 Hall B Radiation Protection Committee – TROP Session Current Issues of Radiation Protection
1205	Tuesday, September 12, 2023 08:00 – 09:30 Hall B Physics Committee – TROP Session Total Body PET Methods
1305	Tuesday, September 12, 2023 09:45 – 11:15 Hall B Physics Committee – TROP Session Quantitative SPECT/CT Imaging
1505	Tuesday, September 12, 2023 15:00 – 16:30 Hall B Physics Committee – TROP Session AI Methods and Applications
1605	Tuesday, September 12, 2023 16:45 – 18:15 Hall B Physics Committee – TROP Session Data Analysis
1705	Wednesday, September 13, 2023 08:00 – 09:30 Hall B Physics Committee – FEATURED Session Dynamic Imaging
1805	Wednesday, September 13, 2023 09:45 – 11:15 Hall B Dosimetry Committee – TROP Session Clinical Dosimetry III-Time & Co

M2M TRACK – TROP & FEATURED SESSIONS

204	Sunday, September 10, 2023 08:00 – 09:30 Hall E2 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session At the Nucleus: Radionuclide Production
304	Sunday, September 10, 2023 09:45 – 11:15 Hall E2 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session Validating Methodology: In Vitro and in Vivo Models
504	Sunday, September 10, 2023 15:00 – 16:30 Hall E2 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session Radioligand Therapy – New and Old Targets
604	Sunday, September 10, 2023 16:45 – 18:15 Hall E2 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session Novel Imaging Targets in Oncology
704	Monday, September 11, 2023 08:00 – 09:30 Hall E2 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session Imaging Inflammatory Processes in Cardiovascular Disease
804	Monday, September 11, 2023 09:45 – 11:15 Hall E2 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session TME and Therapy: Direct Targeting and Secondary Effects
1004	Monday, September 11, 2023 15:00 – 16:30 Hall E2 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session New Roads Towards FAP-Directed Theranostics
1104	Monday, September 11, 2023 16:45 – 18:15 Hall E2 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session Efficient Radiolabelling: Key for Clinical Translation
1204	Tuesday, September 12, 2023 08:00 – 09:30 Hall E2 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session Imaging the Brain from all Angles
1304	Tuesday, September 12, 2023 09:45 – 11:15 Hall E2 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session Emerging Theranostic Concepts
1504	Tuesday, September 12, 2023 15:00 – 16:30 Hall E2 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session Imaging the Components of the TME
1604	Tuesday, September 12, 2023 16:45 – 18:15 Hall E2 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session Understanding and Improving RLT
1704	Wednesday, September 13, 2023 08:00 – 09:30 Hall E2 Dosimetry Committee – TROP Session Clinical Dosimetry II – Tutti Frutti
1804	Wednesday, September 13, 2023 09:45 – 11:15 Hall E2 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee – TROP Session New Therapeutic Radiopharmaceuticals

FURTHER ORAL PRESENTATIONS – TROP & FEATURED SESSIONS

- 207** Sunday, September 10, 2023 | 08:00 – 09:30 | Hall F1
Neuroimaging Committee – FEATURED Session
Methods in NeuroImaging: Spotlight on Brain Connectivity
- 208** Sunday, September 10, 2023 | 08:00 – 09:30 | Hall F2
Paediatrics Committee – TROP Session
Paediatric PET/CT & PET/MR
- 307** Sunday, September 10, 2023 | 09:45 – 11:15 | Hall F1
Neuroimaging Committee – TROP Session
Amyloid, Tau and More in Neurodegenerative Disorders
- 507** Sunday, September 10, 2023 | 15:00 – 16:30 | Hall F1
Paediatrics Committee – TROP Session
Adults General Nuclear Medicine
- 607** Sunday, September 10, 2023 | 16:45 – 18:15 | Hall F1
Cardiovascular Committee- TROP Session
Functional Imaging, Plaque and Total-Body PET
- 608** Sunday, September 10, 2023 | 16:45 – 18:15 | Hall F2
Inflammation & Infection Committee – TROP Session
Infection and Inflammation Imaging: New Frontiers
- 707** Monday, September 11, 2023 | 08:00 – 09:30 | Hall F1
Paediatrics Committee – TROP Session
Neuroblastoma & Non-PET Paediatric Studies
- 807** Monday, September 11, 2023 | 09:45 – 11:15 | Hall F1
Cardiovascular Committee – TROP Session
Clinical Perfusion Imaging with PET
- 808** Monday, September 11, 2023 | 09:45 – 11:15 | Hall F2
Thyroid Committee – FEATURED Session
Iodine-131 Therapy and Beyond in Differentiated Thyroid Cancer
- 1007** Monday, September 11, 2023 | 15:00 – 16:30 | Hall F1
Neuroimaging Committee – TROP Session
Imaging Neurotransmission in Movement Disorders
- 1107** Monday, September 11, 2023 | 16:45 – 18:15 | Hall F1
Inflammation & Infection Committee – TROP Session
Vasculitis and Endocarditis: Current and New Evidence

FURTHER ORAL PRESENTATIONS – TROP & FEATURED SESSIONS

- 1108** Monday, September 11, 2023 | 16:45 – 18:15 | Hall F2
Thyroid Committee – TROP Session
Iodine-131 Therapy in Differentiated Thyroid Cancer: Present and Future Perspective
- 1207** Tuesday, September 12, 2023 | 08:00 – 09:30 | Hall F1
Neuroimaging Committee – FEATURED Session
Breadth of Tracers and Approaches in Neuro-Oncology
- 1307** Tuesday, September 12, 2023 | 09:45 – 11:15 | Hall F1
Cardiovascular Committee – TROP Session
Plaque, Fibrosis and Cardio-Oncology
- 1308** Tuesday, September 12, 2023 | 09:45 – 11:15 | Hall F2
Thyroid Committee – TROP Session
¹⁸F-FDG and Novel Tracers in the Diagnostic Management of Patients with Thyroid Cancers
- 1507** Tuesday, September 12, 2023 | 15:00 – 16:30 | Hall F1
Cardiovascular Committee – TROP Session
Perfusion
- 1607** Tuesday, September 12, 2023 | 16:45 – 18:15 | Hall F1
Neuroimaging Committee – TROP Session
New PET Tracers for Brain Imaging
- 1608** Tuesday, September 12, 2023 | 16:45 – 18:15 | Hall F2
Thyroid Committee – TROP Session
Nuclear Medicine Imaging in Thyroid and Parathyroid Disorders
- 1707** Wednesday, September 12, 2023 | 08:00 – 09:30 | Hall F1
Cardiovascular Committee – TROP Session
Heart Failure, Sarcoidosis and Amyloidosis
- 1807** Wednesday, September 12, 2023 | 09:45 – 11:15 | Hall F1
Inflammation & Infection Committee – TROP Session
COVID-19: Isn't it over yet?
- 1808** Wednesday, September 12, 2023 | 09:45 – 11:15 | Hall F2
Bone & Joint Committee – FEATURED Session
COVID-19: Isn't it over yet?

E-POSTER PRESENTATIONS

- | | |
|-------------|---|
| 209 | Sunday, September 10, 2023 08:00 – 09:30 Hall G2
Oncology & Theranostics Committee
Neuroendocrine Tumours and Gynaecological Malignancies |
| 309 | Sunday, September 10, 2023 09:45 – 11:15 Hall G2
Paediatrics Committee
Paediatric Nuclear Medicine & Adults General Nuclear Medicine |
| 509 | Sunday, September 10, 2023 15:00 – 16:30 Hall G2
Inflammation & Infection Committee
More on Infection and Inflammation Imaging |
| 609 | Sunday, September 10, 2023 16:45 – 18:15 Hall G2
Thyroid Committee
Thyroid and Parathyroid Disease |
| 709 | Monday, September 11, 2023 08:00 – 09:30 Hall G2
Physics Committee
SPECT/CT, PET/CT, PET/MR Quantitating Imaging |
| 809 | Monday, September 11, 2023 09:45 – 11:15 Hall G2
Oncology & Theranostics Committee
Prostate Cancer |
| 1009 | Monday, September 11, 2023 15:00 – 16:30 Hall G2
Cardiovascular Committee
Cardiovascular Imaging e-Posters |
| 1109 | Monday, September 11, 2023 16:45 – 18:15 Hall G2
Neuroimaging Committee
E-Poster Neurology: It's in the Brain! |
| 1209 | Tuesday, September 12, 2023 08:00 – 09:30 Hall G2
Physics Committee
Artificial Intelligence and Radiomics |
| 1309 | Tuesday, September 12, 2023 09:45 – 11:15 Hall G2
Oncology & Theranostics Committee
Haematological and Abdominal Malignancies / localised Treatments |
| 1509 | Tuesday, September 12, 2023 15:00 – 16:30 Hall G2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee
Novel Therapeutic Approaches |
| 1609 | Tuesday, September 12, 2023 16:45 – 18:15 Hall G2
Dosimetry Committee
Dosimetry Symphony |
| 1709 | Wednesday, September 13, 2023 08:00 – 09:30 Hall G2
Oncology & Theranostics Committee
Head and Neck Tumours, Lung, Melanoma and Others |
| 1809 | Wednesday, September 13, 2023 09:45 – 11:15 Hall G2
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee
New Imaging Agents |

CASE REPORT SESSIONS

- | | |
|----------|---|
| 1 | Monday, September 11, 2023 15:00–16:30 Hall G1
Learning from Single Cases in Theranostics |
| 2 | Monday, September 11, 2023 16:45–18:15 Hall G1
Successful Molecular Targeting in Oncology |
| 3 | Wednesday, September 13, 2023 08:00–09:30 Hall G1
Every Day a Discovery with FAP and Novel Targets |
| 4 | Wednesday, September 13, 2023 09:45–11:15 Hall G1
FDG and Conventional Imaging: Still Surprising! |

AWARDS

The EANM will bestow several awards throughout the EANM'23.

EANM MARIE CURIE AWARD

Each year, the prestigious EANM Marie Curie Award honours the best abstract submission of the year. This year, the Marie Curie Award will be granted by the EANM President 2023-2024, Rudi Dierckx, during the EANM Congress Opening Ceremony. **Details: Saturday, September 9, 2023 - 18:00–18:35 CEST – Hall A.**

EANM YOUNG AUTHORS' AWARD

(Kindly supported by United Imaging Healthcare)



The EANM Young Authors' Award aims to support young and talented nuclear medicine investigators. This year, three promising young authors were selected for their outstanding abstracts. The awardees will be able to present their results during the Congress. **Details: Monday, September 11, 2023 - 14:30–15:00 – Exhibition Hall X4, Stand 420**

EANM SANJIV SAM GAMBHIR YOUNG INVESTIGATOR AWARD

(Kindly supported by Telix Pharmaceuticals)



The EANM Sanjiv Sam Gambhir Young Investigator Award aims to encourage collaboration between young professionals from all around the world. The winner of the EANM Sanjiv Sam Gambhir Young Investigator Award will be offered a 3-month visitorship at Stanford University. The jury has selected six candidates, who will fight for this prestigious award in a dedicated session. **Details: Monday, September 11, 2023 - 15:00–16:30 CEST – Hall D (Arena).**

EANM TECHNOLOGISTS' AWARD

(Kindly supported by United Imaging Healthcare)



The purpose of the Technologists' Award is to encourage Nuclear Medicine Technologists to present the abstract of their research project. Four EANM Technologists' Awards will be granted during the EANM'23. **Details: Tuesday, September 12, 2023 - 16:30 CEST – Hall K**

EJNMMI AWARDS

Once again, this year, the EANM and Springer will honour outstanding articles published across the whole journal family with the EJNMMI Awards. **Details: Winners will be notified directly.**



3rd PRECLINICAL MODELS IMAGING WORKSHOP

16 – 20 October 2023, Athens Greece

Once per year, in **BIOEMTECH CRO Laboratories**, we open up our doors and meet with the preclinical community, to **share methodologies, experiences & knowledge**. We welcome **renowned speakers** from the Academia & Industry and share our expertise in our **GLP preclinical laboratories**.

The main points covered during the **5-day Workshop** are the following:

- Multimodal *in vivo* imaging (SPECT/PET/CT/optical) & analysis
- Radiochemistry & radiation protection
- Targeted radioisotopic therapy
- Selected preclinical models: Breast cancer (4T1 & MDA-MB-231) and Gut fibrosis
- Animal handling & model development
- Legislation, ethics and SOPs
- Translational aspects and the route to the clinics
- **Hands-on** sessions on animal handling, radiochemistry, *in vivo* imaging and image post processing.



Program & Registrations

This year, the scientific program is enriched with a **leadership workshop** on team management, **mountain hiking** and **yoga morning classes** (optional sessions).

28 speakers from
Academia & Industry

2 full days of hands-on
sessions in our GLP Labs

3 new animal models
each year

o **Fees:** 800 € early-bird (until July 20th) | 950 € (after July 20th) | 750 € Student | 450 € Virtual



Oral Sessions

OC

Saturday, September 9, 2023, 18:00 - 18:35
Hall A

Opening Ceremony including Awards Ceremony

OP-001
Opening Ceremony including Awards Ceremony
V. Garibotto;
University Hospitals and University of Geneva, Geneva, SWITZERLAND.

101

Saturday, September 9, 2023, 18:35 - 19:35
Hall A

Plenary 1: Highlights Lecture

OP-002
Highlight Lecture
S. Veldhuijzen van Zanten;
Erasmus Medical Center, Amsterdam, NETHERLANDS.

OP-003
Highlight Lecture
S. Morbelli;
San Martino Hospital, University of Genoa, Genoa, ITALY.

OP-004
Highlight Lecture
D. Kersting;
University Hospital, Essen, Department of Nuclear Medicine, Essen, GERMANY.

OP-005
Highlight Lecture
H. Verberne;
University of Amsterdam, NETHERLANDS.

201

Sunday, September 10, 2023, 08:00 - 09:30
Hall A

CME 1 - Inflammation & Infection Committee: Infection and Inflammation - New Guidelines

OP-006
New Guidelines about Infection
G. Abikhzer;
Nuclear Medicine, Jewish General Hospital, Quebec, CANADA.

OP-007
New Guidelines about Inflammation
O. Gheysens;
Nuclear Medicine Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, BELGIUM.

OP-008
FUO Guidelines
D. Albano;
Nuclear Medicine Department, Università degli Studi di Brescia, ASST Spedali Civili of Brescia, Brescia, ITALY.

OP-009
Diabetic Foot Guidelines
R. Chakravartthy;
Nuclear Medicine department, Kings College London Hospital Trust, Shrewsbury, UNITED KINGDOM.

202

Sunday, September 10, 2023, 08:00 - 09:30
Hall D (Arena)

Debate 1 - Cardiovascular Committee: Myocardial Perfusion Imaging after ISCHEMIA

OP-010
Anatomical imaging with coronary CTA is all I need!
A. Rossi;
University Hospital of Zurich, Zurich, SWITZERLAND.

OP-011
Myocardial perfusion imaging: let's go with the flow!
M. Mallah;
Houston Methodist Academic Institute, Houston, UNITED STATES OF AMERICA.

OP-012
Debate

203

Sunday, September 10, 2023, 08:00 - 09:30
Hall E1

LIPS Session 1 - Oncology & Theranostics Committee: Novelties in Radionuclide Therapy

OP-013
Emerging radiopharmaceuticals in radionuclide therapy
L. Unterrainer;
LMU Munich, Department of Nuclear Medicine, Munich, GERMANY.

OP-014
Intra-arterial Peptide Receptor Radionuclide Therapy
A. Braat;
University Medical Center Utrecht, Department of Radiology and Nuclear Medicine, Utrecht, GERMANY.

OP-015
Pancreatic cancer treatment with P-32
Z. Win;
Imperial College Healthcare NHS Trust Hammersmith, St Mary's and Charing Cross Hospitals, Department of Nuclear Medicine, London, UNITED KINGDOM.

204

Sunday, September 10, 2023, 8:00 AM - 9:30 AM
Hall E2

M2M Track - TROP Session: Translational Molecular Imaging & Therapy Committee + Radiopharmaceutical Sciences Committee: At the Nucleus: Radionuclide Production

OP-016
Terbium-149 production: a pragmatic view of its clinical potential
N. van der Meulen¹, P. V. Grundler¹, Z. Talip¹, C. Favaretto¹, C. C. Hillhouse¹, U. Koester², K. Johnston³, R. Schibli¹, R. Eichler¹, C. Mueller¹;
¹Paul Scherrer Institut, Villigen, SWITZERLAND, ²ILL, Grenoble, FRANCE, ³CERN, Geneva, SWITZERLAND.

OP-017
Small-scale production of ¹⁶¹Tb for preclinical studies
M. Skálová, J. Kozempel, M. Vlk, K. Ondrák Fialová, L. Ondrák;
Department of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague, CZECH REPUBLIC.

OP-018
Separation and Purification of ²²⁵Ac for Targeted Alpha Therapy Radiopharmaceuticals
E. Yalcintas Bethune, J. F. Camacaro, S. Chatterjee, C. P. Dunckley, H. A. Fitzgerald, E. Harman, A. L. Lakes, Z. Liao, L. M. Lilley, R. C. Ludwig, K. M. McBride, A. Younes;
TerraPower LLC, Bellevue, WA, UNITED STATES OF AMERICA.

OP-019
Cyclotron based production of ⁶⁴Cu/⁶⁷Cu diagnostic and theragnostic pair
J. Lee, J. Park;
Korea Atomic Energy Research Institute, Jeollabuk-do Jeongeup-si, KOREA, REPUBLIC OF.

OP-020
Production of Lanthanum-133 via the ¹³⁴Ba(p,2n)¹³³La Nuclear Reaction with High Radionuclide Purity for Theranostic Purposes
S. Brühlmann^{1,2}, M. Kreller¹, H. Pietzsch¹, K. Kopka^{1,2}, C. Mamat^{1,2}, M. Walther¹, F. Reissig¹;
¹Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY, ²Technische Universität Dresden, Dresden, GERMANY.

OP-021
Neutron Capture-Based Production via Power Reactor and Potential Market Penetration
C. Horne¹, J. Quirt¹, M. Flagg²;
¹Laurentis Energy Partners (subsidiary of Ontario Power Generation), Pickering, ON, CANADA, ²BWXT Medical, Kanata, ON, CANADA.

OP-022
Testing new resins for ²²⁵Ac separation
O. Lebeda¹, K. Ondrák Fialová¹, L. Ondrák¹, S. Happe², J. Ráliš¹, M. Kleinová¹, I. Dovyhy²;
¹Nuclear Physics Institute of the CAS, Husinec-Rez, CZECH REPUBLIC, ²TRISKEM International, Bruz, FRANCE.

OP-023
Production of gallium-68 using IBA and GE liquid target system - comparison and optimization
A. Uhlending, V. Hugenberg;
Institute of Radiology, Nuclear Medicine and Molecular Imaging, Heart and Diabetes Center North Rhin, Bad Oeynhausen, GERMANY.

OP-024
Radium targets for cyclotron production of Ac-225 in view of targeted alpha therapy
A. Kellerbauer¹, R. Malmbeck¹, C. De Almeida Carrapico¹, E. Jajcisinova^{1,2}, Rachel Eloirdi¹, Ondrej Lebeda³, Alfred Morgenstern¹;
¹European Commission, Joint Research Centre, Karlsruhe, GERMANY, ²KU Leuven, Leuven, BELGIUM, ³Nuclear Physics Institute of the CAS, Řež, CZECH REPUBLIC.

205

Sunday, September 10, 2023, 8:00 AM - 9:30 AM
Hall B

Cutting Edge Science Track - TROP Session: Quality Control, Performance, Standardisation

OP-025

An academic/industrial PET raw data standardisation initiative

K. Thielemans¹, A. L. Kesner², E. Asma³, J. Cabello⁴, M. J. Cook⁵, M. Hansen⁶, J. Jones⁴, N. A. Karakatsanis⁷, E. K. Leung⁸, P. Markiewicz⁹, S. Prevrhal¹⁰, A. Rahmim¹¹, B. Saboury¹², J. Stairs⁶, S. Stute¹³, H. Tashima¹⁴, G. Wells¹⁵;
¹Institute of Nuclear Medicine, London, UNITED KINGDOM, ²Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, ³Canon Medical Research UNITED STATES OF AMERICA, Vernon Hills, IL, UNITED STATES OF AMERICA, ⁴Siemens Medical Solutions UNITED STATES OF AMERICA, Inc, Knoxville, TN, UNITED STATES OF AMERICA, ⁵GE Healthcare, Waukesha, IL, UNITED STATES OF AMERICA, ⁶Microsoft Research, Redmond, WA, UNITED STATES OF AMERICA, ⁷Weill Cornell Medical College, Cornell University, New York, NY, UNITED STATES OF AMERICA, ⁸UIH America, Inc., Houston, TX, UNITED STATES OF AMERICA, ⁹University College London, London, UNITED KINGDOM, ¹⁰Philips Research, Hamburg, GERMANY, ¹¹University of British Columbia, Vancouver, BC, CANADA, ¹²National Institutes of Health (NIH) - Clinical Center, Bethesda, MD, UNITED STATES OF AMERICA, ¹³Nantes University Hospital, CRCI2NA, Nantes, FRANCE, ¹⁴National Institutes for Quantum Science and Technology, Chiba, JAPAN, ¹⁵University of Ottawa Heart Institute, Ottawa, ON, CANADA.

OP-026

A reference-free PET quality metric using multi-scale sharpness index

F. Moradi¹, P. Gurunath Bharathi¹, M. Khalighi¹, K. Su², M. Spangler-Bickel³;
¹Stanford University, Stanford, CA, UNITED STATES OF AMERICA, ²GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA.

OP-027

Mitigating SUV Uncertainties Using Total Body PET Imaging

C. L. C. Smith^{1,2}, G. J. C. Zwezerijnen^{1,2}, M. den Hollander¹, J. Weijland¹, M. Yaqub^{1,2}, R. Boellaard^{1,2};
¹Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Boelelaan 1117, Amsterdam, NETHERLANDS, ²Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, NETHERLANDS.

OP-028

Calibration Procedures for Radionuclide Calibrators to Achieve Traceable Activity Measurements for Lu-177

V. Reijonen¹, P. Tori², M. Tenhunen¹;
¹Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, FINLAND, ²STUK - Radiation and Nuclear Safety Authority, Helsinki, FINLAND.

OP-029

Accuracy of absolute quantification for high count rate holmium-166 SPECT/CT

L. E. L. Westlund Gotby¹, D. Lobeek¹, J. Roosen¹, M. de Bakker¹, M. W. Konijnenberg^{1,2}, J. F. W. Nijssen¹;
¹Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS, ²Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, NETHERLANDS.

OP-030

Design and Development of a Phantom for Commissioning and Quality Assurance of Intraoperative Gamma Probes

A. Stapleton, O. Berry, J. Grey, R. Harding, L. McKinley, E. Norman;
Royal Surrey County Hospital, Guildford, UNITED KINGDOM.

OP-031

Design and manufacture of a 3D printed phantom for PET quality control

J. Robinson^{1,2}, D. Rushforth^{1,2}, I. Murray^{1,2}, G. Flux^{1,2}, J. Gear^{1,2};
¹The Royal Marsden NHS Foundation Trust, Sutton, UNITED KINGDOM, ²The Institute of Cancer Research, London, UNITED KINGDOM.

OP-032

Automatic trending and analysis of SPECT daily quality control data with optical character recognition AI

T. Pan, S. Ding, O. Mawlawi;
The University of Texas, M.D. Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA

OP-033

AI-Based Automatic Positioning in a Digital-BGO PET/CT Scanner: Efficacy and Impact

J. Kennedy^{1,2}, T. Palchan-Hazan¹, Z. Keidar^{1,2};
¹Rambam - Health Care Campus, Haifa, ISRAEL, ²Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, ISRAEL.

206

Sunday, September 10, 2023, 8:00 AM - 9:30 AM
Hall C

Clinical Oncology Track - TROP Session: Prostate Cancer Staging

OP-034

Association of aggressive prostate cancer features on whole-mount pathology with quantitative measures on PSMA PET

I. Sonni^{1,2}, D. H. Kim¹, A. Ter-Pogossyan¹, T. Grogan¹, N. Barroso¹, P. Ahuja¹, J. Calais¹, A. Sisk¹, S. Raman¹;
¹University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, ²Università Magna Graecia, Catanzaro, ITALY.

OP-035

The role of PSMA PET/CT in the diagnosis of clinically significant prostate cancer

A. Kibar¹, O. E. Sahin¹, S. Asa¹, M. Demirebilek², S. Bilgic³, B. Onal⁴, L. Kabasakal¹;
¹Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Urology, Istanbul, TÜRKIYE, ³Sirnak State Hospital, Department of Nuclear Medicine, Sirnak, TÜRKIYE.

OP-036

In-depth analysis of PSMA PET/CT and mpMRI discrepancies in prostate cancer detection with histopathology gold standard

I. Sonni^{1,2}, S. Doddipalli¹, M. Deol¹, D. Ban¹, H. Kim¹, T. Grogan¹, N. Barroso¹, P. Ahuja¹, Y. Zong¹, A. Sisk¹, J. Calais¹, R. Reiter¹, S. Raman¹;
¹University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, ²Università Magna Graecia, Catanzaro, ITALY.

OP-037

Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial

M. Hofman¹, V. Kasivisvanathan¹, E. Link¹, N. Lawrentschuk¹, J. O'Brien¹, J. P. Buteau¹, M. Roberts², R. Francis³, C. Tang⁴, I. Vela⁵, P. Thomas⁶, N. Rutherford⁷, J. M. Martin⁸, M. Frydenberg⁸, R. Shaker⁹, L. Wong¹⁰, K. Taubman¹¹, S. Lee¹², E. Hsiao¹³, M. Nottage¹⁴, I. Kirkwood¹⁵, A. Iravani¹, S. Williams¹, D. Murphy¹;
¹Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ²Royal Brisbane and Women's Hospital, Brisbane, AUSTRALIA, ³The University of Western Australia, Perth, AUSTRALIA, ⁴Sir Charles Gairdner Hospital, Perth, AUSTRALIA, ⁵Princess Alexandra Hospital, Brisbane, AUSTRALIA, ⁶Royal Brisbane and Women's Hospital, Brisbane, AUSTRALIA, ⁷Hunter New England Health, Newcastle, AUSTRALIA, ⁸Monash University, Melbourne, AUSTRALIA, ⁹Monash Health Imaging, Melbourne, AUSTRALIA, ¹⁰St Vincent's Health Melbourne, Melbourne, AUSTRALIA, ¹¹St Vincent's Health, Melbourne, AUSTRALIA, ¹²Austin Health, Melbourne, AUSTRALIA, ¹³Royal North Shore Hospital, Sydney, AUSTRALIA, ¹⁴Dr Jones and Partners Medical Imaging, Adelaide, AUSTRALIA, ¹⁵Royal Adelaide Hospital, Adelaide, AUSTRALIA.

OP-038

Radio-guided surgery with DROP-IN beta probe for 68Ga-PSMA, in high-risk prostate cancer patients eligible for robotic-assisted radical prostatectomy.

F. Ceci¹, F. Collamati², S. Luzzago³, F. A. Mistretta³, L. Muraglia¹, G. Renne⁴, R. Mirabelli², S. Morganti⁵, O. De Cobelli³, N. Fusco⁴, G. Musi³;
¹Division of Nuclear Medicine, IEO European Institute of Oncology, IRCCS, Milan, ITALY, ²INFN National Institute of Nuclear Physics, Section of Rome, Rome, ITALY, ³Division of Urology, IEO European Institute of Oncology, IRCCS, Milan, ITALY, ⁴Division of Pathology, IEO European Institute of Oncology, IRCCS, Milan, ITALY, ⁵INFN National Institute of Nuclear Physics, Section of Rome, Milan, ITALY.

OP-039

[⁶⁸Ga]PSMA PET/CT vs. mpMRI in patients with suspicion of prostate cancer and previous negative biopsy: preliminary data from PROSPET-BX trial.

E. Lopci, M. Lazzeri, L. Disconzi, P. Colombo, A. Saita, D. Maffei, V. Fasulo, R. Hurle, K. Marzo, L. Leonardi, R. Pescechiera, A. Benetti, S. Zandegiacomo, L. Pasini, J. Jandric, R. Zanca, P. Casale, M. Rodari, L. Balzarini, G. Guazzoni, N. Buffi, G. Lughezzani;
IRCCS - Humanitas Research Hospital, Rozzano MI, ITALY.

OP-040

Pre-surgical ⁶⁸Ga-PSMA-11 PET for biochemical recurrence risk assessment: a surrogate of Pelvic Lymph Node Dissection? Follow-up analysis of a Multicenter Prospective Phase 3 Imaging Trial.

L. Djaileb¹, W. Armstrong², D. Thompson³, A. Gafita², A. Farolfi², T. Grogan², M. Cooperberg⁴, P. Carroll⁵, S. Washington⁴, R. Reiter⁶, J. Czernin², H. Thomas³, J. Calais²;
¹University Grenoble-Alpes, INSERM, CHU Grenoble Alpes, Nuclear Medicine Department, LRB, Grenoble, FRANCE, ²UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, ³Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, UNITED STATES OF AMERICA, ⁴Department of Urology, University of California, San Francisco, CA, UNITED STATES OF AMERICA, ⁵Department of Urology, University of California, San Francisco, UCSF, CA, UNITED STATES OF AMERICA, ⁶Institute of Urologic Oncology, University of California, Los Angeles, CA, UNITED STATES OF AMERICA.

OP-041

Updated Automated PROMISE assessment: Treatment response evaluation approach on metastatic prostate cancer patients based on PSMA PET/CT

S. Duriseti^{1,2}, H. Sahlstedt³, J. Brynolfsson³, G. Berenji^{1,2}, S. Tsai², N. Kane¹, W. Fendler⁴, M. Rettig^{1,2}, N. Nickols^{1,2};
¹University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, ²Greater Los Angeles VA Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA, ³Exini Diagnostics AB, Lund, SWEDEN, ⁴University of Essen, Essen, GERMANY.

OP-042

PSMA PET/CT for the Targeting of Prostate Biopsies: Additional Value over MRI?

C. J. W. M. Morré¹, J. J. Boer¹, S. P. Rynja¹, M. J. Hagens², M. A. Noordzij¹;
¹Spaarne Gasthuis, Hoofddorp, NETHERLANDS, ²Antoni van Leeuwenhoek cancer institute, Amsterdam, NETHERLANDS.

207

Sunday, September 10, 2023, 8:00 AM - 9:30 AM
Hall F1

Neuroimaging Committee - Featured Session: Methods in Neuroimaging: Spotlight on Brain Connectivity

OP-043

The Molecular Connectivity in Neurology

M. Perovnik; University Medical Centre Ljubljana, Ljubljana, SLOVENIA.

OP-044

Aging and changes in intrinsic connectivity networks of the brain

S. Ha, I. Chung, W. Ryoo, J. Min, S. Kwon, J. O;
The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF.

OP-045

Dynamic reconfiguration of metabolic brain connectivity during progression from MCI to Alzheimer's disease dementia

S. Caminiti¹, A. Galli², A. Sala³, M. Inglese⁴, L. Presotto⁵, C. Tassorelli¹, D. Perani⁶, the Alzheimer's Disease Neuroimaging Initiative;

¹Department of Brain and Behavioral Sciences, University of Pavia, Pavia, ITALY, ²Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, ITALY, ³GIGA Consciousness, University of Liege, Liege, BELGIUM, ⁴Department of Biomedicine and Prevention, University of Rome Tor Vergata, Roma, ITALY, ⁵Department of Physics, University of Milano-Bicocca, Milano, ITALY, ⁶Vita-Salute San Raffaele University, Milano, ITALY.

OP-046

Is energy consumption linked to structural and functional connectivity in the healthy human brain?

Y. Mayr¹, A. Lizarraga¹, A. Sala^{1,2,3}, I. Yakushev¹;

¹Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, GERMANY, ²Coma Science Group, GIGA-Consciousness, University of Liege, Liege, BELGIUM, ³Centre du Cerveau2, University Hospital of Liege, Liege, BELGIUM.

OP-047

Cortical stimulation-induced ictal [^{99m}Tc]Tc-HMPAO SPECT for surgery planning in epilepsy patients

T. Pyka¹, S. Barlaty², K. Krieger¹, C. Friedrichs-Maeder³, K. Schindler³, A. Rominger¹, M. Baud³;

¹Department of Nuclear Medicine, Inselspital Bern, Bern, SWITZERLAND, ²Department of Neurosurgery, Inselspital Bern, Bern, SWITZERLAND, ³Department of Neurology, Inselspital Bern, Bern, SWITZERLAND.

OP-048

The Value of ¹⁸F-FDG PET/MRI in the Preoperative Localization of Epileptogenic Zone in Patients With Drug-resistant Epilepsy

C. Zeng¹, H. Zhou², X. Ling¹, Y. Tang¹, Z. Tan¹, H. Wu¹, Y. Cheng¹, J. Shang¹, Q. Guo³, H. Xu¹;

¹Department of Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, CHINA, ²Department of Radiology, Central People's Hospital of Zhanjiang, Zhanjiang, CHINA, ³Epilepsy Center, Guangdong 999 Brain Hospital, Affiliated Brain Hospital of Jinan University, Guangzhou, CHINA.

OP-049

Effects of Deep Learning-based Quantification for Amyloid PET on Visual Reading: A retrospective, multicenter, multireader study

H. Ryoo¹, K. Cho², Y. Kim³, S. Ha⁴, S. Kwon⁴, R. Lee⁵, J. Seok⁶, S. Kang⁷, Y. Kang², B. Kim⁷, J. Jeong⁸, H. Yoon⁹, M. Yoo¹⁰, G. Kim¹¹, J. Choi¹², J. Park¹², E. Lee¹³, J. Kim¹⁴, H. Song¹⁴, K. Park¹⁴, J. Ha¹⁵, A. Chong¹⁵, S. Jang¹⁶, J. Bang¹⁶, I. Hong¹⁷, S. Choi¹⁷, S. Jeong¹⁸, I. Jo¹⁸, H. Cho^{19,20};

¹Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF, ²Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF, ³Department of Nuclear Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, KOREA, REPUBLIC OF, ⁴Division of Nuclear Medicine, Department of Radiology, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF, ⁵Department of Nuclear Medicine, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, KOREA, REPUBLIC OF, ⁶Department of Nuclear Medicine, Chung-Ang University Hospital, Seoul, KOREA, REPUBLIC OF, ⁷Department of Nuclear Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, KOREA, REPUBLIC OF, ⁸Department of Neurology, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, KOREA, REPUBLIC OF, ⁹Department of Nuclear Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, KOREA, REPUBLIC OF, ¹⁰Department of Nuclear Medicine, Inha University Hospital, Incheon, KOREA, REPUBLIC OF, ¹¹Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, KOREA, REPUBLIC OF, ¹²Department of Nuclear Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, KOREA, REPUBLIC OF, ¹³Department of Neurology, Soonchunhyang University Bucheon Hospital, Bucheon, KOREA, REPUBLIC OF, ¹⁴Department of Nuclear Medicine, Chonnam National University Hospital, Gwangju, KOREA, REPUBLIC OF, ¹⁵Department of Nuclear Medicine, Chosun University School of Medicine, Gwangju, KOREA, REPUBLIC OF, ¹⁶Department of Nuclear Medicine, CHA Bundang Medical Center, CHA University, Seongnam, KOREA, REPUBLIC OF, ¹⁷Department of Nuclear Medicine, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, KOREA, REPUBLIC OF, ¹⁸Department of Nuclear Medicine, Kyungpook National University Chilgok Hospital, Daegu, KOREA, REPUBLIC OF, ¹⁹Institute of Radiation Medicine, Medical Research Center, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF, ²⁰Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF.

OP-050

Brain metabolic correlates of Cytokine Release Syndrome and Immune effector cell-associated neurotoxicity in patients with Diffuse Large B-Cell Lymphoma (DLCL) treated with CAR-T

T. Di Raimondo¹, M. Gambella², A. Raiola², F. D'Amico¹, L. Sofia¹, F. Lanfranchi¹, C. Ghiggi², C. Lapucci³, G. Sambuceti¹, M. Bauckneht⁴, M. Inglese³, E. Angelucci², S. Morbelli¹;

¹Nuclear Medicine Unit, Department of Health Sciences (DISSAL), University of Genoa, Genova, ITALY, ²Department of Hematology and Cellular Therapy, IRCCS Ospedale Policlinico San Martino, Genova, ITALY, ³Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), IRCCS Ospedale Policlinico San Martino, University of Genoa, Genova, ITALY.

OP-051

A pilot study comparing myelin measurements from [18F]-Florbetaben PET and quantitative T1 map imaging in multiple sclerosis (MS)

L. Sofia¹, M. Donegani¹, A. Donniaquio², A. Chincari³, L. Roccatagliata⁴, M. Pardini², R. Gianeri³, F. Sensi³, F. D'Amico¹, T. Di Raimondo¹, C. Bagnara⁵, M. Riondato¹, G. Novi⁶, A. Laroni², A. Murialdo⁶, G. Ribizzi⁶, A. Uccelli², M. Inglese², S. Morbelli¹;

¹Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Genoa, ITALY, ²Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, ITALY, ³National Institute of Nuclear Physics (INFN), Genoa section, Genoa, Genoa, ITALY, ⁴Neuroradiology Unit, University of Genoa, Genoa, ITALY, ⁵Medical Physics, IRCCS Policlinico San Martino, Genoa, Genoa, ITALY, ⁶Division of Neurology, IRCCS Policlinico San Martino, Genoa, Genoa, ITALY.

208

Sunday, September 10, 2023, 8:00 AM - 9:30 AM

Hall F2

Paediatrics Committee - TROP Session: Paediatric PET/CT & PET/MR

OP-052

Predictive value of FDG PET/CT parameters in pediatric Hodgkin Lymphoma: initial results of an Italian prospective study

E. Lopci¹, C. Elia², V. De Re², L. Mussolin³, A. Piccardo⁴, A. Cistaro⁵, P. Zucchetta⁶, E. Borsatti⁷, M. Bianchi⁷, S. Buffardi⁸, P. Farruggia⁹, A. Garaventa¹⁰, A. Sala¹¹, L. Vinti¹², C. Mauz-Koeholz¹³, M. Mascarin²;

¹IRCCS - Humanitas Research Hospital, Rozzano MI, ITALY, ²CRO, Aviano, ITALY, ³Pediatric Hemato-Oncology Clinic, Padoa, ITALY, ⁴Galliera Hospital, Genoa, ITALY, ⁵Salus Alliance Medical, Genoa, ITALY, ⁶Padova University Hospital, Padoa, ITALY, ⁷Regina Margherita Hospital, Turin, ITALY, ⁸Hospital Santobono-Pausilipon, Naples, ITALY, ⁹A.R.N.A.S. Ospedali Civico, Palermo, ITALY, ¹⁰IRCCS G.Gaslini Hospital, Genoa, ITALY, ¹¹Hospital San Gerardo, Monza, ITALY, ¹²Ospedale Bambino Gesù, Rome, ITALY, ¹³Zentrum für Kinderheilkunde der Justus-Liebig-Universität Gießen, Gießen, GERMANY.

OP-053

Interim TLG and MTV vs Deauville Score as Predictors in Pediatric Non-Hodgkin Lymphoma Patients

G. KAYA¹, B. Volkan Salanci¹, B. Aydın², P. Özgen Kiratlı¹;

¹Hacettepe University Medical School Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Hacettepe University Medical School Department of Pediatric Oncology, Ankara, TÜRKIYE.

OP-054

Application value of 18F-FDG PET/MR whole body imaging in children's rhabdomyosarcoma staging

S. Yun¹;
Hangzhou Universal Imaging diagnostic center, Hangzhou, CHINA

OP-055

Prognostic Value of 18FDG PET/CT Parameters for the Outcome in Pediatric Sarcoma Patients

B. Soydas Turan¹, B. Volkan-Salanci², G. B. Aydın³, P. Özgen Kiratlı⁴;

¹Etilik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TÜRKIYE, ³Hacettepe University Faculty of Medicine, Department of Pediatric Oncology, Ankara, TÜRKIYE.

OP-056

Bone marrow involvement detection by FDG PET-CT in newly diagnosed Ewing Sarcomas : comparison to bone marrow aspiration and biopsy, and assessment of visual interpretation criteria with junior doctors

V. Isnardi¹, A. Guinet¹, H. Bahri¹, E. Paquet¹, M. Fazel¹, L. Besson², M. Brahmi¹, N. Corradini¹, P. Marec-Berard¹;

¹Lumen Centre Léon Bérard, Lyon, FRANCE, ²University Hospital, Saint Etienne, FRANCE.

OP-057

Role of F18 FDG PET/CT inEwing's Sarcoma Family Of Tumours (ESFT)

A. Tiwary Vyas¹, A. Vyas²;

¹Janakpuri Superspeciality Hospital, New Delhi, INDIA, ²Max Superspeciality Hospital Vaishali, New Delhi, INDIA.

OP-058

Pediatric tumor patients scanned with a long axial field of view scanner - a single center experience of reduced administered doses of [¹⁸F]FDG

C. Bregenzner¹, K. Krieger¹, H. Sari^{1,2}, K. Zeimpekis¹, N. Gözlügöl¹, A. Cardoso¹, A. Mendes¹, A. Rominger¹, A. Afshar-Oromieh¹;

¹Department of Nuclear Medicine, Inselspital, University Hospital Bern, University of Bern, Bern, SWITZERLAND, ²Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, SWITZERLAND.

OP-059

Sedation-free pediatric ¹⁸F-FDG imaging on totalbody PET/CT with the assistance of artificial intelligence

X. Zhou¹, S. Xue², Q. Xia¹, A. Rominger², J. Liu¹, K. Shi²;

¹Shanghai Jiaotong University, Shanghai, CHINA, ²Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

209

Sunday, September 10, 2023, 8:00 AM - 9:30 AM

Hall G2

e-Poster Presentations Session 1 - Oncology & Theranostics Committee: Neuroendocrine Tumours and Gynecological Malignancies

EPS-002

SPECT and SPECT/CT Somatostatin Receptor Scintigraphy in the Follow-Up of Neuroendocrine Neoplasms of Appendix

V. Artiko, J. Petrovic, D. Sobic Saranovic, N. Petrovic; Center for Nuclear Medicine, University Clinical Center of Serbia, Faculty of Medicine University of Belgrade, Belgrade, SERBIA.

EPS-003

Total tumour volume in a GEP-NET patient cohort treated with intraarterial Lu-177 DOTATATE PRRT

H. Schmid, S. Kunte, G. Sheikh, A. Holzgreve, P. Bartenstein, L. Unterrainer, M. Zacherl; Departement of Nuclear Medicine University Hospital, LMU Munich, Munich, GERMANY.

EPS-004

Somatostatin receptor antagonist PET/CT imaging provides better staging of lymph node than contrast enhanced CT prior to lymph node dissection in patients with duodenum and pancreatic neuroendocrine tumors

W. Zhu, B. Yin, X. Wang, M. Liu, Q. Xu, W. Wu, L. Huo; Peking Union Medical College Hospital, Beijing, CHINA.

EPS-005

Normalization and 2-bit-quantization of PSMA-PET using the visual miPSMA Score for training a deep learning AI for prostate cancer detection

B. Schemmer; Uniklinik Bonn, Bonn, GERMANY.

EPS-006

Retrospective Analysis of 666 Gallium-68 Labeled Somatostatin Receptor Antagonist PET/CT Imaging in Over 500 Patients: Experience from a Single Center in China

W. Zhu¹, M. Liu¹, Y. Cheng¹, R. Jia², C. Bai¹, L. Huo¹; ¹Peking Union Medical College Hospital, Beijing, CHINA, ²The Fifth Medical Center, General Hospital of PLA, Beijing, CHINA.

EPS-007

[¹⁸F]F-AI-NOTA-Octreotide versus [¹¹¹In]In-DTPA-Octreotide for neuroendocrine tumours imaging: results of first 10 patients

B. Arruda Matheos de Lima¹, R. C. M. Felix¹, P. B. Pujatti¹, D. A. Bulzico¹, M. P. Carneiro¹, M. A. S. Cardoso¹, M. L. Gomes¹, T. T. Guimarães¹, J. W. E. Silva¹, E. R. Oliveira¹, C. H. F. Costa¹, R. G. Silva¹, A. C. Bispo², D. M. Zouain²; ¹Brazilian National Cancer Institute, Rio de Janeiro, BRAZIL, ²R2IBF Radiopharmaceuticals, Rio de Janeiro, BRAZIL.

EPS-008

Quantification of ¹⁷⁷Lu-DOTATATE uptake in neuroendocrine tumors using a fast whole-body 360° CZT-SPECT/CT camera for monitoring and prediction of treatment response

C. Boursier^{1,2,3}, J. Grangeret¹, E. Chevalier¹, G. Karcher³, L. Imbert^{1,2,3}, P. Marie^{1,2,3}; ¹Université de Lorraine, Department of Nuclear Medicine, CHRU Nancy, Vandoeuvre-les-Nancy, FRANCE, ²Université de Lorraine, IADI, INSERM U1254, Nancy, FRANCE, ³Nancyclotep Imaging Platform, Nancy, FRANCE.

EPS-009

Bone marrow absorbed doses during treatment with [¹⁷⁷Lu]Lu-DOTATATE assuming a specific uptake in the red marrow

L. Hagmarker¹, J. Svensson², T. Rydén¹, M. Van Essen³, A. Sundlöf⁴, P. Gjertsson³, K. Sjögren Gleisner⁵, P. Bernhardt¹; ¹Department of Radiation Physics, Gothenburg, SWEDEN, ²Sahlgrenska Academy, Gothenburg, SWEDEN, ³Department of Clinical Physiology, Gothenburg, SWEDEN, ⁴Department of Oncology and Pathology, Clinical Sciences, Lund, SWEDEN, ⁵Department of Radiation Physics, Lund, SWEDEN.

EPS-010

Inpatient admissions for hormone secretion management in patients with neuroendocrine neoplasms treated with [¹⁷⁷Lu]Lu-DOTA-Octreotate therapy over a 3-year period at a single high volume treatment centre

L. Neeson¹, E. Boehm¹, T. Akhurst², R. Alipour¹, A. Cardin¹, C. Chiang¹, M. Hofman¹, M. Lee¹, M. Michael¹, A. S. Ravi Kumar², N. Sachithanandan¹, J. Saghebi¹, H. Wong¹, G. Kong²; ¹Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ²Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, AUSTRALIA.

EPS-011

Impact of volumetric parameters applied to ¹⁷⁷Lu-DOTATATE SPECT-CT in the survival of NET patients after PRRT

S. Menendez-Sanchez¹, V. Beteach-Antar¹, E. Guillen², J. Rosales¹, L. Garcia-Belaustegui², A. Bronte¹, J. Bastidas¹, T. Cuenca¹, P. Echegoyen¹, A. Chopitea¹, E. Prieto¹, J. Martí-Climent¹, J. Arbizu¹; ¹Clínica Universidad de Navarra, Pamplona, Navarra, SPAIN, ²Clínica Universidad de Navarra, Madrid, SPAIN.

EPS-012

Metabolic tumor volume response on FDG-PET after [¹³¹I]MIBG radiotherapy in patients with metastatic pheochromocytomas and paragangliomas predicts their prognosis

J. Takenaka^{1,2}, S. Watanabe^{1,2}, T. Abe³, T. Tsuchikawa⁴, S. Takeuchi⁵, K. Hirata^{1,2,6}, R. Kimura^{1,7}, N. Wakabayashi^{1,2}, N. Shinohara³, K. Kudo^{1,6,7}; ¹Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, JAPAN, ²Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, JAPAN, ³Department of Renal and Genitourinary surgery, Hokkaido University Graduate School of Medicine, Sapporo, JAPAN, ⁴Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, Sapporo, JAPAN, ⁵Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JAPAN, ⁶Division of Medical AI Education and Research, Hokkaido University Graduate School of Medicine, Sapporo, JAPAN, ⁷Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, JAPAN.

EPS-013

Late toxicity after peptide receptor radioligand therapy (PRRT) therapy in neuroendocrine neoplasm.

D. Handkiewicz-Junak, A. Sygula, A. Ledwon, K. Hassse-Lazar, B. Jurecka-Lubieniecka, E. Paliczka-Ciešlik, A. Kropinska, T. Olczyk, T. Gawlik; Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, POLAND.

EPS-014

Radioligand Therapy: is it time to move towards a different dosimetric approach?

A. Filice¹, R. Durmo¹, F. Fioroni², E. Grassi², C. Coruzzi¹, G. Besutti³, S. Fanello⁴, A. Frasoldati⁵, S. Cavuto⁶, L. Savoldi⁶, A. Versari¹; ¹Nuclear Medicine Unit Azienda USL-IRCCS, Reggio Emilia, ITALY, ²Medical Physics Unit Azienda USL-IRCCS, Reggio Emilia, ITALY, ³Radiology Unit, Azienda USL-IRCCS, Reggio Emilia, ITALY, ⁴Medical Oncology Unit Azienda USL-IRCCS, Reggio Emilia, ITALY, ⁵Department of Endocrinology and Metabolism Unit Azienda USL-IRCCS, Reggio Emilia, ITALY, ⁶Clinical Trials and Statistics Unit Azienda USL-IRCCS, Reggio Emilia, ITALY.

EPS-015

Value Of Early Metabolic Response For Predicting Axillary Pathological Complete Response During Neoadjuvant Systemic Therapy In Triple-negative And Her2-positive Breast Cancers: Impact Of Molecular Subtypes

L. Guichard, P. Nunes, S. Jankowski, A. Bertaut, S. Ladoire, E. Michel, C. Coutant, A. Cochet, J. Alberini; Centre George Francois Leclerc, Dijon, FRANCE.

EPS-016

Detection of HER2-low lesions using HER2-targeted PET imaging in patients with HER2-negative metastatic breast cancer

R. Yeh¹, S. K. Lyashchenko¹, B. M. Zeglis^{1,2}, J. S. Lewis¹, G. A. Ulaner^{3,1}; ¹Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, ²Hunter College - City University of New York, New York, NY, UNITED STATES OF AMERICA, ³Hoag Family Cancer Institute, Irvine, CA, UNITED STATES OF AMERICA.

EPS-017

Clinical utility of [¹⁸F]FDG PET/CT in triple-negative breast cancer patients treated with neoadjuvant chemotherapy with or without immunotherapy

R. Seban¹, E. Arnaud², D. Loirat², L. Cabel², P. Cottu², L. Djerroudi³, S. Hescot¹, P. Loap⁴, C. Bonneau⁵, F. Bidard⁶, V. Huchet⁷, N. Jehanno⁷, A. Berenbaum¹, L. Champion¹, I. Buvat⁸; ¹Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, Saint-Cloud, FRANCE, ²Department of Medical Oncology, Institut Curie, Paris, FRANCE, ³Department of Pathology, Institut Curie, Paris, FRANCE, ⁴Department of Radiation Oncology, Institut Curie, Saint-Cloud, FRANCE, ⁵Department of Surgery, Institut Curie, Saint-Cloud, FRANCE, ⁶Department of Medical Oncology, Institut Curie, UVSQ/Paris-Saclay University, Saint-Cloud, FRANCE, ⁷Department of Nuclear Medicine, Institut Curie, Paris, FRANCE, ⁸Laboratoire d'Imagerie Translationnelle en Oncologie, Inserm U1288, PSL University, Institut Curie, Orsay, FRANCE.

EPS-018

Dynamic ¹⁸F-FLT PET Radiomics: a Novel and Promising Approach for an Improved Breast Cancer Prognosis Prediction

M. Inglese^{1,2}, M. Ferrante¹, T. Boccatto¹, N. Toschi^{1,3}; ¹University of Rome Tor Vergata, Rome, ITALY, ²Imperial College London, London, UNITED KINGDOM, ³Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA, UNITED STATES OF AMERICA.

EPS-019

The Influence of Histological Subtypes and Tumour Grade on the Performance of [¹⁸F]FDG-PET/CT and [¹⁸F]FES-PET/CT in Staging Patients with Estrogen Receptor Positive Breast Cancer

J. J. Knip^{1,2}, R. Iqbal^{1,2}, A. van Zweeden³, L. H. Mammatas⁴, J. J. M. Teunissen⁴, S. van der Velde¹, E. Barbé¹, K. M. Duvivier¹, D. E. Oprea-Lager¹, A. D. Windhorst¹, R. Boellaard¹, C. W. Menke-van der Houven van Oordt^{1,2}; ¹Amsterdam UMC, Amsterdam, NETHERLANDS, ²Cancer Center Amsterdam, Amsterdam, NETHERLANDS, ³Ziekenhuis Amstelland, Amstelveen, NETHERLANDS, ⁴Reinier de Graaf Gasthuis, Delft, NETHERLANDS.

EPS-020

Utility of 18F-FDG PET-CT in the evaluation of para-aortic lymph nodes in the staging of locally advanced cervical cancer

G. Cuesta Domingo¹, C. Rodríguez Rey¹, A. Ortega Candil¹, R. Cano Carrizal², P. Nespral¹, P. Bascuñana¹, P. Romero Fernández¹, A. Berardinelli Isea¹, M. Meneses Navas¹, M. Cabrera Martín¹; ¹Department of Nuclear Medicine, Instituto de Investigación Sanitaria San Carlos (IdISSC). Hospital Clínico San Carlos, Universidad Complutense, Madrid, SPAIN, ²Department of Cardiology, Hospital Infanta Sofía, Madrid, SPAIN.

EPS-021

Surgical evidence-based comparison of ⁶⁸Ga-FAPI PET/MRI and DW-MRI for assisting debulking surgery decision in ovarian cancer

X. Li¹, F. Kang¹, S. Liu², T. Han³, J. Wang¹; ¹Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA, ²Department of Gynaecology and Obstetrics, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA, ³Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

210

Sunday, September 10, 2023, 08:00 - 09:30

Hall K

CTE 1 - Technologists Committee / SNMMI: Technologists' Guide launch – Gastro Intestinal Molecular Imaging Studies Launch

OP-060

Introduction
A. Pietrzak; Greater Poland Cancer Centre, Nuclear Medicine Department, Poznan, POLAND.

OP-061

Hepatobiliary and spleen studies

D. Gilmore;

Massachusetts College of Pharmacy and Health Sciences, Boston, UNITED STATES OF AMERICA.

OP-062

Scintigraphy of gastroesophageal reflux, pulmonary aspiration and gastric emptying in children

Z. Bar-Sever;

Schneider Children's Medical Center Israel, Department of Nuclear Medicine, Petah Tikva, ISRAEL.

OP-063

Oncological studies (SPECT & PET)

R. Massa;

The Christie NHS Foundation Trust, Nuclear Medicine Department, Manchester, UNITED KINGDOM.

301

Sunday, September 10, 2023, 09:45 - 11:15

Hall A

CME 2 - Translational Molecular Imaging & Therapy + Oncology & Theranostics + Radiopharmaceutical Sciences Committee: FAP - Moving Towards Therapy

OP-064

FAP Inhibitors and Substrates

J. Milul;

Postdoctoral Scientist at Universitätsspital Basel, University Hospital Basel, University of Basel, Basel, SWITZERLAND.

OP-065

Dosimetric Aspects in FAP Radioligand Therapies

W. Fendler;

Department of Nuclear Medicine, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY.

OP-066

RLT Using Cancer-Associated Fibroblasts as Target in Solid Tumors: First Clinical Experiences

C. Nanni;

NuclearMedicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-067

Theranostic FAP Inhibitors: From Monomers for Diagnosis to Dimers for Therapy?

F. Rösch;

Department of Chemistry-TRIGA, Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, GERMANY.

302

Sunday, September 10, 2023, 09:45 - 11:15

Hall D (Arena)

Challenge the Expert 1 - Thyroid Committee: Integrated Diagnostics of Thyroid Disease

OP-068

Integrated Diagnostics of Thyroid Disease

D. Deandreis; Nuclear Medicine, Università degli Studi di Torino, Turin, ITALY

303

Sunday, September 10, 2023, 09:45 - 11:15

Hall E1

LIPS Session 2 - Radiation Protection Committee / EFOMP: Careers in Radiation Protection

OP-072

The current status of the medical physicist profession in Europe

E. Amato;

University of Messina, Department of Biomedical Sciences, Messina, ITALY.

OP-073

Requirements for the medical physicist training in Europe.

D. Visvikis;

National Institute of Health and Medical Research (INSERM), Medical Imaging Processing Lab, Paris, FRANCE.

OP-074

Building and maintaining competence in radiation protection of nuclear medicine professionals

J. Vassileva;

International Atomic Energy Agency, Radiation Protection of Patients Unit, Vienna, AUSTRIA.

304

Sunday, September 10, 2023, 9:45 AM - 11:15 AM

Hall E2

M2M Track - TROP Session: Validating Methodology: In Vitro and in Vivo Models

OP-076

Role and Impact of Anaesthetic Procedures for Preclinical Radiotracer Development Using Small Animal Positron Emission Tomography-Computed Tomography Imaging

T. Ebenhan^{1,2}, C. H. S. Driver^{1,3}, C. Swanepoel¹, J. Visser¹;

¹Preclinical Imaging Facility, Nuclear Medicine Research Infrastructure NPC, Pretoria, SOUTH AFRICA, ²Nuclear Medicine, University of Pretoria, Pretoria, SOUTH AFRICA, ³Radiochemistry, Necsa, Pelindaba, SOUTH AFRICA.

OP-077

Feasibility of in vivo small animal imaging using a clinical total-body PET/CT scanner

J. Mannheim^{1,2}, W. Lan³, M. A. Krueger¹, C. la Fougère^{2,3}, F. P. Schmidt^{1,3};

¹Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard-Karls University Tuebingen, Tuebingen, GERMANY, ²Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, GERMANY, ³Department of Nuclear Medicine and Clinical Molecular Imaging, University hospital Tuebingen, Tuebingen, GERMANY.

OP-078

Is multiple-mouse PET/MR imaging possible in preclinical oncology?

A. Courteau^{1,2}, A. Oudot², R. Garipov³, P. Doughty³, J. McGrath³, A. Cochet^{1,2,4}, F. Brunotte¹, J. M. Vrigneaud^{1,2};

¹ICMUB laboratory, UMR CNRS 6302, University of Burgundy, Dijon, FRANCE, ²Georges-François Leclerc Cancer Centre, Unicancer, Dijon, FRANCE, ³MR Solutions Ltd, Guildford, UNITED KINGDOM, ⁴CHU François Mitterrand, Dijon, FRANCE.

OP-079

In situ tumour response PET imaging without radiopharmaceuticals in particle therapy: a feasibility study in rats

C. Toramatsu, A. Mohammadi, N. Nitta, C. Seki, Y. Ikoma, I. Kanno, T. Yamaya;

National Institutes for Quantum Science and Technology (QST), Chiba, JAPAN.

OP-080

Demonstrating the Quantitative Potential of Terbium-161 SPECT/CT Imaging: An Anthropomorphic Phantom Study

F. Westerbergh¹, N. P. van der Meulen^{2,3}, C. Müller³, A. Grings⁴, P. Ritt⁴, P. Bernhardt^{1,5};

¹Department of Medical Radiation Sciences, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, SWEDEN, ²Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen-PSI, SWITZERLAND, ³Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen-PSI, SWITZERLAND, ⁴Clinic of Nuclear Medicine, University Hospital Erlangen, Erlangen, GERMANY, ⁵Department of Medical Physics and Biomedical Engineering (MFT), Sahlgrenska University Hospital, Gothenburg, SWEDEN.

OP-081

RadioFACS reveals [¹⁸F]FDG uptake in a KRAS induced lung cancer model is driven by immune cells but not tumor cell metabolism

C. Vranka¹, M. Homolya², T. Patsch¹, A. Spittler³, E. Casanova², S. Grünert¹, M. Hacker¹, C. Philippe¹;

¹Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, ²Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, AUSTRIA, ³Core Facility Flow Cytometry and Department of Surgery, Research Laboratories, Medical University of Vienna, Vienna, AUSTRIA.

OP-082

Impact of inoculation-driven immune response on TSPO and amino acid PET imaging in experimental orthotopic glioblastoma

L. Gold¹, E. Barc², M. Brendel¹, M. Orth³, J. Cheng², S. V. Kirchleitner⁴, L. M. Bartos¹, L. M. Unterrainer¹, L. Kaiser¹, S. Ziegler¹, L. Weidner⁵, M. J. Riemenschneider⁵, M. Unterrainer¹, C. Belka³, J. Tonn⁴, P. Bartenstein¹, M. Niyazi³, L. von Baumgarten⁴, R. Kälin², R. Glass², N. L. Albert¹, A. Holzgreve¹;

¹Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, ²Neurosurgical Research, Department of Neurosurgery, University Hospital, LMU Munich, Munich, GERMANY, ³Department of Radiation Oncology, University Hospital, LMU Munich, Munich, GERMANY, ⁴Department of Neurosurgery, University Hospital, LMU Munich, Munich, GERMANY, ⁵Department of Neuropathology, Regensburg University Hospital, Regensburg, GERMANY.

OP-083

From 2D to 3D: Developing an improved in vitro model for radiopharmaceutical evaluation

L. van den Brink, M. J. Klomp, S. Erkens-Schulze, W. M. van Weerden, S. U. Dalm;

Erasmus Medisch Centrum, Rotterdam, NETHERLANDS.

OP-084

Theranostic Digital Blueprint Predicts Higher Therapeutic Efficacy using Radiopharmaceuticals with Higher Albumin Affinity

A. Fele Paranj¹, C. Uribe¹, F. Benard², A. Rahmim¹, B. Saboury³;

¹University of British Columbia, Vancouver, BC, CANADA, ²BC Cancer, Vancouver, BC, CANADA, ³National Institutes of Health (NIH), Bethesda, MD, UNITED STATES OF AMERICA.

305

Sunday, September 10, 2023, 9:45 AM - 11:15 AM

Hall B

Cutting Edge Science Track - Featured Session: Radiomics

OP-085

State of the Art and Perspectives

M. Hatt;

INSERM, Brest, FRANCE.

OP-086

Prognostic value of [¹⁸F]FDG PET radiomics to detect peritoneal and distant metastases in locally advanced gastric cancer - a side-study of the prospective multicentre PLASTIC study

W. A. Noortman¹, L. C. E. Pullen², L. Triemstra³, C. de Jongh³, F. J. Rademaker², R. Spijkerman², G. M. Kalisvaart¹, E. C. Gertsen³, L. F. de Geus-Oei¹, N. Tolboom³, W. O. de Steur¹, M. Dantuma², R. H. J. A. Slart⁴, R. van Hillegersberg³, P. D. Siersema⁵, J. P. Ruurda³, F. H. P. van Velden¹, E. Vegt⁶, PLASTIC Study Group;

¹Leiden University Medical Center, Leiden, NETHERLANDS, ²University of Twente, Enschede, NETHERLANDS, ³University Medical Center Utrecht, Utrecht, NETHERLANDS, ⁴University Medical Center Groningen, Groningen, NETHERLANDS, ⁵Radboud University Medical Center, Nijmegen, NETHERLANDS, ⁶Erasmus University Medical Center, Rotterdam, NETHERLANDS.

OP-087

Feasibility and reproducibility of radiomic features in real world whole-body [¹⁸F]FDG PET/CT oncology studies

C. S. Constantino, M. Silva, F. P. M. Oliveira, D. C. Costa; Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, PORTUGAL.

OP-088

Explainable machine learning model to diagnose giant cell arteritis based on texture features in aortic [¹⁸F]FDG-PET images

H. Vries^{1,2}, G. van Praagh¹, P. Nienhuis¹, L. Alic², R. Slart^{1,2}; ¹University Medical Centre Groningen, Groningen, NETHERLANDS, ²University of Twente, Enschede, NETHERLANDS.

OP-089

PET-CT Radiomics of Lung Cancer with Local Nodes; Dissemination Features are Linked to Survival

K. Albattat, C. Marshall, R. Smith, N. Morley; Cardiff University, Cardiff, UNITED KINGDOM.

OP-090

The Effect of Feature Selection Methods on Prognostic Analysis of ¹⁸F-FDG PET Radiomics in Lymphoma

L. Yong¹, X. Wong¹, Y. Chen^{2,3}, S. Liu^{1,3}, H. Lin^{4,5}, K. Lue¹; ¹Tzu Chi University of Science and Technology, Hualien, TAIWAN, ²Tzu Chi University, Hualien, TAIWAN, ³Hualien Tzu Chi Hospital, Hualien, TAIWAN, ⁴Chang Gung University, Taoyuan, TAIWAN, ⁵Keelung Chang Gung Memorial Hospital, Keelung, TAIWAN.

OP-091

Exploring Correlations between PSA Levels and PSMA-PET Images in Recurrent Prostate Cancer using Machine Learning, Tensor Radiomics and Deep Features Analysis

A. Toosi¹, S. Harsini², H. Abdollahi¹, F. Bénard^{2,3}, C. F. Uribe^{2,3}, A. Rahmim^{1,4,5}; ¹Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, ²BC Cancer, Vancouver, BC, CANADA, ³Department of Radiology, University of British Columbia, Vancouver, BC, CANADA, ⁴Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA.

OP-092

Improving Outcome Prediction in Multicentric Data: Novel Harmonization Techniques and MCA-Based Imputation for Radiomic Feature Analysis

N. Abdallah¹, J. Marion², C. Tauber¹, T. Carlier³, P. Chauvet², M. Hatt⁴; ¹Imaging & Brain, INSERM, Tours, FRANCE, ²LARIS, Angers, FRANCE, ³CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, FRANCE, ⁴LaTIM, INSERM, Brest, FRANCE.

OP-093

DEBI-NN: Distance-Encoding Biomorphic-Informational Neural Networks in PET Radiomics

B. Ecsedi, D. Haberl, C. P. Spielvogel, T. Traub-Weidinger, M. Hacker, L. Papp; Medical University of Vienna, Vienna, AUSTRIA.

306

Sunday, September 10, 2023, 9:45 AM - 11:15 AM
Hall C

Clinical Oncology Track - Featured Session: Haematological Disease

OP-094

Haematological Disease

OP-095

Significance of ¹¹C-acetate PET/CT for the prediction of complete remission post induction therapy in newly diagnosed multiple myeloma: a prospective study

S. Chen, Y. Wong, K. Wu, J. C. Chim, C. Ho; Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

OP-096

A prospective comparison of ⁶⁸Ga-Pentixafor PET/CT and ¹⁸F-FDG PET/CT for the detection of intramedullary and extramedullary lesions in multiple myeloma

S. Tang, Y. Wang, Y. Tian, C. Li, Z. Xiao, J. Chen, Y. He; Department of nuclear medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, CHINA.

OP-097

Assessment of the Diagnostic and Staging Potential of ⁶⁸Ga-Pentixafor PET/CT in Multiple Myeloma - A Comparison With ¹⁸F-FDG PET/CT

L. Aridhasan Meenakshi, V. Rajaraman, B. Dubashi, D. Halanaik; Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, INDIA.

OP-098

Prognostic value of FDG PET/CT biomarkers in patients with recurrent/refractory MM treated with CAR-T Cells

V. Betech-Antar, F. Minguez, L. Tamariz, A. Bronte, M. Romera, J. Rosales, J. Bastidas, S. Menendez-Sanchez, M. Panizo, S. Hueriga, J. San-Miguel, P. Rodriguez-Otero, M. García-Veloso; Clínica Universidad de Navarra, Pamplona, SPAIN.

OP-099

Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy

C. Voltin¹, S. Flossdorf², A. Paccagnella³, M. Winkelmann⁴, J. Heger¹, B. Casadei³, L. Beckmann¹, K. Herrmann², N. Kutsch¹, P. Borchmann¹, S. Fanti³, W. G. Kunz⁴, M. Subklewe⁴, C. Kobe¹, P. L. Zinzani³, M. Stelljes⁵, K. S. Roth¹, A. Drzezga¹, R. Noppeney², H. C. Reinhardt², B. von Tresckow², R. Seifert^{2,5}, J. C. Albring⁵, V. Blumenberg⁴, A. Farolfi³, P. Gödel¹, C. Hanoun²; ¹University of Cologne, Cologne, GERMANY, ²University of Duisburg-Essen, Essen, GERMANY, ³University of Bologna, Bologna, ITALY, ⁴Ludwig Maximilian University of Munich, Munich, GERMANY, ⁵University of Münster, Münster, GERMANY.

OP-100

Performance of PET/CT using [¹⁸F]Fludarabine for initial staging and therapeutic evaluation of symptomatic multiple myeloma (MM) patients in first line treatment or first relapse : preliminary results of an exploratory multicenter phase 2 study

C. François¹, M. Santiago-Ribeiro^{2,3}, B. Jamet⁴, S. Guillouet⁵, C. Perrio⁵, A. Abbas⁶, F. Gourand⁵, S. Querellou^{7,8}, T. Chalopin⁹, C. Dubegny⁴, C. Touzeau^{10,11}, N. Blin^{10,11}, F. Kraeber-Bodéré^{6,11}, C. Bodet-Milin^{4,11}; ¹Nuclear Medicine department, Lille University Hospital, Lille, FRANCE, ²Nuclear Medicine department, Tours University Hospital, Tours, FRANCE, ³UMR 1253, iBrain, Université de Tours, Inserm, Tours, FRANCE, ⁴Nuclear Medicine department, Nantes University Hospital, Nantes, FRANCE, ⁵Normandie Univ, UNICAEN, CEA, CNRS, UAR 3408 Cyceron, Bd Henri Becquerel, 14000, Caen, FRANCE, ⁶Normandie univ, UNICAEN, PSL Université Paris, EPHE, INSERM, U1077, CHU de Caen, GIP Cyceron, Neuropsychologie et Imagerie de la Mémoire Humaine, 14000, Caen, FRANCE, ⁷Nuclear Medicine department, Brest University Hospital, Brest, FRANCE, ⁸GETBO UMR U_1304, Inserm, UBO, Brest, FRANCE, ⁹Hematology department, Tours University Hospital, Tours, FRANCE, ¹⁰Hematology department, Nantes University Hospital, Nantes, FRANCE, ¹¹Nantes Université, Angers Université, INSERM, CNRS, CRCI2NA, Nantes, FRANCE.

OP-101

Patterns of PET positive residual tissue at early interim staging and risk of treatment failure in advanced-stage Hodgkin's Lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group

J. Ferdinandus¹, L. van Heek¹, K. S. Roth¹, M. Dietlein¹, H. Eich², C. Baues¹, P. Borchmann¹, C. Kobe¹, German Hodgkin Study Group; ¹University Hospital Cologne, Cologne, GERMANY, ²University Hospital Münster, Münster, GERMANY.

OP-102

Combining Baseline and End of Treatment Quantitative PET Parameters to Improve Progression-Free Survival Prediction in DLBCL

G. Zwezerijnen¹, A. L. Bes², M. W. Heymans³, U. Dührsen⁴, J. Eertink⁵, S. Wiegers¹, P. Lugtenburg⁵, A. Hüttmann⁴, L. Kurch⁶, C. Hanoun⁴, N. Mikhaeel⁷, L. Ceriani⁸, E. Zucca⁹, S. Czibor¹⁰, T. Györke¹⁰, M. Chamuleau², S. Fanti¹¹, S. Lee¹², J. Zijlstra², S. Barrington¹³, R. Boellaard¹; ¹Amsterdam UMC, Vrije Universiteit Amsterdam, department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, NETHERLANDS, ²Amsterdam UMC, Vrije Universiteit Amsterdam, department of Hematology, Cancer Center Amsterdam, Amsterdam, NETHERLANDS, ³Amsterdam UMC, Vrije Universiteit Amsterdam, department of Epidemiology and Data Science, Amsterdam Public Health research institute, Amsterdam, NETHERLANDS, ⁴Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, ⁵Erasmus MC Cancer Institute, University Medical Center Rotterdam, department of Hematology, Rotterdam, Rotterdam, NETHERLANDS, ⁶Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Leipzig, Leipzig, GERMANY, ⁷Department of Clinical Oncology, Guy's Cancer Centre and School of Cancer and Pharmaceutical Sciences, King's College London University, London, UNITED KINGDOM, ⁸Department of Nuclear Medicine and PET/CT Centre, IIMSI - Imaging Institute of Southern Switzerland, Bellinzona, Università della Svizzera Italiana,

Bellinzona Switzerland; SAKK - Swiss Group for Clinical Cancer Research, Bern, SWITZERLAND, ⁹Department of Oncology, IOSI - Oncology Institute of Southern Switzerland, Bellinzona; Università della Svizzera Italiana, Bellinzona, Switzerland; SAKK - Swiss Group for Clinical Cancer Research, Bern, SWITZERLAND, ¹⁰Department of Nuclear Medicine, Medical Imaging Centre, Semmelweis University, Budapest, HUNGARY, ¹¹Nuclear Medicine department, Sant'Orsola-Malpighi Hospital, Bologna, ITALY, ¹²Department of Molecular Imaging and Therapy, Austin Health, Melbourne, AUSTRALIA, ¹³King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's Health Partners, Kings College London, London, UNITED KINGDOM.

307

Sunday, September 10, 2023, 9:45 AM - 11:15 AM
Hall F1

Neuroimaging Committee - TROP Session: Amyloid, Tau and More in Neurodegenerative Disorders Tau

OP-103

Quantification of baseline amyloid load in individuals with subjective cognitive decline can identify future risk of amyloid accumulation

G. Kolinger¹, M. Marquie^{2,3}, O. Sotolongo-Grau², N. Roé-Vellvé¹, E. Pérez-Martínez¹, N. Koglin¹, A. Stephens¹, J. Tartari², Á. Sanabria^{2,3}, A. García-Sánchez², L. Tárraga^{2,3}, A. Ruiz^{2,3}, S. Bullich¹, M. Boada^{2,3}; ¹Life Molecular Imaging GmbH, Berlin, GERMANY, ²Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, SPAIN, ³Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, SPAIN.

OP-104

Association of plasma glial fibrillary acidic protein with neurofibrillary tau tangles in the brain and cognitive decline independent of amyloid-B

D. Peretti¹, F. Ribaldi^{1,2}, C. Boccalini^{1,3,4}, M. Marizzoni⁵, N. Ashton^{6,7,8}, H. Zetterberg^{6,9,10}, K. Blennow⁶, G. Frisoni^{1,2}, V. Garibotto^{1,2}; ¹University of Geneva, Geneva, SWITZERLAND, ²Geneva University Hospitals, Geneva, SWITZERLAND, ³Vita-Salute San Raffaele University, Milan, ITALY, ⁴IRCCS San Raffaele Scientific Institute, Milan, ITALY, ⁵IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, ITALY, ⁶The Sahlgrenska Academy at the University of Gothenburg, Molndal, SWEDEN, ⁷Maurice Wohl Clinical Neuroscience Institute, London, UNITED KINGDOM, ⁸NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UNITED KINGDOM, ⁹University College London, London, UNITED KINGDOM, ¹⁰Hong Kong Center for Neurodegenerative Diseases, Hong Kong, CHINA.

OP-105

The functional long-distance relationship of amyloid and tau pathology

M. Hoening¹, A. Weller², E. Doering³, G. Bischoff⁴, A. Drzezga⁴, T. van Eimeren⁴; ¹Research Center Juelich, Juelich, GERMANY, ²University of Cologne, Cologne, GERMANY, ³German Center for Neurodegenerative Diseases, Bonn, GERMANY, ⁴University Clinic Cologne, Cologne, GERMANY.

OP-106

Validation of a topographic visual assessment method for ¹⁸F-Flortaucipir based on Subtype and Stage Inference Model (SuStaln)

G. Mathoux^{1,2}, C. Boccalini^{3,4}, A. Arnone³, D. E. Peretti³, M. Scheffler⁵, G. B. Frisoni^{6,7}, V. Garibotto^{2,3,8};

¹Università degli Studi di Milano-Bicocca, Monza, ITALY, ²Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, SWITZERLAND, ³Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND, ⁴Università Vita e Salute San Raffaele, Milano, ITALY, ⁵Division of Radiology, Geneva University Hospitals, Geneva, SWITZERLAND, ⁶Memory Clinic, Department of Rehabilitation and Geriatrics, Geneva University and University Hospitals, Geneva, SWITZERLAND, ⁷Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, SWITZERLAND, ⁸CIBM Center for Biomedical Imaging, Geneva, SWITZERLAND.

OP-107

A Biological Staging Scheme for Alzheimer's disease: Results from the Tau Propagation over Time (T-POT) Cohort

E. Doering¹, M. Hömig², V. Dzialis¹, J. Lothmann¹, K. Gieh³, H. Theis³, E. Jäger¹, G. Andrassy¹, A. Bauer², D. Elmenhorst², T. Kroll⁴, A. Matusch², P. Krapf⁵, B. Neumaier⁶, C. Lerche², L. Tellmann⁵, S. Frensch², P. Zeyen⁶, F. Sand⁶, N. Richter⁶, F. Jessen⁶, Ö. Onur³, A. Ramirez⁶, T. van Eimeren³, A. Drzezga¹, G. Bischof⁷;

¹University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Nuclear Medicine, Cologne, GERMANY, ²Research Center Jülich, Institute of Neuroscience and Medicine - Molecular Organization of the Brain (INM-2), Juelich, GERMANY, ³University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, GERMANY, ⁴Research Center Jülich, Institute of Neuroscience and Medicine - Nuclear Chemistry (INM-5), Juelich, GERMANY, ⁵Research Center Jülich, Institute of Neuroscience and Medicine - Medical Imaging Physics (INM-4), Juelich, GERMANY, ⁶University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Psychiatry, Cologne, GERMANY.

OP-108

[¹⁸F]PI-2620 PET Imaging of 3R Pick Tau in Frontotemporal Lobar Degeneration - A Multi-Centre Study

H. Barthel¹, M. Brendel², V. Villemagne³, K. Marek⁴, T. van Eimeren⁵, M. Rullmann¹, M. Schroeter¹, D. Saur¹, M. Patt¹, J. Classen¹, J. Seiby⁶, A. Drzezga⁵, O. Sabri¹, German Imaging Initiative for Tauopathies;

¹Leipzig University Medical Centre, Leipzig, Germany, GERMANY, ²Ludwig Maximilian University Munich, Munich, GERMANY, ³University of Pittsburgh, Pittsburgh, AL, UNITED STATES OF AMERICA, ⁴InviCRO, Boston, MA, UNITED STATES OF AMERICA, ⁵University of Cologne, Cologne, GERMANY.

OP-109

Tau-PET signal in Alzheimer's disease is related to immune activation and synaptic signaling measured with CSF proteomics

E. Van de Giessen, R. M. Rikken, E. Vromen, E. M. Coomans, D. Visser, F. Barkhof, L. E. Collij, R. Boellaard, S. V. S. Golla, B. N. M. van Berckel, R. Ossenkoppele, A. den Braber, J. Vijverberg, W. M. van der Flier, Y. A. L. Pijnenburg, C. E. Teunissen, P. J. Visser, B. Tijms; Amsterdam UMC, Amsterdam, NETHERLANDS.

OP-110

Regional Desynchronization of Microglial Activity is Associated with Cognitive Decline in Alzheimer's Disease

A. Zatcepin^{1,2}, J. Gnörich^{1,2}, B. Rauchmann³, L. M. Bartos¹, N. Franzmeier^{4,5,6}, M. Malpette⁷, X. Xiang^{8,9}, Y. Shi², S. Parhizkar¹⁰, M. Grosch¹¹, K. Wind-Mark^{1,2}, S. T. Kunte¹, L. Beyer¹, G. Biechele¹, A. Finze¹, F. Eckenweber¹, P. Bartenstein¹, S. Tahirovic², M. Simons^{2,4,6}, C. Haass^{2,8,6}, R. Rupprecht^{1,2}, N. L. Albert^{1,13,14}, G. U. Höglinger^{2,15,16}, S. I. Zielger¹, M. Brendel^{1,2,6};

¹Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, ²German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY, ³Department of Radiology, University Hospital, LMU Munich, Munich, GERMANY, ⁴Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, GERMANY, ⁵Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, ⁶Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY, ⁷Department of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UNITED KINGDOM, ⁸Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, LMU Munich, Munich, GERMANY, ⁹CAS Key Laboratory of Brain Connectome and Manipulation, the Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundam. Res. Inst., Shenzhen, CHINA, ¹⁰Department of Neurology, Washington University in St. Louis, St. Louis, MO, UNITED STATES OF AMERICA, ¹¹German Center for Vertigo and Balance Disorders, University Hospital of Munich, LMU Munich, Munich, GERMANY, ¹²Department of Psychiatry and Psychotherapy, Molecular Neurosciences, University of Regensburg, Regensburg, GERMANY, ¹³German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ¹⁴Bavarian Cancer Research Center (BZKF), Erlangen, GERMANY, ¹⁵Department of Neurology, University Hospital, LMU Munich, Munich, GERMANY, ¹⁶Department of Neurology, Hannover Medical School, Hannover, GERMANY.

OP-111

PET-based synaptic density measure, its amyloid-independent association with APOE e4 in cognitively impaired individuals

K. He¹, F. Xie¹, Y. Huang², K. Chen³, Y. Guan¹, B. Li⁴, J. Wang⁵, Q. Huang⁵;

¹Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, ²PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, New Haven, CT, UNITED STATES OF AMERICA, ³Banner Alzheimer Institute, Arizona State University, University of Arizona and Arizona Alzheimer's Consortium, Phoenix, AZ, UNITED STATES OF AMERICA, ⁴Clinical Neuroscience Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ⁵Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA.

308

Sunday, September 10, 2023, 09:45 - 11:15

Hall F2

Joint Symposium 1 - Cardiovascular + Inflammation & Infection Committee / EACVI: PET in Valvular Diseases - All In!

OP-112

Endocarditis

P. Erba;

Department of Nuclear Medicine, Ospedale Papa Giovanni XXIII, Bergamo, ITALY.

OP-113

Calcification

J. Kwiecinski;

Department of interventional cardiology and angiology, Institute of Cardiology, Warsaw, POLAND.

OP-114

Myocardial Inflammation and Fibrosis

F. Bengel;

Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY.

309

Sunday, September 10, 2023, 9:45 AM - 11:15 AM

Hall G2

e-Poster Presentations Session 2 - Paediatrics Committee: Paediatric Nuclear Medicine & Adults General Nuclear Medicine

EPS-022

Gravity-Assisted Diuresis Renography with method F+10(sp) for clinical management and post-operative assessment of primary megaureter.

G. Tartaglione¹, F. P. Ieria¹, N. Foschi²;

¹Cristo Re Hospital, Nuclear Medicine, Rome, ITALY, ²Urology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY.

EPS-023

Evaluation of the use of [^{99m}Tc]Tc-MAG3 in the quantification of effective renal plasmatic flow in patients with autosomal dominant renal polycystosis. Preliminary data

L. Baz-Sanz, R. Maestre-Cutillas, G. Rubio-Fernández, M. Álvarez-Nadal, L. Cebollada-Cameo, R. Castro-Velasco, C. Juan-Piriz, J. Pérez-Iruela; Hospital Ramón y Cajal, Madrid, SPAIN.

EPS-024

Comparison Between In Vivo Gates Method and In Vitro Plasma Sampling Technique for Glomerular Filtration Rate Measurement in Voluntary Kidney Donors

M. Radulovic, M. Sisic, B. Miljuš, L. Radosavcev, B. Ajdinovic; Institute of Nuclear Medicine, Military Medical Academy, Belgrade, SERBIA.

EPS-025

Glomerular filtration rate quantification in patients on antiretroviral therapy. Preliminary data

L. Baz-Sanz, R. Maestre-Cutillas, G. Rubio-Fernández, V. Lopes-Martin, L. Cebollada-Cameo, M. Vaquero-Palomo, S. Horcas-Villaverde, J. Pérez-Iruela; Hospital Ramón y Cajal, Madrid, SPAIN.

EPS-026

Body surface area as a determining factor in assessing glomerular filtration rate

G. Rubio-Fernández, R. Maestre-Cutillas, L. Baz-Sanz, L. Cebollada-Cameo, V. Lopes-Martin, M. Vaquero-Palomo, S. Horcas-Villaverde, J. Pérez-Iruela; Hospital Ramón y Cajal, Madrid, SPAIN.

EPS-027

Estimation of GFR Using Camera Based Method- Is There Any Role of CT?

S. Garg¹, S. G. Ravindra¹, A. Khurana¹, K. J. Das², A. Singha², V. Jaiswal², C. S. Bal¹;

¹All India Institute of Medical Sciences, New Delhi, INDIA, ²National Cancer Institute - AIIMS, Jhajjar, INDIA.

EPS-028

Predictive role of ¹⁸F-FDG PET/CT in renal function in patients with kidney disease

H. Jiao, Y. Qiu, Z. Chen, Y. Fan, L. Kang; Peking University First Hospital Beijing, CHINA.

EPS-029

Clinical Significance of SPECT/CT Imaging in Dynamic Renal Scintigraphy for Work-up of Patients with Different Nephro-urological Conditions

T. Sofiyanski¹, S. Sergieva¹, M. Dimcheva¹, B. Robev²; ¹Sofia Cancer Center, Sofia, BULGARIA, ²University Hospital St. Ivan Rilski, Sofia, BULGARIA.

EPS-030

Added value of SPECT/CT to Planar Lymphoscintigraphy in Patients with Secondary Extremity Lymphedema: A Retrospective Cohort Study

H. Yoon¹, D. Kim², K. Woo³, B. Kim¹, J. Kim⁴;

¹Department of Nuclear Medicine, Ewha Womans University School of Medicine, Seoul, KOREA, REPUBLIC OF, ²Department of Emergency Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, KOREA, REPUBLIC OF, ³Department of Plastic Surgery, Ewha Womans University School of Medicine, Seoul, KOREA, REPUBLIC OF, ⁴Department of Nuclear Medicine Ewha Womans University Mokdong Hospital, Seoul, KOREA, REPUBLIC OF.

EPS-031

Analysis and clinical response to bile acid sequestrants of patients with diarrhoea and borderline ⁷⁵SeHCAT results

S. Bondia-Bescós, P. Notta, M. Pudis, B. Hervás-Sanz, J. Díaz-Moreno, A. Rodríguez-Gasen, A. Palomar-Muñoz, J. Robles-Barba, M. Cortés-Romera; Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital, Barcelona, SPAIN.

EPS-032

Ukrainian experience of interictal FDG PET/CT brain scan for pharmaco-resistant epilepsy in children as a part of a presurgical assessment

O. Oliinichenko¹, M. Tkachenko²;
¹Kyiv Center of Nuclear Medicine, Kyiv, UKRAINE,
²Bogomolets National Medical University, Kyiv, UKRAINE.

EPS-033

Age variations in the normal physiological distribution of 18F-FDG

J. Hagerman¹, D. Minarik², E. Trädgårdh¹, J. Oddstig²;
¹Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund/Malmö, SWEDEN, ²Radiation Physics, Skåne University Hospital, Lund/Malmö, SWEDEN.

EPS-034

The impact of the COVID-19 pandemic on oncological disease extent in children at FDG PET/MR staging

Y. Xu;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EPS-035

¹⁸F-FDG PET/MR Imaging findings of pediatric neuroblastoma with different MYCN amplification status

J. Liang;
杭州通用医学影像诊断中心,杭州, CHINA.

EPS-036

Value of qPET in Pediatric Patients With Hodgkin Lymphoma

M. Mehesen^{1,2}, E. Moussa^{3,2}, M. S. Zaghloul^{1,2}, M. Elwakeel^{1,2}, W. Elsayed^{1,2}, N. Ali^{1,2};
¹National Cancer Institute, Cairo, EGYPT,
²Children's Cancer Hospital Egypt, Cairo, EGYPT,
³Menoufya University, Menoufya, EGYPT.

EPS-037

Role of semi-quantitative assessment of ¹²³I-MIBG uptake in pediatric neuroblastoma. Does semiquantitative evaluation of uptake improve the diagnostic accuracy of ¹²³I-MIBG scintigraphy in pediatric neuroblastoma ?

C. Altini¹, M. Villani¹, M. Pizzoferrero¹, A. Castellano², A. Serra², M. De Ioris², D. Ciucci³, C. Polito³, E. Solfaroli Camillocci³, V. Cannata³, E. Villanucci¹, V. Nicoloso¹, G. Marchetti¹, M. Garganese¹;
¹IRCCS Bambino Gesù Children's Hospital, Nuclear Medicine Unit, Imaging Department, Rome, ITALY,
²IRCCS Bambino Gesù Children's Hospital, Department of Oncohematology, Rome, ITALY, ³IRCCS Bambino Gesù Children's Hospital, Medical Physics Unit, Rome, ITALY.

EPS-038

Dynamic Renal Scintigraphy In Pediatric Hydronephrosis: Impact In Therapeutic Decision

L. Zaabar^{1,2}, M. ElOuni³, T. Ben Ghachem^{1,2}, D. Ben Sellem^{1,2}, B. Letaie^{1,2}, A. Mhiri^{1,2};
¹Salah Azaeiz Institute, Tunis, TUNISIA, ²Faculté de Médecine de Tunis, Tunis, TUNISIA, ³Health Ministry, Tunis, TUNISIA.

EPS-039

Predicting the clinical outcome of antenatally detected unilateral pelvi-ureteric junction obstruction.

R. Belakroum;
Central Military Hospital, Algiers, ALGERIA.

EPS-040

A Classic Never Goes Out of Style: Fusion Kidney Malformations, a 10 Years Retrospective Analysis

I. Grierosu^{1,2}, R. Tibu², I. Starcea^{1,3}, A. Mocanu³, R. Bogos³, T. Lazaruc³, R. Stamate², L. Rau², D. Raileanu², V. Cernov², A. Iacoban¹, W. Jalloul¹, T. Ionescu¹, C. Stolniceanu¹, A. Statescu², C. Stefanescu^{1,2};
¹UMF Iasi, ROMANIA, ²County Emergency Hospital „Sf. Spiridon”, Iasi, ROMANIA, ³Emergency Children Hospital „Sf. Maria”, Iasi, ROMANIA.

EPS-041

Risk of renal damage in children with VUR grade III according to ^{99m}Tc-DMSA scan grading

D. Chroustova¹, J. Trnka¹, J. Langer¹, I. Urbanova², L. Cerna¹, R. Kocvara¹;
¹Charles University, 1st Faculty of Medicine and General University Hospital, Prague, CZECH REPUBLIC, ²University Hospital Bulovka, Prague, CZECH REPUBLIC.

310

Sunday, September 10, 2023, 09:45 - 11:15

Hall K

CTE 2 - Technologists Committee: Head and Neck Updates

OP-116

Head and Neck molecular imaging – state of the art

W. Cholewiński;
Greater Poland Cancer Centre/Poznan University of Medical Sciences, Nuclear Medicine/ Electroradiology Department, Poznan, POLAND.

OP-117

Head and Neck cancer patient management using the PET-MRI method

M. Kinggaard Federspiel;
Rigshospitalet, Copenhagen, DENMARK.

OP-118

New radiopharmaceuticals for Head and Neck tumours evaluation and therapy

G. Gorgoni;
IRCCS Sacro Cuore, Department of Radiopharmacy, Negrar di Valpolicella Verona, ITALY.

401

Sunday, September 10, 2023, 11:30 - 13:00

Hall A

Plenary 2: New Imaging Techniques - Jump Aboard or Watch and Wait

OP-119

Introduction by Chairpersons

OP-120

AI technology: living up to expectations?

F. Buffa;
Bocconi University, Department of Computing Sciences, Milan, ITALY.

OP-121

SPECT/CT CZT based systems: jump aboard

L. Imbert;
CHRU Nancy, Nancy, FRANCE.

OP-122

SPECT/CT CZT based systems: watch and wait?

J. Dickson;
University College London Hospitals, Institute of Nuclear Medicine, London, UNITED KINGDOM.

OP-123

Total Body PET: watch and wait?

A. Dimitrakopoulou-Strauss;
German Cancer Research Center, Heidelberg, GERMANY.

OP-124

Total Body PET: jump aboard

A. Rominger;
University of Bern, Inselspital, Dept. of Nuclear Medicine, Bern, SWITZERLAND.

OP-125

PET/MR: is it still worth it?

S. Wan;
University College London Hospitals, Institute of Nuclear Medicine, London, UNITED KINGDOM.

OP-126

Innovation and sustainability in Nuclear Medicine: the IAEA perspective

May Abdel-Wahab;
IAEA, Vienna, AUSTRIA

501

Sunday, September 10, 2023, 15:00 - 16:30

Hall A

CME 3 - Cardiovascular Committee: Nuclear Imaging in Cardiac Amyloidosis - What Else?

OP-127

Background and novel therapies

M. Papathanasiou;
University Hospital Essen, University Duisburg-Essen, West German Heart- and Vascular Center, Department of Cardiology and Vascular Medicine, Essen, GERMANY.

OP-128

Bone scan – all you need to know

O. Lairez;
Cardiology Department, Rangueil University Hospital, Toulouse, FRANCE.

OP-129

PET – do we really need it?

D. Genovesi;
Fondazione Toscana Gabriele Monasterio, Division of Nuclear Medicine, Pisa, ITALY.

OP-130

Nuclear imaging for therapy response

H. Tingen;
University Medical Center G, Groningen, NETHERLANDS.

502

Sunday, September 10, 2023, 15:00 - 16:30

Hall D (Arena)

Challenge the Expert 2 - Oncology & Theranostics Committee: Risk in Diagnostic and Therapeutic Nuclear Medicine

OP-131

Radiation risks in Nuclear Medicine: informed consent and effective communication

S. Leide Svegborn;
Skåne University Hospital, Department of Radiation Physics, Malmö, SWEDEN.

OP-132

Challenger cases

R. Teixeira Ferreira;
Hospital Garcia de Orta, E.P.E., Department of Nuclear Medicine, Almada, PORTUGAL.

OP-133a

Challenger cases

J. Castro Ferro;
Department of Nuclear Medicine, Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E, Porto, PORTUGAL.

OP-133b

Challenger cases

B. Ribeiro Pereira;
Department of Nuclear Medicine, Centro Hospitalar Universitário de São João, E.P.E, Porto, PORTUGAL.

OP-133c

Challenger cases

M. Monteiro;
Department of Nuclear Medicine, Centro Hospitalar e Universitário de Coimbra, E.P.E, Coimbra, PORTUGAL.

503

Sunday, September 10, 2023, 15:00 - 16:30

Hall E1

LIPS Session 3 - Thyroid Committee: Rational Use of PET/CT with 18F-FDG in DTC

OP-134

Adding FDG-PET to the diagnostic work-up of indeterminate thyroid nodules: expensive gadget or cost-effective?

L. de Geus-Oei;
Leiden University Medical Center (LUMC), Department of Radiology, Leiden, NETHERLANDS.

OP-135

18F-FDG in staging DTC: when and why

S. Kusacic Kuna;
Clinical Department of Nuclear Medicine and Radiation Protection, University Hospital Centre, Zagreb, CROATIA

OP-136

Role of 18F-FDG in restaging DTC and as a tool for response evaluation

M. Tuncel;

Department of Nuclear Medicine, Hacettepe University, Ankara, TÜRKIYE.

504

Sunday, September 10, 2023, 3:00 PM - 4:30 PM
Hall E2

M2M Track - TROP Session: Radioligand Therapy - New and Old Targets

OP-137

Preclinical Characterization of a Novel EphA2-Targeted Peptide Radioligand for Treatment of Solid Tumors

G. Li¹, R. Clift¹, S. Richardson¹, T. Ehara², H. Yanagida², I. Hung¹, Z. Amso¹, K. Salvador¹, M. Guest¹, G. Han¹, A. Bhat¹, D. Cole¹, E. Bischoff¹;

¹RayzeBio, San Diego, CA, UNITED STATES OF AMERICA, ²PeptiDream, Kawasaki-Shi, JAPAN.

OP-138

Preclinical Characterization of a Novel Peptide Binder to Glypican-3 for Targeted Radiopharmaceutical Therapy of Hepatocellular Carcinoma

G. Li¹, F. Lin¹, R. Clift¹, T. Ehara², H. Yanagida², S. Horton¹, K. Salvador¹, S. Richardson¹, M. Guest¹, A. Noncovich¹, A. Bhat¹, G. Han¹;

¹RayzeBio, San Diego, CA, UNITED STATES OF AMERICA, ²PeptiDream, Kawasaki, JAPAN.

OP-139

A Novel Anti-L1CAM Antibody-Radionuclide-Conjugate (ARC) as New Treatment Option for Ovarian Cancer

C. Geraths¹, M. Behe², D. Winkler¹, M. Hackebeil¹, A. Blanc², T. Chiorazzo², S. Imobersteg², R. van der Kant^{3,4}, J. Schymkowitz^{3,4}, F. Rousseau^{3,4};

¹CIS Pharma AG, Bubendorf, SWITZERLAND, ²Paul-Scherrer-Institut, Villigen, SWITZERLAND, ³Switch Laboratory - VIB KU Leuven Center for Brain and Disease Research, Leuven, BELGIUM, ⁴KU Leuven - Department of Cellular and Molecular Medicine, Leuven, BELGIUM.

OP-140

In vitro evaluation of [²²⁵Ac]Ac-DOTA-C595 for pancreatic ductal adenocarcinoma

A. Hull¹, W. Hsieh², W. Tieu³, A. Borysenko⁴, D. Bartholomeusz², E. Bezak¹;

¹University of South Australia, Adelaide, AUSTRALIA, ²SA Medical Imaging, Adelaide, AUSTRALIA, ³The University of Adelaide, Adelaide, AUSTRALIA, ⁴Environment Protection Authority, Adelaide, AUSTRALIA.

OP-141

Preclinical Comparison of the GRPR Antagonists AMTG and RM2 Labelled With Terbium-161 and Lutetium-177 - A PRISMAP Project

T. Günther¹, N. Holzleitner¹, T. Cwojdzinski¹, R. Beck¹, N. Urtz-Urban¹, C. C. Hillhouse², P. V. Grundler², N. P. van der Meulen², Z. Talip², S. Ramaekers³, M. Van de Voorde³, B. Ponsard³, A. Casini¹;

¹Technical University of Munich, Garching, GERMANY, ²Paul Scherrer Institute, Villigen, SWITZERLAND, ³Belgian Nuclear Research Centre, Mol, BELGIUM.

OP-142

Preclinical Evaluation of a ⁶⁸Ga/¹⁷⁷Lu-based CXCR4 Radioligand: A Theranostic Tool Against Advanced Prostate Cancer

I. Astiazaran-Rascon^{1,2}, H. Kuo¹, H. Merken¹, N. Colpo¹, P. Ng¹, C. Ong^{2,3}, Y. Wang^{1,2,3}, K. Lin^{1,2}, F. Bénard^{1,2};

¹BC Cancer, Vancouver, BC, CANADA, ²University of British Columbia, Vancouver, BC, CANADA, ³Vancouver Prostate Center, Vancouver, BC, CANADA.

OP-143

Albumin Binder-modified Radiolabeled Heterodimer Probe for Cancer Imaging and Therapy

B. Yang, Y. Gai, X. Song, X. Lv, Y. Long, Y. Wang, Y. Feng, R. An, X. Lan;

Dept of Nuclear Medicine and PET center, Union Hospital, Tongji Medical College, HUST, Wuhan, CHINA.

OP-144

Preclinical Evaluation of [²¹²Pb]VMT-α-NET Targeted Alpha Therapy for High-Risk Metastatic Neuroblastoma

D. Liu¹, J. T. Ewald¹, Z. Dai², C. Robels-Plannels³, B. S. Cagle¹, S. N. Rodman III¹, M. Li¹, R. Rastogi², E. Sagastume¹, F. L. Johnson¹, D. Zepeda-Orozco³, M. K. Schultz^{1,2};

¹Perspective Therapeutics Inc, Coralville, IA, UNITED STATES OF AMERICA, ²University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA, ³Nationwide Children's Hospital, Columbus, OH, UNITED STATES OF AMERICA.

OP-145

Preclinical Evaluation of ²²⁵Ac-rhPSMA-10.1, a Novel Radiohybrid PSMA Compound for Targeted Alpha Therapy of Prostate Cancer

V. Vassileva¹, B. Waldron¹, A. Wurzer², C. D'Alessandria², R. Veggerby Grønlund³, M. Wikke Hallund³, D. Gauden¹, D. Stevens¹, **C. Foxton**¹;

¹Blue Earth Therapeutics, Oxford, UNITED KINGDOM, ²Department of Nuclear Medicine, Technical University of Munich, Munich, GERMANY, ³Minerva Imaging, Ølstykke, DENMARK.

505

Sunday, September 10, 2023, 3:00 PM - 4:30 PM
Hall B

Cutting Edge Science Track - TROP Session: From Cells to Human via the Fish

OP-146

Radiosensitivity of neuroendocrine cancer cells to ¹⁷⁷Lu-DOTATATE and radiobiological implications for peptide radionuclide therapy

G. Tamborino^{1,2}, P. Engbers^{2,1}, T. de Wolf^{2,1}, T. Reuvers^{2,1}, M. Konijnenberg¹, J. Nonnekens^{2,1};

¹Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, NETHERLANDS, ²Department of Molecular Genetics, Erasmus University Medical Center, Rotterdam, NETHERLANDS.

OP-147

Stochastic microscale dosimetry in breast cancer micrometastasis model for alpha-emitter radiopharmaceutical therapy

R. Bastiaannet, M. Hasan, I. Liatsou, R. F. Hobbs, G. Sgouros;

Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.

OP-148

Nephron Morphology Influences the Dosimetry of Microscopic Renal Tissues of Non-Uniform Activity Distributions of Alpha Particle and Low Energy Electron Emitters

M. Andersson^{1,2}, N. Goudin³, M. Pontoglio⁴, H. Levillain², N. Reynaert², C. Saldarriaga Vargas¹;

¹Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM, ²Faculté de Médecine, Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ³Necker Bioimage Analysis platform SFR Necker US24/UAR 3633, Paris, FRANCE, ⁴Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Université de Paris, Paris, FRANCE.

OP-149

Small-scale anatomical modeling of the salivary gland for alpha-particle and beta-particle radiopharmaceutical therapy

R. Hobbs, I. Marsh, R. Bastiaannet, I. Liatsou, C. Brayton, K. Gabrielson, T. Yusufaly;

Johns Hopkins, Baltimore, MD, UNITED STATES OF AMERICA.

OP-150

Zebrafish embryos as experimental model to advance pre-clinical research in nuclear medicine

C. Morgat^{1,2}, G. Siefried^{3,4}, S. Bodin^{1,2}, F. Cavelier⁵, E. Hindie^{1,2,6}, M. Khatib³;

¹Nuclear Medicine Department - University Hospital of Bordeaux, Bordeaux, FRANCE, ²INCLIA, University of Bordeaux, CNRS, EPHE, UMR 5287, Bordeaux, FRANCE, ³RyTME, Bordeaux Institute of Oncology (BRIC)-UMR1312 Inserm, Pessac, FRANCE, ⁴Xenofish, Pessac, FRANCE, ⁵Institut des Biomolécules Max Mousseron IBMM, UMR 5247 Pôle Chimie Balard, Montpellier, FRANCE, ⁶Institut Universitaire de France, Paris, FRANCE.

OP-151

Biodistribution and dosimetry of lipiodol with various beta emitters: a preclinical study

A. Dieudonne¹, R. Santus², P. Vera¹, S. Becker¹, X. Violas²;

¹LITIS-Quantif, Centre Henri Becquerel, Rouen, Rouen, FRANCE, ²Research and Development Division, Laboratoire Guerbet, Aulnay-sous-Bois, FRANCE.

OP-152

DNA damage repair in PBMCs after internal ex vivo irradiation with ¹⁷⁷Lu

I. Strobel¹, H. Scherthan², J. Hahn¹, J. Müller¹, S. Schumann¹, A. K. Buck¹, M. Port², M. Lassmann¹, U. Eberlein¹;

¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, GERMANY.

OP-153

From bench to bedside: ⁶⁴Cu/¹⁷⁷Lu 1C1m-Fc anti TEM-1: mice-to-human dosimetry extrapolations for future theranostic applications

J. Delage¹, N. Chouin², M. Cherep³, S. M. Dunn⁴, N. Schaefer⁵, A. Faivre-Chauvet³, J. O. Prior⁵, S. Gnesin⁶;

¹Radiopharmacy Unit, Department of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, ²University of Nantes, Inserm, CNRS, University of Angers, Oniris, CRCI2NA, Nantes, FRANCE, ³University of Nantes, CHU Nantes, CNRS, Inserm, CRCINA, Nantes, FRANCE, ⁴LabCore, Ludwig Institute for Cancer Research, Lausanne University Hospital and University of Lausanne, Epalinges, SWITZERLAND, ⁵Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, ⁶Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND.

OP-154

Simulations of the relative effectiveness of tumor stroma and cancer cell targeting radiopharmaceuticals

Y. Song^{1,2}, J. Brosch-Lenz¹, C. D'Alessandria¹, K. Shi³, W. Weber¹;

¹Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, GERMANY, ²Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ³Department of Nuclear Medicine, Inselspital, University of Bern, Bern, SWITZERLAND.

506

Sunday, September 10, 2023, 3:00 PM - 4:30 PM
Hall C

Clinical Oncology Track - TROP Session: Gastrointestinal Malignancies

OP-155

Evaluation of [64Cu]Cu-ATSM PET-CT as a response predictor to neoadjuvant therapy in locally advanced rectal cancer: preliminary results

M. Le Thiec¹, L. Ferrer^{1,2}, M. Colombié¹, M. Lacombe³, A. Devillers⁴, P. Salaün^{5,6}, S. Hiret¹, J. Raimbourg¹, L. Doucet¹, E. Rio¹, S. Lesourd⁴, P. Tremolières³, M. Heymann^{1,7}, N. Varmenot^{1,2}, A. Vidal^{8,9,10}, F. Haddad^{8,9,10}, N. Allam¹, M. Chérel^{1,2}, F. Kraeber-Bodéré^{1,2}, L. Champion¹, M. Bourgeois^{11,2,8}, C. Rousseau^{1,2};

¹ICO Gauducheau, Saint Herblain, FRANCE, ²Nantes Université, Univ Angers, INSERM, CNRS, CRCI2NA, Nantes, FRANCE, ³ICO Papin, Angers, FRANCE, ⁴Cancer Institute Eugène Marquis, Rennes, FRANCE, ⁵University Hospital, Brest, FRANCE, ⁶UMR Inserm 1304 GETBO, University Western Brittany, Brest, FRANCE, ⁷Research pathology platform, Tumor Heterogeneity and Precision Medicine, Saint-Herblain, FRANCE, ⁸Arronax, Saint-Herblain, FRANCE, ⁹SUBATECH, IMT Atlantique, CNRS/IN2P3, Nantes, FRANCE, ¹⁰Université de Nantes, Nantes, FRANCE, ¹¹CHU Nantes, Nantes, FRANCE.

OP-156

The effect of free thyroxine on glucose metabolic activity in primary hepatic neoplasm: A study of PET-CT scans

Z. Zhao¹, X. Wang², J. Xiao¹, D. Wang¹, Z. Luo¹;
¹Affiliated Hospital of Guangdong Medical University, Zhanjiang, CHINA, ²Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, CHINA.

OP-157

Assesment of biological parameters of esophageal cancer in pre-, and post-treatment 18F-FDG-PET/CT in patient with early relapse.

A. Filipczuk¹, A. Lewandowska¹, A. Pietrzak¹, W. Cholewiński²;
¹Greater Poland Cancer Center, Poznan, POLAND, ²Medical University of Poznan, Poznan, POLAND.

OP-158

Comparison of 18F-FDG PET/CT and 18F-FDG PET/MRI in Detection of Liver Lesions in Hepatocellular Carcinoma for Staging and Restaging

B. Demir¹, C. Soydal¹, E. Dursun¹, M. Araz¹, D. Kuru Oz², N. O. Kucuk¹;
¹Ankara University School of Medicine Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Ankara University School of Medicine Department of Radiology, Ankara, TÜRKIYE.

OP-159

A proposed first-line treatment regime for Lenvitinib or Nivolumab based on dual-tracer PET/CT may improve progression free survival for advanced stage HCC patients

S. Chen, S. Cheung, K. Cheng, Y. Yip, W. Leung, C. Ho;
Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

OP-160

18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as Early Predictive Factors of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib: a prospective multicentric study

V. BESSON¹, C. Tabouret-Viaud¹, A. Fouquier², J. Bronowicki³, E. Chevalier⁴, A. Heurgue⁵, D. Papanthassiou⁶, J. Blanc⁷, J. Pinaquy⁸, L. Bengrine⁹, X. Palard¹⁰, H. Bourien¹¹, A. Bertaut², S. Manfredi¹², A. Cochet¹³;

¹Department of Nuclear Medicine, Centre Georges François Leclerc, Dijon, FRANCE, ²Department of Statistics, Centre Georges-François Leclerc, Dijon, FRANCE, ³Department of Gastro-Enterology and Hepatology, University Hospital of Nancy, Nancy, FRANCE, ⁴Department of Nuclear Medicine, University Hospital of Nancy, Nancy, FRANCE, ⁵Department of Hepato-Gastro-Enterology, University Hospital of Reims, Reims, FRANCE, ⁶Department of Nuclear Medicine, Institut Jean Godinot, Reims, FRANCE, ⁷Department of Hepato-Gastro-Enterology, University Hospital of Bordeaux, Bordeaux, FRANCE, ⁸Department of Nuclear Medicine, University Hospital of Bordeaux, Bordeaux, FRANCE, ⁹Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, FRANCE, ¹⁰Department of Nuclear Medicine, Centre Eugene-Marquis, Rennes, FRANCE, ¹¹Department of Medical Oncology, Centre Eugene-Marquis, Rennes, FRANCE, ¹²Department of Hepato-Gastro-Enterology, Dijon, FRANCE, ¹³ICMUB, UMR CNRS 6302, University of Burgundy, Dijon, FRANCE.

OP-161

Assessing the performance of 68Ga-Fibroblast activating protein inhibitor-04 (FAPI) PET/CT in the diagnosis of cholangiocarcinoma - A prospective pilot study.

D. Halanaik, V. Rajaraman, L. Aridhasan Meenakshi, A. Jeba Selvaraj, B. Pottakkat;
Jawaharlal Institute of postgraduate medical education and Research, Puducherry, INDIA.

OP-162

Static and Dynamic 68Ga-FAPI PET/CT in Mass Forming Pancreatitis and Pancreatic Ductal Adenocarcinomas (PDAC)

M. Preussig¹, M. Lang², C. Schroeter¹, E. Gutjahr³, U. Haberkorn¹, M. Röhrich¹;
¹Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY, ²Department of General, Visceral, and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, GERMANY, ³Department of Pathology, University Hospital Heidelberg, Heidelberg, GERMANY.

OP-163

The Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT on Detecting Lesions and Altering Stage in Patients With Digestive System Malignancies With Non-FDG-avid Lesions

G. Beydagi¹, N. Alan-Selcuk¹, K. Akcay¹, E. Demirci¹, O. Sonmez², M. Ocak³, T. Toklu¹, S. Celik⁴, B. B. Oven⁴, L. Kibasakal^{1,5};
¹Yeditepe University, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²Yeditepe University, Faculty of Medicine, Istanbul, TÜRKIYE, ³Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul, TÜRKIYE, ⁴Yeditepe University, Department of Medical Oncology, Istanbul, TÜRKIYE, ⁵Istanbul University-Cerrahpasa, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

507

Sunday, September 10, 2023, 3:00 PM - 4:30 PM
Hall F1

Paediatrics Committee - TROP Session: Adults General Nuclear Medicine

OP-164

The value of chemokine receptor type 4 targeted PET imaging in primary aldosteronism preoperative localization diagnosis compared with adrenal venous sampling

N. Lu¹, C. Li¹, Y. Tian¹, Z. Xiao¹, D. Xing¹, J. Zhong¹, W. Li¹, D. Zeng¹, W. Luo¹, H. Guo¹, Z. Meng², Y. He¹;
¹Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA, ²Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, CHINA.

OP-165

Incidental Findings on 18F-Fluorocholine PET for Parathyroid Imaging

A. Namazova¹, A. NAZARI¹, B. Ince², S. Sağer¹, K. Sonmezöglü¹;
¹Istanbul University-Cerrahpaşa, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²Istanbul University-Cerrahpaşa, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

OP-166

Correlation between kidney 18F-FDG uptake and renal function in patients with chronic kidney disease.

F. Dondi¹, A. Talin², D. Albano², A. Calabrò², M. T. Volpe², P. Furtuna², F. Bertagna²;
¹Spedali Civili di Brescia, Brescia, ITALY, ²Università degli Studi di Brescia, Brescia, ITALY.

OP-167

Renal blood flow quantification for the evaluation of stress induced kidney imaging using Rubidium-82 PET/CT

A. van de Burgt^{1,2}, F. H. P. van velden², F. Smit^{1,2}, L. F. de Geus-Oei^{2,3,4}, I. A. Dekkers²;
¹Alrijne hospital, Leiderdorp, NETHERLANDS, ²Leiden University Medical Center, Leiden, NETHERLANDS, ³University of Twente, Enschede, NETHERLANDS, ⁴Delft University of Technology, Delft, NETHERLANDS.

OP-168

Segmentation and Volumetric Analysis of Pulmonary Reperfusion after Pulmonary Thromboembolism using Lung Perfusion SPECT/CT

N. Alvarez Mena, F. Sebastián Palacid, M. García Aragón, R. Zambrano Infantino, A. Hurtado Romero, R. Ruano Pérez;
Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

OP-169

Could FAPI and MIBI scans help in diagnostic dilemmas in interstitial lung disease (ILD) for distinguishing fibroinflammatory process? Ongoing translational exploratory study

M. Assadi¹, M. Bahtouee², E. Jafari¹, R. Mazarei², M. Khazaei³;
¹Department of Nuclear Medicine, Molecular Imaging, and Theranostics, Bushehr Medical University Hospital, School of Medicine, Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF, ²Department of Internal Medicine (Division of Pulmonary Medicine), Bushehr Medical Center Hospital, Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF, ³Department of Radiology, Bushehr Medical Center Hospital, Bushehr University of Medical Sciences, Bushehr, IRAN, ISLAMIC REPUBLIC OF.

OP-170

The Role Of [99mTc] Sodium Pertechnetate Pulmonary Ventilation Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) In The Early Location Of Prolonged Pulmonary Air Lack In Adults. Our Experience.

A. Peñaherrera Cepeda, F. Gómez Caminero, J. Villanueva Curto, J. Badell Martínez, E. Campaña Díaz, P. García Talavera, E. Martín Gómez, S. Rama Alonso, M. Fuentes Gago, P. Tamayo Alonso;
Complejo asistencial universitario de Salamanca, Salamanca, SPAIN.

OP-171

Oropharyngo-esophageal scintigraphy (OPES) in Systemic Sclerosis Patients: A Valuable Tool for Evaluating Dysphagia

A. Marciano¹, M. Di Battista², M. Scarpuzza¹, A. Ambrogio¹, G. Nonne¹, A. Leo¹, E. Esposito¹, A. Valevich², M. Grosso¹, D. Volterrani¹;
¹Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, ITALY, ²Rheumatology Unit, University of Pisa, Pisa, ITALY.

OP-172

Correlation Between Lymphoscintigraphy And Clinical Staging In Diagnosis Of Lymphedema

A. Kilicaslan, B. Okudan Tekin;
Ankara City Hospital, Ankara, TÜRKIYE.

508

Sunday, September 10, 2023, 15:00 - 16:30
Hall F2

Joint Symposium 2 - Oncology & Theranostics Committee / EORTC: Nuclear Medicine Imaging of the Immune System

OP-173

Molecular Imaging of the Immune System

W. Cai;
University of Wisconsin, Molecular Imaging and Nanotechnology Laboratory, Madison, UNITED STATES OF AMERICA.

OP-174

Radiolabeled Markers of Immune Response
S. Heskamp;

Radboud University Medical Center, Department of Medical Imaging (Nuclear Medicine), Nijmegen, NETHERLANDS.

OP-175

Imaging Tumor Metabolism and its Heterogeneity
E. Lopci;

IRCCS-Humanitas Research Hospital, Nuclear Medicine, Milan, ITALY.

OP-176

Translating Immuno-PET for immune-oncology treatments into the Clinic
E. G. E. de Vries;

University Medical Centre Groningen, Department of Medical Oncology, Groningen, NETHERLANDS.

509

Sunday, September 10, 2023, 3:00 PM - 4:30 PM
Hall G2

e-Poster Presentations Session 3 - Inflammation & Infection Committee: More on Infection and Inflammation Imaging

EPS-042

Role of scintigraphy in the staging of necrotizing otitis externa in diabetics

T. Ben Ghachem, R. Ghodhbane, L. Zaabar, I. Slim, A. Mhiri; Salah Azaiez Institute, Tunis, TUNISIA.

EPS-043

A promising tool for excluding knee and hip prosthetic infection with a novel semiquantitative index in double-phase bone scintigraphy

R. Zambrano Infantino, J. Piñerúa-Gonsálves, F. Sebastian Palaciá, N. Álvarez Mena, M. Alonso Rodríguez, M. García Aragón, B. Pérez López, C. Gamazo Laherran, M. González Soto, R. Ruano Pérez; Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

EPS-044

Assessment of disease severity in Sjögren's syndrome using semi- quantitative parameters on salivary gland scintigraphy.

T. Singhal, P. Singh, A. Rehman, K. Kandula, G. Parida, P. Kumar, K. Bishnoi, R. Emerson, S. Patro, K. Agrawal; AIIMS Bhubaneswar, Bhubaneswar, INDIA.

EPS-045

Oral Gallium -67 citrate Scintigraphy as a new highlighter for guided biopsies colonoscopy in Inflammatory bowel disease.

J. Calegari, J. Tajra^{1,2}, J. Tajra³; ¹Secretaria de Estado de Saúde, Brasília, BRAZIL, ²Hospital de Base do Distrito Federal, Brasília, BRAZIL, ³Centro Universitário UNIEURO, Brasília, BRAZIL.

EPS-046

Evolving Nuclear Imaging of Infection - The South African Initiative for Novel Radiopharmaceuticals

T. Ebenhan^{1,2}, A. H. Mdlophane^{3,4}, J. Duvenhage¹, C. A. Grouws^{5,1}, M. Katho-Lundie⁶, O. Gheysens⁷, T. Govender^{8,3}, T. Naicker^{5,3}, H. G. Kruger⁵, J. Zeevaart^{4,2,3}, M. M. Sathekege^{3,9}; ¹Preclinical Imaging Facility, Nuclear Medicine Research Infrastructure NPC, Pretoria, SOUTH AFRICA, ²Nuclear Medicine, University of Pretoria, Pretoria, SOUTH AFRICA, ³Nuclear Medicine Research Infrastructure NPC, Pretoria, SOUTH AFRICA, ⁴Radiochemistry, Necs, Pelindaba, SOUTH AFRICA, ⁵Catalysis and Peptide Research Unit, University of KwaZulu Natal, Durban, SOUTH AFRICA, ⁶Radiochemistry, Sefako Makgatho Health Science University, Pretoria, SOUTH AFRICA, ⁷Department of Nuclear Medicine, Cliniques Universitaires Saint- Luc, and Institute of Clinical and Experimental Research, Université Catholique de Louvain, Leuven, BELGIUM, ⁸Department of Chemistry, University of Zululand, KwaDlangezwa, SOUTH AFRICA, ⁹Nuclear Medicine and Steve Biko Academic Hospital, University of Pretoria, Pretoria, SOUTH AFRICA.

EPS-047

The Importance of FDG PET/CT in the Diagnosis of Left Ventricular Assist Device Infection

Y. Okar, I. Sezgin, R. Horal, M. Urhan, B. Akkas; Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TÜRKIYE.

EPS-048

Clinical Value and Utility of the ¹⁸F-FDG PET/CT in Detecting Prosthetic Infection After the Aortic Valve and Thoracic Aorta Reconstruction.

V. Carrero-Vásquez¹, I. Sánchez-Rodríguez¹, F. Escrihuela-Vidal², L. Gracia-Sánchez¹, P. Notta¹, M. Pudiš¹, S. Bondia-Bescós¹, A. Blasco³, B. Hervás-Sanz¹, C. Martínez-Ramos¹, P. Perlaza-Jiménez¹, M. Cortés-Romera¹; ¹Nuclear Medicine Department, Bellvitge University Hospital, Barcelona, SPAIN, ²Infectious Diseases Department, Bellvitge University Hospital, Barcelona, SPAIN, ³Cardiovascular Surgery Department, Bellvitge University Hospital, Barcelona, SPAIN.

EPS-049

Role of [¹⁸F]FDG PET/CT in patients with suspected ventricular assist device infection. Experience in a PET/CT dedicated cardio center.

B. Hervás Sanz¹, L. M. Gràcia-Sánchez¹, I. E. Sánchez-Rodríguez¹, P. C. Notta¹, V. A. Carrero-Vásquez¹, C. Martínez-Ramos¹, A. Palomar-Muñoz¹, M. Pudiš¹, S. Bondia-Bescós¹, J. L. Díaz-Moreno¹, C. Díez-López², J. González-Costello², L. Herrador-Galindo², F. Escrihuela-Vidal³, N. Sabé-Fernández³, D. Ortiz-Berbel⁴, K. Osorio-Higa⁴, M. Cortés-Romera¹; ¹Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ²Cardiology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ³Infectious Disease Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ⁴Cardiovascular Surgery Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EPS-050

Assesment Of Splenic And Bone Hypermetabolism As Indirect Signs Of Infection/ Inflammation In Patients With Suspected Infective Endocarditis Or Implantable Cardiac Device Infection.

A. Padilla Bermejo¹, F. J. Pena Pardo¹, M. Amo Salas², M. N. Sicilia Pozo¹, C. Lucas Lucas¹, M. Contreras Ameduri¹, L. García Zoghby³, M. Cruz Montijano³, E. Noriega Álvarez¹, A. M. García Vicente³, Á. Soriano Castrejón³, M. P. Talavera Rubio¹, V. M. Poblete García¹; ¹Nuclear Medicine Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN, ²Mathematics Department, Castilla la Mancha University of Ciudad Real, Ciudad Real, SPAIN, ³Nuclear Medicine Department, University General Hospital of Toledo, Toledo, SPAIN.

EPS-051

Assessment in clinical practice of the valvular uptake index with [¹⁸F]FDG-PET/CT in patients with prosthetic valve endocarditis

S. Guzmán Ortiz, B. Rodríguez Alfonso, K. Velásquez Díaz, I. Obedkova, M. Grajeda Gallardo; Puerta de Hierro University Hospital, Madrid, SPAIN.

EPS-052

Utility of PET/CT with ¹⁸F-FDG for the localization of malignant and pre-malignant colorectal disease and its correlation with different microorganisms in patients studied for suspected prosthetic infective endocarditis and/or intracardiac devices.

J. Badell, F. Gómez-Caminero López, P. García-Talavera San Miguel, J. C. Cañadas Salazar, E. Campaña Díaz, S. López Puche, S. Rama Alonso, E. Casillas Sagrado, P. Tamayo Alonso; Hospital Clínico Universitario de Salamanca, Salamanca, SPAIN.

EPS-053

The Role of [¹⁸F]FDG-PET/MRI in Patients with Large-Vessel Vasculitis

G. Argalia¹, M. Fogante², G. Biscontin¹, F. M. Fringuelli¹, A. Palucci¹, C. Romagnolo¹, C. Cottignoli¹, N. Schicchi², P. Esposto Pirani², P. Fraticelli³, L. Burroni¹; ¹Nuclear Medicine, Department of Radiological Sciences, University Hospital of Marche, Ancona, ITALY, ²Radiology, Department of Radiological Sciences, University Hospital of Marche, Ancona, ITALY, ³Internal Medicine, Department of Radiological Sciences, University Hospital of Marche, Ancona, ITALY.

EPS-054

Role of ¹⁸F-FDG PET/CT in patients with Hemophagocytic lymphohistiocytosis (HLH)

R. Goel, K. Chandekar, N. A. Damle, Y. Dharmashaktu, C. Bal, R. Kumar, M. Tripathi, P. Kumar; All India Institute of Medical Sciences (AIIMS), New Delhi, INDIA.

EPS-055

Establishing The Ideal Time Point In Imaging Patients With ^{99m}Tc-Ethambutol Scintigraphy In Extrapulmonary Tuberculosis

D. Khan, N. A. Damle, S. Sagar, A. Ghazal, V. Tiwari, C. Bal, M. Tripathi, S. Sikdar, P. Ranjan, V. Manhas, P. Kumar; AIIMS Delhi, Delhi, INDIA.

EPS-056

¹⁸F-FDG PET/CT metabolic parameters as predictors of immune status and disease severity in the patients with non-tuberculous mycobacteria

D. Chen¹, Y. Chen², S. Yang¹, T. Li¹, K. Liu¹, Z. Wang¹, T. Zhang¹, G. Wang¹, K. Zhao¹, X. Su¹; ¹Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA, ²State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Hangzhou, CHINA.

EPS-057

Correlation of Total Lesion Glycolysis with Inflammatory and Immune Biomarkers in Talaromyces Marneffeii Infection Patients: A Cross-sectional and Longitudinal FDG PET/CT Study

W. Bao¹, X. Zhang¹, Q. Huang¹, S. Ren¹, F. Hua², C. Zuo¹, F. Xie¹, Y. Guan¹; ¹Huashan Hospital, Shanghai, CHINA, ²Longhua Hospital, Shanghai, CHINA.

EPS-058

Head-to-head comparison of ¹⁸F-FDG PET and labelled leucocyte scintigraphy for the monitoring of treatment response in malignant external otitis

S. Melki¹, M. Hurstel¹, A. Vasseur², D. Nguyen², C. Rumeau², A. Verger^{1,3}; ¹Department of Nuclear Medicine and Nancyclotep, University Hospital of Nancy, Nancy, FRANCE, ²Department of ENT, University Hospital of Nancy, Nancy, FRANCE, ³IADI, INSERM, UMR 1254, Université de Lorraine, 54000, Nancy, FRANCE.

EPS-059

Dynamic [¹⁸F]FDG PET/CT imaging with a LAFOV PET/CT camera system to differentiate between infection and inflammation.

N. D. van Rijsewijk, J. H. van Snick, F. F. A. Ijpmma, M. Wouthuyzen-Bakker, J. van Sluis, A. W. J. M. Glaudemans; University Medical Center Groningen, Groningen, NETHERLANDS.

EPS-060

Exploring the clinical ambit of ⁶⁸Ga-NOTA-UBI PET/CT as an infection imaging technique

N. Damle, Y. Dharmashaktu, A. Singhal, S. Ballal, R. Goel, S. D. Maurya, V. Tiwari, A. Gawande, S. Sagar, J. Jaleel, C. Bal, M. Ansari, V. Kumar; All India Institute of Medical Sciences, New Delhi, INDIA.

EPS-061

Correlation Between Emotional and Psychological Symptoms and Brain Glucose Metabolism on PET/CT in Patients with Long Covid

L. Wichert-Ana, D. L. Ferreira, L. E. Lopes-Santos, A. C. Trevisan, G. D. Angelis, J. S. Sakamoto, B. G. Coretti, L. Alexandre-Santos, M. P. Foss, O. Y. Fukumori, M. Kato, F. A. Pitella, V. Tumas, F. B. Rodrigues; Ribeirão Preto Medical School - University of São Paulo, Ribeirao Preto, BRAZIL.

EPS-062

Brain Perfusion SPECT, DAT SPECT, and [18F]FDG PET/CT and PET/MRI Findings in Patients with Long COVID

L. Wichert-Ana¹, L. S. C. Wellington¹, L. E. Lopes-Santos¹, K. J. C. C. Lacerda¹, V. R. Sá², F. E. Padovan-Neto²;
¹Ribeirão Preto Medical School - University of São Paulo, Ribeirão Preto, BRAZIL, ²Department of Psychology, Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, Ribeirão Preto, BRAZIL.

510

Sunday, September 10, 2023, 3:00 PM - 4:30 PM
Hall K

Technologists Oral Presentations 1: SPECT-CT in Diagnosis and Therapy

OP-177

Deep learning-based abnormality classification in ¹²³I-ioflupane SPECT imaging

T. Yamao, R. Yamakuni, N. Takahashi, K. Miwa, Y. Kaneko, N. Miyaji, H. Ito;
Fukushima Medical University, Fukushima, JAPAN.

OP-178

Quantitative evaluation of SPECT/CT performance for therapeutic Lu177 radionuclide with NEMA standards

P. Dwivedi¹, V. Sawant¹, A. Jha², V. Rangarajan²;
¹Advanced Centre for Treatment Research and Education In Cancer, Mumbai, INDIA, ²Tata Memorial Hospital, Mumbai, INDIA.

OP-179

Broad quantification calibration of various isotopes for quantitative analysis and the assessment of their SUVs in a SPECT/CT scanner

H. Ko, J. Choi, S. Park;
Asan Medical Center, Seoul, KOREA, REPUBLIC OF.

OP-180

Differential Diagnosis of Lewy Body Dementia and Alzheimer's Disease in ECD SPECT Images Using 2D and 3D CNN Methods

Y. Ni¹, Z. Lin¹, S. Tsen¹, M. Pa², P. Chiu³, G. Hung⁴, K. Lin⁵, I. Hsiao⁶, C. Chang⁷, Y. Chang⁸;
¹Health Physics Division, Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, TAIWAN, ²Alzheimer's Disease Research Center, National Cheng Kung University Hospital, Taiwan, TAIWAN, ³Department of Neurology, Show Chwan Memorial Hospital, Changhua, TAIWAN, ⁴Department of Nuclear Medicine, Chang Bing Show Chwan Memorial Hospital, Changhua, TAIWAN, ⁵Department of Nuclear Medicine and Molecular Imaging Center, Linkou Chang Gung Memorial Hospital, Taoyuan, TAIWAN, ⁶Department of Medical Imaging and Radiological Sciences & Healthy Aging Center, Chang Gung University, Taoyuan, TAIWAN, ⁷Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TAIWAN, ⁸Department of Neurology, Institute of translational research in biomedicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, TAIWAN.

OP-181

Validation of dramatic CT topogram dose reduction with use of tin filter

K. Christensen¹, P. C. Holdgaard¹, L. L. Østergård¹, N. A. Bebbington²;
¹Lillebaelt University Hospital, Vejle, Vejle, DENMARK, ²Siemens Healthcare A/S, Aarhus, DENMARK.

OP-182

Clinical Application of SPECT Phantoms Created Using Paper Phantoms

T. Nagahara¹, T. Katafuchi², T. Inagaki¹, R. Isobe¹, K. Kato¹;
¹Nagoya University Graduate School of Medicine, Nagoya, JAPAN, ²Gifu University, Gifu, JAPAN.

OP-183

SPECT/CT-ONLY Imaging for Sentinel Lymph Node Biopsy in Breast Cancer: Efficient and Effective

B. Bosveld¹, R. A. Valdés Olmos², W. van der Bruggen¹, C. D. Bavelaar-Croon³, B. F. Bulten¹;
¹Slingeland Hospital, Doetinchem, NETHERLANDS, ²Leiden University Medical Center, Leiden, NETHERLANDS, ³Alexander Monro Hospital, Bilthoven, NETHERLANDS.

OP-184

Contamination of the Isolation Room After Iodine-131 Ablation Treatment

K. Levänen, N. Miettinen, H. Leskinen, J. Heikkinen;
Department of Radiology and Nuclear Medicine, The wellbeing services county of South Savo, Mikkeli, FINLAND.

OP-185

Dose rate evaluation of patients performing diagnostic Nuclear Medicine procedures

A. Santos, P. Colarinho;
Hospital Cuf Descobertas, Lisbon, PORTUGAL.

511

Sunday, September 10, 2023, 3:00 PM - 4:30 PM
Hall G1

Theranostics Track - Oncology & Theranostics Committee / EARL - Featured Session: Old but Novel Techniques

OP-186

K. Herrmann;
University Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY.

OP-187

Predictive value of [18F]F-Choline and PSMA-based quantitative parameters for response to [177Lu]Lu-PSMA-617 therapy in mCRPC: The added value of dynamic FDG acquisition using Patlak method

S. Miet¹, B. Maucherat¹, P. Baumgartner¹, E. Picot-Dilly¹, P. Lalire¹, A. Morel-Thierry¹, D. Rusu¹, M. Le Thiec¹, V. Nicolas², F. Rolland¹, C. Rousseau², L. Ferrer²;
¹ICO René Gauducheau, F-44800 Saint-Herblain, Nantes, FRANCE, ²ICO René Gauducheau, F-44800 Saint-Herblain, Nantes Université, Univ Angers, INSERM, CNRS, CRCI2NA, F-44000, Nantes, FRANCE.

OP-188

FAP-Targeted Radiopeptide Therapy using ¹⁷⁷Lu-, ²²⁵Ac-and⁹⁰Y-labeled 3BP-3940 in Diverse Advanced Solid Tumors: First-in-Humans Results

J. Zhang¹, V. Jakobsson¹, A. Mishra², A. Eismant², L. Greifenstein³, C. Kramer², A. Klega², C. Landvogt², C. Mueller², R. P. Baum²;
¹National University of Singapore, Singapore, SINGAPORE, ²Curanosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY.

OP-189

Static and dynamic ⁶⁸Ga-FAPI-46 PET in ¹⁸F-FDG-negative pulmonary lesions - target validation and imaging properties

M. Roehrich, J. Daum, J. Hoppner, F. Eichhorn, K. Schlamp, E. Gutjahr, H. Winter, U. Haberkorn;
University Hospital Heidelberg, Heidelberg, GERMANY.

OP-190

⁶⁸Ga-FAPI-46 vs ¹⁸F-FDG PET/CT and contrast-enhanced CT in patients with advanced gastrointestinal stroma tumors (GIST)

T. Bartel¹, K. M. Pabst¹, A. Milosevic², S. Bauer³, J. Falkenhorst³, H. Lanzafame¹, I. A. Mavroei³, M. Nader¹, J. T. Siveke^{3,4,5}, K. Herrmann¹, R. Hamacher³, W. P. Fendler¹;
¹Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, GERMANY, ²Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, GERMANY, ³Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany, Essen, GERMANY, ⁴Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, GERMANY, ⁵Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, Partner Site Essen) and German Cancer Research Center, DKFZ, Heidelberg, GERMANY.

OP-191

Radiolabeled Somatostatin Receptor Antagonist versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-resistant Meningiomas - Phase 0 Part of the Promenade Study

C. Eigler¹, L. McDougall¹, A. Bauman¹, P. Bernhardt², M. Hentschel¹, K. A. Blackham¹, G. Nicolas¹, M. Fani¹, D. Cordier¹, D. Wild¹;
¹University Hospital Basel, Basel, SWITZERLAND, ²University of Gothenburg, Gothenburg, SWEDEN.

OP-192

Inter-institutional differences and common ground in ¹⁷⁷Lu-PSMA radionuclide therapy: International survey in 95 theranostic centers

A. Farolfi^{1,2}, W. Armstrong², L. Djaileb³, A. Gafita⁴, M. Hotta², M. Auerbach², L. Unterrainer², W. P. Fendler⁵, M. Rettig⁶, M. Eiber⁷, M. Hofman⁸, B. Hadaschik⁹, K. Herrmann⁵, J. Czernin², J. Calais², M. Benz²;
¹Division of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ²Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, ³Nuclear Medicine Department, Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, FRANCE, ⁴The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA, ⁵Department of Nuclear Medicine and German Cancer

Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, ⁶Department of Urology, University of California Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, ⁷Department of Nuclear Medicine, Klinikum Rechts Der Isar, Technical University of Munich, Munich, GERMANY, ⁸Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ⁹Department of Urology, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, GERMANY.

OP-193

Safety and dosimetry evaluation of personalized dose I131-apamistamab prior to HCT in the phase 3 SIERRA trial for patients with relapsed/refractory acute myeloid leukemia (R/R AML)

N. Pandit-Taskar¹, M. Natwa², M. Chen³, W. Yap⁴, G. Wiseman⁵, E. Leung⁶, A. Desai⁷, P. Brodin⁷, E. Haeuber⁷, A. Nahar⁷, R. L. Wahl⁸;
¹Molecular Imaging and Therapy, Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, ²Ohio State University, Columbus, OH, UNITED STATES OF AMERICA, ³Yale New Haven Hospital, New Haven, CT, UNITED STATES OF AMERICA, ⁴University of Kansas Medical Center, Kansas City, KS, UNITED STATES OF AMERICA, ⁵Mayo Clinic Rochester, Rochester, MN, UNITED STATES OF AMERICA, ⁶The Ottawa Hospital, Ottawa, ON, CANADA, ⁷Actinium Pharmaceuticals, Inc., New York, NY, UNITED STATES OF AMERICA, ⁸Washington University St. Louis, St. Louis, MO, UNITED STATES OF AMERICA.

OP-194

⁸⁹Zr-DFO-girentuximab PET/CT imaging for clear cell renal cell carcinoma - ZIRCON study results of diagnostic performance, including in very small lesions

S. Martina¹, P. Mulders², B. M. Shuch³, A. J. Pantuck³, M. A. Morris⁴, V. Master⁵, A. Scott^{6,7,8}, C. van Praet⁹, C. Bailly¹⁰, B. Önal^{11,12}, T. Aksoy¹³, R. Merks², D. M. Schuster⁵, S. Lee¹⁴, N. Pandit-Taskar^{15,16}, A. C. Fan¹⁷, L. Tauchmanova¹, K. Schmidt¹⁸, P. Allman¹⁹, K. Vadali¹, C. Hayward¹, J. Bernhard²⁰;
¹Telix Pharmaceuticals, Melbourne, AUSTRALIA, ²Radboud University Medical Center, Nijmegen, NETHERLANDS, ³UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, ⁴Advanced Molecular Imaging and Therapy, Glen Burnie, MD, UNITED STATES OF AMERICA, ⁵Emory University School of Medicine, Atlanta, GA, UNITED STATES OF AMERICA, ⁶Austin Health, Melbourne, AUSTRALIA, ⁷University of Melbourne, Melbourne, AUSTRALIA, ⁸Olivia Newton-John Cancer Research Institute, Melbourne, AUSTRALIA, ⁹Universitair Ziekenhuis Gent, Gent, BELGIUM, ¹⁰Nantes University Hospital, Nantes, FRANCE, ¹¹Istanbul University, Istanbul, TÜRKIYE, ¹²Cerrahpasa Medical, Istanbul, TÜRKIYE, ¹³Istanbul Training and Research Hospital, Istanbul, TÜRKIYE, ¹⁴Austin Health, Heidelberg, AUSTRALIA, ¹⁵Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, ¹⁶Weill Cornell Medical Center, New York, NY, UNITED STATES OF AMERICA, ¹⁷Stanford University School of Medicine, Stanford, CA, UNITED STATES OF AMERICA, ¹⁸ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH, Dresden, GERMANY, ¹⁹Premier Research, Morrisville, NC, UNITED STATES OF AMERICA, ²⁰CHU de Bordeaux, Bordeaux, FRANCE.

601

Sunday, September 10, 2023, 16:45 - 18:15
Hall A

CME 4 - Oncology & Theranostics
Committee: Update in Multiple Myeloma

OP-195

Genomic vs FDG Patterns

C. Nanni;
IRCCS Azienda Ospedaliero-Universitaria di Bologna,
Nuclear Medicine, Bologna, ITALY.

OP-196

Radioligand Therapy

A. Buck;
University Hospital Würzburg, Dept. Of Nuclear
Medicine, Würzburg, GERMANY.

OP-197

FDG PET/CT, DWI or Both?

C. Mesguich;
Nuclear Medicine Department, Centre Hospitalier
Universitaire de Bordeaux, Pessac, FRANCE.

OP-198

ImmunoPET

F. Krabere-Bodere;
Nuclear Medicine department, CHU Nantes, ICO,
CRCINA, Nantes University, Nantes, FRANCE.

602

Sunday, September 10, 2023, 16:45 - 18:15
Hall D (Arena)

Challenge the Expert 3 - Dosimetry
Committee: Dosimetry Live

OP-199

Dosimetry Calculation Live on Stage

M. Konijnenberg;
Eurasmus MC, Radiology & Nuclear
Medicine, Rotterdam, NETHERLANDS.

OP-200

Dosimetry Calculation Live on Stage

J. Gear;
Royal Marsden NHSFT, Sutton, UNITED KINGDOM.

OP-201

Dosimetry Calculation Live on Stage

C. Stokke;
Division of Radiology and Nuclear Medicine, Oslo
University Hospital, Oslo, NORWAY, Department
of Physics, University of Oslo, Oslo, NORWAY.

603

Sunday, September 10, 2023, 16:45 - 18:15
Hall E1

LIPS Session 4 - Oncology & Theranostics
Committee: Residents for Residents

OP-206

PET/CT cases in thoracic oncological disorders

R. Metz;
CHU Nantes, Service de Médecine
Nucléaire, Nantes, FRANCE.

OP-207

PET/CT cases in abdominal/pelvic oncological
disorders

S. Himmen;
University Hospital Essen, Nuclear
Medicine, Essen, GERMANY.

OP-208

PET/CT cases in neurology

S. Sperti;
University of Padova, Nuclear Medicine, Padova, ITALY.

OP-209

PET/CT cases in infectious diseases

S. Erdkamp;
Amsterdam UMC, Department of Radiology and
Nuclear Medicine, Amsterdam, NETHERLANDS.

604

Sunday, September 10, 2023, 4:45 PM - 6:15 PM
Hall E2

M2M Track - TROP Session: Novel Imaging
Targets in Oncology

OP-212

Computer-Aided Development of Trop-2-Targeted
Peptides for Radiotheranostic Applications for
Pancreatic Cancer

H. Hong¹, J. Hu¹, Y. Cong¹, X. Li¹, Y. Wang²;
¹Nanjing University, Nanjing, CHINA, ²China
Pharmaceutical University, Nanjing, CHINA.

OP-213

Glioblastoma and Pancreatic Adenocarcinoma -
Versatile radiolabeled probe targeting Low Density
Lipoprotein Receptors (LDLR)

I. Tworowska¹, L. Flores¹, X. Qu¹, C. Malicet², R. Zielinski³, P.
Lecorche¹, E. Delpassand⁴, J. Temsamani⁵;
¹RadioMedix Inc., Houston, TX, UNITED STATES
OF AMERICA, ²Vect-Horus, Marseille, FRANCE,
³MDAnderson, Houston, TX, UNITED STATES OF
AMERICA, ⁴RadioMedix, Houston, TX, UNITED STATES OF
AMERICA, ⁵Vect-Horus, Marseille Cedex 15, FRANCE.

OP-214

Preparation and preclinical evaluation of ACE1
targeting molecular probe ⁶⁸Ga-DOTA-BPP

Q. Zhang, Z. Yang, Z. Hua;
Peking University Cancer Hospital, Beijing, CHINA.

OP-215

Construction of a novel PET probe of Iodine-124
labeled ADC for Trop-2 targeting and Micro-PET
imaging

Z. Zeng¹, D. Li¹, X. Yan², L. Li¹, J. Ding¹, X. Sheng², H. Zhu¹, Z.
Yang¹;
¹Department of Nuclear Medicine, Peking University
Cancer Hospital & Institute, Beijing, CHINA, ²Department
of Genitourinary Oncology, Peking University
Cancer Hospital & Institute, Beijing, CHINA.

OP-216

Immuno-PET Imaging of Tumor Mesothelin
Expression with Gallium-68 Radiolabeled
Nanobody

X. Lv^{1,2}, Z. Xu³, X. Song^{1,2}, Y. Gai^{1,2}, D. Jiang^{1,2}, P. Lei³, W. Wei⁴,
Y. Zhang^{1,2}, R. An^{1,2}, X. Lan^{1,2};
¹Department of Nuclear Medicine, Union Hospital,
Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, CHINA, ²Hubei
Province Key Laboratory of Molecular Imaging,
Wuhan, CHINA, ³Department of Immunology, School
of Basic Medicine, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, CHINA,
⁴Department of Nuclear Medicine, Institute of Clinical
Nuclear Medicine, Renji Hospital, School of Medicine,
Shanghai Jiao Tong University, Shanghai, CHINA.

OP-217

CD70-targeted immunoPET imaging of renal
carcinomas

X. Zhou, Q. Xia, J. Liu, W. Wei;
shanghai jiaotong university, Shanghai, CHINA.

OP-218

Screening, development and preliminary
evaluation of CLDN18.2 specific peptide PET probes

Z. Wang¹, C. Zhao², J. Ding¹, H. Zhu¹;
¹Key Laboratory of Carcinogenesis and Translational
Research (Ministry of Education/Beijing), Key Laboratory for
Research Evaluation of Radiopharmaceuticals (National
Medical Products Administration), Department of Nuclear
Medicine, Peking University Cancer Hospital, Beijing, CHINA,
²Key Laboratory of Carcinogenesis and Translational
Research (Ministry of Education/Beijing), Department of
Biochemistry and Molecular Biology, Peking University
Cancer Hospital and Institute, Beijing, Beijing, CHINA.

OP-219

Immuno-PET of Colorectal Cancer with A CEA-
Targeted ⁶⁸Ga-Nanobody: From Bench to Bedside

L. Li¹, X. Lin¹, X. Ma¹, F. Liu¹, B. Jia², Z. Yang¹;
¹Peking University Cancer Hospital & Institute,
Beijing, CHINA, ²Peking University, Beijing, CHINA.

OP-220

Increasing the Tumor-to-Blood Ratio by Click-
Cleavable Radioimmunoimaging with [⁸⁹Zr]Zr-DFO-
Trans-Cyclooctene-Trastuzumab in Mice

K. E. de Roode^{1,2}, M. Vlastara¹, R. Rossin¹, F. J. M. Hoeben³,
M. Boswinke², L. H. J. Kleijn¹, J. Nagarajah², S. Heskamp², M.
Rijkema², M. S. Robillard¹;
¹Tagworks Pharmaceuticals, Nijmegen, NETHERLANDS,
²Department of Medical Imaging, Radboud
University Medical Centre, Nijmegen, NETHERLANDS,
³SyMO-Chem, Eindhoven, NETHERLANDS.

605

Sunday, September 10, 2023, 4:45 PM - 6:15 PM
Hall B

Cutting Edge Science Track - TROP Session:
Segmentation and Denoising

OP-221

Deep learning is a promising tool for fully automatic
malignant lesions identification and segmentation
in whole-body bone scans

F. Oliveira, A. Silva, J. Castanheira, M. Silva, C. Constantino,
D. C. Costa;
Champalimaud Foundation, Lisboa, PORTUGAL.

OP-222

Using a 3-D UNet artificial intelligence model to
segment PSMA-avid lesions in ⁶⁸Ga-PSMA-11 PET/
CT images

E. Greenblatt¹, M. Maker¹, A. Kadumberi¹, S. Wail², P. Kuo¹;
¹Invicro, Needham, MA, UNITED STATES OF AMERICA,
²Telix Pharmaceuticals, North Melbourne, AUSTRALIA.

OP-223

A Feature-Based Ensemble of 3D U-Nets
for Computed Tomography (CT) Lung Lobe
Segmentation

E. Amini^{1,2}, R. Klein^{1,3,4};
¹Ottawa Hospital Research Institute, Ottawa, ON,
CANADA, ²Carleton University, Ottawa, ON, CANADA,
³The Ottawa Hospital Department of Nuclear
Medicine, Ottawa, ON, CANADA, ⁴University of Ottawa
Department of Medicine, Ottawa, ON, CANADA.

OP-224

Improving Automated Lesion Detection and
Segmentation in PET/CT Scans: A Comparative
Study of 3D UNet-Based Configurations

M. Namías, Y. V. Rotstein Habarnau;
Fundación Centro Diagnóstico Nuclear,
Buenos Aires, ARGENTINA.

OP-225

A Hybrid Neural Network Architecture to improve
low-dose PET Image Reconstruction

S. Kaviani¹, A. Sanaat², M. Mokri¹, C. Cohalan³, J. Carrier^{1,4};
¹Université de Montréal, Montréal, QC, CANADA,
²University of Geneva, Geneva, SWITZERLAND,
³CHUM - Centre hospitalier de l'Université de Montréal,
Montréal, QC, CANADA, ⁴CHUM - Centre hospitalier
de l'Université de Montréal, Montreal, QC, CANADA.

OP-226

A deep learning method for the recovery of
standard-dose imaging quality from ultra-low-dose
PET on wavelet domain

S. Xue¹, F. Liu¹, H. Wang², M. Viscione¹, R. Guo², A.
Rominger¹, B. Li², K. Shi¹;
¹University of Bern, Bern, SWITZERLAND, ²Shanghai Jiao
Tong University School of Medicine, Shanghai, CHINA.

OP-227

Sequential Deep Learning Image Enhancement Models Improve Diagnostic Confidence, Lesion Detectability and Image Reconstruction Time in PET
M. Dedja¹, A. Mehranian², K. M. Bradley³, M. D. Walker¹, S. D. Wollenweber⁴, R. Johnsen⁴, D. R. McGowan^{1,5};
¹Oxford University Hospitals, Oxford, UNITED KINGDOM, ²GE Healthcare, Oxford, UNITED KINGDOM, ³Cardiff University, Cardiff, UNITED KINGDOM, ⁴GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA, ⁵University of Oxford, Oxford, UNITED KINGDOM.

OP-228

The Effect of Multimodal Anatomical Images in Deep Learning-enhanced Low-dose Amyloid PET Imaging
S. Kuo¹, M. Lee¹, C. Ko², K. T. Chen¹;
¹National Taiwan University, Taipei, TAIWAN, ²National Taiwan University Hospital, Taipei, TAIWAN.

OP-229

Iterative Deep-Learning Denoising in Bone SPECT-CT Reconstruction Based on Simulations from Clinical Data
O. Ziv¹, B. Yuzefovich¹, J. Sachs¹, G. Kovalski¹;
GE Healthcare, Haifa, ISRAEL.

606

Sunday, September 10, 2023, 4:45 PM - 6:15 PM
Hall C

Clinical Oncology Track - TROP Session: Neuroendocrine Tumors Treatment

OP-230

A phase I theranostic study evaluating the safety and tolerability of ¹⁷⁷Lu-satoreotide tetraxetan with ⁶⁸Ga-satoreotide trizoxetan companion imaging in participants with extensive-stage small-cell lung cancer (ES-SCLC) on atezolizumab maintenance therapy
L. Emmett¹, J. Cardaci², K. O'Byrne³, S. Arulananda⁴, A. Prawira⁵, B. Pais^{6,7}, M. Crumbaker¹, N. Lenzo⁸;
¹St Vincent's Hospital, Sydney, AUSTRALIA, ²Hollywood Private Hospital, Nedlands, AUSTRALIA, ³Princess Alexandra Hospital, Brisbane, AUSTRALIA, ⁴Monash Health, Clayton, AUSTRALIA, ⁵Obatica, Zetland, AUSTRALIA, ⁶Ariceum Therapeutics, Berlin, GERMANY, ⁷SRT-Biomedical, Soest, NETHERLANDS, ⁸GenesisCare, Murdoch, AUSTRALIA.

OP-231

Evaluation of Progression-Free Survival (PFS) in Patients with Advanced, Non-resectable, Progressive GEP-NET Treated Using Combine Radioligand and CAPTEM therapy.
J. Cwikla¹, A. Zrajtkowska², G. Nowicka³, J. Pałucki⁴, N. Seklecka², A. Kolasińska-Cwikla²;
¹University of Warmia and Mazury, Olsztyn, POLAND, ²Diagnostic and Therapy Center – "Gammed" Warsaw, Poland, Warsaw, POLAND, ³Warsaw Medical University, Warsaw, POLAND, ⁴Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, POLAND.

OP-232

Safety and organs-at-risk dosimetry in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy (PRRT): data from prospective phase II clinical trial
M. Mileva¹, C. Van Bogaert², G. Marin³, H. Levillain³, C. Artigas¹, C. Marin³, R. Danieli³, A. Deleporte⁴, C. Jungels⁴, B. Vanderlinden³, Z. Wimana^{1,5}, A. Hendlisz⁴, P. Flamen¹, I. Karfis¹;
¹Nuclear Medicine Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM, ²Nuclear Medicine Department, Hôpital Erasme, H.U.B, Brussels, BELGIUM, ³Medical Physics Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM, ⁴Medical Oncology Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM, ⁵Radiopharmacy Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM.

OP-233

Efficacy and Safety of ¹⁷⁷Lu-DOTATATE in Lung Neuroendocrine Tumors: A multicenter study
M. Mitjavila Casanovas¹, V. Pubul², P. Belló³, B. Miguell⁴, J. Cano⁵, D. Balaguer⁶, A. García-Burillo⁷, A. Mariño Méndez⁸, E. Rodeño⁹, A. Custodio¹⁰, A. Piñero¹¹, L. García-Cañamaque¹², M. Castellon¹³, M. Orduña¹⁴, A. Carmona-Bayonas¹⁵, P. Jimenez-Fonseca¹⁶;
¹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, SPAIN, ²Hospital Complejo Universitario Santiago, Santiago de Compostela, SPAIN, ³Hospital Universitario La Fe, Valencia, SPAIN, ⁴Hospital Universitario de Burgos, Burgos, SPAIN, ⁵Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN, ⁶Hospital Universitario Doctor Peset, Valencia, SPAIN, ⁷Hospital Universitario Vall d'Hebron, Barcelona, SPAIN, ⁸Hospital Universitario Central Asturias, Oviedo, SPAIN, ⁹Hospital Universitario Cruces, Bilbao, SPAIN, ¹⁰Hospital Universitario La Paz, Madrid, SPAIN, ¹¹Hospital Universitario Virgen de las Nieves, Granada, SPAIN, ¹²HM Hospitales Madrid, Madrid, SPAIN, ¹³Hospital Universitario Virgen de la Arrixaca, Murcia, SPAIN, ¹⁴Hospital Ramón y Cajal, Madrid, SPAIN, ¹⁵Hospital Universitario Morales Meseguer, Murcia, SPAIN, ¹⁶Hospital Universitario Central de Asturias, Oviedo, SPAIN.

OP-234

Cylindrical TGR as Early Radiological Predictor of RLT Progression in GEPNETs. A Proof of Concept
F. Scalorbi¹, E. Garanzini¹, G. Calareso¹, C. Marzi², S. Mazzaglia³, G. Di Rocco^{1,4}, G. Argiroffi¹, L. Mascitti^{1,4}, M. Cuomo^{1,4}, S. Pusceddu¹, M. Milione¹, M. Baccini², E. Seregni¹, A. Marchianò¹, M. Maccauro¹;
¹Istituto Nazionale Tumori Milano, Milan, ITALY, ²Department of Statistics, Computer Science, Applications (DiSIA), University of Florence, Firenze, ITALY, ³ASST Santi Paolo e Carlo, San Paolo University Hospital, Milan, ITALY, ⁴University of Milan, Milan, ITALY.

OP-235

Safety and Efficacy of Lu-177-DOTATATE in Metastatic or Inoperable Pheochromocytoma/Paraganglioma: An Interim Analysis
F. Lin¹, J. Carrasquillo¹, J. del Rivero¹, I. Shami¹, Z. Joy¹, B. Turkbey¹, J. Klubo¹, Y. Teng², A. Jha¹, E. Mena¹, M. L. Lindenberg¹, C. Chen¹, P. Herscovitch¹, C. Millo¹, K. Pacak¹;
¹National Institutes of Health, Bethesda, MD, UNITED STATES OF AMERICA, ²Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, UNITED STATES OF AMERICA.

OP-236

Efficacy and safety of dosimetry-based, personalized ¹⁷⁷Lu-DOTATATE PRRT of neuroendocrine tumours: an update from the P-PRRT trial
M. Morin¹, F. A. Buteau¹, A. Beaulieu¹, F. Arsenault¹, G. Bouvet¹, A. Desy¹, N. Lafrenière¹, G. April¹, J. M. Beaugregard¹;
Department of Radiology and Nuclear Medicine, and Cancer Research Center, Université Laval, Quebec City, Canada; Department of Medical Imaging, and Research Center (Oncology Axis), CHU de Québec – Université Laval, Quebec City, QC, CANADA.

OP-237

Extended Peptide Receptor Radionuclide Therapy: Evaluation of Nephrotoxicity and Therapeutic Effectiveness in Neuroendocrine Tumor Patients Receiving More Than Four Treatment Cycles
X. Fan¹, T. Zhao², V. Jakobsson², X. Chen², R. P. Baum³, J. Zhang²;
¹Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, CHINA, ²Department of Diagnostic Radiology Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE, ³CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY.

OP-238

Outcome prediction in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy (PRRT): results from a prospective phase II clinical trial
M. Mileva¹, G. Marin², H. Levillain², C. Artigas¹, C. Van Bogaert³, C. Marin², R. Danieli², A. Deleporte⁴, C. Jungels⁴, B. Vanderlinden³, Z. Wimana^{1,5}, A. Hendlisz⁴, P. Flamen¹, I. Karfis¹;
¹Nuclear Medicine Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM, ²Medical Physics Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM, ³Nuclear Medicine Department, Hôpital Erasme, H.U.B, Brussels, BELGIUM, ⁴Medical Oncology Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM, ⁵Radiopharmacy Department, Institut Jules Bordet, H.U.B, Brussels, BELGIUM.

607

Sunday, September 10, 2023, 4:45 PM - 6:15 PM
Hall F1

Cardiovascular Committee - TROP Session: Functional Imaging, Plaque and Total-Body PET

OP-239

Comparing left ventricular function derived from CMR and gated ¹³N-ammonia PET-MPI - An evaluation of reproducibility using hybrid PET/MR
D. F. Sager¹, N. Manz², S. Manser², L. Laubscher³, A. W. Stark⁴, J. Schuetz⁴, P. A. Kaufmann¹, C. Gränit⁴, R. R. Buechel¹;
¹Department of Nuclear Medicine, University Hospital Zurich, Zurich, SWITZERLAND, ²Faculty of Medicine, University of Bern, Bern, SWITZERLAND, ³Department of Health Science and Technology, ETH Zurich, Zurich, SWITZERLAND, ⁴Department of Cardiology, University Hospital Bern, Bern, SWITZERLAND.

OP-240

Use of First-Pass Non-Gated ¹⁵O-water PET for Evaluation of Left Heart Remodelling and Cardiac Function in Severe Mitral Regurgitation
J. Sigfridsson¹, H. J. Harms¹, J. Bergsten¹, M. Lubberink¹, T. Kero¹, T. Baron¹, F. A. Flachskampf¹, J. Sörensen¹;
Uppsala University, Uppsala, SWEDEN.

OP-241

Added value of automatic coronary artery calcium scoring from low dose CT ¹⁵O-water PET scans in MACE prediction in comparison to the reference, calcium scoring CT scans.
M. Dobrolinska¹, R. Jukema², S. van Velzen³, P. van Diemen³, M. Greuter¹, N. Prakken¹, N. van der Werf⁴, P. Rajmakers³, R. Slart¹, P. Knaapen³, I. Isgum³, I. Danad⁴;
¹UMCG, Groningen, NETHERLANDS, ²UMC Amsterdam, Amsterdam, NETHERLANDS, ³Amsterdam UMC, Amsterdam, NETHERLANDS, ⁴UMC Utrecht, Utrecht, NETHERLANDS.

OP-242

Impact of data driven motion correction on accuracy of summed stress and rest scores measured with NH3 cardiac PET.
S. Lazarenko¹, L. van Wunnik¹, F. M. van der Zant¹, T. S. Martinez-Lucio², O. I. Mendoza-Ibanez³, C. Hayden³, B. Spottiswoode³, R. J. J. Knol¹;
¹Noordwest Ziekenhuisgroep, Alkmaar, NETHERLANDS, ²University Medical Centre Groningen, Groningen, NETHERLANDS, ³Siemens Medical Solutions United States Of America, Inc., Knoxville, TN, UNITED STATES OF AMERICA.

OP-243

The role of motion correction tools in left ventricular function parameters as measured by gated ¹³N-NH₃ PET/CT
T. Martinez-Lucio¹, R. J. J. Knol², O. I. Mendoza-Ibanez¹, L. van Wunnik², F. M. van der Zant², C. Tsoumpas¹, R. H. J. A. Slart¹, S. V. Lazarenko²;
¹University Medical Center Groningen, Groningen, NETHERLANDS, ²Northwest Clinics Alkmaar, Alkmaar, NETHERLANDS.

OP-244

The prognostic value of non-perfusion parameters on CZT SPECT in patients with normal myocardial perfusion imaging: a large scale single-center retrospective cohort study.
K. Ko¹, C. Lin², L. Tang², C. Liu², D. Wang³;
¹National Taiwan University Cancer Center, Taipei, TAIWAN, ²National Taiwan University Hospital, Taipei, TAIWAN, ³Tri-Service General Hospital, Taipei, TAIWAN.

OP-245

A machine-learning-based prediction model of lethal arrhythmic events by using the ¹²³I-meta-iodobenzylguanidine derived late heart-to-mediastinum ratio: Application into separate Japanese and European cohorts
K. Nakajima¹, T. Doi², T. Nakata³, H. Tada¹, D. O. Verschuer⁴, V. Frantellizzi⁵, H. J. Verberne⁶;
¹Kanazawa University, Kanazawa, JAPAN, ²Teine Keijinkai Hospital, Sapporo, JAPAN, ³Hokodate-Goryokaku Hospital, Hokodate, JAPAN, ⁴Zaans Medical Center, Zaans, NETHERLANDS, ⁵Sapienza University of Rome, Rome, ITALY, ⁶University of Amsterdam, Amsterdam, NETHERLANDS.

OP-246

Long-axial field-of-view PET/CT scanners improve the detection of inflamed coronary artery plaques with [⁶⁸Ga]Ga-DOTA-TOC imaging

C. Mingels, C. Bregenzer, N. Gözlügöl, L. Knappe, I. Alberts, A. Rominger, **F. Caobelli**;
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

OP-247

Adequacy of whole-body parametric imaging of regional tissue perfusion using the recent total-body PET system and i.v. ¹⁵O-water

H. Iida¹, H. Merisaari², N. Ono³, N. Kudomi⁴, T. Tolvanen⁵, V. Saunavaara⁵, H. Sari⁶, J. Knuuti¹, L. Nummenmaa¹, P. Nuutila¹;
¹Turku PET Centre, University of Turku and Turku University Hospital, Turku, FINLAND, ²Department of Radiology, University of Turku, Turku, FINLAND, ³Nara Institute of Science and Technology, Ikoma, JAPAN, ⁴Kagawa University School of Medicine, Kagawa, JAPAN, ⁵Department of Medical Physics, Turku University Hospital, Turku, FINLAND, ⁶Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, SWITZERLAND.

608

Sunday, September 10, 2023, 4:45 PM - 6:15 PM
Hall F2

Inflammation & Infection Committee - TROP Session: Infection and Inflammation Imaging: New Frontiers

OP-248

^{99m}Tc-Ethambutol Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) Scan in Pulmonary Tuberculosis: Correlation of ^{99m}Tc-Ethambutol Avidity with CT Manifestations

F. Aghahosseini^{1,2}, Y. Salehi^{1,2}, S. Farzanefer^{1,2}, M. Abbasi^{1,2}, F. Saboktakin^{1,2}, N. Vahidfar^{1,2}, P. Sheikhzadeh¹;
¹Tehran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Nuclear Medicine Department, Valiasr Hospital, Imam Khomeini Complex Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF.

OP-249

Head to head comparison of ultrasound and Tc - 99m glucosamine SPECT/CT imaging of patients with rheumatoid arthritis of the knee.

O. Evbuomwan, G. Engelbrecht;
University of The Free State, Bloemfontein, SOUTH AFRICA.

OP-250

SUV-Based Assessment of Known or Suspected Polyarthritis on Double-Phase Whole-Body Bone Tomoscintigraphies Provided by a High-Speed CZT Camera

F. Rajadhas¹, C. Morizot², D. Loeuille², I. Chary-Valckenaere², V. Roch¹, P. Marie^{1,3}, L. Imbert^{1,3}, A. Bahloul^{1,3};
¹CHRU-Nancy, Department of Nuclear Medicine and Nancyclotep Imaging Platform, Nancy, FRANCE, ²CHRU-Nancy, Department of Rheumatology, Nancy, FRANCE, ³Université de Lorraine, INSERM U1254, IADI, Nancy, FRANCE.

OP-251

Assessing the augmentive value of 18F-FDG PET/CT over 99mTc-MDP bone scan in distinguishing infection from aseptic loosening of prostheses.

S. Shamim, H. Khairwa, S. Sagar, D. Khan, K. Sivashankar, N. Kundu, N. Kumar, G. Arora, R. Kumar;
AIIMS New Delhi, Delhi, INDIA.

OP-252

[¹⁸F]FDG PET/CT identified infections and inflammation in persistent critical illness

B. van Leer, K. M. Demenaga, M. W. N. Nijsten, J. H. van Snick, R. H. J. A. Slart, A. W. J. M. Glaudemans, J. Pillay;
UMCG, Groningen, NETHERLANDS.

OP-253

Comparison of [¹⁸F]FDG and [¹⁸F]DPA714 for the visualization of the pathogenesis of pulmonary tuberculosis in rhesus monkeys (Macaca mulatta)

M. Stammes¹, M. Vierboom¹, C. Sombroek¹, J. Bakker¹, R. Vervenne¹, S. Hofman¹, A. Windhorst², J. Langermans^{1,3}, F. Verreck¹;
¹BPRC, Rijswijk, NETHERLANDS, ²Amsterdam UMC, Amsterdam, NETHERLANDS, ³Utrecht University, Utrecht, NETHERLANDS.

OP-254

⁶⁸Ga-triacetylfusarinine C (TAFC) Siderophore PET/CT for Detection of Invasive Aspergillus Infection: the SPECIFIC Clinical Trial Protocol

S. M. Levy^{1,2,3}, B. Z. Sim^{4,2}, M. Haskali^{1,2}, C. Decristoforo⁵, H. Haas⁶, M. Slavin^{4,2}, M. Hofman^{1,2}, A. Douglas^{4,2};
¹Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ²Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, AUSTRALIA, ³Department of Nuclear Medicine, The Royal Melbourne Hospital, Melbourne, AUSTRALIA, ⁴Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ⁵Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, AUSTRIA, ⁶Institute of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, AUSTRIA.

OP-255

FAPI PET/CT Imaging of Pulmonary Hypertension Caused by Fibrosing Mediastinitis and FAPI Radiotargeted Therapy

L. Song, Z. Wu, C. Zan;
First Hospital of Shanxi Medical University, Taiyuan, CHINA.

OP-256

Increased Colonic TSPO Expression in Inflammatory Bowel Diseases by the Translocator Protein 18kDa Radioligand [¹⁸F]DPA-714

Q. He¹, D. Jiang², Y. Guan², A. Fei¹, F. Xie²;
¹Department of General Medicine, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, CHINA, ²Department of Nuclear Medicine & PET center, Huashan Hospital, Fudan University, Shanghai, CHINA.

609

Sunday, September 10, 2023, 4:45 PM - 6:15 PM
Hall G2

e-Poster Presentations Session 4 - Thyroid Committee: Thyroid and Parathyroid Disease

EPS-063

Implementing a Clinical Pathway for Treatment with I 131 for Differentiated Thyroid Cancer: Evaluation of Quality Objectives

J. Cruz Vasquez, A. Alonso Echarte, I. Blanco Saiz, E. Anda Apiñaniz, A. Alomar Casanovas, I. Saura Lopez, A. Barrera Cerpa, N. Rudic Chipe, M. Ribelles Segura, E. Goñi Gironés, A. Camarero Salazar;
Hospital Universitario de Navarra, Pamplona, SPAIN.

EPS-064

FNA-Tg in Metastatic Lymph Node Predictions Local Recurrence Following Lateral Neck Dissection in Papillary Thyroid Carcinoma

Y. Yang¹, X. Jia¹, J. Hu², A. Yang¹, R. Gao¹;
¹the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, CHINA, ²Shaanxi Cancer Hospital, Xi'an, Shaanxi, CHINA.

EPS-065

Role of ¹⁸F-NaF PET/CT on bone evaluation in patients with differentiated thyroid cancer undergoing radioactive iodine therapy and ¹⁸F-FDG PET/CT: preliminary results

F. Volpe¹, C. Nappi¹, E. Zampella¹, E. Nicolai², L. Piscopo¹, D. Bianco³, C. Vallone¹, F. Volpicelli¹, M. Falzarano¹, L. Pace⁴, A. Cuocolo¹, M. Klain¹;
¹Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy, Napoli, ITALY, ²IRCCS SDN, Diagnostic Imaging, Naples, Napoli, ITALY, ³CIRA - Italian Aerospace Research Centre, Capua, ITALY, Capua, ITALY, ⁴Dipartimento di Medicina, Chirurgia e Odontoiatria "Scuola Medica Salernitana" /DIPMED, Salerno, ITALY.

EPS-066

Correlation of thyroglobulin reduction index after ¹³¹I therapy with RECIST1.1 assessment results in DTC with microscopic pulmonary metastases

T. Tian, R. Huang;
West China Hospital, Sichuan University, Chengdu, CHINA.

EPS-067

Towards clinical translation of a novel antibody-based ¹⁷⁷Lu-labeled radiopharmaceutical for treatment of anaplastic thyroid cancer

A. Mortensen^{1,2}, H. Berglund², T. Mohajer Shojaei², H. Lotsholm Persson³, A. Stenman¹, P. Jha², C. Juhlin¹, P. Bernhardt⁴, J. Zedenius¹, F. Frejd², M. Nestor^{2,3,3};
¹Karolinska Institutet, Stockholm, SWEDEN, ²Uppsala University, Uppsala, SWEDEN, ³Science for Life Laboratory, Stockholm, SWEDEN, ⁴University of Gothenburg, Gothenburg, SWEDEN.

EPS-068

Differentiating subcentimeter pulmonary metastases in differentiated thyroid cancer patients by integration of machine learning and deep learning: a retrospective, multicenter study

X. Gao;
Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, CHINA.

EPS-069

Modeling Clinical Radioiodine Uptake by Using Organoids Derived from Differentiated Thyroid Cancer

X. Zhang¹, J. Liu², Z. Li², R. Huang¹;
¹Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA, ²Department of Thyroid Surgery, West China Hospital Sichuan University, Chengdu, CHINA.

EPS-070

Cytoreductive efficacy of radioiodine treatment in hyperfunctioning thyroid nodules.

A. Alomar, I. Blanco, F. Lozada, A. Irigaray, J. Pineda, M. Ollero, I. Saura, J. Cruz, A. Barrera, N. Rudic, M. Ribelles, A. Camarero, E. Anda, E. Goñi;
Hospital Universitario de Navarra (HUN), Pamplona, SPAIN.

EPS-071

The effect of radioiodine therapy I-131 in patients with non-toxic nodular goitre

S. Abdelrazek, J. Mysliwiec, P. Szumowski, W. Madra, L. Zukowski;
Department of Nuclear Medicine, Medical University of Bialystok, Bialystok, POLAND.

EPS-072

Variables Associated With Positive [¹⁸F]F-Choline Pet/Ct Uptake In Primary Hyperparathyroidism With Negative [^{99m}Tc]Tc-Mibi Scintigraphy

M. Guerra Gómez, J. Cuenca Cuenca, N. Valerdez Menéndez, A. Rodríguez Pajuelo, J. Tirado Hospital, J. Jiménez-Hoyuela García;
University Hospital Virgen del Rocío, Seville, SPAIN.

EPS-073

Incremental value of Tc-99m-sestamibi SPECT/CT in patients with positive planar scintigraphy in the detection of additional lesions in patients with Primary hyperparathyroidism

R. Goel, N. Damle, Y. Dharmashaktu, C. Bal, P. Kumar, A. Goyal, R. Gupta, Y. Gupta, R. Aphale, G. Puri, S. Chumber;
All India Institute of Medical Sciences (AIIMS), New Delhi, INDIA.

EPS-074

¹⁸F-Choline PET/MR for the Localization of Hyperplastic Parathyroid: Preliminary Analysis from a Monocentric Study

C. Gagliani, P. Bartoletti, V. Camozzi, S. Sperti, F. Torresan, M. Iacobone, L. Evangelista;
Azienda Ospedaliera Universitaria di Padova, Padova, ITALY.

EPS-075

CXCR4-directed [⁶⁸Ga]Ga-PentixaFor PET/CT as a novel diagnostic modality in primary aldosteronism

A. Chaman Baz¹, M. Gotthardt¹, W. Spiering², B. de Keizer², J. Deinum¹, J. F. Langenhuijsen¹;
¹Radboudumc, Nijmegen, NETHERLANDS, ²UMC Utrecht, Utrecht, NETHERLANDS.

EPS-076

Role of 68Ga-DOTANOC, 18F-FDOPA and 68 Ga-Exendin PET/CT imaging in adult patients with Hyperinsulinemic Hypoglycemia(HI)
S. Sagar, N. A. Damle, D. Khan, P. Kumar, C. Bal, M. Tripathi, N. Tandon, Y. Gupta;
AIIMS, Delhi, INDIA.

EPS-077

Association between BAT detection (and activity) with FDG PET/CT and cancer prognostic: an Artificial Intelligence (AI) enhanced systematic review.

P. Jané¹, E. Jané², E. Pirazzo Teixeira¹, V. Garibotto¹, K. Gariani³;

¹Service of Nuclear Medicine and Molecular Imaging, Hôpitaux Universitaires de Genève, Genève, SWITZERLAND, ²Universidad Politécnica de Madrid, Madrid, SPAIN, ³Service of Endocrinology, Diabetes, Nutrition and Therapeutic education, Hôpitaux Universitaires de Genève, Genève, SWITZERLAND.

EPS-078

⁶⁸Ga-DOTATATE PET/CT versus ¹⁸F- FDG PET/CT in TENIS syndrome - Impact in management and theranostics strategies - Pilot study

L. Almeida¹, A. Santos¹, T. O. Costa², M. Araújo¹, L. Assumpção¹, M. Lima¹, T. Souza¹, D. Wittmann¹, E. Etchebehere¹;

¹Campinas University, Campinas, BRAZIL, ²Ebserh, Bahia, BRAZIL.

EPS-079

Role of Integrated ¹⁸F-Fluorocholine PET/4DCT in the localization of culprit lesions in patients with primary hyperparathyroidism

Y. Dharmashakti, N. A. Damle, C. Bal, M. Tripathi, P. Kumar, R. N. Wakankar, S. Chumber, Y. Gupta, D. K. S. Agarwal, C. Kumar, R. Goel;
All India Institute of Medical Sciences, Delhi, INDIA.

EPS-080

¹⁸F-Fluorocholine PET/CT and scintigraphy detection rate stratified by PTH levels in parathyroid imaging

N. Jacquet-Francillon, I. Morelec, M. Dietz, A. Clotagatide, J. Tordo, L. Al-Mansour, S. Isal, A. Flaus;
Hospices Civils de Lyon, Lyon, FRANCE.

EPS-081

Concordance between ¹⁸F-Fluorocholine PET-CT and surgery in the localization of parathyroid adenomas in patients with primary hyperparathyroidism

P. Daudén Oñate¹, A. Ortega Candil¹, C. Rodríguez Rey¹, G. Cuesta Domingo¹, S. Ochagavía Cámara¹, R. Cano Carriza², I. Domínguez Serrano¹, S. Mera Carreiro¹, M. Meneses Navas¹, P. Nespral Torres¹, P. Romero Fernández¹, A. Berardinelli¹, M. Cabrera Martín¹, P. Bascuñana Almarcha¹;
¹Hospital Clínico San Carlos, Madrid, SPAIN, ²Hospital Infanta Sofia, Madrid, SPAIN.

EPS-082

Impact of Radioactive Iodine on Survival outcomes for Differentiated Thyroid Carcinoma - Understanding the Factors at Play

A. Al ibraheem, U. Al-Rasheed, A. S. Abdulkadir, N. Mashhadani, S. Ruzzeh, D. A. Al-Adhami, I. Mohamad, B. Hamdan, R. Kheetan, M. E. Juweid, A. Mansour, F. Istatieh;
King Hussein Cancer Center, Amman, JORDAN.

EPS-083

Differential serum miRNA profile in well differentiated thyroid cancer and benign thyroid disease. Prognosis of patients with this miRNA profile five years after radioiodine treatment

O. Bourogianni¹, N. Kapsoritakis¹, E. Tsitoura², A. Tsaroucha¹, G. Lamprakopoulos¹, M. Stathaki¹, E. Papadaki¹, S. Koukouraki³;

¹Department of Nuclear Medicine, University Hospital of Crete, Heraklion, GREECE, ²Laboratory of Molecular and Cellular Pneumology, Medical School, University of Crete, HERAKLION, GREECE, ³Department of Nuclear Medicine, Medical School, University of Crete, Heraklion, GREECE.

610

Sunday, September 10, 2023, 16:45 - 18:15

Hall K

CTE 3 - Technologists Committee: Patient Care in Nuclear Medicine

OP-257

Improving understanding of patients' experience

A. Grilo;

Escola Superior de Tecnologia da Saúde, Instituto Politécnico, Lisbon, PORTUGAL.

OP-258

Looking beyond the images: practical examples in paediatrics

I. Baeta;

Kings College Hospital NHS Foundation Trust, Nuclear Medicine and PET/CT Department, London, UNITED KINGDOM.

OP-259

Shaping patient experience in PET-CT, PET-MRI, and Clinical Trials

P. Turco;

Department of Medicine DIMED, University-Hospital of Padova, Padova, ITALY.

611

Sunday, September 10, 2023, 16:45 - 18:15

Hall G1

Special Symposium 1 - EANM/EARL: Harmonisation and Accreditation Accelerate Research and Clinical Translation

OP-260

To EARL" or "Not To EARL" in Clinical Practice?

S. Stroobants;

Antwerp University Hospital, Antwerp, BELGIUM.

OP-261

EARL 1 and EARL 2. Where are we now?

I. Hristova;

EARL, Vienna, AUSTRIA.

OP-262

Accreditation for Brain PET studies

R. Boellaard;

Amsterdam UMC, Amsterdam, NETHERLANDS.

OP-263

Harmonisation in quantitative SPECT and its challenges

J. Tran-Gia;

Universitätsklinikum Würzburg, Würzburg, GERMANY.

701

Monday, September 11, 2023, 08:00 - 09:30

Hall A

CME 5 - Oncology & Theranostics Committee: Will the Microenvironment Become Even More Important in Nuclear Medicine?

OP-269

The future of the oldest Megaimportant Nuclear Medicine marker of the menvironment

S. Carrilho Vaz;

Champalimaud Centre for the Unknown, Champalimaud Foundation, Department of Nuclear Medicine - Radiopharmacology, Lisbon, PORTUGAL.

OP-270

Hypoxia - The importance of spotting such a hostile menvironment

W. Weber;

Technical University of Munich, Department of Nuclear Medicine, Munich, GERMANY.

OP-271

Immune system – Immunotherapy enthusiasm will fuel new techniques in Nuclear Medicine?

N. Schäfer;

Lausanne University Hospital, Nuclear Medicine and Molecular Imaging Department, Lausanne, SWITZERLAND.

OP-272

Cancer-associated fibroblasts - Highlighting no-malignant cells that are in the dark, serving malignant cells

S. Dalm;

Erasmus MC, Radiology & Nuclear Medicine Department, Rotterdam, NETHERLANDS.

702

Monday, September 11, 2023, 08:00 - 09:30

Hall D (Arena)

Debate 2 - Neuroimaging Committee: What is the Best Tracer for Molecular Brain Tumour Imaging?

OP-273

Conventional tracers: Is it all about amino acid tracers or is there still a role for FDG?

F. Cicone;

Dipartimento di Medicina Sperimentale e Clinica (DMSC) Università degli Studi "Magna Graecia" di Catanzaro (ITALY) Università degli Studi "Magna Graecia" di Catanzaro, Catanzaro, ITALY.

OP-274

Novel radiotracers: why do we need more than amino acid tracers?

N. Albert;

Klinikum der Ludwig-Maximilians-Universität, Munich, GERMANY.

703

Monday, September 11, 2023, 08:00 - 09:30

Hall E1

LIPS Session 5 - Cardiovascular + Physics Committee: Challenges in MBF Quantification

OP-279

Patient motion and data-driven motion correction

I. Armstrong;

Manchester University NHS Foundation Trust, Nuclear Medicine, Manchester, UNITED KINGDOM.

OP-280

SPECT: is there anybody out there?

L. Imbert;

CHRU Nancy Brabois, Nuclear Medicine Department, Nancy, FRANCE.

OP-281

Accuracy of MBF estimates and cut-off values

M. Lubberink;

Uppsala University, Nuclear Medicine & PET, Uppsala, SWEDEN.

OP-282

Challenges of using quantification in clinical practise

I. Danad;

Utrecht University Medical Centre / Amsterdam University Medical Centre, Cardiology, Utrecht, NETHERLANDS.

704

Monday, September 11, 2023, 8:00 AM - 9:30 AM

Hall E2

M2M Track - TROP Session: Imaging Inflammatory Processes in Cardiovascular Diseases

OP-284

Dynamic Expression of Myocardial Sigma-1 Receptor in Doxorubicin-Induced Cardiomyopathy using Radioiodine Labeled 2-[4-(2-iodophenyl) piperidino]cyclopentanol (OISV) Imaging
Z. Chen¹, H. Wakabayashi¹, H. Mori¹, T. Hiromasa¹, X. Zhang¹, T. Kozaka², K. Ogawa³, S. Kinuya¹, J. Taki^{4,1};
¹Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN, ²Division of Probe Chemistry for Disease Analysis, Research Center for Experimental Modeling of Human Disease, Kanazawa University, Kanazawa, JAPAN, ³Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, JAPAN, ⁴PET Center, Kanazawa Advanced Medical Center, Kanazawa, JAPAN.

OP-285

Early evaluation of organ fibrosis in Angiotensin II-induced hypertensive mouse model using ⁶⁸Ga-FAPI46 PET
J. Byun^{1,2,3}, Y. Kim^{1,3}, Y. Lee¹, J. Paeng¹, K. Kang¹, G. Cheon¹;
¹Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF, ²Department of Biomedical Sciences, Seoul National University, Seoul, KOREA, REPUBLIC OF, ³Cancer Research Institute, Seoul National University, Seoul, KOREA, REPUBLIC OF.

OP-286

The evolution and prognostic value of ⁶⁸Ga-Pentixafor uptake in the myocardium after acute infarction
P. Wu^{1,2}, S. He³, M. Yan¹, H. Wang^{1,2}, X. Liu⁴, Z. Xiang¹, L. Xu^{1,5}, Y. Zhao^{1,5}, X. Li⁶, M. Hacker⁶, Z. Wu^{1,2}, S. Li^{1,2};
¹Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, CHINA, ²Shanxi Key Laboratory of Molecular Imaging, Shanxi Medical University, Taiyuan, CHINA, ³Department of Radiology, First Hospital of Shanxi Medical University, Taiyuan, CHINA, ⁴Department of Radiology, Shanxi Bethune Hospital(Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University), Taiyuan, CHINA, ⁵Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, Taiyuan, CHINA, ⁶Division of Nuclear Medicine, Department of Biomedical Imaging and ImageGuided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

OP-287

Translocator protein 18kDa positron emission tomography imaging of ¹⁸F-FDPA in rabbits with vulnerable atherosclerosis plaques
W. Dong, J. Jiao, T. Mou, Y. Zhang, H. Mi;
Beijing Anzhen Hospital, Beijing, CHINA.

OP-288

^{99m}Tc-AFN: A Nanobody-Based SPECT Radiotracer with Clinical Potential for Noninvasive Monitoring of Fibroblast Activity After Myocardial Infarction
X. Zhang¹, Z. Ai¹, C. Li², B. Jia², M. Yang¹;
¹Department of Nuclear Medicine, Beijing Chaoyang Hospital, Beijing, CHINA, ²Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, CHINA.

OP-289

Temporal characterisation of inflammation and active collagen biosynthesis in the rat heart post myocardial infarction, using novel Positron Emission Tomography (PET) radiotracers.
V. Reid^{1,2}, M. G. MacAskill^{1,2}, K. Pandya¹, A. Arcidiacono¹, C. Alcaide Corral^{1,2}, T. E. F. Morgan^{1,2}, V. Balogh¹, L. M. Riley³, T. Fujisawa¹, N. L. Mills^{1,4}, R. J. Lennen^{1,2}, M. A. Jansen^{1,2}, G. A. Gray¹, A. H. Baker^{1,5}, D. E. Newby¹, A. Sutherland³, A. A. S. Tavares^{1,2};
¹Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UNITED KINGDOM, ²Edinburgh Imaging, University of Edinburgh, Edinburgh, UNITED KINGDOM, ³School of Chemistry, University of Glasgow, Glasgow, UNITED KINGDOM, ⁴The Usher Institute, University of Edinburgh, Edinburgh, UNITED KINGDOM, ⁵CARIM, School for Cardiovascular Diseases, Maastricht University, Maastricht, NETHERLANDS.

OP-290

Positive Protective Effects of Sigma-1 Receptor Stimulation with Fluvoxamine after Myocardial Ischemia and Reperfusion in Rat
X. Zhang¹, H. Wakabayashi¹, H. Mori¹, T. Hiromasa¹, Z. Chen¹, T. Kozaka², K. Ogawa³, S. Kinuya¹, J. Taki^{4,1};
¹Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, JAPAN, ²Division of Probe Chemistry for Disease Analysis, Research Center for Experimental Modeling of Human Disease, Kanazawa University, Kanazawa, Ishikawa, JAPAN, ³Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, Ishikawa, JAPAN, ⁴PET Center, Kanazawa Advanced Medical Center, Kanazawa, Ishikawa, JAPAN.

OP-291

C-X-C Motif Chemokine Receptor 4-Directed PET Signal in the Arterial Tree is not Consistently Linked to Calcified Plaque Burden and Cardiovascular Risk
N. Hasenauer¹, A. Kosmala¹, S. E. Serfling¹, K. Michalski¹, M. Fröhlich², N. Dreher¹, P. E. Harttrampf¹, T. Higuchi^{1,3}, A. K. Buck¹, A. Weich^{2,4}, T. Reiter⁵, R. A. Werner^{1,4,6};
¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Internal Medicine II, University Hospital Würzburg, Würzburg, GERMANY, ³Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, JAPAN, ⁴NET-Zentrum Würzburg, European Neuroendocrine Tumor Society Center of Excellence (ENETS CoE), University Hospital Würzburg, Würzburg, GERMANY, ⁵Internal Medicine I, University Hospital Würzburg, Würzburg, GERMANY, ⁶Johns Hopkins School of Medicine, The Russel H Morgan Department of Radiology and Radiological Sciences, Baltimore, MD, UNITED STATES OF AMERICA.

OP-292

Molecular Imaging in Cardio-Oncology: Detecting Radiotoxicity of Breast Cancer Treatments Through Radionuclide Ventriculography and Novel Cardiac Biomarkers Assessment
A. Lazar¹, M. Mutuleanu^{1,2}, I. Irimescu^{1,3}, R. Maaz¹, C. Petroiu¹, M. Gherghe^{1,2};
¹Institute of Oncology "Professor Doctor Alexandru Trestioreanu", Bucharest, ROMANIA, ²University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA, ³Applied Sciences Doctoral School, Politehnica University, Bucharest, ROMANIA.

705

Monday, September 11, 2023, 8:00 AM - 9:30 AM
Hall B

Cutting Edge Science Track - Featured Session: Imaging Guided Surgery

OP-293

Surgical Radioguidance with Beta emitting Radionuclides
P. Frago Costa;
Department of Nuclear Medicine at University Hospital Essen, Essen, GERMANY.

OP-294

Translation of a drop-in beta probe for robotic radio guided surgery
F. Collamati¹, R. Mirabelli¹, R. Faccini², F. Ceci³, E. Bertani⁴, G. Musi⁵, M. N. van Oosterom⁶, F. van Leeuwen⁷, S. Morganti¹;
¹INFN Rome, Roma, ITALY, ²Università Roma Sapienza, Roma, ITALY, ³I.EO European Institute of Oncology, Nuclear Medicine, Milano, ITALY, ⁴I.EO European Institute of Oncology, Division of Digestive Surgery, Milano, ITALY, ⁵I.EO European Institute of Oncology, Division of Urology, Milano, ITALY, ⁶Leiden University Medical Center | Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden, NETHERLANDS, ⁷Leiden University Medical Center | Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden, ITALY.

OP-295

Live Nuclear/X-ray Imaging during Radioembolization Interventions using a Novel Hybrid C-arm Scanner
M. Dietze, M. B. M. Meddens, R. van Rooij, A. J. A. T. Braat, B. de Keizer, R. C. G. Bruijnen, M. G. E. H. Lam, M. L. J. Smits, H. W. A. M. de Jong;
University Medical Center Utrecht, Utrecht, NETHERLANDS.

OP-296

Investigation of a CZT-based hand-held gamma-camera for pre-clinical imaging of alpha-emitter ²²⁵Ac
D. Roth¹, Z. Ellis², M. Dahlborn², J. Strand^{3,4}, C. Mona^{2,5}, P. Jean Jean^{2,5}, M. Ljungberg¹, S. Strand¹;
¹Medical Radiation Physics, Lund, Lund University, Lund, SWEDEN, ²Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California – Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, ³Department of Clinical Sciences Lund, Oncology, Lund University, Lund, SWEDEN, ⁴Department of Hematology, Oncology, Radiation Physics, Skåne University Hospital, Lund University, Lund, SWEDEN, ⁵Jonsson Comprehensive Cancer Center, University of California – Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA.

OP-297

CT-guided percutaneous marking of small pulmonary nodules with [^{99m}Tc]Tc-Macrosalb is very accurate and allows minimally invasive lung-sparing resection: a single-centre quality control
N. Doncic, C. J. Zech, D. Wild, H. Bachmann, M. Mallaev, N. Tsvetkov, A. Hojski, M. T. L. Takes, D. Lardinois;
Basel University Hospital, Basel, SWITZERLAND.

OP-298

A truncated 14-amino acid myelin protein zero targeting peptide for fluorescence-guided nerve preserving surgery
N. Berehova, M. P. van Meerbeek, S. Azargoshasb, L. J. Slof, S. Navaei Lavasani, M. N. van Oosterom, F. W. B. van Leeuwen, T. Buckle;
Leiden University Medical Center, Leiden, NETHERLANDS.

OP-299

Metabolic 18F FDG PET/CT Guided Intrathoracic Tumor Biopsies: An Analysis of Initial Experience from Central India.
M. Ravina, R. Ganga, A. Behera, T. Lukose, S. Krishna, S. Dasgupta, R. Kote, A. Rath;
All India Institute of Medical Sciences, Raipur, Raipur, INDIA.

OP-300

Gamma-Flex, a novel flexible gamma probe for minimal invasive laparoscopic interventions
M. van Oosterom¹, L. J. Slof¹, S. Navaeilavasan¹, S. Azargoshasb¹, K. Schwenkenbecher², J. Scheltes³, F. W. B. van Leeuwen¹;
¹Leiden University Medical Center, Leiden, NETHERLANDS, ²Crystal Photonics, Berlin, GERMANY, ³DEAM, Amsterdam, NETHERLANDS.

OP-301

Performance Evaluation of ¹⁸F-PSMA and ⁶⁸Ga-PSMA in a Novel MicroPET/CT System Dedicated to Radioguided Surgery
A. Moraitis¹, C. Darr², T. Kah², L. Püllen², W. Jentzen¹, D. Kersting¹, B. Hadaschik², K. Herrmann¹, W. P. Fendler¹, P. Frago Costa¹;
¹Department of Nuclear Medicine at University Hospital Essen, Essen, GERMANY, ²Department of Urology at University Hospital Essen, Essen, GERMANY.

706

Monday, September 11, 2023, 8:00 AM - 9:30 AM
Hall C

Clinical Oncology Track - TROP Session: Neuroendocrine Tumors - Diagnosis

OP-302

First-in-human Study of an Optimized, potential Kit-type, SSTR Antagonist ⁶⁸Ga-DATAsm-LM4 in Neuroendocrine Tumors
J. Zhang¹, L. Greifenstein², V. Jakobsson¹, C. Kramer³, C. Landvogt², C. Mueller², R. P. Baum²;
¹National University of Singapore, Singapore, SINGAPORE, ²Curanosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, GERMANY.

OP-303

A Prospective Evaluation of [¹⁸F]AIF-NOTA-LM3 in Patients with Well-differentiated Neuroendocrine Tumors: Head-to-head Comparison with ⁶⁸GaDOTATATE
M. Liu, W. Zhu, Y. Zhang, C. Ren, H. Zhang, Z. Huang, L. Huo;
Peking Union Medical College Hospital, Beijing, CHINA.

OP-304

Superiority of ⁶⁸Ga-DOTATATE PET/CT compared to ¹⁸F-FDG PET/CT, MRI of the spine, and whole-body diagnostic CT and MRI in the detection of spinal bone metastases associated with pheochromocytoma and paraganglioma
A. Jha¹, M. Patel¹, A. Ling¹, R. Shah¹, C. C. Chen¹, C. Millo¹, M. A. Nazari¹, N. Sinaii¹, K. Charles¹, M. J. Kuo¹, T. Prodanov¹, B. Saboury¹, S. Talvacchio¹, A. Derkyi¹, J. del Rivero¹, G. O'Sullivan Coyne¹, A. P. Chen¹, N. Nilubol¹, P. Herscovitch¹, F. I. Lin¹, D. Taïeb¹, A. C. Civelek², J. A. Carrasquillo¹, K. Pacak¹;
¹National Institutes of Health, Bethesda, MD, UNITED STATES OF AMERICA, ²Johns Hopkins Medicine, Baltimore, MD, UNITED STATES OF AMERICA.

OP-305

Prognostic Value of C-X-C motif Chemokine Receptor 4-directed Molecular Imaging in Patients with Advanced Adrenocortical Carcinoma
W. Schlötelburg¹, P. E. Hartrampf¹, A. Kosmala¹, S. E. Serfling¹, A. Schirbel¹, A. K. Buck¹, M. Fassnacht², S. Hahner², R. A. Werner^{1,3};
¹Department of Nuclear Medicine, University Hospital of Würzburg, GERMANY, ²Division of Endocrinology and Diabetes, Department of Medicine I, University Hospital of Würzburg, GERMANY, ³The Russel H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, MD, UNITED STATES OF AMERICA.

OP-306

"Novel ^{99m}Tc-labelled somatostatin antagonists in the diagnostic algorithm of neuroendocrine neoplasms" - results of a multicenter phase I clinical trial - TECANT
M. Opalinska¹, I. Virgolini², L. Lezaic³, G. di Santo², C. Decristoforo², P. Kolenc³, R. Mikolajczak⁴, A. Studen⁵, P. Garnuszek⁴, U. Simoncic⁵, M. Trofimuk-Muldner¹, C. Ranger², B. Glowa⁶, K. Skorkiewicz², M. Fani², A. Sowa-Staszczak¹, B. Janota⁴, M. Kroselj³, S. Rep³, A. Hoermann², A. Hubalewska-Dydejczyk¹;
¹Chair and Department of Endocrinology, Jagiellonian Medical College, Krakow, POLAND, ²Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA, ³Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, ⁴National Centre for Nuclear Research Radioisotope Centre POLATOM, Otwock, POLAND, ⁵Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, SLOVENIA, ⁶Nuclear Medicine Unit, University Hospital in Krakow, Krakow, POLAND, ⁷Universitätsspital Basel, Basel, SWITZERLAND.

OP-307

Comparison of [⁶⁸Ga]Ga-DOTANOC and [⁶⁸Ga]Ga-DATA^{5m}-LM4 PET/CT in the same patient group with neuroendocrine tumors.
R. V¹, S. Ballal¹, M. Yadav¹, F. Roesch², P. Sheokand¹, M. Martin², M. Tripathi¹, R. Sahoo¹, C. Bal¹;
¹AIIMS, Delhi, INDIA, ²Johannes Gutenberg university of Mainz, Mainz, GERMANY.

OP-308

Prognostic value of the post-treatment ¹⁷⁷Lu-DOTATOC scintigraphy in NET patients undergoing PRRT.
S. Leyser^{1,2}, H. Lanzafame^{1,2}, D. Kersting^{1,2}, R. Seifert^{1,2}, F. Zarrad¹, H. Lahner³, N. Unger³, W. P. Fendler^{1,2}, K. Herrmann^{1,2}, M. M. Weber^{1,4};
¹Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, GERMANY, ²German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, GERMANY, ³Department of Endocrinology West German Cancer Center, University Hospital Essen, Essen, GERMANY, ⁴German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany, Essen, GERMANY.

OP-309

Optimized segmentation of neuroendocrine tumor lesions on somatostatin receptor PET/CT imaging for therapy response assessment
A. Chaban¹, J. Brosch-Lenz¹, Y. Song¹, V. Dinkel¹, L. Bode², W. Weber¹;
¹Klinikum rechts der Isar, der Technischen Universität München, Munich, GERMANY, ²Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

OP-310

Diagnostic performance of functional imaging with ⁶⁸Ga-DOTATATE PET/CT, ¹⁸F-FDG PET/CT, and ¹⁸F-FDG PET/CT, and anatomic imaging with whole-body CT and/or MRI in the detection of SDHD-related pheochromocytoma and paraganglioma - A comparative prospective study
A. Jha, M. Patel, A. Ling, C. C. Chen, C. Millo, K. Charles, M. Kuo, T. Prodanov, M. A. Nazari, S. Talvacchio, A. Derkyi, J. del Rivero, A. P. Chen, N. Nilubol, P. Herscovitch, F. I. Lin, D. Taïeb, J. A. Carrasquillo, A. C. Civelek, K. Pacak;
National Institutes of Health, Bethesda, MD, UNITED STATES OF AMERICA.

707

Monday, September 11, 2023, 8:00 AM - 9:30 AM
Hall F1

Paediatrics Committee - TROP Session: Neuroblastoma & Non-PET Paediatric Studies

OP-311

Prognostic and predictive value of imaging features in neuroblastoma using pre-treatment ¹²³I-MIBG SPECT/CT: is there a place for radiomics?
M. Luporsi¹, H. Brisse², C. Nioche³, N. Jehanno¹, H. Fokem-Fosso³, I. Buvat³, G. Schliepacher⁴, F. Orhac³;
¹Department of nuclear medicine, Institut Curie, PSL Research University, Institut Curie, Inserm, LITO-U1288, Paris, FRANCE, ²Institut Curie, Inserm, LITO-U1288, Department of radiology, Institut Curie, PSL Research University, Paris, FRANCE, ³Institut Curie, Inserm, LITO-U1288, Orsay, FRANCE, ⁴SiREDO Integrated Pediatric, adolescents and young adults Oncology Center, Laboratory of translational research in pediatric oncology INSERM-U830, Institut Curie, Paris, FRANCE.

OP-312

Comprehensive Analysis of ¹⁸F-MFBG Biodistribution and Variability in Pediatric Neuroblastoma Patients
P. Wang^{1,2}, H. Zhang¹, Y. Zhang¹, T. Li¹, H. Jing¹, F. Li¹, J. Zhang²;
¹Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, CHINA, ²Department of Diagnostic Radiology, National University of Singapore, Singapore, SINGAPORE.

OP-313

The ¹⁸F-FDG PET/MRI radiomics nomogram for differentiating high-risk and non-high-risk patients of the International Neuroblastoma Risk Group Staging System
J. Liang;
杭州通用医学影像诊断中心,杭州, CHINA.

OP-314

First clinical experience with [⁶⁴Cu]Cu-NOTA-ch14.18/CHO to visualize GD2 by PET in several pediatric tumor entities - Biodistribution and preliminary dosimetry
N. Trautwein^{1,2}, J. Schwenck^{1,2,3}, C. Seitz^{4,5}, S. von Beschwitz¹, G. Reischl⁶, S. Scheuermann^{4,5}, P. Lang⁴, J. Schaefer⁶, B. Pichler^{2,3}, C. la Fougère^{1,3}, H. Dittmann¹;
¹Department of Nuclear Medicine and Clinical Molecular Imaging, Tuebingen, GERMANY, ²Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Tuebingen, GERMANY, ³Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", Tuebingen, GERMANY, ⁴Department of General Pediatrics, Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, GERMANY, ⁵Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", Tuebingen, GERMANY, ⁶Department of Diagnostic and Interventional Radiology, Tuebingen, GERMANY.

OP-315

Reaching the target dose with one single [¹³¹I]-mIBG treatment in high-risk neuroblastoma. The determinant impact of the primary tumour
F. Fiz¹, A. Cirone¹, S. Righi¹, M. Massollo¹, L. Amoroso², G. Bottoni¹, M. Conte², M. Gambaro¹, F. Massone¹, G. Semino Bruzzone¹, S. Orengo¹, S. Sorrentino², A. Garaventa², A. Piccardo¹;
¹Ospedale Galliera, Genova, ITALY, ²IRCCS Istituto Giannina Gaslini, Genova, ITALY.

OP-316

Utility and Optimal Scan Time of Diagnostic and Post-therapeutic Whole-Body Scan in Children and Young Adult Patients Administered with Iodine-131
P. Kumar, C. Bal, N. A. Damle;
All India Institute of Medical Sciences, New Delhi, INDIA.

OP-317

SPECT/CT in the diagnosis of Ectopic Gastric Mucosa-Meckel's Diverticulum
Z. Koç¹, P. Özcan¹, F. Tunçel², C. İsbir³, Y. Usta⁴;
¹Mersin University Hospital Nuclear Medicine Dpt., Mersin, TÜRKIYE, ²Mersin University Hospital Pathology Dpt., Mersin, TÜRKIYE, ³Mersin University Hospital Pediatric Surgery Dpt., Mersin, TÜRKIYE, ⁴Mersin University Hospital Pediatric Gastroenterology Dpt., Mersin, TÜRKIYE.

OP-318

Re-evaluating the milk scan protocol, perplexing or potentially prognostic?
K. Hlongwa¹, A. Brink¹, S. M. Peters², S. More¹;
¹Red Cross War Memorial Children's Hospital and University of Cape Town, Cape Town, SOUTH AFRICA, ²Groote Schuur Hospital and School of Public Health and Family Medicine, University of Cape Town, Cape Town, SOUTH AFRICA.

OP-319

Predictive Value of Diuretic Renogram for Progressive Hydronephrosis in Perinatally Detected Unilateral Hydronephrosis
C. Lin¹, P. Chuang², I. Tsai³, M. Cheng⁴;
¹National Taiwan University Hospital, Taipei City, TAIWAN, ²Department of Nuclear Medicine, National Taiwan University Hospital Yunlin Branch, Douliu City, TAIWAN, ³PEDIATRICS National Taiwan University Children Hospital and National Taiwan University College of Medicine, Taipei City, TAIWAN, ⁴Nuclear Medicine National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, TAIWAN.

708

Monday, September 11, 2023, 08:00 - 09:30
Hall F2

Special Symposium 2 - Inflammation & Infection Committee: Usefulness of PET in the Evaluation of Inflammatory Rheumatisms

OP-320

Clinical spectrum and imaging of inflammatory rheumatism: a clinician's perspective
K. van der Geest;
University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen, NETHERLANDS.

OP-321

[¹⁸F]FDG PET/CT in inflammatory rheumatic disorders in elderly (PMR vs EORA vs SpA)
F. Besson;
Hôpitaux Universitaires Paris-Saclay, AP-HP, CHU Bicêtre, Department of Nuclear Medicine and Molecular Imaging, Paris, FRANCE.

OP-322a

[¹⁸F]FDG PET/CT in rheumatoid arthritis and other rheumatic disorders
P. Guglielmo;
Istituto Oncologico Veneto, Castelfranco Veneto, ITALY.

OP-322b

Beyond [¹⁸F]FDG in inflammatory rheumatism
C. van der Laken;
Amsterdam UMC, Department of Rheumatology, Amsterdam, NETHERLANDS.

709

Monday, September 11, 2023, 8:00 AM - 9:30 AM
Hall G2

e-Poster Presentations Session 5 - Physics
Committee: SPECT/CT, PET/CT, PET/MR
Quantitative Imaging

EPS-084

ThyroPIX - Mobile Compton camera based on Timepix3 technology for monitoring of thyroid gland cancer treatment

E. Trojanova¹, D. Doubravova¹, R. Kaderabek², V. Poriz³, T. Kracmerova⁴;

¹ADVACAM s.r.o, Prague, CZECH REPUBLIC,
²Radalytica a.s., Prague, CZECH REPUBLIC,
³Radalytica a.s., Prague, CZECH REPUBLIC, ⁴Fakultní nemocnice v Motole, Prague, CZECH REPUBLIC.

EPS-085

Quantification of amyloid load from [¹⁸F] florbetaben PET scans agrees with histopathology, visual read, and clinical progression

G. Kolinger¹, L. Tiraboschi¹, F. Padovano², D. Braca², M. Spilliti², G. Lucidi Pressanti³, S. Bullich¹, R. Mazza²;
¹Life Molecular Imaging GmbH, Berlin, GERMANY, ²Nuclear Medicine Unit, "G. Mazzini" Hospital, Teramo, ITALY,
³Services Department, "G. Mazzini" Hospital, Teramo, ITALY.

EPS-086

2-layer Hemispheric PET featuring different materials on each layer

K. Scheiff¹, A. Pashazadeh, C. Hoeschen;
Otto-von-Guericke-University Magdeburg, Magdeburg, GERMANY.

EPS-087

Survey of Patient Journeys throughout Nuclear Medicine Services

A. Brink¹, K. Pathmaraj², M. Marengo³, B. Arends⁴, Z. Jawa⁵, R. Jaimovich⁶, T. Pascual⁷, S. Rubow⁸, L. Torres⁹, S. Vinjamuri¹⁰, E. Woodrow¹¹, M. Dondi¹, D. Paez¹;
¹International Atomic Energy Agency, Vienna, AUSTRIA,
²Austin Health, Melbourne, AUSTRALIA, ³University of Bologna, Bologna, ITALY, ⁴Catharina Ziekenhuis, Eindhoven, NETHERLANDS, ⁵SQUH, Muscat, OMAN, ⁶Universidad Católica de Chile, Santiago, CHILE, ⁷PNRI, Manila, PHILIPPINES, ⁸University of Stellenbosch, Stellenbosch, SOUTH AFRICA, ⁹CENTIS, Havana, CUBA, ¹⁰Liverpool University Hospital, Liverpool, UNITED KINGDOM, ¹¹Singapore General Hospital, Singapore, SINGAPORE.

EPS-088

Development of phantom analysis software package for Japanese Society of Nuclear Medicine PET imaging site qualification program

K. Matsumoto¹, H. Daisaki², S. Yoshida³, K. Nishida³, N. Tamaki¹;
¹Kyoto College Of Medical Science, Kyoto, JAPAN, ²Gunma Prefectural College of Health Sciences, Maebashi, JAPAN, ³Nihon Medi-Physics Co.,Ltd., Tokyo, JAPAN.

EPS-089

Insertion of Synthetic Lesions for the Clinical Assessment of AI-based reconstruction algorithms

Q. Maronnier¹, A. Latgé¹, K. Su², F. Courbon¹, O. Caselles¹;
¹Oncopole Claudius Regaud, Toulouse, FRANCE, ²GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA.

EPS-090

Anatomy-based correction of kidney PVE on ¹⁷⁷Lu SPECT images

J. Salvadori¹, O. Allegrini¹, I. Namer^{1,2};
¹Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg, FRANCE, ²ICUBE UMR 7357, Strasbourg, FRANCE.

EPS-091

The optimum earliest total-body ⁶⁸Ga-FAPI-04 PET scan timing: An evidence-based single-centre study

Z. Zheng¹, H. Gao, Y. Lin, H. Yu, W. Mao, R. Yang, Y. He, X. Chen, H. Wu, P. Hu, H. Shi;
Zhongshan Hospital, Fudan University, Shanghai, CHINA.

EPS-092

Comparison of a 3D printed wall-less phantom with a conventional NEMA phantom for establishing threshold-based segmentation methods

A. Zounek¹, A. Zatcepin^{1,2}, A. Delker¹, F. Gildehaus¹, A. Bollenbacher¹, G. Böning¹, P. Bartenstein^{1,2}, N. L. Albert^{1,3,4}, S. Ziegler¹, L. Kaiser¹;
¹Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, ²German Center for Neurodegenerative Diseases (DZNE), Munich, GERMANY, ³German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Munich, GERMANY, ⁴Bavarian Cancer Research Center (BZKF), Erlangen, GERMANY.

EPS-093

Discrepancies in commercial Y-90 vial's activity assessments: Monte Carlo simulations provide a possible explanation

L. Auditore^{1,2}, D. Pistone^{1,2}, A. Italiano^{3,4}, E. Amato^{1,2}, S. Gnesin⁵;
¹Department of Biomedical and Dental Sciences and of Morphofunctional Imaging (BIOMORF), University of Messina, Italy, Messina, ITALY, ²INFN, National Institute for Nuclear Physics, Section of Catania, Italy, Catania, ITALY, ³Istituto Nazionale di Fisica Nucleare (INFN) - Sezione di Catania, Catania, ITALY, ⁴Department of Mathematical and Computer Science, Physical Sciences and Earth Sciences (MIFT), University of Messina, Italy, Messina, ITALY, ⁵Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND.

EPS-094

Characterization of an innovative small animal PET scanner based on a proprietary acquisition method

F. M. Ribeiro¹, P. M. C. C. Encarnação¹, P. M. M. Correia¹, A. L. M. Silva¹, A. X. Pinto¹, R. G. Oliveira¹, A. C. M. Magalhães¹, J. Sereno², A. Abrunhosa², I. F. Castro³, J. F. C. A. Veloso¹;
¹Institute for Nanostructures, Nanomodelling and Nanofabrication (i3N), Department of Physics, University of Aveiro, Aveiro, PORTUGAL, ²Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, PORTUGAL, ³Radiation Imaging Technologies Lda. (RI-TE), University of Aveiro Incubator, PCI - Creative Science Park, Ilhavo, PORTUGAL.

EPS-095

Triple and dual PET quantification of a Small-Animal Multi-Pinhole PET/SPECT/CT System

P. Echegoyen¹, T. Cuenca Bandín, M. Eca, E. Prieto, M. Collantes, F. Pareja, J. Simón Martínez, I. Peñuelas, J. Martí-Climent;
Clínica Universidad de Navarra, Pamplona, SPAIN.

EPS-096

ComBat harmonization in different PET imaging scenarios

M. Gandia-Ferrero¹, I. Torres-Espallardo^{2,1}, S. Prado-Wohlwend², B. Martínez-Sanchis², E. Muñoz³, C. Morera³, P. Bello-Arques², M. Vázquez-Martínez², S. Ginés-Cárdenas¹, Á. Almendros-Riaza¹, L. Martí-Bonmat^{2,1};
¹Health Research Institute La Fe, Valencia, SPAIN, ²La Fe University and Polytechnic Hospital, Valencia, SPAIN, ³Oncovision, Valencia, SPAIN.

EPS-097

Elimination of not yet Reported Artifacts in Myocardial Perfusion Imaging Studies on Semiconductor Cardiac Gamma Camera by Covering Radiopharmaceutical Injection Site with a Shield

A. Owczarek¹, P. Cichocki¹, Z. Adamczewski¹, A. Plachcinska²;
¹Nuclear Medicine Department, Medical University of Lodz, Lodz, POLAND, ²Department of Quality Control and Radiological Protection, Medical University of Lodz, Lodz, POLAND.

EPS-098

Match/mismatch between aortic Na^{[18}F]F uptake on PET and macrocalcifications on CT

G. van Praagh¹, M. Davidse², J. M. Wolterink², R. H. J. A. Slart¹;
¹University Medical Center Groningen, Groningen, NETHERLANDS, ²University of Twente, Enschede, NETHERLANDS.

EPS-099

Metabolic connectivity changes of patients with post-COVID-19 condition: a reorganization of the olfactory cognitive pathway?

M. Doyen^{1,2}, T. Horowitz², A. Bruyere⁴, F. Goehringer⁴, A. Verger^{1,2}, E. Guedj³;
¹Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, F-54000 Nancy, FRANCE, ²Université de Lorraine, IADI, INSERM U1254, F-54000 Nancy, FRANCE, ³Nuclear Medicine Department, Aix-Marseille University, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Marseille, France, Marseille, FRANCE, ⁴Department of Infectious Diseases, CHRU Nancy, 54000, Nancy, FRANCE.

EPS-100

Impact of ⁶⁸Ga-specific PET Reconstruction on Image Quality of Patient Data

P. Gavriilidis^{1,2,3}, A. Marinus^{4,1}, M. Koole³, T. W. Deller⁵, F. P. Jansen⁵, F. M. Mottaghy^{6,1,2}, R. Wierth^{1,2};
¹Maastricht University Medical Center, Maastricht, NETHERLANDS, ²Maastricht University, Maastricht, NETHERLANDS, ³Katholieke Universiteit Leuven, Leuven, BELGIUM, ⁴Eindhoven University of Technology, Eindhoven, NETHERLANDS, ⁵GE HealthCare, Waukesha, WI, UNITED STATES OF AMERICA, ⁶RWTH University Hospital, Aachen, GERMANY.

EPS-101

Clinical evaluation of a deep learning-based CT-free attenuation and scatter correction

S. Xue¹, H. Zhou¹, R. Guo², M. Viscione¹, A. Rominger¹, B. Li², K. Shi¹;
¹University of Bern, Bern, SWITZERLAND, ²Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

EPS-102

Influence of coils and attenuation correction methods on the performance and image quality of a preclinical PET/MR insert

C. Kuntner¹, J. Friske¹, A. Stessl², M. Haas³, L. Breyer¹, T. Wanek¹, M. Hacker¹, T. Helbich¹, I. Rausch¹;
¹Medical University of Vienna, Vienna, AUSTRIA, ²University of Applied Science, Wiener Neustadt, AUSTRIA, ³Bruker BioSpin Preclinical Imaging Division, Ettlingen, GERMANY.

EPS-103

Impact of patient size on image quality of OSEM3D and BSREM reconstruction in [⁶⁸Ga]Ga-DOTA-TATE PET/MR

C. P. W. Cox¹, T. Brabander, F. A. Verburg, M. Segbers;
Erasmus MC, Rotterdam, NETHERLANDS.

EPS-104

Impact of 2.5-dimensional Deep Learning for Zero-TE MR-based Attenuation Correction on Chest FDG PET/MRI: Comparison with Conventional and 2-dimensional Deep Learning Approach

M. Tachibana¹, M. Nogami^{2,3}, H. Matsuo¹, M. Nishio¹, J. Inukai-Inoue¹, F. Zeng¹, T. Kurimoto⁴, K. Kubo², T. Murakami^{1,2};
¹Kobe University Graduate School of Medicine, Kobe, JAPAN, ²Department of Radiology, Kobe University Hospital, Kobe, JAPAN, ³Division of Medical Imaging, Biomedical Imaging Research Center, University of Fukui, Fukui, JAPAN, ⁴GE Healthcare, Hino, JAPAN.

710

Monday, September 11, 2023, 8:00 AM - 9:30 AM
Hall K

Technologists Oral Presentations 1: All about PET-CT!

OP-323

Double acquisition protocol for the study of washout in PET/CT parathyroids examination with ¹⁸F-Choline

M. Anelli¹, M. Nicoletto², A. Zambelli³, A. Di Nicola¹;
¹Azienda Sanitaria Locale di Pescara, Pescara, ITALY, ²Policlinico di Abano Terme, Abano Terme (PD), ITALY, ³Azienda Ospedaliera Universitaria di Padova, Padova, ITALY.

OP-324

Reduction of scan time in ¹⁸F-FMM PET/CT-scans in the diagnosis of Alzheimer's disease

J. Terzic^{1,2}, J. K. Fuglsang², R. Ismail³;
¹Vejlle Hospital, Vejle, DENMARK, ²Aalborg University, Aalborg, DENMARK, ³Odense University Hospital, Odense, DENMARK.

OP-325

Optimization of TOF-BPL reconstruction using clinical images in [¹⁸F]flutemetamol amyloid PET
S. Fukuda¹, K. Miwa², K. Wagatsuma^{1,3}, Y. Yakushiji¹, T. Yamao², Y. Kamitaka³, T. Hasegawa¹;
¹Kitasato University Graduate School of Medical Sciences, Kanagawa, JAPAN, ²Fukushima Medical University, Fukushima, JAPAN, ³Tokyo Metropolitan Institution of Gerontology, Tokyo, JAPAN.

OP-326

Influence of the number of iterations on image quality and semiquantitative accuracy in [¹⁸F]FDG PET imaging using a Long Axial Field-of-View PET/CT system
M. van der Vegt, R. A. J. O. Dierckx, A. W. J. M. Glaudemans, J. van Sluis;
University Medical Centrum Groningen, Groningen, NETHERLANDS.

OP-327

Comparison of the quadratic scheme suggested by EANM guidelines and manufacturer-recommended dose factor for Fluorine-18 FDG imaging on PET-CT system with SiPM detectors: evaluation on image quality
A. Hurtado de Mendoza, M. Yaryes, C. Soza-Ried, H. Amaral;
Positronmed, Santiago, CHILE.

OP-328

The Impact of a New Breathing Movement Correction Method On FDG Uptake and Volume Determination of Body Lesions
M. Schiavini¹, F. Buffoni¹, M. Bardo¹, M. Giavarini², D. Capolongo¹, R. Leo¹, M. Rognoni¹, C. Sdraiati¹, L. Sembele³, M. Castellani¹;
¹IRCCS Fondazione "Cà Granda" Osp. Maggiore Policlinico di MILANO, Milan, ITALY, ²UNIMI, Milan, ITALY, ³Latvian Maritime Medical Center, Riga, LATVIA.

OP-330

Occupational Radiation exposure from PET/CT during patient positioning
R. Siyanbola, M. Coelho, P. Fragoso Costa, A. Moraitis, K. Herrmann, H. Hautzel;
Department of Nuclear Medicine, University Hospital Essen, University Duisburg - Essen, Essen, GERMANY.

OP-331

Eye lens exposure of nuclear medicine technologists during PET/CT procedures: compliance with dose limits and eye lens vs whole-body dosimetry
M. Ryser, S. Figueiredo, S. Medici, J. O. Prior, N. Cherbuin;
CHUV, Lausanne, SWITZERLAND.

711

Monday, September 11, 2023, 8:00 AM - 9:30 AM
Hall G1

Theranostics Track - TROP Session: What's New in Prostate Cancer?

OP-332

Radioligand Therapy with [¹⁷⁷Lu]Lu-PSMA I&T in the Elderly - Safety, Efficacy and Prognosticators of Survival
S. Weber¹, A. Seitz², H. Kübler³, A. K. Buck¹, R. A. Werner^{1,3}, P. E. Hartrampf¹;
¹University Hospital Wuerzburg, Department of Nuclear Medicine, Wuerzburg, GERMANY, ²University Hospital Wuerzburg, Department of Urology and Paediatric Urology, Wuerzburg, GERMANY, ³Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.

OP-333

Evaluation of Nephrotoxicity of Extended Lu¹⁷⁷-PSMA in Patients with Metastatic Castration-Resistant Prostate Cancer
E. Topal¹, B. Kovari¹, D. Has Simsek¹, C. Civan¹, M. Sanli², M. Basaran³, Y. Sanli¹;
¹Istanbul University, Istanbul Medical Faculty, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²Istanbul University, Istanbul Medical Faculty, Department of Urology, Istanbul, TÜRKIYE, ³Istanbul University, Oncology Institute, Department of Medical Oncology, Istanbul, TÜRKIYE.

OP-334

Safety and Efficacy of Extended ¹⁷⁷Lu-PSMA Therapy: Multi-Center Retrospective Analysis
T. Telli^{1,2,3}, R. Seifert^{1,2,3}, C. Lapa⁴, T. Hekimsoy⁵, W. Weber⁶, C. Pfob⁴, K. Herrmann^{1,2,3}, K. Rahbar⁶, M. Eiber⁵, W. Fendler^{1,2,3};
¹Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY, ²German Cancer Consortium (DKTK), University Hospital Essen, Essen, GERMANY, ³West German Cancer Center, University Hospital Essen, Essen, GERMANY, ⁴Department of Nuclear Medicine, University Hospital Augsburg, Augsburg, GERMANY, ⁵Department of Nuclear Medicine, University Hospital of Munich Technical University, Munich, GERMANY, ⁶Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY.

OP-335

AcTION: A phase 1 study of [²²⁵Ac]Ac-PSMA-617 in men with PSMA-positive prostate cancer with or without prior [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy
M. Sathekge¹, M. Crumbaker², A. M. Joshua², F. Bruchertseifer³, T. Kreis⁴, S. Emineni⁵, J. Wehbe⁶, M. Korn⁴, A. Morgenstern^{6,7}, L. Emmett^{8,2};
¹University of Pretoria and Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA, ²St Vincent's Hospital, Sydney, AUSTRALIA, ³European Commission, Joint Research Centre, Karlsruhe, GERMANY, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, UNITED STATES OF AMERICA, ⁵Novartis India, Hyderabad, Telangana, INDIA, ⁶Novartis Institutes for BioMedical Research, Basel, SWITZERLAND, ⁷*Co-senior author, GERMANY, AUSTRALIA.

OP-336

Prediction of resistance to PSMA-617 Lu-177 by assessment of circulating tumor DNA biomarkers
O. Sartor¹, E. Ledet², M. Huang¹, J. Schwartz², A. Lieberman², B. Lewis², J. Layton², A. Jang², O. Pocha², S. Lanka², M. Hawkins², K. Harris²;
¹Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA, ²Tulane University, New Orleans, LA, UNITED STATES OF AMERICA.

OP-337

Implementation of PSMA-PET/CT improves treatment outcomes after salvage radiotherapy for recurrent or persistent prostate cancer after surgery
C. Zamboglou^{1,2}, P. Staus³, M. Wolkewitz³, N. S. Schmidt Hegemann⁴, T. Wiegel⁵, L. Emmett⁶, S. Fanti⁷, A. L. Grosu², S. Koerber⁸, S. G. C. Kroeze⁹, F. Ceci¹⁰, J. C. Peeken¹¹, S. Hayoz¹², D. M. Aebbersold¹³, A. Vrachimis¹, P. Ghadjar¹⁴;
¹German Oncology Center, Limassol, CYPRUS, ²Department of Radiation Oncology, University of Freiburg - Medical Center, Freiburg, GERMANY, ³Institute of Medical Biometry and Statistics, Division Methods in Clinical Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany, Freiburg, GERMANY, ⁴Department of Radiation Oncology, University of Munich, Munich, GERMANY, ⁵Department of Radiation Oncology, University of Ulm, Ulm, GERMANY, ⁶St Vincent's Public Hospital Sydney, University of New South Wales, Sydney, AUSTRALIA, ⁷Department of Nuclear Medicine, University of Bologna, Bologna, ITALY, ⁸Department of Radiation Oncology, University of Heidelberg, Heidelberg, GERMANY, ⁹Department of Radiation Oncology, University of Zuerich, Zuerich, SWITZERLAND, ¹⁰European Institute of Oncology, Milano, ITALY, ¹¹Department of Radiation Oncology, Technical University of Munich, Munich, GERMANY, ¹²Swiss Group for Clinical Cancer Research (SAKK), Bern, SWITZERLAND, ¹³Department of Radiation Oncology, University of Bern, Bern, SWITZERLAND, ¹⁴Department of Radiation Oncology, Charite Berlin, Berlin, GERMANY.

OP-338

LuTectomy: phase 1/2 study evaluating dosimetry, safety and potential benefit of pre-surgery [¹⁷⁷Lu] Lu-PSMA-617 radioligand therapy in patients with high-risk localised prostate cancer
M. Hofman¹, R. Eapen¹, J. P. Buteau¹, P. Jackson¹, C. Mitchell¹, S. Oon¹, O. Alghazo², L. McIntosh¹, N. Dhantravan³, J. O'Brien¹, A. McVey¹, S. Sandhu¹, A. A. Azad¹, S. G. Williams¹, G. Sharma¹, B. Emmerson¹, M. B. Haskali¹, M. Bressel¹, D. Moon¹, N. Lawrentschuk¹, P. Neeson¹, D. G. Murphy¹;
¹Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ²Flinders University, Adelaide, AUSTRALIA, ³Royal Brisbane & Women's Hospital, Brisbane, AUSTRALIA.

OP-339

Lutetium-177-PSMA-617 in oligo-metastatic hormone sensitive prostate cancer (Bullseye)
B. Privé¹, C. H. J. Muselaers¹, D. Meijer², W. A. Van Gemert¹, B. Timmermans¹, M. J. R. Janssen¹, M. A. Jonker¹, M. de Groot¹, I. M. van Oort¹, N. Mehra¹, W. R. Gerritsen¹, E. Alevroudis³, A. Vrachimis³, J. A. Gietema⁴, M. Gotthardt¹, A. N. Vis², I. J. de Jong⁴, A. J. Witjes¹, W. Noordzij¹, D. E. Oprea-Lager², J. Nagarajah¹;
¹Radboudumc, Nijmegen, NETHERLANDS, ²Amsterdam University Medical Centers, Amsterdam, NETHERLANDS, ³German Oncology Center, Limassol, CYPRUS, ⁴University Medical Center Groningen, Groningen, NETHERLANDS.

OP-340

Association of baseline quantitative [⁶⁸Ga]Ga-PSMA-11 PET imaging parameters with clinical outcomes in patients with mCRPC receiving [¹⁷⁷Lu] Lu-PSMA-617: a VISION sub-study
P. H. Kuo¹, M. Morris², A. T. Kendi³, K. Rahbar⁴, X. X. Wei⁵, B. Fang⁶, A. J. Armstrong⁷, J. Hesterman⁸, K. Chi⁹, J. de Bono¹⁰, K. Fizazi¹¹, B. Krause¹², O. Sartor³, S. T. Tagawa¹³, S. Ghebremariam¹⁴, M. Brackman¹⁵, C. Wong¹⁶, A. M. Catafau¹⁷, T. Benson¹⁸, K. Herrmann¹⁹;
¹University of Arizona, Tucson, AZ, UNITED STATES OF AMERICA, ²Memorial Sloan Kettering Center, New York City, NY, UNITED STATES OF AMERICA, ³Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA, ⁴University Hospital Münster, Münster, GERMANY, ⁵Dana-Farber Cancer Institute, Boston, MA, UNITED STATES OF AMERICA, ⁶Astera Cancer Care, East Brunswick, NJ, UNITED STATES OF AMERICA, ⁷Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, UNITED STATES OF AMERICA, ⁸Invivo, Needham, MA, UNITED STATES OF AMERICA, ⁹British Columbia Cancer Agency, Vancouver Centre, Vancouver, BC, UNITED STATES OF AMERICA, ¹⁰The Institute of Cancer Research and Royal Marsden Hospital, London, UNITED KINGDOM, ¹¹Gustave Roussy Institute, University of Paris Saclay, Villejuif, FRANCE, ¹²Rostock University Medical Center, Rostock, GERMANY, ¹³Weill Cornell Medicine, New York City, NY, UNITED STATES OF AMERICA, ¹⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, UNITED STATES OF AMERICA, ¹⁵Novartis Pharmaceuticals Corporation, Indianapolis, IN, UNITED STATES OF AMERICA, ¹⁶Novartis Pharmaceuticals Corporation, Cambridge, MA, UNITED STATES OF AMERICA, ¹⁷Novartis Pharmaceuticals Corporation, Geneva, SWITZERLAND, ¹⁸Novartis Pharmaceuticals Corporation, St George, UT, UNITED STATES OF AMERICA, ¹⁹University Hospital Essen, Essen, GERMANY.

801

Monday, September 11, 2023, 09:45 - 11:15
Hall A

CME 6 - Dosimetry Committee: Understanding Radiobiology for Dosimetry-Guided Molecular Radiotherapy

OP-341

General Aspects of Radiobiology Applied to Molecular Radiotherapy
J. Pouget;
Cancer Research Institute/INSERM, Montpellier, FRANCE.

OP-342

Radiobiological Aspects Applied to Different Molecular Radiotherapies
D. Taieb;
La Timone University Hospital, Department of Nuclear Medicine, Marseille, FRANCE.

OP-343

Relevance of the Absorbed Dose, Fractionation, and Time Interval Between Cycles
L. Strigari;
University of Bologna, Department of Medical and Surgical Sciences, Bologna, ITALY.

OP-344

Particular Aspects of the Radiobiology of Alpha and Beta Emitters

J. Nonnekens;

Erasmus Medical Center, Department of Radiology and Nuclear Medicine, Rotterdam, NETHERLANDS.

802

Monday, September 11, 2023, 09:45 - 11:15

Hall D (Arena)

Round Table 1 - Translational Molecular Imaging & Therapy + Oncology & Theranostics + Radiopharmaceutical Sciences Committee: Dialogue with the Treating Physician

OP-345

Dialogue with the Treating Physician - Immunocologist

A. Digkila;

Centre hospitalier universitaire Vaudois, Department of Oncology, Lausanne, SWITZERLAND.

OP-346

Dialogue with the Treating Physician - Cardiologist

C. Kamani;

Leeds Teaching Hospitals NHS Trust, Cardiorespiratory Department, Leeds, UNITED KINGDOM.

OP-347

Dialogue with the Treating Physician - Urologist

T. Maurer;

Universitätsklinikum Hamburg-Eppendorf, Martini-Klinik, Department of Urology, Hamburg, GERMANY.

OP-348

Dialogue with the Treating Physician - Dermatologist

E. Guenova-Hoetzenecker;

CHUV, Department of Dermatology, Lausanne, SWITZERLAND.

OP-349

Dialogue with the Treating Physician - Nuclear Medicine Physician

E. Lopci;

RCCS - Humanitas Research Hospital, Nuclear Medicine, Department of diagnostic imaging, Rozzano, ITALY.

OP-350

Dialogue with the Treating Physician - Radiopharmacist

P. Laverman;

Radboud University Medical Center, Department of Radiology and Nuclear Medicine, Nijmegen, NETHERLANDS.

803

Monday, September 11, 2023, 09:45 - 11:15

Hall E1

LIPS Session 6 - Neuroimaging + Cardiovascular + Inflammation & Infection Committee: Molecular Imaging to Solve the Problem of Long COVID

OP-351

The lung impairment in long COVID

D. Albano;

Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, ITALY.

OP-352

The vascular impairment in long COVID

M. Sollini;

Department of Biomedical Sciences, Humanitas University, Milan, ITALY.

OP-353

The brain impairment in long COVID

E. Guedj;

Aix Marseille Universite, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Marseille, FRANCE.

804

Monday, September 11, 2023, 9:45 AM - 11:15 AM

Hall E2

M2M Track - TROP Session: TME and Therapy: Direct Targeting and Secondary Effects

OP-355

Optimisation of FAP-targeted radionuclide therapy through molecular evolution of OncoFAP derivatives and combination with immunocytokines

A. Galbiati¹, M. Bocci¹, E. Gilardoni¹, J. Mock¹, D. Neri², S. Cazzamalli¹;

¹Philochem AG, Otelfingen, SWITZERLAND,

²Philogen, Siena, ITALY.

OP-356

Tumor-targeted Interleukin-2 Boosts the Anti-cancer Activity of FAP-directed Radioligand Therapeutics

P. Backhaus^{1,2}, P. Dorten², A. Galbiati³, E. Gilardoni³, F. Gierse², M. Bocci³, A. Zana³, J. Mock³, M. Claesener¹, J. Cufe¹, F. Büther¹, K. Schäfers², S. Hermann², D. Neri^{4,5}, M. Schäfers¹, S. Cazzamalli³;

¹University Hospital Münster, Münster, GERMANY,

²European Institute for Molecular Imaging, University of Münster, Münster, GERMANY, ³Philochem AG,

R&D department, Otelfingen, SWITZERLAND,

⁴Swiss Federal Institute of Technology, Department of Chemistry and Applied Biosciences, Zurich,

SWITZERLAND, ⁵Philogen S.p.A, Siena, ITALY.

OP-357

FAP directed target modules for UniCART cell therapy and radionuclide-based tumour theranostics

C. Neuber, L. Loureiro, L. Hoffmann, M. Kubeil, C. Arndt, A. Feldmann, M. Bachmann;

Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY.

OP-358

Evaluation of Therapeutic and Immunological Action of CAIX-Targeted Lutetium-177 Radionuclide Therapy Combined with Immune Checkpoint Inhibition

S. Kleinendorst¹, M. Konijnenberg¹, G. Franssen¹, J. Molkenboer-Kuennen¹, S. Wenker¹, D. Boreel¹, D. Kroon¹, M. Gludemans¹, K. Twumasi-Boateng², M. Wheatcroft², E. Oosterwijk³, S. Heskamp¹;

¹Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS, ²Telix Pharmaceuticals Ltd., Melbourne, AUSTRALIA,

³Department of Urology, Radboud University Medical Center, Nijmegen, NETHERLANDS.

OP-359

RAYZ-15170, a novel small-molecule binder to carbonic anhydrase IX (CA9) for targeted radiopharmaceutical therapy of clear cell renal cell carcinoma and other CA9 expressing tumors

N. Smith, J. Tran, A. Lai, Y. Bravo, A. Cieniewicz, P. Mondala, R. Clift, T. Lo, G. Chen, G. Li, K. Lidberg, L. Nyiranshuti, S. Richardson, A. Hudson;

RayzeBio, Inc., San Diego, CA, UNITED STATES OF AMERICA.

OP-360

[²²⁵Ac]Ac-DPI-4452, a new peptide radioligand targeting Carbonic Anhydrase IX, displays strong anti-tumoral activity in colorectal cancer and clear cell renal cell carcinoma mouse models

N. Wiedemann, A. Attinger, E. Da Costa Branquinho, U. Andersson;

Debiopharm International SA, Lausanne, SWITZERLAND.

OP-361

Extracellular Matrix-Targeted Radionuclide Therapy Remodels Tumor Microenvironment Landscape and Enhances Immunotherapy in Triple-Negative Breast Cancer

L. Li, Z. Zeng, F. Liu, X. Ma, B. Jia, Z. Yang;

Peking University Cancer Hospital & Institute, Beijing, CHINA.

OP-362

Profiling the influencing factors of radiopharmaceutical therapy: spatial transcriptomics and computational modeling in microenvironment

J. Hong¹, S. Bae², L. Cavinato³, M. Ryhiner¹, A. Rominger¹, H. Choi², K. Shi¹;

¹University of Bern/Inselspital, Bern, SWITZERLAND,

²Seoul National University Hospital, Seoul, KOREA,

REPUBLIC OF, ³Politecnico di Milano, Milan, ITALY.

805

Monday, September 11, 2023, 9:45 AM - 11:15 AM

Hall B

Cutting Edge Science Track - TROP Session: Image Reconstruction and Data Corrections

OP-363

Fast Penalized Maximum Likelihood Method for Positron Lifetime Image Reconstruction Using Adaptive Time Framing

J. Qi, B. Huang;

UC Davis, Davis, CA, UNITED STATES OF AMERICA.

OP-364

Direct versus indirect parametric whole body [¹⁸F] FDG Patlak imaging using a LAFOV PET/CT system

J. van Sluis¹, L. Providencia¹, J. H. van Snick¹, A. W. J. M. Gludemans¹, R. H. J. A. Slart¹, R. A. J. O. Dierckx¹, C. Tsoumpas¹, R. Boellaard^{1,2};

¹University Medical Center Groningen, Groningen,

NETHERLANDS, ²Amsterdam University Medical Centers, Amsterdam, NETHERLANDS.

OP-365

O-15 water in acceptance angle comparison high sensitivity vs ultra-high sensitivity

H. Merisaari¹, N. Ono², T. Tolvanen^{3,4}, V. Saunavaara^{3,4}, J. Knuuti³, L. Nummenmaa³, P. Nuutila³, H. Iida³;

¹Department of Radiology, University of Turku, Turku,

FINLAND, ²Department of Information Science, Nara

Institute of Science and Technology, Turku, FINLAND,

³Turku PET Centre, University of Turku and Turku University

Hospital, Turku, FINLAND, ⁴Department of Medical

Physics, Turku University Hospital, Turku, FINLAND.

OP-366

Impact of different collimator response models on quantitative ¹⁷⁷Lu-SPECT reconstructions

W. Claeys¹, W. Deckers², V. Nuttens³, C. Deroose^{1,2}, K. Goffin^{1,2}, K. Baete^{1,2}, M. Koole¹;

¹KU Leuven, Leuven, BELGIUM, ²UZ Leuven, Leuven,

BELGIUM, ³OLV Aalst, Aalst, BELGIUM.

OP-367

Towards the clinical implementation of quantitative ¹⁷⁷Lu SPECT/CT with a ring-shaped CZT-based camera: comparison of OSEM and Q.Clear reconstruction algorithms

R. Danieli¹, M. Stella², J. Leube³, J. Tran Gia³, H. Levillain¹, C. Marin¹, B. Vanderlinden¹, N. Reynaert¹, P. Flamen¹;

¹Institut Jules Bordet, Brussels, BELGIUM, ²GE

HealthCare, Diegem, BELGIUM, ³University

Hospital Würzburg, Würzburg, GERMANY.

OP-368

Positron-Range Correction for an On-Chip PET Scanner using Deep Learning

C. Clement¹, G. Birindelli¹, F. Pagano^{2,3}, M. Pizzichemi^{2,3}, M. Kruthof-De Julio¹, S. Ziegler⁴, A. Rominger¹, E. Auffray², K. Shi¹;

¹Inselspital Bern, Bern, SWITZERLAND, ²CERN, Geneva,

SWITZERLAND, ³University of Milano-Bicocca, Milan,

ITALY, ⁴University Hospital Munich, Munich, GERMANY.

OP-369

Implementation and performance evaluation of artificial intelligence based SPECT attenuation correction on clinical SPECT images

M. Szolikova¹, A. Kovacs¹, B. Husztik¹, N. Meszaros¹, F. Nagy², I. Gara², S. Barna²;

¹Mediso Ltd., Budapest, HUNGARY, ²ScanoMed Nuclear Medicine Centers, Debrecen, HUNGARY.

OP-370

Deep-Learning-based Partial Volume Correction in SPECT

T. Kaprélán, A. Extebeste, D. Sarrut; Université de Lyon, CREATIS; CNRS UMR5220; Inserm U1044; INSA-Lyon; Université Lyon 1; Centre Léon Bérard, France., Lyon, FRANCE.

OP-371

Deep-learning based partial volume correction for ¹⁷⁷Lu SPECT/CT imaging based on a large Monte Carlo simulated dataset

J. Leube¹, J. Gustafsson², M. Lassmann¹, M. Salas Ramirez², J. Tran-Gia¹;

¹University Hospital Würzburg, Würzburg, GERMANY, ²Lund University, Lund, SWEDEN.

806

Monday, September 11, 2023, 9:45 AM - 11:15 AM
Hall C

Clinical Oncology Track - Featured Session: FAP Imaging

OP-372

FAP Imaging

J. Calais; UCLA, Los Angeles, UNITED STATES OF AMERICA.

OP-373

Dual-phase ⁶⁸Ga-FAPI-04 PET/CT: the pancreatic FAPI uptake characteristics and differentiation of pancreatic diseases

H. Wu, C. Li, Y. Tian, Z. Xiao, Y. Jiang, Y. He; Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, CHINA.

OP-374

⁶⁸Ga-labeled Fibroblast Activation Protein Inhibitor PET/CT in the clinical diagnosis and management of breast cancer: Comparison with [¹⁸F]FDG PET/CT

W. Guo¹, W. Xu¹, H. Fu¹, Y. Pang¹, L. Zhao¹, L. Sun¹, H. Chen²;

¹The first affiliated hospital of Xiamen University, Xiamen, CHINA, ²The first affiliated hospital of Xiamen University, Xiamen city, CHINA.

OP-375

Role of PET/CT using [⁶⁸Ga]Ga-DOTA-FAPI-04 in the Detection of Lesions and Staging of Various Malignancies, Excluding Gastrointestinal Tract Malignancies with Non-FDG Avid Lesions.

G. Beydagi¹, N. Alan-Selcuk¹, K. Akcay¹, E. Demirci¹, O. Sonmez¹, M. Ocak², T. Toklu¹, S. Celik³, B. Oven³, L. Kabasakal⁴;

¹Yeditepe University, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul, TÜRKIYE, ³Yeditepe University, Department of Medical Oncology, Istanbul, TÜRKIYE, ⁴Istanbul University-Cerrahpasa, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

OP-376

Impact of ⁶⁸Ga-FAPI PET/CT imaging in the diagnosis and management of primary and recurrent epithelial ovarian cancer

K. Xu, J. Chen, C. Li, Y. Tian, L. Li, Y. Jiang, Z. Xiao, D. Xing, B. Wen, Y. He;

Zhongnan Hospital of Wuhan University, Wuhan, China, CHINA.

OP-377

Fibroblast activation protein and glycolysis in lymphoma diagnosis: comparison of ⁶⁸Ga-FAPI PET/CT and ¹⁸F-FDG PET/CT

X. Chen, S. Wang, Y. Lai, G. Wang, M. Wei, X. Jin, J. Ding, Y. Zhang, Y. Shi, F. Wang, H. Zhu, Z. Yang, X. Wang; Peking University Cancer Hospital & Institute, Beijing, CHINA.

OP-378

[⁶⁸Ga]GaFAPI-RGD PET/CT in the evaluation of renal carcinoma: comparison with [¹⁸F]FDG/[⁶⁸Ga]Ga-PSMA PET/CT

R. Lin¹, J. Zang¹, C. Wang¹, S. Chen¹, J. Zhang¹, Y. Yang¹, F. Xu¹, J. Zhang², X. Chen², W. Miao¹;

¹Department of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian Province, CHINA, ²National University of Singapore, Singapore, SINGAPORE.

OP-379

Diagnostic Accuracy of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT for Localizing Primary Tumor in the Head and Neck Cancer of Unknown Primary

B. Gu, X. Du, Z. Yang, S. Song, Z. Yang; Fudan University Shanghai Cancer Center, Shanghai, CHINA.

OP-380

Head-to-head comparison of ⁶⁸Ga-FAPI46 PET/CT, ¹⁸F-FDG PET/CT, and contrast-enhanced CT in patient with various solid tumors

M. Watanabe, H. Grafe, N. Hirmas, R. Hamacher, H. Lanzafame, K. M. Pabst, M. Nader, J. T. Siveke, W. P. Fendler, K. Herrmann, M. Weber; Essen University Hospital, Essen, GERMANY.

807

Monday, September 11, 2023, 9:45 AM - 11:15 AM
Hall F1

Cardiovascular Committee - TROP Session: Clinical Perfusion Imaging with PET

OP-381

Cardiac one stop shop: Performance of a Rapid Diagnostic Outpatient Clinic using Rubidium-82 PET-CT Imaging.

J. Boer, M. Ros, P. Bot;

Spaarne Gasthuis, Haarlem, NETHERLANDS.

OP-382

Prognostic value of coronary flow capacity by rubidium-82 PET/CT in patients with suspected CAD and normal myocardial perfusion imaging

A. D'Antonio¹, E. Zampella¹, R. Assante¹, T. Mannarino¹, V. Gaudieri¹, P. Buongiorno¹, M. Falzarano¹, F. Reina¹, F. Reina¹, M. Panico², P. Arumugam³, A. Cuocolo¹, W. Acampa¹;

¹Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, ITALY, ²Institute of Biostructure and Bioimaging, CNR, Naples, ITALY, ³Department of Nuclear Medicine, Central Manchester Foundation Trust, Manchester, UNITED KINGDOM.

OP-383

Quantitative relationship between coronary artery calcium and myocardial blood flow by hybrid rubidium-82 PET/CT imaging in heart transplanted patients

T. Mannarino¹, R. Assante¹, E. Zampella¹, A. D'Antonio¹, F. Cacciatore², C. Amarelli³, M. Falzarano¹, F. Reina¹, R. Lepre¹, I. Mattucci³, R. Chiappetti², V. Gaudieri¹, P. Buongiorno¹, M. Panico¹, C. Maiello³, A. Cuocolo¹, W. Acampa¹;

¹Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY, ²Department of Translational Medical Sciences, University of Naples "Federico II", Naples, ITALY, ³Department of Cardiac Surgery and Transplantation, Monaldi, Azienda Ospedaliera dei Colli, Naples, Naples, ITALY.

OP-384

MPI - from Rb to [¹⁵O]water with a dedicated cyclotron

M. Lonsdale, S. Fuglsang, M. Krakauer, A. Larsen, I. Rasmussen, U. Talleruphuus, P. Hovind; Bispebjerg Hospital, Copenhagen, DENMARK.

OP-385

⁸²Rb and [¹⁵O]H₂O Myocardial perfusion PET imaging - a prospective head to head comparison

L. Marner¹, M. Krakauer¹, A. Ismail¹, U. Talleruphuus¹, A. C. Henriksen¹, M. N. Lonsdale¹, I. L. Rasmussen¹, S. Fuglsang¹, E. Prescott², P. Hovind¹, L. Marner¹;

¹Copenhagen University Hospital Bispebjerg, Department of Clinical Physiology and Nuclear Medicine, Copenhagen NV, DENMARK, ²Copenhagen University Hospital Bispebjerg, Department of Cardiology, Copenhagen NV, DENMARK.

OP-386

Splenic switch-off as marker of adenosine response in myocardial perfusion imaging with O-15-H₂O PET

M. Jochumsen^{1,2}, L. C. Gormsen^{1,2}, L. P. Tolbod^{1,2}, J. Brorson^{1,2};

¹Dept of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, DENMARK, ²Department of Clinical Medicine, Aarhus University, Aarhus, DENMARK.

OP-387

RV to LV Myocardial Blood Flow Ratio With ¹⁵O-water PET as a Risk Marker for Cardiac Events in Patients With Left Ventricular Hypertrophy

P. Svanström, J. Sigfridsson, H. J. Harms, T. Kero, K. Eggers, N. Regula, M. Lubberink, J. Sörensen; Uppsala University, Uppsala, SWEDEN.

OP-388

Evaluation of DOTA as a marker of myocardial blood flow by comparison of ⁶⁸Ga-DOTA to ¹⁵O-water-PET

M. Lubberink¹, S. Kvernby¹, C. Rischpler², K. Azarbar¹, J. Sörensen¹, I. Velikyan¹, T. Kero¹;

¹Uppsala University, Uppsala, SWEDEN, ²Klinikum Stuttgart, Stuttgart, GERMANY.

OP-389

The Second Phase-3 Multi-Center Trial of ¹⁸F-Flurpiridaz PET Myocardial Perfusion Imaging for Coronary Artery Disease Evaluation

J. Knuuti¹, D. Agostini², T. Bateman³, J. J. Bax⁴, R. Beanlands⁵, D. Berman⁶, S. Dorbala⁷, E. V. Garcia⁸, J. Feldman⁹, G. V. Heller¹⁰, P. Martinez-Clark¹¹, M. Pelletier-Galarneau¹², B. Shepple¹³, N. Tamaki¹⁴, F. Tranquart¹⁵, J. E. Udelson¹⁶, J. Maddahi¹⁷;

¹Turku University Hospital, Turku, FINLAND, ²University Hospital Caen, Caen, FRANCE, ³Mid-America Heart, Kansas City, KS, UNITED STATES OF AMERICA, ⁴Leiden University Medical Center, Leiden, NETHERLANDS, ⁵Ottawa Heart Institute, Ottawa, ON, CANADA, ⁶Cedars Sinai Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA, ⁷Brigham and Women's Hospital, Boston, MA, UNITED STATES OF AMERICA, ⁸Emory University, Atlanta, GA, UNITED STATES OF AMERICA, ⁹Memorial City and Katy Cardiology, Katy, TX, UNITED STATES OF AMERICA, ¹⁰Morristown Medical Center, Morristown, NJ, UNITED STATES OF AMERICA, ¹¹North Miami Beach, Miami, FL, UNITED STATES OF AMERICA, ¹²Montreal Heart Institute, Montreal, QC, CANADA, ¹³University of Tennessee Medical Center, Tennessee, TN, UNITED STATES OF AMERICA, ¹⁴Kyoto Prefectural University of Medicine, Kyoto, JAPAN, ¹⁵GE Healthcare, Chalfont St Giles, UNITED KINGDOM, ¹⁶Tufts Medical Center, Boston, MA, UNITED STATES OF AMERICA, ¹⁷David Geffen School of Medicine at University of California, Los Angeles, CA, UNITED STATES OF AMERICA.

808

Monday, September 11, 2023, 9:45 AM - 11:15 AM
Hall F2

Thyroid Committee- Featured Session: Iodine-131 Therapy and Beyond in Differentiated Thyroid Cancer

OP-390

An Overview on Nuclear Medicine Therapy of Differentiated Thyroid Cancer

M Kreissl;

University Hospital Magdeburg, Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, Magdeburg, GERMANY.

OP-391

Radioactive Iodine Therapy for Low-risk Papillary Thyroid Cancer: Long-term Recurrence Risk Reduction in a Matched Cohort Study

S. Bilgic¹, R. C. Mera², M. S. Sağer³, K. Sönmezoğlu³;

¹Sirnak State Hospital, Sirnak, TÜRKIYE, ²University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

OP-392

Comparison of 1.1 gqb and 2.2 gqb¹³¹I activities in patients with low-risk differentiated thyroid cancer requiring postoperative iodine-131 therapy.

A. Campenni¹, R. Ruggeri¹, M. Garo², A. Raffa¹, M. Siracusa¹, G. Restuccia¹, A. Rappazzo¹, H. Rosarno¹, A. Nicocia¹, D. Cardile¹, P. Petranović Ovcariček², S. Baldari¹, L. Giovanella⁴;

¹Ospedale Gaetano Martino, Messina, ITALY, ²Mathsly Research, Roma, ITALY, ³University Hospital Center Sestre Milosrdnice, 10 000 Zagreb, CROATIA, ⁴Clinic for Nuclear Medicine and Competence Centre for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, SWITZERLAND.

OP-393

Integrating ¹³¹I SPECT-based RPT dosimetry into stereotactic external beam treatment planning for patients with metastatic radioiodine-refractory thyroid cancer, preliminary clinical trial results

I. Marsh¹, H. Quon¹, P. Santhanam¹, P. Ladenson¹, B. He², D. Kaplin¹, K. Lowe¹, H. Wang¹, G. Sgouros¹, R. F. Hobbs¹;

¹Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, ²RAPID LLC, Baltimore, MD, UNITED STATES OF AMERICA.

OP-394

Is radio iodine therapy really as bad as it is made out to be? A look at secondary neoplasms using the SEER database.

B. Schemmer;

Uniklinik Bonn, Bonn, GERMANY.

OP-395

Radioguided Occult Lesion Localization (ROLL) in patients with persistence/recurrence of differentiated thyroid cancer: a 10-years single-centre experience

C. Manni¹, G. Follacchio¹, G. Gesuelli², R. Scibè², G. Ferrara³, M. Capponi⁴, G. Ciccioi⁴, F. Capocchetti¹;

¹Nuclear Medicine Unit, Macerata Hospital, Italy, Macerata, ITALY, ²Surgery Unit, Macerata Hospital, Italy, Macerata, ITALY, ³Anatomic Pathology and Cytopathology Unit, Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Naples, ITALY, ⁴Radiology Unit, Macerata Hospital, Italy, Macerata, ITALY.

OP-396

High Ki-67 LI is an Important Factor for Good Early Outcomes After Radioiodine Therapy in Patients with Intermediate to High-Risk Papillary Thyroid Cancer

X. Luo, W. Ouyang;

Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, CHINA.

OP-397

Redifferentiation Therapy for RAI-Refractory Differentiated Thyroid Cancers Based on Tumor Genomic Assay

D. Shen^{1,2}, H. Chan¹, F. Tsai¹, Y. Chiu¹, T. Liang¹, Y. She¹, S. Li¹;

¹Kaohsiung Veterans General Hospital, Kaohsiung, TAIWAN, ²Tri-Service General Hospital, Taipei, TAIWAN.

OP-398

Radioligand Therapy with ¹⁷⁷Lu-EB-FAPI for the Treatment of Metastatic Radioiodine Refractory Thyroid Cancer: First-in-Human Dose-Escalation Clinical Trial

H. Fu, J. Huang, W. Guo, L. Sun, H. Wu, H. Chen;

The First Affiliated Hospital of Xiamen University, Xiamen, CHINA.

809

Monday, September 11, 2023, 9:45 AM - 11:15 AM

Hall G2

e-Poster Presentations Session 6 - Oncology & Theranostics Committee: Prostate Cancer

EPS-105

The Probability of Prostate Cancer Metastases within different Prostate-Specific Antigen ranges using Primary Staging Prostate-Specific Membrane Antigen PET/CT in Patients with Newly Diagnosed Prostate Cancer

W. Luining¹, M. J. Hagens², D. Meijer¹, S. Srbljin³, J. C. C. Koppes¹, R. J. J. Knol⁴, P. J. van Leeuwen², A. N. Vis¹, D. E. Oprea-Lager¹;

¹Amsterdam UMC, Amsterdam, NETHERLANDS, ²Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NCI-AVL), Amsterdam, NETHERLANDS, ³Zaans Medisch Centrum, Zaandam, NETHERLANDS, ⁴Northwest Clinics, Alkmaar, NETHERLANDS.

EPS-106

A systematic review and meta-analysis of the diagnostic test accuracy of PSMA PET for tumor staging in newly diagnosed prostate cancer patients, compared to histopathology

F. Gossili^{1,2}, A. W. Mogensen^{1,2}, T. C. Konnerup³, K. Bouchelouche⁴, I. L. Alberts⁵, A. Afshar-Oromieh⁵, H. D. Zacho^{1,2};

¹Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, DENMARK, ²Department of Clinical Medicine, Aalborg University, Aalborg, DENMARK, ³Unit of Clinical Biostatistics, Aalborg University Hospital, Aalborg, DENMARK, ⁴Department of Nuclear Medicine & PET-Centre, Aarhus University Hospital, Aarhus, DENMARK, ⁵Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

EPS-107

A multi-center European study to explore the detection of oligometastatic disease by PSMA-PET/CT in intermediate to high-risk Prostate Cancer

G. Zuccotti¹, F. Mattana¹, A. Barone¹, L. Muraglia¹, R. Mei², A. Farolfi², P. Rajwa³, M. Miszczyk⁴, V. Kasivisvanathan⁵, F. Zattoni⁶, G. Gandaglia⁷, A. Briganti⁷, S. Shariat³, P. Castellucci², S. Fanti², F. Ceci¹;

¹Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS, Milano, ITALY, ²Service of Nuclear Medicine, Sant'Orsola-Malpighi University Hospital IRCCS, Bologna, ITALY, ³Department of Urology, University of Vienna, Vienna, AUSTRIA, ⁴Department of Nuclear Medicine, Narodowy Instytut Onkologii, Gliwice, POLAND, ⁵Department of Urology, Imperial College of London, London, UNITED KINGDOM, ⁶Department of Urology, University of Padova, Padova, ITALY, ⁷Department of Urology, San Raffaele Hospital, Milano, ITALY.

EPS-108

Role of AL¹⁸F-labeled prostate specific membrane antigen (PSMA-BCH) PET/CT in detecting extracapsular extension of localized prostate cancer.

Z. Jie¹, Y. Zh², L. Chen²;

¹Shanxi Cancer Hospital, Taiyuan, CHINA, ²Peking University Cancer Hospital and Institute, Beijing, CHINA.

EPS-109

Exploring the Correlation between Multiparameters Detected in Primary Prostate Cancer using 18F-PSMA-1007 PET/MRI and thier Potential for Predicting Lymph Node and Bone Metastases

S. Cheewadhanaraks¹, K. Sereebornwornthanasak², C. Chotipanich¹, D. Siripongsatian¹, C. Promteangtrong¹, A. Kunawudhi¹, P. Kiatkittikul¹, A. Jantarato¹, N. Boonsingma¹, N. Boonkawin¹;

¹National Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, THAILAND, ²Bhumibol Adulyadej Hospital, Bangkok, THAILAND.

EPS-110

The Updated Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE V2.0) Framework for Standardized Reporting of PSMA-PET

R. Seifert¹, L. Emmett², K. Herrmann¹, B. Hadaschik¹, J. Calais³, S. Fant⁴, T. A. Hope⁵, M. S. Hofman⁶, M. Eiber⁷, W. P. Fendler¹;

¹University Hospital Essen, Essen, GERMANY, ²St Vincent's Hospital, Sydney, AUSTRALIA, ³David Geffen School of Medicine at UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, ⁴IRCCS AOU di Bologna, Bologna, ITALY, ⁵University of California, San Francisco, San Francisco, CA, UNITED STATES OF AMERICA, ⁶University of Melbourne, Melbourne, AUSTRALIA, ⁷Technical University of Munich, Munich, GERMANY.

EPS-111

PRIMARY scores on PSMA PET/CT and MpMRI: Role in initial evaluation of prostate cancer.

S. Kumar, Y. Mathur, H. Singh, B. Mittal, R. Kumar;
PGIMER, Chandigarh, INDIA.

EPS-112

European Association of Urology Biochemical Recurrence (EAU BCR) Risk Groups after radical prostatectomy in the era of PSMA PET/CT

C. Artigas, C. Leplat, Q. Shagera, T. Jabbour, R. Diamand, P. Flamen;
Institut Jules Bordet, Université Libre de Bruxelles, Brussels, BELGIUM.

EPS-113

Multispectral fluorescence imaging as a means to separate healthy from diseased lymphatics during radioguided robotic surgery

F. van Leeuwen¹, A. Berrens², M. van Oosterom¹, P. van Leeuwen², I. Slof¹, t. buckle¹, h. van der Poel²;

¹Leiden University Medical Center, Leiden, NETHERLANDS, ²NETHERLANDS cancer institute, Amsterdam, NETHERLANDS.

EPS-114

Significance of interim ¹⁸F-PSMA-1007 PET/CT for early prediction of ¹⁷⁷Lu-PSMA-I&T treatment effect in metastatic castration-resistant prostate cancer patients

S. Cheung, S. Chen, Y. Wong, Y. Yip, C. Ho;
Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

EPS-115

Absorbed dose prediction for subsequent therapy cycles from 1st cycle of ¹⁷⁷Lu-PSMA-617 therapy of mCRPC patients

J. Brosch-Lenz¹, N. Colpo², I. Bloise¹, X. Hou¹, W. R. Parulekar³, C. Dellar³, F. Saad⁴, K. Chi², D. Wilson², F. Bénard², A. Rahmim¹, C. Uribe²;

¹BC Cancer Research Institute, Vancouver, BC, CANADA, ²BC Cancer, Vancouver, BC, CANADA, ³Canadian Cancer Trials Group, Queen's University Kingston, Kingston, ON, CANADA, ⁴Prostate cancer research, Montreal Cancer Institute / CRCHUM, Montreal, QC, CANADA.

EPS-116

Pre-treatment ⁶⁸Ga-PSMA PET/CT Parameters Could Predict Response to ¹⁷⁷Lu-PSMA Treatment and Overall Survival in Metastatic Castration Resistant Prostate Carcinoma Patients Treated with ¹⁷⁷Lu-PSMA

E. Özkan¹, B. Demir¹, M. Ozturk¹, M. Araz¹, C. Soydal¹, B. Dursun², Y. Urun², N. O. Kucuk¹;
¹Ankara University School of Medicine Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Ankara University School of Medicine Department of Medical Oncology, Ankara, TÜRKIYE.

EPS-117

Changes in PSA levels after two cycles of radioligand therapy appear superior to changes in PSMA PET for outcome prediction

P. Hartrampf¹, T. Hüttmann¹, A. K. Seitz², H. Kübler², T. Higuchi¹, S. E. Serfling¹, W. Schlötelburg¹, K. Michalski¹, A. K. Buck¹, R. A. Werner¹;
¹Klinik und Poliklinik für Nuklearmedizin, Würzburg, GERMANY, ²Klinik und Poliklinik für Urologie, Würzburg, GERMANY.

EPS-118

Analysing the Tumour Transcriptome of Prostate Cancer to Predict Efficacy of Lu-PSMA Therapy

A. Handke¹, C. Kesch¹, W. Fendler¹, T. Tell¹, Y. Liu², A. Hakansson², E. Davicioni², J. Hughes², H. Song³, K. Lücknerath¹, K. Herrmann¹, B. Hadaschik¹, R. Seifert¹;
¹Universitätsklinikum Essen, Essen, GERMANY, ²Decipher Bioscience, Vancouver, BC, CANADA, ³Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

EPS-119

Initial clinical study results of ⁶⁸Ga/¹⁷⁷Lu-NYM032, a new generation of PSMA-targeting theranostic radiopharmaceuticals, in patients with metastatic prostate cancer

H. He¹, Y. Wang¹, Y. Mi¹, C. Yan², P. Fang², W. Eng², H. Fu¹, C. Yu¹;
¹Affiliated Hospital of Jiangnan University, Wuxi, CHINA, ²Norroy bioscience Co. Ltd., Wuxi, CHINA.

EPS-120

Detection Rate of ⁶⁴Cu-SAR-Bombesin-PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal ⁶⁸Ga-PSMA-11-PET/CT

S. Li¹, A. Nguyen^{1,2}, W. Counter¹, N. John¹, J. De Leon³, G. Hruby^{4,5}, A. M. Joshua^{6,7,8}, P. Stricker^{9,10}, K. Wong¹, V. Liu¹, E. Lengyelova¹¹, S. Agrawal^{1,6,7}, L. Emmett^{1,7,2};
¹Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, AUSTRALIA, ²St Vincent's Clinical School, University of New South Wales, Sydney, AUSTRALIA, ³Genesis Cancer Care, Sydney, AUSTRALIA, ⁴Department of Radiation Oncology, Royal North Shore Hospital, Sydney, AUSTRALIA, ⁵Faculty of Medicine, University of Sydney, Sydney, AUSTRALIA, ⁶The Kinghorn Cancer Care Centre, St Vincent's Hospital, Sydney, AUSTRALIA, ⁷Garvan Institute of Medical Research, Sydney, AUSTRALIA, ⁸St. Vincent's Clinical School, University of New South Wales, Sydney, AUSTRALIA, ⁹Department of Urology, St Vincent's Hospital, Sydney, AUSTRALIA, ¹⁰Faculty of Medicine, University of New South Wales, Sydney, AUSTRALIA, ¹¹Clarity Pharmaceuticals, Sydney, AUSTRALIA.

EPS-121

Impact of ⁶⁸Ga-PSMA-11 PET/CT on salvage radiation treatment concept in males with early biochemical relapse of prostate cancer after radical prostatectomy

M. Dyankova^{1,2}, T. Stoeva¹, Z. Dancheva¹, S. Chausheva¹, T. Yordanova¹, B. Chaushev¹, A. Klisarova¹;
¹Medical University Varna "Prof. Dr. Paraskev Stoyanov", Department of Imaging Diagnostics, Interventional Radiology and Radiotherapy, Varna, BULGARIA, ²St. Marina University Hospital, Department of Nuclear Medicine, Varna, BULGARIA.

EPS-122

Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study

I. Sonni^{1,2}, A. Gafita^{1,3}, R. M. Alano¹, S. Lira¹, L. Unterrainer^{1,4}, J. Shen¹, A. Drakaki¹, T. Grogan¹, M. B. Rettig¹, J. Czernin¹, J. Calais¹;
¹University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, ²Università Magna Graecia, Catanzaro, ITALY, ³Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, ⁴Ludwig-Maximilians-University, Munich, GERMANY.

EPS-123

Comparison of SUV and tumour net uptake rate values using dynamic whole-body ⁶⁸Ga-PSMA-11 PET/CT in patients with metastatic castrate-resistant prostate cancer

N. Payan¹, J. M. Vrigneaud^{1,2}, A. Cochet^{1,2};
¹George François Leclerc Centre, Department of Nuclear Medicine, Dijon, FRANCE, ²ICMUB Laboratory, UMR CNRS 6302, University of Burgundy, Dijon, FRANCE.

EPS-124

Predictive ¹⁸F-rhPSMA 7.3 PET parameters for outcome assessment of ¹⁷⁷Lu-PSMA RLT

K. Hansen, C. Fütterer, T. Langbein, M. Heck, W. A. Weber, M. Eiber, I. Rauscher;
Klinikum rechts der Isar, Munich, GERMANY.

EPS-125

Associations between antihormonal-treatment status and ⁶⁸Ga-PSMA-HBED-CC PET biodistribution

K. Kluge¹, D. Haberl¹, H. Einspieler¹, D. Muin¹, L. Shiyam Sundar², S. Gutschmayer², L. Kenner³, A. Haug¹, M. Hacker¹;
¹Medical University of Vienna - Dept. of Nuclear Medicine, Vienna, AUSTRIA, ²Medical University of Vienna - Dept. of Medical Physics, Vienna, AUSTRIA, ³Medical University of Vienna - Dept. of Pathology, Vienna, AUSTRIA.

810

Monday, September 11, 2023, 09:45 - 11:15

Hall K

CTE 4 - Technologists Committee: Prostate Cancer Theranostics

OP-399

Prostate Cancer Theranostics – What's its Role and Why we Need it?

P. Sandach;
Universitätsklinikum, Nuclear Medicine Department, Essen, GERMANY.

OP-400

The utility of Theranostics in Various Stages of Prostate Cancer

R. Madru;
Skånes Universitetssjukhus, Lund, SWEDEN.

OP-401a

The role of Nuclear Medicine Technologist in Theranostics

A. Santos;
NuclearMedicine Department, CUF Descobertas Hospital, Lisbon, PORTUGAL.

OP-401b

The role of Nuclear Medicine Technologist in Theranostics in the USA

D. Beyder;
Barnes-Jewish Hospital, Mallinckrodt Institute of Radiology, Missouri, UNITED STATES OF AMERICA.

811

Monday, September 11, 2023, 09:45 - 11:15

Hall G1

Special Symposium 3 - EANM / EJNMMI: You, the EANM and the EJNMMI

OP-402

Setting a world stage for the EANM Journal: a voyage through 50 volumes

A. Chiti;
Professor in Diagnostic Imaging and Radiotherapy Faculty of Medicine and Surgery, Vita-Salute San Raffaele University
Director, Department of Nuclear Medicine, IRCCS Ospedale San Raffaele
Editor in Chief, European Journal of Nuclear Medicine and Molecular Imaging, Milan, ITALY.

OP-403

Ethics and metrics of scientific publication: what you should know

I. Carriò;
Autonomous University of Barcelona, Barcelona, SPAIN.

901

Monday, September 11, 2023, 11:30 - 13:00

Hall A

Plenary 3: Radiotheranostics: What's New?

OP-406

PRRT in Neuroendocrine Tumours as a Paradigm for Progress in Radiopharmaceuticals: Where are we and where will we be?

J. Strosberg;
Moffitt Cancer Center Tampa, Florida, UNITED STATES OF AMERICA.

OP-407

2023: PSMA State of the Art

M. Hofman;
Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, AUSTRALIA

OP-408

PSMA 2.0

S. Heskamp;
Radboud University Nijmegen Medical Centre, Nijmegen, NETHERLANDS.

OP-409

CXCR4: Ready for Prime Time!

A. Buck;
Universitätsklinikum Würzburg, Würzburg, GERMANY.

OP-410

Targeting the Tumour Microenvironment: Next Breakthrough?!

K. Lücknerath;
UniversityHospital Essen, Essen, GERMANY.

OP-411

Dark Horses of Theranostics

L. Unterrainer;
Department of Nuclear Medicine, LMU Munich, Munich, GERMANY, Department of Nuclear Medicine, UCLA, UNITED STATES OF AMERICA.

1001

Monday, September 11, 2023, 15:00 - 16:30

Hall A

CME 7 - Thyroid + Dosimetry Committee: New NM Guidelines of Benign Thyroid Disease

OP-414

Radioiodine Therapy of Hyperthyroidism: An Overview on the New EANM GL

A. Campenni;
UniversityHospital "Gaetano Martino", Messina. Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, Messina, ITALY.

OP-415

Radioiodine Therapy in Hyperthyroid Pediatric Patients

F. Verburg;
Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 CE, Rotterdam, NETHERLANDS.

OP-416

Radioiodine Therapy in Non-Toxic Benign Thyroid Disorders: Who, When, How

B. Katica;
Department of Nuclear Medicine, University Medical Centre Ljubljana and Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

OP-417

Adverse Effects of Radioiodine Therapy: A Real Point of View

P. Petranović Ovcariček;
UniversityHospital Center Sestre Milosrdnice, Department of Oncology and Nuclear Medicine Hospital/Institute; School of Medicine, University of Zagreb, Zagreb, CROATIA.

1002

Monday, September 11, 2023, 15:00 - 16:30
Hall D (Arena)

Award Session: EANM Sanjiv Sam Gambhir Award - Compete and Win!

1003

Monday, September 11, 2023, 15:00 - 16:30
Hall E1

LIPS Session 7 - Inflammation & Infection Committee: Tips and Tricks in the Study of Prosthesis Infection

OP-424

Tips and Tricks in Orthopedic Prosthesis
E. Noriega-Álvarez;

General University Hospital of Ciudad Real, Department of Nuclear Medicine, Ciudad Real, SPAIN.

OP-425

Tips and Tricks in Heart Valve Prosthesis
L. Leccisotti;

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Nuclear Medicine Unit, Rome, ITALY.

OP-426

Tips and Tricks in Vascular Prosthesis
A. Glaudemans;

University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS.

1004

Monday, September 11, 2023, 3:00 PM - 4:30 PM
Hall E2

M2M Track - TROP Session: New Roads Towards FAP-directed Theranostics

OP-427

Clinical Evaluation of ⁶⁸Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin $\alpha_v\beta_3$ in Various Cancer Types

Y. Pang, I. Zhao, W. Xu, J. Cai, L. Sun, H. Chen; Department of Nuclear Medicine & Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China, xiamen, CHINA.

OP-428

Quantitative SPECT/CT Imaging of the Radiation Dosimetry of ^{99m}Tc-Labeled FAPI Tracer in Healthy Subjects, and Compared with ⁶⁸Ga-PET/CT in Gastrointestinal Tumor

C. Zhou, G. Li, F. Kang, J. Wang; Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China, CHINA.

OP-429

Preclinical evaluation of a novel ¹⁸F-labeled probe for fibroblast activation protein-targeted imaging and side by side comparison with FAPI-04

F. Elvas, N. Filippi, Y. Van Rymenant, S. Grintsevich, L. Cianni, I. De Meester, P. Van der Veken; University of Antwerp, Wilrijk, BELGIUM.

OP-430

Enhancing the tumor-to-background ratio of FAP-positive PET/CT scans with the novel ⁶¹Cu-Kalios derivatives: synthesis, in vitro and in vivo characterization

J. Millul, T. Basaco Bernabeu¹, R. H. Gaonkar¹, F. De Rose², L. Jaafar-Thiel², R. Mansi¹, M. Fani¹; ¹University Hospital Basel, Basel, SWITZERLAND, ²Nuclidium AG, Basel, SWITZERLAND.

OP-431

Effects of Linker and Attachment Position on Binding Affinity, Tumor Uptake and Tumor-to-background Contrast of ⁶⁸Ga-labeled Pyridine-based Fibroblast Activation Protein Inhibitors

A. Verena, H. Kuo, H. Merkens, N. Colpo, P. Ng, F. Bénard, K. Lin; BC Cancer Research Centre, Vancouver, BC, CANADA.

OP-432

Preclinical side by side comparison of two [¹⁷⁷Lu] Lu-labeled FAP-based inhibitors: A promising therapeutic approach for targeted radionuclide therapy of stromal tumors

T. Lämpchen¹, A. Bilinska¹, E. Pilatis¹, E. Menéndez¹, S. Imlimthan¹, E. S. Moon², F. Rösch², A. Rominger¹, E. Gournil¹; ¹Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, SWITZERLAND, ²Department of Chemistry - TRIGA site, Johannes Gutenberg - University Mainz, 55128 Mainz, GERMANY.

OP-433

Novel Co-culture Model of Pancreatic Cancer to Accurately Predict the Efficacy of Fibroblast Activation Protein Targeted Radionuclide Therapy using [¹⁶¹Tb]Tb-FAP-2286 and [¹⁷⁷Lu]Lu-FAP-2286

C. D. van der Heide¹, A. Lak¹, R. McMorrow^{1,2,3}, L. Mezzanotte^{1,2}, S. U. Dalm¹; ¹Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS, ²Department of Molecular Genetics, Erasmus MC, Rotterdam, NETHERLANDS, ³Perucros B.V, Leiden, NETHERLANDS.

OP-434

Radioligand Therapy in GBM: Fibroblast Activation Protein (FAP) Promises

P. Jeanjean^{1,2}, S. Kwok^{1,2}, T. Cloughesy¹, J. Calais^{1,2}, J. Czernin^{1,2}, G. Carlucci^{1,2}, D. Nathanson^{1,2}, C. Mona^{1,2}, E. Besserer-Offroy^{1,2}; ¹Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, ²Ahmanson Translational Theranostics Division, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA.

OP-435

Targeted Covalent Radiopharmaceutical (TCR) Could be a Promising Modality for Delivering Radionuclides to Tumor

X. Cui¹, Z. Liu^{2,1}; ¹Changping Lab, Beijing, CHINA, ²Peking University, Beijing, CHINA.

1005

Monday, September 11, 2023, 3:00 PM - 4:30 PM
Hall B

Cutting Edge Science Track - TROP Session: Clinical Dosimetry I - ¹⁷⁷Lu / ²²⁵Ac and ¹⁶¹Tb RLT

OP-436

Bone Marrow Dosimetry in Radioligand Therapy using AI-Enabled Whole Body Spongiosa Segmentation and Complementary Marrow/Lesion Maps from ^{99m}Tc-Sulfur Colloid SPECT/CT and [⁶⁸Ga] Ga-PSMA-11 PET/CT

A. Peterson^{1,2}, S. J. Wilderman¹, J. Blakkisrud^{1,3}, K. Wong¹, K. A. Frey¹, Y. K. Dewaraja¹;

¹University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA, ²Wayne State University, Detroit, MI, UNITED STATES OF AMERICA, ³Oslo University Hospital, Oslo, NORWAY.

OP-437

Radiation absorbed dose in patients with metastatic castration-resistant prostate cancer treated with [¹⁶¹Tb]Tb-PSMA-I&T: first results of the VIOLET phase I/II study

B. Emmerson¹, L. McIntosh¹, J. P. Buteau^{1,2}, P. Jackson^{1,2}, L. Kostos^{2,3}, T. Akhurst^{1,2}, R. Alipour^{1,2}, A. Cardin^{1,2}, A. S. Ravi Kumar^{1,2}, R. Kashyap¹, R. Ravi¹, G. Kong^{1,2}, J. Saghebi¹, S. Sandhu^{2,3}, B. Tran^{2,3}, M. B. Haskal^{2,4}, C. Martin⁵, P. Opar⁶, E. Medhurst^{1,2}, A. Azad^{2,3}, M. S. Hofman^{1,2}; ¹Prostate Cancer Theranostics and Imaging Centre of Excellence; Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ²Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, AUSTRALIA, ³Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ⁴Radiopharmaceutical Production and Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ⁵Parkville Cancer Clinical Trials Unit, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ⁶Centre of Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

OP-438

Evaluation of a Phantom-Independent Dual-Energy Quantitative Computed Tomography (PI-DEQCT) Method for Selecting Bone-Site Specific S-Values in Bone Marrow Dosimetry in Molecular Radiotherapy

J. Pereira-Cubillo¹, E. Mora-Ramirez², M. Salas-Ramirez³; ¹University of Costa Rica, Escuela de Física, San José, COSTA RICA, ²University of Costa Rica, Escuela de Física, CICANUM, San José, COSTA RICA, ³University Hospital of Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY.

OP-439

Hematological Toxicity Correlates with Monte Carlo-derived Absorbed Dose to the Red Marrow in Patients Treated with [¹⁷⁷Lu]Lu-DOTA-TATE

J. Blakkisrud^{1,2}, G. Kinginer¹, A. B. Peterson^{1,3}, S. J. Wilderman¹, K. Wong¹, K. A. Frey¹, Y. K. Dewaraja¹; ¹University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA, ²Oslo University Hospital, Oslo, NORWAY, ³Wayne State University, Detroit, MI, UNITED STATES OF AMERICA.

OP-440

Dosimetry estimates of ¹⁷⁷Lu-PNT2002 in oligorecurrent prostate cancer: preliminary dosimetry results from a randomized phase 2 trial (LUNAR)

Z. Ellis¹, L. Unterrainer^{1,2}, D. Sennung¹, R. Alano¹, K. Booker¹, C. Felix¹, A. Daley¹, A. Farolfi^{1,3}, J. Czernin¹, M. Dahlbom¹, A. Kishan¹, J. Calais¹; ¹University of California - Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, ²Ludwig Maximilian University of Munich, Munich, GERMANY, ³Universita di Bologna, Bologna, ITALY.

OP-441

Modelling the effect of daughter migration on dosimetry estimates for actinium-225 in targeted alpha therapy

S. Tronchin¹, J. C. Forster^{1,2}, K. Hickson^{2,3}, E. Bezak^{1,4}; ¹Department of Physics, The University of Adelaide, Adelaide, AUSTRALIA, ²Medical Physics & Radiation Safety, South Australia Medical Imaging, Adelaide, AUSTRALIA, ³Allied Health & Human Performance, University of South Australia, Adelaide, AUSTRALIA, ⁴Cancer Research Institute, University of South Australia, Adelaide, AUSTRALIA.

OP-442

Image Quantification and Quality Assessment of Dual-Isotope ^{99m}Tc and ¹⁷⁷Lu SPECT for Bone Marrow Dosimetry: a Simulation Study

C. Miller, X. Hou, J. Brosch-Lenz, A. Rahmim, C. Uribe; BC Cancer Research Institute, Vancouver, BC, CANADA.

OP-443

Uncertainty analysis for Lu-177-PSMA in clinical routine

V. Nuttens¹, M. Koole², O. De Winter¹, P. De Bondt¹; ¹OLVZ, Aalst, BELGIUM, ²KU Leuven, Leuven, BELGIUM.

OP-444

Tumour dosimetry after ¹⁷⁷Lu-RPT with a ring-shaped CZT-based camera requires inclusion criteria based on volume and activity concentration

R. Danielli¹, C. Marin¹, M. Stella², B. Vanderlinden¹, H. Levillain¹, N. Reynaert¹, P. Flamen¹; ¹Institut Jules Bordet, Brussels, BELGIUM, ²GE HealthCare, Diegem, BELGIUM.

1006

Monday, September 11, 2023, 3:00 PM - 4:30 PM
Hall C

Clinical Oncology Track - Featured Session: Melanoma

OP-445
Pitfalls in Melanoma Imaging

OP-446
Predictive value of baseline quantitative parameters of 2-[¹⁸F]FDG-PET/CT for brain metastases in melanoma patients
F. Kalantari^{1,2}, L. Hehenwarter¹, G. Rendl¹, G. Schweighofer-Zwinkl¹, W. Hitzl³, P. Koelblinger⁴, C. Pirich¹, M. Beheshti¹;
¹Division of Molecular Imaging & Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University Salzburg, Salzburg, AUSTRIA, ²Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Biostatistics and Publication of Clinical Trial Studies, Research and Innovation Management (RIM), Paracelsus Medical University Salzburg, Salzburg, AUSTRIA, ⁴Department of Dermatology, University Hospital, Paracelsus Medical University Salzburg, Salzburg, AUSTRIA.

OP-447
Lymphoid organs' glucose metabolism and its role in predicting the outcomes of patients with malignant melanoma treated with immunotherapy
L. Evangelista¹, A. Bianchi², A. Annovazzi³, R. Sciuto³, S. Di Treglia³, A. G. Nappi⁴, C. Ferrari⁴, G. Rubini⁴, S. Panareo⁵, L. Urso⁶, M. Bartolomei⁶, D. Arico⁷, M. Bombaci⁷, D. Caponnetto⁷, S. Gusella⁸, A. Spimpolo⁸, C. Carriere⁹, M. Balma², A. Buschiazzo², R. Gallicchio¹⁰, G. Storto¹⁰, M. L. De Rimini¹¹;
¹Nuclear Medicine Unit, University of Padua, Padova, ITALY, ²Nuclear Medicine Unit, SC Medicina Nucleare ASO S.Croce e Carle Cuneo, Cuneo, ITALY, ³Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy, Rome, ITALY, ⁴Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy, Bari, ITALY, ⁵Nuclear Medicine Unit, Oncology and Haematology Department, University Hospital of Modena, Italy, Modena, ITALY, ⁶Nuclear Medicine Unit, Oncology and Specialistic Department, University Hospital of Ferrara, Italy, Ferrara, ITALY, ⁷Servizio di Medicina Nucleare, Humanitas Istituto Clinico Catanese, Misterbianco (CT), Italia, Catania, ITALY, ⁸Nuclear Medicine Department, Central Hospital Bolzano (SABES-ASDAA), Bolzano-Bozen, Italy, Bolzano, ITALY, ⁹Dermatology Department, Central Hospital Bolzano (SABES-ASDAA), Bolzano-Bozen, Italy, Bolzano, ITALY, ¹⁰Nuclear Medicine Unit, IRCCS CROB Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), Italia, Rionero in Vulture, ITALY, ¹¹Nuclear Medicine Unit - Department of Health Service-AORN Ospedali dei Colli, Naples, Italy, Naples, ITALY.

OP-448
First-in-human PET imaging and evaluation of melanin-targeted ¹⁸F-DMPY2 in malignant melanoma patients.
Y. Yang¹, M. Zhou¹, N. Chen¹, J. Su², X. Chen², S. Hu¹;
¹Department of Nuclear medicine, Xiangya Hospital, Central South University, Changsha City, Hunan Province, CHINA, ²Department of Dermatology, Xiangya Hospital, Central South University, Changsha City, Hunan Province, CHINA.

OP-449
The prognostic value of [¹⁸F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria
C. Sachpekidis¹, V. Weru¹, A. Kopp-Schneider¹, J. C. Hassel², A. Dimitrakopoulou-Strauss¹;
¹German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ²National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, GERMANY.

OP-450
Early monitoring of immunotherapy using ¹⁸F-FDG-PET-CT in patients with stage IV melanoma treated with PD-1 inhibitors
D. Hochmuth¹, C. Sachpekidis¹, J. Hassel², L. Pan¹, A. Dimitrakopoulou-Strauss¹;
¹German Cancer Research Center, CCU Nuclear Medicine, Heidelberg, GERMANY, ²Department of Dermatology, University Hospital Heidelberg and NCT Heidelberg, Heidelberg, GERMANY.

OP-451
FDG PET/CT Biomarker Dissemination Features In Metastatic Melanoma Patients Treated With Immunotherapy: Association With Survival
H. Saadani^{1,2}, E. A. Aalbersberg¹, M. T. Kayembe¹, J. B. A. G. Haanen¹, O. S. Hoekstra², R. Boellaard², M. P. M. Stokkel¹;
¹NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS, ²Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NETHERLANDS.

OP-452
Correlation of thyroid FDG uptake on 18F-FDG PET/CT with response to immunotherapy in metastatic melanoma patients
K. Zevnik^{1,2}, N. Hribernik^{1,2}, K. Strašek³, A. Studen^{3,4}, A. Doma^{1,2}, K. Škalič¹, M. Reberšek^{1,2};
¹Oncology Institute Ljubljana, Ljubljana, SLOVENIA, ²Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA, ³Faculty of Mathematics and Physics University of Ljubljana, Ljubljana, SLOVENIA, ⁴Experimental Particle Physics Department, Jožef Stefan Institute, Ljubljana, SLOVENIA.

OP-453
Prediction of Additional Regional Lymph Node Metastases in Cutaneous Melanoma Patients With Positive Sentinel Lymph Node Biopsy
L. Radosavcev¹, M. Rajovic², M. Radulovic¹, N. Petrov³, L. Kandolf Sekulovic⁴;
¹Institute of Nuclear Medicine, Military Medical Academy, Belgrade, SERBIA, ²Clinic for Plastic and Reconstructive Surgery, Military Medical Academy, Belgrade, SERBIA, ³Institute of Pathology and Forensic Medicine, Military Medical Academy, Belgrade, SERBIA, ⁴Department of Dermatology and Venereology, Military Medical Academy, Belgrade, SERBIA.

1007

Monday, September 11, 2023, 3:00 PM - 4:30 PM
Hall F1

Neuroimaging Committee - TROP Session: Imaging Neurotransmission in Movement Disorders

OP-454
Effects Of Medications On Dopamine Transporter Imaging Using ¹²³I-FP-CIT SPECT In Routine Practice
Y. Piatkova¹, M. Doyen¹, S. Frismand², L. Hopes², L. Imbert¹, A. Verger¹;
¹Université de Lorraine, Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, Nancy, FRANCE, ²Université de Lorraine, Department of Neurology, CHRU Nancy, Nancy, FRANCE.

OP-455
Disease-tailored z-score cut-offs for striatal binding ratio of DaT SPECT for the diagnosis of Dementia with Lewy Bodies (DLB): a multicenter study
F. Lanfranchi^{1,2}, D. Arnaldi^{2,3}, V. Garibotto⁴, C. Boccalini⁴, L. Bonanni⁵, M. V. Mattoli⁶, V. Costa^{2,3}, S. Raffa^{1,2}, S. Chiola^{1,2}, F. Massa^{2,3}, M. Losa^{2,3}, M. Pardini^{2,3}, G. Frisoni⁷, N. Nicastrò⁸, G. Sambucetti^{1,2}, M. Bauckneht^{1,2}, S. Morbelli^{1,2};
¹Nuclear Medicine Unit, Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY, ²IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, ³Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOEMI), University of Genoa, Genoa, ITALY, ⁴Division of Nuclear Medicine and Molecular Imaging, University Hospitals and NIMTLab, Geneva University, Geneva, SWITZERLAND, ⁵Department of Neuroscience, Imaging and Clinical Sciences, University G. d'Annunzio, Chieti-Pescara, ITALY, ⁶Nuclear Medicine Unit, Presidio Ospedaliero Santo Spirito, Pescara, ITALY, ⁷Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, SWITZERLAND, ⁸Division of Neurorehabilitation, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, SWITZERLAND.

OP-456
Dopamine dysregulation in depression: a 123I-FP-CIT SPET study
D. Pizzuto¹, E. Perrone^{1,2}, F. Cocciolillo¹, F. Pesaresi^{3,4}, L. Di Benedetto^{3,4}, A. D'Onofrio^{3,4}, G. Camardese^{3,4}, D. Di Giuda^{1,2};
¹Nuclear Medicine Unit, Diagnostic Imaging, Radiation Oncology and Hematology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, ²Nuclear Medicine Institute, University Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore, Rome, ITALY, ³Institute of Psychiatry and Psychology, Department of Geriatrics, Neuroscience and Orthopedics, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, ⁴Department of Psychiatry, Università Cattolica del Sacro Cuore, Rome, ITALY.

OP-457
Comparison of ¹²³I-FP-CIT SPECT and ¹⁸F-FE-PE2I PET in patients with parkinsonism and persistent diagnostic uncertainty
M. Dhadamus^{1,2}, A. Delva³, W. Vandenberghe³, K. Van Laere^{1,2};
¹Division of Nuclear Medicine, University Hospitals Leuven, Leuven, BELGIUM, ²Nuclear Medicine and Molecular Imaging, KU Leuven, Leuven, BELGIUM, ³Neurology, University Hospitals Leuven, Leuven, BELGIUM.

OP-458
Within-subject comparison of ¹¹C-PE2I and ¹⁸F-FE-PE2I PET for dopamine transporter availability and relative blood flow measures
M. Jonasson, L. Appel, S. Roslin, G. Antoni, D. Nyholm, T. Danfors, M. Lubberink;
Uppsala University, Uppsala, SWEDEN.

OP-459
Relationship between cerebral blood flow and dopamine transporter availability in healthy individuals
M. Jonasson, L. Appel, S. Roslin, D. Nyholm, T. Danfors, M. Lubberink;
Uppsala University, Uppsala, SWEDEN.

OP-460
FDG-PET related pattern expression and survival in Parkinson's disease
G. Martí-Andrés¹, V. Beteck², E. Prieto², C. Espinoza-Vinces², M. Rivero², M. Luquin², J. Arbizu²;
¹Hospital Universitario de Navarra, Pamplona, SPAIN, ²Clínica Universidad de Navarra, Pamplona, SPAIN.

OP-461
Identification of Synaptic Alterations in Idiopathic REM Sleep Behavior Disorder: A Preliminary Study using ¹⁸F-SynVest-1 PET/CT Imaging
J. Li¹, J. Huang², J. Guo², S. Hu¹;
¹1. Department of Nuclear Medicine (PET Center), Xiangya Hospital Central South University, Changsha, CHINA, ²1. Department of Neurology, Xiangya Hospital Central South University, Changsha, CHINA.

OP-462
Neurobiological dysfunctional substrates for the self-medication hypothesis in adult individuals with ADHD and cocaine use disorder: an 18F-FDG PET study
A. Martini¹, G. Carli², M. Bruscoli³, L. Presotto⁴, C. Mazzeo¹, S. Sestini¹, D. Perani⁵;
¹Unit of Nuclear Medicine, Department of Diagnostic Imaging, N.O.P. - S. Stefano, U.S.L. Toscana Centro, Prato, ITALY, ²Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, NETHERLANDS, ³UFC Farmacotossicodipendenza, Department of Drug Addiction, N.O.P. - S. Stefano, U.S.L. Toscana Centro, Prato, ITALY, ⁴Department of Physics G. Occhialini, Università degli Studi di Milano Bicocca, Milano, ITALY, ⁵In vivo human molecular and structural neuroimaging Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute; Nuclear Medicine Unit, San Raffaele Hospital, Milano, ITALY.

1008

Monday, September 11, 2023, 15:00 - 16:30
Hall F2

Joint Symposium 3 - Translational Molecular Imaging & Therapy Committee + Oncology & Theranostics + Physics / EAU: Metastases Directed Prostate Cancer Surgery - Translational Challenges and Possibilities

OP-463
Surgical removal of nodal metastases in prostate cancer, what is the clinical value?
E. Mazzone;
Dept. of Urology, San Raffaele Scientific Institute, URI - Urological Research Institute, Milan, ITALY.

OP-464

Translation and implementation of (radio)tracers for nodal management of prostate cancer

T. Buckle;
Leiden University Medical center,
Radiology, Leiden, NETHERLANDS.

OP-465

An engineers overview of radioguided surgery modalities that support targeted nodal dissections in the pelvis

T. Wendler;
Technical University Munich, CAMP, Munich, GERMANY.

OP-466

State of the art in PSMA-guided surgery

S. Knipper;
Vivantes Klinikum am Urban, Urology, Berlin, GERMANY.

1009

Monday, September 11, 2023, 3:00 PM - 4:30 PM
Hall G2

e-Poster Presentations Session 7 - Cardiovascular Committee: Cardiovascular Imaging e-Posters

EPS-126

Positron Range Correction for ⁸²Rb myocardial PET: Validation in a healthy cohort

M. Lassen^{1,2}, **H. Kertesz**³, **I. Rausch**⁴, **A. Kjaer**^{1,2}, **V. Panin**⁵, **D. Bharkhada**⁵, **R. DeKemp**⁶, **T. Beyer**⁴, **P. Hasbak**¹;
¹Department of Clinical Physiology and Nuclear Medicine, University Hospital Copenhagen – Rigshospitalet, Copenhagen, DENMARK, ²Cluster for Molecular Imaging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DENMARK, ³Image X Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, AUSTRALIA, ⁴QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA, ⁵Siemens Medical Solutions UNITED STATES OF AMERICA, Inc, Knoxville, TN, UNITED STATES OF AMERICA, ⁶National Cardiac PET Centre, University of Ottawa Heart Institute, Ottawa, ON, CANADA.

EPS-127

Metabolic pretest calculator to improve cardiac FDG PET/CT imaging

S. Hartikainen¹, **T. Tompuri**¹, **T. M. Laitinen**¹, **T. Laitinen**^{1,2};
¹Kuopio University Hospital, Kuopio, FINLAND,
²University of Eastern Finland, Kuopio, FINLAND.

EPS-128

Diagnostic accuracy of global parameters obtained during dynamic PET/CT with ¹³N-Ammonia and vasodilator stress in patients with triple-vessel stenotic lesion of coronary arteries and stable form of CAD

A. Shakhova, **E. Golukova**, **I. Aslanidis**, **I. Shurupova**, **N. Surkova**, **M. Rumyantseva**, **I. Ekaeva**;
A.N. Bakulev Scientific Center for Cardiovascular Surgery of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION., Moscow, RUSSIAN FEDERATION.

EPS-129

Does global value of myocardial flow reserve using ¹³N-ammonia positron emission tomography independently predict identification of multivessel coronary artery disease

A. Shakhova, **E. Golukhova**, **I. Aslanidis**, **I. Shurupova**, **N. Surkova**, **M. Rumyantseva**, **I. Ekaeva**;
A.N. Bakulev Scientific Center for Cardiovascular Surgery of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EPS-130

Defining a Significant Change with serial assessment of myocardial perfusion metrics, obtained during dynamic Positron Emission Tomography with ¹³N-Ammonia in patients with CAD

A. Shakhova, **E. Golukhova**, **I. Aslanidis**, **I. Shurupova**, **M. Rumyantseva**, **N. Surkova**, **I. Ekaeva**;
A.N. Bakulev Scientific Center for Cardiovascular Surgery of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EPS-131

Relationship between myocardial flow reserve measured by a dynamic cadmium-zinc-telluride camera and increase rate in myocardial uptake of radionuclide during exercise

T. Niimi¹, **K. Hirayama**¹, **S. Yoshida**²;
¹Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, JAPAN,
²Nagoya University, Nagoya, JAPAN.

EPS-132

Stress-only versus rest-stress SPECT MPI in the detection and diagnosis of myocardial ischemia and infarction by machine learning

F. Wang¹, **H. Yuan**¹, **L. Jiang**^{1,2};
¹PET Center, Department of Nuclear Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, CHINA, ²Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application, Guangzhou, CHINA.

EPS-133

A Meta-Analysis of Bone Tracer Scintigraphy in the Diagnosis of Cardiac Amyloid ATTR and AL, Comparing HMDP with DPD and PYP Sensitivity and Specificity in Biopsy Proven Cases

A. ALDEHLAUI^{1,2}, **C. Fowler**²;
¹King Abdullah Medical City, Makkah, SAUDI ARABIA,
²King's College London, London, UNITED KINGDOM.

EPS-134

CT-free attenuation correction for cardiac-dedicated CZT SPECT: preliminary results of the CASCTEC study

M. Hesse, **B. El Jari**, **F. Dupont**, **O. Gheysens**, **R. Lhomme**, **V. Roelants**;
Cliniques Universitaires Saint-Luc, Brussels, BELGIUM.

EPS-135

The effect of Ursodeoxycholic Acid on early hepatic clearance of ^{99m}Tc-sestamibi in patients undergoing myocardial perfusion scintigraphy

E. Hosseinzadeh, **M. Ghodsirad**, **H. Garavand**;
Nuclear medicine department, shohadaye tajrish hospital, Shahidbehshiti university, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EPS-136

The Role Of Myocardial Perfusion Scintigraphy In Asymptomatic Patients With 50-70% Coronary Artery Stenosis In Coronary Ct

A. Doulmas¹, **D. Boundas**², **E. Giannoula**¹, **P. Exadaktylou**¹, **A. Tsangaridi**¹, **N. Papadopoulos**¹, **G. Gerasimou**¹, **E. Papanastasiou**¹, **I. Iakovou**¹;
¹Aristotle University, Thessaloniki, GREECE, ²Private Nuclear Medicine Centre, Ippokratris, Thessaloniki, GREECE.

EPS-137

Artefacts and False Positive Results of Myocardial Perfusion SPECT with CZT D-SPECT Camera

M. Esnault¹, **D. Legallois**², **D. Agostini**², **P. Richard**³, **M. Alain**²;
¹Caen University, Caen, FRANCE, ²Caen University Hospital, Caen, FRANCE, ³Hospital Privé Saint Martin, Caen, FRANCE.

EPS-138

Impact of Initial Myocardial Perfusion Imaging versus Coronary Angiography on Costs and Outcomes in Patients with Coronary Artery Disease in China

L. Yang, **Y. Hu**, **S. Li**;
First Hospital of Shanxi Medical University, Taiyuan, CHINA.

EPS-139

The value of gated blood pool SPECT in assessment of stress-induced changes of the right ventricular contractile function.

V. Shipulin, **S. Andreev**, **V. M. Shipulin**, **S. Polikarpov**, **K. Zavadovsky**;
Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.

EPS-140

Simultaneous PET/MRI myocardial perfusion measurements using Gd-DOTA CMR and ⁶⁸Ga-DOTA-PET

S. Kvernby¹, **T. Kero**¹, **K. Azarbar**¹, **C. Rischpler**², **J. Sørensen**¹, **I. Velikyan**¹, **M. Lubberink**¹;
¹Uppsala University, Uppsala, SWEDEN,
²Klinikum Stuttgart, Stuttgart, GERMANY.

EPS-141

Detection of mental stress induced myocardial ischemia with myocardial perfusion imaging in patients with anxiety and/or depression after coronary revascularization

W. Dong, **J. Jiao**, **N. Nan**, **T. Mou**, **H. Mi**, **X. Song**;
Beijing Anzhen Hospital, Beijing, CHINA.

EPS-142

Radionuclide Assessment of Myocardial Mitochondrial Dysfunction in Patients with Multivessel Coronary Artery Disease

K. Zavadovsky¹, **A. Kalinovsky**², **M. Gulya**¹, **K. Kopyeva**¹, **N. Kamenshikov**¹;
¹Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION, ²Siberian State Medical University, Tomsk, RUSSIAN FEDERATION.

EPS-143

Multidisciplinary approach for the early detection of amyloid in patients who undergo carpal tunnel syndrome or lumbar stenosis surgery. Results of an ongoing study.

N. Orta^{1,2}, **T. Ripoll**^{3,4}, **S. Rubí**^{1,2,4}, **J. Pons**^{1,2}, **E. Fortuny**^{1,2}, **M. Bosch**^{1,2,4}, **C. Nadal**¹, **I. Torralba**¹, **G. Salvà**^{1,4}, **N. Mora**^{1,4}, **S. Lirola**¹, **R. Marfí**, **J. Femenias**¹, **M. Llabrés**¹, **A. Álvarez**¹, **B. Barceló**^{1,2,4}, **V. Daza-Cajigal**^{1,2}, **A. Pérez**^{1,2}, **D. Heine**^{1,2}, **A. Sharma**¹, **A. Piñar**¹, **M. Villar**¹, **C. Peña**^{1,2};
¹Hospital Universitari Son Espases, Palma, SPAIN, ²IdISBa, Palma, SPAIN, ³Hospital Universitari Son Llàtzer, Palma, SPAIN, ⁴Department of Medicine, University of the Balearic Islands, Palma, SPAIN, ⁵Hospital Sant Joan de Déu, Palma-Inca, SPAIN.

EPS-144

A 3-month of physical exercise reduces stress-related neurobiological activity in obese women: a prospective ¹⁸F-FDG PET/CT study

K. Pahk, **H. Kwon**, **S. Kim**;
Korea University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EPS-145

Prognostic Value of ¹⁸F-FDG PET/CT Brain metabolism and Brain Network in Patients with Heart Failure

Y. Bai, **M. Yun**, **X. Zhang**;
Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA.

EPS-146

Characterization of brain structure and metabolism in heart failure patients with reduced or preserved ejection fraction: a simultaneous PET/MR study

C. Zheng¹, **Y. Cui**¹, **Q. Ge**², **Y. Yang**³, **X. Li**⁴, **J. Lu**¹;
¹Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, CHINA, ²Central Research Institute, United Imaging Healthcare, Shanghai, CHINA, ³Beijing United Imaging Research Institute of Intelligent Imaging, Beijing, CHINA, ⁴Division of Nuclear Medicine Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital Medical University of Vienna, Vienna, AUSTRIA.

1010

Monday, September 11, 2023, 3:00 PM - 4:30 PM
Hall K

Technologists' e-Poster Presentations Session - Technologists Committee: Techs' e-Posters

TEPS-001

Description of an imaging protocol in patients with glioblastoma treated with [¹⁷⁷Lu]Lu-DOTA-TATE.

E. Córdoba Cañete¹, **M. Caballero Vivancos**¹, **N. González Corredera**¹, **E. Triviño Ibañez**¹, **R. Sánchez Sánchez**²;
¹Hospital Universitario Virgen de las Nieves, Granada, SPAIN, ²Hospital Universitario Virgen de las Nieves, Maracena, SPAIN.

TEPS-002

[¹⁸F]AIF-complexation of pamidronic acid, a NOTA-conjugated bisphosphonate, as a potential tracer for PET bone imaging

H. Hassan¹, M. Othman², H. Abdul Razak³, Z. Zakaria⁴, F. Ahmad Saad¹;

¹Universiti Putra Malaysia, Serdang, MALAYSIA, ²Universiti Teknologi MARA, Bandar Puncak Alam, MALAYSIA, ³University of Exeter, Devon EX1 2LU, UNITED KINGDOM, ⁴Universiti Malaysia Sabah, Kota Kinabalu, MALAYSIA.

TEPS-003

Evaluation of Variation method to Improve the Sensitivity of Immunoradiometric Assay

W. Kwon, J. Kim;

Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, KOREA, REPUBLIC OF.

TEPS-004

Comprehensive management of paediatrics in nuclear medicine: sharing the experience of technologists in a leading cancer center

M. GOLVET, M. Luporsi, N. Jehanno, S. Lasalle, N. Sanchez Bertomeu;

Department of nuclear medicine, Institut Curie, Paris, FRANCE.

TEPS-005

Ultra-fast Gallium-68 is it possible in the era of digital PET/CT imaging

Z. Alqallaf¹, L. Ghadhanfer², A. Sadeq¹, H. Alfake¹, F. Marafi¹;

¹Jaber Al Ahmed Center For Nuclear Medicine & Molecular Imaging, Sabah Medical area, KUWAIT, ²Faculty of Allied Health Kuwait university, Jabriya, KUWAIT.

TEPS-006

The Effect of Using Radiopharmaceutical Multidose Injector for 18F FDG on the Received Effective Doses of Radiographers

D. Sercic, J. Peric, U. Cotar;

Institute of Oncology Ljubljana, Ljubljana, SLOVENIA.

TEPS-007

Decontamination of Lu-177-PSMA and Tc-99m-Pertechnetate Spills from Laboratory Floor: Comparing Four Cleansing Agents

S. Rajala¹, I. Rantala¹, L. Elg², A. Honkanen², J. Lehto², E. Hippeläinen², V. Ahtainen^{1,3}, M. Ladev¹, M. Eskola¹, S. Keskimäki⁴, K. Kiviluoto⁴, J. Tervonen⁴, M. Salomaa¹, V. Reijonen¹;

¹HUS Comprehensive Cancer Center, Helsinki, FINLAND, ²HUS Diagnostic Center, Helsinki, FINLAND, ³University of Helsinki, Helsinki, FINLAND, ⁴HUS Pharmacy, Helsinki, FINLAND.

TEPS-008

Development of a specialized image reconstruction technique for dedicated breast positron emission tomography

K. Hanaoka¹, S. Watanabe¹, D. Ishikawa-Morimoto¹, Y. Yamakawa², T. Kobayashi², A. Ohtani², S. Kumakawa², T. Ito³, Y. Komoike³, H. Kaida¹, K. Ishii¹;

¹Institute of Advanced Clinical Medicine, KINDAI University, Osaka-sayama, JAPAN, ²Shimadzu Corporation, Kyoto, JAPAN, ³Division of Breast and Endocrine Surgery, KINDAI University, Osaka-sayama, JAPAN.

TEPS-009

Impact of Image Space PSF Correction on Quantitative Values and SNR of Clinical PET Images in SiPM-based PET/CT with List-Mode Acquisition

Y. Shirakawa, K. Ebine, M. Kawada, J. Suyama;

Kyorin University Hospital, Tokyo, JAPAN.

TEPS-010

Comparison between MIRD-based and Monte Carlo simulation-based patient-specific dosimetry in ¹⁷⁷Lu-DOTATATE

N. Miyaji¹, K. Miwa¹, K. Yamashita², T. Yamao¹, K. Hasegawa¹, N. Oriuchi³, T. Terauchi²;

¹Fukushima Medical University, Fukushima, JAPAN, ²Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JAPAN, ³Advanced Clinical Research Center, Fukushima Medical University, Fukushima, JAPAN.

TEPS-011

[¹⁸F]fluorocholine PET is more resource-effective than conventional [^{99m}Tc]sestamibi scintigraphy in patients with primary hyperparathyroidism

S. Rep^{1,2}, I. Slodnjak¹, K. Sirca³, K. Zaletel^{1,4}, M. Hocevar³, L. Lezaic^{1,4};

¹Department for Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, ²University of Ljubljana, Faculty of Health Sciences, Medical Imaging and Radiotherapy Department, Ljubljana, SLOVENIA, ³Department of Oncological Surgery, Institute of Oncology Ljubljana, Ljubljana, SLOVENIA, ⁴University of Ljubljana, Faculty of Medicine, Ljubljana, SLOVENIA.

TEPS-012

Does ¹⁸F-FDG-PET require withdrawal of Glucagon-like peptide 1 (GLP-1) analogs in diabetic patients?

B. Olsson¹, U. Bitzén¹, S. Garpered¹, S. Leide-Svegborn², A. Stenvall²;

¹Clinical Physiology and Nuclear Medicine, Malmö/Lund, SWEDEN, ²Radiation Physics, Malmö/Lund, SWEDEN.

TEPS-013

^{99m}Tc-Colloid residuals dependency on the syringe and needles

D. Teixeira Macarico¹, C. Laurins¹, L. Hogg², R. Williamson¹, J. Dennis¹, A. Nicol¹;

¹Nuclear Medicine Department, Queen Elizabeth University Hospital, Department of Clinical Physics and Bioengineering, NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM, ²Medical Physics, Royal Alexandra Hospital, Department of Clinical Physics and Bioengineering, NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM.

TEPS-014

Usefulness of ^{99m}Tc-MIBI Myocardial SPECT/CT Subtraction Protocol with CZT Gamma Camera

K. Nam, H. Cho, J. Lee, W. Lee;

Seoul National University Bundang Hospital, Seoul, KOREA, REPUBLIC OF.

TEPS-015

Validation of Diagnostic Accuracy for Primary Aldosteronism with Quantitative Adrenal SPECT: Comparison with Adrenal Venous Sampling

T. Sato¹, N. Matsutomo², T. Yamamoto², M. Fukami², T. Kono³;

¹Chiba Aoba Municipal Hospital, Chiba, JAPAN, ²Kyorin University, Tokyo, JAPAN, ³Chiba University, Chiba, JAPAN.

TEPS-016

Image characteristics of ^{99m}Tc myocardial perfusion SPECT/CT using a new multi-focal collimator: comparison with conventional SPECT with LEHR collimator

K. Takami¹, M. Onoguchi¹, T. Shibutani¹, A. H. Vija², F. Massanes², T. Shimizu², H. Yoneyama³, T. Konishi³, K. Nakajima⁴;

¹Department of Quantum Medical Technology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa Japan, Kanazawa, JAPAN, ²Siemens Medical Solutions UNITED STATES OF AMERICA, Inc., Hoffman Estates, IL, UNITED STATES OF AMERICA, ³Department of Radiological Technology, Kanazawa University Hospital, Kanazawa Japan, Kanazawa, JAPAN, ⁴Department of Functional imaging and Artificial Intelligence, Kanazawa University, Kanazawa Japan, Kanazawa, JAPAN.

TEPS-017

The effect of data-driven respiratory gating on myocardial SPECT

T. Shibutani¹, M. Onoguchi¹, A. H. Vija², F. Massanes², T. Shimizu², H. Yoneyama³, T. Konishi³, K. Nakajima⁴;

¹Department of Quantum Medical Technology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Ishikawa, JAPAN, ²Siemens Medical Solutions UNITED STATES OF AMERICA, Inc., Hoffman Estates, IL, UNITED STATES OF AMERICA, ³Department of Radiological Technology, Kanazawa University Hospital, Kanazawa, Ishikawa, JAPAN, ⁴Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa, Ishikawa, JAPAN.

TEPS-018

High dose adenosine overcomes the effect of caffeine intake in Rubidium PET perfusion

B. Ribeiro, S. Townrow, C. Pacheco, C. Lopez Martinez, E. Reyes, L. Menezes;

Barts Health NHS Trust, London, UNITED KINGDOM.

TEPS-019

Dose reduction for nuclear medicine technicians through implementation of automated dispensing and infusion devices: a retrospective study

E. Hendrikse, W. Huisman, J. Medema, P. H. Elsinga, A. T. M. Willemsen;

University Medical Center Groningen, Groningen, NETHERLANDS.

TEPS-020

A comparative study regarding deep inhalation breath-hold and free-breathing total-body PET/CT with half-dose [¹⁸F]-FDG

J. Jia, K. Yuan, M. Liu, Y. Cui, S. Tang, C. Zhou, W. Zhang;

Sun Yat-Sen University Cancer Center, Department of Nuclear Medicine, Guangzhou, Guangdong, China., Guangzhou, CHINA.

TEPS-021

Developments in Radiochemical Processing of Solid Targets for Radiopharmaceuticals Production

G. Sciacca¹, P. Martini², S. Cisternino¹, L. Mou¹, G. Balajan¹, J. Amico³, J. Esposito¹, G. Gorgoni³, **E. Cazzola³**;

¹INFN-LNL, Legnaro, ITALY, ²University of Ferrara, Ferrara, ITALY, ³Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, ITALY.

1011

Monday, September 11, 2023, 3:00 PM - 4:30 PM
Hall G1

Case Report Session 1 - TROP Session: Learning from Single Cases in Theranostics

OP-467

Feasibility of ¹⁷⁷Lu-PSMA-617 radioligand therapy in a patient with recurrent high-grade glioma

A. Holzgreve¹, A. Delker¹, V. Wenter¹, M. J. Zacherl¹, N. Thon², P. Harter³, M. Brendel¹, L. M. Unterrainer¹, M. Niyazi⁴, P. Bartenstein¹, L. von Baumgarten², N. L. Albert¹;

¹Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, ²Department of Neurosurgery, University Hospital, LMU Munich, Munich, GERMANY, ³Center for Neuropathology and Prion Research, LMU Munich, Munich, GERMANY, ⁴Department of Radiation Oncology, University Hospital, LMU Munich, Munich, GERMANY.

OP-468

First-In-Human CXCR4 & FAP Instillation Theranostics in Muscle invasive bladder cancer patients predicted not to respond to Neoadjuvant chemotherapy within the Bladder BRIDGster.

R. Wirtz^{1,2,3}, L. Kastner⁴, P. C. Voß⁵, F. Friedersdorff⁶, D. Barski⁷, T. Otto⁸, M. Waldner⁹, E. Veltrup¹, F. Linden¹, M. Schwandt¹, R. Hake³, S. Eidt¹, J. Roggisch¹⁰, C. Rieger⁴, S. Koch^{11,12}, T. H. Ecke¹³, A. Heidenreich¹⁴, L. Greifenstein¹⁵, R. P. Baum^{2,15};

¹STRATIFYER Molecular Pathology GmbH, Cologne, GERMANY, ²ICPO Foundation, Ravensburg, GERMANY, ³Institute of Pathology at the St. Elisabeth Hospital, Cologne, GERMANY, ⁴Dpt. of Urology, University Clinic Cologne, Cologne, GERMANY, ⁵Dpt. of Urology, Charité - Universitätsmedizin Berlin, Berlin, GERMANY, ⁶Dpt. of Urology, Evangelisches Krankenhaus Königin Elisabeth Herzberge, Berlin, GERMANY, ⁷Dpt. of Urology, Rheinlandklinikum, Neuss, GERMANY, ⁸Dpt. of Urology, Rheinlandklinikum, Cologne, GERMANY, ⁹Dpt. of Urology St. Elisabeth Hospital, Cologne, GERMANY, ¹⁰Institute of Pathology, HELIOS Hospital, Cologne, GERMANY, ¹¹Brandenburg Medical School, DE-14770 Brandenburg, Berlin, GERMANY, ¹²Institute of Pathology, HELIOS Hospital, Bad Saarow, GERMANY, ¹³Department of Urology, HELIOS Hospital, Berlin, GERMANY, ¹⁴Dpt. of Urology, University Clinic Cologne, Cologne, GERMANY, ¹⁵CURANOSTICUM Wiesbaden-Frankfurt, Wiesbaden, GERMANY.

OP-469

Dual-tracer PET/CT imaging in response assessment to peptide receptor radionuclide therapy - a case report

I. Próspero, G. Ferreira, J. C. Ferro, D. Barbosa, D. G. Silva, S. Fontão de Castro, J. P. Teixeira, H. Duarte, I. Lucena Sampaio;

Instituto Português de Oncologia do Porto, Porto, PORTUGAL.

OP-470

Bone-Marrow dosimetry with ¹⁷⁷Lu-DOTATATE treatment in a hemodialysis patient.

S. CHAIB^{1,2}, P. Tylski¹, C. Lachachi¹, T. Keniza¹, E. Levigoureux^{1,2};

¹Hospices Civils de Lyon, Lyon, FRANCE, ²Claude Bernard Lyon 1 University, Lyon Neuroscience Research Center, CNRS, INSERM, Lyon, FRANCE.

OP-471

Evaluation of the potential use of [¹⁸F]F-AI-NOTA-Octreotide as a theranostic probe for PRRT with [¹⁷⁷Lu]Lu-DOTA-TATE compared to [¹¹¹In]In-DTPA-Pentetreotide

B. A. M. Lima, R. C. M. Felix, D. A. Bulzico, P. B. Pujatti;
Brazilian National Cancer Institute, Rio de Janeiro, BRAZIL.

OP-472

Peptide receptor radionuclide therapy (PRRT) with [¹⁷⁷Lu]Lu-DOTA-TATE in the treatment of malignant insulinoma: a case report of remarkable clinical and imaging response

D. Barbosa, H. Duarte, A. Paula Santos, J. Ferro, I. Próspero, D. Silva, S. Gil-Santos, R. Calheiros, S. Fontão de Castro, G. Ferreira, J. P. Teixeira, I. Lucena Sampaio;
Portuguese Institute of Oncology, Oporto, PORTUGAL.

OP-473

Peptide receptor radionuclide therapy as neoadjuvant treatment in pancreatic neuroendocrine tumours

I. Próspero, G. Ferreira, J. C. Ferro, D. Barbosa, D. G. Silva, S. Fontão de Castro, J. P. Teixeira, H. Duarte, I. Lucena Sampaio;
Instituto Português de Oncologia do Porto, Porto, PORTUGAL.

OP-474

Safety and Efficacy in a Recurrent Squamous Cell Carcinoma of the Foot treated with Sequential Applications of 188Re-resin

L. Vetrone¹, P. Castellucci², C. Baraldi³, S. Vichi⁴, F. Zagni⁵, B. Piraccini³, L. Strigari⁵, S. Fanti^{1,6};
¹Nuclear medicine, Alma Mater Studiorum University of Bologna, BOLOGNA, ITALY, ²Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, BOLOGNA, ITALY, ³Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, BOLOGNA, ITALY, ⁴Clinical Engineering Department, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, BOLOGNA, ITALY, ⁵Medical Physics Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, BOLOGNA, ITALY, ⁶Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

1101

Monday, September 11, 2023, 16:45 - 18:15
Hall A

CME 8 - Oncology & Theranostics Committee: Assessing Response to Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Tumors

OP-475

PRRT Combinations in On-Going Trials

I. Virgolini;
Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA.

OP-476

RECIST and Beyond: How Can Radiological Assessment Be Improved?

L. Solnes;
The Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins School of Medicine, Baltimore, UNITED STATES OF AMERICA.

OP-477

Functional Nuclear Medicine Parameters (Predictive and/or Prognostic)

V. Ambrosini;
NuclearMedicine, Alma Mater Studiorum, University of Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-478

How to Structure Pts' Follow-Up After PRRT: Guidelines and Beyond

J. Strosberg;
Moffitt Cancer Center Tampa, Tampa, UNITED STATES OF AMERICA.

1102

Monday, September 11, 2023, 17:15 - 18:15
Hall D (Arena)

Debate 3 - Physics Committee: AI in Nuclear Medicine: Fear or Embrace?

OP-479

Embrace Artificial Intelligence

M. Sollini;
Department of Nuclear Medicine, IRCCS Humanitas Research Hospital, Milan, ITALY.

OP-480

Beware of Artificial Intelligence

G. Gaglio;
Professor of Sociology, Research Group in Law, Economics and Management (GREDEG), Côte d'Azur University, Nice, FRANCE.

1103

Monday, September 11, 2023, 16:45 - 18:15
Hall E1

LIPS Session 8 - Cardiovascular Committee: Stiff to Sweet - Infiltration and Inflammation

OP-481

Infiltrative cardiac disease: Harder muscle, softer interpretation

S. Ben Haim;
University Hospital Hadassah, Jerusalem, Department of Nuclear Medicine, Jerusalem, ISRAEL.

OP-482

Inflammatory cardiac diseases. The sweeter it gets, the hottest it is.

F. Caobelli;
Universitätsklinik für Nuklearmedizin Inselspital Bern, Bern, SWITZERLAND.

OP-483

Quantification: The cherry on top?

M. Burniston;
Head of Nuclear Medicine Physics
Barts Health NHS Trust, London, UNITED KINGDOM.

1104

Monday, September 11, 2023, 4:45 PM - 6:15 PM
Hall E2

M2M Track - TROP Session: Efficient Radiolabelling: Key for Clinical Translation

OP-487

Functionalized rigidified pentadentate chelators useful for the [Al¹⁸F]²⁺ labeling of biomolecules

L. Tei¹, J. Martinelli¹, L. Russell², G. Multhoff³, C. D'Alessandria²;
¹Department of Science and Technological Innovation, University of Piemonte Orientale, Alessandria, ITALY, ²Department of Nuclear Medicine, Technical University Munich, Munich, GERMANY, ³Department of Radiation Oncology, TranslaTUM, Technical University Munich, Munich, GERMANY.

OP-488

Development of a kit formulation of Technetium-99m labeled holmium microspheres as scout dose for radioembolization treatment planning.

M. Boswinkel¹, P. Laverman¹, T. Weisheit², R. Drescher², J. F. W. Nijssen¹;
¹Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS, ²Clinic of Nuclear Medicine, University Hospital Jena, Jena, GERMANY.

OP-489

Large-scale, GMP-compliant production and quality control of Al[¹⁸F]F-NOTA-Octreotide

V. Kramer^{1,2}, A. Bispo³, C. Gomez³, D. Zouain³, L. Cantuarias¹, C. Soza-Ried^{1,2}, N. Emmanuel⁴, G. Decoux⁴, C. Goncalves Gameiro⁴;
¹Positronpharma, Santiago de Chile, CHILE, ²Nuclear Medicine & PET/CT Center Positronmed, Santiago de Chile, CHILE, ³R2IBF, Rio de Janeiro, BRAZIL, ⁴Ion Beam Applications, Louvain-la-Neuve, BELGIUM.

OP-490

Fully Automated Radiosynthesis of [⁸⁹Zr]Zr-Cremirumab Berdoxam for Clinical Multi-Centre PET Imaging of CD8⁺ T-Cell Trafficking

C. Wichmann¹, Z. Cao¹, A. McDonald¹, N. Guo¹, S. Poniger², F. Scott¹, F. Jia³, K. Brady³, W. Le³, A. Scott¹;
¹Olivia Newton John Cancer Research Institute, Heidelberg, AUSTRALIA, ²iPhase Technologies Pty Ltd, Rowville, AUSTRALIA, ³ImaginAb Inc., Inglewood, CA, UNITED STATES OF AMERICA.

OP-491

Radiopharmaceutical production of [⁶¹Cu]Cu-NODAGA-LM3 injection solution

M. Alejandro Lafont¹, T. Basaco Bernabeu¹, M. Blagoev², A. Johayem², F. De Rose³, C. Porcelli³, L. Jaafar-Thiel³, M. Fani¹;
¹Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, SWITZERLAND, ²Department of Nuclear Medicine, University Hospital of Zürich, Zürich, SWITZERLAND, ³Nuclidium AG, Basel, SWITZERLAND.

OP-492

Development of an ACE2-Targeting Radiotracer for PET Imaging of the SARS-CoV-2 Entry Receptor

C. Müller¹, D. Beyer¹, J. Wang², C. Vaccarin¹, Y. He², L. Mu², J. W. Bode², R. Schibli¹;
¹Paul Scherrer Institute, Villigen-PSI, SWITZERLAND, ²ETH Zurich, Zurich, SWITZERLAND.

OP-493

One-pot combinatorial 18F fluorination: Innovative high-throughput radiolabelling for acceleration of tracer development

S. Xiao¹, M. Kominia¹, A. Domling², B. Cornelissen¹, P. Elsinga¹;
¹University Medical Center Groningen, Groningen, NETHERLANDS, ²Palacky University, Department of Innovative Chemistry, Olomouc-Holice, CZECH REPUBLIC.

OP-494

To Have and To Hold: The exceptional attraction of ²²⁵Ac and Macropa

A. Amor Coarasa^{1,2}, M. Friebe¹, S. Ponnala¹, P. K. Singh¹, S. DiMugno¹, J. W. Babich¹;
¹Ratio Therapeutics Inc, Boston, MA, UNITED STATES OF AMERICA, ²Albert Einstein College of Medicine, Bronx, NY, UNITED STATES OF AMERICA.

1105

Monday, September 11, 2023, 4:45 PM - 6:15 PM
Hall B

Cutting Edge Science Track - TROP Session: Current Issues of Radiation Protection

OP-495

Radiation Protection of Undertakers (Transport/Embalming of the Body) and Crematorium Staff in Case of a Patient Death Shortly After Radionuclide Therapy

C. Michel, H. Caplin, D. Célier, E. Blanchardon, A. Mathieu, A. Isambert;
Institute for Radiation Protection and Nuclear Safety (IRSN), Fontenay-aux-Roses, FRANCE.

OP-496

Justification of the radiation dose to a pregnant carer and comforter

E. Morris^{1,2}, F. Sansum², M. Easty², L. Biassoni², M. Burniston¹;
¹Barts Health NHS Trust, London, UNITED KINGDOM, ²Great Ormond Street Hospital for Children, London, UNITED KINGDOM.

OP-497

Investigating the contamination risk during ¹⁷⁷Lu-PSMA and ²²⁵Ac-PSMA therapies of advanced prostate cancer patients

J. Brosch-Lenz, S. Nekolla, L. Tischendorf, J. Allmann, W. Weber, M. Eiber;
Klinikum rechts der Isar, der Technischen Universität München, Munich, GERMANY.

OP-498

Assessment of Occupational Radiation Exposure During Administration of [¹⁷⁷Lu]Lu-DOTA-TATE Using Active and Passive Dosimetry

M. Riveira-Martin¹, L. Struelens², J. Muñoz Iglesias³, W. Schoonjans², J. M. Nogueiras Alonso⁴, O. Tabuenca³, F. J. Salvador Gomez⁵, A. Lopez Medina⁵;

¹Galicia Sur Health Research Institute, Vigo, SPAIN, ²Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM, ³Meixoeiro Hospital, University Hospital of Vigo, Nuclear Medicine Department (SERGAS), Vigo, SPAIN, ⁴Meixoeiro Hospital, University Hospital of Vigo, Nuclear Medicine Department (GALARIA), Vigo, SPAIN, ⁵Meixoeiro Hospital, University Hospital of Vigo, Medical Physics and RP Department (GALARIA), Vigo, SPAIN.

OP-499

Tracer validation for non [¹⁸F]FDG PET pharmaceuticals in automatic injector

M. Hammar¹, R. Solem², F. Mörnjö Centofanti², E. Evetovic², A. Akbari¹, K. Benner², B. Olsson¹, E. Höjler², J. Oddstig²;

¹Skane University Hospital, Malmö, SWEDEN, ²Skane University Hospital, Lund, SWEDEN.

OP-500

Implementation of CT tin filter in PET-CT: dose savings and image quality evaluation for tissues and dose levels relevant to PET-CT

P. Holdgaard¹, N. A. Bebbington², K. B. Christensen¹, L. L. Østergård¹;

¹Lillebælt University Hospital, Vejle, DENMARK, ²Siemens Healthcare A/S, Aarhus, DENMARK.

OP-501

Ultra-low Dose CT With and Without Tin Filter for PET Attenuation Correction: Dose Savings and Quantification

N. Bebbington¹, K. B. Christensen², L. L. Østergård², P. C. Holdgaard²;

¹Siemens Healthcare A/S, Aarhus, DENMARK, ²Department of Nuclear Medicine, Lillebælt University Hospital, Vejle, DENMARK.

OP-502

How Low Can You Go With Ultra-low-dose Tin Filter CT in PET-CT? Evaluation of Dose and Artifacts in a Whole-body Patient Phantom

N. Bebbington¹, K. B. Christensen², P. C. Holdgaard², L. L. Østergård²;

¹Siemens Healthcare A/S, Aarhus, DENMARK, ²Department of Nuclear Medicine, Lillebælt University Hospital, Vejle, DENMARK.

OP-503

Ultra-low-dose CT for Long Axial Field of View PET/CT: A Phantom Study

S. Mostafapour¹, M. Greuter², P. van Snick¹, J. van Sluis¹, A. A. Lammertsma¹, C. Tsoumpas¹;

¹Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, NETHERLANDS, ²Department of Radiology, University Medical Center Groningen, Groningen, NETHERLANDS.

1106

Monday, September 11, 2023, 4:45 PM - 6:15 PM
Hall C

Clinical Oncology Track - TROP Session: Prostate Cancer Biochemical Recurrence

OP-504

Final Analysis of a Prospective, Single-center, Phase II/III Imaging Trial of ⁶⁸Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer

H. Duan¹, F. Moradi, G. A. Davidzon, T. Liang, H. Song, A. Loening, S. Vasanawala, S. Srinivas, J. D. Brooks, S. L. Hancock, A. Igaru;

Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

OP-505

Prospective Single-Centre Phase II Clinical Trial On The Diagnostic Accuracy of Fully Hybrid [⁶⁸Ga]Ga-PSMA-11 PET/MRI and [⁶⁸Ga]Ga-RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer

S. Ghezzi^{1,2}, P. Mapelli^{1,2}, A. Samanes Gajate², A. Palmisano³, V. Cucchiara^{4,5}, G. Brembilla^{1,3}, C. Bezzi^{1,2}, N. Suardi⁶, P. Scifo², A. Briganti^{1,4,5}, F. De Cobelli^{1,3}, A. Chiti^{1,2}, A. Esposito^{1,3}, M. Picchio^{1,2};

¹Vita-Salute San Raffaele University, Milan, ITALY, ²Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ³Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ⁴Department of Urology, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ⁵Division of Experimental Oncology, URI, Urological Research Institute, Milan, ITALY, ⁶IRCCS Ospedale San Martino, Genova, ITALY.

OP-506

Higher Preoperative Maximum Standardised Uptake Values (SUV_{max}) are Associated with Higher Biochemical Recurrence Rates After Robot-Assisted Radical Prostatectomy for ⁶⁸Ga-PSMA-11 and ¹⁸F-DCFPyL PET/CT

K. De Bie¹, H. Veerman¹, Y. J. L. Bodar¹, D. Meijer¹, P. J. van Leeuwen², H. G. van der Poel², M. Donswijk², A. N. Vis¹;

¹Amsterdam UMC, Amsterdam, NETHERLANDS, ²Nederlands Kanker Instituut, Amsterdam, NETHERLANDS.

OP-507

Staging with [⁶⁸Ga]Ga-PSMA-11 PET/CT in patients with intermediate and high-risk prostate cancer prior surgery. Is there any association between semiquantitative parameters and biochemical recurrence?

J. Rosales¹, J. Bastidas¹, A. Bronte¹, V. Beteche-Antar¹, F. Minguez¹, M. Romera¹, F. Pareja¹, E. Guillen², S. Menendez-Sanchez¹, C. Beorlegui³, J. Arbizu¹, J. Pérez Gracia⁴, M. Rodriguez-Fraile¹;

¹Nuclear Medicine Department, University Clinic Of Navarra, Pamplona, SPAIN, ²Nuclear Medicine Department, University Clinic Of Navarra, Madrid, SPAIN, ³Planning Evaluation and Knowledge Management Health Department, Government of Navarra, Pamplona, SPAIN, ⁴Oncology Department, University Clinic Of Navarra, Pamplona, SPAIN.

OP-508

From CHARTED low- and high-volume disease to PSMA PET imaging volume in mHSPC patients: an international multicenter retrospective study

L. Unterrainer^{1,2}, T. A. Hope², H. Ndlovu⁴, F. Barbato⁵, W. P. Fendler^{5,6}, K. Herrmann^{5,6}, M. Sathekge⁴, J. Czernin¹, J. Calais¹;

¹UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, ²LMU Munich, Munich, GERMANY, ³UCSF, San Francisco, CA, UNITED STATES OF AMERICA, ⁴University of Pretoria, Pretoria, SOUTH AFRICA, ⁵University Hospital Essen, Essen, GERMANY, ⁶German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY.

OP-509

Head-to-head comparison of ⁶⁸Ga-PSMA-11 PET with ^{99m}Tc-MDP bone scan for detection of bone disease in prostate cancer patients with biochemical progression during ADT: a single center prospective study

A. Gafita¹, R. Alano, M. Rettig, J. Shen, W. Armstrong, T. R. Grogan, S. Liu, M. R. Benz, J. Czernin, J. Calais;

University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA.

OP-510

Factors Affecting Diagnostic Performance of Ga-68 PSMA PET/MRI in Biochemical Recurrent Prostate Cancer and Nomogram Model

S. Küçükali¹, U. Aydos, E. Balci, Ü. Akdemir, L. Atay; Gazi University, Faculty of medicine, Ankara, TÜRKIYE.

OP-511

The diagnostic performance of ⁶⁸Ga-PSMA-11 PET/CT versus multiparametric MRI for detecting intraprostatic radiorecurrent prostate cancer

A. Light¹, S. Lazić², M. Bayne³, M. J. Connor¹, H. Tam², H. U. Ahmed¹, T. T. Shah¹, T. D. Barwick²;

¹Imperial Prostate, Imperial College London, London, UNITED KINGDOM, ²Department of Radiology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM, ³Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

OP-512

The imaging characteristics of theranostic ^{99m}Tc/¹⁸⁸Re-PSMA-GCK01 is equivalent to dedicated diagnostic ^{99m}Tc-HYNIC-iPSMA in prostate cancer

E. Mamlins¹, J. Cardinale^{1,2}, M. Krotov¹, E. Winter², H. Rathke^{2,3}, U. Haberkorn², C. Kratochwil², F. Giesel¹;

¹Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, GERMANY, ²Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY, ³Department of Nuclear Medicine, Inselspital Bern, Bern, SWITZERLAND.

1107

Monday, September 11, 2023, 4:45 PM - 6:15 PM
Hall F1

Inflammation & Infection Committee - TROP Session: Vasculitis and Endocarditis: Current and New Evidence

OP-513

^{99m}Tc-white blood cell scintigraphy performance in thoracic aortic vascular graft infection: be careful in early post-operative period

B. Mahida^{1,2}, M. Para^{2,3}, C. Regis^{1,4}, L. Deconinck⁵, K. Ben Ali^{1,2}, X. Duval^{3,6}, B. IUNG^{3,7}, F. Rouzet^{1,2};

¹Nuclear medicine department, Bichat Hospital, AP-HP, Paris, FRANCE, ²Université Paris Cité, Paris, FRANCE, ³Department of Cardiovascular Surgery and Transplantation, Bichat Hospital, AP-HP, Paris, FRANCE, ⁴Department of Medical Imaging, Institut de cardiologie de Montréal, Université de Montréal, Montréal, QC, CANADA, ⁵Infectious Disease Department, Bichat Hospital, AP-HP, Paris, FRANCE, ⁶Clinical Investigation Center, Bichat Hospital, AP-HP, Paris, FRANCE, ⁷Cardiology Department, Bichat Hospital, AP-HP, Paris, FRANCE.

OP-514

Fast-Track Pathway for Early Diagnosis and Management of Giant Cell Arteritis At University College London Hospital: Positive Impact of FDG PET-CT for Detection of Active Vasculitis

A. Alduraibi^{1,2}, D. Ludwiga³, S. Vööä⁴, V. Morrisa³;

¹Department of Radiology, College of Medicine, Qassim University, qassim, SAUDI ARABIA, ²University College London Hospitals Nhs Foundation Trust, London, UNITED KINGDOM, ³Department of Rheumatology, University College London Hospital, University College London Hospitals NHS Foundation Trust (UCLH) and Institute of Nuclear Medicine, UCLH, London, UNITED KINGDOM, ⁴Institute of Nuclear Medicine, University College London Hospital, London, UNITED KINGDOM.

OP-515

[¹⁸F]FDG-PET/CT as a Prognostic Inflammatory Imaging Marker in Giant Cell Arteritis

P. Nienhuis¹, Y. Van Sleen, E. Brouwer, R. H. J. A. Slart; University Medical Center Groningen, Groningen, NETHERLANDS.

OP-516

¹⁸F-FDG-PET/CT imaging on the LAFOV-PET/CT in patients with suspected large vessel vasculitis: reference values and diagnostic performance.

L. Knappe¹, C. Bregenzer, N. Gözlügöl, C. Mingels, A. Rominger, F. Caobelli; Department of Nuclear Medicine, Inselspital Bern, Bern, SWITZERLAND.

OP-517

C-X-C Motif Chemokine Receptor 4-directed PET/CT in Newly Diagnosed Giant Cell Arteritis - Initial Results from a Phase II Trial

M. Fröhlich¹, S. E. Serfling², K. V. Guggenberger³, T. Higuchi², M. Gernert¹, S. Samnick², M. Schmalzing¹, A. K. Buck², T. A. Bley³, R. A. Werner²;

¹Medical Department II, Rheumatology, University Hospital Würzburg, Würzburg, GERMANY, ²Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany, Würzburg, GERMANY, ³Institute of Diagnostic and Interventional Radiology, University Hospital Würzburg, Würzburg, GERMANY.

OP-518

[⁶⁸Ga]Ga-FAPI-46 PET/CT in patients with Large Vessel Vasculitis and comparison with age gender-matched controls.

J. Rosales¹, J. Hoppner², U. Haberkorn², W. Merkt², P. Kvacskay², M. Röhrich²;
¹University Clinic Of Navarra, Pamplona, SPAIN, ²University Hospital of Heidelberg, Heidelberg, GERMANY.

OP-519

Improved [¹⁸F] FDG PET/CT diagnostic accuracy for infective endocarditis: cardiac motion correction using different gating strategies

D. ten Hove^{1,2}, B. Sinha^{1,2}, P. J. H. Van Snick^{1,2}, R. H. J. A. Slart^{1,2}, A. W. J. M. Glaudemans^{1,2};
¹Rijksuniversiteit Groningen, Groningen, NETHERLANDS, ²University Medical Center Groningen, Groningen, NETHERLANDS.

OP-520

Impact and diagnostic performance of dedicated cardiac [¹⁸F]-FDG digital PET/CT in infective endocarditis

S. Notohamiprodjo¹, K. Scheidhauer¹, M. Eiber¹, I. Yakushev¹, S. Kleiner¹, J. Kraus-Deuringer¹, H. W. A. Krebs-Fleischmann¹, A. G. Villagran Asiares¹, S. G. Nekolla¹, R. Eggerstedt², B. Eglseder³, W. A. Weber¹;
¹Technical University of Munich, Munich, GERMANY, ²German Heart Centre Munich, Munich, GERMANY, ³Krankenhaus GmbH Landkreis Weilheim-Schongau, Weilheim, GERMANY.

OP-521

New semiquantitative parameters to improve diagnostic accuracy of FDG-PET/CT in suspected endocarditis

C. Bregenzer¹, L. Knappe¹, C. Mingels¹, N. Gözlügöl, A. Rominger¹, F. Caobelli¹;
Department of Nuclear Medicine, Inselspital, University Hospital Bern, University of Bern, Bern, SWITZERLAND.

1108

Monday, September 11, 2023, 4:45 PM - 6:15 PM
Hall F2

Thyroid Committee - TROP Session: Iodine-131 Therapy in Differentiated Thyroid Cancer: Present and Future Perspective

OP-522

Efficacy of ¹³¹I therapy and its influencing factors in children and adolescents with differentiated thyroid cancer lung metastases: comparative analysis with youth using propensity score matching

X. Zhang¹, H. Feng²;
¹Department of Nuclear Medicine, Zhujiang Hospital Southern Medical University, Guangzhou, Guangdong Province, CHINA, ²Department of Nuclear Medicine, Zhujiang Hospital Southern Medical University, 广州市, CHINA.

OP-523

Prognostic factors in children with differentiated thyroid cancer

S. Zakavi¹, F. Nesari Javan¹, E. Askari¹, S. Shafiee¹, V. Roshanravan¹, A. Aghaei¹, N. Ayati²;
¹Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ²Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

OP-524

Impact of micro-extrathyroidal extension and bilateral topography of malignancy on clinical initial staging and early outcome of differentiated thyroid cancer (<4cm) patients.

A. Campenni¹, R. Ruggeri¹, M. Siracusa¹, D. Cardile¹, S. Russo¹, A. Nicocia¹, A. Rappazzo¹, V. Davi¹, A. Alibrandi¹, S. Baldari¹, L. Giovannella²;
¹Ospedale Gaetano Martino, Messina, ITALY, ²Ente Ospedaliero Cantonale, 6500 Bellinzona, SWITZERLAND.

OP-525

Postoperative Thyroglobulin as a Yard-stick for Radioiodine Therapy: Decision Tree Analysis in a European Multicenter Series of 1317 Patients with Differentiated Thyroid Cancer

L. Giovannella¹, L. Milan¹, W. Roll², M. Weber³, S. Schenke⁴, M. Kreiss⁵, A. Vrachimis⁶, K. Pabst⁶, T. Murat⁷, P. Petranović Ovcariček⁸, B. Riemann⁹, L. Ceriani¹, A. Campenni¹⁰, R. Goerges⁶;
¹Imaging Institute of Southern Switzerland, Bellinzona, SWITZERLAND, ²University Hospital Muenster, Muenster, GERMANY, ³University Hospital of Essen, Essen, GERMANY, ⁴University Hospital Magdeburg, Magdeburg, GERMANY, ⁵German Oncology Center, Limassol, CYPRUS, ⁶University Hospital Essen, Essen, GERMANY, ⁷Hacettepe University, Ankara, TÜRKIYE, ⁸University Hospital Center "Sestre milosrdnice", Zagreb, CROATIA, ⁹University Hospital Münster, Münster, GERMANY, ¹⁰Ospedale Universitario di Messina, Messina, ITALY.

OP-526

Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma is Related to A Poor Outcome: A Comparison Study Using Propensity Score Matching

L. Yang¹, M. Zhao¹, L. Xiao¹, L. Li¹, P. Dong¹;
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.

OP-527

Radiomics approaches for predicting non-iodine-avid status of lung metastases in patients with differentiated thyroid cancer based on CT: a prospective observational study

X. Gao¹;
Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, CHINA.

OP-528

Could Coprococcus catus be used as a biomarker for the treatment response of I-131 in thyroid cancer patients?

A. Fernandes¹, R. Soares², P. Barata Coelho³;
¹Centro Hospitalar e Universitário São João, Porto, PORTUGAL, ²Faculdade de Medicina da Universidade do Porto, Porto, PORTUGAL, ³Universidade Fernando Pessoa, Porto, PORTUGAL.

OP-529

Determination of whole-body effective half-life of I-131 on differentiated thyroid cancer patients with a cloud-based remote dose meter

L. Kääriä^{1,2}, M. Lapela^{3,2}, M. Seppänen^{4,2}, J. Ruohola^{3,2}, A. Ålgars^{5,2}, T. Noponen^{6,2};
¹Department of Nuclear Medicine, Turku University Hospital and Wellbeing services county of Southwest Finland, Turku, FINLAND, ²University of Turku, Turku, FINLAND, ³Department of Oncology, Turku University Hospital and Wellbeing services county of Southwest Finland, Turku, FINLAND, ⁴Department of Clinical Physiology, Nuclear Medicine and Turku PET Centre, Turku University Hospital and Wellbeing services county of Southwest Finland, Turku, FINLAND, ⁵Department of Oncology, Turku University Hospital and Wellbeing services county of Southwest Finland, Turku, FINLAND, ⁶Department of Clinical Physiology, Nuclear Medicine, Turku PET Centre and Medical Physics, Turku University Hospital and Wellbeing services county of Southwest Finland, Turku, FINLAND.

OP-530

Preliminary results from a clinical trial combining ¹³¹I and external beam radiotherapy for treatment of metastatic radioiodine-refractory thyroid cancer

R. Hobbs¹, I. Marsh¹, H. Quon¹, P. Santhanam¹, P. Ladenson¹, B. He¹, D. Kaplin¹, K. Lowe¹, H. Wang¹, G. Sgouros¹;
Johns Hopkins, Baltimore, MD, UNITED STATES OF AMERICA.

1109

Monday, September 11, 2023, 4:45 PM - 6:15 PM
Hall G2

e-Poster Presentations Session 8 - Neuroimaging Committee: E-Poster Neurology: It's in the Brain!

EPS-147

Improving the quantification of tau pathology in Alzheimer's Disease: A data-driven analysis using 18F-PI2620 PET.

G. Bischof^{1,2}, M. Kanekiyo³, M. Irrizarri³, A. Stephens⁴, T. van Eimeren¹, A. Drzezga^{1,2,5};
¹University Hospital Cologne, Cologne, GERMANY, ²Molecular Organization of the Brain, Institute for Neuroscience and Medicine (INM2), Juelich, GERMANY, ³Eisai Inc., Nutley, NJ, UNITED STATES OF AMERICA, ⁴Life Molecular Imaging, Berlin, GERMANY, ⁵German Center for Dementia Research (DZNE), Bonn, GERMANY.

EPS-148

Single Tracer ATN Assessment With Dynamic 18F-PI-2620 Recordings

J. Gnörich¹, M. Zaganjori¹, M. Groß¹, M. Scheifele¹, A. Bronte², R. Perneczky³, K. Bürger⁴, J. Levin⁵, O. Sabri⁶, P. Bartenstein¹, H. Barthel⁶, N. Franzmeier⁴, M. Brendel¹;
¹LMU Munich, Department of Nuclear Medicine, Munich, GERMANY, ²Universidad de Navarra, Pamplona, SPAIN, ³LMU Munich, Department of Psychiatry and Psychotherapy, Munich, GERMANY, ⁴Institute for Stroke and Dementia Research, LMU Munich, Munich, GERMANY, ⁵LMU Munich, Department of Neurology, Munich, GERMANY, ⁶Department of Nuclear Medicine, Leipzig, GERMANY.

EPS-149

Early-phase [18F]FBB PET vs [18F]FDG PET in atypical dementia: preliminary data from a multicentric study (AMY-ITA).

D. Cecchin¹, A. Chincari², S. Mozzetta³, C. Gagliani³, A. Osele³, S. Morbelli⁴, S. Sestini⁵, F. Dore⁶, M. Dottorini⁷, L. Ruffini⁸, G. Trifirò⁹, M. Farsad¹⁰, L. Turk³, A. Cagnin³;
¹Nuclear Medicine University Hospital Padova, Padova, ITALY, ²Istituto Nazionale di Fisica Nucleare (INFN), Genova, ITALY, ³University of Padova, Padova, ITALY, ⁴University of Genoa, Genoa, ITALY, ⁵Hospital of Prato, Prato, ITALY, ⁶Azienda sanitaria universitaria Giuliano Isontina, Trieste, ITALY, ⁷Azienda Ospedaliera di Perugia, Perugia, ITALY, ⁸Azienda Ospedaliera Universitaria di Parma, Parma, ITALY, ⁹ICS Maugeri, Pavia, ITALY, ¹⁰Ospedale di Bolzano, Bolzano, ITALY.

EPS-150

Clinical outcomes up to 9 years after [¹⁸F] flutemetamol amyloid-PET in a symptomatic memory clinic population

L. Collij^{1,2}, G. Farrar³, M. Zwan¹, E. M. van de Giessen¹, R. Ossenkoppele^{1,2}, F. Barkhof^{1,4}, A. Rozemuller¹, Y. Pijnenburg¹, W. M. Van der Flier¹, F. Bouwman¹;
¹Amsterdam UMC, location VUmc, Amsterdam, NETHERLANDS, ²Lund University, Lund, SWEDEN, ³GE Healthcare, Amersham, UNITED KINGDOM, ⁴University College London, London, UNITED KINGDOM.

EPS-151

Gender influences the expression of metabotropic glutamate receptor 5 in the brain of cognitively impaired individuals: a PET/MR study

W. Jie¹, Y. Guan², F. Xie²;
¹Fudan University, Shanghai, CHINA, ²Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA.

EPS-152

Prevalence of Limbic-predominant Age-related TDP-43 Encephalopathy (LATE) in Tertiary Care Cognitive Disorder Clinics

E. Park¹, C. J. Cliatt-Brown¹, Y. Anzai¹, S. Minoshima¹;
University of Utah, Salt Lake City, UT, UNITED STATES OF AMERICA.

EPS-153

Application of principal component analysis on amyloid-PET and clinical data to predict conversion from mild cognitive impairment to Alzheimer's disease

E. Perrone^{1,2}, F. Cocciolillo², S. Taralli², D. Quaranta³, D. Santoni⁴, M. Mazzei⁴, C. Marra⁵, M. L. Calcagni^{1,2};
¹Nuclear Medicine Institute, University Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore, Rome, ITALY, ²Nuclear Medicine Unit, Diagnostic Imaging, Radiation Oncology and Hematology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, ³Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, ⁴Institute for System Analysis and Computer Science "Antonio Ruberti", National Research Council of Italy, Rome, ITALY, ⁵Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY.

EPS-154

Clinical utility of Amyloid Brain PET in patients with Mild Cognitive Impairment

M. Pudis¹, L. Rodríguez-Bel¹, M. Suarez-Piñera¹, C. Martínez-Ramos¹, J. Gascón-Bayarri², J. Campdelacreu-Fumado², S. Bondía-Bescós¹, B. Hervás-Sanz¹, J. Diaz-Moreno¹, M. Cortés-Romera¹;

¹Nuclear Medicine - PET (IDI), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN, ²Neurology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN.

EPS-155

Unilateral Nasal Septal Deviation Mediates Contralateral Loss of Striatal Dopamine Transporter Uptake in Patients with Parkinson's Disease

J. Wang^{1,2}, J. Ge¹, F. Liu³, M. Tian², J. Wang³, C. Zuo¹;

¹Department of Nuclear Medicine/PET center, Huashan Hospital, Fudan University, Shanghai, CHINA, ²Human Phenome Institute, Fudan University, Shanghai, CHINA, ³Department of Neurology, Huashan Hospital, Fudan University, Shanghai, CHINA.

EPS-156

Dopamine D₁ receptor availability in Gilles de la Tourette syndrome measured by [11C]SCH23390 PET

M. Rullmann¹, D. Gkotsoulas², S. Schmitt³, C. Fremer³, C. Klages³, K. Hartung³, A. Bujanow², F. Zientek¹, K. Messerschmidt¹, M. Patt¹, O. Sabri¹, K. Müller-Vahl³, H. Möller³, H. Barthel¹;

¹Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY, ²Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, GERMANY, ³Clinic of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, GERMANY.

EPS-157

Multiparametric ¹¹C-MET PET/MR for predicting survival of postsurgical glioma patients

Y. Xu, C. Li, F. Liu, F. Hu, W. Ruan, X. Lan;

Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EPS-158

A Feasibility Study of Ga68-PSMA PET/CT in Differentiating Brain Metastases from Radiation Necrosis

F. Lattuada¹, S. Wagemaker², L. de Wit-van der Veen², D. Brandsma², M. Stokke²;

¹Post Graduate School of Nuclear Medicine, University of Milano-Bicocca, Milano, ITALY, ²NKI-AVL, Amsterdam, NETHERLANDS.

EPS-159

Feasibility and initial experience of chemokine receptor-4 receptor-4 (CXCR4) expression using ⁶⁸Ga-Pentixafor and O-2-18F-fluoroethyl-L-tyrosine (18F-FET) PET-MR image fusion in low- and high-grade gliomas

H. Dadgar^{1,2}, N. Norouzbeigi¹, M. Assadi³, B. Al-balooshi⁴, A. Al-Ibraheem⁵, Y. Omar⁶, H. Muhsin Al-Alawi⁷, S. Usmani⁸, M. Ricci⁹, A. Cimini¹⁰, H. Arabi¹¹, H. Zaidi^{11,12,13};

¹Nuclear Medicine and Molecular imaging research center, Mashad, IRAN, ISLAMIC REPUBLIC OF, ²Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, Iran, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ³The Persian Gulf Nuclear

Medicine Research Center, Department of Molecular imaging and Radionuclide Therapy, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, IRAN, Bushehr, IRAN, ISLAMIC REPUBLIC OF, ⁴Dubai Nuclear Medicine & amp; Molecular imaging center-Dubai Academic Health corporation-DAHC, UAE, Dubai, UNITED ARAB EMIRATES, ⁵Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan-Devison of Nuclear Medicine/Department of Radiology and Nuclear Medicine, University of Jordan, Amman, Jordan, Amman, JORDAN, ⁶PET-CT department at Misr Radiology Center, Heliopolis, Egypt, Heliopolis, EGYPT, ⁷Nuclear Medicine department, Amir Al-momineen Specialty Hospital, Al-Najaf Governorate, Iraq Middle Euphrates Cancer Hospital, Al-Najaf Governorate, Iraq, Mashad, IRAQ, ⁸Department of Nuclear Medicine Sultan Qaboos Comprehensive Cancer Care and Research Center (SQCCRC), Seeb, Oman, Seeb, OMAN, ⁹Nuclear Medicine Unit, Cardarelli Hospital, Campobasso, Italy, Campobasso, ITALY, ¹⁰Nuclear Medicine Unit, St. Salvatore Hospital, 67100 L'Aquila, Italy, L'Aquila, ITALY, ¹¹Division of Nuclear Medicine and Molecular Imaging, Department of Medical Imaging, Geneva University Hospital, CH-1211 Geneva 4, Switzerland, Geneva, SWITZERLAND, ¹²Geneva Neuroscience Center, Geneva University, CH-1205 Geneva, Switzerland, Geneva, SWITZERLAND, ¹³Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, NETHERLANDS, Groningen, NETHERLANDS.

EPS-160

Histopathological validation of 18F-FACBC uptake in high- and low-grade glioma

B. Vindstad¹, L. K. Pedersen², E. M. Berntsen^{1,3}, O. Solheim^{3,1}, I. Reinertsen^{4,1}, H. Johansen³, A. J. Skjulsvik^{1,3}, L. Eikenes¹, A. Karlberg^{1,3};

¹Norwegian University of Science and Technology, Trondheim, NORWAY, ²University Hospital of North Norway, Tromsø, NORWAY, ³St. Olavs Hospital, Trondheim, NORWAY, ⁴SINTEF Digital, Trondheim, NORWAY.

EPS-161

Prognostic Role of Preoperative [¹¹C]Methionine PET in IDH-Wildtype Astrocytomas

G. Ninatti¹, M. Sollini^{2,3}, B. Bono², L. Antunovic⁴, F. Gelardi², C. Landoni^{1,5}, F. Pessina^{2,3}, M. Rodari³, A. Chiti^{6,4};

¹University of Milano Bicocca, Monza, ITALY, ²Humanitas University, Pieve Emanuele, ITALY, ³IRCCS Humanitas Research Hospital, Rozzano, ITALY, ⁴IRCCS San Raffaele Scientific Institute, Milan, ITALY, ⁵IRCCS-San Gerardo, Monza, ITALY, ⁶Vita-Salute San Raffaele University, Milan, ITALY.

EPS-162

^{99m}Tc-ECD SPECT Predicts Neurological Recovery in Cardiac Arrest Survivors

P. Chuang¹, Y. Chen², Y. Huang³, C. Wang³, W. Chang⁴, Y. Wu⁵, M. Cheng²;

¹Department of Nuclear Medicine, National Taiwan University Hospital Yunlin Branch, Douliu City, TAIWAN, ²Department of Nuclear Medicine, National Taiwan University Hospital, Taipei City, TAIWAN, ³Department of Emergency Medicine, National Taiwan University Hospital Yunlin Branch, Douliu City, TAIWAN, ⁴Department of Emergency Medicine and Cardiology, National Taiwan University Hospital, Taipei City, TAIWAN, ⁵Department of Nuclear Medicine and Cardiology, Far Eastern Memorial Hospital, New Taipei City, TAIWAN.

EPS-163

Cerebral perfusion imaging with [¹⁵O]H₂O and an image derived input function from an additional scan of the heart

L. Marnier¹, M. E. Larsen^{1,2}, A. O. Kellberg¹, A. C. Henriksen¹, S. Fuglsang¹, M. N. Lonsdale¹, L. Marnier³;

¹Copenhagen University Hospital Bispebjerg, Department of Clinical Physiology and Nuclear Medicine, Copenhagen NV, DENMARK, ²Copenhagen University Hospital Rigshospitalet, Department of Anesthesiology, Copenhagen, DENMARK, ³Copenhagen University Hospital Bispebjerg, Department of Clinical Physiology and Nuclear Medicine, Copenhagen, DENMARK.

EPS-164

Hypermetabolism in the Cerebellum is Related to M1 Microglial Activation in Temporal Lobe Epilepsy

Y. Tang, L. Xiao, J. Yang, J. Hou, B. Chen, S. Hu;

Xiangya Hospital Central South University, Changsha, CHINA.

EPS-165

Brain Networks Involved in Cancer Treatment Response: Insights from 18F-FDG PET Scans

M. Namías¹, M. Perovnik², D. T. Huff³, C. Tinetti^{1,4}, M. Azar⁴, R. Jeraj^{5,6};

¹Fundación Centro Diagnóstico Nuclear, Buenos Aires, ARGENTINA, ²University Medical Center Ljubljana, Ljubljana, SLOVENIA, ³University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA, ⁴Instituto de Oncología "Ángel H. Roffo", Buenos Aires, ARGENTINA, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI, UNITED STATES OF AMERICA, ⁶Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, SLOVENIA.

EPS-166

Correlation between neovascularization and macrophage inflammation in carotid atherosclerotic plaques evaluated by hybrid ¹⁸F-FDG PET/MR: a fused image-based histological validation study

Y. Zhang^{1,2}, B. Cui^{1,2}, H. Yang^{1,2}, Y. Ma³, J. Lu^{1,2};

¹Department of Radiology and Nuclear Medicine, Xuanwu Hospital Capital Medical University, Beijing, CHINA, ²Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, CHINA, ³Department of Neurosurgery, Xuanwu Hospital Capital Medical University, Beijing, CHINA.

EPS-167

Brain-dedicated PET system shows non-inferiority compared to conventional PET-CT

P. Nespral¹, P. Bascañana¹, G. Cuesta Domingo¹, A. Canora¹, A. Delgado-Cano¹, J. Matías-Guiz², J. Carreras-Delgado¹, M. Cabrera-Martin¹;

¹Department of Nuclear Medicine, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Universidad Complutense, Madrid, SPAIN, ²Department of Neurology, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Universidad Complutense, Madrid, SPAIN.

1110

Monday, September 11, 2023, 16:45 - 18:15

Hall K

CTE 5 - Technologists Committee: Cardiac Inflammatory Disease

OP-531

Nuclear Medicine's input in Cardiac Inflammation – clinical overview

P. Erba;

Università di Pisa, Department of Translational Research on New Technologies in Medicine and Surgery, Bergamo, ITALY.

OP-532

The importance of patient preparation

V. Mautone;

Instituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS, Meldola, ITALY.

OP-533a

Nuclear Medicine's input in Cardiac Amyloidosis

O. Gheysens;

UCLouvain Louvain-la-Neuve Belgium, Nuclear Medicine Department, Brussels, BELGIUM.

OP-533b

Multimodality in cardiac imaging: who are the imagers?

S. Pereira;

King's College London and Guy's and St Thomas' Hospital NHS Foundation Trust, Clinical PET Centre, London, UNITED KINGDOM.

1111

Monday, September 11, 2023, 4:45 PM - 6:15 PM

Hall G1

Case Report Session 2 - TROP Session: Successful Molecular Targeting in Oncology

OP-534

Triple Imaging in a Patient with Symptomatic Multiple Myeloma at Staging: Which Is More Informative?

M. Di Franco¹, D. Bezzi¹, A. Cattabriga², S. Brocchi², C. Mosconi^{2,3}, E. Zamagni⁴, M. Talarico⁴, C. Gaudiano², L. Vetrone¹, R. Mei⁵, S. Fanti^{1,5}, C. Nanni⁵;

¹Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Department of Radiology, IRCCS Azienda Ospedaliero Universitaria Di Bologna, Bologna, ITALY, ³DIMEC, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁵Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-535

Anthraxosis: a potential pitfall in 18F-FCH PET/CT and 18F-PSMA-1007 PET/CT interpretation

A. Cimini¹, M. Ricci², A. Marzullo¹, M. Menichini¹, F. Di Stasio¹, M. Di Pietro¹, H. Arabi³, H. Dadgar⁴, G. L. Gravina⁵; ¹Nuclear Medicine Unit, St. Salvatore Hospital, L'Aquila, ITALY, ²Nuclear Medicine Unit, Cardarelli Hospital, Campobasso, ITALY, ³Division of Nuclear Medicine and Molecular Imaging, Department of Medical Imaging, Geneva University Hospital, Geneva, SWITZERLAND, ⁴Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ⁵Department of Applied Clinical Sciences and Biotechnologies Division of Radiotherapy, University of L'Aquila, L'Aquila, ITALY.

OP-536

Epididymal metastasis of prostate adenocarcinoma in [⁶⁸Ga]Ga-PSMA-11

B. Martins¹, T. Timóteo, C. Loewenthal; Hospital da Luz, Lisboa, PORTUGAL.

OP-537

PET/CT with ¹⁸F-FDG and ⁶⁸Ga-DOTATOC: a case of negative findings in a Solitary Fibrous Tumor.

L. Jonghi-Lavarini¹, F. Bono², A. Tuoro³, C. Crivellaro⁴, L. Guerra^{4,1}, C. Landoni^{4,5,6}; ¹University Milano-Bicocca, Milan, ITALY, ²Department of Pathology, IRCCS San Gerardo dei Tintori Hospital, Monza, ITALY, ³Thoracic Surgery Department, IRCCS San Gerardo dei Tintori Hospital, Monza, ITALY, ⁴Department of Nuclear Medicine, IRCCS San Gerardo dei Tintori Hospital, Monza, ITALY, ⁵University of Milano-Bicocca, Milan, ITALY, ⁶Tecnomed Foundation, Monza, ITALY.

OP-538

Flip-flop phenomenon on dual SSTR PET and amino acid PET in a case of pre-treated atypical meningioma CNS WHO grade 2

A. Holzgreve¹, S. Quach², P. Harter³, R. Forbrig⁴, C. Schichor², J. Tonn², M. Niyazi⁵, P. Bartenstein¹, L. von Baumgarten², N. L. Albert¹; ¹Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, ²Department of Neurosurgery, University Hospital, LMU Munich, Munich, GERMANY, ³Center for Neuropathology and Prion Research, LMU Munich, Munich, GERMANY, ⁴Institute of Neuroradiology, University Hospital, LMU Munich, Munich, GERMANY, ⁵Department of Radiation Oncology, University Hospital, LMU Munich, Munich, GERMANY.

OP-539

"Not always a zebra" - Clear Cell Renal Cell Carcinoma Metastasis detected in [⁶⁸Ga]Ga-DOTA-NOC PET/CT

J. C. Ferro¹, J. P. Teixeira, I. Próspero, D. Barbosa, D. G. Silva, S. Fontão de Castro, G. Ferreira, L. Violante, F. Lopes, H. Duarte, I. Lucena e Sampaio; Instituto Português de Oncologia do Porto Francisco Gentil, Oporto, PORTUGAL.

OP-540

Brain [¹⁸F]FET PET/CT in acute myeloid leukemia

G. Crosta¹, A. Castello², S. Pacella², V. Longari², L. Florimonte², M. Castellani²; ¹University of Milan, Milan, ITALY, ²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, ITALY.

OP-541

Two Cases of Diffuse Mild-Moderate 18F-Fluoroestradiol Lung Uptake in Women with Metastatic Estrogen Receptor Positive Breast Cancer

E. Phillips¹, P. Karak; Hartford Hospital, Hartford, CT, UNITED STATES OF AMERICA.

OP-542

The ultimate indication for surgical probe use: a case of an ectopic intraesophageal parathyroid adenoma.

A. Doumas¹, I. Pliakos², T. Papavramidis², P. Exadaktylou¹, D. Boundas³, E. Giannoula¹, A. Tsangaridi¹, G. Gerasimou¹, E. Papanastasiou¹, N. Papadopoulos¹, I. Iakovou¹; ¹Aristotle University, Thessaloniki, GREECE, ²1st Surgery Clinic of Aristotle University of Thessaloniki, University Hospital AXEPA, Thessaloniki, GREECE, ³Private Nuclear Medicine Centre, Ippokratis, Thessaloniki, GREECE.

1201

Tuesday, September 12, 2023, 08:00 - 09:30

Hall A

CME 9 - Bone & Joint + Physics Committee: Current Bone SPECT/CT (including 360 CZT)

OP-543

360 CZT Bone SPECT/CT How to report it and Case Examples

D. Little¹; Royal United Hospital, Radiology Department, Bath, UNITED KINGDOM.

OP-544

CT findings in SPECT/CT - Bone and Incidental

I. Bruno¹; Regional General Hospital "F. Miulli", Bari, ITALY.

OP-545

Extent of scan in SPECT/CT Whole Body vs Single and Multiple Fields of View

S. Redman¹; Royal United Hospital, Radiology Department, Bath, UNITED KINGDOM.

OP-546

SUV in Bone SPECT/CT

B. Geist¹; Medical University of Vienna, Department of Biomedical Imaging and Image-guided Therapy, Vienna, AUSTRIA.

1202

Tuesday, September 12, 2023, 08:00 - 09:30

Hall D (Arena)

Round Table 2 - Radiation Protection Committee: Establishing and Running a Theranostics Center in a Clinical Setting

OP-547

Why theranostics and future challenges, the clinical perspective

K. Herrmann¹; University-Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY.

OP-548

Staff, infrastructure and instrumentation, and related regulatory issues

A. Sundlöv¹; Swedish Medical Products Agency, Uppsala, SWEDEN.

OP-549

Patient management and radiation protection considerations of staff, patients, carers, and the public

N. Cherbuin¹; Centre Hospitalier Universitaire Vaudois, Institut de Radiophysique, Lausanne, SWITZERLAND.

OP-550

New theranostic agents and future challenges

S. Heskamp¹; Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Center Nijmegen, Nijmegen, NETHERLANDS.

1203

Tuesday, September 12, 2023, 08:00 - 09:30

Hall E1

LIPS Session 9 - Paediatrics Committee: Paediatric Nephro-Urology - Beyond Hydro-Nephrosis

OP-551

Renal scintigraphy in kidney abnormalities other than hydronephrosis

A. Santos¹; Hospital Garcia de Orta, Nuclear Medicine Department, E.P.E., Almada, PORTUGAL.

OP-552

MAG3 or DMSA in congenital renal malformation

J. Rogasch¹; Charité-Universitätsmedizin Berlin, Department of Nuclear Medicine, Berlin, GERMANY.

OP-553

DMSA, MAG3, sonography and functional MRI: contribution in complex ectopic, duplex and horseshoe kidneys

P. Zucchetta¹; Padova University Hospital, Department of Medicine, Nuclear Medicine Unit, Padova, ITALY.

1204

Tuesday, September 12, 2023, 8:00 AM - 9:30 AM

Hall E2

M2M Track - TROP Session: Imaging the Brain from all Angles

OP-555

First imaging of PARP1 in the living human brain - a translational PET study with [¹¹C]AZ3391

M. Schou^{1,2}, A. Pike³, A. Jucaite^{1,2}, P. Johnström^{1,2}, M. Cortes Gonzalez², A. Högnäsbacka², K. Dahl^{1,2}, A. Ghosh⁴, J. Johannes⁴, A. Staniszevska³, E. Leo³, P. Hamerlik³, B. Davies³, S. Cosulich³, J. Swales³, R. Lawrence³, M. Squatrito³, N. Mueller⁵, V. Sousa², J. Bartek², G. Stragliotto², P. Stenkrona², L. Farde², C. Halldin², Z. Cselényi^{1,2}; ¹AstraZeneca, Stockholm, SWEDEN, ²Karolinska Institutet, Stockholm, SWEDEN, ³AstraZeneca, Cambridge, UNITED KINGDOM, ⁴AstraZeneca, Waltham, MA, UNITED STATES OF AMERICA, ⁵AstraZeneca, Gaithersburg, MD, UNITED STATES OF AMERICA.

OP-557

Development of a PET imaging agent for the detection of amyotrophic lateral sclerosis

B. Guérin¹, S. Ait-Mohand¹, V. Dumulon-Perreault², J. Rousseau¹, O. Sarrhin², S. Tremblay¹, M. Maier³, M. Salzmann³; ¹Université de Sherbrooke, Sherbrooke, QC, CANADA, ²CRCHUS/CIUSSSE CHUS, Sherbrooke, QC, CANADA, ³Neurimmune AD, Zurich, SWITZERLAND.

OP-558

In vivo performance of different ¹⁸F-labelled cannabinoid receptor 2 radioligands

D. Guendel¹, W. Deuther-Conrad¹, L. Ueberham², R. Teodoro^{1,3}, G. Bormans⁴, M. Toussaint¹, E. Hey-Hawkins², K. Kopka^{5,6}, P. Brust^{1,7}, R. Moldovan¹; ¹Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Neuroradiopharmaceuticals, Leipzig, GERMANY, ²Leipzig University, Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Leipzig, GERMANY, ³Life Molecular Imaging GmbH, Berlin, GERMANY, ⁴Laboratory for Radiopharmacy, KU Leuven, Leuven, BELGIUM, ⁵Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, GERMANY, ⁶Faculty of Chemistry and Food Chemistry, School of Science, Technische Universität Dresden, Dresden, GERMANY, ⁷University Medical Center Schleswig-Holstein, The Lübeck Institute of Experimental Dermatology, Lübeck, GERMANY.

OP-559

¹⁸F-FDS PET imaging as a quantitative marker to investigate the magnitude and dynamics of enhanced of blood-brain barrier permeability induced by regadenoson

B. Hosten¹, S. Goutal, S. Leterrier, A. Winkler, L. Breuil, M. Goisard, C. Truillet, N. Tournier; Université Paris-Saclay, INSERM, CNRS, CEA, Biomaps, Orsay, FRANCE.

OP-560

The 5-HT1A receptor modulates motor/exploratory activity, object recognition and DAT binding in the dorsal and ventral striatum of the rat

S. Nikolaus¹, M. Beu¹, J. Henke¹, C. Antke¹, B. Fazari², E. Mamlins¹, F. L. Giesel¹;

¹University Hospital Düsseldorf, Düsseldorf, GERMANY, ²Heinrich-Heine University, Düsseldorf, GERMANY.

OP-561

Brain mitochondrial function and cerebral glucose utilization in non-human primate of Parkinson disease model with α -synuclein propagation via the olfactory system: a ¹⁸F-BCPP-EF and ¹⁸F-FDG PET imaging study

H. Onoe¹, M. Sawamura², T. Hirato², H. Tsukada³, T. Nakako⁴, T. Nakayama⁴, K. Ikeda⁴, C. Chen⁵, K. Isa⁵, M. Nakamura⁵, T. Isa⁵, R. Takahashi²;

¹Human Brain Research Center, Kyoto University Graduate School of Medicine, Kyoto, JAPAN, ²Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, JAPAN, ³Central Research Laboratory, Hamamatsu Photonics K.K., Hamakita, JAPAN, ⁴Sumitomo Pharma Co., Ltd., Osaka, JAPAN, ⁵Department of Physiology and Neurobiology, Kyoto University Graduate School of Medicine, Kyoto, JAPAN.

OP-562

Discovery of Novel PET tracer [¹⁸F] F-diarylbiathiazoles for α -Synucleinopathies Imaging

B. Hooshyar Yousefi¹, B. Uzegunam², S. Bagheri³, G. B. Kotipalli³, W. Paslawski⁴, J. L⁵, E. Nasis⁶, F. Geibl⁶, M. Henrich⁶, P. Svenningsson⁴, H. Ågren⁵, M. Luster⁷, W. Weber⁸, T. Arzberger⁹, D. Librizzi¹⁰;

¹Nuclear Medicine Department, Radiopharmacy section, Philipps University Marburg, Marburg, GERMANY, ²Nuclear Medicine Department, Radiopharmacy section, Philipps University, Munich, GERMANY, ³Nuclear Medicine Department, Radiopharmacy section, Philipps University, Marburg, GERMANY, ⁴Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SWEDEN, ⁵Department of Physics and Astronomy, Uppsala University, Uppsala, SWEDEN, ⁶Department of Neurology, Philipps University Marburg, Marburg, GERMANY, ⁷Nuclear Medicine Department, Philipps University, Marburg, GERMANY, ⁸Department of Nuclear Medicine, Technical University of Munich, Munich, GERMANY, ⁹Neurobiobank Munich, Ludwig-Maximilians-University of Munich, Munich, GERMANY, ¹⁰Nuclear Medicine Department, Philipps University Marburg, Marburg, GERMANY.

OP-563

In vivo quantification of [¹¹C]BIO-1819578, a novel radioligand for O-GlcNAcase, in non-human primates using Positron Emission Tomography

M. Bolin¹, S. Nag¹, P. Datta¹, R. Arakawa¹, Y. Khani Meynaq¹, E. Lin², N. Genung², H. Hering², K. Guckian², L. Martarello², M. Kaliszczak², L. Farde¹, P. Stenkrona¹, C. Halldin¹, A. Forsberg Morén¹;

¹Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm Health Care Services, Region Stockholm, Stockholm, SWEDEN, ²BIOGEN MA Inc., 225 Binney St., Cambridge, MA, UNITED STATES OF AMERICA.

1205

Tuesday, September 12, 2023, 8:00 AM - 9:30 AM
Hall B

Cutting Edge Science Track - TROP Session: Total Body PET Methods

OP-564

Application of the long axial field-of-view PET/CT with direct and indirect Patlak parametric imaging

L. Pan, C. Sachpekidis, A. Dimitrakopoulou-Strauss; German Cancer Research Center, Heidelberg, GERMANY.

OP-565

Kinetic modeling and parametric imaging of ¹⁸F-PSMA-11: an evaluation based on total-body dynamic PET scan

H. Yuan, L. Jiang; Guangdong Provincial People's Hospital, Guangzhou, CHINA.

OP-566

Multi-tracer image-derived input function validation using a long axial field of view PET scanner

X. Palard-Novello^{1,2}, D. Visser², N. Tolboom³, C. Smith², G. Zwezerijnen², E. van der Giessen², M. den Hollander², F. Barkhof², B. Windhorst², B. N. M. van Berckel², R. Boellaard², M. Yacub²;

¹Centre Eugène Marquis, Rennes, FRANCE, ²Amsterdam Universitair Medische Centra, Amsterdam, NETHERLANDS, ³Universitair Medisch Centrum Utrecht, Utrecht, NETHERLANDS.

OP-567

The ENHANCE-PET Framework: An initiative to engage the imaging community in Advancements in Total-Body PET Analysis

L. Shiyam Sundar¹, B. A. Spencer², J. Callahan³, S. R. Cherry², R. D. Badawi², I. Buvat⁴, D. Lewis⁵, D. Ferrara¹, S. Gutschmayer¹, R. Hicks³, M. Lassen⁶, J. Mannheim⁷, O. Muzik⁸, M. Pires¹, J. Yu¹, T. Beyer¹;

¹Medical University of Vienna, Vienna, AUSTRIA, ²University of California-Davis, Davis, CA, UNITED STATES OF AMERICA, ³Melbourne Theranostics Innovation Center, Melbourne, AUSTRALIA, ⁴Institut Curie, Paris, FRANCE, ⁵CRUK Glasgow, Glasgow, UNITED KINGDOM, ⁶Rigshospitalet Copenhagen, Copenhagen, DENMARK, ⁷Uniklinikum Tuebingen, Tuebingen, GERMANY, ⁸Wayne State University, Detroit, MI, UNITED STATES OF AMERICA.

OP-568

Walk-Through Flat-Panel Total Body PET: System Design and Comparison of Body Motion with a standard PET-CT

F. Muller¹, J. Maebe¹, N. Withofs², S. Vandenberghe¹; ¹Medical Image and Signal Processing, Faculty of Engineering and Architecture, Ghent University, Ghent, BELGIUM, ²Division of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, CHU of Liege, Quartier Hôpital, Liège, BELGIUM.

OP-569

TOF Data Compression Strategies for 3D Fourier-Based Analytical Reconstruction of Long Axial Field of View (LAFOV) scanners data

V. Panin; Siemens Medical Solutions United States Of America, Knoxville, TN, UNITED STATES OF AMERICA.

OP-570

Comparison of the standard and ultra-high sensitivity modes on a long axial FOV PET/CT system

M. Roy, J. van Sluis, J. H. van Snick, A. W. J. M. Glaudemans, C. Tsoumpas; University Medical Center Groningen, Groningen, NETHERLANDS.

OP-571

Sub-minute acquisition with deep-learning reconstruction in the diagnosis of colorectal cancers using total-body ¹⁸F-FDG PET/CT

E. Liu, Z. Lyu, L. Jiang; Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, CHINA.

OP-572

Diagnostic image quality and quantitative PET parameters of low-dose ¹⁸F-FDG-PET/CT in a total-body PET/CT scanner: How low can we go?

E. Calderón¹, F. P. Schmidt^{1,2}, W. Lan¹, H. Dittmann¹, C. la Fougère^{1,3}, L. S. Kiefer¹; ¹Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tübingen, Tübingen, GERMANY, ²Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard-Karls University Tübingen, Tübingen, GERMANY, ³Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, GERMANY.

1206

Tuesday, September 12, 2023, 8:00 AM - 9:30 AM
Hall C

Clinical Oncology Track - TROP Session: Gynaecological Malignancies

OP-573

Molecular imaging predicts response absence to T-DM1 in advanced HER2-positive breast cancer: final results from a prospective phase II ZEPHIR trial

M. Mileva¹, E. G. de Vries², T. Guiot³, Z. Wimana⁴, A. Deleu¹, C. Schröder^{5,6}, Y. Lefebvre¹, M. Paesmans⁷, S. Stroobants⁸, M. Huizing⁹, P. Aftimos¹⁰, J. Tol¹¹, W. Van der Graaf¹², W. Oyen^{13,14,15}, D. Vugts¹⁶, C. Menke-van der Houven van Oordt¹², A. Brouwers¹⁷, M. Piccart-Gebhart¹⁰, P. Flamen¹, G. Gebhart¹;

¹Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ²Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, ³Department of Medical Physics, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ⁴Department of Radiopharmacy, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de

Bruxelles (ULB), Brussels, BELGIUM, ⁵Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, ⁶Department of Medical Oncology, Antoni van Leeuwenhoek-NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS, ⁷Data center, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ⁸Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Antwerp, BELGIUM, ⁹Department of Medical Oncology, Antwerp University Hospital, Edegem, Antwerp, BELGIUM, ¹⁰Department of Medical Oncology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ¹¹Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, NETHERLANDS, Den Bosch, NETHERLANDS, ¹²Department of Medical Oncology, Amsterdam UMC location VUMC, Cancer Centre Amsterdam, Amsterdam, NETHERLANDS, ¹³Humanitas Clinical and Research Center, Humanitas University, Milan, ITALY, ¹⁴Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, NETHERLANDS, ¹⁵Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, NETHERLANDS, ¹⁶Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, NETHERLANDS, ¹⁷Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.

OP-574

First Clinical experience with ⁶⁸Ga-Nitroimidazole imaging in cancer of the cervixuteri

K. Mokoala^{1,2}, I. O. Lawal^{3,1}, L. C. Maserumule^{1,2}, K. N. Hlongwa⁴, H. Ndlovu¹, J. D. Reed¹, J. Jeong⁵, J. Mahapane¹, C. Davis^{1,2}, C. van de Wiele⁶, A. Maes⁷, M. Vorster⁸, M. M. Satheke^{9,10};

¹University of Pretoria, Pretoria, SOUTH AFRICA, ²Nuclear Medicine Research Infrastructure (NuMeRI), Pretoria, SOUTH AFRICA, ³Emory University, Atlanta, GA, UNITED STATES OF AMERICA, ⁴University of Cape Town, Cape Town, SOUTH AFRICA, ⁵Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF, ⁶Katholieke University Leuven, Leuven, BELGIUM, ⁷University of Ghent, Ghent, BELGIUM, ⁸University of Kwazulu Natal, Durban, SOUTH AFRICA.

OP-575

²-[¹⁸F]FDG-PET/CT in the early prediction of histopathological response in breast carcinoma: results of the German multi-center Gepar-PET study

B. Krause¹, W. Mohnike², S. Dresel³, H. Rudolf⁴, F. H. H. Müller⁵, J. Farahati⁶, H. Palmedo⁷, S. M. Schwarzenböck¹, M. Untch⁸, J. Kurth¹, K. Mohnike²;

¹Department of Nuclear Medicine, University Medical Center Rostock, Rostock, GERMANY, ²Center for Nuclear Medicine, DTZ Berlin, Berlin, GERMANY, ³Department of Nuclear Medicine, Helios Clinics Berlin-Buch, Berlin, GERMANY, ⁴Institute for Biostatistics and Informatics in Medicine and Ageing Research, University Medical Center Rostock, Rostock, GERMANY, ⁵Radiologie und Nuklearmedizin Ludwigshafen, Ludwigshafen, GERMANY, ⁶Department of Nuclear Medicine, Ev. Krankenhaus BETHESDA zu Duisburg, Duisburg, GERMANY, ⁷Institute of Nuclear Medicine and Radiology, Kaiserpassage, PET/CT Center Johanner Hospital, Bonn, GERMANY, ⁸Department of Gynecology and Obstetrics, Helios Clinics Berlin-Buch, Berlin, GERMANY.

OP-576

Evaluation of a Dual Integrin $\alpha v\beta 3$ and Gastrin-Releasing Peptide Receptor Targeting PET tracer [^{68}Ga]Ga-RM26-RGD in Breast Cancer Patients

R. Wang^{1,2,3}, X. Wen⁴, P. Xu⁵, X. Zhang⁶, Z. Guo⁴, Z. Zhu^{1,2,3}, X. Chen^{6,7,8}, J. Zhang^{6,7,8};

¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, CHINA, ²State Key Laboratory of Complex Severe and Rare Diseases, Beijing, CHINA, ³Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, CHINA, ⁴State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, CHINA, ⁵Institute of Clinical Pharmacy & Pharmacology, Jining First People's Hospital, Jining Medical University, Jining, CHINA, ⁶Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE, ⁷Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE, ⁸Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.

OP-577

Tumor and metastatic lymph nodes metabolic activity on ^{18}F -FDG PET/CT to predict progression-free survival in locally advanced cervical cancer

J. Song;
Zhejiang Cancer Hospital, Hangzhou, CHINA.

OP-578

HER2-specific Affibody Molecule [$^{99\text{m}}\text{Tc}$]Tc-ZHER2:41071: phase I clinical trial

V. Tolmachev¹, O. Bragina², M. Larkina³, A. Rybina², R. Zelchan², M. Oroujeni¹, A. Loftenius⁴, A. Orlova⁵, J. Sörensen⁶, F. Frejd¹, V. Chernov⁷;

¹Department of Immunology, Genetics and Pathology (IGP), Uppsala University, Uppsala, SWEDEN, ²Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, RUSSIAN FEDERATION, ³Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, ⁴Affibody AB, Solna, SWEDEN, ⁵Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN, ⁶Radiology and Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN.

OP-579

HER2-targeting [^{68}Ga]Ga-ABY-025 PET Predicts Early Metabolic Response in Metastatic Breast Cancer

A. Alhuseinalkhudhur^{1,2}, H. Lindman², P. Liss³, T. Sundin⁴, F. Y. Frejd^{2,5}, J. Hartman^{6,7}, V. Iyer¹, J. Feldwisch⁸, M. Lubberink^{1,8}, C. Rönnlund^{6,7}, V. Tolmachev², I. Velikyan¹, **J. Sörensen**¹;

¹Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, ²Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN, ³Radiology, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN, ⁴Clinical Research and Development Unit, Uppsala University Hospital, Uppsala, SWEDEN, ⁵Affibody AB, Solna, SWEDEN, ⁶Department of Oncology-Pathology, Karolinska Institute, Stockholm, SWEDEN, ⁷Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, SWEDEN, ⁸Medical Physics,

Uppsala University Hospital, Uppsala, SWEDEN.

OP-580

^{68}Ga -NeoB PET for Glioma and Breast Cancer: First Results from a Prospective Observational Trial

D. Kersting¹, L. Lazaridis², F. Barbato¹, S. Kebir², S. Kümme³, A. Welt⁴, L. Umutlu⁵, A. Milosevic⁵, M. Nader¹, P. Fragoso Costa¹, T. Schmidt⁶, C. Oster², C. Deuschl⁶, U. Sure¹, M. Stuschke⁶, C. Kleinschnitz⁷, B. Scheffler⁷, H. Hautzel¹, M. Schuler⁴, M. Glas², W. P. Fendler¹, K. Herrmann¹;

¹Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, ²Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University of Duisburg-Essen, Essen, GERMANY, ³Breast Unit Kliniken Essen-Mitte, Essen, GERMANY, ⁴Department of Medical Oncology, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, ⁵Institute of Diagnostic, Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, ⁶Department of Radiotherapy, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, ⁷DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), DKTK Partner Site, University Medicine Essen, University Duisburg-Essen, Essen, GERMANY.

OP-581

Prognostic Value Of [^{18}F]FDG PET/CT In Patients With Metastatic Breast Cancer Treated With Cyclin-Dependent Inhibitors

D. Maccora¹, A. Annovazzi¹, S. Rea¹, L. Pizzuti², G. Ferretti³, P. Vici⁴, F. Cappuzzo², R. Sciuto¹;

¹Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, ITALY, ²Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, ITALY, ³Division of Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, ITALY, ⁴Phase IV Clinical Trial Unit, IRCCS Regina Elena National Cancer Institute, Rome, ITALY.

1207

Tuesday, September 12, 2023, 8:00 AM - 9:30 AM

Hall F1

Neuroimaging Committee - Featured Session

OP-582

Breadth of Tracers and Approaches in Neuro-Oncology

I. Law, University of Copenhagen, Faculty of Health and Medical Sciences Consultant Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, Copenhagen, DENMARK.

OP-583

Fibroblast activation protein staining in tissue samples of high-grade gliomas

N. Tolboom, S. Sabunchi, A. Mühlebner, P. A. J. T. Robe, T. J. Snijders;
University Medical Centre Utrecht, Utrecht, NETHERLANDS.

OP-584

Postoperative ^{68}Ga -DOTATATE-/PET-CT imaging is prognostic for progression-free survival survival in meningioma WHO grade 1:A prospective single center study

N. Teske, A. Biczok, S. Quach, F. J. Dekorsy, R. Forbrig, R. Bodensohn, M. Niyazi, J. Tonn, N. L. Albert, C. Schichor, M. Ueberschaer;
Munich University Hospital, LMU Munich, Munich, GERMANY.

OP-585

^{18}F -DOPA PET imaging in re-irradiation with proton therapy of recurrent glioblastoma.

D. Donner¹, D. Amelio², D. Scartoni², L. Picori¹, S. Agostini¹, F. Magnani¹, A. Palermo¹, M. Cianchetti², F. Chierichetti¹;

¹Nuclear Medicine Unit, Azienda Provinciale per i Servizi Sanitari, Trento, ITALY, ²Centro di Protonterapia, Azienda Provinciale per i Servizi Sanitari, Trento, ITALY.

OP-586

Amino-acid PET for monitoring temozolomide adjuvant therapy after a Stupp protocol in gliomas

T. Zaragori^{1,2}, S. Ahari^{1,2}, A. Zinsz², A. Mortada², L. Taillandier^{3,4}, M. Blonski^{3,4}, F. Rech^{5,4}, L. Imbert^{1,2}, A. Verger^{1,2};

¹Université de Lorraine, IADI, INSERM, UMR 1254, Vandoeuvre-lès-Nancy, FRANCE, ²Department of Nuclear Medicine & Nancyclotep Imaging Platform, CHRU-Nancy, Université de Lorraine, Vandoeuvre-lès-Nancy, FRANCE, ³Department of Neuro-Oncology, CHRU-Nancy, Université de Lorraine, Nancy, France, Vandoeuvre-lès-Nancy, FRANCE, ⁴Centre de Recherche en Automatique de Nancy CRAN UMR 7039, CNRS, Université de Lorraine, Vandoeuvre-lès-Nancy, FRANCE, ⁵Department of Neurosurgery, CHRU-Nancy, Université de Lorraine, Vandoeuvre-lès-Nancy, FRANCE.

OP-587

Predictive values of preoperative [^{68}Ga]Ga-PSMA-11 PET/CT in patients with suspected brain tumours of glial origin.

K. Pelka^{1,2}, K. Koczyk³, L. Koperski⁴, T. Dziedzic³, A. Nowak³, L. Królicki¹, P. Kunert³, J. Kunikowska¹;

¹Nuclear Medicine Department, Medical University of Warsaw, Warsaw, POLAND, ²Laboratory of Centre for Preclinical Research, Department of Research Methodology, Medical University of Warsaw, Warsaw, POLAND, ³Department of Neurosurgery, Medical University of Warsaw, Warsaw, POLAND, ⁴Department of Pathology, Medical University of Warsaw, Warsaw, POLAND.

OP-588

Tumoral TSP0-radioligand uptake on PET prior to radiotherapy is associated with overall survival in glioblastoma patients

A. Holzgreve¹, D. V. Nelwan¹, D. F. Fleischmann², S. Quach³, K. von Rohr¹, L. Kaiser¹, N. Teske³, L. M. Unterrainer¹, L. M. Bartos¹, V. C. Ruff¹, M. Brendel¹, M. J. Riemenschneider⁵, C. Wetzel⁶, J. Herms⁷, R. Rupprecht⁸, N. Thon³, J. Tonn³, C. Belka², P. Bartenstein¹, L. von Baumgarten³, M. Niyazi², M. Unterrainer¹, N. L. Albert¹;

¹Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, ²Department of Radiation Oncology, University Hospital, LMU Munich, Munich, GERMANY, ³Department of Neurosurgery, University Hospital, LMU Munich, Munich, GERMANY, ⁴Center for Neuropathology and Prion Research, LMU Munich, Munich, GERMANY, ⁵Department of Neuropathology, Regensburg University Hospital, Regensburg, GERMANY, ⁶Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, GERMANY.

OP-589

Imaging PD-L1 in the brain - journey from the lab to the clinic

G. Kramer-Marek^{1,2}, D. Dar¹, M. Rodak², C. Da Pieve¹, M. Niedbala³, G. Sharma¹, I. Gorczewska², P. Bzowski², A. d'Amico², E. Chmielik², B. Bobek-Bilewicz², E. Nowicka², R. Tarnawski², W. Kaspera³;

¹The Institute of Cancer Research, London, UNITED KINGDOM, ²Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, POLAND, ³Medical University of Silesia, Katowice, POLAND.

OP-590

Profiling Functional Clusters of Short Chain Fatty Acids Metabolism in Primary Brain Gliomas for Phenotype Prediction

M. Inglese^{1,2}, T. Boccatto¹, M. Ferrante¹, S. Islam², M. Williams², A. D. Waldman³, K. O'Neill⁴, E. O. Aboagye², N. Toschi^{1,5};

¹University of Rome "Tor Vergata", Rome, ITALY, ²Imperial College London, London, UNITED KINGDOM, ³University of Edinburgh, Edinburgh, UNITED KINGDOM, ⁴Imperial College Healthcare NHS Trust, London, UNITED KINGDOM, ⁵Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA, UNITED STATES OF AMERICA.

1208

Tuesday, September 12, 2023, 08:00 - 09:30

Hall F2

Joint Symposium 4 - Dosimetry Committee / ESTRO: Dosimetry in Different Modalities - Where We Are and Where We Want To Be

OP-591

Dosimetry for EBRT and Brachytherapy

E. Gershkevitch;
North Estonia Medical Centre, Tallinn, ESTONIA.

OP-592

Dosimetry for Selective Internal Radiotherapy

C. Hindorf;
Karolinska University Hospital, Solna, SWEDEN.

OP-593

Dosimetry for Molecular Radiotherapy

J. Gear;
Royal Marsden NHSFT and Institute of Cancer Research, Joint Department of Physics, Sutton, UNITED KINGDOM.

OP-594

Comparisons and future perspectives

M. Cremonesi;
Istituto Europeo Di Oncologia, Department of Medical Imaging and Radiation Sciences, Milan, ITALY.

1209

Tuesday, September 12, 2023, 8:00 AM - 9:30 AM
Hall G2

e-Poster Presentations Session 9 - Physics Committee: Artificial Intelligence and Radiomics

EPS-168

Development of deep learning model for generalized utilization to restore short-scanning PET images using three radiopharmaceuticals

Y. Jeong¹, S. Cheon¹, H. Park², K. Jeon²;
¹Dong-A University Hospital, Busan, KOREA, REPUBLIC OF,
²National Institute for Mathematical Science, Daejeon, KOREA, REPUBLIC OF.

EPS-169

Deep-learning based classification of dual-phase 18F-FP-CIT PET images for the diagnosis of Parkinsonism

D. Kim¹, K. Choo¹, D. Kim², H. Lim², M. Yun²;
¹Yonsei University, Seoul, KOREA, REPUBLIC OF, ²Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EPS-170

Feasibility of transfer learning in decoding hibernating myocardium from rest myocardial perfusion images

B. Khangembam, J. Jaleel, A. Roy, P. Gupta, C. Patel;
All India Institute of Medical Sciences, New Delhi, INDIA.

EPS-171

Synthetic Attenuation Correction Maps for SPECT Imaging using Deep Learning: A Study on Myocardial Perfusion Imaging

M. Namias¹, M. A. Prieto Canalejo², A. Palau San Pedro¹, R. Geronazzo¹, D. M. Minsky³, L. E. Juarez Orozco⁴;
¹Fundación Centro Diagnóstico Nuclear, Buenos Aires, ARGENTINA, ²Universidad Tecnológica Nacional, Facultad Regional Buenos Aires, Buenos Aires, ARGENTINA, ³Comisión Nacional de Energía Atómica, San Martín, ARGENTINA, ⁴University Medical Center Utrecht, Utrecht, NETHERLANDS.

EPS-172

Human vs Machine: Comparison of manual and deep learning semantic segmentation algorithm generated tumour volumes on [177Lu]Lu-PSMA-617 post therapy SPECT/CT images

R. Karri, P. Jackson, L. McInosh, J. P. Buteau, G. Kong, T. Akhurst, A. S. Ravi Kumar, D. G. Murphy, S. Sandhu, M. S. Hofman;
Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

EPS-173

Primary tumour type impacts 3D U-Net for [18F]FDG PET lesion segmentation performance in cases of lung cancer, melanoma, and lymphoma

M. Sobral^{1,2}, M. Oliveira^{1,3}, C. Constantino¹, F. Oliveira¹, N. Matela⁴, D. C Costa¹;
¹Champalimaud Foundation, Lisboa, PORTUGAL, ²Departamento de Física, Faculdade de Ciências, Universidade de Lisboa, Lisboa, PORTUGAL, ³Escola Superior de Biotecnologia, Universidade Católica Portuguesa, Porto, PORTUGAL, ⁴Instituto de Biofísica e Engenharia Biomédica, Faculdade de Ciências, Universidade de Lisboa, Lisboa, PORTUGAL.

EPS-174

A systemic analysis of [18F]FDG PET/CT data for early detection of cachexia in lung cancer patients

D. Ferrara¹, A. Frille², E. Abenavoli³, T. Beyer¹, S. Duke⁴, S. Gruenert⁵, M. Hacker⁶, S. Hesse², L. Hofmann², S. Holm⁴, M. Rullmann², R. Sciagrà³, L. Shiyam Sundar¹, A. Tönjes², H. Wirtz², J. Yu^{1,5}, O. Sabri²;
¹QIMP Team, Medical University of Vienna, Vienna, AUSTRIA, ²University Hospital of Leipzig, Leipzig, GERMANY, ³Division of Nuclear Medicine, Azienda Ospedaliero Universitaria Careggi, Florence, ITALY, ⁴University of Copenhagen, Copenhagen, DENMARK, ⁵Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA.

EPS-175

Comparison of a deep learning model to denoise low dose 18F-FDG PET images trained using synthetic image versus acquired low dose images

L. Sibille, R. Chamberlain;
Subtle Medical, Menlo Park, CA, UNITED STATES OF AMERICA.

EPS-176

Multi-tracer Deep Learning-based Time-of-Flight (DL-ToF) Image Enhancement of non-TOF PET Scans

A. Mehranian¹, S. Wollenweber², K. Bradley³, M. Walker⁴, K. Su², R. Johnsen², F. Jansen², D. McGowan^{4,5};
¹GE HealthCare, Oxford, UNITED KINGDOM, ²GE HealthCare, Waukesha, WI, UNITED STATES OF AMERICA, ³Wales Research and Diagnostic PET Imaging Centre, University Hospital of Wales, Cardiff, UNITED KINGDOM, ⁴Oxford University Hospitals NHS FT, Oxford, UNITED KINGDOM, ⁵Department of Oncology, University of Oxford, Oxford, UNITED KINGDOM.

EPS-177

Deep learning based missing data retrieval of small animal PET using a conditional GAN (Pix2Pix)

Z. Karimi¹, A. Ghafari², M. Farahani², P. Sheikhzadeh³, M. Ay²;
¹Faculty of Physics, University of Isfahan, Isfahan, IRAN, ISLAMIC REPUBLIC OF, ²Research Center for Molecular and Cellular Imaging (RCMCI), Advanced Medical Technologies and Equipment Institute (AMTEI), Tehran University of Medical Sciences (TUMS), Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EPS-178

Enhanced characterization of functionally significant coronary lesions using machine learning techniques with radiomics-based analysis

G. Kalykakis^{1,2}, F. V. Driest³, A. Broersen⁴, D. Terentes-Printzios⁵, A. Antonopoulos⁵, N. Anousakis Vlachichristou¹, R. Liga⁶, D. Visvikis⁷, A. Scholte⁸, J. Knuuti⁹, D. Neglia¹⁰, C. D. Anagnostopoulos¹;
¹Biomedical Research Foundation Academy of Athens, Athens, GREECE, ²Ionio University, Corfu, GREECE, ³Leiden University Medical Center, Department of Cardiology, Leiden, NETHERLANDS, ⁴University Medical Center, Division of Image Processing, Leiden, NETHERLANDS, ⁵Hippocraton General Hospital of Athens, Athens, GREECE, ⁶University of Pisa, Pisa, ITALY, ⁷University of Bretagne Occidentale, Brest, FRANCE, ⁸Leiden University Medical Center, Leiden, NETHERLANDS, ⁹Turku University Hospital, Turku, FINLAND, ¹⁰Institute of Clinical Physiology, Pisa, ITALY.

EPS-179

Volume dependence and repeatability of ^{99m}Tc SPECT radiomic parameters

A. Gemmell^{1,2,3}, C. Brown^{1,2}, S. Ray³, S. Small^{1,2};
¹Nuclear Medicine, Gartnavel General Hospital, Glasgow, UNITED KINGDOM, ²Department of Clinical Physics & Bioengineering, Glasgow, UNITED KINGDOM, ³School of Mathematics & Statistics, University of Glasgow, Glasgow, UNITED KINGDOM.

EPS-180

The biological counterpart of radiomics in pancreatic cancer: a preliminary simulation study

L. Cavinato¹, J. Hong², S. Reinhard², M. Wartenberg², F. Ieva^{1,3}, K. Shi²;
¹Politecnico di Milano, Milano, ITALY, ²University of Bern, Bern, SWITZERLAND, ³Human Technopole, Milan, ITALY.

EPS-181

A machine learning approach based on rest myocardial perfusion image radiomics to detect the presence of hibernating myocardium: a single institutional experience on 239 patients with 371 perfusion defects

C. Patel, B. Khangembam, J. Jaleel, A. Roy, P. Gupta;
All India Institute of Medical Sciences, New Delhi, INDIA.

EPS-182

Clinical Evaluation of ¹⁸F-FDG PET Radiomics Stability to Respiratory Motion Using a Data-Driven Respiratory Gating Algorithm

K. Lue¹, K. Kan^{2,3}, Y. Chen^{2,4}, S. Liu^{1,2}, I. Shih⁵, H. Lin^{6,7};
¹Tzu Chi University of Science and Technology, Hualien, TAIWAN, ²Hualien Tzu Chi Hospital, Hualien, TAIWAN, ³Fu Jen Catholic University Hospital, New Taipei City, TAIWAN, ⁴Tzu Chi University, Hualien, TAIWAN, ⁵GE HealthCare, Taipei, TAIWAN, ⁶Chang Gung University, Taoyuan, TAIWAN, ⁷Keelung Chang Gung Memorial Hospital, Keelung, TAIWAN.

EPS-183

Does fdg pet-based radiomics have an added value for prediction of overall survival in non-small cell lung cancer?

G. Giovacchini¹, E. Giovannini¹, F. Tutino¹, A. Milano¹, L. Florimonte², E. Bonatto³, C. Bareggi², L. Dellavedova⁴, A. Castello⁵, C. Aschele¹, M. Castellani², A. Ciarmiello¹;
¹S. Andrea Hospital, La Spezia, ITALY, ²Fondazione IRCCS Ca' Granda, Milano, ITALY, ³University of Milan, Milano, ITALY, ⁴ASST Ovest Milanese, Legnano, ITALY, ⁵IRCCS Ca' Granda, Milano, ITALY.

EPS-184

Improving Outcome Prediction in Multicentric Data: Novel harmonization and clustering Techniques for Radiomic Feature Analysis

N. Abdallah¹, J. Marion², C. Tauber¹, T. Carlier³, P. Chauvet², M. Hatt⁴;
¹Imaging & Brain, INSERM, Tours, FRANCE, ²LARIS, Angers, FRANCE, ³CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, FRANCE, ⁴LaTIM, INSERM, Brest, FRANCE.

EPS-185

[18F]FDG-PET/CT Tumor Spread and Dissemination Measured from the Spleen in Lymphoma: How Predictive of the Outcome?

K. Girum¹, A. Cottureau², J. Clerc², L. Vercellino³, O. Casanovas⁴, F. Morschhauser⁵, C. Thieblemont⁶, I. Buvat¹;
¹LITO laboratory, U1288 Inserm, Institut Curie, University Paris-Saclay, Orsay, FRANCE, ²Department of Nuclear Medicine, Cochin Hospital, AP-HP, Paris Descartes University, Paris, FRANCE, ³Department of Nuclear Medicine, Saint-Louis Hospital, AP-HP, Paris, FRANCE, ⁴Department of Hematology, University Hospital of Dijon, Dijon, FRANCE, ⁵Department of Hematology, Claude Huriez hospital, University Lille, EA 7365, Research Group on Injectable Forms and Associated Technologies, Lille, FRANCE, ⁶Department of Hematology, Saint Louis Hospital, AP-HP, Paris, FRANCE.

EPS-187

Quantitative Analysis of Dual Time Point in FDG PET/CT images

N. Reshtebari¹, S. Hosseini¹, A. Rahmim², p. Sheikhzadeh³;
¹Sharif University of Technology, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²University of British Columbia, Vancouver, BC, CANADA, ³Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EPS-188

Predicting overall survival in non-Hodgkin lymphoma patients using baseline ¹⁸F-FDG PET radiomic features

T. Husevåg, A. M. Løndalen, J. Blakkisrud, C. Stokke;
Oslo University Hospital, Oslo, NORWAY.

1210

Tuesday, September 12, 2023, 08:00 - 09:30
Hall K

CTE 6 - Technologists Committee: Extravasation Incidents Management

OP-595

Extravasation incidents – theoretical principles and examples in Conventional Nuclear Medicine

M. Cruz;
Centro Hospitalar de Lisboa Ocidental, EPE - Hospital de Santa Cruz, Nuclear Medicine, Carnaxide, PORTUGAL.

OP-596

Extravasation incidents with PET agents and contrast media

J. Elliott;
Canterbury Christ Church University, School of Allied and Public Health Professions (Diagnostic Radiography), Canterbury, UNITED KINGDOM.

OP-597

Extravasation in radionuclide therapy – a step by step guide

N. Ahmadi Bidakhvidi;
UZ Leuven, Nuclear Medicine and Molecular Imaging, Leuven, BELGIUM.

1211

Tuesday, September 12, 2023, 08:00 - 09:30
Hall G1

Special Symposium 4 - Lung scintigraphy for pulmonary embolism diagnosis and long term management

OP-598

Clinical challenge of acute pulmonary embolism diagnosis

H. Robert-Ebadi;

Division of angiology and hemostasis, Geneva, SWITZERLAND.

OP-599

Clinical challenge of long-term management after an acute pulmonary embolism

G. Le Gal;

University of Ottawa, Department of Medicine, Ottawa, CANADA.

OP-600

Role and interpretation of lung scintigraphy for the diagnosis and follow up of pulmonary embolism

P. Le Roux;

University Hospital of Brest, Department of Nuclear Medicine - UMR U1304 -GETBO, Brest, FRANCE.

1301

Tuesday, September 12, 2023, 09:45 - 11:15
Hall A

CME 10 - Radiation Protection + Paediatrics Committee + Women's Empowerment Task Force: Radiation Protection in Motherhood and Childhood - What is so Special?

OP-602

Radiobiological aspects to consider during pregnancy, neonates and small children

U. Eberlein;

University of Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY.

OP-603

Dilemmas of the pregnant or breastfeeding radiation worker, patient and carer

S. Leide-Svegborn;

Department of Radiation Physic, Skåne University Hospital Malmö, Lund University, Lund, SWEDEN.

OP-604a

Common diseases during childhood and the role of Nuclear Medicine

P. Zucchetta;

University of Padua, Nuclear Medicine Unit, Padua, ITALY.

OP-604b

Family management in therapeutics and diagnostics of children

L. Cunha;

IsoPor-Azores, Department of Nuclear Medicine and Molecular Imaging, Azores, PORTUGAL.

1302

Tuesday, September 12, 2023, 09:45 - 11:15
Hall D (Arena)

Debate 4 - Physics + Oncology & Theranostics Committee: Whole Body Parametric Imaging

OP-605

Whole-body parametric imaging is ready for clinic

A. Tavares;

University/BHF Centre for Cardiovascular Science, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, UNITED KINGDOM.

OP-606

Whole-body parametric imaging is not ready for clinic

D. Visvikis;

National Institute of Health and Medical Research (INSERM), Medical Image Processing Lab, Brest, FRANCE.

1303

Tuesday, September 12, 2023, 09:45 - 11:15
Hall E1

LIPS Session 10 - Neuroimaging Committee: The Sunrise of Alpha-Synuclein in vivo Brain Imaging

OP-611

The Need of an Alpha-Synuclein Biomarker

R. Smith;

Lund University, Memory Clinic at Skåne University Hospital, Lund, SWEDEN.

OP-612

Alpha-Synuclein in Parkinson's Disease

D. Van Weehaeghe;

UZ Gent, Gent BELGIUM.

OP-613a

Alpha-Synuclein in Lewy Body Dementia

N. Tolboom;

University Medical Centre Utrecht, Department of Radiology, Utrecht, NETHERLANDS.

OP-613b

Alpha-Synuclein in Multi System Atrophy

H. Barthel;

Leipzig University Medical Centre, Department of Nuclear Medicine, Leipzig, GERMANY.

1304

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM
Hall E2

M2M Track - TROP Session: Emerging Theranostic Concepts

OP-614

Radio-theragnostics targeting CXCR4 based on the endogenous ligand EPI-X4 for oncological applications

R. Gaonkar¹, J. Millul¹, R. Mansi¹, M. Harms², J. Münch², M. Fani¹;

¹University Hospital Basel, Basel, SWITZERLAND, ²Institute of Molecular Virology, Ulm University Medical Center, Ulm, GERMANY.

OP-615

Next Generation Theranostics Based on the Tetratine Ligation

U. Battisti^{1,2}, V. Shalgunov¹, C. B. M. Poulie¹, L. Hvass³, M. Müller², A. S. Clausen³, E. Hansson⁴, E. H. K. Aneheim⁵, M. El Fakiri⁶, M. Eder⁶, S. Lindegren⁵, A. Kjaer³, H. J. Jensen⁷, A. T. I. Jensen¹, M. M. Herth^{1,2};

¹Tetrakit Technologies, Copenhagen, DENMARK, ²Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DENMARK, ³Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, DENMARK, ⁴Atley solution, Gothenburg, SWEDEN, ⁵Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, ⁶Faculty of Medicine, Albert-Ludwigs-Universität Freiburg, Freiburg, GERMANY, ⁷PET and Cyclotron Unit, Copenhagen University Hospital, Copenhagen, DENMARK.

OP-616

CD83 as a Theranostic Target for Acute Myeloid Leukemia

K. Ott¹, A. J. Robertson¹, J. P. Gallant¹, K. K. Walton², B. C. Betts², A. M. LeBeau¹;

¹The University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA, ²The University of Minnesota, Minneapolis, MN, UNITED STATES OF AMERICA.

OP-617

Development of [¹⁸F]F-[^{nat}Lu]Lu-/[¹⁹F]F-[¹⁷⁷Lu]Lu-DOTA-rhCCK-84, a Radiohybrid-Based Minigastrin Analogue With High Tumour and low Kidney Accumulation: A Viable Clinical Option for Imaging and Radioligand Therapy of Medullary Thyroid Carcinoma?

T. Günther¹, N. Holzleitner¹, I. Maniyankerikalam¹, L. Greifenstein², R. Beck¹, D. Di Carlo¹, R. P. Baum², H. Wester¹;

¹Technical University of Munich, Garching, GERMANY, ²CURANOSTICUM Wiesbaden-Frankfurt, Wiesbaden, GERMANY.

OP-618

Construction and preclinical evaluation of a ¹²⁴I/¹²⁵I-labeled specific antibody targeting CD147 in pan-cancer

X. Ma, T. Liu, H. Zhu, Z. Yang;

Peking University Cancer Hospital, Beijing, CHINA.

OP-619

CD47-targeted nanobody theranostics

W. Wei;

Shanghai Jiao Tong University, Shanghai, CHINA.

OP-620

Preclinical Evaluation of [¹⁸F]F-[^{nat}Lu]Lu-/[¹⁹F]F-[¹⁷⁷Lu]Lu DOTA-rhCCK-18, a Radiohybrid-Based Minigastrin Analog With High Target Affinity and Tumor Accumulation: First Steps Towards Clinical Translation

N. Holzleitner¹, T. Günther¹, L. Greifenstein², N. Urtz-Urban¹, D. Di Carlo¹, C. Lapa³, R. Baum², H. Wester¹;

¹Technical University Munich, Munich, GERMANY,

²Center for Advanced Radiomolecular Precision

Oncology, Wiesbaden, GERMANY, ³University of Augsburg, Augsburg, GERMANY.

OP-621

In vitro and in vivo evaluation of BCY18469, a novel EphA2-targeting Bicycle® for radiotheranostic applications

M. El Fakiri^{1,2,3}, G. E. Mudd⁴, J. Mitschke^{5,1}, P. Huxley⁴, K. McDonnell⁴, A. R. Regupathy⁴, N. Klemm⁵, L. Domogalla^{2,1}, A. C. Eder^{1,2}, T. Reinhecker^{5,1}, M. Eder^{1,2};

¹German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ), Freiburg, GERMANY, ²Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY, ³Faculty of Biology, University of Freiburg, Freiburg, GERMANY, ⁴BicycleTx Limited, Cambridge, UNITED KINGDOM, ⁵Institute of Molecular Medicine and Cell Research, University of Freiburg, Freiburg, GERMANY.

OP-622

Theranostic role of ⁸⁹Zr/¹⁷⁷Lu-labeled aflibercept in triple-negative breast cancer

L. Kang, Q. Yang, Z. Chen, Y. Qiu, W. Huang, L. Song;

Peking University First Hospital, Beijing, CHINA.

1305

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM
Hall B

Cutting Edge Science Track - TROP Session: Quantitative SPECT/CT Imaging

OP-623

Comparison of lesion detectability in Whole-Body Bone Scan images: A Monte Carlo study of CdZnTe- and NaI(Tl)-based Gamma Cameras

R. Madru¹, N. Karindotter-Borgendah², M. Dahlbeck², M. Ljungberg³;

¹Skane University Hospital, Lund, SWEDEN,

²Skane Sjukhus Nordost, Kristianstad, SWEDEN,

³Lund University, Lund, SWEDEN.

OP-624

CZT swiveling-detectors ring SPECT enables 3D dynamic acquisitions

M. Hesse, F. Dupont, R. Lhommel;

Cliniques Universitaires Saint-Luc, Brussels, BELGIUM.

OP-625

SPECT image reconstruction from sparse projection data using deep learning model trained by randomly generated training phantom

R. Yano¹, Y. Okura², M. Yamamoto²;

¹Graduate School of Medical Technology and Health Welfare Sciences, Hiroshima International University, Higashihiroshima, JAPAN, ²Department of Clinical Radiology Faculty of Health Sciences, Hiroshima International University, Higashihiroshima, JAPAN.

OP-626

Assessing the Efficacy of the Relative Difference Prior for SPECT Dosimetry

L. Polson¹;

University of British Columbia, Vancouver, BC, CANADA.

OP-627

Head-to-head comparison of SPECT and MRI based holmium-166 dosimetry

L. E. L. Westlund Gotby¹, Y. X. Mak², N. J. M. Klaassen¹, J. Roosen¹, M. W. M. van Wijk¹, M. W. Konijnenberg^{1,3}, M. Abayazid², J. F. W. Nijssen¹;

¹Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS, ²Robotics and Mechatronics, University of Twente, Enschede, NETHERLANDS, ³Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, NETHERLANDS.

OP-628

Holmium-166 SPECT/CT imaging for dosimetry: a multi-center optimization study in the Netherlands

L. E. L. Westlund Gotby¹, M. Stella², C. D. E. van Speybroeck¹, D. Lobeek¹, D. M. V. de Vries-Huizing³, B. J. de Wit-van de Veen³, E. J. Rijkhorst⁴, R. Wiert⁵, M. K. Stam⁶, F. H. P. van Velden⁶, P. Dibbets-Schneider⁶, R. van Rooij²;

¹Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS, ²Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, NETHERLANDS, ³Department of Nuclear Medicine, NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS, ⁴Department of Medical Physics and Technology, NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS, ⁵Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, NETHERLANDS, ⁶Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS.

OP-629

Quantitative ¹⁷⁷Lu SPECT/CT imaging with a ring-shaped CZT-based camera: 208 vs 113 keV photopeak

R. Danielli¹, M. Stella², C. Marin¹, J. Tran Gia³, J. Leube³, C. Uribe-Munoz¹, M. Hesse⁵, H. Levillain¹, B. Vanderlinden¹, N. Reynaert¹, P. Flamen¹;

¹Institut Jules Bordet, Bruxelles, BELGIUM, ²GE HealthCare, Diegem, BELGIUM, ³University Hospital Würzburg, Würzburg, GERMANY, ⁴University of British Columbia, Vancouver, BC, CANADA, ⁵Cliniques Universitaires Saint-Luc, Bruxelles, BELGIUM.

OP-630

Hyperthyroidism Etiological Diagnosis: a Multilabel Classification using Convolutional Neural Networks on Thyroid Scans

M. Abdi¹, Q. Naili¹, M. Habbeche¹, M. Bourouba², S. Berrani³;

¹Centre d'imagerie scintigraphique Blida, Blida, ALGERIA, ²Clinique Fatema Al Azhar, Alger, ALGERIA, ³National Polytechnic School of Algiers (Ecole Nationale Polytechnique), Algiers, ALGERIA.

OP-631

Fundamental study on brain SPECT denoising using deep image prior

T. Zeniya¹, A. Yabe¹, Y. Aita¹, K. Matsubara², K. Koshino³, H. Watabe⁴, T. Yuasa⁵;

¹Hirosaki University, Hirosaki, JAPAN, ²Akita Prefectural University, Yurihonjo, JAPAN, ³Hokkaido Information University, Ebetsu, JAPAN, ⁴Tohoku University, Sendai, JAPAN, ⁵Yamagata University, Yonezawa, JAPAN.

1306

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM

Hall C

Clinical Oncology Track - TROP Session: Lung

OP-632

Residual total metabolic tumor volume, assessed on post-therapeutic 18F-FDG PET/CT, is a game-changer in the early monitoring of patients with metastatic non-small cell lung cancer treated with immunotherapy.

P. Tricarico¹;

Centre Antoine Lacassagne, Nice, FRANCE.

OP-633

Predictive value of primary tumor metabolic heterogeneity of ¹⁸F-FDG PET/CT for lung cancer progression

X. Li^{1,2}, M. Hou³, X. Wang^{1,2}, C. Cui^{1,2}, Z. Wu^{1,2};

¹Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, CHINA, ²Collaborative Innovation Center for Molecular Imaging of Precision Medicine Shanxi Medical University, Taiyuan, Shanxi, CHINA, ³Department of Respiratory, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, CHINA.

OP-634

Prognostic role of pre-operative 18F-FDG PET/CT in surgically treated patients with early-stage non-small-cell lung cancer

S. Taralli¹, F. Vocaturo^{1,2}, E. Perrone^{1,2}, P. C. Pafundi³, S. Ricciardi⁴, G. Cardillo⁴, M. L. Calcagni^{1,2};

¹Nuclear Medicine Unit, Diagnostic Imaging, Radiation Oncology and Hematology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, ²Nuclear Medicine Institute, University Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore, Rome, ITALY, ³Epidemiology and Biostatistics Research Core Facility, GEMELLI GENERATOR, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, ⁴Thoracic Surgery Unit, San Camillo Forlanini Hospital, Rome, ITALY.

OP-635

The variability and diagnostic value of respiratory-gated 4D PET/CT based radiomics features in lung lesions compared to ungated PET/CT

S. Huang¹, C. Cao², L. Guo¹, C. Li¹, W. Mu^{2,3}, Y. Liang^{1,4};

¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, CHINA, ²School of Engineering Medicine, Beihang University, Beijing, CHINA, ³Key Laboratory of Big Data-Based Precision Medicine, Ministry of Industry and Information Technology of the People's Republic of China, Beijing, CHINA, ⁴National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA.

OP-636

Improved imaging of small lung nodules using LAFOV [¹⁸F]FDG-PET and data-driven motion compensation method

C. Bregenzer¹, C. Mingels¹, M. Viscione¹, H. Sari^{1,2}, K. Shi¹, A. Rominger¹, T. Pyka¹;

¹Department of Nuclear Medicine, Inselspital, University Hospital Bern, University of Bern, Bern, SWITZERLAND, ²Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, SWITZERLAND.

OP-637

Predicting survival of metastatic non-small cell lung cancer (NSCLC) patients treated by anti-PD-1 by combining clinical and radiomic features

J. Auriac¹, N. Captier¹, E. Woff^{1,2}, M. Luporsi^{1,3}, C. Nioche¹, N. Girard⁴, I. Buvat¹, F. Orhac¹;

¹Institut Curie, Inserm, Université Paris-Saclay, U1288-LITO, Orsay, FRANCE, ²Université libre de Bruxelles, Jules Bordet Institut, Department of Nuclear Medicine, Bruxelles, BELGIUM, ³Institut Curie, Department of Nuclear Medicine, Paris, FRANCE, ⁴Institut du Thorax Curie-Montsouris, Paris, FRANCE.

OP-638

Variables Derived From 18F-FDG PET/CT In Predicting Patterns Of Recurrence In Patients With Non-Small Cell Lung Cancer (Stage I-III)

G. Jimenez Londoño¹, A. M. Garcia Vicente², J. J. Bosque³, J. Perez-Beteta³, M. Amo-Salas⁴, A. F. Honguero-Martinez⁵, E. Noriega Alvarez¹, C. Lucas Lucas¹, V. M. Perez-Garcia³, A. M. Soriano Castrejon²;

¹Department of Nuclear Medicine, Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN, ²Department of Nuclear Medicine, Complejo Hospitalario Universitario de Toledo, Toledo, SPAIN, ³Department of Mathematics, Mathematical Oncology Laboratory (MOLAB), Universidad de Castilla-La Mancha, Ciudad Real, SPAIN, ⁴Department of Mathematics, Universidad de Castilla-La Mancha, Ciudad Real, SPAIN, ⁵Department of Surgery, Hospital General Universitario de Albacete, Albacete, SPAIN.

OP-639

18F-FDG PET/CT and Coefficient of Variation of Primary Tumors and Metastatic Lymph Nodes To Assess the Heterogeneity of Glycolytic Phenotype in Patients With Advanced NSCLC

S. Pellegrino¹, R. Fonti¹, C. Vallone¹, A. Catapano¹, R. Morra², S. De Placido², S. Del Vecchio¹;

¹Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, ²Department of Clinical Medicine and Surgery, University Federico II, Naples, ITALY.

OP-640

Use of 18F-FDG PET Imaging after Curative Treatment of Non-Small Cell Lung Cancer Patients: A Nationwide Cohort Study

K. Guldbrandsen¹, L. Sopina², T. R. Rasmussen³, B. M. Fischer¹;

¹Dept. of Clinical Physiology, Nuclear Medicine & PET, Copenhagen University Hospital, Rigshospitalet, Copenhagen, DENMARK, ²Danish Centre for Health Economics, DaCHE, Dept. of Public Health, University of Southern Denmark, Odense, DENMARK, ³Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, DENMARK.

1307

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM

Hall F1

Cardiovascular Committee - TROP Session: Plaque, Fibrosis and Cardio-Oncology

OP-641

Value of Na[¹⁸F]F and 2-[¹⁸F]FDG PET/CT imaging in early stages of aortic valve degeneration assessment after transcatheter aortic valve (TAVI) implantation

M. Opalinska¹, D. Sorysz², A. Sowa-Staszczak¹, A. Grochowska³, A. Dziewierz², K. Malinowski⁴, N. Maruszak², M. Bagieński⁵, S. Bartus², D. Dudek⁶;

¹Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND, ²2nd Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, POLAND, ³Department of Radiology, University Hospital, Krakow, POLAND, ⁴Department of Bioinformatics and Telemedicine, Jagiellonian University Medical College, Krakow, POLAND, ⁵Intensive Cardiac Care Unit, University Hospital, Krakow, POLAND, ⁶Center for Digital Medicine and Robotics, Jagiellonian University Medical College, Krakow, POLAND.

OP-642

The relationship between arterial calcification and hypoxia of the arterial wall detected by [¹⁸F]F-Fluoromisonidazole Positron Emission Tomography

J. Bellinge^{1,2}, I. Barry³, R. Francis^{1,2}, F. Picazo-Pineda³, N. Altaf³, C. Schultz³;

¹University of Western Australia, Perth, AUSTRALIA, ²Sir Charles Gairdner Hospital, Perth, AUSTRALIA, ³Royal Perth Hospital, Perth, AUSTRALIA.

OP-643

Morphological and component features of advanced carotid plaque on MRI in correlation with inflammation on PET: a hybrid ¹⁸F-FDG PET/MRI study

F. Yu, Y. Zhang, J. Lu;

Xuanwu Hospital, Capital Medical University, Beijing, CHINA.

OP-644

Comparison between Cardiac ¹⁸F-FAPI PET/CT and MRI for Assessment of Myocardial Fibrosis in Hypertrophic Cardiomyopathy
L. Wang¹, Y. Wang², Y. Zhang¹, Z. Dong³, J. Wang³, X. Xi¹, B. Chen¹, S. Zhao³, M. Yang¹;
¹Beijing Chaoyang Hospital, Beijing, CHINA,
²Beijing Tsinghua Changgung Hospital, Beijing, CHINA, ³Fuwai Hospital, Beijing, CHINA.

OP-645

Coronary microvascular dysfunction: main characteristics and prognostic value
K. Kopeva, E. Grakova, A. Maltseva, A. Mochula, A. Gusakova, A. Smorgon, K. Zavadovsky;
Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.

OP-646

Comparative analysis of multi-modality cardiac imaging for prediction of cardiovascular outcomes in patients undergoing coronary artery bypass grafting
M. Gao¹, W. Wen², J. Meng², M. Yun², H. Li¹, Y. Yu¹, X. Zhang²;
¹Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA, ²Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA.

OP-647

Coronary artery calcium score and epicardial adipose tissue from unenhanced whole-body PET-CT imaging in oncological patients with and without standard modifiable cardiovascular risk factors
C. Vallone¹, C. Nappi¹, R. Lepre¹, L. Basile¹, A. Ponsiglione¹, C. Ferraioli¹, R. Green¹, V. Cantoni¹, C. Mainolfi¹, M. Imbriaco¹, M. Petretta², A. Cuocolo¹;
¹Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY, ²IRCCS Synlab SDN, Naples, ITALY.

OP-648

Immune checkpoint inhibitor treatment may induce abated reactive arterial inflammation in lung cancer patients with history of systemic therapy: trained immunity before immunotherapy?
R. Calabretta, L. Beer, H. Prosch, D. Kifjak, P. Binder, S. Grünert, W. Langsteiger, M. Mitterhauser, X. Li, M. Hacker;
Medical University of Vienna, Vienna, AUSTRIA.

OP-649

Leg-muscle perfusion preserve on ^{99m}Tc-MIBI stress-rest scintigraphy : the novel use of radionuclide imaging in peripheral arterial disease
G. Parida, T. Singhal, P. Singh, P. Kumar, R. Emerson, K. Bishnoi, A. Rehaman, S. Patro, K. Agrawal;
All India Institute Of Medical Sciences, Bhubaneswar, INDIA.

1308

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM
Hall F2

Thyroid Committee - TROP Session: ¹⁸F-FDG and Novel Tracers in the Diagnostic Management of Patients with Thyroid Cancers

OP-650

Investigating the role of F18-FDG PET/CT and Ga68 DOTATOC PET/CT in the evaluation of differentiated thyroid cancer patients with increased serum thyroglobulin and negative I-131 whole body scan
A. Aghaee, K. Aryana, M. Esmatinia, V. Roshan Ravan;
Nuclear Medicine Research Center, Mashhad University Of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

OP-651

Exploring the role of new angiogenic tracer, ⁶⁸Ga DOTAGA- IAC and comparison of its diagnostic performance with ¹⁸F-FDG PET/CT in patients with radioiodine refractory differentiated thyroid carcinoma
S. Ananth Kumar, A. Sood, J. Shukla, R. Kumar, P. Aggarwal, B. Rai Mittal;
Postgraduate Institute Of Medical Education and Research, Chandigarh, Chandigarh, INDIA.

OP-652

Lactate dehydrogenase A is associated with glucose metabolism, radioiodine avidity and prognosis in differentiated thyroid cancer
T. Tian, H. Dai, R. Huang;
West China Hospital, Sichuan University, Chengdu, CHINA.

OP-653

The Complementary Role of PSMA Expression and [¹⁸F]FDG PET/CT in Predicting Thyroid Cancer Outcome — from Black and White to Shades of Grey, in the Era of Precision Oncology
C. Pini¹, M. Sollini^{2,3}, M. Kirienco⁴, L. Di Tommaso^{2,5}, F. Gelardi^{2,3}, S. Ariano^{2,6}, C. Landoni^{1,7}, A. G. Lania^{2,6}, G. Mazziotti^{2,6}, G. Mercante^{2,8}, A. Chiti^{2,3};
¹School of Medicine and Surgery, University of Milano-Bicocca, Monza, ITALY, ²Department of Biomedical Sciences - Humanitas University, Pieve Emanuele, ITALY, ³Nuclear Medicine – IRCCS Humanitas Research Hospital, Rozzano, ITALY, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, ITALY, ⁵Pathology - IRCCS Humanitas Research Hospital, Rozzano, ITALY, ⁶Endocrinology - IRCCS Humanitas Research Hospital, Rozzano, ITALY, ⁷Nuclear Medicine Department, IRCCS Monza, San Gerardo Hospital, Monza, ITALY, ⁸Otorhinolaryngology, IRCCS Humanitas Research Hospital, Rozzano, ITALY.

OP-654

Prospective study on the usefulness of 18FDOPA PET-CT in the management of medullary thyroid cancer patients with high residual calcitonin rate after surgery
M. Terroir Cassou Mounat¹, A. Lusque¹, E. Hindié², D. Taieb³, L. Vija¹, J. Sarini¹, F. Courbon¹, A. Decotte⁴, S. Grunenwald⁵, S. Zerdoud¹;
¹IUCT Oncopole, toulouse, FRANCE, ²University Hospital of Bordeaux, Bordeaux, FRANCE, ³La Timone University Hospital, Marseille, FRANCE, ⁴University Hospital Rangueil-Larrey, toulouse, FRANCE, ⁵Centre Hospitalier Universitaire de Toulouse, toulouse, FRANCE.

OP-655

CCK₂-receptor targeted PET/CT in patients with medullary thyroid cancer using [⁶⁸Ga]Ga-DOTA-CCK-66 - First clinical experience
O. Viering¹, T. Günther², N. Holzleitner², H. Wester², A. Dierks¹, M. Kircher¹, G. Wienand¹, C. H. Pfof¹, R. A. Bundschuh¹, C. Lapa¹;
¹Nuclear Medicine, faculty of medicine, University of Augsburg, Augsburg, GERMANY, ²Chair of Pharmaceutical Radiochemistry, Technische Universität München, Munich, GERMANY.

OP-656

PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [¹⁸F]SITATE - first clinical experiences
S. Kunte¹, V. Wenter¹, G. T. Sheikh¹, M. Unterrainer¹, S. Lindner¹, J. Toms¹, K. Jurkschat², C. Wängler³, B. Wängler³, R. Schirmacher⁴, J. Rübenthaler¹, C. J. Auernhammer¹, C. Spitzweg¹, P. Bartenstein¹, A. Holzgreve¹, L. M. Unterrainer¹;
¹LMU, Munich, GERMANY, ²Technische Universität Dortmund, Dortmund, GERMANY, ³Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, GERMANY, ⁴University of Alberta, Edmonton, Edmonton, AL, CANADA.

OP-657

Clinical Impact of Ga68-DOTATATE PET/CT Imaging in Medullary Thyroid Carcinoma, a retrospective single center study
A. Abdelrahman, R. Akinlusi, S. Gavane;
Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.

OP-658

¹⁸F tetrafluoroborate-pet in evaluation of thyroid cancer patients: preliminary results
K. Saglam, O. Sahin, E. Karayel, H. Pehlivanoglu, R. Uslu Besli, A. Aygun, S. Asa, K. Sonmezoglu;
Istanbul University-Cerrahpasa Cerrahpasa Medical Faculty, Istanbul, TÜRKIYE.

1309

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM
Hall G2

e-Poster Presentations Session 10 -
Oncology & Theranostics Committee:
Haematological and Abdominal
Malignancies / Localised Treatments

EPS-189

Role of ⁶⁸Ga-DOTATATE PET/CT Quantitative Parameters in the Differential Diagnosis of Adrenal Lesions
D. Denizmen¹, D. Has Simsek¹, E. G. Isik¹, H. Hacısahinogullari², S. Kuyumcu¹;
¹Istanbul University Istanbul Faculty of Medicine Nuclear Medicine Department, Istanbul, TÜRKIYE, ²Istanbul University Istanbul Faculty of Medicine Endocrinology and Metabolic Diseases Department, Istanbul, TÜRKIYE.

EPS-190

Role of ⁶⁸Ga-PSMA-11 PET/CT in staging metastatic renal cell cancer: A pilot study
P. Aggarwal, H. Singh, C. K. Das, R. S. Mavuduru, A. Lal, N. Kakkar, R. Kumar, U. Gorski, B. R. Mittal;
Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA.

EPS-191

Incremental value of ⁶⁸Ga-FAPI-04 to dual-tracer PET/CT for the evaluation of hepatobiliary masses with indeterminate CT/MR findings
I. Ho^{1,2}, S. Chen², K. Cheng², K. Wu², C. Ho²;
¹The Chinese University of Hong Kong, Hong Kong, HONG KONG, ²Hong Kong Sanatorium & Hospital, Hong Kong, HONG KONG.

EPS-192

Utility of CT-free attenuation and scatter correction in dual-tracer PET/CT for Evaluation of Gastric Cancer
S. Xue¹, Y. Miao², M. Viscione¹, H. Wang², A. Rominger¹, R. Guo², B. Li², K. Shi¹;
¹University of Bern, Bern, SWITZERLAND, ²Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

EPS-193

⁶⁸Ga-NY104 PET/CT in patients with recurrent/metastatic clear cell renal cell carcinoma suspicion: a comparative study with ¹⁸F-FDG
W. Zhu, X. Li, Y. Zhang, L. Huo;
Peking Union Medical College Hospital, Beijing, CHINA.

EPS-194

First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified ⁶⁸Ga-HER2 Affibody
M. Zhang, T. Xing, J. Wang, T. Ma, G. Li, Z. Quan, W. Yang, F. Kang, J. Wang;
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

EPS-195

Biodistribution of Monoclonal Antibodies: Defining New Baselines for ⁸⁹Zr-Immuno-PET-Derived Target Engagement In Vivo.

H. J. Sebus^{1,2}, J. E. Wijngaarden^{3,2}, I. H. C. Miedema^{1,2}, J. J. Eertink^{1,2}, I. Bahce⁴, A. J. De Langen^{4,5}, E. F. Smit⁶, M. Cleveland⁷, D. J. Vugts³, G. J. C. Zwezerijnen^{3,2}, M. C. Huisman^{3,2}, C. W. Menke - van der Houven van Oordt^{1,2}; ¹Amsterdam UMC location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, Amsterdam, NETHERLANDS, ²Cancer Center Amsterdam, Imaging & Biomarkers, Amsterdam, NETHERLANDS, ³Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Boelelaan 1117, Amsterdam, NETHERLANDS, ⁴Department of Pulmonary Diseases, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, NETHERLANDS, ⁵Department of Thoracic Oncology, NKI-AvL, Amsterdam, NETHERLANDS, ⁶Department of Pulmonology, Leiden University Medical Center, Leiden, NETHERLANDS, ⁷Bioimaging, Platform Technology and Science, GlaxoSmithKline, Stevenage, UNITED KINGDOM.

EPS-196

Smouldering multiple myeloma: progression to symptomatic disease predicted by 18F-FDG PET-CT

C. Caldarella¹, S. Taralli¹, F. Coccillo¹, T. Za², V. De Stefano^{2,3}, M. L. Calcagni^{1,4}; ¹Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, UOC di Medicina Nucleare, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY, ²Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, UOC Servizio e Day Hospital di Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY, ³Dipartimento di Scienze Radiologiche ed Ematologiche, Istituto di Ematologia, Università Cattolica del Sacro Cuore, Rome, ITALY, ⁴Dipartimento di Scienze Radiologiche ed Ematologiche, Istituto di Medicina Nucleare, Università Cattolica del Sacro Cuore, Rome, ITALY.

EPS-197

A novel prognostic index for diffuse large B-cell lymphoma combined baseline metabolic tumour volume with clinical and pathological risk factors

T. Yuan, X. Chen, Y. Zhang, M. Wei, H. Zhu, Z. Yang, X. Wang; Peking University Cancer Hospital & Institute, Beijing, CHINA.

EPS-198

Lung dose prediction in radioembolization: ¹⁶⁶Ho-microspheres scout for ¹⁶⁶Ho-microspheres treatment vs. ^{99m}Tc-MAA scout for ⁹⁰Y-microspheres treatment

M. Wagemans, R. van Rooij, A. J. A. T. Braat, M. L. J. Smits, R. C. G. Bruijnen, H. W. A. M. de Jong, M. G. E. H. Lam; Department of Radiology and Nuclear Medicine, UMC Utrecht, Utrecht, NETHERLANDS.

EPS-199

Comparison of response evaluation criteria in diffuse large B-cell lymphoma: Lugano versus RECIL, and PERCIST

P. Tang, R. Tian, M. Su; Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.

EPS-200

Voxel-Based Dosimetry with Integrated Y-90 PET/MRI Following TARE with Glass Microspheres and Dose-Response Relationships - Preliminary Results

B. Demir¹, E. C. Celebioglu², C. Soydal¹, N. O. Kucuk¹, D. Kuru Oz², M. S. Bilgic², K. M. Kir¹; ¹Ankara University School of Medicine Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Ankara University School of Medicine Department of Radiology, Ankara, TÜRKIYE.

EPS-201

Dose Distribution Pattern of Fractionally Administered Transarterial Radioembolization Holmium Microspheres in Non-Tumorous Human Liver Tissue

A. van den Brekel¹, T. J. Snoeijsink¹, J. Roosen¹, S. J. S. Ruiter², V. E. de Meijer², J. F. W. Nijsen¹; ¹Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS, ²Department of HPB Surgery and Liver Transplantation, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.

EPS-202

Can Circulating Angiogenic Factors Predict ⁹⁰Y Microsphere Treatment Outcomes ?

M. Mavi¹, B. Volkan Salanc², I. Lay³, F. G. Eldem⁴, B. Peynircioglu⁴, S. Yalcin⁵, Ö. Uğur², M. F. Bozkurt²; ¹Karaman Training and Research Hopital Nuclear Medicine Department, Karaman, TÜRKIYE, ²Hacettepe University Nuclear Medicine Department, Ankara, TÜRKIYE, ³Hacettepe University Medical Biochemistry Department, Ankara, TÜRKIYE, ⁴Hacettepe University Interventional Radiology Department, Ankara, TÜRKIYE, ⁵Hacettepe University Medical Oncology Department, Ankara, TÜRKIYE.

EPS-203

Improvement of minimally invasive parathyroidectomy through the introduction of radioguided surgical approach.

A. Alomar, I. Blanco, I. Saura, J. Cruz, A. Barrera, P. Salvador, E. Anda, N. Rudic, F. Lozada, M. Ribelles, A. Camarero, E. Goñi; Hospital Universitario de Navarra (HUN), Pamplona, SPAIN.

EPS-204

¹⁸⁸Re-N-DEDC lipiodol trans-arterial radionuclide therapy (TART) in HCC patients: Modification in lung Shunt fraction (LSF) criteria and clinical implication on therapeutic dose estimation using scout dose of ¹⁸⁸Re-N DEDC lipiodol

N. Kumar, P. Gupta, S. A. Shamim, S. Gamanagatti, S. Shalimar, C. Bal; All India Institute of Medical Sciences, New Delhi, INDIA.

EPS-205

A controlled administration device for MRI-guided holmium-166 transarterial radioembolisation: MR-safe and fractional microsphere administration

M. W. M. van Wijk¹, G. van Wolfswinkel², J. Roosen¹, M. J. Arntz¹, M. J. R. Janssen¹, J. F. W. Nijsen¹; ¹Department of Medical Imaging, Radboud university medical center, Nijmegen, NETHERLANDS, ²R&D TIO, Quirem Medical B.V. - a Terumo company, Deventer, NETHERLANDS.

EPS-206

NOBLE (Nobody Left Behind) Registry: Initial Experience of [^{99m}Tc]Tc-HYNICIPMSA Imaging in the Detection of Prostate Cancer

S. Martina¹, P. Tually², V. Garcia Quinto³, Y. Omar⁴, R. Yudistiro⁵, M. Sathekege⁶, G. Currie⁷, P. Galette¹, N. Patel¹, T. Brown¹, G. Bolland⁸, R. Lo bue⁸, C. Hayward¹; ¹Telix Pharmaceuticals, Melbourne, AUSTRALIA, ²TeleMed Nuclear Imaging, Kalgoorlee, AUSTRALIA, ³Hospital Galenia, Cancun, MEXICO, ⁴Misr Rediology Center, Cairo, EGYPT, ⁵Siloam International Hospitals, Tangerang, INDONESIA, ⁶University of Pretoria, Pretoria, SOUTH AFRICA, ⁷Charles Sturt Univeristy, Wagga Wagga, AUSTRALIA, ⁸Oncidium Foundation, Brussels, BELGIUM.

EPS-207

BPH-related False Positive of [⁶⁸Ga]Ga-PSMA PET/CT in the Diagnosis of Prostate Cancer: the Achilles' Heel of Biopsy-free Radical Prostatectomy?

Y. Tang, L. Xiao, J. Yang, J. Hou, B. Chen, S. Hu; Xiangya Hospital Central South University, Changsha, CHINA.

EPS-208

FDG-PET/CT for lymph node staging prior to radical cystectomy

M. Markus¹, V. Pihl², F. Liedberg², E. Trägårdh¹; ¹Clinical Physiology and Nuclear Medicine, Malmö, SWEDEN, ²Department of Urology, Malmö, SWEDEN.

EPS-209

One-day dual-tracer PET/CT protocol with [⁶⁸Ga]-DOTA-FAPI-04 for negative orequivocal [¹⁸F]FDG

H. Li, Z. Xiao, C. Li, Y. Tian, N. Lu, J. Chen, D. Xing, Y. He; Zhongnan Hospital of Wuhan University, Wuhan, CHINA.

1310

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM Hall K

Technologists Oral Presentations 3: NM Technologists: Competencies and Training

OP-659

Technologists' interests and barriers toward healthcare research.

C. H. Led¹, C. Baun^{1,2}, M. G. Hildebrandt^{1,2}; ¹Department of Nuclear Medicine, Odense C, DENMARK, ²Department of Clinical Research, University of Southern Denmark, Odense, DENMARK.

OP-660

Framework for Online Radiographer Clinical Education (FORCE): results of students' evaluation of the Nuclear Medicine strand

P. Costa¹, J. Lemos¹, R. Strudwick², P. Bezzina³, N. Dalen⁴, J. T. Huhtanen⁵, M. Jaronen⁶, T. Salla⁶, C. Kamp⁷, L. Rainford⁸, K. Matthews⁹; ¹Nuclear Medicine Department, School of Health - Polytechnic Institute of Porto (ESS)P.Porto, Porto, PORTUGAL, ²School of Health and Sports Sciences - University of Suffolk, Suffolk, UNITED KINGDOM, ³Faculty of Health Sciences - University of Malt, Msida, MALTA, ⁴Department of Health and Functioning - Western Norway University of Applied Sciences, Bergen, NORWAY, ⁵Health and Well-being, Rehabilitation, Oral Health Care and Diagnostic Services - Turku University of

Applied Sciences, Turku, FINLAND, ⁶Social Services and Health Care - Tampere University of Applied Sciences, Tampere, FINLAND, ⁷University of Applied Sciences FH Campus Wien, Wien, AUSTRIA, ⁸School of Medicine - University College Dublin, Dublin, IRELAND.

OP-661

The evolution of our PSMA PET imaging service
L. Thomas; St Vincent's Hospital Melbourne, Melbourne, AUSTRALIA.

OP-662

Comparison of calculated Left Ventricular Ejection Fraction (LVEF) from F-18 FDG dual-gated PET/CT, single-gated PET/MRI, and cardiac MRI
P. Toompong, A. Jantarato, D. Siripongsatian, P. Panpere, C. Promteangtrong, A. Kunawudh, P. Kiatkittikul, P. Lersirisuk, S. Sombon, C. Chotipsnich; National Cyclotron and PET Centre, Bangkok, THAILAND.

OP-663

A. Resende Geao, A. Santos, P. Colarinha; Hospital Cuf Descobertas, Lisboa, PORTUGAL.

OP-664

Short and long-term outcomes prediction using baseline FDG PET imaging in mCRPC patients treated with ¹⁷⁷Lu-PSMA radioligand therapy
Q. Shagera, C. Broeckaert, T. Guiot, E. Barraco, S. Albeaini, L. Taraji, I. Karfis, P. Flamen, C. Artigas; Jules Bordet Institute, Université Libre de Bruxelles (ULB), Brussels, BELGIUM.

OP-665

Comparison of non-specific bone uptake of [¹⁸F] AIF-PSMA-11 in prostate cancer patients acquired at different time intervals.
I. Cordero^{1,2}, K. Suanes^{1,2}, P. Duarte¹, O. Alonso^{1,2}; ¹Centro Uruguayo de Imagenología Molecular, Montevideo, URUGUAY, ²Unidad Académica de Medicina Nuclear e Imagenología Molecular, Facultad de Medicina, Universidad de la República, Montevideo, URUGUAY.

OP-666

The relentless pursuit for the best compromise between image quality and dose reduction - a single center experience with pediatric patients undergoing 18F-FDG PET/CT with long axial field of view scanner
A. Cardoso, A. Mendes, C. Bregenzer, K. Krieger, H. Sari, K. Zeimpekis, N. Gözlügöl, A. Rominger, A. Afshar-Oromieh; Department of Nuclear Medicine, Inselspital, University Hospital Bern, University of Bern, Bern, SWITZERLAND.

OP-667

Measuring GFR Using ⁵¹Cr-EDTA: a Clinical Case Requiring Gamma Ray Spectra Analysis
P. Geleijnse, S. Jentjens, K. Goffin, W. Deckers, K. Baete; Nuclear Medicine, University Hospitals Leuven, Leuven, BELGIUM.

1311

Tuesday, September 12, 2023, 9:45 AM - 11:15 AM
Hall G1

Theranostics Track - TROP Session: What's New in Neuroendocrine Tumors?

OP-668

Primary tumor resection followed by PRRT in the treatment of patients with metastatic neuroendocrine ileal cancer: preliminary data from a retrospective single center study.

F. Mattana¹, G. A. Zuccotti¹, A. Barone¹, E. Pisa², N. Fazio³, U. Fumagalli Romario⁴, C. M. Grana¹, F. Ceci^{1,5}, E. Bertani⁶; ¹IEO European Institute of Oncology, Nuclear Medicine, Milano, ITALY, ²IEO European Institute of Oncology, Pathology, Milano, ITALY, ³IEO European Institute of Oncology, Division of Gastrointestinal Medical Oncology, Milano, ITALY, ⁴IEO European Institute of Oncology, Division of Digestive Surgery, Milano, ITALY, ⁵Department of Oncology and Hemato-Oncology, University of Milan, ITALY.

OP-669

First results from IEO 676 clinical study of PRRT in neuroendocrine tumors: is there still space for Y-90-DOTATOC?

C. Grana, A. Barone, S. Papi, P. Rocca, S. Fracassi, M. Ferrari, F. Botta, F. Mattana, F. Ceci, C. Fodor, F. Spada, I. Clerici, N. Fazio, M. Rubino; European Institute of Oncology, IRCCS, Milano, ITALY.

OP-670

Intra-arterial PRRT, a Prospective Clinical Study in NET Patients with Hepatic Metastases

S. Ebberts¹, M. W. Barentsz¹, D. M. V. de Vries-Huizinga², M. W. J. Versleijen², L. G. Klompenhouwer², M. E. T. Tesselaaar², M. P. M. Stokkel², T. Brabander³, H. Hofland³, A. Moelker³, A. J. A. T. Braat¹, M. G. E. H. Lam¹; ¹University Medical Center Utrecht, Utrecht, NETHERLANDS, ²Netherlands Cancer Institute, Amsterdam, NETHERLANDS, ³Erasmus Medical Center, Rotterdam, NETHERLANDS.

OP-671

Diagnostic Performance of [¹⁸F]F-meta-fluorobenzylguanidine ([¹⁸F]MFBG) PET/CT in Patients with Pheochromocytoma and Paraganglioma

P. Wang¹, F. Li¹, J. Zhang², H. Jing¹, Y. Zhang¹; ¹Peking Union Medical College Hospital, Beijing, CHINA, ²National University of Singapore, Singapore, SINGAPORE.

OP-672

²²⁵Ac-DOTATATE Dosimetry Results from Part 1 of the ACTION-1 Trial

M. Morris¹, G. Ulaner², T. Delie¹, S. Kotiah³, D. Ferreira⁴, K. Ma¹, J. Rearden⁴, J. Li⁴, S. Moran⁴, E. Sneed⁴, B. He⁵, M. Ghaly⁵, E. Frey⁶, A. Scott¹, C. Huffman¹, G. Sgouros⁵; ¹Advanced Molecular Imaging and Therapy, Glen Burnie, MD, UNITED STATES OF AMERICA, ²Hoag Family Cancer Institute, Newport Beach, CA, UNITED STATES OF AMERICA, ³Mercy Medical Center, Baltimore, MD, UNITED STATES OF AMERICA, ⁴RayzeBio, San Diego, CA, UNITED STATES OF AMERICA, ⁵Radiopharmaceutical Imaging and Dosimetry, LLC (Rapid), Baltimore, MD, UNITED STATES OF AMERICA, ⁶The Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

OP-673

Early results of ²¹²Pb-VMT-α-NET Targeted Alpha Therapy in Metastatic Gastro-entero-pancreatic Neuroendocrine Tumors: First in Human Clinical Experience on Safety and Efficacy

D. Malik¹, I. Sen¹, P. Thakral¹, S. Das¹, M. Schultz²; ¹Fortis Memorial research institute (FMRI), Gurugram, INDIA, ²University of Iowa, Iowa, IA, UNITED STATES OF AMERICA.

OP-674

The increase of LutaThera Therapy posology due to dosimetry could be give a better progression free survival (PFS) in GEPNets patients?

M. Cuomo^{1,2}, G. Argiroffo², A. Lorenzoni², G. Aliberti², M. Bagnalasta², F. Scalorbi², M. Kirienco², C. Chiesa², E. Seregni², M. Maccauro²; ¹University of the study of Milan, Milan, ITALY, ²Istituto Nazionale Tumori Milano, Milan, ITALY.

OP-675

Personalized, dosimetry-based PRRT therapy in patients with neuroendocrine tumors using [177Lu] Lu-DOTA-TATE or [177Lu]Lu/[90Y]Y-DOTA-TATE mixture - the initial results of DUONEN multicenter study

M. Opalinska¹, G. Kaminski², M. Dedecjus³, A. Kowalska⁴, M. Kolodziej², M. Saracyn², D. Gasior-Perczak⁴, W. Lenda-Tracz⁵, A. Sowa-Staszczak¹, A. Borkowska⁶, A. Budzynska⁷, A. Kubik⁷, W. Chalewska³, K. Kacperski⁷, P. Szubstarska⁷, P. Garnuszek⁸, R. Mikolajczak⁸, A. Hubalewska-Dydejczyk¹; ¹Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND, ²Department of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, POLAND, ³Department of Endocrine Oncology and Nuclear Medicine, National Institute of Oncology, Warsaw, POLAND, ⁴Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, POLAND, ⁵Department of Endocrinology, Oncological Endocrinology and Nuclear Medicine, University Hospital, Krakow, POLAND, ⁶Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, POLAND, ⁷Department of Nuclear Medicine, Military Institute of Medicine - National Research Institute, Warsaw, POLAND, ⁸Radioisotope Center POLATOM, National Centre for Nuclear Research, Otwock, POLAND.

OP-676

Quantitative somatostatin receptor image assessment for survival prediction: a full-body, longitudinal, individual lesion analysis of neuroendocrine tumors in patients treated with peptide receptor radiation therapy

V. Santoro-Fernandes¹, B. Schott¹, A. Deatsch¹, Q. Keigley², T. Francken¹, R. Meeker¹, R. Lyer³, F. Christos³, S. Perlman^{2,4}, R. Jeraj^{1,4}; ¹Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, UNITED STATES OF AMERICA, ²Section of Nuclear Medicine and Molecular Imaging, Department of Radiology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, UNITED STATES OF AMERICA, ³Division of GI Medicine, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, UNITED STATES OF AMERICA, ⁴Carbone Cancer Centre, University of Wisconsin, Madison, WI, UNITED STATES OF AMERICA.

1401

Tuesday, September 12, 2023, 11:30 - 13:00
Hall A

Plenary 4: Diagnostic Imaging: Proven Beyond Doubt?

OP-677

AI technology: FDG PET imaging and lymphomas: a proven certainty

J. Zijlstra; Amsterdam UMC, Amsterdam, NETHERLANDS.

OP-678

PET imaging in every oncological guideline: what is still missing?

S. Carrilho Vaz; Champalimaud Foundation, Lisbon, PORTUGAL.

OP-679

Impact without a cure: prospective evidence for diagnostic neuroimaging

A. Drzezza; University Hospital of Cologne, Cologne, GERMANY.

OP-680

Cardiac imaging: prospective studies and the EURECA registry

D. Neglia; Fondazione CNR/Regione Toscana G. Monasterio, Pisa, ITALY.

OP-681

Cost effectiveness molecular imaging studies

M. Gauthé; SCINTEP, Grenoble, FRANCE.

OP-682

Real world data: an answer to all questions?

J. Kleesiek; Institute for AI in Medicine (IKIM), Essen, GERMANY.

1501

Tuesday, September 12, 2023, 15:00 - 16:30
Hall A

CME 11 - Paediatrics Committee: Pediatric Lymphoma and Update on FDG

OP-685

Clinical background on pediatric lymphoma and what do clinicians expect from nuclear medicine

A. Attarbaschi; St Anna's Kinderspital, Department of Hematology, Vienna, AUSTRIA.

OP-686

Role of Molecular Imaging (FDG PET-CT) in the evaluation pediatric lymphoma patients

P. Ozgen Kiratli; Hacettepe University Hospital Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-687

Response to therapy assessment via FDG PET-CT

L. Kurch; University of Leipzig Hospital, Department of Nuclear Medicine, Leipzig, GERMANY.

1502

Tuesday, September 12, 2023, 15:00 - 16:30
Hall D (Arena)

Challenge the Expert 4 - Neuroimaging Committee: Amyloid vs. Tau PET: Which is First in suspected Alzheimer Patients? Germany versus Italy

OP-688

Tau PET first in the AD flow-chart - Germany

H. Barthel; Department of Nuclear Medicine, University of Leipzig, Leipzig, GERMANY.

OP-689

Challengers case - Germany

K. Messerschmidt; Department of Nuclear Medicine, Leipzig University Hospital Centre, Leipzig, GERMANY.

OP-690

Challengers case - Germany

J. Gnörich; Department of Nuclear Medicine, Ludwig Maximilian University Munich, Munich, GERMANY.

OP-691a

Amyloid PET first in the AD flow-chart - Italy

S. Morbelli; Department of Nuclear Medicine, University of Genoa, Genoa, ITALY.

OP-691b

Challengers case - Italy

G. Polverari; PET/CT Center, AFFIDEA-IRMET S.P.A., Turin, ITALY.

OP-691c

Challengers case - Italy

A. Martini; Nuclear Medicine Unit, Department of Diagnostic Imaging, N.O.P. - S. Stefano, U.S.L. Toscana Centro, Prato, ITALY.

1503

Tuesday, September 12, 2023, 15:00 - 16:30
Hall E1

LIPS Session 11 - Bone & Joint Committee: Pitfalls and Common Bony Findings in PET-CT/MRI using Novel Tracers

OP-692

PSMA PET/CT - atypical bony patterns using different radioligands - tips on assessment of bone metastases

A. Maurer;
University Hospital Zurich, Nuclear Medicine, Zurich, SWITZERLAND.

OP-693

FAPI PET/CT - what should be considered in interpretation of bony lesion?

K. Pabst;
University Hospital Essen, Nuclear Medicine, Essen, GERMANY.

OP-694

PET/MRI - Pitfalls and normal variations in assessment of bone metastases

S. Wan;
Institute of Nuclear Medicine, University College London, London, UNITED KINGDOM.

1504

Tuesday, September 12, 2023, 3:00 PM - 4:30 PM
Hall E2

M2M Track - TROP Session: Imaging the Components of the TME

OP-697

STING-targeted PET Tracer for Early Assessment of CRC Tumor Immunogenicity after Chemotherapy

D. Xu^{1,2,3}, X. Lu^{1,3}, F. Yang^{2,3}, D. Lj^{3,2};
¹Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, CHINA, ²Department of Nuclear Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, CHINA, ³Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, CHINA.

OP-698

Targeting PD-1 on Chronically Activated T cells with Radioimmunotherapy as a Novel Therapeutic Strategy for Multiple Sclerosis.

C. Frank¹, H. E. Salapa^{2,3,4}, K. J. H. Allen¹, M. C. Levin^{2,3,4}, W. Dawicki⁵, E. Dadachova¹;
¹College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, CANADA, ²Office of Saskatchewan Multiple Sclerosis Clinical Research Chair, CMSNRC (Cameco MS Neuroscience Research Center), College of Medicine, University of Saskatchewan, Saskatoon, SK, CANADA, ³Department of Medicine, Neurology Division, University of Saskatchewan, Saskatoon, SK, CANADA, ⁴Department of Anatomy, Physiology and Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, SK, CANADA, ⁵Department of Biochemistry, Microbiology and Immunology, College of Medicine, University of Saskatchewan, Saskatoon, SK, CANADA.

OP-699

The synthesis of a novel molecular imaging probe⁶⁸Ga-DOTA-PDL1P and application in malignant melanoma

Z. Yang;
Fudan University Shanghai Cancer Center, Shanghai, CHINA.

OP-700

A Novel PET Tracer ⁶⁸Ga-NOTA-XH05 Targeting LAG-3 for Evaluating the Efficacy of Immunotherapy in Tumors

P. Yuan^{1,2}, Y. Long^{1,2}, N. Wei^{1,2}, Y. Gai^{1,2}, Y. Zhang^{1,2}, R. An^{1,2}, X. Lan^{1,2};
¹Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ²Hubei Key Laboratory of Molecular Imaging, Wuhan, CHINA.

OP-701

Preclinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma

W. Zhu, X. Li, Y. Zhang, L. Huo;
Peking Union Medical College Hospital, Beijing, CHINA.

OP-702

A Radiopharmaceutical Capture System for In Vivo CAR T Cell Tracking in Ovarian Cancer

L. Gajecski, L. Eibler, K. Kurtz, S. Lovibond, D. Veach, S. Larson, D. Scheinberg, S. Krebs;
Memorial Sloan Kettering, New York, NY, UNITED STATES OF AMERICA.

OP-703

Discovery and development of high-affinity macrocyclic peptide for PET imaging of human Granzyme-B

T. Nayak¹, J. Schubert¹, Z. Zhou¹, I. Bennacef¹, X. Meng¹, M. Stenslik¹, K. Getty¹, J. Patteson¹, H. Zokian², J. Lee², E. DiNunzio², H. Wan², F. Orvieto³, V. Piacenti³, A. Saldanha², A. Walji¹, E. Hostetler¹;
¹MSD, West Point, PA, UNITED STATES OF AMERICA, ²MSD, Kenilworth, NJ, UNITED STATES OF AMERICA, ³IRBM S.p.A, Rome, ITALY.

OP-704

Evaluation of Affinity Matured Affibody Molecules for Imaging of Immune Check-Point Protein B7-H3

M. Oroujeni¹, E. Bezverkhniaia², T. Xu¹, Y. Liu¹, E. Plotnikov¹, E. Ryer³, I. Karlberg³, A. Orlova¹, F. Frejd¹, V. Tolmachev¹;
¹Uppsala University, Uppsala, SWEDEN, ²Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, ³Affibody AB, Stockholm, SWEDEN.

OP-705

A ⁶⁸Ga labelled CD25 targeted cyclopeptide probe for activated T cell imaging

F. Liu¹, S. Wang², P. Wang¹, Z. Yang¹;
¹Peking University Cancer Hospital & Institute, Beijing, CHINA, ²Peking University Health Science Center, Beijing, CHINA.

1505

Tuesday, September 12, 2023, 3:00 PM - 4:30 PM
Hall B

Cutting Edge Science Track - TROP Session: AI Methods and Applications

OP-706

Primary prostate characterization in PSMA-11 PET on real quantum computers

L. Papp, C. P. Spielvogel, M. Hacker, W. Drexler, S. Moradi;
Medical University of Vienna, Vienna, AUSTRIA.

OP-707

Image-based PSMA PET/MRI deep learning model for automatic prostate cancer grading

E. Solari¹, S. Schachoff¹, I. Rauscher¹, M. Eiber¹, W. Weber¹, N. Navab², S. G. Nekolla¹;
¹Klinikum rechts der Isar, Technical University Munich, München, GERMANY, ²School of Informatics, Technical University Munich, München, GERMANY.

OP-708

Increased sensitivity for AI-based detection of lymph node metastases on [18F]-PSMA-1007 PET-CT when adding synthetic data to the training data

E. Tragardh^{1,2}, J. Ulén³, O. Enqvist^{3,4}, L. Edenbrandt⁵, M. Larsson³;
¹Skåne University Hospital, Malmö, SWEDEN, ²Lund University, Malmö, SWEDEN, ³Eigenvision AB, Malmö, SWEDEN, ⁴Chalmers University of Technology, Gothenburg, SWEDEN, ⁵Sahlgrenska Academy, Gothenburg, SWEDEN.

OP-709

Deep learning-based PET Image harmonization improves robustness and discriminative power of quantitative imaging markers in multi-institutional studies

D. Haberl¹, C. P. Spielvogel¹, D. Iommi¹, I. Buvat², A. R. Haug¹, L. Papp³;
¹Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, ²LITO laboratory, U1288 Inserm, Institut Curie, University Paris-Saclay, Orsay, FRANCE, ³Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA.

OP-710

[¹¹C] CFT PET to [¹²³I] FP-CIT SPECT Domain Adaptation: A CycleGAN harmonization approach

L. Lopes^{1,2}, S. Xu¹, J. Lu³, T. Pyka¹, K. Krieger¹, R. Fahmi⁴, B. Spottiswoode⁴, A. Soliman⁴, R. Buchert⁵, M. Brendel⁶, J. Hong^{1,2}, C. Clement^{1,2}, C. Bassetti⁷, A. Rominger¹, P. Wu³, K. Shi¹;
¹Department of Nuclear Medicine, Inselspital, University of Bern, Bern, SWITZERLAND, ²Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, SWITZERLAND, ³Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, ⁴Siemens Medical Solutions United States Of America, Inc., Knoxville, TN, UNITED STATES OF AMERICA, ⁵Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY, ⁶Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, ⁷Department of Neurology, University of Bern, Bern, SWITZERLAND.

OP-711

Estimating the Tumor Localization Performance via Class-Activation Map Explanations of a Slice Classification Neural Network Without Pixel-Level Supervision

S. Ahamed^{1,2}, C. F. Uribe^{1,3}, A. Rahmim^{1,2};
¹University of British Columbia, Vancouver, BC, CANADA, ²BC Cancer Research Institute, Vancouver, BC, CANADA, ³BC Cancer, Vancouver, BC, CANADA.

OP-712

Early experiences with the use of triplet networks for histological subtype classification in Non-Small Cell Lung Cancer

F. Gelardi^{1,2}, F. Aksu¹, A. Chiti^{1,2}, P. Soda^{3,4};
¹Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), ITALY, ²Department of Nuclear Medicine, IRCCS Humanitas Research Hospital, Rozzano (MI), ITALY, ³Research Unit of Computer Systems and Bioinformatics, Campus Bio-Medico University of Rome, Rome, ITALY, ⁴Department of Radiation Sciences, Radiation Physics, Biomedical Engineering, Umea University, Umea, SWEDEN.

OP-713

Development and Multicenter Validation of an Artificial Intelligence System for the Detection of Cardiac Amyloidosis in ^{99m}Tc Scintigraphy

C. Spielvogel¹, D. Haberl¹, J. Ning², R. Calabretta¹, T. Traub-Weidinger¹, R. H. Davies³, I. Pierce⁴, K. Patel⁴, K. Kluge¹, T. Nakuz¹, A. Goellner¹, D. Amareller¹, M. Weber¹, M. Zhao⁵, X. Ma⁶, X. Li¹, A. R. Haug¹, L. Menezes⁴, T. A. Treibel⁷, M. Hacker¹, C. Nitsche¹, CS and DH are first authors with equal contribution;
¹Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, ²Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, AUSTRIA, ³Institute of Cardiovascular Science, University College London, London, UNITED KINGDOM, ⁴Department of Cardiology, Bart's Heart Centre, St Bartholomew's Hospital, West Smithfield, London, UNITED KINGDOM, ⁵Department of Nuclear Medicine, First Xiangya Hospital, Central South University, Changsha, CHINA, ⁶Department of Nuclear Medicine, Second Xiangya Hospital, Central South University, Changsha, CHINA, ⁷Department of Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, AUSTRIA.

OP-714

Deep learning-based image classification in differentiating lymphoma pulmonary involvement and other hypermetabolic pulmonary diseases on ¹⁸F-FDG PET/CT

R. Cheng¹, Y. Peng¹, M. Quan², B. Li¹, N. Wen², J. Hu¹;
¹Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ²Department of Radiology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

1506

Tuesday, September 12, 2023, 3:00 PM - 4:30 PM
Hall C

Clinical Oncology Track - TROP Session:
Prostate Cancer Treatment

OP-715

Can pre-therapy ⁶⁸Ga-PSMA-11 PET SUVs predict absorbed doses across multiple cycles of ¹⁷⁷Lu-PSMA-617 therapy of mCRPC patients?

J. Brosch-Lenz¹, N. Colpo², I. Bloise¹, X. Hou¹, W. R. Parulekar³, C. Dellar³, F. Saad⁴, K. Chi², D. Wilson², F. Bénard², A. Rahmim¹, C. Uribe²;

¹BC Cancer Research Institute, Vancouver, BC, CANADA, ²BC Cancer, Vancouver, BC, CANADA, ³Canadian Cancer Trials Group, Queen's University Kingston, Kingston, ON, CANADA, ⁴Prostate cancer research, Montreal Cancer Institute / CRCHUM, Montreal, QC, CANADA.

OP-716

Safety and efficacy of PSMA-targeted radionuclide therapy with ¹⁷⁷Lu-ITG-PSMA-1 in metastatic castration resistant prostate cancer patients: Update on the prospective, multicentre, Swiss registry study

A. Chirindel¹, A. Bauman¹, M. Fani¹, F. Forrer², A. Afshar-Oromieh³, M. del Sol Pérez Lago⁴, J. Blautzik⁵, N. Schaefer⁶, E. Nitzsche⁷, D. Wild¹, G. Nicolas¹;

¹University Hospital Basel, Basel, SWITZERLAND, ²Kantonsspital St. Gallen, St Gallen, SWITZERLAND, ³Inselspital, Berne, SWITZERLAND, ⁴Luzerner Kantonsspital, Lucerne, SWITZERLAND, ⁵Hirslanden Klinik St. Anna, Lucerne, SWITZERLAND, ⁶University Hospital Lausanne, CHUV, Lausanne, SWITZERLAND, ⁷Kantonsspital Aarau, Aarau, SWITZERLAND.

OP-717

Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of ²²⁵Ac/¹⁷⁷Lu-PSMA-therapy

G. Sheikh¹, M. J. Zacherl¹, A. Holzgreve¹, S. C. Kunte¹, V. Wenter¹, M. Unterrainer², W. Kunz³, J. Casuscelli⁴, C. Stief⁵, P. Bartenstein¹, L. M. Unterrainer¹;

¹Department of Nuclear Medicine, LMU Klinikum, Munich, GERMANY, ²Die Radiologie, Munich, GERMANY, ³Department of Radiology, LMU Klinikum, Munich, GERMANY, ⁴Department of Urology, LMU Klinikum, Munich, GERMANY.

OP-718

ProstACT GLOBAL: A Phase 3 Study of ¹⁷⁷Lu-DOTA-rosopatomab (TLX591) With and Without the Best Standard of Care for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment with a Novel Androgen Axis Drug

S. Martina¹, C. Hawkins¹, N. Patel¹, J. Gibson¹, T. Brown¹, N. Lenzo², C. Hayward¹;

¹Telix Pharmaceuticals, Melbourne, AUSTRALIA, ²Genesis Care, Alexandria NSW 2015, AUSTRALIA.

OP-719

[²²⁵Ac]Ac-PSMA-617 mutational landscape in circulating tumor DNA (ctDNA): early clinical outcome prediction in metastatic castration-resistant prostate cancer

M. Amghar¹, T. Rausch², T. Hielscher¹, H. Ozgur², M. Roscher¹, U. Bauder-Wüst¹, M. Schick¹, Y. Remde¹, G. Bakos¹, M. Schäfer¹, F. Bruchertseifer³, A. Morgenstern³, V. Beneš², C. Kratochwil⁴, M. Benešová-Schäfer¹;

¹DKFZ, Heidelberg, GERMANY, ²EMBL, Heidelberg, GERMANY, ³European Commission, Joint Research Centre (JRC), Karlsruhe, GERMANY, ⁴Department of Nuclear Medicine, University Hospital, Heidelberg, GERMANY.

OP-720

Evaluation of labeling parameters of PSMA-617 with ²¹³Bi for targeted alpha-radionuclide therapy of metastatic castration-resistant prostate cancer

H. khoshhosn¹, M. Davarpanah, H. Khoshhosn², A. Gravand, Y. Tavakoli, N. Soltani, M. Harati, B. Kalantari, F. Johri;

Pars Isotope company, Tehran, IRAN, ISLAMIC REPUBLIC OF.

OP-721

Safety, Dosimetry and Response of ¹⁷⁷Lu-LNC1003 in Patients with Metastatic Castration Resistant Prostate Cancer

J. Zhang¹, G. Wang², T. Zhao³, Y. Yang¹, W. Miao¹, Z. Zhu², J. Zhang³, X. Chen³;

¹Department of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, Fuzhou, CHINA, ²Department of Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science and PUMC, Beijing, CHINA, ³Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.

OP-722

Extension of a ⁶⁸Ga-PSMA PET-based nomogram for outcome prediction of ¹⁷⁷Lu-PSMA radioligand therapy for the use of ¹⁸F-rhPSMA-7.3

I. Rauscher¹, K. Hansen¹, A. Gafita¹, W. A. Weber¹, M. Eiber²;

¹Department of Nuclear Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, GERMANY, ²Technical University of Munich, Klinikum rechts der Isar, Munich, GERMANY.

OP-723

¹⁷⁷Lu-PSMA-617 therapy in advanced mCRPC patients: preliminary results of the phase 2 prospective trial IRST-185.03

I. Marini¹, M. Sansovini, G. Paganelli, I. Grassi, F. Matteucci, S. Nicolini, U. De Giorgi, E. F. Giunta, F. Foca, M. Monti, M. Celli, P. Caroli, V. Di Iorio, A. Sarnelli, C. Lolli, G. Schepisi, N. Brighi, S. Severi;

IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY.

1507

Tuesday, September 12, 2023, 3:00 PM - 4:30 PM
Hall F1

Cardiovascular Committee - TROP Session:
Perfusion

OP-724

Prognostic role of coronary microvascular dysfunction in non-obstructive coronary artery disease

K. Kopeva¹, A. Maltseva, E. Grakova, A. Mochula, K. Zavadovsky;

Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.

OP-725

Impact of coronary flow reserve on the mortality and major adverse cardiac and cerebrovascular event in hemodialysis patients, regardless of diabetes

S. Ohshima¹;

Nagoya Kyoritsu Hospital, Nagoya, JAPAN.

OP-726

Relationship between monocyte to high density lipoprotein cholesterol ratio and myocardial perfusion imaging findings

M. Sadic¹;

Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, WA, UNITED STATES OF AMERICA.

OP-727

Analysis of related factors of persistent or recurrent chest pain in patients with coronary artery disease after PCI based on gated myocardial perfusion imaging

Z. Yang^{1,2}, J. Wang^{1,2}, Y. Wang^{1,2};

¹Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, CHINA, ²Institute of Clinical Translation of Nuclear Medicine and Molecular Imaging, Soochow University, Changzhou, Jiangsu Province, CHINA.

OP-728

Association between myocardial perfusion and peripheral endothelial function in patients with coronary artery disease

N. Vartiainen¹, J. E. K. Hartikainen, T. M. Laitinen, H. Mussalo, P. Kuikka, T. P. Laitinen;

Kuopio University Hospital, Kuopio, FINLAND.

OP-729

Relative stress perfusion deficit is an independent predictor of significant stenosis in a heterogeneous population of patients examined with [¹⁵O]H₂O PET

P. Mark¹, E. Prescott², L. Marner¹, P. Hovind¹, M. Krakauer¹;

¹Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Bispebjerg Frederiksberg Hospital, Bispebjerg Bakke 23, 2400 Copenhagen, DENMARK, ²Department of Cardiology, Copenhagen University Hospital - Bispebjerg Frederiksberg Hospital, Bispebjerg Bakke 23, 2400 Copenhagen, DENMARK.

OP-730

Cardiac ¹⁵O-water PET/CT predicts progression of Cardiac Dysfunction in Patients with Type 2 Diabetes and Diabetic Foot Ulcers

N. Christensen^{1,2,3}, L. P. Tolbod^{1,2}, K. Bouchelouche^{1,2}, M. A. Madsen¹, C. S. BuhP, J. Sørensen¹;

¹Department of Nuclear Medicine & PET, Aarhus University Hospital, Aarhus N, DENMARK, ²Aarhus University, Aarhus C, DENMARK, ³Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus N, DENMARK.

OP-731

Prevalence, characteristics and effect of cardiac motion in ¹³N-ammonia PET/CT dynamic acquisitions

O. Mendoza-Ibanez¹, T. S. Martinez Lucio¹, F. van der Zant², C. Hayden³, R. J. J. KnoP, R. H. J. A. Slart¹, S. V. Lazarenko²;

¹University Medical Center Groningen, Groningen, NETHERLANDS, ²Northwest Clinics Alkmaar, Alkmaar, NETHERLANDS, ³Siemens Medical Solutions, Inc. United States Of America, TN, UNITED STATES OF AMERICA.

OP-732

Role of motion correction tools in the estimation of microvascular coronary function by ¹³N-ammonia hybrid-positron emission tomography

O. Mendoza-Ibanez¹, R. J. J. KnoP, R. H. J. A. Slart¹, C. Hayden³, T. S. Martinez Lucio¹, S. V. Lazarenko²;

¹University Medical Center Groningen, Groningen, NETHERLANDS, ²Northwest Hospital Group Alkmaar, Alkmaar, NETHERLANDS, ³Siemens Medical Solutions United States Of America, Tennessee, TN, UNITED STATES OF AMERICA.

1508

Tuesday, September 12, 2023, 15:00 - 16:30
Hall F2

Joint Symposium 5 - Oncology &
Theranostics Committee / ESMO: Prostate
Cancer Theranostics: Where Do We Go?

OP-733

Biology and Treatment Landscape in advanced Prostate Cancer and unmet Medical Needs

E. Castro¹;

12 de Octubre University Hospital, Department of Medical Oncology, Madrid, SPAIN.

OP-734

Potential combination partners for PSMA radioligand therapy

B. Krause¹;

University Medical Center, University of Rostock, Department of Nuclear Medicine, Rostock, GERMANY.

OP-735

Moving PSMA RLT to earlier lines

B. Privé¹;

Erasmus Medical Center, Department of Radiation oncology, Rotterdam, NETHERLANDS.

OP-736

The future role of radiotherapy of prostate cancer

1509

Tuesday, September 12, 2023, 3:00 PM - 4:30 PM
Hall G2

**e-Poster Presentations Session 11 -
Translational Molecular Imaging & Therapy
Committee + Radiopharmaceutical
Sciences Committee: Novel Therapeutic
Approaches**

EPS-210

**In Vitro Evaluation of Radiation-induced DNA
Damage and Repair within Targeted Radionuclide
Therapies in Comparison to External Radiation**

R. Winter, U. Bauder-Wüst, M. Schäfer, M. Roscher, R. Lopez
Perez, M. Benešová-Schäfer;
German Cancer Research Center, Heidelberg, GERMANY.

EPS-211

**Three-dimensional spheroids as in vitro preclinical
model for radiobiology studies: the example of
radium-223 in prostate cancer spheroids**

A. Pires Lourenço^{1,2,3}, I. A. Marques^{4,2,5}, D. Cancelinha^{4,6}, G.
Costa⁷, A. M. Abrantes^{4,2,3}, M. F. Botelho^{4,2,3};

¹Institute of Biophysics, Coimbra Institute for Clinical
and Biomedical Research (iCIBR) area of CIMAGO,
Faculty of Medicine, University of Coimbra, Coimbra,
PORTUGAL, ²Center for Innovative Biomedicine and
Biotechnology (CIBB), University of Coimbra, Coimbra,
PORTUGAL, ³Clinical Academic Center of Coimbra
(CACC), Coimbra, PORTUGAL, ⁴Univ Coimbra, Coimbra
Institute for Clinical and Biomedical Research (iCIBR)
area of Environment Genetics and Oncobiology
(CIMAGO), Institute of Biophysics, Faculty of Medicine,
Coimbra, PORTUGAL, ⁵Faculty of Pharmacy, University of
Coimbra, Coimbra, PORTUGAL, ⁶Faculty of Science and
Technology, University of Coimbra, Coimbra, PORTUGAL,
⁷Department of Nuclear Medicine, Centro Hospitalar e
Universitário de Coimbra (CHUC), Coimbra, PORTUGAL.

EPS-212

**Comparison of biological effects produced by
radioactively labeled antibodies in human cancer
cells and fungal cells**

J. Bonet, M. E. Malo, K. J. Allen, C. Frank, R. Jiao, E.
Dadachova;
University of Saskatchewan, Saskatoon, SK, CANADA.

EPS-213

**HDACi Treatment Increases SSTR2 mRNA and
Protein Expression in Tumor-Bearing Animals: What
is the Effect on Radiolabeled DOTATATE uptake?**

M. J. Klomp, L. van den Brink, P. M. van Koetsveld, C. M. A.
de Ridder, D. C. Stuurman, L. J. Hofland, S. U. Dalm;
Erasmus MC, Rotterdam, NETHERLANDS.

EPS-214

**Preclinical efficacy of novel anti-oxMIF/
HSG bispecific antibody for pretargeted
radioimmunotherapy**

A. Puchol Tarazona, I. Mirkina, M. Thiele, A. Schinagl;
OncoOne Research & Development
GmbH, Vienna, AUSTRIA.

EPS-215

**Combined Treatment with ¹⁷⁷Lu-DOTATOC
and Histone Deacetylase Inhibitors on SSTR2
Expression and Uptake in vivo**

H. Bakr^{1,2}, A. Al-Awar¹, E. Forssell-Aronsson^{1,2};
¹Department of Medical Radiation Sciences, Institute
of Clinical Sciences, Sahlgrenska Center for Cancer
Research, Sahlgrenska Academy, University of
Gothenburg, Gothenburg, SWEDEN, ²Department
of Medical Physics and Biomedical Engineering,
Sahlgrenska University Hospital, Gothenburg, SWEDEN.

EPS-216

**Effective treatment of SSTR2 positive small cell lung
cancer using ²¹¹At-containing targeted α -particle
therapy agent which promotes endogenous anti-
tumor immune response.**

F. Yu, S. Qin, J. Zhang, M. Yang;
Department of Nuclear Medicine, Shanghai
Tenth People's Hospital, Tongji University
School of Medicine, Shanghai, CHINA.

EPS-217

**DOTAGA-modified DB15 mimics for theranostic use
in prostate cancer**

P. Kanellopoulos¹, A. Mattsson¹, A. Abouzayed¹, K. Obeid¹,
B. A. Nock², V. Tolmachev¹, T. Maina³, A. Orlova¹;

¹Uppsala University, Uppsala, SWEDEN, ²INRASTES,
NCSR "Demokritos", Athens, GREECE, ³INRASTES, NSCR
"Demokritos",
Athens, GREECE.

EPS-218

**Development and preclinical evaluation of
biodistribution and dosimetry of ¹⁷⁷Lu-labelled
PSMA targeting therapeutic with optimized linker
for treatment of disseminated prostate cancer**

A. Orlova¹, A. Abouzayed¹, K. Seitova², F. Lundmark¹, V.
Bodenko², M. Oroujeni¹, V. Tolmachev¹, U. Rosenström¹;

¹Uppsala University, Uppsala, SWEDEN, ²Tomsk
Polytechnic University, Tomsk, RUSSIAN FEDERATION.

EPS-219

**Theranostic approach in CD30 positive cancers
with a radiolabeled antibody conjugated to the
radiosensitizing antitubulin monomethyl auristatin
E payload**

C. Petitot¹, J. Frenay², A. M. M. Dias¹, A. Oudot¹, A. Helbling¹,
M. Moreau³, M. Monterrat¹, M. Guillemin¹, N. Ranjit¹, A.
Cochet⁴, P. S. Bellaye⁵, B. Collin⁶;

¹Pirp - Service de Médecine Nucléaire, Centre Georges-
François Leclerc, Dijon, FRANCE, ²Icb - Umr Cnrs 6303 /
Pirp - Service de Médecine Nucléaire, Centre Georges-
François Leclerc, Dijon, FRANCE, ³Icmub - Umr Cnrs 6302,
Dijon, FRANCE, ⁴Icmub - Umr Cnrs 6302 / Pirp - Service
de Médecine Nucléaire, Centre Georges-François Leclerc
/ Chu François Mitterrand, Dijon, FRANCE, ⁵Pirp - Service
de Médecine Nucléaire, Centre Georges-François Leclerc
/ Lnc - Umr Inserm 1231, Dijon, FRANCE, ⁶Icmub - Umr
Cnrs 6302 / Pirp - Service de Médecine Nucléaire,
Centre Georges-François Leclerc, Dijon, FRANCE.

EPS-220

**Testing the potential therapeutic use of [¹⁸⁸Re]Re-
maSSS/maSES-PEG2-RM26 as part of a theranostic
pair with their [^{99m}Tc]Tc-labeled counterparts**

P. Kanellopoulos, Q. Yu, A. Abouzayed, E. Bezverkhniaia, V.
Tolmachev, A. Orlova;
Uppsala University, Uppsala, SWEDEN.

EPS-221

**Alpha-emitter radium-223 mediates tumor
eradication via STING-dependent pyroptosis**

F. Yu, M. Yang, S. Qin, J. Zhang;
Department of Nuclear Medicine, Shanghai
Tenth People's Hospital, Tongji University
School of Medicine, Shanghai, CHINA.

EPS-222

**Fractionated therapy of the PSMA-targeted
radioligand ²¹²Pb-AB001 significantly delays tumor
growth**

A. Kjoel Tornes^{1,2}, V. Y. Stenberg^{1,2}, A. Repetto-Llamazares¹,
R. H. Larsen^{3,1}, A. Juzeniene²;

¹ArtBio AS, Oslo, NORWAY, ²Department of
Radiation Biology, Oslo University Hospital, Oslo,
NORWAY, ³Sciencons AS, Oslo, NORWAY.

EPS-223

**Biodistribution Study and Pre-clinical
Radiopharmaceutical Therapy with a CXCR4-
targetted Compound on a Human CXCR4 Positive
Multiple Myeloma Orthotopic Model**

I. Bloise, H. Kuo, N. Colpo, H. Merckens, P. Ng, D. Kwon, L.
Escano, F. Kuchenbauer, K. Lin, F. Benard;
BC Cancer, Vancouver, BC, CANADA.

EPS-224

**Design and evaluation of a new generation of
long-acting SSTR2 antagonists for enhanced
radionuclide therapy of NETs**

M. Handula¹, S. Beekman¹, Y. Seimbille^{1,2};
¹Erasmus MC, Rotterdam, NETHERLANDS,
²TRIUMF, Vancouver, BC, CANADA.

EPS-225

**DOTA-MGS5, a novel cholecystokinin-2 receptor-
targeting peptide analogue for use in targeted
therapy, preclinical evaluation for clinical
translation**

T. Zavvar¹, A. A. Hoermann¹, M. Klingler¹, J. Hagenbuchner²,
L. Joosten³, G. Franssen³, P. Laverman³, M. W. Konijnenberg⁴,
I. Skvortsova⁵, L. Gruber⁶, E. von Guggenberg¹;

¹Department of Nuclear Medicine, Medical University of
Innsbruck, Innsbruck, AUSTRIA, ²Department of Pediatrics
II, Medical University of Innsbruck, Innsbruck, AUSTRIA,
³Department of Medical Imaging, Radboud University
Medical Center, Nijmegen, NETHERLANDS, ⁴Department
of Radiology and Nuclear Medicine, Erasmus Medical
Center, Rotterdam, NETHERLANDS, ⁵Department of
Therapeutic Radiology and Oncology, Medical University of
Innsbruck, Innsbruck, AUSTRIA, ⁶Department of Radiology,
Medical University Innsbruck, Innsbruck, AUSTRIA.

EPS-227

**Preclinical evaluation of a radiotheranostic single-
domain antibody against Fibroblast Activation
Protein alpha**

Y. Dekempeneer¹, S. Massa¹, F. Santens¹, L. Navarro¹,
M. Berdal¹, M. M. Lucero¹, A. Pombo Antunes¹, J. A.
Van Ginderachter^{2,3}, T. Lahoutte^{1,4,3}, N. Devoogdt^{1,3}, M.
D'Huyvetter^{1,3};

¹PRECIRIX NV/SA, Brussels, BELGIUM, ²VIB
Center for Inflammation Research, Brussels,
BELGIUM, ³Vrije Universiteit Brussel, Brussels,
BELGIUM, ⁴UZ Brussel, Brussels, BELGIUM.

EPS-228

**Auger electron therapy of prostate cancer: a
preclinical evaluation of ^{58m}Co-DOTA-PSMA-617**

C. Baun^{1,2,3}, J. H. Dam¹, J. D. Ewald^{4,2}, B. W. Kristensen⁴, V. S.
Laursen^{1,2}, M. G. Hildebrandt^{1,2,3}, B. B. Olsen¹, H. Thisgaard^{1,2};

¹Department of Nuclear Medicine, Odense University
Hospital, Odense C, DENMARK, ²Department of
Clinical Research, University of Southern Denmark,
Odense, DENMARK, ³Center for Personalized Response
Monitoring in Oncology (PREMIO), Odense University
Hospital, Odense, DENMARK, ⁴Department of Pathology,
Odense University Hospital, Odense C, DENMARK.

EPS-229

**Polymeric Micelles as Drug Delivery System
for PARP Inhibitor-Based Chemo-Radiotherapy
Combination Against Triple-Negative Breast Cancer**

L. Schäfer¹, A. Wang², Q. Peña², E. Henrard¹, T. Lammers²,
E. M. Buh³, M. Frings⁴, C. Bolm⁴, A. Morgenroth¹, F. M.
Mottaghy^{1,5};

¹Department of Nuclear Medicine, RWTH Aachen
University Hospital, 52074 Aachen, GERMANY, ²Institute
for Experimental Molecular Imaging, RWTH Aachen
University Hospital, 52074 Aachen, GERMANY, ³Electron
Microscopy Facility, Institute of Pathology, RWTH
Aachen University Hospital, 52074 Aachen, GERMANY,
⁴Institute of Organic Chemistry, RWTH Aachen
University, 52074 Aachen, GERMANY, ⁵Department of
Radiology and Nuclear Medicine, Maastricht University
Medical Center, 6229 ER Maastricht, NETHERLANDS.

EPS-230

**Successful treatment of human high-risk
neuroblastoma using ¹⁷⁷Lu-octreotide combined
with Lorlatinib in a mouse model**

E. Forssell-Aronsson^{1,2}, A. Romiani¹, D. Pettersson¹, K.
Simonsson¹, H. Bakr^{1,2}, D. Lind¹, A. Kovacs^{1,2}, R. Palmer¹, B.
Hallberg¹, K. Helou¹, J. Spetz¹;

¹University of Gothenburg, Gothenburg, SWEDEN,
²Sahlgrenska University Hospital, Gothenburg, SWEDEN.

1510

Tuesday, September 12, 2023, 15:00 - 16:30
Hall K

**CTE 7 - Technologists & Thyroid
Committee: Molecular Thyroid Imaging -
Qualitative and Quantitative Approaches**

OP-737

Best practice on thyroid imaging: What's to know?!

M. Punda;
University Clinical Hospital Center "Sestre Milosrdnice",
Department of Oncology and Nuclear Medicine,
Zagreb, CROATIA.

OP-738

**MIBI-Imaging of the thyroid and parathyroid: How
to get most out of it.**

M. Jessop;
Brighton and Sussex University Hospitals, Department
of Nuclear Medicine, Brighton, UNITED KINGDOM.

OP-739

Imaging of thyroid cancer: From I-131 to FAPI.
J. Nagarajah;
Radboud UMC, Department of Nuclear Medicine,
Nijmegen, NETHERLANDS.

OP-740

Update on new developments in thyroid ultrasound
T. Wendler;
Technical University of Munich, TUM
School of Computation, Information and
Technology, Munich, GERMANY.

1511

Tuesday, September 12, 2023, 15:00 - 16:30
Hall G1

**EU Policy Symposium 1 - Policy &
Regulatory Affairs Committee: Supply &
Shortages of Radiopharmaceuticals**

OP-742

Supply & Shortages of Radiopharmaceuticals

1601

Tuesday, September 12, 2023, 16:45 - 18:15
Hall A

**CME 12 - Physics + Oncology &
Theranostics + Translational Molecular
Imaging & Therapy + Technologists
Committee: Long Axial Field-of-View PET
Scanners - A Copernical Revolution**

OP-749

Hybrid Total Body PET scanners
I. Tsoumpas;
UMCG, Nuclear Medicine, Groningen, NETHERLANDS.

OP-750

Clinical Perspectives of Total Body PET/CT
A. Dimitrakopoulou-Strauss;
DKFZ, Nuclear Medicine, Heidelberg, GERMANY.

OP-751

**Parametric Imaging with dynamic PET for
oncological applications**
J. van Sluis;
UMCG, Nuclear Medicine, Groningen, NETHERLANDS.

OP-752

Non Oncological applications
R. Boellaard;
Amsterdam UMC, Radiology and nuclear medicine,
Amsterdam, NETHERLANDS.

1602

Tuesday, September 12, 2023, 16:45 - 18:15
Hall D (Arena)

**Debate 5 - Bone & Joint + Cardiovascular
Committee: NaF PET in cardiology and
MSK: pro or cons?**

OP-753

NaF PET in cardiology: pro
P. Høiland-Carlsen;
Odense University Hospital, Clinical Physiology and
Nuclear Medicine Department, Odense, DENMARK.

OP-754

NaF PET in cardiology: cons
F. Hyafil;
Hopital européen Georges Pompidou, Nuclear
medicine Department, Paris, FRANCE.

OP-755

NaF PET in musculoskeletal imaging: pro
H. Zacho;
Kræftforsknings-Center, Aalborg
Universitetshospital og, Aalborg, DENMARK.

OP-756

NaF PET in musculoskeletal imaging: cons
D. Mak; Guys and St Thomas' NHS, Nuclear medicine
Department, London, UNITED KINGDOM.

1603

Tuesday, September 12, 2023, 16:45 - 18:15
Hall E1

**LIPS Session 12 - Neuroimaging +
Inflammation & Infection Committee: The
Role of FDG PET in the Diagnosis of Auto-
Immune Encephalitis**

OP-760

**Interpretation of auto-immune encephalitis with
brain FDG PET**
A. Verger;
CHRU Nancy, Nuclear Medicine, Nancy, FRANCE.

OP-761

**The role of the whole-body FDG PET in autoimmune
encephalitis**
I. Apostolova;
Department of Diagnostic and Interventional
Radiology and Nuclear Medicine, University Medical
Center Hamburg-Eppendorf, Hamburg, GERMANY.

OP-762

**The complementary PET/MRI modalities in
autoimmune encephalitis**
D. Cecchin;
Department of Medicine, Nuclear Medicine Unit,
University-Hospital of Padova, Padova, ITALY.

1604

Tuesday, September 12, 2023, 4:45 PM - 6:15 PM
Hall E2

**M2M Track - TROP Session: Understanding
and Improving RLT**

OP-764

**Novel DNA polymerase theta inhibitors induce
efficient X-ray and proton therapy sensitisation in
vitro and in vivo**
J. Barlow¹, A. Cicconi¹, M. Ranzani¹, G. Rodriguez-
Berriguete², R. Prev², M. Boursier¹, A. Galbiati¹, L. Geo¹,
D. Grande¹, R. A. Heald¹, J. Majithiya¹, D. Piscitello¹, E.
Rajendra¹, M. Stockley¹, P. Mariniello³, G. Sawakuchi³, G.
Smith¹, G. S. Higgins², H. Robinson¹;
¹Artios Pharma, Cambridge, UNITED KINGDOM,
²University of Oxford, Oxford, UNITED KINGDOM,
³University of Texas MD anderson Cancer Center,
Houston, TX, UNITED STATES OF AMERICA.

OP-765

**Dissecting signaling network response to
radiolabeled minigastrin analog reveals
radiosensitizing targets in CCKBR-positive cancers**
M. Grzmil¹, Y. Qin¹, A. Blanc¹, T. Chiorazzo¹, P. Berger², S.
Frank³, R. Schibli^{1,4}, M. Behe¹;
¹Center for Radiopharmaceutical Sciences, Paul Scherrer
Institute, Villigen PSI, SWITZERLAND, ²Laboratory of
Nanoscale Biology, Paul Scherrer Institute, Villigen
PSI, SWITZERLAND, ³Division of Neuropathology,
Institute of Pathology, University of Basel, Basel,
SWITZERLAND, ⁴Department of Chemistry and Applied
Biosciences, ETH Zürich, Zürich, SWITZERLAND.

OP-766

**p53 Stabilisation Potentiates ¹⁷⁷Lu-DOTATATE
Treatment in Neuroblastoma**
H. Berglund¹, S. Lundsten Salomonsson², T. Mohajershaj¹,
D. P. Lane^{1,3,4}, M. Nestor¹;
¹Department of Immunology, Genetics and Pathology,
Uppsala University, Uppsala, SWEDEN, ²Ridgeview
Instruments AB, Uppsala, SWEDEN, ³Department of
Microbiology, Tumour and Cell Biology, Karolinska
Institute, Stockholm, SWEDEN, ⁴p53Lab, Agency for Science
Technology and Research (A*STAR), Singapore, SINGAPORE.

OP-767

**Substantial Reduction of the Activity Retention
in the Kidneys of Radiohybrid-Based Minigastrin
Analogues by Modifying the Charge Distribution
Within the Linker Section**
N. Holzleitner¹, T. Günther¹, S. Fischer¹, R. Beck¹, C. Lapa², H.
Wester¹;
¹Technical University Munich, Munich, GERMANY,
²University of Augsburg, Augsburg, GERMANY.

OP-768

**Internalising radioimmunoconjugates to target
KRAS in pancreatic cancer cells for simultaneous
radionuclide therapy and radiosensitisation**
K. Vallis¹, J. Lourenco¹, N. Sereesongsang², O. Tietz², T.
Rabbits²;
¹University of Oxford, Oxford, UNITED KINGDOM,
²Institute of Cancer Research, London, UNITED
KINGDOM, ³Macquarie University, Sydney, AUSTRALIA.

OP-769

**Human hematopoietic stem cells show SSTR2
expression and specific binding of radioligands
providing a potential explanation for the
hematotoxicity of ¹⁷⁷Lu-DOTA-JR11**
S. Kossatz¹, Y. Min¹, N. T. Nguyen¹, J. Rivière¹, M. van der
Garde¹, S. Ghosh², L. Bartos³, M. Brendel³, F. Bassermann¹, K.
Götze¹, A. Azhdarinia⁴, W. A. Weber¹;
¹Klinikum rechts der Isar at Technical University Munich,
Munich, GERMANY, ²University of Texas Health Science
Center at Houston, Houston, VT, UNITED STATES
OF AMERICA, ³University Hospital of Munich, LMU
Munich, Munich, GERMANY, ⁴University of Texas Health
Science Center at Houston, Munich, GERMANY.

OP-770

**Reducing the Effective Specific Activity of [²²⁵Ac]-
PSMA-617 to Minimize Salivary Gland and Renal
Toxicity**
T. Esposito, T. Kalidindi, R. Payne, Z. Faudemer, K. Jones, N.
Pillarsetty;
Memorial Sloan Kettering Cancer Center, New York City,
NY, UNITED STATES OF AMERICA.

OP-771

**Improvement of the pharmacokinetic properties of
PSMA-617 by introducing sarcosine moieties**
N. M. Geis^{1,2,3}, N. Steinacker^{1,2}, L. Domogalla^{1,2}, P. T. Meyer^{1,2},
M. Eder^{1,2}, A. Eder^{1,2};
¹Department of Nuclear Medicine, University Medical
Center Freiburg, Freiburg im Breisgau, GERMANY,
²Division of Radiopharmaceutical Development,
German Cancer Consortium, Freiburg im Breisgau,
GERMANY, ³Faculty of Biology, University of
Freiburg, Freiburg im Breisgau, GERMANY.

OP-772

**Preclinical toxicity study of [²¹¹At]PSMA5 in mice
and for the FIH clinical trial of targeted alpha
therapy against refractory prostate cancer**
T. Watabe¹, K. Kaneda-Nakashima¹, Y. Kadonaga¹, K. Ooe¹,
T. Sampunta¹, X. Yin², H. Haba², Y. Kon¹, A. Toyoshima¹,
J. Cardinale³, F. L. Giese³, K. Fukase³, N. Tomiyama¹, Y.
Shirakami¹;
¹Osaka University, Suita, JAPAN, ²RIKEN, Wako, JAPAN,
³University Hospital Duesseldorf, Duesseldorf, GERMANY.

1605

Tuesday, September 12, 2023, 4:45 PM - 6:15 PM
Hall B

**Cutting Edge Science Track - TROP Session:
Data Analysis**

OP-773

**Using timestamps in fast time-of-flight positron
emission tomography detectors to encode the
depth of interaction of 511 keV gamma-photons in
scintillators**
V. Nadig¹, K. Herweg¹, K. Weindel¹, D. Schug^{1,2}, H.
Radermacher¹, F. Mueller¹, B. Weissler^{1,2}, V. Schulz^{1,2}, S.
Gundacker¹;
¹RWTH Aachen University, Aachen, GERMANY, ²Hyperion
Hybrid Imaging Systems GmbH, Aachen, GERMANY.

OP-774

Brain PET Quantitative and Qualitative Interpretation Using Sparse Detector Ring Configuration PET System

R. Fahmi¹, J. Cabello¹, G. Platsch², B. Spottiswoode¹;
¹Siemens Healthineers, Knoxville, TN, UNITED STATES OF AMERICA, ²Siemens Healthineers, Erlangen, GERMANY.

OP-775

PUMA: PET Unification for Multi-Tracer Applications in Multiplexed PET Imaging

S. Gutschmayer¹, B. A. Spencer², Y. G. Abdelhafez², R. D. Badawi², S. R. Cherry², T. Beyer¹, L. Shiyam Sundar¹;
¹Quantitative Imaging and Medical Physics (QIMP) Team, Medical University of Vienna, Vienna, AUSTRIA, ²Department of Biomedical Engineering and Radiology, University of California-Davis, Davis, CA, UNITED STATES OF AMERICA.

OP-776

Comparison of Standardized Uptake Values of [18F] FDG-PET/CT imaging of healthy volunteers: a multi-country PET/CT study

D. Ferrara¹, R. Badawi², T. Beyer¹, Z. Chen³, S. Cherry⁴, B. Geist⁵, S. Gutschmayer¹, M. Hacker⁵, S. Kinuya³, L. Shiyam Sundar¹, B. Spencer⁶, S. Takeda⁶, J. Taki⁶, H. Wakabayashi³;
¹QIMP Team, Medical University of Vienna, Vienna, AUSTRIA, ²Department of Radiology, UC Davis, Sacramento, CA, UNITED STATES OF AMERICA, ³Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, JAPAN, ⁴Department of Biomedical Engineering, UC Davis, Davis, CA, UNITED STATES OF AMERICA, ⁵Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, ⁶PET Center, Kanazawa Advanced Medical Center, Kanazawa, Ishikawa, JAPAN.

OP-777

Non-rigid anatomical standardization of whole-body PET/CT identifies variation of FDG distribution with age and sex: an AI-assisted study

K. Hirata^{1,2,3}, S. Watanabe^{1,2}, J. Takenaka^{1,2}, N. Wakabayashi^{1,2}, R. Kimura^{1,4}, T. Nagai⁵, T. Ogawa⁶, K. Kudo^{1,3,4};

¹Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, JAPAN, ²Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, JAPAN, ³Global Center for Biomedical Science and Engineering, Faculty of Medicine, Sapporo, JAPAN, ⁴Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, JAPAN, ⁵Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JAPAN, ⁶Faculty of Information Science and Technology, Hokkaido University, Sapporo, JAPAN.

OP-778

Noise and Sharpness estimation in Positron Emission Tomography (PET) images using radiomics and deep learning

P. Gurunath Bharathi¹, F. Moradi¹, M. Khalighi¹;
Stanford Medicine, Palo Alto, CA, UNITED STATES OF AMERICA.

OP-779

Evaluation of potential dose reduction in O-15 water PET by simulation of low count data and sinogram denoising

M. Voskamp^{1,2}, F. Büther³, M. Mamach^{4,2}, J. Lücke^{5,6}, S. Salwig⁵, H. Mousavi⁵, F. M. Bengel¹, T. Lenarz^{2,2}, G. Berding^{1,2};
¹Department of Nuclear Medicine, Hannover Medical

School, Hannover, GERMANY, ²Cluster of Excellence "Hearing4all", Hannover, GERMANY, ³Department of Nuclear Medicine, University Hospital, Münster, GERMANY, ⁴Department of Medical Physics and Radiation Protection, Hannover Medical School, Hannover, GERMANY, ⁵Department of Medical Physics and Acoustics, Carl von Ossietzky University Oldenburg, Oldenburg, GERMANY, ⁶Cluster of Excellence "Hearing4all", Oldenburg, GERMANY, ⁷Department of Otolaryngology, Hannover Medical School, Hannover, GERMANY.

OP-780

Intra-arterial super-selective delivery of Yttrium-90 for the treatment of recurrent Glioblastoma: feasibility and safety results in virtual patients' cohort

G. Paolani¹, S. Strolin¹, S. Minosse², M. Santoro¹, N. Pucci², L. Oddo³, Y. Toumia³, E. Guida⁴, F. Di Giuliano⁴, R. Floris⁴, F. Garaci⁴, S. Dolci⁴, G. Paradossi³, F. Domenici³, V. Da Ros⁴, L. Strigari¹;

¹Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ²UOC Diagnostica per Immagini, University Hospital of Rome "Tor Vergata", Rome, ITALY, ³Department of Chemical Science and Technologies, University of Rome "Tor Vergata", Rome, ITALY, ⁴Department of Biomedicine and Prevention, University Hospital of Rome "Tor Vergata", Rome, ITALY.

OP-781

Variational autoencoder for detecting coronary artery disease in myocardial perfusion SPECT

K. Okuda¹, K. Nakajima², T. Hara³, H. Yoneyama², S. Kinuya²;
¹Hirosaki University, Hirosaki, JAPAN, ²Kanazawa University, Kanazawa, JAPAN, ³Gifu University, Gifu, JAPAN.

1606

Tuesday, September 12, 2023, 4:45 PM - 6:15 PM

Hall C

Clinical Oncology Track - TROP Session: Head and Neck Imaging

OP-782

Dual time-point imaging of FAPI-04 in head and neck squamous cell carcinoma

J. Yaqun¹, L. Chongjiao¹, H. Yong¹;
Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA.

OP-783

Effectiveness of HAN-MI-RADS (Head and Neck Molecular Imaging-Reporting and Data System) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy

M. Gupta¹, A. Jajodia², P. Ahlawat³, M. Gairola³, M. Agarwal⁴, S. Goyal⁵, P. Choudhury¹;
¹Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA, ²Department of Radiology, Juravinski Hospital, McMaster University, ON, CANADA, ³Department of Radiotherapy, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA, ⁴Department of Surgical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA, ⁵Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, INDIA.

OP-784

[18F]FDG PET/CT in the Therapy Response Evaluation of Head and Neck Carcinoma. How to approach it?

V. Carrero-Vásquez¹, B. Hervas-Sanz¹, L. Rodríguez-Bel¹, G. Reynes-Llompant², R. Martín-Vaello², A. Lozano-Borbalas³, O. Bermejo-Segu⁴, P. Perlaza-Jiménez¹, C. Martínez-Ramos¹, M. Cortés-Romera¹;

¹Nuclear Medicine Department, Bellvitge University Hospital, Barcelona, SPAIN, ²Radiophysics Department, Bellvitge University Hospital, Barcelona, SPAIN, ³Radiation Oncology Department, Bellvitge University Hospital, Barcelona, SPAIN, ⁴Plastic Surgery Department, Bellvitge University Hospital, Barcelona, SPAIN.

OP-785

C-X-C motif chemokine receptor 4-directed PET/CT in newly diagnosed Head and Neck Squamous Cell Carcinoma - Initial Experience

S. Serfling¹, R. Werner¹, S. Andreas¹, H. Takahiro¹, A. K. Buck¹, A. Kosmala¹, R. Hagen¹, S. Hackenberg¹, A. Scherzag¹, E. Gerhard-Hartmann¹, Y. Zhi¹;
University Hospital Würzburg, Würzburg, GERMANY.

OP-786

Targeted imaging of αvβ6-integrin in patients of Head and Neck Squamous Cell Carcinoma and Pancreatic Ductal Adenocarcinoma with ⁶⁸Ga-Trivehexin PET/CT scan and correlation with immunohistochemistry- a pilot study

S. Das¹, I. B. Sen¹, D. Malik¹, P. Thakral¹;
Fortis Memorial Research Institute, Gurugram, INDIA.

OP-787

Role of pet biomarkers (suvmax, tlg and mtv) in the response to treatment in patients with nasopharyngeal carcinoma and its evolution.

S. Lopez Puche¹, F. Gómez-Camínero López¹, P. García-Talavera San Miguel¹, L. Diaz Gonzalez¹, E. Casillas Sagrado¹, J. Badell Martinez¹, S. Rama Alonso¹, E. Campaña Diaz¹, P. Tamayo Alonso¹;
Hospital Universitario de Salamanca, Salamanca, SPAIN.

OP-788

Evaluation of relationship between Total Tumor Metabolic Volume and tumour tissue modified viral Human papilloma virus DNA levels at initial staging in HPV driven oropharyngeal squamous cell carcinoma.

R. Kulkarni¹, M. Posner¹, S. Roof¹, N. Ghesani¹;
Mount Sinai Hospital, New York, NY, UNITED STATES OF AMERICA.

OP-789

A prospective Comparison of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/MR in the Diagnosis of Residual Tumor Tissue for Head and Neck Squamous Cell Carcinoma Patients after Neoadjuvant Treatment

X. Zhong¹, Y. Luo², M. Su³, X. Peng², W. Zhang⁴;
¹Nuclear Medicine Department and Biomedical Big Data Center, West China Hospital of Sichuan University, Chengdu, CHINA, ²Cancer Center, West China Hospital of Sichuan University, Chengdu, CHINA, ³Nuclear Medicine Department, West China Hospital of Sichuan University, Chengdu, CHINA, ⁴Biomedical Big Data Center, West China Hospital of Sichuan University, Chengdu, CHINA.

OP-790

Preclinical and clinical evaluation of ⁶⁸Ga-FAPI-LM3 for PET imaging in nasopharyngeal carcinoma

L. Zhao¹, H. Chen¹, Q. Lin¹;
the First Affiliated Hospital of Xiamen University, Xiamen, CHINA.

1607

Tuesday, September 12, 2023, 4:45 PM - 6:15 PM

Hall F1

Neuroimaging Committee - TROP Session: New PET Tracers for Brain Imaging

OP-791

Potentially incremental role of ¹⁸F-DPA714 PET to conventional MRI in the detection and therapeutic monitoring of autoimmune encephalomyelitis

M. Zhang¹, H. Meng², S. Chen², B. Li¹;
¹Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ²Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

OP-792

Activated Microglia Detected by TSPO PET in Anti-N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis: Distinct Pattern of Disease

J. Ge¹, J. Wang¹, P. Wu¹, Y. Guan¹, C. Zuo¹;
Huashan Hospital, Shanghai, CHINA.

OP-793

Safety, biodistribution, and dosimetry of [18F]OP-801, a novel neuroinflammation PET biomarker, in healthy individuals

F. Moradi¹, M. Jovin¹, N. Malik¹, J. H. Park¹, V. Ferri¹, M. L. James¹, J. L. Cleland², S. Maricich²;
¹Stanford University, Stanford, CA, UNITED STATES OF AMERICA, ²Ashvattha Therapeutics, Redwood City, CA, UNITED STATES OF AMERICA.

OP-794

Dopaminergic Damage Pattern Predicts Phenoconversion Time in Isolated Rapid Eye Movement Sleep Behaviour Disorder

J. Ge¹, Q. Xu¹, H. Lin¹, Y. Guan¹, C. Zuo¹, P. Wu¹, H. Yu¹;
Huashan Hospital, Shanghai, CHINA.

OP-795

[18F]F-SynVesT-1 and [18F]F-FDG PET imaging in the pre-surgical evaluation of MRI-negative children with focal cortical dysplasia

L. Xiao¹, Y. Tang¹, J. Yang¹, S. Hu¹;
Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, CHINA.

OP-796

Mapping Sudden sensorineural hearing loss-related brain activation: a preliminary study by Using [18 F] SynVesT-1 and PET Imaging.

J. Zhong¹, S. Hu¹, E. Zhou²;
¹Department of Nuclear Medicine, XiangYa Hospital, Central South University, Changsha, CHINA, ²Department of Otolaryngology Head and Neck Surgery, Hunan Provincial People's Hospital (First Affiliated Hospital of Hunan Normal University), Changsha, CHINA.

OP-797

Lower synaptic density and its association with cognitive dysfunction in patients with obsessive-compulsive disorder

J. Hou, Q. Xiao, L. Xiao, S. Hu;
Xiangya Hospital, Central South University, Changsha, CHINA.

OP-798

A1 adenosine receptor availability and perfusion in the human brain during acute normobaric hypoxia measured with [F-18]CFFPX PET/MRI

H. Weis^{1,2}, M. Michno³, J. Schmitz⁴, A. Foerges³, S. Beer³, B. Neumaier⁵, A. Drzezga¹, D. Aeschbach⁴, A. Bauer³, J. Tank⁴, E. Elmenhorst⁶, D. Elmenhorst³;
¹Department of Nuclear Medicine, University Cologne, Germany, Cologne, GERMANY, ²Institute of Aerospace Medicine, German Aerospace Center, Cologne, Germany, GERMANY, ³Institute of Neuroscience and Medicine (INM-2), Forschungszentrum Jülich, Jülich, GERMANY, ⁴Institute of Aerospace Medicine, German Aerospace Center, Cologne, GERMANY, ⁵Institute of Neuroscience and Medicine (INM-5), Forschungszentrum Jülich, Jülich, GERMANY, ⁶Institute of Aerospace Medicine, German Aerospace Center, Cologne, Cologne, GERMANY.

OP-799

mGluR5 and glutamate involvement in Autism spectrum disorder (ASD) adult patients : a multimodal imaging study

A. Dupont^{1,2}, N. Arlicot^{1,2,3}, L. Barantin⁴, J. Vercouillie⁴, C. Tauber⁵, V. Gissot⁶, F. Bonnet-Brilhault^{7,2}, M. Santiago-Ribeiro^{8,2,3};
¹Radiopharmacie, CHRU Tours, Tours, FRANCE, ²Inserm U 1253, Tours, FRANCE, ³Inserm CIC 1415, Tours, FRANCE, ⁴Inserm U 1253, Tours, FRANCE, ⁵Inserm U1253, Tours, FRANCE, ⁶CIC1415, Chru Tours, Tours, FRANCE, ⁷Centre Universitaire de Pédopsychiatrie, Chru Tours, Tours, FRANCE, ⁸Médecine nucléaire, Chru Tours, Tours, FRANCE.

1608

Tuesday, September 12, 2023, 4:45 PM - 6:15 PM
Hall F2

Thyroid Committee - TROP Session: Nuclear Medicine Imaging in Thyroid and Parathyroid Disorders

OP-800

The Risk of Malignancy of Thyroid PET-Avidomas on ¹⁸F-FDG PET/CT using the Bethesda System for Reporting Thyroid Cytopathology

H. Coerts¹, F. J. van Kemenade¹, F. A. Verburg¹, B. de Keizer², J. L. F. Raithel¹, T. M. van Ginhoven¹;
¹Erasmus Medical Center, Rotterdam, NETHERLANDS, ²University Medical Center Utrecht, Utrecht, NETHERLANDS.

OP-801

Iodine-123 diagnostic imaging in the early follow-up of differentiated thyroid cancer patients: wich is the best acquisition timing ?

A. Campenni¹, R. Ruggeri¹, M. Siracusa¹, A. Rappazzo¹, V. Davi¹, A. Nicocia¹, D. Cardile¹, S. Baldari¹, L. Giovannella²;
¹Ospedale Gaetano Martino, Messina, ITALY, ²Ente Ospedaliero Cantonale, 6500, Bellinzona, SWITZERLAND.

OP-802

Prospective comparison of F-18-TFB and I-124 PET/CT in metastatic thyroid cancer

P. Backhaus^{1,2}, K. Pentlow², A. L. Ho^{2,3}, A. Mauguen², J. A. Fagin², N. V. K. Pillarsetty², S. K. Lyashchenko², E. Burnazi³, R. A. Ghossein², S. Chhabra², M. Abusamra², S. M. Larson², H. Schöder², J. O'Donoghue², W. Weber⁴, R. K. Grewal²;
¹University Hospital Münster, Münster, GERMANY, ²Memorial Sloan Kettering Cancer Center, New York City, NY, UNITED STATES OF AMERICA, ³Weill Cornell Medical College, New York City, NY, UNITED STATES OF AMERICA, ⁴Technical University Munich, München, GERMANY.

OP-803

Diagnostic value of [99mTc] Tc-HYNIC-TOC scintigraphy in the management of differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan

A. Aghaee, E. Askari, S. Shafiei, K. Aryana;
Nuclear Medicine Research Center, Mashhad University Of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

OP-804

Dual time ¹⁸F-Fluorocholine PET/CT in patients with primary hyperparathyroidism

L. Vija¹, A. Latgé¹, M. Sinigaglia¹, C. Renaud², S. Grunenwald², P. Pascal¹, S. Kanoun¹, S. Zerdoud¹, S. Brillouet¹, M. Terroir Cassou-Mounat¹, T. Cassou Mounat¹, L. O. Dierickx¹, F. Courbon¹;
¹Institut Claudius Regaud-Oncopole, Toulouse Cedex 9, FRANCE, ²CHU Toulouse, Toulouse Cedex 9, FRANCE.

OP-805

¹⁸F-fluorocholine (FCH) PET/CT performance to detect hyperfunctioning parathyroid glands in patients with no definite kidney disease and whose PTH serum level and/or calcemia are within the normal range. 786 PET/CTs in one centre.

J. Talbot¹, C. Aveline², J. Zhang-Ying², O. Belissant-Benesty², J. Ohnona², S. Périé³, S. Gaujoux⁴, I. Wagner², M. Bennis⁵, F. Ménégau⁴, S. Christin-Maître⁵, J. Haymann¹, B. Baujat⁶, S. Balogova⁷, F. Montravers²;
¹APRAMEN, Hopital Tenon, Paris, FRANCE, ²Hopital Tenon, Paris, FRANCE, ³CH privé Ambroise Paré Hartmann, Neuilly sur seine, FRANCE, ⁴GH Pitié-Salpêtrière, Paris, FRANCE, ⁵Hôpital St Antoine, Paris, FRANCE, ⁶Hôpital Tenon, Paris, FRANCE, ⁷Comenius University, Bratislava, SLOVAKIA.

OP-806

First-line FCH PET/CT versus MIBI SPECT/CT in the surgical management of primary hyperparathyroidism: the multicentre APACH2 phase III trial

E. Quak¹, A. Lasne-Cardon¹, M. Cavarec², B. Lireux¹, V. Bastit¹, N. Roudaut², P. Salaun², N. Keromnes², G. Potard², P. Vaduva³, A. Esvant³, F. Jegoux³, O. Crouy-Chane³, A. Devillers⁴, C. Guery⁴, C. Lasnon¹, R. Ciappuccini¹, M. Sali-Dauda¹, B. Legrand¹, A. Estienne¹, J. Grellard¹, S. Bardet¹, B. Clarisse¹;
¹Francois Baclesse Cancer Centre, Caen, FRANCE, ²University Hospital of Brest, Brest, FRANCE, ³University Hospital of Rennes, Rennes, FRANCE, ⁴Eugene Marquis Cancer Institute, Rennes, FRANCE.

OP-807

PET/CT with [¹¹C]-methionine in the diagnosis of tertiary hyperparathyroidism

M. Kolodziej¹, M. Saracyn¹, A. Lubas², M. Dziuk³, A. Mazurek³, J. Smozna², O. Kaminska³, S. Niemczyk², G. Kaminski¹;
¹Department of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warszawa, POLAND, ²Department of Internal Medicine, Nephrology and Dialysis, Military Institute of Medicine - National Research Institute, Warszawa, POLAND, ³Department of Nuclear Medicine, Military Institute of Medicine - National Research Institute, Warszawa, POLAND.

OP-808

Performance of multiphase iodine contrast enhanced CZT SPECT-CT in the detection of parathyroid adenomas

M. Ochoa Figueroa, F. Askling, T. Lööw, P. Norberg, M. Ressner, J. Dahl, V. Sanchez-Rodriguez;
Universitetssjukhuset i Linköping, Linköping, SWEDEN.

1609

Tuesday, September 12, 2023, 4:45 PM - 6:15 PM
Hall G2

e-Poster Presentations Session 12 - Dosimetry Committee: Dosimetry Symphony

EPS-231

Estimation of absorbed tumour doses in patients treated with Yttrium-90 radioembolization in the prospective TRACE trial

B. Lambert¹, Y. D'Asseler², E. Dhondt², L. Hermie², L. Huyck², H. Van Vlierberghe³, L. Defreyne³;
¹AZ Maria Middelaers en AZ Jan Palfijn Gent, Gent, BELGIUM, ²Ghent University Hospital, Gent, BELGIUM, ³Ghent University, Gent, BELGIUM.

EPS-232

A Dosimetric Study of Liver and Tumors for Patients Undergoing HO-166 Microspheres Radioembolization

L. Miseso¹, G. Iaccarino¹, M. D'Andrea¹, S. Ungania¹, A. Soriani¹, F. Murtas¹, M. Pacilio², D. Maccora³, R. Sciuto³, G. E. Vallati⁴, B. Cassano¹;
¹Laboratory of Medical Physics and Expert Systems, IRCCS Regina Elena National Cancer Institute, Rome, ITALY, ²Medical Physics Division, Azienda Ospedaliera-Universitaria Policlinico Umberto I, Rome, ITALY, ³Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, ITALY, ⁴Interventional Radiology Unit, IRCCS Regina Elena National Cancer Institute, Rome, ITALY.

EPS-233

Quantification accuracy evaluation of Yttrium-90 PET for post-therapeutic voxelised dosimetry on three generations PET/CT scanners: a phantom study

G. Croes, J. van Sluis, A. Willemsen, W. Noordzij, O. Ivashchenko;
UMCG, Groningen, NETHERLANDS.

EPS-234

Overestimation in 90Y-PET/CT based mean lung doses following 90Y-radioembolization

S. Kappadath, B. P. Lopez, E. C. Henry, B. M. Kelley, A. Mahvash;
UT MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

EPS-235

A Model to Describe the DNA Damage Response in Blood Cells During Radioiodine Therapy

S. Schumann¹, H. Scherthan², S. Schoof³, P. Hartrampf⁴, A. K. Buck¹, M. Port², M. Lassmann¹, U. Eberlein¹;
¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, GERMANY.

EPS-236

Validation of a Monte Carlo Simulation Model for Quantification of DNA Double-Strand Breaks in Lymphocyte Nuclei by Ex Vivo Internal Irradiation with Radionuclides

M. Salas Ramirez¹, L. Maigne², G. Fois², H. Scherthan³, M. Lassmann¹, U. Eberlein¹;
¹University Hospital Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY, ²Physics Laboratory of Clermont, University of Clermont Auvergne, Clermont, FRANCE, ³Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, GERMANY.

EPS-237

Dose-dependent relative biological effectiveness of ²²⁵Ac compared to ¹⁷⁷Lu during [²²⁵Ac]Ac-PSMA and [¹⁷⁷Lu]Lu-PSMA radionuclide therapy

M. Rumiantcev¹, W. Li², S. Lindner¹, G. Liubchenko¹, S. Resch¹, P. Bartenstein¹, S. Ziegler¹, G. Böning¹, A. Delker¹;
¹Department of Nuclear Medicine, LMU Hospital, Munich, GERMANY, ²Federal Office for Radiation Protection, Oberschleißheim, GERMANY.

EPS-238

PET Quantification Performance of the Oversize-Volume-of-Interest Approach in the Context of Tumour Dosimetry in Radionuclide Therapy Planning

N. Hammersen, W. Jentzen, F. Stawitzki, K. Herrmann, D. Kersting, P. Fragoso Costa, A. Moraitis; Department of Nuclear Medicine at University Hospital Essen, Essen, GERMANY.

EPS-239

Investigating various parameters on the labeling efficiency of ⁶⁷Ga-phytate and its absorbed dose estimation in humans based on mouse data

z. bayat¹, N. Vahidfar², E. Saeezadeh¹, M. Sadeghi³, S. Farzanefar²;

¹Radiation Medical Engineering, Science and Research branch, Islamic Azad University, Tehran, Iran, ISLAMIC REPUBLIC OF, ²Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran, ISLAMIC REPUBLIC OF, ³Medical Physics Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran, ISLAMIC REPUBLIC OF.

EPS-240

Head-to-head comparison of ¹⁷⁷Lu-DOTATATE dosimetry between high-speed 360° CZT-SPECT/CT and conventional SPECT/CT systems

L. Imbert, C. Boursier, V. Roch, E. Chevalier, P. Marie; CHU Nancy Hopital Brabois Adultes, Vandoeuvre Les Nancy, FRANCE.

EPS-241

Validation of Lu-177 PSMA dosimetry from 113keV energy peak using digital 3D SPECT/CT imaging system

H. Gröhn, M. Hakulinen, K. T. Tapani, T. M. Laitinen; Kuopio University Hospital, Kuopio, FINLAND.

EPS-242

Semiautomatic Segmentation for Tumour Dosimetry in PSMA Radiopharmaceutical Therapy using a Novel Digital Twins Framework

R. Fedrigo^{1,2}, L. Polson^{1,2}, C. Li^{1,2}, S. Harsini¹, I. Bloise¹, J. Brosch-Lenz¹, B. Saboury³, F. Bénard^{1,2,4}, A. Rahmim^{1,2,4}, C. Uribe^{1,2,4};

¹BC Cancer Research Institute, Vancouver, BC, CANADA, ²University of British Columbia, Vancouver, BC, CANADA, ³National Institutes of Health (NIH), Bethesda, MD, UNITED STATES OF AMERICA, ⁴BC Cancer, Vancouver, BC, CANADA.

EPS-243

Does urinary excretion rate change over the courses of ¹⁷⁷Lu-PSMA therapies ?

L. Ferrer^{1,2}, M. CHABIRON³, C. Rousseau^{1,2}, N. Varmenot^{1,2}; ¹ICO René Gauducheau, St Herblain cedex, FRANCE, ²Nantes Université, Univ Angers, INSERM, CNRS, CRCI2NA, Nantes, FRANCE, ³Nantes Université, Nantes, FRANCE.

EPS-244

Outcome-Driven Assessment of Single-Time-Point Dosimetry for PSMA-Directed Radiopharmaceutical Therapy

J. Hu, S. Xue, C. Vinicius Gomes Ferreira, L. Mercolli, A. Afshar-Oromieh, A. Rominger, K. Shi; University of Bern, Department of Nuclear Medicine, 3008 Bern, SWITZERLAND.

EPS-245

Comparison of the Images Taken at the 1st and 4th Hours After ^{99m}Tc-MAA Injection in ⁹⁰Y TARE Treatment Planning

B. Kovan¹, E. Işık¹, Y. Şanlı¹, S. Kuyumcu¹, B. Demir²; ¹Istanbul Faculty of Medicine, Nuclear Medicine Department, Istanbul, TÜRKIYE, ²Istanbul University, Faculty of Science, Istanbul, TÜRKIYE.

EPS-246

Evaluation of a portable high-resolution gamma camera for personalized dosimetry during radioiodine treatment of thyroid diseases

T. Bossis^{1,2}, M. Verdier^{1,2}, L. Pinot¹, F. Bouvet¹, T. Beaumont³, D. Broggio³, S. Lamart³, O. Caselles⁴, S. Zerdoud⁴, L. Ménard^{1,2};

¹IJCLab - CNRS/IN2P3, Université Paris-Saclay, Orsay, FRANCE, ²IJCLab - CNRS/IN2P3, Université Paris Cité, Orsay, FRANCE, ³Internal Dose Assessment Laboratory, IRSN, Fontenay-aux-Roses, FRANCE, ⁴Institut Claudius Regaud, IUCTO, Toulouse, FRANCE.

EPS-247

3D Whole-Body SPECT images for dosimetry of ¹⁷⁷Lu-PSMA treatment using a 360° CZT gamma camera

L. Vergnaud¹, A. Giraudet², E. Paquet², T. Baudier¹, J. Badel¹, D. Sarrot¹;

¹Centre Léon Bérard / CREATIS, Lyon, FRANCE, ²Centre Léon Bérard, Lyon, FRANCE.

EPS-248

Comparison of Model Implementations in SAAM II and MATLAB/SimBiology: a PBPK model for PRRT with [¹⁷⁷Lu]Lu-DOTATATE

V. Vasic^{1,2}, J. Gustafsson³, E. Yousefzadeh-Nowshahr^{1,2}, A. Beer¹, K. Sjögren Gleisner³, G. Glattig^{1,2};

¹Department of Nuclear Medicine, Ulm University Medical Centre, Ulm, GERMANY, ²Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, Germany, Ulm, GERMANY, ³Medical Radiation Physics, Lund University, Lund, Sweden, Lund, SWEDEN.

EPS-249

Current Practice in Reporting Internal Dosimetry for [¹⁷⁷Lu]Lu-DOTA-TATE Therapy: Literature Review

O. Ivashchenko¹, J. O'Doherty², T. Perez³, J. Tran-Gia⁴, E. Hippeläinen⁵, M. Sandström⁶, C. Stokke⁷, G. Glattig⁸, M. Cremonesi⁹;

¹University Medical Center Groningen, Groningen, NETHERLANDS, ²Siemens Medical Solutions, Malvern, PA, UNITED STATES OF AMERICA, ³University Hospital of Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, SPAIN, ⁴University Hospital Würzburg, Würzburg, GERMANY, ⁵University of Helsinki and Helsinki University Hospital, Helsinki, FINLAND, ⁶Uppsala University, Uppsala, SWEDEN, ⁷Oslo University Hospital, Oslo, NORWAY, ⁸Ulm University Hospital, Ulm, GERMANY, ⁹European Institute of Oncology IRCCS, Milan, ITALY.

EPS-250

Clinical dosimetry in [¹⁷⁷Lu]Lu-PSMA therapy: kidney mean absorbed dose difference between subsequent cycles

E. Owers, E. Rijkhorst, M. Dotinga, L. J. de Wit-van der Veen, D. M. V. de Vries - Huizing; Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS.

EPS-251

Implementation of an ¹⁸F PET / ¹⁷⁷Lu SPECT Phantom Study for Personalized Theranostics in PSMA Radiopharmaceutical Therapies

R. Fedrigo^{1,2}, J. Tran-Gia³, J. Brosch-Lenz¹, P. Petric⁴, L. Fougner¹, K. Sabo⁴, R. Ralea⁵, S. Harsini¹, I. Bloise¹, J. Beauregard⁶, F. Bénard^{1,2,4}, A. Rahmim^{1,2,4}, C. Uribe^{1,2,4}; ¹BC Cancer Research Institute, Vancouver, BC, CANADA, ²University of British Columbia, Vancouver, BC, CANADA, ³University of Würzburg, Würzburg, GERMANY, ⁴BC Cancer, Vancouver, BC, CANADA, ⁵Vancouver General Hospital, Vancouver, BC, CANADA, ⁶Laval University, Laval, QC, CANADA.

1610

Tuesday, September 12, 2023, 16:45 - 18:15
Hall K

CTE 8 - Technologists Committee: Gynaecological Studies

OP-809

Gynaecological studies: where NM is and its importance

K. Dendl; Heidelberg University Hospital, Department of Nuclear Medicine, Heidelberg, GERMANY.

OP-810

Radiotracers used in gynaecological studies

N. Hartman; Swansea University, Head of nuclear medicine, Singleton Hospital, Swansea, UNITED KINGDOM.

OP-811

The role of the Technologists in Gynaecological studies: protocols and patient care

G. Paixão; Hospital Garcia de Orta, Departamento de Medicina Nuclear Hospital Garcia de Orta, Almada, PORTUGAL.

1611

Tuesday, September 12, 2023, 16:45 - 18:15
Hall G1

EU Policy Symposium 2 - Policy & Regulatory Affairs Committee: Regulatory Challenges of Radiopharmaceuticals

OP-813

Regulatory Challenges of Radiopharmaceuticals

1701

Wednesday, September 13, 2023, 08:00 - 09:30
Hall A

CME 13 - Translational Molecular Imaging & Therapy + Oncology & Theranostics + Radiopharmaceutical Sciences Committee: Diagnostic Imaging and Theranostics in Breast Cancer - Old Targets, New Tracers

OP-819

Targeting HER2 from Preclinical to the Clinics

M. Keyaerts; Department of Nuclear Medicine, Faculty of Medicine and Pharmacy, University Hospital Brussels, Free University Brussels, Jessa Hospital, Hasselt, BELGIUM.

OP-820

Estrogen Receptor-Targeted Imaging: Appropriate Use Criteria (AUC) and Interpretation

G. Ulaner; Hoag Family Cancer Institute, New Port Beach, UNITED STATES OF AMERICA.

OP-821

Clinical Targets Beyond the Classical Approaches

P. Backhaus; Department of Nuclear Medicine, University Hospital Munster, Münster, GERMANY.

1702

Wednesday, September 13, 2023, 08:00 - 09:30
Hall D (Arena)

Debate 6 - Oncology & Theranostics Committee / EHA: Staging Lymphoma - Ann Arbour Outdated and Replaced by MTV?

OP-822

Staging Lymphoma: Ann Arbour outdated and replaced by Metabolic Tumor Volume? - Pro

A. Cottreau; Department of Nuclear Medicine, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, FRANCE.

OP-823

Staging Lymphoma: Ann Arbour outdated and replaced by Metabolic Tumor Volume? - Contra

B. von Tresckow; Department of Hematology and Stem Cell Transplantation, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY.

1703

Wednesday, September 13, 2023, 08:00 - 09:30
Hall E1

LIPS Session 13 - Dosimetry Committee:
Case Reading - Dosimetry in SIRT

OP-827

Dosimetry in whole liver and whole lobe targeting
E. Garin;
Cancer Centre Eugene Marquis, Department
of Nuclear Medicine, Rennes, FRANCE.

OP-828

**Dosimetry in specific tumour and oligosegmental
targeting**
A. Hartevelde;
Erasmus Medical Center, Department of Radiology
and Nuclear Medicine, Rotterdam, NETHERLANDS.

OP-829

Dosimetry of off-target accumulation
C. Chiesa;
Department of Nuclear Medicine, Fondazione
IRCCS Istituto Nazionale Tumori, Milan, ITALY.

1704

Wednesday, September 13, 2023, 8:00 AM - 9:30 AM
Hall E2

Dosimetry Committee - TROP Session:
Clinical Disimetry II - Tutti Frutti

OP-831

**An Update on Normal Tissue Absorbed Doses
for Patients Treated with [¹⁷⁷Lu]Lu-lilotomab
satetraxetan; Results From Two Studies**
J. Blakkisrud^{1,2}, A. Løndalen¹, R. Midthun¹, C. Stokke^{1,3};
¹Oslo University Hospital, Oslo, NORWAY, ²University
of Michigan, Ann Arbor, MI, UNITED STATES OF
AMERICA, ³University of Oslo, Oslo, NORWAY.

OP-832

**Absorbed Doses to Kidneys and Tumours for Alpha-
Emitter Peptide Receptor Radionuclide Therapies
Estimated with [¹⁷⁷Lu]Lu-DOTATATE SPECT Images
and Biokinetic Models**
M. Kvasshem^{1,2}, J. Blakkisrud^{1,3}, M. E. Revheim^{4,2,5}, A. J.
Tulipan^{4,6}, C. Stokke^{1,7};
¹Department of Physics and Computational Radiology,
Division of Radiology and Nuclear Medicine, Oslo University
Hospital, Oslo, NORWAY, ²Faculty of Medicine, University of
Oslo, Oslo, NORWAY, ³University of Michigan, Ann Arbor,
MI, UNITED STATES OF AMERICA, ⁴Department of Nuclear
Medicine, Division of Radiology and Nuclear Medicine,
Oslo University Hospital, Oslo, NORWAY, ⁵The Intervention
Centre, Oslo University Hospital, Oslo, NORWAY, ⁶Nuclear
Medicine/PET center, Department of Radiology, Haukeland
University Hospital, Bergen, NORWAY, ⁷Department
of Physics, University of Oslo, Oslo, NORWAY.

OP-833

**Comparison of Commercial Software Solutions for
¹⁷⁷Lu Labelled Radiopharmaceutical Therapies**
S. Beykan, M. Lassmann, S. Schlögl;
University Hospital Würzburg, Würzburg, GERMANY.

OP-834

**Determination of the treatment coverage of
theragnostic ¹²⁴I-8H9 antibody to treat diffuse
pontine glioma by convective enhance delivery**
A. França Velo¹, A. Giantini Larsen^{2,3}, J. Humm¹, P.
Zanzonico¹, M. Souweidane³, N. Pandit-Taskar⁴;
¹Department of Medical Physics, Memorial Sloan
Kettering Cancer Center, New York, NY, UNITED STATES
OF AMERICA, ²Department of Neurosurgery, Memorial
Sloan Kettering Cancer Center, New York, NY, UNITED
STATES OF AMERICA, ³Department of Neurological
Surgery, Weill Medical College of Cornell University, New
York, NY, UNITED STATES OF AMERICA, ⁴Department
of Radiology, Memorial Sloan Kettering Cancer
Center, New York, NY, UNITED STATES OF AMERICA.

OP-835

**Accuracy of single-time-point dosimetry using a
population-based model selection and Bayesian
fitting method**
B. Patrianeshah¹, A. Jundi¹, M. Naqiyun², D. Hardiansyah¹;
¹Medical Physics and Biophysics Research Group, Physics
Department, Faculty of Mathematics and Natural
Sciences, Universitas Indonesia, Depok, INDONESIA, ²Nuclear Medicine Department,
MRCCC Siloam Hospital, Jakarta, INDONESIA.

OP-836

**AI-Generated Synthetic Intermediate Projections
could enable SPECT-based bone marrow dosimetry
with reduced acquisition time**
K. Smits¹, F. Westerbergh¹, J. Hemmingsson¹, J. Svensson², T.
Rydén³, P. Bernhardt^{1,3};
¹Department of Medical Radiation Sciences, Institute
of Clinical Sciences, Sahlgrenska Academy at
University of Gothenburg, Gothenburg, SWEDEN,
²Department of Oncology, Institution of Clinical
Sciences, Sahlgrenska Academy at University of
Gothenburg, Gothenburg, SWEDEN, ³Department of
Medical Physics and Biomedical Engineering (MFT),
Sahlgrenska University Hospital, Gothenburg, SWEDEN.

OP-837

**RPT-TEC assessment of normal organ toxicity
avoidance thresholds for alpha-emitter
radiopharmaceutical therapy - an appeal for data.**
J. Hesterman¹, R. Hobbs², G. Sgouros²;
Radiopharmaceutical Therapy Normal Tissue Effects in the
Clinic (RPT-TEC);
¹Ratio Therapeutics, Boston, MA, UNITED
STATES OF AMERICA, ²Johns Hopkins University,
Baltimore, MD, UNITED STATES OF AMERICA.

OP-838

**Impact Of Small Patient Motion During SPECT/CT
Scans Onto Activity Quantification Of ¹⁷⁷Lu-PSMA
Based on A Phantom Simulation**
S. Resch¹, X. Shen¹, M. Reymann², F. Basi Massanes³, P.
Bartenstein¹, G. Platsch², A. Vija³, G. Böning¹, A. Delker¹;
¹LMU Klinikum Großhadern, München, GERMANY,
²Siemens Healthcare GmbH, Molecular Imaging,
Forchheim, GERMANY, ³Siemens Medical Solutions
UNITED STATES OF AMERICA Inc., Molecular Imaging,
Hoffman Estates, IL, UNITED STATES OF AMERICA.

OP-839

**Comparison of transmission-dependent and
energy-window based scatter correction methods
for quantitative SPECT imaging for ²²⁵Ac**
G. Liubchenko, M. Rumiantcev, S. Resch, M. Zacherl, F.
Gildehaus, P. Bartenstein, S. Ziegler, G. Böning, A. Delker;
LMU Klinikum Munich, Munich, GERMANY.

1705

Wednesday, September 13, 2023, 8:00 AM - 9:30 AM
Hall B

Cutting Edge Science Track - Featured
Session: Dynamic Imaging

OP-840

State of the Art in Quantitative Dynamic Imaging
G. Wang;
Department of Radiology, University of California Davis
Health, Scacramento, UNITED STATES OF AMERICA

OP-841

**Prediction of bone turnover in chronic kidney
disease with hemodialysis patients using K₁-Patlak
dynamic ¹⁸F-NaF PET/CT imaging**
K. Khamwan¹, V. Sanoesan¹, J. Phannajit¹, T. Sawatnatee²,
B. Phromphao², C. Sukprakhun¹, P. Susantitaphong¹, K.
Kingpetch¹;
¹Chulalongkorn University, Bangkok, THAILAND, ²King
Chulalongkorn Memorial Hospital, Bangkok, THAILAND.

OP-842

**Automated and reproducible processing and
kinetic modelling of whole-body [¹⁵⁰]H₂O PET/CT
data**
S. Palonen¹, J. Tuisku², H. Kärijoki², S. Nesterov², V.
Oikonen², R. Klén², L. Nummenmaa², J. Knuuti¹;
¹Turku PET centre, Turku University, Turku,
FINLAND, ²Turku PET centre, Turku, FINLAND.

OP-843

**Shortening Dynamic [¹¹C]PK11195 PET Protocol for
Parametric Imaging Using Supervised Clustering to
Improve Clinical Feasibility**
D. B. A. Mantovani¹, M. S. Pitombeira¹, P. N. Schuck², C.
Buchpiguel¹, D. de Paula Faria¹, A. Marques da Silva¹;
¹University of Sao Paulo, Sao Paulo, BRAZIL, ²Weill Cornell
Medical College, New York, NY, UNITED STATES OF AMERICA.

OP-844

**Feasibility of Dynamic Total-Body Pre-therapy PET
for Predicting Radiopharmaceutical Therapy (RPT)
Dosimetry: a simulation study**
J. Hong¹, M. Kassar², A. Rominger¹, K. Shi¹;
¹University of Bern/Inselspital, Bern, SWITZERLAND,
²Technical University Munich, Munich, GERMANY.

OP-845

**Voxel-wise parametric imaging of 4D PET data
:evaluation of new software solution for [¹⁸F]-FDG
PET kinetic modeling at the whole FOV level.**
F. Besson^{1,2}, E. Marchal¹, S. Faure³;
¹CEA / Inserm / CNRS / Université Paris Saclay,
BioMaps, Orsay, FRANCE, ²Department of Nuclear
Medicine-Molecular Imaging, Hôpitaux Universitaires
Paris Saclay, AP-HP, Le Kremlin-Bicêtre, FRANCE,
³Laboratoire de Mathématique d'Orsay, CNRS,
Université Paris Saclay, Orsay, FRANCE.

OP-846

**Incorporating prior knowledge with physics-
informed neural networks to predict arterial input
functions from dynamic PET images**
M. Ferrante¹, M. Inglese¹, L. Brusaferrri², A. C. Whitehead³, M.
L. Loggia⁴, N. Toschi¹;
¹University of Rome Tor Vergata, Roma, ITALY,
²Department of Radiology, Athinoula A. Martinos
Center for Biomedical Imaging, Boston, MA, UNITED
STATES OF AMERICA, ³Institute of Nuclear Medicine,
University College London, (UNITED KINGDOM),
London, UNITED KINGDOM, ⁴Department of
Radiology, Athinoula A. Martinos Center for Biomedical
Imaging, Boston, MA, UNITED STATES OF AMERICA.

OP-847

**Impact of AI-based Image Denoising on
Quantitative Kinetic Analysis in Dynamic PET
imaging**
B. Liu¹, G. Hu², X. Wang², L. Huo², H. Ding¹, H. Zhang¹;
¹Tsinghua University, Beijing, CHINA, ²Peking Union
Medical College Hospital, Beijing, CHINA.

OP-848

**Myocardial Dynamic Positron Emission Tomography
Later Time Frames Prediction Using Deep Learning**
M. Mokri¹, M. Safari², L. Archambault², S. Kaviani¹, D.
Juneau³, C. Cohalan³, J. Carrier^{1,3};
¹Université de Montréal, Montreal, QC, CANADA, ²Université
Laval, Quebec City, QC, CANADA, ³Centre hospitalier
de l'Université de Montréal, Montreal, QC, CANADA.

1706

Wednesday, September 13, 2023, 8:00 AM - 9:30 AM
Hall C

Clinical Oncology Track - TROP Session:
Localised Treatments

OP-849

**Is there any factor that influences the quality of the
I125 placement in non palpable breast lesions?**
O. Ajuria Illarramendi, A. Martinez Lorca, U. Vera
Schmulling, P. Azpeitia Hernandez, M. Gutierrez Guerrero, P.
Paredes Rodriguez, T. Navarro Martinez, M. Orduña Diez;
Hospital universitario ramon y cajal, Madrid, SPAIN.

OP-850

**Investigation on Dose-Toxicity and Dose-Response
Relationship in Neuroendocrine Liver Metastases
treated with Holmium-166 Radioembolization**
K. Ramdhani, J. J. Verduin, S. C. Ebbers, M. L. J. Smits, R. C.
G. Bruijnen, M. G. E. H. Lam, A. J. A. T. Braat;
University Medical Center Utrecht, Utrecht, NETHERLANDS.

OP-851

Radioembolization of HCC Patients for Curative Intent with Personalized Yttrium-90 Dosimetry (RAPY90D)

S. Kappadath, E. C. Henry, B. P. Lopez, A. Mahvash; UT MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

OP-852

166Holmium-SIRT after PRRT (HEPAR PLuS) versus PRRT-only in Patients with Metastatic Neuroendocrine Tumors: a Propensity-score Matched Analysis

A. Braat¹, T. Walter², D. de Vries-Huizinga³, J. Theysohn⁴, S. Barton⁵, E. Ekkelenkamp⁶, B. Lachach², R. de Jong⁶, L. van Golen³, H. Lanzafame⁴, L. Milot², H. Lahner¹, W. Veldhuis¹, M. Tesselaa³, M. Lam¹;

¹University Medical Center Utrecht, Utrecht, NETHERLANDS, ²Hospices Civils de Lyon, Lyon, FRANCE, ³NKI-AVL, Amsterdam, NETHERLANDS, ⁴University Hospital Essen, Essen, GERMANY, ⁵Barton Biostatistics Ltd, London, UNITED KINGDOM, ⁶Medical Affairs Interventional Oncology Terumo Europe NV, Leuven, BELGIUM.

OP-853

Intratumoral Holmium-166 Microsphere Brachytherapy in Patients with Pancreatic Ductal Adenocarcinoma: The Sloth Project

C. Y. Willink, S. F. M. Jenniskens, M. W. J. Stommel, M. J. R. Janssen, J. J. Fütterer, K. J. H. M. van Laarhoven, J. F. W. Nijssen; Radboudumc, Nijmegen, NETHERLANDS.

OP-854

A phase II trial to evaluate the accuracy of an intra-operative radio-guided approach with a beta probe for 68Ga-DOTATOC in patients affected by GEP-NET of the ileum.

F. Mattana¹, E. Bertani², F. Collamati³, R. Mirabelli³, A. M. Bonomi², A. Barone¹, L. L. Travaini¹, M. Ferrari⁴, E. Pisa⁵, N. Fusco⁵, U. Fumagalli Romario², F. Ceci^{1,6};

¹IEO European Institute of Oncology, Nuclear Medicine, Milano, ITALY, ²IEO European Institute of Oncology, Division of Digestive Surgery, Milano, ITALY, ³INFN National Institute of Nuclear Physics, Nuclear Physics, Rome, ITALY, ⁴IEO European Institute of Oncology, Medical Physics, Milano, ITALY, ⁵IEO European Institute of Oncology, Pathology, Milano, ITALY, ⁶Department of Oncology and Hemato-Oncology, University of Milan, ITALY.

OP-855

Prediction of acute radiation-induced lung toxicity after SBRT using dose-volume parameters from functional mapping on Gallium-68 lung perfusion PET/CT

P. Le Roux, D. Bourhis, F. Pinot, M. Hamya, G. Goasduff, F. Blanc, S. Hennebicq, M. Mauguen, K. Kerleguer, U. Schick, M. Consigny, O. Pradier, G. Le Gal, P. Salaun, V. Bourbonne, F. Lucia; Brest University Hospital, Brest, FRANCE.

OP-856

Intra-arterial Administration of PRRT in Patients with Advanced Meningioma

A. Amerein¹, A. Rinscheid², A. Gäble¹, A. Krebold¹, O. Viering¹, A. Berlis³, C. Maurer³, C. Lapa¹, C. Pfob¹, R. Bundschuh¹;

¹Nuclear Medicine, faculty of medicine, University of Augsburg, Augsburg, GERMANY, ²Medical Physics, University Hospital Augsburg, Augsburg, GERMANY, ³Neuroradiology, faculty of medicine, University of Augsburg, Augsburg, GERMANY.

OP-857

Preliminary Clinical data in the Phase 1/2a Dose Escalation Trial of 186RNL (Rhenium-186 nanoliposome) (186Re) Obisbameda in Leptomeningeal Metastases (LM): the ReSPECT-LM Trial

W. Phillips¹, A. Bao², N. LaFrance³, M. Hedrick³, M. Moore³, T. Patel⁴, J. Floyd¹, M. Youssef¹, J. Michalek¹, A. Brenner¹;

¹The University of Texas Health Science Center at San Antonio, San Antonio, TX, UNITED STATES OF AMERICA, ²Case Western Reserve University, San Antonio, TX, UNITED STATES OF AMERICA, ³Plus Therapeutics, Inc, Austin, TX, UNITED STATES OF AMERICA, ⁴UT Southwestern Medical Center, Dallas, TX, UNITED STATES OF AMERICA.

1707

Wednesday, September 13, 2023, 8:00 AM - 9:30 AM
Hall F1

Cardiovascular Committee - TROP Session: Heart Failure, Sarcoidosis and Amyloidosis

OP-858

Current practices and access to cardiac bone scans for the detection of transthyretin cardiac amyloidosis based on the results of a large national electronic survey

F. Hyafil^{1,2}, W. Amara³, T. Bardin⁴, B. Bouquillon⁵, G. Canal⁶, M. Dubois⁶, P. Fournier⁷, S. Guignard⁸, C. Labeyrie⁹, D. Legallois¹⁰, S. Oghina¹¹, N. Piriou¹², P. Sabouret¹³, C. Sauvage⁵, O. Toulza¹⁴, R. Tresorier¹⁵, M. Walle¹⁶, T. Damy¹⁷;

¹AP-HP, Paris, FRANCE, ²APHP, European Hospital Georges-Pompidou, Department of Nuclear Medicine, Paris, FRANCE, ³GHI Le Raincy-Montfermeil, Department of Cardiology, Montfermeil, FRANCE, ⁴University Hospital Strasbourg, Department of Internal Medicine, Strasbourg, FRANCE, ⁵Carely, Lille, FRANCE, ⁶Pfizer, Paris, FRANCE, ⁷University Hospital Toulouse, Department of Cardiology, Toulouse, FRANCE, ⁸University Hospital Henri Mondor, UPEC, Department of Rheumatology, Créteil, FRANCE, ⁹University Hospital Bicêtre, Referral Center for Familial Amyloid Neuropathy and other Rare Peripheral Neuropathies, Department of Neurology, Paris, FRANCE, ¹⁰University Hospital of Caen-Normandy, Department of Cardiology, Caen, FRANCE, ¹¹APHP (Assistance Publique-Hôpitaux de Paris), Department of Cardiology, French Referral Centre for Cardiac Amyloidosis, Cardiogen Network, Henri Mondor University Hospital, Paris, FRANCE, ¹²University Hospital of Nantes, Department of Cardiology, Thorax Institute, Nantes, FRANCE, ¹³Cardiovascular Prevention Institute, Paris, FRANCE, ¹⁴University Hospital of Toulouse, Department of Geriatrics, Toulouse, France, Toulouse, FRANCE, ¹⁵University Hospital of Clermont Ferrand, Department of Cardiology, Clermont Ferrand, FRANCE,

¹⁶Edouard Herriot Hospital, HCL, Department of Upper Limb Orthopedic Surgery, Lyon, FRANCE, ¹⁷APHP (Assistance Publique-Hôpitaux de Paris), Department of Cardiology, French Referral Centre for Cardiac Amyloidosis, Cardiogen Network, Henri Mondor University Hospital, Créteil, FRANCE.

OP-859

SPECT/CT SUV based metrics: a promising diagnostic tool in patients with suspected transthyretin cardiac amyloidosis.

S. Koukouraki^{1,2}, N. Kapsoritakis^{1,2}, O. Bourogianni^{1,2}, M. Stathaki^{1,2}, I. Zaganas^{3,4}, A. Patrianakos^{3,5}, A. Plevritaki^{1,5}, D. Corela⁶, M. Marketou⁷, E. Foukarakis⁶;

¹Medical School, University of Crete, Heraklion-Crete, GREECE, ²Nuclear Medicine department, Medical School, University of Crete, Heraklion, crete, GREECE, ³Medical School, University of Crete, HERAKLION, CRETE, GREECE, ⁴Neurology Department, Medical School, University of Crete, Heraklion, crete, GREECE, ⁵Cardiology Department, Medical School University of Crete, Heraklion, crete, GREECE, ⁶Cardiology Department Venizeleion Hospital, Heraklion-Crete, GREECE, ⁷Cardiology Department, Medical School, University of Crete, Heraklion-Crete, GREECE.

OP-860

99mTc-hydroxydiphosphonate Uptake in Soft Tissue Reflects Amyloid Load in Subcutaneous Abdominal Fat Tissue and Harbors Prognostic Value in Wild Type Transthyretin Amyloidosis Patients

H. Tingen¹, D. Groothof¹, A. Tubben¹, E. J. Houwerzijl¹, F. L. H. Muntinghe¹, P. van der Meer¹, B. P. C. Hazenberg¹, H. L. A. Nienhuis¹, R. H. J. A. Slart^{1,2};

¹University Medical Center Groningen, Groningen, NETHERLANDS, ²University Twente, Enschede, NETHERLANDS.

OP-861

Agreement of 68Ga-DOTANOC PET/CT with 18F-FDG PET/CT and Cardiac MR in sarcoid patients with suspected cardiac involvement: A tertiary care center experience

R. Solanki, A. Sood, S. Kumar, B. R. Mittal; Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, INDIA.

OP-862

Cardiac Viability Imaging With 15O-H2O/18F-FDG Positron Emission Tomography Does Not Predict Left Ventricular Ejection Fraction Improvement After Revascularization in Patients With Chronic Ischemic Heart Failure

M. Gram Kjærulff¹, K. Pryds², R. Nielsen², S. Madsen¹, T. V. Luong¹, L. P. Tolbod¹, L. C. Gormsen¹;

¹Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, DENMARK, ²Department of Cardiology, Aarhus University Hospital, Aarhus, DENMARK.

OP-863

Epicardial adipose tissue is differently associated with myocardial remodeling and perfusion in heart failure with reduced and preserved ejection fraction

Y. Cui, C. Zheng, S. Gu, J. Lu; Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, CHINA.

OP-864

Relationship between left ventricular mechanical dyssynchrony with cardiac resynchronization therapy response in chronic heart failure patients with CRT-D

T. Atabekov, A. Mishkina, R. Batalov, S. Sazonova, S. Krivolapov, V. Saushkin, M. Khlynin, Y. Varlamova, K. Zavadovsky, S. Popov; Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences", Tomsk, RUSSIAN FEDERATION.

OP-865

The prognostic value of mechanical and electrical dyssynchrony and hibernating myocardium in patients with ischemic heart failure: a comparative study of medical and revascularization therapy

L. Shan¹, X. Zhang²; ¹Department of Cardiology, Beijing Anzhen Hospital, Beijing, CHINA, ²Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Beijing, CHINA.

OP-866

C-X-C Motif Chemokine Receptor 4-directed Molecular Imaging of the Cardiac Lymphatic System after Acute Myocardial Infarction - Initial Results from the Phase II LOMI Trial

A. Kosmala¹, A. Dörrler¹, N. Hasenauer¹, N. Kraus², S. E. Serfling¹, P. E. Hartrampf¹, A. K. Buck^{1,3}, T. Higuchi^{1,3,4}, T. Reiter², R. A. Werner^{1,3,5};

¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Department of Internal Medicine I, Cardiology, University Hospital Würzburg, Würzburg, GERMANY, ³Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, GERMANY, ⁴Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, JAPAN, ⁵The Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.

1708

Wednesday, September 13, 2023, 08:00 - 09:30
Hall F2

Joint Symposium 6 - Neuroimaging Committee / EAN: Progress in Multimodal Imaging of Parkinson's Disease

OP-867

Novel MR Techniques to Image Parkinson's Disease

E. van de Giessen; Amsterdam UMC, Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-868

Transcranial Sonography to Image Parkinson's Disease

R. Yilmaz; Ankara University Faculty of Medicine, Ilni Sina Hospital, Ankara, TÜRKIYE.

OP-869

Novel PET Tracers to Image Parkinson's Disease
S. Jakobsen Mo;
Umeå University, Department of Radiation Sciences,
Umeå, SWEDEN.

1709

Wednesday, September 13, 2023, 8:00 AM - 9:30 AM
Hall G2

**e-Poster Presentations Session 13 -
Oncology & Theranostics Committee:
Head and Neck Tumours, Lung, Melanoma
and Others**

EPS-252

**Predictors for Disease Free and Progression
Free Survival in Metabolic Responders and
Non-responders on follow-up FDG PET/CT after
Chemoradiation in Nasopharyngeal Cancers**
**M. Zaman¹, N. Fatima², R. Tahseen³, A. Ahmed¹, A. Zaman⁴,
S. Zaman⁵, U. Zaman⁶;**
¹Dept of Radiology, Aga Khan University Hospital, Karachi,
PAKISTAN, ²Dept of Radiology, Aga Khan University
Hospital, KARACHI, PAKISTAN, ³Dept of Radiation Oncology,
Aga Khan University Hospital, Karachi, PAKISTAN, ⁴Dept
of Medicine, Sunny Downstate Medical Centre, NY,
New York, NY, UNITED STATES OF AMERICA, ⁵Dept of
Medicine, Dr Ruth Pfau Hospital, Karachi, PAKISTAN,
⁶Dept of Hem Oncology, Oklahoma University, Okla,
Oklahoma, OK, UNITED STATES OF AMERICA.

EPS-253

**Performance of hybrid [¹⁸F]FDG PET-MRI for staging
of head and neck cancer**
**E. Droogers, I. J. Pruis, A. W. A. van der Eerden, A. A.
Harteveld, R. Valkema, S. E. M. Veldhuijzen van Zanten;
Erasmus Medical Center, Rotterdam, NETHERLANDS.**

EPS-254

**The Validity of F-18-FDG PET/CT in the Management
of the Patients with Laryngeal Carcinoma After
Therapy**
**J. Petrovic, J. Milovanovic, A. Jotic, D. Sobic Saranovic;
Center for Nuclear Medicine, University
Clinical Center of Serbia, Faculty of Medicine,
University of Belgrade, Belgrade, SERBIA.**

EPS-255

**PET/CT-guided GTV delineation during
radiotherapy planning and prognosis evaluation in
recurrent oral cavity squamous cell carcinoma**
**Y. Tian, Y. Zhang, C. Li, Y. He;
Zhongnan Hospital of Wuhan University, Wuhan, CHINA.**

EPS-256

**Detection of Perineural Tumour Spread in Head and
Neck Cancers by 18F-FDG PET/CT**
**A. Ormanci, M. Tuncel;
Hacettepe University Faculty of Medicine, Department
of Nuclear Medicine, Ankara, TÜRKIYE.**

EPS-257

**18F-FDG PET CT and Tumour Tissue Modified Viral
(TTMV) -Human papilloma virus DNA : Role in
Recurrent HPV driven oropharyngeal squamous cell
carcinoma.**
**R. Kulkarni, M. Posner, S. Roof, M. Ghesani, N. Ghesani;
Mount Sinai Hospital, New York, NY,
UNITED STATES OF AMERICA.**

EPS-258

**Convolutional Neural Network for Prediction of
Early Disease Progression in Patients with Advanced
Epidermal Growth Factor Receptor-Mutated
Lung Adenocarcinoma Receiving Tyrosine Kinase
Inhibitor Therapy Based on 18F-FDG PET Images**
K. Lue¹, Y. Chen^{2,3}, L. Yong¹, X. Wong¹, S. Liu^{1,2}, H. Lin^{4,5};
¹Tzu Chi University of Science and Technology,
Hualien, TAIWAN, ²Hualien Tzu Chi Hospital, Hualien,
TAIWAN, ³Tzu Chi University, Hualien, TAIWAN, ⁴Chang
Gung University, Taoyuan, TAIWAN, ⁵Keelung Chang
Gung Memorial Hospital, Keelung, TAIWAN.

EPS-259

**Role Of Novel Geometric Variables Derived From
18F-FDG PET/CT As Predictive Factors In Patients
With Non-Small Cell Lung Cancer**
**G. Jimenez Londoño¹, A. M. Garcia Vicente², J. J. Bosque³,
J. Perez-Beteta³, M. Amo-Salas⁴, A. F. Hongoero-Martinez⁵, E.
Noriega Alvarez¹, C. Lucas Lucas¹, V. M. Perez-Garcia³, A. M.
Soriano Castrejon²;**
¹Department of Nuclear Medicine, Hospital General
Universitario de Ciudad Real, Ciudad Real, SPAIN,
²Department of Nuclear Medicine, Complejo Hospitalario
Universitario de Toledo, Toledo, SPAIN, ³Department
of Mathematics, Mathematical Oncology Laboratory
(MOLAB), Universidad de Castilla-La Mancha,
Ciudad Real, SPAIN, ⁴Department of Mathematics,
Universidad de Castilla-La Mancha, Ciudad Real,
SPAIN, ⁵Department of Surgery, Hospital General
Universitario de Albacete, Albacete, SPAIN.

EPS-260

**Correlation between 18F-FDG-PET parameters and
outcome od Durvalumab treatment in unresectable
locally advanced Non Small Cell Lung Cancer
(NSCLC, stage IIIa-b-c)**
**K. Beshiri¹, F. G. Dall'Olio¹, M. Aldea¹, C. Genova², F. Barlesi¹,
A. Botticella¹, A. Levy¹, C. Le Pechoux¹, P. Lavaud¹, M. Frelaut¹,
P. Abdayem¹, J. Remon Masip¹, D. Planchard¹, B. Besse¹, S.
Ponce-Aix¹, F. Selhane¹, D. Deandreis¹, M. Bauckneht², C.
Garcia¹;**
¹Institute Gustave Roussy, Villejuif, FRANCE, ²IRCCS
Ospedale Policlinico San Martino, Genova, ITALY.

EPS-262

**Usefulness of imaging parameters by FDG-PET/
CT and conventional CT in early T-stage lung
adenocarcinoma patients who underwent surgery**
**S. Tsukamoto, S. Koyasu, M. Hamaji, H. Date, Y. Nakamoto;
Kyoto University, Kyoto, JAPAN.**

EPS-263

**Prognostic Value of Total Body Metabolic Tumour
Volume in Patients with Advanced SCLC Treated by
Chemotherapy and Immunotherapy.**
**A. CABARET¹, C. GARCIA¹, F. DALL-OLIO¹, E. AUCLIN², B.
BESSE¹, P. LAVAUD¹;**
¹Institut Gustave Roussy, Villejuif, FRANCE,
²Hopital George Pompidou, Paris, FRANCE.

EPS-264

**Lymph Node Ultrasound Prior to Sentinel Lymph
Node Biopsy in 414 Patients with Melanoma:
Usefulness in the Era of Adjuvant Systemic Therapy**
**G. Horvatic Herceg¹, S. Kusacic-Kuna², M. Cigliar-Hlasc², D.
Herceg³, L. Simatec³, D. Mijatovic⁴;**
¹University Hospital Zagreb, Zagreb, CROATIA, ²Department
of nuclear medicine and radiation protection, University
Hospital Zagreb, Zagreb, CROATIA, ³Clinic of oncology,
University Hospital Zagreb, Zagreb, CROATIA, ⁴Clinic of
surgery, University Hospital Zagreb, Zagreb, CROATIA.

EPS-265

**Could lymphadenectomy be avoided in a selection
of patients diagnosed with cutaneous melanoma
with metastatic sentinel lymph node biopsy?**
**B. Hervás-Sanz¹, M. T. Bajén-Lázaro¹, J. G. Reyes-Junca¹,
A. M. Benítez-Segura¹, I. E. Sánchez-Rodríguez¹, S. Maymó-
Garrido², J. L. Díaz-Moreno¹, M. A. Crespi-Busquets²,
M. Pudiš¹, S. Bondia-Bescós¹, R. M. Penín-Mosquera³, J.
Marcoval-Caus⁴, J. O. Bermejo-Segú⁵, J. J. Martín-Libera⁶, I.
Linares-Galiana⁷, M. Cortés-Romera¹;**
¹Nuclear Medicine-PET (IDI) Department, Bellvitge
University Hospital-IDIBELL, L'Hospitalet de Llobregat,
SPAIN, ²Radiopharmaceutical Department, Bellvitge
University Hospital-IDIBELL, L'Hospitalet de Llobregat,
SPAIN, ³Anatomical Pathology Department, Bellvitge
University Hospital-IDIBELL, L'Hospitalet de Llobregat,
SPAIN, ⁴Dermatology Department, Bellvitge University
Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ⁵Plastic
Surgery Department, Bellvitge University Hospital-IDIBELL,
L'Hospitalet de Llobregat, SPAIN, ⁶Medical Oncology
Department, Institut Català d'Oncologia, L'Hospitalet de
Llobregat, SPAIN, ⁷Radiation Oncology Department, Institut
Català d'Oncologia, L'Hospitalet de Llobregat, SPAIN.

EPS-266

**Can physiologic colonic [18F]FDG uptake in PET/
CT imaging predict response to immunotherapy in
metastatic melanoma?**
**C. Sachpekidis¹, C. K. Stein-Thoeringer², A. Kopp-
Schneider¹, V. Weru¹, A. Dimitrakopoulou-Strauss¹, J. C.
Hassel³;**
¹German Cancer Research Center (DKFZ), Heidelberg,
GERMANY, ²Laboratory of Translational Microbiome
Science, Internal Medicine I, University Clinic Tuebingen,
Tuebingen, GERMANY, ³Department of Dermatology
and National Center for Tumor Diseases (NCT),
University Hospital Heidelberg, Heidelberg, GERMANY.

EPS-267

**The role of 18F-FDG PET/CT in changing the
therapeutic plan in cutaneous melanoma patients
at different clinical stages and time points of the
disease.**
**Z. Dancheva, T. Stoeva, M. Dyankova, S. Chausheva, T.
Yordanova, B. Chaushev, A. Klisarova;
Medical University, "Prf. Dr. Paraskev
Stoyanov", Varna, BULGARIA.**

EPS-268

**Prognostic Value of Restaging FDG-PET/CT for
Detecting Recurrence in Patients with Malignant
Cutaneous Melanoma**
**M. Contreras Ameduri¹, E. Noriega-Álvarez¹, M. Sicilia
Pozo¹, C. Lucas Lucas¹, A. Padilla Bermejo¹, M. Cruz
Montijano², L. García Zoghby², F. Pena Pardo¹, M. Talavera
Rubio¹, A. García Vicente², Á. Soriano Castrejon², V. García
Poblete¹;**
¹Servicio de Medicina Nuclear, Hospital General
Universitario de Ciudad Real, Ciudad Real,
SPAIN, ²Servicio de Medicina Nuclear, Hospital
Universitario de Toledo, Toledo, SPAIN.

EPS-269

**Survival and risk factors analysis for locoregional
and distant metastases in patients with sentinel
lymph node-negative cutaneous melanoma**
**A. Leiva Montejo, A. Blesa Jimenez, A. De Agrela Serrao,
C. Ruiz Corbalán, D. Cáceres Silva, J. Contreras Gutierrez, J.
Navarro Fernández, A. Hernandez Martinez, T. Rodriguez
Lorcano, L. Frutos Esteban, L. Mohamed Salem, M.
Castellon Sánchez;
Hospital Virgen de la Arrixaca, Murcia, SPAIN.**

EPS-270

**A steerable modality for simultaneous radio- and
fluorescence-guidance during robotic surgery**
**M. van Oosterom^{1,2}, L. J. Slof¹, S. I. van Leeuwen¹, S.
Azargoshasb¹, A. Berrens², K. Houwing¹, H. G. van der Poel²,
F. W. B. van Leeuwen¹;**
¹Leiden University Medical Center, Leiden, NETHERLANDS,
²NETHERLANDS Cancer Institute - Antoni van
Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.

EPS-271

**Feasibility of [99mTc] Tc-FAPI-SPECT Imaging for
Detection of Primary Tumors, Lymph Node, and
Distant Metastasis in Various Cancers**
**S. Rezaei, E. Gharepapagh, S. Dabiri Oskue;
Department of Nuclear Medicine, Medical
School, Tabriz University of Medical Sciences,
Tabriz, IRAN, ISLAMIC REPUBLIC OF.**

EPS-272

**The Role of [18F]FDG PET/CT for predicting
histology and prognosis in patients with thymic
lesions**
**A. Castello¹, P. Mendogni², M. Cattaneo², L. Rosso², G. A.
Crocì³, S. Pacella¹, L. Florimonte¹, F. Lococo⁴, S. Margaritora⁴,
S. Ferrero³, M. Nosotti², M. Castellani¹;**
¹Department of Nuclear Medicine, Fondazione
IRCCS Ca' Granda, Ospedale Maggiore Policlinico,
Milan, ITALY, ²Thoracic Surgery, Fondazione IRCCS
Ca' Granda, Ospedale Maggiore Policlinico, Milan,
ITALY, ³Division of Pathology, Fondazione IRCCS
Ca' Granda, Ospedale Maggiore Policlinico, Milan,
ITALY, ⁴Department of Thoracic Surgery, Fondazione
Policlinico Universitario A. Gemelli, IRCCS, Rome, ITALY.

1710a

Wednesday, September 13, 2023, 08:00 - 09:00
Hall K

Mini Course 1 - Technologists Committee: Radiotherapy Planning Using PET/CT and PET/MR

OP-871

Hybrid imaging in radiotherapy and the role of technologists

B. Bak;
Radiotherapy Department II, Greater Poland Cancer Centre, Poznan, POLAND.

OP-872

PET/CT based radiotherapy planning

V. Mautone;
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS U.o.s Medicina Nucleare Diagnostica, Meldola (FC), ITALY.

OP-873

PET/MRI based radiotherapy planning

D. Sipos;
Somogy County Kaposi Mór Teaching Hospital, Dr. József Baka Center, Department of Radiation Oncology, Kaposvár, HUNGARY.

1710b

Wednesday, September 13, 2023, 09:05 - 10:05
Hall K

Mini Course 2 - Technologists Committee: AI in the Technologists Practice

OP-875

Improving PET imaging based on artificial intelligence

M. De Summa;
Medipass S.p.a. c/o Fondazione Policlinico Universitario A. Gemelli IRCCS, PET-CT, Radiopharmacy and AI Research Laboratory, Rome, ITALY.

OP-876

AI in the Technologists Practice.

C. Votta;
Fondazione Policlinico Universitario A. Gemelli IRCCS, Department of Diagnostic Imaging, Oncological, Radiotherapy and Hematology, Rome, ITALY.

1710c

Wednesday, September 13, 2023, 10:15 - 11:15
Hall K

Mini Course 3 - Technologists Committee: Phantoms Management

OP-940

The use of phantoms in QC & QA

K. Matuszewski;
Greater Poland Cancer Centre, Medical Physics Dep, Poznan, POLAND.

OP-941

Gamma Camera & PET-CT vs PET-MRI phantoms management

D. Sørensen;
Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK.

OP-942

Phantoms in practice & Computer-based phantom models

C. Abreu;
Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM.

1711

Wednesday, September 13, 2023, 8:00 AM - 9:30 AM
Hall G1

Case Report Session 3 - TROP Session: Every Day a Discovery with FAP and Novel Targets

OP-878

FAPi imaging identified occurrence of fibrosis may indicate rapid progression of liver failure induced by immune checkpoint inhibitor

X. Jia¹, R. Tao¹, Y. Yang¹, Y. Wang¹, X. Li¹, B. Jia², R. Gao¹;
¹The first hospital of Xi'an jiaotong university, Xi'an, CHINA, ²Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, CHINA.

OP-879

Is This a Real [68Ga]Ga-FAPI Scan? The Strange Case of [68Ga]Ga-FAPI-avid Liver

E. Fortunati¹, G. Cuzzani¹, S. Telo², C. Nanni³, P. Castellucci³, A. Farolfi³, L. Zanon³, T. Galasso⁴, M. Ferrari⁴, F. Natali⁴, G. Bandelli⁴, P. Candoli⁴, S. Fanti^{1,3};
¹Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear Medicine Unit, AUSL Romagna, Cesena, ITALY, ³Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Interventional Pulmonology Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-880

Role of 68Ga FAPI-04 PET/CT in detecting cardiac sarcoidosis in a patient mimicking malignancy and its comparison with 18F-FDG PET/CT

S. Patel, P. Sundaram, P. Sundaram, F. Saju;
Amrita Institute of Medical Sciences & Research Center, Kochi, INDIA.

OP-881

An Example of How [68Ga]Ga-FAPI PET/CT can Potentially Help Changing The Therapeutic Process of Patients with Sarcoma

G. Cuzzani¹, E. Fortunati¹, M. Focaccia², S. Telo³, A. Farolfi⁴, C. Nanni⁴, P. Castellucci⁴, T. Frisoni², B. Spazzoli², C. Plenteda⁵, D. M. Donati², S. Fanti^{1,4};
¹Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Orthopaedic Oncology Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, ITALY, ³Nuclear Medicine Department, AUSL Romagna, Romagna, ITALY, ⁴Nuclear Medicine IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁵Hematology and Bone Marrow Transplant Center Unit, Parma University Hospital, Parma, ITALY.

OP-882

[68Ga]Ga-FAPI PET/CT: a Valid Aid in Breast Cancer Not Only for Malignancies Reporting

G. Cuzzani¹, E. Fortunati¹, S. Telo², C. Nanni³, P. Castellucci³, A. Farolfi³, S. Zanotti⁴, S. Grendele⁵, D. Rosini⁴, M. Taffurelli⁴, S. Fanti^{1,3};
¹Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear Medicine Department, AUSL Romagna, Romagna, ITALY, ³Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Breast Surgery, Department of Oncology and Hematological Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁵Breast Surgery, Department of Functional Oncology, AULSS 7 Pedemontana, Santorso Hospital, Vicenza, ITALY.

OP-883

Comparative PET/CT imaging in a patient with metastatic clear cell renal cell carcinoma: 68Ga-NY104 versus 68Ga-PSMA versus 18F-FDG

W. Zhu, X. Li, Y. Zhang, Y. Li, L. Huo;
Peking Union Medical College Hospital, Beijing, CHINA.

OP-884

[99mTc]Tc-HYNIC-TOC as an alternative to [123I]mIBG for Neuroblastoma Staging, a Comparative Case Series

K. Hlongwa, A. Brink, O. Kolade, A. Alnabulsi, S. More;
Red Cross War Memorial Children's Hospital and University of Cape Town, Cape Town, SOUTH AFRICA.

OP-885

[18F]F-SynVesT-1 PET In a Rare Case of Paraneoplastic Neurological Syndrome Associated With Isolated Anti-amphiphysin Antibodies

Y. Tang, L. Xiao, J. Yang, S. Hu;
Xiangya Hospital Central South University, Changsha, CHINA.

1801

Wednesday, September 13, 2023, 09:45 - 11:15
Hall A

CME 14 - Neuroimaging + Paediatric Committee: Modern Imaging of Paediatric Epilepsy

OP-886

Clinical Point of View on Paediatric Epilepsy with a Focus on [18F]FDG PET/MR

L. De Palma;
Ospedale Pediatrico Bambino Gesù, Dipartimento di Neuroscienze e Neuroriabilitazione, Rome, ITALY.

OP-887

Cortical Morphology and MR Post Processing in Paediatric Epilepsy

A. Hammers;
Kings College, London, UNITED KINGDOM.

OP-888

How Imaging Helps the Surgeon in Paediatric Epilepsy

K. Goffin;
UZ Leuven, Leuven, BELGIUM.

OP-889

Are We Really Ready to Go with New PET Tracers in Paediatric Epilepsy?

D. Van Weehaeghe;
UZ Gent, Gent BELGIUM.

1802

Wednesday, September 13, 2023, 09:45 - 11:15
Hall D (Arena)

Round Table 3 - Women's Empowerment Task Force: Women in Science - Special Focus on Nuclear Medicine

OP-890

Women in Nuclear Medicine: the past and the present

O. Israel;
Nuclear Medicine, Rambam Health Care Campus, Haifa, ISRAEL.

OP-891a

The challenges of Women Technologists in Nuclear Medicine

A. Santos;
Department of Nuclear Medicine, Hospital Cuf Descobertas, Lisbon, PORTUGAL.

OP-891b

Women in Nuclear Medicine: the present and the future

L. de Geus-Oei;
Department of Radiology, Leiden University Medical Center (LUMC), Leiden, NETHERLANDS.

OP-891c

Radiochemist and to be a woman: what are the main challenges?

E. Eppard;
Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, GERMANY.

OP-891d

Physicist, Woman, Nuclear Medicine: how to conjugate them?

C. Stokke;
Department of Physics and Computational Radiology,
Division of Radiology and Nuclear Medicine, Oslo, NORWAY.

1803

Wednesday, September 13, 2023, 09:45 - 11:15
Hall E1

LIPS Session 14 - Translational Molecular Imaging & Therapy + Physics + Radiation Protection + Oncology & Theranostics + Ethics Committee: Beta Emitters for Radioguided Surgery - Challenges and Opportunities

OP-892

Developments in instrumentation and probes

K. Shi;
Department of Nuclear Medicine, Inselspital, Bern
University Hospital, University of Bern, Bern, SWITZERLAND.

OP-893

Radiation protection in beta RGS nuts and bolts

E. Ciarrocchi;
Department of Physics "E. Fermi",
University of Pisa, Pisa, ITALY.

OP-894

Protocols and clinical relevance of beta RGS

C. Darr;
Department of Urology, University Hospital Essen,
Essen, GERMANY.

1804

Wednesday, September 13, 2023, 9:45 AM - 11:15 AM
Hall E2

M2M Track - TROP Session: New Therapeutic Radiopharmaceuticals

OP-895

Radiometal modification of JMV6659 for theranostic approach of NTS1 targeting

S. Bodin^{1,2}, S. Previti³, S. Fernandez⁴, D. Vimont², F. Masmjean², E. Rémond³, A. Khatib⁵, P. Garrigue^{4,6}, B. Guillet^{4,6}, E. Hindie^{7,2}, F. Cavellier³, C. Morgat^{1,2};
¹Radiopharmacy, Nuclear Medicine, Bordeaux Hospital University Center, Bordeaux, FRANCE, ²IMT, INCIA UMR-5287 CNRS, University of Bordeaux, Bordeaux, FRANCE, ³Univ. Montpellier, CNRS, Institut des Biomolécules Max Mousseron, IBMM, UMR-5247, Montpellier, FRANCE, ⁴Aix Marseille Univ, CNRS, CERIMED, Marseille, FRANCE, ⁵RyTME, Bordeaux Institute of Oncology (BRIC), UMR 1312 Inserm, University of Bordeaux, Bordeaux, FRANCE, ⁶Radiopharmacy, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, FRANCE, ⁷Nuclear Medicine, Bordeaux Hospital University Center, Bordeaux, FRANCE.

OP-896

Prostate Specific Membrane Antigen in Human and Mouse Tissue

T. Kalidindi, T. Esposito, D. Adilbay, P. Demetrio De Souza Franca, R. Payne, N. Pillarsetty;
Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

OP-897

DARPin platform for the development of powerful targeting agents for radioligand therapy

C. Lizak¹, A. Bosshart¹, S. Wullschleger¹, M. Behe², A. Blanc², S. Imobersteg², A. Constantinescu¹, J. Blunschli¹, L. Abdul¹, S. Schütz¹, J. Wolter¹, Z. Ziauddin Siddiqui¹, M. Matzner¹, A. Auge¹, N. Fic¹, W. Ali Abobaker Hassan¹, T. Chiorazzo², C. Reichen¹, A. Croset¹, A. Villa¹, P. Legenne¹, A. Goubier¹, R. Schibbl², D. Steiner¹;
¹Molecular Partners AG, Schlieren, SWITZERLAND, ²Paul Scherrer Institute, Villigen, SWITZERLAND.

OP-898

[198Au]Au Labeled Gold Nanoparticle Depot ([198Au]Au-NPD) Inhibits the Growth of a 4T1 Murine Mammary Carcinoma Tumor on Immunocompetent BALB/c Mice without Normal Tissue Toxicity and Causes an Abscopal Effect on a Distant Non-irradiated Tumor

Z. Cai¹, C. J. Georgiou¹, M. Kondo¹, C. Chan¹, R. Liu¹, M. Moran², A. Armstrong², R. M. Reilly^{1,3,4};
¹Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, CANADA, ²McMaster Nuclear Reactor, McMaster University, Hamilton, ON, CANADA, ³Department of Medical Imaging, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, CANADA, ⁴Joint Department of Medical Imaging and Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CANADA.

OP-899

Radioactive immuno-imaging and radioimmunotherapy of 131I-labeled human single-chain variable fragment antibodies against anaplastic thyroid cancer in tumor-bearing nude mice

Q. Liu¹, H. Pang²;
¹the Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Ho, Chengdu, Sichuan, CHINA, ²The First Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China, Chongqing, Sichuan, CHINA.

OP-900

Preparation of 47SC-labeled DOTA-RGD4 tetramer and preliminary preclinical study on its application in iodine-refractory differentiated thyroid carcinoma

X. Jiang;
Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital), chengdu, CHINA.

OP-901

PSMA-Targeted Single Domain Antibody Fragment NB7: Preliminary Evaluation as a Scaffold for Targeted α -particle Therapy of Prostate Cancer

T. Huynh¹, Y. Feng¹, R. Meshaw¹, X. Zhao¹, L. Rosenfeld², N. Papo², M. Zalutsky¹;
¹Duke University, Durham, NC, UNITED STATES OF AMERICA, ²Ben-Gurion University of the Negev, Beer-Sheva, ISRAEL.

OP-902

177Lu-labeled aflibercept for theranostic application in renal cancer models

L. Kang, Z. Chen, Q. Yang, Y. Qiu, W. Huang, L. Song, X. Sun;
Peking University First Hospital, Beijing, CHINA.

OP-903

Development of cobalt-55 labelled neurotensin antagonist NOTA-SR142948 for cobalt-58m NTSR1 targeted radionuclide therapy

W. Lin¹, G. O. Fonseca Cabrera², E. Aluicio Sarduy¹, T. E. Barnhart¹, Z. Li², Z. Wu², J. W. Engle¹;
¹University of Wisconsin Madison, Madison, WI, UNITED STATES OF AMERICA, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, UNITED STATES OF AMERICA.

1805

Wednesday, September 13, 2023, 9:45 AM - 11:15 AM
Hall B

Cutting Edge Science Track - TROP Session: Clinical Dosimetry III - Time & Co.

OP-904

Single-time-point [68Ga]Ga-DOTATATE-PET/CT for model-based prediction of the time-integrated activity of [177Lu]Lu-DOTATATE during therapy

V. Vasic^{1,2}, J. Gustafsson³, E. Yousefzadeh-Nowshahr^{1,2}, A. Beer¹, K. Sjögren Gleisner³, G. Glatting^{1,2};
¹Department of Nuclear Medicine, Ulm University Medical Centre, Ulm, GERMANY, ²Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, Germany, Ulm, GERMANY, ³Medical Radiation Physics, Lund University, Lund, Sweden, Lund, SWEDEN.

OP-905

Accuracy of predicted kidney's absorbed doses in [177Lu]Lu-PSMA-617 therapy using single-time-point data and non-linear mixed effect modelling

D. Hardiansyah¹, E. Yousefzadeh-Nowshahr², F. Kind³, A. J. Beer², J. Ruf³, G. Glatting², M. Mix³;
¹Universitas Indonesia, Depok, INDONESIA, ²Ulm University, Ulm, GERMANY, ³University of Freiburg, Freiburg, GERMANY.

OP-906

Accuracy and Uncertainty Analysis of Reduced Time Point Imaging Effect on Time-Integrated Activity for [177Lu]Lu-DOTA-TATE PRRT in Clinical Patients and Realistic Simulations

A. Peterson^{1,2}, D. M. Miranda³, Y. K. Dewaraja¹;
¹University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA, ²Wayne State University, Detroit, MI, UNITED STATES OF AMERICA, ³MIM Software Inc, Beachwood, OH, UNITED STATES OF AMERICA.

OP-907

Non-Uniqueness of Multiexponential Time-Activity Curves in Few-Timepoint Theranostic Workflows Can Increase Dosimetric Error

D. Balfour, J. Sage, J. Willaime, D. Boukerroui;
Mirada Medical Ltd., Oxford, UNITED KINGDOM.

OP-908

Estimating Biochemical PSA Dynamics after Radioligand Therapy with [177Lu]Lu-PSMA-I&T Using a Population Pharmacokinetic/ Pharmacodynamic Model

H. Siebinga^{1,2}, B. J. de Wit - van der Veen¹, D. M. V. de Vries - Huizing¹, J. J. M. A. Hendriks^{1,2}, A. D. R. Huitema^{2,3,4};
¹Department of Nuclear Medicine, NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS, ²Department of Pharmacy and Pharmacology, NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS, ³Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, NETHERLANDS, ⁴Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, NETHERLANDS.

OP-909

Population-based model selection for iodine kinetics in benign thyroid disease

D. Hardiansyah¹, A. Riana¹, H. Hänscheid², M. Lassmann², G. Glatting³;
¹Universitas Indonesia, Depok, INDONESIA, ²University Hospital Würzburg, Würzburg, GERMANY, ³Ulm University, Ulm, GERMANY.

OP-910

131I Thyroid lesion dosimetry with quantitative imaging

E. Richetta, C. Cutaia, A. Codegone, V. Garbaccio, R. Pellerito, M. Stasi;
Ordine Mauriziano Hospital, Turin, ITALY.

OP-911

Evaluation of images from patients treated with 224Ra-CaCO3-microparticles for peritoneal metastases - can 224Ra be quantified using SPECT/CT?

S. Grønningsæter¹, L. G. Mikalsen^{1,2}, J. Blakkisrud¹, M. Revheim^{1,3}, S. Westrom⁴, S. Selboe¹, Ø. Bruland^{5,6}, S. Larsen⁷, C. Stokke^{1,8};
¹Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY, ²Department of Life Sciences and Health, Oslo Metropolitan University, Oslo, NORWAY, ³Faculty of Medicine, University of Oslo, Oslo, NORWAY, ⁴Oncoinvent AS, Oslo, NORWAY, ⁵Department of Oncology, Oslo University Hospital, Oslo, NORWAY, ⁶Institute of Clinical Medicine, Oslo University Hospital, Oslo, NORWAY, ⁷Department of Gastroenterological Surgery, Oslo University Hospital, Oslo, NORWAY, ⁸Department of Physics, University of Oslo, Oslo, NORWAY.

OP-912

90Y Voxel S-Values updated Monte Carlo database including Internal Bremsstrahlung and new analytical model extending the evaluation to any voxel size

D. Pistone^{1,2}, L. Auditore^{1,2}, A. Italiano^{2,3}, E. Amato^{1,2,4};
¹Department of Biomedical and Dental Sciences and of Morphofunctional Imaging (BIOMORF), University of Messina, Messina, ITALY, ²INFN, National Institute for Nuclear Physics, Section of Catania, Catania, ITALY, ³Department of Mathematical and Computer Science, Physical Sciences and Earth Sciences (MIPT), University of Messina, Messina, ITALY, ⁴Health Physics Unit, University Hospital "Gaetano Martino", Messina, ITALY.

1806

Wednesday, September 13, 2023, 9:45 AM - 11:15 AM
Hall C

Clinical Oncology Track - TROP Session:
Radiomics

OP-913

Texture Analysis of 68Ga-DOTATOC PET/CT Images For the Prediction of Outcome in Patients With Neuroendocrine Tumors

S. Pellegrino¹, R. Fonti¹, R. Bologna¹, M. Panico¹, R. Morra², G. Palmieri², M. Giuliano², S. De Placido², S. Del Vecchio¹; ¹Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, ²Department of Clinical Medicine and Surgery, University Federico II, Naples, ITALY.

OP-914

Association Between Absorbed Dose Heterogeneity and Metabolic Response in HCC Patients Undergoing Transarterial Radioembolization with Y-90 Resin Microspheres

N. Coskun¹, M. Kartal², A. Erdogan², E. Ozdemir¹; ¹Ankara Bilkent City Hospital, Ankara Yildirim Beyazit University, Ankara, TÜRKIYE, ²Ankara Bilkent City Hospital, Ankara, TÜRKIYE.

OP-915

Development of clinical-radiomic model on baseline FDG-PET images in non-small-cell-lung cancer patients, referred to radical lung surgery

L. Travaini, G. Zuccotti, F. Botta, S. Netti, M. Casiraghi, M. Ferrari, A. Gaeta, P. Rocca, F. Mattana, S. Fracassi, A. Barone, G. Buonsanti, G. Petralia, L. Spaggiari, F. Ceci; EUROPEAN INSTITUTE OF ONCOLOGY, Milano, ITALY.

OP-916

Texture Analysis of 18F-FDG PET/CT Images for the Prediction of Outcome in Patients with Multiple Myeloma

S. Pellegrino¹, D. Origlia¹, C. Vallone¹, R. Della Pepa², S. Del Vecchio¹, R. Fonti¹; ¹Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY, ²Department of Clinical Medicine and Surgery, University Federico II, Naples, ITALY.

OP-917

Inter-institutional validation of a [18F]-FDG PET radiomic signature to predict the location of tumor recurrence after re-irradiation in head and neck cancer in an independent cohort

A. Beddok^{1,2}, K. Grogg², L. Rozenblum^{3,2}, C. Nioche¹, F. Orhac¹, H. Shih⁴, T. Marin², I. Buvat¹, G. El Fakhri²; ¹Institut Curie, PSL Research University, University Paris Saclay, Inserm LITO, Paris, FRANCE, ²Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA, ³Department of Nuclear Medicine, AP – HP Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Sorbonne Université, Paris, FRANCE, ⁴Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA.

OP-918

Multi-imaging adaptive radiotherapy for locally advanced head and neck cancer: preliminary results from the RadiomicART study

F. Gelardi^{1,2}, C. Franzese^{1,3}, M. Teriaca³, M. Badalamenti³, M. Rogh³, D. Dei^{1,3}, C. Giannitto⁴, M. Rodari³, M. Scorsetti^{1,3}; ¹Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), ITALY, ²Department of Nuclear Medicine, IRCCS Humanitas Research Hospital, Rozzano (MI), ITALY, ³Department of Radiation Oncology, IRCCS Humanitas Research Hospital, Rozzano (MI), ITALY, ⁴Department of Diagnostic Imaging, IRCCS Humanitas Research Hospital, Rozzano (MI), ITALY.

OP-919

Application of an artificial intelligence-based tool in [18F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma

C. Sachpekidis¹, O. Enqvist², J. Ulén³, A. Kopp-Schneider¹, L. Pan¹, A. Jauch⁴, M. Hajjiyanni⁵, L. John⁵, N. Weinhold⁵, S. Sauer⁵, H. Goldschmidt⁵, L. Edenbrandt⁶, A. Dimitrakopoulou-Strauss¹; ¹German Cancer Research Center (DKFZ), Heidelberg, GERMANY, ²Department of Electrical Engineering, Chalmers University of Technology, Department of Electrical Engineering, Chalmers Uni, SWEDEN, ³Eigenvision AB, Eigenvision AB, SWEDEN, ⁴Institute of Human Genetics, University of Heidelberg, Heidelberg, GERMANY, ⁵Department of Internal Medicine V, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), Heidelberg, GERMANY, ⁶Department of Clinical Physiology, Region Västra Götaland, Sahlgrenska University Hospital, Department of Clinical Physiology, Region Västra G, SWEDEN.

OP-920

Development and validation of 18F-PSMA PET/CT-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy

T. Li, K. Zhao, X. Su; The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CHINA.

OP-921

Radiomic analysis of pre-surgery FDG-PET images in early-stage Non-Small Lung Cancer patients can improve outcome stratification

L. Travaini, G. Zuccotti, M. Ferrari, M. Casiraghi, F. Botta, M. Colandrea, F. Mattana, C. Zanini, L. Gilardi, M. Calabrese, F. Bellerba, L. Spaggiari, G. Petralia, F. Ceci; European Institute Of Oncology, Milano, ITALY.

1807

Wednesday, September 13, 2023, 9:45 AM - 11:15 AM
Hall F1

Inflammation & Infection Committee -
TROP Session: COVID-19: Isn't it over yet?

OP-922

Noninvasive imaging of inflammatory processes by macrophage-directed PET-tracers during a SARS-CoV-2-infection in cynomolgus macaques (Macaca fascicularis)

M. Stammes¹, G. Koopman¹, T. Wagner², B. Traenkle², P. Kaiser², A. Maurer³, J. Schwenck³, U. Rothbauer³, M. Kneiling³, D. Sonanini³; ¹BPRC, Rijswijk, NETHERLANDS, ²University of Tübingen, Reutlingen, GERMANY, ³Eberhard Karls University, Tübingen, GERMANY.

OP-923

Role of 18F-FDG PET/CT in detecting residual or recurrent disease after surgery in patients with rhino-orbital-cerebral mucormycosis: a pilot study

A. Phulia¹, I. Singh¹, R. Kumar²; ¹Maulana Azad Medical College, New Delhi, INDIA, ²All India Institute of Medical Sciences, New Delhi, INDIA.

OP-924

Covid-19. Before and after in the diagnosis of pulmonary embolism in nuclear medicine. Our experience.

C. Ruiz Corbalán, A. Leiva Montejó, A. De Agrela Serrao, D. Cáceres Silva, M. Castellón Sanchez, L. Mohamed Salem, J. Navarro Fernandez, T. Rodriguez Locarno, A. Hernandez Martinez, L. Frutos Esteban, J. Contreras Gutierrez; Arrixaca, Murcia, SPAIN.

OP-925

Results of V/Q SPECT in the evaluation of pulmonary Long COVID - a two-year analysis of the pandemic

J. Lepej^{1,2}, I. Marin^{1,2}, K. Lepejová³, I. Kuglová¹, A. Obušeková¹, I. Polčová¹, O. Zahornický⁴, M. Duránik⁵; ¹Institut of Nuclear and Molecular Medicine, Košice, SLOVAKIA, ²Clinic of Nuclear Medicine UPJŠ LF and INMM, Košice, SLOVAKIA, ³Department of Clinical Biochemistry, Haematology and Immunology - Cumulus s.r.o., Košice, SLOVAKIA, ⁴Clinic of Infectious Diseases and Travel Medicine, UPJŠ and UNLP, Košice, SLOVAKIA, ⁵Faculty of Medicine University P.J. Šafarik, Košice, SLOVAKIA.

OP-926

Incidental Acute COVID-19 Infection during Radioligand Therapy

A. Mishra, R. P. Baum, C. Müller, C. Landvogt; Curanosticum, Wiesbaden, GERMANY.

OP-927

FDG PET CT in the Neurological manifestations of COVID-19

N. Seniary¹, R. Verma¹, R. Ranjan², E. Belho¹, H. Mahajan¹; ¹Mahajan Imaging & labs, New Delhi, INDIA, ²Department of Neurology, Sir Ganga Ram Hospital, New Delhi, INDIA.

OP-928

Neuroinflammation in post-COVID individuals with and without persistent complaints 2 years after infection: a [18F]DPA-714 PET study

D. Visser^{1,2}, S. S. V. Golla^{1,2}, S. C. J. Verfaillie³, A. Verveen³, D. W. Koch³, R. M. Rikken^{1,2}, E. van de Giessen^{1,2}, M. E. den Hollander¹, J. Horn^{2,4}, C. M. van Heugten⁵, M. D. de Jong^{6,7}, C. C. van den Wijngaard⁸, T. van der Maaden⁸, Y. M. G. van Os⁹, M. Prins^{6,10}, J. M. A. Visser-Meijl¹¹, P. Schober¹², R. C. Schuit^{1,2}, A. D. Windhorst^{1,2}, S. Biere-rafi¹³, B. Appelman^{6,14}, M. van Vugt^{6,15}, F. Barkhof^{1,16}, B. N. M. Berckel^{1,2}, R. Boellaard^{1,2}, H. Knoop³, N. Tolboom¹⁷;

¹Department of Radiology & Nuclear Medicine, Amsterdam

Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS, ²Amsterdam Neuroscience, Brain Imaging, Amsterdam, NETHERLANDS, ³Department of Medical Psychology, University of Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS, ⁴Amsterdam UMC location University of Amsterdam, Intensive Care, Meibergdreef 9, Amsterdam, NETHERLANDS, ⁵Department of Psychiatry and Neuropsychology, Maastricht University Faculty of Health Medicine and Life Sciences & department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience Maastricht University, Maastricht, NETHERLANDS, ⁶Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, NETHERLANDS, ⁷Amsterdam UMC location University of Amsterdam, Medical Microbiology & Infection Prevention, Meibergdreef 9, Amsterdam, NETHERLANDS, ⁸National Institute for Public Health and the Environment (RIVM), Center for Infectious Disease Control, Bilthoven, NETHERLANDS, ⁹Occupational Health Office, Department of Human Resources, University Medical Center Utrecht, Utrecht, NETHERLANDS, ¹⁰Amsterdam UMC location University of Amsterdam, Infectious Diseases, Meibergdreef 9, Amsterdam, NETHERLANDS, ¹¹Department of Rehabilitation, Physical Therapy Science and Sports, University Medical Centre Utrecht, Utrecht, NETHERLANDS, ¹²Department of Anaesthesiology, Location VUMC, Amsterdam UMC, Amsterdam, NETHERLANDS, ¹³C-support, 's-Hertogenbosch, NETHERLANDS, ¹⁴Amsterdam UMC location University of Amsterdam, Center for Experimental and Molecular Medicine, Meibergdreef 9, Amsterdam, NETHERLANDS, ¹⁵Amsterdam UMC location University of Amsterdam, Division of Infectious Diseases, Tropical Medicine, Department of Medicine, Meibergdreef 9, Amsterdam, NETHERLANDS, ¹⁶Institute of Neurology and Healthcare Engineering, University College London, London, UNITED KINGDOM, ¹⁷Department of Radiology & Nuclear Medicine, University Medical Centre Utrecht, Utrecht, NETHERLANDS.

OP-929

Little recovery of brain metabolic impairment in patient with persistent long COVID: a [18F]FDG PET study

T. Horowitz, P. Dudouet, E. Kaphan, T. Radulesco, S. Gonzalez, S. Cammilleri, A. Menard, E. Guedj; APHM, Marseille, FRANCE.

OP-930

Extracerebral findings from [18F]DPA-714 PET/CT using a long axial field of view PET scanner in post-COVID

D. Visser^{1,2}, X. Palard-Novello^{1,2,3}, M. Yaqub^{1,2}, E. van der Giessen^{1,2}, M. den Hollander^{1,2}, A. D. Windhorst^{1,2}, S. C. J. Verfaillie⁴, F. Barkhof^{1,2,5}, H. Knoop⁴, B. N. M. van Berckel^{1,2}, S. S. V. Golla^{1,2}, N. Tolboom⁶, R. Boellaard^{1,2}; ¹Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS, ²Amsterdam Neuroscience, Brain Imaging, Amsterdam, NETHERLANDS, ³Centre Eugène Marquis, Rennes, FRANCE, ⁴Department of Medical Psychology, University of Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS, ⁵Queen Square Institute of Neurology and Centre for Medical Image Computing, University College, London, UNITED KINGDOM, ⁶Department of Radiology & Nuclear Medicine, University Medical Centre Utrecht, Utrecht, NETHERLANDS.

1808

Wednesday, September 13, 2023, 9:45 AM - 11:15 AM
Hall F2

Bone & Joint Committee - Featured Session: Unconventional Bone & Joint: FAPI and Beyond

OP-931

Unconventional Bone & Joint

S. Annunziata;

Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, ITALY.

OP-932

68Ga-FAPI PET/CT novel diagnostic tool in sarcoma.

H. Lanzafame^{1,2}, R. Hamacher^{2,3}, I. A. Mavroei^{2,3}, K. M. Pabst^{1,2}, N. Hirmas¹, L. Kessler^{1,2}, T. Bartel^{1,2}, S. Leyser^{1,2}, F. Barbato^{1,2}, M. Schuler^{2,3}, S. Bauer², J. T. Siveke^{2,3,4}, K. Herrmann^{1,2}, W. P. Fendler¹;

¹Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, GERMANY, ²German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, GERMANY, ³Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, GERMANY, ⁴Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, GERMANY.

OP-933

Head-to-head Comparison of [68Ga]Ga-FAPI04 and [18F]-FDG PET/CT Imaging in Recurrent/Metastatic Solitary Fibrous Tumor Patients

R. Wang^{1,2,3}, J. Wang^{1,2,3}, G. Wang^{1,2,3}, L. Li^{1,2,3}, Z. Zhu^{1,2,3}, X. Chen^{4,5,6}, J. Zhang^{4,5,6};

¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, CHINA, ²State Key Laboratory of Complex Severe and Rare Diseases, Beijing, CHINA, ³Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, CHINA, ⁴Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE, ⁵Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE, ⁶Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.

OP-934

Prognostic value of fluorodeoxyglucose positron emission tomography derived metabolic parameters and textural features in soft tissue and bone sarcomas

N. Aydin, G. Mützelizade, G. Gümüşer, E. Sayıt Bilgin; Celal Bayar University, Manisa, TÜRKIYE.

OP-935

Assessing bone metabolism in chronic kidney disease-mineral bone disease (CKD-MBD) using 18F-NaF PET/CT Imaging

M. Usmani¹, N. Ahmed², F. Marafi³, G. Gnanasegaran⁴, T. Van den Wyngaert⁵;

¹Sultan Qaboos Comprehensive Cancer Care and Research center (SQCCRC), Muscat, OMAN, ²Jack

Brignall PET/CT Centre, Castle Hill Hospital, Cottingham, UNITED KINGDOM, ³Jaber Al-Ahmad Molecular Imaging Center, Kuwait, kuwait, KUWAIT, ⁴Royal Free Hospital NHS Trust, London, UNITED KINGDOM, ⁵Antwerp University Hospital, Antwerp, BELGIUM.

OP-936

99mTc-HDP-SPECT/CT in axial pain: comparison with magnetic resonance imaging and impact on image guided therapeutic intervention.

M. ROMERA¹, Á. Bronte¹, V. Betech-Antar¹, F. Mínguez¹, S. Menéndez-Sánchez¹, J. Bastidas¹, E. Guillén², L. Sancho², L. García-Belaustegui², J. Arbizu¹, M. García Velloso¹, M. Rodríguez¹, A. Arcadi¹, V. Rodrigo¹, N. Varela¹, F. Pareja¹, J. Rosales¹;

¹Clínica Universidad de Navarra, Navarra, SPAIN, ²Clínica Universidad de Navarra, Madrid, SPAIN.

OP-937

The value of Tc-99m-DPD bone scintigraphies in patients with alkaptonuria. A promising imaging tool for disease monitoring?

D. Schmitt¹, S. vom Dahl², K. Mattes-György¹, E. Novruzov¹, M. Dabir¹, S. David², K. Jan Philipp¹, T. Lüdde², M. Busch², E. Mamlin¹, F. Giesel¹;

¹Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, GERMANY, ²Clinic for Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, GERMANY.

OP-938

^{99m}Tc-NTP15-5, proteoglycan tracer: Phase I trial (CARSPECT)

M. Chanchou¹, P. Auzeloux¹, N. Sas¹, T. Billoux¹, S. Levesque¹, E. Thivat¹, E. Jouberton¹, E. Miot-Noirault², M. Galmier², M. Couderc³, S. Mathieu³, X. Durando¹, F. Cachin¹;

¹Centre Jean Perrin/UMR1240 INSERM (IMoST)/UCA, Clermont-Ferrand, FRANCE, ²UMR1240 INSERM (IMoST)/UCA, Clermont-Ferrand, FRANCE, ³CHU/UCA, Clermont-Ferrand, FRANCE.

OP-939

Comparison and Clinical Significance of Hybrid Imaging and Planar Bone Scintigraphy in Patients With Oncological Lesions

P. Korol¹, O. Shcherbina¹, M. Tkachenko²;

¹Shupik National University Healthcare of Ukraine, Kyiv, UKRAINE, ²Bogomolets National Medical University of Ukraine, Kyiv, UKRAINE.

1809

Wednesday, September 13, 2023, 9:45 AM - 11:15 AM
Hall G2

e-Poster Presentations Session 14 - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy - New Imaging Agents

EPS-273

Molecular PET/CT mapping of rhACE2 distribution and quantification in organs: a helper for SARS-CoV-2 targeting therapy

Z. Wang^{1,2}, C. Zhao³, C. Li⁴, Q. Liu⁵, H. Zhu^{6,5}, Y. Liu¹;

¹School of Basic Medical Science, Southwest Medical University, Luzhou, CHINA, ²Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cance, Beijing, CHINA, ³Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital and Institute, Beijing, CHINA, ⁴Department of Nuclear Medicine, First Affiliated Hospital of Hebei North University, Zhangjiakou, CHINA, ⁵Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Shenzhen, CHINA, ⁶Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Product Administration), Department of Nuclear Medicine, Peking University Ca, Beijing, CHINA.

EPS-274

Evaluating a suite of anti-FAP nanobody constructs as PET imaging agents.

J. Gallant, Z. T. Rosenkrans, K. L. Ott, N. Y. Luo, A. S.

Thickens, R. Hernandez, A. M. LeBeau; University of Wisconsin, School of Medicine and Public Health, Madison, WI, UNITED STATES OF AMERICA.

EPS-275

Close but no cigar? In vitro properties of small molecule PD-L1 ligands assessed by real-time radioligand binding in comparison to peptides and antibodies.

C. Donat¹, F. Krutzeck¹, K. Zarschler¹, K. Kopka^{1,2,3}, S. Stadlbauer^{1,2};

¹Helmholtz Centre Dresden-Rossendorf, Dresden, GERMANY, ²Technical University Dresden, Dresden, GERMANY, ³National Center for Tumor Diseases, Dresden, GERMANY.

EPS-276

Al18F-DX600-BCH

J. Ding¹, Q. Zhang¹, J. Jiang¹, N. Zhou¹, Z. Yu¹, Z. Wang¹, X. Meng¹, T. Liu¹, F. Wang¹, z. Lu¹, X. Yang², Z. Yang¹, P. Du¹, Z. Hua¹;

¹Peking University Cancer Hospital & Institute, Beijing, CHINA, ²Peking University First Hospital, Beijing, CHINA.

EPS-277

Development of a dual-modality imaging probe targeting SSTR2 via a trifunctional chelate

D. Chapeau, S. Beekman, Y. Seimbille; ErasmusMC, Rotterdam, NETHERLANDS.

EPS-278

Conjugation of different chelators to a HER2 targeting single domain antibody for Ga-68 and Lu-177 radiolabelling

B. Altunay, L. Obradović, F. M. Mottaghy, A. T. J. Vogg; University Hospital RWTH Aachen, Aachen, GERMANY.

EPS-279

More than sweet: TRAP-based Sugar Trimers for Functional Liver Imaging with 68Ga

M. A. Zierke¹, C. Rangger¹, K. Samadikhah², A. Schmid², R. Haubner¹;

¹Nuclear Medicine, Innsbruck, AUSTRIA, ²Werner Siemens Imaging Center, Tübingen, GERMANY.

EPS-280

Novel Dual-Modality Imaging Agents Targeting the CCK2 Receptor by Chelator Scaffolding

G. GARIGLIO¹, K. Bendová², M. Hermann³, M. Petrik², E. von Guggenberg¹, D. Putzer⁴, C. Decristoforo¹;

¹Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA, ²Faculty of Medicine and Dentistry, Palacky University Olomouc, Institute of Molecular and Translational Medicine, Olomouc, CZECH REPUBLIC, ³Department of Anesthesiology and Critical Care Medicine, Medical University of Innsbruck, Innsbruck, AUSTRIA, ⁴Department of Radiology, Medical University Innsbruck, Innsbruck, AUSTRIA.

EPS-281

Construction and immnoPET imaging of an iodine-labeled specific antibody for targeting MMP2 detection in pan-cancer

X. Ma, T. Liu, H. Zhu, Z. Yang;

Peking university, Beijing, CHINA.

EPS-282

Novel fluorinated Osimertinib analogue for medical nuclear imaging of EGFRm-positive non-small cell lung cancer

Y. Brief, H. Grievink, G. Abourbeh, E. Mishani, O. Shamni; Cyclotron & Radiochemistry unit, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, ISRAEL.

EPS-283

FAPI-functionalised melanin nanoparticles for PET/MRI/PA imaging of glioma

L. Wen, H. Wang, S. Yang, X. Long, C. Zheng, D. Jiang;

Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EPS-284

Preclinical PET imaging with 89Zr-labelled oxMIF-specific antibody delineates subcutaneous tumours in colorectal murine models

F. Bachmann, A. Puchol Tarazona, I. Mirkina, M. Thiele, A. Schinagl;

OncoOne Research & Development GmbH, Vienna, AUSTRIA.

EPS-285

Preparation and preclinical evaluation of anti ROR1 labeled with 64Cu as a Radioimmunoconjugate for ROR1+ breast cancer Imaging

B. Alirezapour¹, H. Rabbani²;

¹Nuclear Science and technology research Institute (NSTRI), Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Antigen and Antibody Engineering Department, Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EPS-286

Radiosynthesis and preclinical evaluation of [Zr89] mAb1 and [Zr89]mAb2 as PET tracers for B7:H3-positive tumors

B. Fernandes¹, F. Basuli², C. P. Olkowski¹, D. Nambiar¹, S. Adler³, G. L. Griffiths³, F. I. Lin¹, P. Choyke¹;

¹Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, UNITED STATES OF AMERICA, ²Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD, UNITED STATES OF AMERICA, ³Clinical Research Directorate, Frederick National Laboratory for Cancer Research Frederick, Frederick, MD, UNITED STATES OF AMERICA.

EPS-287

A Zirconium Coordination Platform for Positron Emission Tomography Traceable Cargo Delivery

H. Hong, X. Jiao, X. Li, Y. Cong, J. Hu, Y. Jiang;
Nanjing University, Nanjing, CHINA.

EPS-288

Organotrifluoroborate sugar conjugates for a guided boron neutron capture therapy: radioisotopic exchange reactions for PET imaging

A. Erhard¹, L. Confalonieri², D. Imperio², M. Balcerzyk¹, L. Panza²;

¹Centro Nacional de Aceleradores, Sevilla, SPAIN, ²University of Eastern Piedmont Amedeo Avogadro, Novara, ITALY.

EPS-289

Preclinical characterization of novel radiolabeled and fluorescent-labeled Fibroblast Activation Protein (FAP)-targeting ligands using gamma counting, SPECT imaging and Cryo-Fluorescence Tomography (CFT)

J. Hesterman¹, A. Novicki¹, K. Orcutt¹, S. DiMaggio¹, S. Hillier¹, S. Patel¹, A. Amor¹, B. Burke², S. Archibald³, J. Wright³, J. Domarkas³, J. Heimann², V. Yost², E. White⁴, C. Stokes⁴, M. Silva⁴, A. Cordova⁴, S. Toddes⁴, J. Babich¹, J. Hoppin¹;

¹Ratio Therapeutics, Boston, MA, UNITED STATES OF AMERICA, ²Invicro, Needham, MA, UNITED STATES OF AMERICA, ³University of Hull, Hull, UNITED KINGDOM, ⁴Emit Imaging, Baltimore, MD, UNITED STATES OF AMERICA.

EPS-290

68Ga-NOTA-ACN376 imaging as a non-invasive approach to diagnose CLDN18.2-positive tumors

c. yan^{1,2}, Z. Hua³, Z. Hua³, Z. Hua³;

¹Beijing cancer hospital, Beijing, CHINA, ²Guizhou University Medicine College, Guizhou, CHINA, ³Beijing Cancer Hospital, Beijing, CHINA.

EPS-291

61Cu-PSMA PET in prostate cancer: development and selection of the first radioligand for clinical translation

T. Basaco Bernabeu¹, R. Mansi¹, L. Del Pozo¹, S. Zangerl¹, M. Blagojev², R. H. Gaonkar¹, L. McDougall¹, A. Johayem², L. Jaafar-Thiel³, M. Fani¹;

¹Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, SWITZERLAND, ²Department of Nuclear Medicine, University Hospital of Zürich, Zürich, SWITZERLAND, ³Nuclidium AG, Basel, SWITZERLAND.

EPS-292

Preclinical 68Ga-EMP100 PET Imaging to quantify c-Met Expression in non-small cell lung cancer (NSCLC)

A. Prignon^{1,2}, T. Rusu^{2,1}, R. Anita², C. Portal³, J. Cadranet²;

¹Sorbonne University, UMS28, LIMP, Paris, FRANCE, ²THERANOSCAN Clinical Research Group of the Pneumology and Thoracic Oncology Department Tenon Hospital AP-HP, Paris, FRANCE, ³Edinburgh Molecular Imaging, Edinburgh, UNITED KINGDOM.

EPS-293

Early detection of CD38 using a novel 68Ga-labeled peptide lymphoma murine models

L. Kang¹, Q. Yang¹, X. Li², L. Song¹, W. Huang¹, X. Sun¹, Z. Wang²;

¹Peking University First Hospital, Beijing, CHINA, ²National Center for Nanoscience and Technology, Beijing, CHINA.

1811

Wednesday, September 13, 2023, 9:45 AM - 11:15 AM

Hall G1

Case Report Session 4 - TROP Session: FDG PET and Conventional Imaging: Still Surprising!

OP-943

Pre- and post-CAR-T therapy FDG PET/CT images and limitations of the Deauville Criteria: A Pictorial Essay

S. Kwon¹, S. Ha¹, J. Min², J. O¹, Catholic University Lymphoma Group (CULG);

¹Seoul St Mary's Hospital, Seoul, KOREA, REPUBLIC OF, ²The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF.

OP-944

Dramatic treatment response images of a metastatic lung adenocarcinoma case with Osimertinib treatment on 18F-FDG PET/CT

B. Ince, A. Namazova, M. Bodur, S. Asa, L. Uslu-Besli, S. Sager, H. Sayman, K. Sonmezoglu;

Istanbul University-Cerrahpasa, Istanbul, TÜRKIYE.

OP-945

Imaging Plasmacytoid Dendritic Cell Neoplasm with FDG PET/CT: Atypical Presentation of a Rare Disease in a Child

M. Ben Nasr, O. Ben Hamida, R. Belayouni, C. Mhiri, I. Slim, I. Meddeb, A. Mhiri;

Salah Azaiez Institute of Tunis, Tunis, TUNISIA.

OP-946

Utility of 18F-FDG PET/CT in Rhabdomyosarcoma of Prostate

S. Jain¹, H. Goyal²;

¹All India Institute of Medical Sciences, Bhopal, INDIA, ²Jipmer, Puducherry, INDIA.

OP-947

When Histopathology is Wrong and Bone Scintigraphy is Right - an Exemplary Case of a Rare Genetic Metabolic Disease (Familial Expansile Osteolysis) Repeatedly Mistaken for Fibrous Dysplasia and Paget's Disease

D. Filipan¹, E. Koumakis^{2,3}, V. Cormier-Daire⁴, T. Funck-Brentano⁵, F. Paycha⁶;

¹University Department of Oncology and Nuclear Medicine, Sestre Milosrdnice University Hospital Centre, Zagreb, CROATIA, ²Centre de Référence des Maladies Osseuses Constitutionnelles, Service de Rhumatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE, ³INSERM UMR 1163, Institut Imagine, Hôpital Necker, Paris, FRANCE, ⁴Service de Génétique Clinique Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE, ⁵Service de Rhumatologie & BIOSCAR UMR 1132, INSERM, Université Paris Cité, Paris, FRANCE, ⁶Service de Médecine Nucléaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE.

OP-948

Delayed Onset Angiosarcoma Arising from a Femur Infarct Pictured by [99mTc]bisphosphonates SPECT/CT and [18F]FDG-PET/CT: Caution with Tumour Necrosis and Haemorrhage Phenomena in Molecular Imaging analysis!

D. Filipan¹, N. Saleh², R. Kaci³, F. Paycha²;

¹University Department of Oncology and Nuclear Medicine, Sestre Milosrdnice University Hospital Centre, Zagreb, CROATIA, ²Service de Médecine Nucléaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE, ³Service d'Anatomie et de Cytologie Pathologiques, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE.

OP-949

Facial asymmetry unmasked by bone scintigraphy

L. Sobral Torres, A. Oliveira, P. Soeiro;

Centro Hospital Universitário de São João, Porto, PORTUGAL.

OP-950

Unexpected Finding of Myeloma in Myocardial Perfusion Imaging Study with 99mTc-sestamibi

P. Cichocki¹, A. Plachcińska², Z. Adamczewski¹;

¹Nuclear Medicine Department, Medical University of Lodz, Lodz, POLAND, ²Department of Quality Control and Radiation Protection, Medical University of Lodz, Lodz, POLAND.

OP-951

Ga-68 DOTATOC PET/CT and I-123 MIBG scan in a refractory case of pediatric neuroblastoma: imaging biomarkers with complete mismatch and implications for patient management

L. Vija¹, A. Latgé¹, M. Gambart¹, L. Guillon², S. Brillouet¹, D. Vallot¹, L. Dierickx¹, S. Zerdoud¹, F. Courbon¹;

¹Institut Claudius Regaud-Oncopole, Toulouse Cedex 9, FRANCE, ²CHU Toulouse, Toulouse Cedex 9, FRANCE.

1901

Wednesday, September 13, 2023, 11:25 - 11:45

Hall A

Closing Session

OP-952

Closing Session

V. Garibotto;

University Hospitals and University of Geneva, Geneva, SWITZERLAND.

e-Posters

EP-01

e-Poster Area

A: Preclinical Studies -> A1 Medical Preclinical -> A11 In Vitro Studies

EP-0001

An exploratory study on the mechanism of pralatrexate killing gemcitabine-resistant pancreatic cancer cells

W. Weng, J. Hong, D. Jiang, B. Chen, S. Zheng; The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

EP-0002

Androgen-induced cell cycle arrest in prostate carcinoma cells as a potential risk for pseudoprogression during diagnosis with prostate-specific membrane antigen (PSMA) radiopharmaceuticals and treatment failure with PSMA radioligands. An in vitro study.

B. Meller¹, P. Thelen², V. Unterkircher³, J. Bucerius¹, L. Trojan², C. O. Sahlmann¹, F. Bremmer³;

¹University Medical Center Göttingen, Clinic of Nuclear Medicine, Göttingen, GERMANY, ²University Medical Center Göttingen, Clinic of Urology, Göttingen, GERMANY, ³University Medical Center Göttingen, Institute of Pathology, Göttingen, GERMANY.

EP-0003

Synthesis and in vitro evaluation of a small molecule ^{99m}Tc-G2C-CBM as potential PD-L1 imaging agent

Z. Chen^{1,2,3}, D. Zhu^{1,4}, C. Lu^{1,2,3};

¹Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA, ²NHC Key Laboratory of Nuclear Medicine, Wuxi, CHINA, ³Jiangsu Key Laboratory of Molecular Nuclear Medicine, Wuxi, CHINA, ⁴Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, CHINA.

EP-0004

Robustness of radiomic features in dopamine transporter imaging with single photon emission tomography

V. Laskov^{1,2}, P. Choniawko^{1,2}, D. Rotbauer²;

¹University Hospital Kralovske Vinohrady, Department of Radiology and Nuclear medicine, Prague, CZECH REPUBLIC, ²Third Faculty of Medicine, Charles University, Prague, CZECH REPUBLIC.

EP-0005

Sinomenine Hydrochloride enhances Trametinib-induced iodide-handling gene expression and radioiodine uptake

J. Zhang, A. Yang;

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CHINA.

EP-0006

"In house" radiolabeling of anti-PD-L1 monoclonal antibodies with ¹¹¹Indium for in vivo imaging

F. Silva¹, R. Lopes¹, A. S. Capacho¹, M. Fortunato^{1,2}, S. Vaz¹, F. Oliveira¹, C. João¹, D. Costa¹;

¹Champalimaud Foundation, Lisbon, PORTUGAL, ²Nova School of Science and Technology, Lisbon, PORTUGAL.

EP-0007

The high affinity angiotensin AT2 receptor agonist, C21, inhibits proliferation and induces cell death in prostate cancer cells by an AT2 receptor-independent mechanism

Y. Zhao, M. Marx, U. Lützen, M. Zuhayra;

Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, UKSH, Kiel, GERMANY.

EP-0008

Microleakage evaluation of new composite resins for posterior teeth: bioactive resins vs bulk fill resins

A. Pires Lourenço^{1,2,3}, C. M. Marto^{2,3,4}, A. Coelho^{2,3,4}, M. V. Pinto⁴, P. Neves⁴, I. Amaro^{2,3,4}, J. Sousa⁴, M. Marques Ferreira^{2,3,5}, E. Carrilho^{2,3,4}, M. Laranjo^{1,2,3}, A. M. Abrantes^{1,2,3}, M. F. Botelho^{1,2,3}, A. B. Paula^{2,3,4};

¹Univ Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics and Oncobiology (CIMAGO), Institute of Biophysics, Faculty of Medicine, Coimbra, PORTUGAL, ²Univ Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, PORTUGAL, ³Clinical Academic Center of Coimbra (CACC), Coimbra, PORTUGAL, ⁴Univ Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics and Oncobiology (CIMAGO); Institute of Integrated Clinical Practice and Laboratory for Evidence-Based Sciences and Precision Dentistry, Faculty of Med, Coimbra, PORTUGAL, ⁵Univ Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics and Oncobiology (CIMAGO); Institute of Endodontics and Laboratory for Evidence-Based Sciences and Precision Dentistry, Faculty of Medicine, Coimbra, PORTUGAL.

EP-0009

[^{99m}Tc][Tc-HYNIC-scFvD2B] vs [^{99m}Tc][Tc(CO)3(scFvD2B-HisTag)] for the imaging SPECT of prostate cancer: preliminary in vitro studies

C. Gobbi¹, L. Melendez-Alafort², B. Spolaore³, N. Salvarese¹, D. Carpanese², V. Rossi², A. Rosato^{2,4}, G. Fracasso⁵, C. Bolzati¹;

¹Institute of Condensed Matter Chemistry and Energy Technologies - National Research Council, Padua, ITALY, ²Istituto Oncologico Veneto IOV-IRCCS, Padua, ITALY, ³Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, ITALY, ⁴Department of Surgery, Oncology and Gastroenterology, University of Padua, Padova, ITALY, ⁵Department of Biomedical Sciences, University of Padua, Padua, ITALY.

EP-0010

¹⁶¹Tb-PSMA-I&T and ¹⁷⁷Lu-PSMA-I&T treatment in T23 and ST4787 prostate cancer cell lines - a model representative of ¹⁷⁷Lu-PSMA-resistant prostate cancer phenotype

M. Kirienko, E. Jachetti, R. Sulsenti, C. Pascali, A. Bogno, M. Colombo, E. Seregni;

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY.

EP-0011

αvβ3 integrin-selective RGDechi peptides labelled with [^{99m}Tc][Tc(N)(PNP)]- and [^{99m}Tc][Tc-HYNIC]-systems: an in vitro comparison

C. Bolzati¹, C. Gobbi¹, N. Salvarese¹, A. Giorgio², D. Carpanese³, V. Rossi³, L. Melendez-Alafort³, A. Rosato^{3,4}, M. Saviano⁵, A. Del Gatto², L. Zaccaro²;

¹Institute of Condensed Matter Chemistry and Energy Technologies, ICMATE-CNR, PADOVA, ITALY, ²Institute of Biostructures and Bioimaging, IBB-CNR, Napoli, ITALY, ³Istituto Oncologico Veneto, IOV-IRCCS, PADOVA, ITALY, ⁴Department of Surgery, Oncology and Gastroenterology, University of Padua, DiSCOG-UniPD, Padova, ITALY, ⁵Institute of Crystallography, IC-CNR, Bari, ITALY.

EP-0012

Let's label biomolecules in mild conditions with the [^{99m}Tc][Tc(N)(PNP)]-system: the PNP3OH experience

C. Bolzati¹, N. Salvarese¹, B. Spolaore², C. Gobbi¹, A. Vittadini¹, D. Forer¹, S. Ghiani³, A. Maiocchi⁴;

¹Institute of Condensed Matter Chemistry and Energy Technologies, ICMATE-CNR, PADOVA, ITALY, ²Department of Pharmaceutical and Pharmacological Sciences, University of Padua, PADOVA, ITALY, ³Bracco Research Centre, Bracco Imaging SpA, Torino, ITALY, ⁴Bracco SpA, Milano, ITALY.

EP-0013

To study uptake of ¹⁸F-AVT-011 in different cell lines expressing p-glycoprotein.

R. Thakur¹, M. Kumar¹, P. Chaudhari², P. Kumar¹;

¹National Institute of mental health and neurosciences, Bangalore, INDIA, ²Advanced Centre for Treatment, Research and Education, Mumbai, INDIA.

EP-0014

Dual-radionuclide detection for radiopharmaceutical studies

J. Campeiro, C. D. van der Heide, J. de Swart, S. U. Dalm; Erasmus Medical Center, Rotterdam, NETHERLANDS.

EP-02

e-Poster Area

A: Preclinical Studies -> A1 Medical Preclinical -> A12 Preclinical Cardiology and Neurology

EP-0015

Age Related Changes of Cellular Contributions in FDG Uptake Correlate with Metabolic Connectivity

J. Gnörich, L. Bartos, A. Zatcepin, R. Schäfer, S. Kunte, P. Beumers, P. Bartenstein, N. Albert, S. Ziegler, M. Brendel;

LMU Munich, Munich, GERMANY.

EP-0016

Inhibition of PFKFB3 counteracts atherosclerosis via NLRP3/Caspease1/IL-1β pathway in macrophages

M. Zhao¹, X. Wang², W. Wu¹, Y. Bai², X. Li³;

¹The Third Xiangya Hospital of Central South University, Changsha, CHINA, ²Xiangya Hospital of Central South University, Changsha, CHINA, ³Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

EP-0017

In vivo [¹⁸F]SMBT-1 imaging of reactive astrocytes in mouse models of Alzheimer's disease - temporospatial relationship with amyloid, tau and microgliosis

R. Ni¹, Y. Kong², C. Maschio¹, B. Yao³, J. Xiao², Q. Huang², Y. Guan²;

¹University of Zurich, Zurich, SWITZERLAND, ²PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA, ³Radiopharmacy and Molecular Imaging Center, School of Pharmacy, Fudan University, Shanghai, CHINA.

EP-0018

A comparison of the biodistribution and the patient dose estimation of [¹⁸F]FEPP and [¹⁸F]FEAO, potential radiotracers for PET myocardial perfusion imaging

K. Gotowicz^{1,2}, U. Karczmarczyk³, S. Krajewski¹, E. Witkowska-Patena⁴, L. Steczek¹, J. Towpik¹, P. Kozanecki¹, M. Mazur², M. Dziuk^{4,5}, J. Włostowska¹, C. Kozanecki¹, P. Garnuszek²;

¹Synektik SA, Research & Development Centre, Warsaw, POLAND, ²Department of Chemistry, University of Warsaw, Warsaw, POLAND, ³National Centre for Nuclear Research, Radioisotope Centre POLATOM, Warsaw, POLAND, ⁴Military Institute of Medicine - National Research Institute, Nuclear Medicine Department, Warsaw, POLAND, ⁵Affidea Poland, Warsaw, POLAND.

EP-0019

Early brain [¹⁸F]FDG PET imaging predicts the long-term behavioral impact of exposure to sublethal doses of organophosphates: a longitudinal study in mice exposed to NIMP, a sarin surrogate

A. Soyer¹, A. Champault², S. Leterrier¹, C. Corvo¹, L. Breuil¹, B. Hosten¹, W. Saba¹, C. Leroy¹, A. Winkler¹, G. Dal Bo², K. Thibault², N. Tournier¹;

¹Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Université Paris-Saclay, Orsay, FRANCE, ²Institut de Recherche Biomédicale des Armées (IRBA), Bretagne-sur-Orge, FRANCE.

EP-0020

Comparison of intravenous and oral administration of [¹⁸F]MC225: a feasibility study in rats

G. Salvi de Souza^{1,2}, J. W. Sijbesma¹, J. Doorduyn¹, A. M. Marques da Silva^{3,4}, C. R. Furin^{2,5}, A. A. Lammertsma¹, C. Tsoumpas¹, G. Luurtsema¹;

¹Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, ²School of Medicine, PUCRS, Porto Alegre, BRAZIL, ³Faculdade de Medicina, Universidade de São Paulo, São Paulo, BRAZIL, ⁴Medical Imaging & Data Analytics, San Diego, CA, UNITED STATES OF AMERICA, ⁵Laboratory of Cognition and Memory Neurobiology, Brain Institute, PUCRS, Porto Alegre, BRAZIL.

EP-0021

Short-term synaptic remodeling in a rat model of alcohol binge drinking assessed using [¹¹C]UCB-J PET imaging

C. CORVO¹, C. Leroy², S. Letterier², S. Gouta¹, F. Caille², A. Soyer², M. Goisard², S. Amargier², N. Tournier², W. Saba²;

¹Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), ORSAY, FRANCE, ²Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Orsay, FRANCE.

EP-0022

Sex differences in [18F]-FDG uptake and behavioral impairment following repetitive mild traumatic brain injury (rmTBI)

R. Moraga-Amaro, M. Bankstahl, J. P. Bankstahl; Hannover Medical School, Hannover, GERMANY.

EP-0023

Longitudinal [18F]-FDG PET Characterization of Alzheimer's Disease P301S Transgenic Mice

L. García-Varela^{1,2,3}, A. Custodia^{4,3}, L. Barro Rico^{1,3}, N. Gomez Lado^{1,3}, J. Codesido^{2,3,5}, A. Cuartero⁵, A. Fernández-Ferreiro⁵, D. Romas Sanjurjo^{4,3}, A. Ouro^{4,3}, T. Sobrino^{4,3}, P. Aguiar^{1,2,3};

¹Molecular Imaging and Pharmacokinetic Modelling Group, CIMUS, USC, Santiago de Compostela, SPAIN, ²Nuclear Medicine and Molecular Imaging Group, University Clinical Hospital, IDIS, Santiago de Compostela, SPAIN, ³Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, SPAIN, ⁴NeuroAging Group (NEURAL), Clinical Neurosciences Research Laboratory (LINC), IDIS, Santiago de Compostela, SPAIN, ⁵Pharmacology Group, University Clinical Hospital of Santiago de Compostela, IDIS, Santiago de Compostela, SPAIN.

EP-0024

Applicability of early phase imaging with 18F-PI-2620 and 18F-Florbetaben in mouse models with Tau and Amyloid pathology

A. Englert, L. Slemann, S. Hummel, L. Hörmann, L. Kunze, C. Palleis, K. Wind-Mark, S. Lindner, P. Bartenstein, S. Ziegler, N. Albert, J. Levin, M. Brendel, J. Gnörlich; LMU Klinikum Campus Großhadern, Munich, GERMANY.

EP-0025

Brain Metabolic Effects of Coca-paste Acute Systemic Administration in Rats

R. Ferrando^{1,2}, L. Reyes², J. Prieto³, A. Paolino², A. Abin-Carriquiry⁴, P. Oliver², E. Savio², M. Scorza³;

¹University of the Republic, Montevideo, URUGUAY, ²Uruguayan Centre for Molecular Imaging (CUDIM), Montevideo, URUGUAY, ³Departamento de Neurofarmacología Experimental, Instituto de Investigaciones Biológicas Clemente Estable., Montevideo, URUGUAY, ⁴Departamento de Neuroquímica, Instituto de Investigaciones Biológicas Clemente Estable., Montevideo, URUGUAY.

EP-03

e-Poster Area

A: Preclinical Studies -> A1 Medical Preclinical -> A13 Preclinical Oncology

EP-0026

A study on the volume of preclinical xenograft tumours assessed by ultrasound imaging and MRI compared to calliper measurements

J. Strand¹, C. Ceberg², M. Safi¹, S. Strand², F. Szczepankiewicz², D. Roth²;

¹Clinical Sciences, Oncology, Lund University, Lund, SWEDEN, ²Medical Radiation Physics, Clinical Sciences, Lund University, Lund, SWEDEN.

EP-0027

Construction and Preclinical Evaluation of a 68Ga-Labeled Single-chain Fragment Variable Targeting PD-L2 in Lung Cancer

Y. Yao, N. Li; Peking university cancer hospital, Beijing, CHINA.

EP-0028

Preparation and evaluation of Evans blue modified aptamer probe targeting to EpCAM

M. Zhang, J. Ye, Z. Xie, W. Yang, F. Kang, J. Wang; Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

EP-0029

Evaluation of a Long-circulating PSMA-targeting Peptide in a Xenograft Model of Bone Metastatic Prostate Cancer.

W. Lo, Y. Huang, M. Chen, A. Lu, S. Wang, L. Chen, S. Farn; Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

EP-0030

Goat milk-derived extracellular vesicle engineered for multimodal imaging of cancer stem cells

Y. Gao, Y. Zhang, X. Lan, R. An; Wuhan Union Hospital, Wuhan, CHINA.

EP-0031

Porphyrin-modified strategy contributes to aptamers' tumor targeting

S. Yang, X. Lan, D. Jiang; Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China, Wuhan, CHINA.

EP-0032

Tumours inducing cachexia driven by Fn14 show enhanced 18F-FDG uptake in mice versus tumours that do not induce cancer cachexia: a quantitative PET analysis

I. Burvenich^{1,2}, L. Osellame^{1,2,3}, A. Rigopoulos¹, N. Hoogenraad³, A. M. Scott^{1,2,4};

¹Olivia Newton-John Cancer Research Institute, Heidelberg, AUSTRALIA, ²School of Cancer Medicine, La Trobe University, Bundoora, AUSTRALIA, ³Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, AUSTRALIA, ⁴Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, AUSTRALIA.

EP-0033

89Zr-anti-murine CD103 PET imaging for non-invasive assessment of immune checkpoint inhibitor therapy

X. Fan, N. P. Holland, A. Plat, H. W. Nijman, P. H. Elsinga, M. d. Bruyn; University of Groningen, Groningen, NETHERLANDS.

EP-0034

In vivo testing of a novel anti-B4GALNT1 nanobody as a potential theragnostic tool for osteosarcoma tumors.

M. Collantes¹, N. Mendoza², J. Simón³, F. Pareja³, M. Eca¹, G. Quincoces³, M. García-Moure⁴, A. J. Schuhmacher², I. Peñuelas³;

¹Translational Molecular Imaging Unit (UNIMTRA), Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, SPAIN, ²Instituto de Investigación Sanitaria Aragón, Zaragoza, SPAIN, ³Radiopharmacy Unit, Department of Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, SPAIN, ⁴Solid Tumors Program, CIMA-Universidad de Navarra, Pamplona, SPAIN.

EP-0035

Development of neurotensin analogues stabilized by Lys8-Lys9 reduction and linker modifications

C. Morgat^{1,2}, S. Previti³, S. Bodin^{1,2}, L. Balasse⁴, E. Rémond³, P. Garrigue⁴, F. Debordeaux¹, B. Guillet⁴, F. Lamare², D. Vimont², E. Hindié^{1,2}, F. Cavelier³;

¹Nuclear Medicine Department - University Hospital of Bordeaux, Bordeaux, FRANCE, ²University of Bordeaux, CNRS, EPHE, INCIA, UMR 5287, Bordeaux, FRANCE, ³Institut des Biomolécules Max Mousseron, IBMM, UMR 5247, CNRS, Université de Montpellier, ENSCM, Montpellier, FRANCE, ⁴CERIMED, Aix-Marseille University, Marseille, FRANCE.

EP-0036

In vivo evaluation of luteinizing hormone-releasing hormone antagonists in triple negative breast tumor-bearing model by using SPECT/CT imaging

M. Weng, S. Farn; Institute of Nuclear Energy Research, Taoyuan City, TAIWAN.

EP-0037

Enhancing PSMA-RLT efficacy with STING agonist in syngeneic models of prostate cancer

B. Louis^{1,2}, M. Taddio^{1,2}, K. Rashid^{1,2}, E. Abt^{1,2}, E. Rosser^{1,2}, T. Le^{1,2}, K. Lueckerath^{3,4}, C. Radu^{1,2}, J. Czernin^{1,2}, C. Mona^{1,2};

¹University of California at Los Angeles, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, Ahmanson Translational Therapeutics Division, Los Angeles, CA, UNITED STATES OF AMERICA, ²Jonsson Comprehensive Cancer Center, Los Angeles, CA, UNITED STATES OF AMERICA, ³Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY, ⁴German Cancer Consortium—University Hospital Essen, Essen, GERMANY.

EP-0038

[18F](2S,4R)4-Fluoroglutamine illustrates ability to distinguish KRAS mutation in pancreatic carcinoma

S. Liu, F. Liu, X. Xu; Peking University Cancer Hospital, Beijing, CHINA.

EP-0039

A novel 18F labeled TKI-PET tracer for targeting EGFR mutation

S. Liu, F. Liu, Z. Yang; Peking University Cancer Hospital, Beijing, CHINA.

EP-0040

Lenvatinib strengthened I-131-trastuzumab radioimmunotherapy in HER2 positive tumor model

I. Lim, S. Cho; Korea Cancer Center Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0041

GRPR-antagonists based on AU-RM26-M1 and their [111In]In-radioligands: Preclinical evaluation for prostate cancer imaging

A. Abouzayed¹, K. Obeid¹, P. Kanellopoulos¹, A. Mattsson¹, B. A. Nock², V. Tolmachev¹, T. Maina², A. Orlova¹; ¹Uppsala University, Uppsala, SWEDEN, ²Molecular Radiopharmacy, NCSR Demokritos, Athens, GREECE.

EP-0042

Using [89Zr]Zr-Oxine ex-vivo labelled macrophages and [89Zr]Zr-DFO-anti-F4/80 to investigate the effect of moderate-dose external beam radiation therapy on macrophage polarisation

V. De Santis¹, A. Banu¹, S. Langdon¹, J. Cheng¹, M. Cleveland², M. Ma¹, S. Terry¹; ¹King's College London, London, UNITED KINGDOM, ²Glaxosmithkline, Stevenage, UNITED KINGDOM.

EP-0043

[68Ga]Ga-Bedaquiline - A Potential Diagnostic Radiotracer for Overexpressed Mitochondrial ATP Synthase Composing Proteins in Lung Carcinoma

A. Chakraborty¹, M. Tawate¹, A. Mitra², S. Sahu¹, S. Lad¹, S. Rakshit¹, G. Dhotre³, M. K. Ray¹, A. Damle¹, U. Pandey², S. Kulkarni¹; ¹Bhabha Atomic Research Centre, Mumbai, INDIA, ²Board of Radiation & Isotope Technology, Mumbai, INDIA, ³Tata Institute of Fundamental Research, Mumbai, INDIA.

EP-0044

Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor Bearing Mice

y. Ren¹, Z. Yang²; ¹Guizhou University, Guiyang, CHINA, ²Peking University Cancer Hospital and Institute, Beijing, CHINA.

EP-0045

Preclinical evaluation of 64Cu-DOTHA2-FAPI for PET Imaging of head and neck cancer

I. Ben-Salem¹, E. Croteau¹, V. Dumulon-Perreault², N. Saidi¹, O. Sarrhini¹, S. Ait-Mohand¹, O. Bélistant¹, E. Turcotte¹, A. Oweida¹, B. Guérin¹, E. Rousseau¹; ¹Département de médecine nucléaire et radiobiologie, Université de Sherbrooke, Sherbrooke, QC, CANADA, ²Centre d'Imagerie Moléculaire de Sherbrooke (CIMS), Centre de Recherche du CHUS (CRCHUS), Sherbrooke, QC, CANADA.

EP-0046

Evaluation of 89Zr-DFO-C23 in immuno-PET imaging of A549 xenograft models with high TIM3 expression

J. Tao¹, Z. Zeng², H. Zhu³; ¹Peking University Cancer Hospital, Beijing, Beijing, CHINA, ²Peking University Cancer Hospital, Beijing, CHINA, ³Peking University Cancer Hospital and Institute, Beijing, CHINA.

EP-0047

Preparation and Application of Bioorganic Nanoparticle Enhanced PDL1 Targeted Small Molecule Probe

C. He, L. Xia; Beijing Institute of Cancer Prevention and Treatment, Beijing, CHINA.

EP-0048

Preclinical evaluation of novel PSMA-targeting ligands labelled with gallium-68

Z. Novy¹, K. Hajduova¹, M. Petrik¹, K. Bendova¹, M. Benesova², M. Hajdich¹;

¹Faculty of Medicine and Dentistry, Olomouc, CZECH REPUBLIC, ²German Cancer Research Center, Heidelberg, GERMANY.

EP-0049

Design of novel small molecules targeting Fibroblast activating protein and preclinical exploration of 47Sc labeling

Y. Xia;

Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital, Chengdu, CHINA.

EP-0050

Lead Optimisation Strategy for the Development Of New Grpr Radioantagonists

P. Paraiso¹, C. van Deurzen², Y. Seimbille^{1,3};

¹Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, NETHERLANDS, ²Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, NETHERLANDS, ³Life Sciences Division, TRIUMF, Vancouver, BC, CANADA.

EP-0051

Normal organs uptake values in F 18- FDG PET/CT in relation to serum blood glucose

R. Mostafa¹, H. Askar², M. Helbawi², H. Mahmoud²;

¹Nuclear Medicine Unit, Department of Radiation Oncology and Nuclear Medicine, South Egypt Cancer Institute, Assiut University, Assiut, EGYPT, ²Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Assiut University, Assiut, Assiut, EGYPT.

EP-0052

Synthesis and preliminary assessment of 68Ga/177Lu-TATE-EB-01 for the theranostic in neuroendocrine tumor

X. Wen¹, P. Xu², J. Liu¹, J. Zhang³, Z. Guo¹, X. Chen³;

¹State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, CHINA, ²Institute of Clinical Pharmacy & Pharmacology, Jining First People's Hospital, Jining Medical University, Jining, CHINA, ³Department of Diagnostic Radiology, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, SINGAPORE.

EP-0053

[18F]FDG-PET/CT and MRI to assess treatment response to anti-PD1 in an orthotopic mouse renal cancer model.

O. Bejuy, H. Poinot, D. Colin, A. Pommier, V. Garibotto; University of Geneva, Geneva, SWITZERLAND.

EP-04

e-Poster Area

A: Preclinical Studies -> A1 Medical Preclinical -> A14 Preclinical Therapy

EP-0054

FAP-targeted cancer theranostics

W. Wei;

Shanghai Jiao Tong University, Shanghai, CHINA.

EP-0055

Development of INER-PP-F11N as the Radionuclide Theragnostics Agent against Cholecystokinin B Receptor-overexpressed Tumors

M. Chang, C. CHEN, P. CHIANG, C. PENG;

Institute of Nuclear Energy Research, Taipei, TAIWAN.

EP-0056

Local Infusion of 177Lu-Labeled Gold Nanoparticles Combined with anti-PD1 Checkpoint Immunotherapy Prolongs Survival of C57BL/6 Mice Bearing Orthotopic GL261 Murine Gliomas

C. Georgiou¹, Z. Cai¹, J. T. Rutka², M. Winnik¹, R. M. Reilly¹;

¹University of Toronto, Toronto, ON, CANADA, ²The Hospital for Sick Children, Toronto, ON, CANADA.

EP-0057

Compositedegradablepolymer microspheresloaded with 177Lufor Transarterial Radioembolization therapy of Rat hepatocellular carcinoma

L. Xiao, H. Cai, L. Li;

Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0058

Nucleic acid nanospheres for PET imaging and antioxidant therapy of hepatic ischemia-reperfusion injury

H. Wang, X. Lan, D. Jiang;

Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0059

Continuous enzymatic hypoxia relief with NIR-II moderate photothermal assistance for enhanced Yttrium-90 microspheres oncotherapy

J. Li, X. Su;

The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, CHINA.

EP-0060

Prostate-specific membrane antigen-targeted endogenous radiotherapy of triple-negative breast cancer

A. Heesch¹, J. Maurer^{2,3}, A. Florea¹, A. Morgenroth¹, F. M. Mottaghy^{1,4};

¹Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, GERMANY, ²Department of Obstetrics and Gynecology, University Hospital RWTH Aachen, Aachen, GERMANY, ³Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), GERMANY, ⁴Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, NETHERLANDS.

EP-0061

Impact of injection velocity during transarterial radioembolization, an in vitro analysis

T. Snoeijink¹, J. L. van der Hoek², H. Mirgolbabaee², E. Groot

Jebbink², J. F. W. Nijssen¹;

¹Radboud University Medical Centre, Nijmegen, NETHERLANDS, ²University of Twente, Enschede, NETHERLANDS.

EP-0062

Sn-117m Homogeneous Colloid is a Disease-Modifying Device in the Treatment of Osteoarthritis

C. Doerr¹, A. Bendele², J. Simon³, N. Stevenson⁴, G. Gonzales¹;

¹Serene, LLC, The Woodlands, TX, UNITED STATES OF AMERICA, ²Inotiv, Boulder, CO, UNITED STATES OF AMERICA, ³Isotherapeutics Group, LLC, Angleton, TX, UNITED STATES OF AMERICA, ⁴Exubion Therapeutics, Buford, GA, UNITED STATES OF AMERICA.

EP-0063

Therapeutic potential of a Claudin 18.2 targeted alpha therapeutic [225Ac]-FPI-2474 in a pre-clinical gastric cancer tumor model

S. Almasi, T. Kostelnik, V. Subramony, N. Robinson, W.

Turnbull, B. L. Thériault, C. P. Leamon, J. Valliant;

Fusion pharmaceuticals, Hamilton, ON, CANADA.

EP-0064

Development and evaluation of fluorescent SSTR2-antagonists for intraoperative image-guided surgery of NETs

M. Handula¹, S. Beekman¹, Y. Seimbille^{1,2};

¹Erasmus MC, Rotterdam, NETHERLANDS,

²TRIUMF, Vancouver, BC, CANADA.

EP-0065

Preclinical studies for optimal implementation of GRPR radiotracers in clinical studies

T. S.T. Damiana¹, P. Paraiso¹, C. de Ridder², D. Stuurman¹, L. van den Brink¹, Y. Seimbille¹, S. U. Dalm¹;

¹Department of Radiology & Nuclear Medicine, Erasmus Medical Center, Rotterdam, NETHERLANDS,

²Department of Experimental Urology, Erasmus

Medical Center, Rotterdam, NETHERLANDS.

EP-0066

Restoration of impaired portal glucose sensing by targeted manipulation of GLP-1r density in a translational model of insulin resistance

C. Malbert¹, R. Allouche², M. Horowitz³, K. L. Jones³;

¹INRAE - Aniscan, Saint-Gilles, FRANCE, ²Paltech,

Paris, FRANCE, ³Adelaide Medical School, The

University of Adelaide, Adelaide, AUSTRALIA.

EP-0067

Long-term characterization of a radiolabeled hydrogel after intrastriatal injection in rats to improve post-stroke brain repair

N. Hugues¹, C. Pin-Barre², O. Nachar¹, V. Nail¹, L. Balasse¹, B.

Guillet¹, T. Trimaille³, J. Laurin⁴, P. Garrigue¹;

¹Centre Européen de Recherche en Imagerie Médicale

(CERIMED), Marseille, FRANCE, ²Syncrosome,

Marseille, FRANCE, ³Institut de Chimie Radicalaire

(ICR), Marseille, FRANCE, ⁴Institut de Neurobiologie

de la Méditerranée (INMED), Marseille, FRANCE.

EP-0068

miRNAs as Early Biomarkers of GEPNET Disease Progression. Evaluation of Feasibility and Preliminary Results

F. SCALORBI, M. Gariboldi, L. Roz, G. Centonze, F.

Facchinetti, G. Calareso, E. Garanzini, V. Lagano, G. Argiroffi,

S. Pusceddu, M. Maccauro, E. Seregni, M. Milione;

Istituto Nazionale Tumori Milano, MILAN, ITALY.

EP-0069

Implementation of a human brain tumour model in large animals, to translate holmium-166 microbrachytherapy towards the clinic.

N. Klaassen¹, M. Boswinkel¹, N. C. Morsink², S. A. van Nimwegen², J. F. W. Nijssen¹;

¹Department of Medical Imaging, Radboud

University Medical Center, Nijmegen, NETHERLANDS,

²Utrecht University, Department of Clinical

Sciences of Companion Animals, Faculty of

Veterinary Medicine, Utrecht, NETHERLANDS.

EP-0070

Targeted Alpha Therapy Using Terbium-149 with Somatostatin Analogues: Comparison of [149Tb]Tb-DOTA-LM3 and [149Tb]Tb-DOTATATE

S. D. Busslinger¹, A. K. Mapanao¹, C. Favaretto^{1,2}, P. V.

Grundler¹, U. Köster³, K. Johnston⁴, R. Schibli^{1,5}, N. P. van der

Meulen¹, C. Müller^{1,5};

¹Paul Scherrer Institut, Villigen-PSI, SWITZERLAND,

²University Hospital Basel, Basel, SWITZERLAND, ³Institut

Laue-Langevin, Grenoble, FRANCE, ⁴ISOLDE/CERN, Geneva,

SWITZERLAND, ⁵ETH Zurich, Zurich, SWITZERLAND.

EP-0071

Radiation dosimetric and biodistribution comparison of the PSMA agonists 177Lu-PSMA I&T, 99mTc-Hynic PSMA and 99Tc-PSMA I&T to the 177Lu-RM2 antagonist

G. Limouris^{1,2}, M. Paphiti³, A. Zafeirakis²;

¹Nuclear Medicine, Medical School, National

and Kapodistrian University of Athens, Athens,

GREECE, ²Nucl Med Dept, Army Share Fund

Hospital of Athens, Athens, GREECE, ³Cyclotron

Section, Pharmazac SA, Athens, GREECE.

EP-05

e-Poster Area

A: Preclinical Studies -> A1 Medical Preclinical -> A15 Other Medical Preclinical

EP-0072

WAY100635 and altanserin differentially modulate nigrostriatal and mesolimbic D2 receptor binding

S. Nikolaus¹, H. J. Wittsack¹, M. Beu¹, C. Antke¹, B. Fazar², H.

Hautzel³, E. Mamlins¹, H. Müller¹, G. Antoch¹, F. L. Giesel¹;

¹University Hospital Düsseldorf, Düsseldorf, GERMANY,

²Heinrich-Heine University, Düsseldorf, GERMANY,

³University Hospital Essen, Düsseldorf, GERMANY.

EP-0073

5-HT1A and 5-HT2A receptor agonists and antagonists modulate behavior and regional DAT binding in the rat brain

S. Nikolaus, M. Beu;

University Hospital Düsseldorf, Düsseldorf, GERMANY.

EP-0074

Somatostatin receptor imaging in mice with different positive rate of SSTR2

Q. Xie, X. Meng, Z. Yang, J. Yu;

Peking University Cancer Hospital & Institute, Beijing, CHINA.

EP-0075

Assessment of macrophage inflammatory activity on visceral adipose tissue in high-fat diet-induced obese mice by 18F-FDG PET/CT

K. Pahnk, H. Kwon, S. Kim;
Korea University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0076

IPCEF1 serves as a novel biomarker and correlates with immune infiltration in PTC

X. Jia, R. Gao, J. zhang, H. Xu, Y. Yang, A. Yang;
The first hospital of Xi'an jiaotong university, Xi'an, CHINA.

EP-0077

Pilot study: non-invasive imaging of CD8+ T-cell infiltration during the development of type 1 diabetes in non-obese diabetic mice

S. Tokgöz¹, C. Frielink¹, P. J. Wierstra¹, I. M. Hagemans², M. Verdoes², S. Heskamp¹, M. Gotthardt¹, M. Boss¹;
¹Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS, ²Department of Tumor Immunology, Radboud University Medical Center, Nijmegen, NETHERLANDS.

EP-0078

68Ga-siderophores for Klebsiella pneumoniae detection by positron emission tomography

K. Bendová¹, M. Zappeová¹, P. Mlynářčík², Z. Nový¹, M. Popper¹, M. Hajdúch¹;
¹Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, CZECH REPUBLIC, ²Department of Microbiology, Faculty of Medicine and Dentistry, Palacký University, Olomouc, CZECH REPUBLIC.

EP-0079

Renal-clearable gambogic acid nanoparticles for PET imaging-guided acute kidney injury treatment

N. Liu, X. Su;
PET Center, Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

EP-0080

A longitudinal PET study of an open blast induced TBI model in NHP (Cynomolgus macaques) by [11C]PBR28 and [18F]Flumazenil longitudinal PET study of an open blast induced TBI model in NHP (Cynomolgus macaques) by [11C]PBR28 and [18F]Flumazenil

P. Padmanabhan¹, K. K. Ghosh¹, C. Yang², Z. Wang¹, K. Ng³, B. Ogden⁴, J. Lu³, C. Hallidin¹, B. Gulyás¹;
¹LKC School of Medicine, NTU, Singapore, SINGAPORE, ²Singapore General Hospital, Singapore, SINGAPORE, ³DSO National Laboratories, Singapore, SINGAPORE, ⁴SingHealth Experimental Medicine Centre, Singapore, SINGAPORE.

EP-0081

GPT-MI: An automated GPT-based pipeline to meta-analyse the field of molecular imaging

P. Jané¹, X. Xu², V. Taelman², E. Jané³, K. Gariani¹, R. Dumont², M. Gómez¹, M. Walter²;
¹Hôpitaux Universitaires de Genève, Geneva, SWITZERLAND, ²University of Lucerne, Lucerne, SWITZERLAND, ³Universidad Politécnica de Madrid, Madrid, SPAIN, ⁴Hospital Universitario Ramón y Cajal, Madrid, SPAIN.

EP-0082

Pilot PET study of molecular processes disturbing the electrode nerve interface in a guinea pig model of cochlear implantation

P. Deutsch^{1,2}, M. Mamach^{3,2}, J. Schweiger^{4,2}, J. Bankstahl¹, F. M. Bengel¹, T. Lenarz^{4,2}, V. Scheper^{4,2}, G. Berding^{1,2};
¹Department of Nuclear Medicine, Hannover Medical School, Hannover, GERMANY, ²Cluster of Excellence Hearing4all, German Research Foundation, GERMANY, ³Department of Radiation Protection and Medical Physics, Hannover Medical School, Hannover, GERMANY, ⁴Department of Otolaryngology, Hannover Medical School, Hannover, GERMANY.

EP-0083

Evaluating the Relevance of Non-invasive Measurement of Protein Synthesis by Gallium-68-DOTA-puromycin PET/MRI for Imaging of Mycobacterial Infection - a Preclinical Report

J. Kleynhans^{1,2}, S. Eigner³, M. M. Satheke^{4,2}, T. Ebenhan^{2,4};
¹Radiopharmaceutical Research, Catholic University of Leuven, Leuven, BELGIUM, ²Nuclear Medicine Research Infrastructure NPC, Pretoria, SOUTH AFRICA, ³Nuclear Physics Institute, Academy of Science of the Czech Republic, Rez near Prague, CZECH REPUBLIC, ⁴Nuclear Medicine and Steve Biko Academic Hospital, University of Pretoria, Pretoria, SOUTH AFRICA.

EP-06

e-Poster Area

B: Imaging Clinical Studies -> B10 Other Imaging Clinical Studies -> B101 Other Clinical Studies

EP-0084

Performance of 68Ga-FAPI PET/CT in evaluation of Erdheim-Chester disease: compared with 18F-FDG PET/CT

J. Ma;
Peking Union Medical College Hospital, Beijing, CHINA.

EP-0085

Effects of Aromatase inhibitors on bone mineral density and trabecular bone score in patients with breast cancer

V. Dabbagh¹, F. Homae Shandiz², A. Taghizadeh Kermani³, F. Nesari Javan¹;
¹Nuclear Medicine Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ²Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ³Omid Hospital, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0086

Bone SPECT-CT in the study of facet arthropathy

B. Martins, A. Duarte, M. Correia, A. Figueiredo, S. Matos, N. Canto, D. Calado, C. Loewenthal;
Hospital da Luz, Lisboa, PORTUGAL.

EP-0087

Usefulness of bone scan in the management of Paget's disease

N. Ben Fekih¹, W. El Ajmi², S. Cherif³, A. Sellem², H. Hammami²;
¹faculty of medicine monastir, Tunis, TUNISIA, ²Military Hospital of Tunis, Tunis, TUNISIA, ³faculty of medicine Tunis, Tunis, TUNISIA.

EP-0088

Is there any added value of a DXA scan of the distal forearm to lumbar and hip DXA values in predicting osteoporotic bone fractures?

M. ROMERA¹, Á. Bronte¹, V. Betech-Antar¹, F. Mínguez¹, J. Rosales¹, S. Menéndez-Sánchez¹, J. Bastidas¹, E. Guillén², L. Sancho², L. García-Belaustegui², J. Arbizu¹, M. García Velloso¹, F. Pareja¹, M. Rodríguez¹;
¹Clínica Universidad de Navarra, Pamplona, SPAIN, ²Clínica Universidad de Navarra, Madrid, SPAIN.

EP-0089

Optimization of SPECT/CT reconstruction parameters for intrapancreatic accessory spleen imaging

D. Šfiligoj Planjšek, S. Rep, A. Cuderman, J. Jamsek, L. Lezaic;
UMC Ljubljana, Ljubljana, SLOVENIA.

EP-0090

Identifying immunotherapy progressors by 18F-FLT PET/CT in solid tumours: a pilot study

P. Aravind¹, M. Lythgoe¹, J. Evans², L. Tookman², W. E. Park², N. Sarwar², A. Sita-Lumsden³, D. J. Pinato², T. D. Barwick^{1,2}, E. O. Aboagye¹, R. Sharma^{1,2};
¹Imperial College London, London, UNITED KINGDOM, ²Imperial College Hospital NHS TRUST, London, UNITED KINGDOM, ³Guys and St Thomas' NHS Foundation Trust, London, UNITED KINGDOM.

EP-07

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B11 Central Nervous System

EP-0091

Unraveling the Relationship Between Glioma Tumor Residuals from Incongruent 18F-FET PET/ MR Imaging and Tumor Proliferation Utilizing Multiparametric MRI Radiomics Analysis

X. Li^{1,2}, Y. Cheng³, X. Han¹, H. Yang¹, B. Cui^{1,2}, J. Li^{1,2}, G. Xu³, Q. Lin³, X. Xiao³, J. Tang³, J. Lu^{1,2};
¹Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, CHINA, ²Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Capital Medical University, Beijing, CHINA, ³Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, CHINA.

EP-0092

[18F]FDG-PET Radiomics Improves Outcome Prognostication in Patients With Primary CNS Lymphoma

S. Chen¹, O. Yildirim², A. Mauguen², C. Grommes², H. Schöder², M. E. Mayerhoefer², S. Krebs²;
¹Weill Cornell Medical College, New York, NY, UNITED STATES OF AMERICA, ²Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-07

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B12 Head and Neck

EP-0093

Somatostatin Receptor-Directed Theranostics in Paragangliomas of the Head and Neck

S. Serfling¹, Y. Zhi², E. Gerhard-Hartmann³, A. Weich⁴, T. Higuchi⁵, S. Hackenberg⁶, R. Hagen², H. Remde², A. Scherzad¹, M. Fassnacht⁸, R. A. Werner¹;
¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, University Hospital Würzburg, Würzburg, GERMANY, ³Institute of Pathology and Comprehensive Cancer Center Mainfranken, Würzburg, GERMANY, ⁴ENETS Center of Excellence, University Hospital Würzburg, Würzburg, GERMANY, ⁵University Hospital Würzburg, Würzburg, GERMANY, ⁶RWTH Aachen University, Aachen, GERMANY, ⁷Internal Medicine II, Gastroenterology, University Hospital Würzburg, Würzburg, GERMANY, ⁸Internal Medicine I, Endocrinology, University Hospital Würzburg, Würzburg, GERMANY.

EP-0094

Prediction of Nodal Metastasis by FDG PET/CT in Untreated Laryngeal Carcinoma; Comparison to MRI

A. Al ibraheem, A. S. Abdlkadir, H. KHCC Group, D. Al-adhami;
King Hussein Cancer Center, Amman, JORDAN.

EP-0095

Diagnostic utility of Semiquantitative parameters on FDG PET/CT for lymph node metastases in patients with laryngeal Squamous Carcinoma

A. Al ibraheem, A. Abdlkadir, D. Al-Adhami, King Hussein Cancer Center Head and neck cancer Group, H. KHCC Group;
King Hussein Cancer Center, Amman, JORDAN.

EP-0096

Role of F-18-FDG PET/CT in staging and assessment of treatment response to neoadjuvant chemotherapy in patients with extra-ocular retinoblastoma (EORB) - a single centre initial experience

S. G Ravindra, S. Garg, A. Khurana, J. Pathak, N. Lomi, R. Seth, R. Kumar, C. S. Bal;
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0097

The impact of the COVID 19 pandemic on nasopharyngeal carcinoma extent at FDG PET/MR staging:the NPCOVIPEt study
Y. Xu;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0098

Use of 18F-FDG PET/MR as an initial staging procedure for nasopharyngeal carcinoma
Y. Xu;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0099

A diagnostic model of nasopharyngeal carcinoma based on PET/MRI radiomics and semi-quantitative parameters
J. Liang;
杭州通用医学影像诊断中心, 杭州, CHINA.

EP-0100

Detection of metastatic lymph nodes with multiparametric PET/MR in head and neck imaging
A. Hartevelde, E. H. M. Kemper, N. D. Sijtsema, P. A. Wielopolski, D. H. J. Poot, M. Segbers, F. A. Verburg; Erasmus MC, Rotterdam, NETHERLANDS.

EP-0101

Clinical Value of [18F]FDG PET-CT In the Study of Head and Neck Carcinoma of Unknown Origin.
V. Carrero-Vásquez, L. Rodríguez-Bel, C. Martínez-Ramos, P. Notta, L. Gracia-Sánchez, I. Sanchez-Rodriguez, A. Palomar-Muñoz, M. Cortés-Romera; Nuclear Medicine Department, Bellvitge University Hospital, Barcelona, SPAIN.

EP-0102

Pretreatment PET-derived GLCM & TLG model predicts therapy outcome in patients with Head & Neck S.C.C.
M. Elahmadawy¹, A. Ashraf¹, H. Moustafa², M. Kotb¹; ¹Nuclear Medicine Unit, National Cancer Institute (NCI), Cairo University, Cairo, EGYPT, ²Nuclear Medicine Unit, Kasr Al-Ainy (NEMROCK Center), Cairo University, Cairo, EGYPT.

EP-0103

Application value of 18F-FDG PET/MRI in scanning for cephalic and cervical lymph node metastasis of nasopharyngeal carcinoma
J. Liang;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0104

Application value of 18F-FDG PET/MRI in monitoring the staging and treatment effectiveness of nasopharyngeal carcinoma
J. Liang;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0105

Deciphering Organ-Specific Interactions in Cancer-Associated Cachexia in Head and Neck Squamous Cell Carcinoma Using FDG PET/CT Imaging
J. Yu¹, D. Ferrara², S. Gutschmayer², M. Moreira Pires², L. Shiyam Sundar², C. Spielvogel¹, D. Haber¹, T. Beyer², M. Hacker¹; ¹Medical University of Vienna, Vienna, AUSTRIA, ²QIMP Team, Medical University of Vienna, Vienna, AUSTRIA.

EP-08

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B13 Breast

EP-0106

Comparison of 1 day protocol and 2 day protocol of lymphoscintigraphy by subareolar injection in the detection of sentinel lymph nodes in breast cancer patients.
J. Seok;
Chung-Ang University, College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0107

The comparative study of the validation for Tc-99m Tin-colloid and Tc-99m Phytate in sentinel node detection in breast cancer patients.
J. Seok;
Chung-Ang University, College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0108

Prediction of HER2 expression status in breast cancer based on 18F-FDG PET-CT radiomics
D. Han^{1,2}, X. Duan¹, N. Yu²; ¹the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CHINA, ²Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, CHINA.

EP-0109

Detection of internal mammary lymph node chain infiltration in breast cancer patients by 18F-FDG-PET/MRI. Impact on patient management
M. Kauak Kuschel, J. García Garzón, A. Compte, E. Valls, P. Bassa, M. Minoves, E. Llinares, L. Mont, E. Riera, M. Blanch Labrador; CETIR ASCIRES, Barcelona, SPAIN.

EP-0110

A pilot study of the use of positron emission tomography to evaluate early oestrogen receptor changes in patients with advanced and/or relapsed breast cancer administered endocrine therapy and CDK4/6 inhibitor combination therapy
I. Kuji¹, K. Matsuura², A. Osaki², T. Yamane¹, H. Ishiguro², T. Saeki²; ¹Department of Nuclear Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, JAPAN, ²Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, JAPAN.

EP-0111

Is subcutaneous/cutaneous uptake on [18F] FDG PET/CT a prognostic marker for breast cancer patients undergoing surgery?
Y. Kitano¹, K. Miyake², T. Nobashi¹, T. Ishimori³, R. Nakamoto¹, S. Koyasu¹, M. Kataoka¹, K. Kawaguchi⁴, Y. Takeuchi⁵, M. Toi⁶, Y. Nakamoto¹; ¹Diagnostic Imaging and Nuclear Medicine, Kyoto University Hospital, Kyoto, JAPAN, ²Department of Advanced Imaging in Medical Magnetic Resonance, Kyoto University Hospital, Kyoto, JAPAN, ³Diagnostic Radiology, Medical Research Institute Kitano Hospital, PIIF Tazuke Kofukai, Osaka, JAPAN, ⁴Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, JAPAN, ⁵Clinical Bio Resource Center, Kyoto University Hospital, Kyoto, JAPAN, ⁶Breast Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, JAPAN.

EP-0112

[18F]FDG-PET/MRI in Breast Cancer
G. Argalia¹, F. M. Fringuelli¹, G. Biscontini¹, A. Palucci¹, C. Romagnolo¹, C. Cottignoli¹, P. Ercolani², B. F. Simonetti², S. Borgoforte Gradassi², L. Burroni¹; ¹Nuclear Medicine, Department of Radiological Sciences, University Hospital of Marche, Ancona, ITALY, ²Radiology, Department of Radiological Sciences, University Hospital of Marche, Ancona, ITALY.

EP-0113

Automated Lesion Detection for 18F-Fluoroestradiol PET/CT Images Demonstrates Lesion Heterogeneity in Patients with ER+ Metastatic Breast Cancer
M. Battle¹, K. Wangerin², R. Miller¹, S. S. Houshmandi³, D. T. Huff², A. J. Weisman³, T. G. Perk³, G. A. Ulaner⁴; ¹GE HealthCare, Little Chalfont, UNITED KINGDOM, ²GE HealthCare, Marlborough, MA, UNITED STATES OF AMERICA, ³AIQ Solutions, Madison, WI, UNITED STATES OF AMERICA, ⁴Hoag Family Cancer Institute, Long Beach, CA, UNITED STATES OF AMERICA.

EP-0114

Potential role of 18F-FDG PET/CT in the initial staging of breast cancer.
R. Sanchez Sanchez¹, A. González Jimenez², T. Aroui Luquin¹, A. Piñero Donis¹, J. Villa Palacios¹; ¹Hospital Virgen de las Nieves, Granada, SPAIN, ²Hospital Universitario de Jaén, Granada, SPAIN.

EP-0115

Standardized Uptake Values of Breast Cancer in Sub-millimetre 18F-FDG-PET/CT: Direct Correlation with Histopathology
L. Maris^{1,2}, M. Göker³, K. De Man⁴, B. Van den Broeck⁴, R. Van Hoen², V. Keereman^{1,2}, K. Van de Vijver^{5,6}, C. Vanhove^{1,7}; ¹Department of Electronics and Information Systems, Ghent University, Ghent, BELGIUM, ²XEOS Medical, Ghent, BELGIUM, ³Department of Gynaecology, Ghent University Hospital, Ghent, BELGIUM, ⁴Department of Medical Imaging, Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM, ⁵Department of Pathology, Ghent University Hospital, Ghent, BELGIUM, ⁶Department of Diagnostic Sciences and Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, BELGIUM, ⁷INFINITY Lab, Ghent University, Ghent, BELGIUM.

EP-0116

The Role Of F-18 FDG PET/CT In The Prediction of Residual Cancer Burden After Neoadjuvant Chemotherapy In Locally Advanced Breast Cancer
E. KAYA¹, O. VURAL TOPUZ¹, B. E. AKKAS¹, M. KAYA¹, T. SOYLEMEZ AKKURT², E. ACAR¹; ¹University of Health Sciences, Başakşehir Cam and Sakura City Hospital, Department of Nuclear Medicine, Istanbul, Türkiye., Istanbul, TÜRKIYE, ²University of Health Sciences, Başakşehir Cam and Sakura City Hospital, Department of Pathology, Istanbul, Türkiye., Istanbul, TÜRKIYE.

EP-0117

Therapeutic impact of [18F]FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive and triple negative breast cancer
C. François¹, A. Mailliez², S. Chrétien², L. Ceugnart³, A. Oudoux¹, O. Cougnenc⁴, A. Olivier¹; ¹Department of Nuclear Medicine, Centre Oscar Lambret, Lille, FRANCE, ²Department of Medical Oncology, Centre Oscar Lambret, Lille, FRANCE, ³Department of Radiology, Centre Oscar Lambret, Lille, FRANCE, ⁴Department of Clinical Pharmacy, Centre Oscar Lambret, Lille, FRANCE.

EP-0118

The Role of Primary Tumor PET/MR Quantitative Values in Predicting Pathological Complete Response after Neoadjuvant Treatment in Breast Cancer
Y. Ünlüer Ates, U. Aydos, E. Balci, L. Atay; Gazi University Medicine Faculty, Nuclear Medicine, Ankara, TÜRKIYE.

EP-0119

Can Tumor Heterogeneity in TNBC Obtained With FDG PET/CT Predict Survival? a Novel Method: Heterogeneity index3
G. B. Babacan¹, M. Öner Tamam¹, S. Saraçoğlu¹, M. N. Acar¹, M. C. Şahin¹, G. Kulduk², H. Özçevik³; ¹University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Department of Pathology, Istanbul, TÜRKIYE, ³University of Health Sciences, Hamidiye Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

EP-0120

The Role Of 68ga Dotatate Pet/Ct In Breast Cancer Imaging; A Prospective Study Compared With 18F Fdg Pet/Ct
C. Sezgin, T. Coşkun, Y. Parlak, G. Mutevelizade, E. Sayit, G. Gümüşer; Celal Bayar University, Manisa, TÜRKIYE.

EP-0121

FAPI-04 uptake in healthy breast glandular tissue
Y. Zhang, M. Su; Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0122

Role of semi quantitative 18F-FDG PET/CT parameters in prediction of the hormone status and progression free survival of advanced stage breast carcinoma patients
S. Sarswat, A. Singhal, K. J. Das; AIIMS DELHI, Delhi, INDIA.

EP-0123

The Detection Value of 18F-FDG PET/MR for Breast Cancer Liver Metastasis

X. Chenjie;

Hangzhou Universal Medical Imaging Diagnostic Center, hangzhou, CHINA.

EP-0124

Dose Reduction for 89Zr ImmunoPET Imaging Using LAFOV PET/CT: An Analysis Based on Count-Reduced Images

P. Mohr, J. van Sluis, L. Providência, A. A. Lammertsma, A. H. Brouwers, C. Tsoumpas; University Medical Center Groningen, Groningen, NETHERLANDS.

EP-0125

Prone FDG PET/CT in breast cancer restaging (Response to treatment evaluation)

M. Agolti, L. Solari;

Centro de Medicina Nuclear Clinica Modelo, Parana, ARGENTINA.

EP-0126

Comparison of whole-body PET/CT and dedicated breast PET with F-18 Fluoroestradiol for breast cancer detection in patients with newly diagnosed ER-positive breast cancer

K. Miyake¹, M. Takada², Y. Shimizu¹, S. Yuge¹, Y. Kitano¹, T. Ishimori³, M. Kataoka¹, M. Kawashima², K. Kawaguchi², T. Oishi¹, K. Itagaki², Y. Yamada², Y. Takeuchi², M. Toi⁴, Y. Nakamoto¹;

¹Kyoto University Graduate School of Medicine, Kyoto, JAPAN, ²Kyoto University Hospital, Kyoto, JAPAN, ³Kitano Hospital, Osaka, JAPAN, ⁴Komagome Hospital, Tokyo, JAPAN.

EP-0127

18F-FDG PET/CT for monitoring treatment response in bone-dominant metastatic breast cancer patients.

P. Portilla Merino, C. Escobias del Pozo, Y. Abadi Sedraoui, E. López Llobet, L. Giraldo Gonzalez, S. Rizkallal Monzon, D. Monachello Araujo, C. Lancha Hernández, S. Rodado Marina, M. Coronado Poggio, J. Cordero García, L. Domínguez Gadea; Hospital Universitario La Paz, Madrid, SPAIN.

EP-0128

Metabolic Parameters of FDG PET/CT to Predict Disease Progression in Breast Cancer Type

J. Park¹, J. Choi¹, Z. Kim¹, C. Lim¹, J. Yoon², C. Lim³, S. Park³, J. Moon¹, S. Seo⁴, S. Woo⁵, J. Choi⁶;

¹Soonchunhyang University Bucheon Hospital, Bucheon, KOREA, REPUBLIC OF, ²Ajou University Medical Center, Suwon, KOREA, REPUBLIC OF, ³Soonchunhyang University Seoul Hospital, Seoul, KOREA, REPUBLIC OF, ⁴Pai Chai University, Daejeon, KOREA, REPUBLIC OF, ⁵Korea Institutes of Radiological and Medical Sciences, Seoul, KOREA, REPUBLIC OF, ⁶Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0129

Comparative Analysis of Immunohistochemistry Markers for Breast Carcinoma (ER, PR And HER 2 NEU) With Respect to Bone Metastasis

N. Kumar Gupta, V. K Dhingra, S. Jha, A. S.; AIIMS Rishikesh, Rishikesh, INDIA.

EP-0130

Depth of response using total tumor volume with [18F]-Fluorodeoxyglucose PET/CT for monitoring therapy response to Cyclin Dependent 4/6 Kinase Inhibitors

O. Garcia-Perez, P. Cabrera Galeana, I. Soldevilla Gallardo, E. Bargallo, D. Gutierrez-Cruz, A. Franco-Ardila; Instituto Nacional de Cancerologia, Mexico city, MEXICO.

EP-0131

Does Body Mass Index correlate with risk of recurrence in patients with breast cancer undergoing [18F]FDG PET/CT ?

N. Quartuccio, S. Ialuna, S. Pulizzi, D. D'Oppido, M. Antoni, A. M. Moreci; Nuclear Medicine Unit, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY.

EP-09

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B14 Lung (including Mesothelioma)

EP-0132

PERCIST and Beyond : revisiting 18FDG PET/CT response patterns to ICPIs for non-small cell lung cancer considering atypical response, and their long-term prognostic value.

M. Masse¹, D. Chardin^{1,2}, P. Tricarico¹, N. Martin¹, J. Darcourt¹, J. Otto¹, O. Humbert^{1,2}; ¹Centre Antoine Lacassagne, Nice, FRANCE, ²TIRO-UMR E 4320, UCA/CEA, Nice, FRANCE.

EP-0133

Comparison of Diagnostic Performance Between 68Ga-FAPI-04 and 18F-FDG PET/CT in Patients with Non-Small Cell Lung Cancer

C. Li¹, Y. Tian¹, Z. Xiao¹, J. Chen¹, L. Li¹, N. Lu¹, H. Li¹, J. Zhong¹, D. Zeng¹, B. Wen¹, Q. Chen², Y. He²;

¹Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, CHINA, ²Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, CHINA.

EP-0134

First-in-human PET imaging of KRAS p.G12C mutation status in NSCLC and CRC patients using 18F-AMG510

J. Ye, X. Li, M. Zhang, W. Yang, F. Kang, J. Wang; Xijing Hospital, Xi'an, CHINA.

EP-0135

Qualitative Analysis of Pericardial Metastasis in Oncologic F-18 FDG PET/CT

H. Lee; Dongnam Institute of Radiological and Medical Sciences, Busan, KOREA, REPUBLIC OF.

EP-0136

Comparison of FDG PET/CT and PET/MR Imaging for Primary Staging of Newly Diagnosed Lung Cancer

E. Erbil, U. Aydos, Ü. Akdemir, N. Karabacak, L. Atay; Gazi University Faculty of Medicine, Ankara, TÜRKIYE.

EP-0137

Added diagnostic sensitivity of MTV and TLG in the assessment of left adrenal gland metastasis in lung cancer with [18F]FDG PET/CT

H. Hautzel¹, F. Özkan², C. Laschinsky¹, D. Kersting¹, M. Opitz³, D. Theegarten⁴, K. Darwiche², K. Herrmann¹;

¹Department of Nuclear Medicine, University Hospital Essen, University Duisburg - Essen, Essen, GERMANY, ²Department of Pneumology, Section of Interventional Pneumology, Ruhrlandklinik Essen, Universitätsmedizin Essen, Essen, GERMANY, ³Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg - Essen, Essen, GERMANY, ⁴Institute of Pathology, University Hospital Essen, University Duisburg - Essen, Essen, GERMANY.

EP-0138

Value of 18F-FDGPET/CT in the Differential Diagnosis of Tuberculous Pulmonary Cavity and Lung Cancer Cavity

M. Zhao^{1,2}, L. Ma¹;

¹Shandong Cancer Hospital of China, Ji Nan, CHINA, ²Department of Nuclear Medicine, Zibo Central Hospital, Shandong Province, Zibo City, CHINA.

EP-0139

Contribution of 18F-FDG PET-CT in initial staging of non-small cell lung cancers

H. Noamen^{1,2}, H. Charfi², I. Jardak¹, R. Sfar², I. Touil², K. Chatti², K. Chtourou¹, F. Guermazi¹;

¹University hospital of Habib Bourguiba, Sfax, TUNISIA, ²University of Monastir, Monastir, TUNISIA.

EP-0140

Prediction of mediastinal node involvement in non-small lung cancer by baseline 18 F-FDG PET/CT metabolic parameters

H. Noamen^{1,2}, H. Charfi², I. Jardak¹, R. Sfar², I. Touil², K. Chatti², K. Chtourou¹, F. Guermazi¹;

¹University hospital of Habib Bourguiba, Sfax, TUNISIA, ²University of Monastir, Monastir, TUNISIA.

EP-0141

PET attenuation correction of chest FDG PET/MRI: Deep learning-based denoising and pseudo-CT generation using fast zero-TE MRI and unpaired PET/CT data

M. Nogami^{1,2}, H. Matsuo³, M. Nishio³, M. Tachibana³, J. Inukai-Inoue³, F. Zeng³, K. Kubo¹, T. Kurimoto⁴, T. Murakami^{3,1};

¹Kobe University Hospital, Kobe, JAPAN, ²University of Fukui, Fukui, JAPAN, ³Kobe University Graduate School of Medicine, Kobe, JAPAN, ⁴GE Healthcare, Hino, JAPAN.

EP-0142

Prediction of 131I Uptake in Lung Metastases of Differentiated Thyroid Cancer Using Deep Learning before Radioiodine Therapy: a Pilot Study

H. Song; Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA.

EP-0143

The value of 18F-FDG PET/CT radiologic features and radiomics features predicting the bronchogenic carcinomas with ALK rearrangement fused gene

Y. Xu; Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0144

The value of PET/MRI radiomics features in predicting synchronous brain metastases in non-small cell lung cancer

J. Liang;

杭州通用医学影像诊断中心, 杭州, CHINA.

EP-0145

The Application of Three-dimensional Ventilation/Perfusion single photon emission tomography/computed tomography in Asthma and COPD

H. Xie, L. Li;

West China Hospital of Sichuan University, Chengdu, CHINA.

EP-0146

68Ga-SSO-120 versus 18F-FDG PET in the Initial Staging of Small-Cell Lung Cancer Patients

D. Kersting¹, P. Sandach¹, M. Sraieb¹, M. Wiesweg², M. Metznermacher², K. Darwiche³, F. Oezkan³, S. Bölükbas⁴, M. Stuschke⁵, L. Umutlu⁶, M. Nader¹, R. Hamacher⁷, W. P. Fendler¹, J. Wienker³, W. Eberhardt², M. Schuler², K. Herrmann¹, H. Hautzel¹;

¹Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, ²Department of Medical Oncology, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, ³Department of Pulmonology, Section of Interventional Pulmonology, University Medicine Essen - Ruhrlandklinik, University of Duisburg-Essen, Essen, GERMANY, ⁴Department of Thoracic Surgery and Thoracic Endoscopy, University Medicine Essen - Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, Essen, GERMANY, ⁵Department of Radiotherapy, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY, ⁶Institute of Diagnostic, Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY.

EP-0147

Ongoing Trial on the Role of the Promising Oncological PET/CT Tracer [68Ga]Ga-FAPI-46 for Staging Suspected/Confirmed Lung Cancer: Preliminary Results on Patients who Underwent Radical Surgery

E. Fortunati¹, L. Zanoni², G. Cuzzani¹, C. Nanni², F. Lodì², F. Antonacci³, P. Solli³, F. Giunchi⁴, A. Degiovanni⁵, M. Ferrarè⁶, F. Natali⁵, T. Galasso⁵, G. Bandelli⁵, P. Candoli⁵, A. D'Errico⁴, S. Fanti^{1,2};

¹Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Division of Thoracic Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Pathology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁵Interventional Pulmonology Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0148

Can [18F] FDG PET/CT parameters Predict Pathological Response in Locally Advanced NSCLC? Findings from NADIM Study

R. Jimeno Pernett¹, J. Mucientes Rasilla¹, J. Gonzalez Larriba², A. Martinez Mart³, E. Nadal⁴, N. Viñolas⁵, J. Bosch Barrera⁶, A. Insa Mallá⁷, J. Casal Rubio⁸, M. Cobo Dols⁹, R. Bernabe Caro¹⁰, M. Mitjavila Casanovas¹, V. Calvo de Juan¹, M. Provencio Pulla¹;

¹Hospital Universitario Puerta De Hierro, Madrid, SPAIN, ²Hospital Universitario Clínico San Carlos, Madrid, SPAIN, ³Hospital Universitario Vall d'Hebrón, Barcelona, SPAIN, ⁴ICO Hospitalet, Barcelona, SPAIN, ⁵Hospital Clínic Barcelona, Barcelona, SPAIN, ⁶Instituto Catalán de Oncología Médica de Girona, Barcelona, SPAIN, ⁷Hospital Clínico Universitario de Valencia, Valencia, SPAIN, ⁸Hospital Álvaro Cunqueiro, Vigo, SPAIN, ⁹Hospital Carlos Haya, Málaga, SPAIN, ¹⁰Hospital Virgen del Rocío, Sevilla, SPAIN.

EP-0149

Relationship between [18]FDG myocardial uptake and subsequent evolution towards cachexia and outcome in lung cancer patients. Assessment from the retrospective LuCaPET database.

E. Abenavoli¹, A. Grosso², T. Beyer³, S. Duke⁴, D. Ferrara³, A. Fille⁵, S. Gruenert⁶, M. Hacker⁶, S. Hesse⁶, L. Hofmann⁷, S. Holm⁴, O. Sabri⁷, L. Sundar³, J. Yu³, R. Sciagra¹;

¹Department of Nuclear Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY, ²Department of Pneumology, Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY, ³QIMP Team, Medical University of Vienna, Vienna, AUSTRIA, ⁴University of Copenhagen, Copenhagen, DENMARK, ⁵University Hospital of Leipzig, Leipzig, GERMANY, ⁶Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, ⁷University Hospital of Leipzig, Leipzig, AUSTRIA.

EP-10

e-Poster Area

**B: Imaging Clinical Studies -> B1
Oncological Imaging Clinical Study -> B15
Gastro-Intestinal (including Liver and Non-Endocrine Pancreas)**

EP-0150

Diagnostic and prognostic value of TOF-18F-FDG PET/CT in patients with malignant pancreatic tumors

S. Stanzel, T. Nazerani-Zemann, R. M. Aigner; Division of Nuclear Medicine, Graz, AUSTRIA.

EP-0151

Diagnostic and prognostic value of time-of-flight 18F-FDG PET/CT in staging of patients with pancreatic ductal adenocarcinoma using TrueX and Q.Clear reconstruction

S. Stanzel, T. Nazerani-Zemann, R. M. Aigner; Medical University of Graz, Department of Nuclear Medicine, Division of Nuclear Medicine, Graz, AUSTRIA.

EP-0152

Evaluation of Liver Lesions with Diffusion Weighted Imaging PET/MRI in Transarterial Radioembolization Treatment Patients

A. Kibar, F. Aghazada, L. Uslu-Besli, O. E. Sahin, S. Asa, S. Sager, K. Sonmezoglu;

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

EP-0153

Comparison of Tc-99m Mebrofenin Scintigraphy with Other Parameters in Prediction of Patient Status in Y-90 Patients

A. Kibar, S. Asa, F. Aghazada, N. Yeyin, M. Abuqbeith, K. Sahin, C. Guneren, K. Saglam, B. Ince, S. Sager, K. Sonmezoglu;

Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

EP-0154

Dual-tracer PET/CT protocol with [18F]FDG and [68Ga]Ga-FAPI-46 outperforms single-tracer PET/CT with [18F]FDG in gastrointestinal and head and neck cancer, due to higher tumour to background ratio and larger gross and functional tumour volume.

K. Roth¹, S. Wegen², J. Weindler¹, C. Voltin¹, L. van Heek¹, K. Schomäcker¹, T. Fischer¹, S. Marnitz², C. Kobe¹, A. Drzezga¹;

¹Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, Cologne, Germany, Cologne, GERMANY, ²Department of Radiation Oncology, Cyberknife and Radiotherapy, Faculty of Medicine and University Hospital Cologne, Cologne, Germany, Cologne, GERMANY.

EP-0155

Surveillance 18F-FDG PET/CT in predicting the prognosis of esophageal cancer patients

S. Chan, C. Tseng, S. Llu;

Hualien Tzu Chi Hospital, Hualien, TAIWAN.

EP-0156

A dose optimization study using Visual Grading Regression in [68Ga]-FAPI-46 PET imaging of patients with pancreatic lesions

T. Nilsson¹, P. Rasinski^{1,2}, S. af Burén^{1,2}, Ö. Smedby³, A. Blomgren¹, M. Löhr^{2,4}, E. Sparrelid⁵, T. Tran^{6,7}, R. Axelsson^{1,8}, M. Holstenson^{1,2};

¹Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Huddinge, SWEDEN, ²Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, SWEDEN, ³Department of Biomedical Engineering and Health Systems, KTH Royal Institute of Technology, Stockholm, SWEDEN, ⁴Department of Upper Gastrointestinal Diseases, Karolinska University Hospital, Huddinge, SWEDEN, ⁵Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, SWEDEN, ⁶Department of Oncology-Pathology, Karolinska Institutet, Stockholm, SWEDEN, ⁷Department of Radiopharmacy, Karolinska University Hospital, Stockholm, SWEDEN, ⁸Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, SWEDEN.

EP-0157

The prognostic value of metabolic parameters and heterogeneity index of PET/CT in patients with advanced gastric adenocarcinoma

Y. Tian, T. Zhao, W. Cai, Y. Dong, X. Ma, P. Ma, Q. Zhao; General Hospital of Ningxia Medical University, Yinchuan, CHINA.

EP-0158

Incremental value of 18F-FDG PET-CECT over conventional imaging in evaluation of Gall Bladder Carcinoma.

P. Singh, T. Singhal, P. Kumar, G. Parida, R. Emerson, K. Bishnoi, A. Rehman, K. Kandula, K. Agrawal, S. Patro; AIIMS Bhubaneswar, Bhubaneswar, INDIA.

EP-0159

Prognostic value of negative FDG PET/CT in curatively treated colorectal carcinomas with rising CEA levels during surveillance

A. Suresh¹, V. Rangarajan², N. Purandare³, A. Agrawal³, S. Shah², A. Puranik², A. Saklani²;

¹Tata Memorial Centre, Varanasi, INDIA, ²Tata Memorial Centre, Mumbai, INDIA.

EP-0160

Comparison of 18F-FAPI-04 and 18F-FDG PET/CT in detecting the primary tumor and metastatic lesions in patients with initial pancreatic ductal adenocarcinoma

L. Lin, G. Wang, X. Su;

Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

EP-0161

Comparison of Diagnostic Efficacy of 18FAI-NOTA-FAPI-04 and 18F-FDG PET/CT for recurrence and/or metastasis in patients with gastric cancer

K. Zheng, Y. Zhang, H. Ye, A. Xie;

Hunan Cancer Hospital (the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University), Changsha, CHINA.

EP-0162

Prognostic value of semiquantitative [18F]F-FDG PET/MRI parameters in patients with a newly diagnosed Pancreatic Adenocarcinoma

G. Mango¹, P. Bartoletti², S. Serafini³, R. Guastella⁴, C. Berto⁵, S. Da Pozzo⁶, M. Sitara², G. Fichera⁷, C. Giraud², L. Evangelista²;

¹Nuclear Medicine, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY, ²Nuclear Medicine Unit, Department of Medicine DIMED, University of Padua, Padua, ITALY, ³General Surgery Padua University Hospital, Padua, ITALY, ⁴Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, Padua University Hospital, Padua, ITALY, ⁵Radiology Unit, Department of Medicine DIMED, University of Padua, Padua, ITALY, ⁶Radiology Unit, Azienda Ospedaliera di Padua, Padua, ITALY, ⁷Pediatric Radiology Unit, Padua University Hospital, Padua, ITALY.

EP-0163

Head-to-head comparison of 18F-FDG and 68Ga-DOTA-FAPI PET/CT for staging and therapeutic evaluation of esophageal cancer

W. Hou, R. Tian;

West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0164

Comparison of 3D Voxel-Based Yttrium-90 Dosimetry Quantification of using Y90 PET/CT Versus Y90 SPECT/CT

N. Kokabi^{1,2}, M. Xing³, D. Brandon², H. Dabbous², J. R. Galt⁴, I. Sethi², S. Kappadath⁵, A. Villalobos¹, D. M. Schuster²;

¹University of North Carolina School of Medicine, Chapel Hill, NC, UNITED STATES OF AMERICA, ²Emory University School of Medicine, Atlanta, GA, UNITED STATES OF AMERICA, ³University of North Carolina School of Public Health, Chapel Hill, NC, UNITED STATES OF AMERICA, ⁴Emory University School of Medicine, Atlanta, GA, UNITED STATES OF AMERICA, ⁵MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

EP-0165

2-[18F]FDG PET/CT derived semi-quantitative parameters in predicting response to chemoradiation in oesophageal squamous cell carcinoma

L. Lemos¹, I. Lopo¹, P. Lapa^{1,2}, G. Costa^{1,2};

¹Nuclear Medicine Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, ²Faculdade de Medicina, Universidade de Coimbra, Coimbra, PORTUGAL.

EP-0166

Role of whole-body FDG PET/CT in the detection of peritoneal metastases in cases of gastroesophageal junction adenocarcinoma

S. Thakur, N. Purandare, V. Rangarajan, A. Agrawal, S. Shah, A. Puranik, C. Pramesh, G. Karimundackal, K. Prabhash, S. Jinwani, D. Niyogi, R. Kumar;

Tata Memorial Hospital, Mumbai, INDIA.

EP-0167

18F-AIF-NOTA-FAPI PET/CT in the evaluation of gastric, liver, and pancreatic cancer and comparison with 18F-FDG PET/CT

w. xu, J. Cai, Y. Pang, L. Sun, H. Chen;

Department of Nuclear Medicine & Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China, xiamen, CHINA.

EP-0168

Diagnostic Efficiency of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Malignant Biliary Obstruction

Z. Koç¹, P. Özcan¹, E. Reyhan², M. Yaldız³, E. Üçbilek⁴;

¹Mersin University Hospital Nuclear Medicine Dpt., Mersin, TÜRKIYE, ²Mersin University Hospital Surgical Oncology Dpt., Mersin, TÜRKIYE, ³Mersin University Hospital Pathology Dpt., Mersin, TÜRKIYE, ⁴Mersin University Hospital Gastroenterology Dpt., Mersin, TÜRKIYE.

EP-0169

Characterization of pancreatic lesions by PETMR and evaluation of the diagnostic efficacy of this technique correlated to anatomopathological findings

C. A. Field Galán, L. Delgado Niño, I. Plaza de las Heras, R. de Teresa Herrera, P. Recarte Ortega, L. García Cañamaque; HM Hospitales Madrid, Madrid, SPAIN.

EP-0170

Diagnostic Value of Integrated PET/MR in Postoperative Recurrence of Liver Cancer
X. Chenjie;

Hangzhou Universal Medical Imaging Diagnostic Center, hangzhou, CHINA.

EP-0171

Prospective Intra-individual comparison of 68Ga-FAPI and 18F-FDG PET/CT in the diagnosis and staging of gastric malignancies

M. Jayanthi, S. BATCHU, A. Sekaran, G. VENKAT RAO, N. Duvvur;

AIG Hospitals, Hyderabad, INDIA.

EP-0172

The value of 18F-FDG PET/MR radiomics features in predicting regenerative nodules (RN), dysplastic nodules (DN) and small hepatocellular carcinoma nodules (SHCC) in cirrhosis

Y. Xu;

Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0173

The Detection Value of 18F-FDG PET/MR for Small Hepatocellular Carcinoma

X. Chenjie;

Hangzhou Universal Medical Imaging Diagnostic Center, hangzhou, CHINA.

EP-0174

Application value of 18F-FDG PET/MR in postoperative metastasis and restating of gastric cancer

S. Yun;

Hangzhou Panoramic Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0175

Comparative analysis of early and late-phase of [18F]F-Fluorocholine PET/CT acquisition in the assessment of hepatocellular carcinoma

D. Rivas-Navas, J. Fernández-Fernández, E. Triviño-Ibáñez, J. Villa-Palacios, A. Rodríguez-Fernández; Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0176

Impact of [18F]F-Fluorocholine PET/CT in the management and prognosis of hepatocellular carcinoma.

D. Rivas-Navas, J. Fernández-Fernández, E. Triviño-Ibáñez, J. Villa-Palacios, A. Rodríguez-Fernández; Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0177

The prediction value of metabolic parameters of 18F-FDG PET/CT for risk stratification of hypermetabolic gastrointestinal stromal tumors

L. Zhang, W. Cao, Y. Ding, Y. Liu, Y. Deng, H. Chen; Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA.

EP-0178

Prospective study of the diagnostic value of 68Ga-FAPI-04 PET/CT for gallbladder cancer: comparison with 18F-FDG

L. Liu, Y. Huang, Q. Liu, D. Xu;

The Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital), Chengdu, CHINA.

EP-0179

Impact Of FDG PET CT On Management Of Patients With Treatment Naive HCC Intended For Local Surgical/Ablative Or Embolisational Therapies

M. SARMA, B. S T, W. Jose;

Amrita Institute of Medical Sciences and Research, Cochin, INDIA.

EP-0180

Diagnostic role of FAPI PET/CT in the detection of peritoneal metastases in cases of stomach and gastroesophageal junction adenocarcinoma

S. Thakur, V. Shukla, M. Manikandan, S. Arvind;

Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, INDIA.

EP-0181

Role of 99mTc-Mebrofenin SPECT/CT in preoperative determination of global and segmental liver function

A. Bakos¹, T. Czékus¹, I. Farkas¹, L. Libor², Z. Mikó¹, S. Nagy¹, R. Németh¹, L. Pávics¹, G. Sipka¹, S. Urbán¹, M. Bukva³, Z. Besenyi¹;

¹University of Szeged Nuclear Medicine Department, Szeged, HUNGARY, ²University of Szeged Department of Surgery, Szeged, HUNGARY, ³University of Szeged Department of Immunology, Szeged, HUNGARY.

EP-0182

Diagnostic Performance of [18F]PSMA-1007 PET/CT on Hepatocellular Carcinoma: a Prospective Clinical Study

K. Michalski¹, F. Reiter², A. Kosmala¹, P. E. Hartrampf¹, S. E. Serfling¹, T. A. Bley², A. Geier², A. K. Buck¹, R. A. Werner¹, A. Weich²;

¹University hospital Würzburg - Department of Nuclear Medicine, Würzburg, GERMANY, ²University hospital Würzburg - Internal Medicine II, Würzburg, GERMANY, ³University hospital Würzburg - Department of Diagnostic and Interventional Radiology, Würzburg, GERMANY.

EP-0183

Gallium-68 Prostate-Specific Membrane Antigen (68Ga-PSMA) PET Metabolic Metrics in Patients with Hepatocellular carcinoma with and without Hepatitis B Infection

N. Nyakale^{1,2}, L. M. Harry³, C. Aldous³, A. Maes⁴, C. van de Wiele⁵, M. M. Sathegke^{6,7};

¹Department of Nuclear Medicine, Sefako Makgatho Health Sciences University and Dr George Mukhari Academic Hospital, Pretoria, SOUTH AFRICA, ²Department of Nuclear Medicine, University of Kwa-Zulu Natal, Durban, SOUTH AFRICA, ³Department of Genetics, College of Health Sciences, University of KwaZulu Natal, Durban, South Africa., Durban, SOUTH AFRICA, ⁴Katholieke University Leuven, Kortrijk, BELGIUM, ⁵Ghent University, Ghent, BELGIUM, ⁶Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA, ⁷Nuclear Medicine Research Infrastructure (NuMeRI), Pretoria, SOUTH AFRICA.

EP-0184

Prognostic Value of F18-FDG PET-CT in Patients With Localized Oesophageal Cancer Treated With Neoadjuvant Chemoradiation: The Use of Hopkins Criteria for Treatment Response Assessment

N. Bin Essa, A. Alderaibi, M. Hawkins, J. Bomanji, S. Vöö; University College of London Hospital, London, UNITED KINGDOM.

EP-0185

The Evaluation Of Relationship Between F18 Fdg Pet/Ct Parameters And Sarcopenia In Esophagus Can

M. ACAR TAYYAR¹, M. ÖNER TAMAM¹, G. B. BABACAN¹, M. ŞAHİN¹, H. ÖZÇEVİK², N. GÜRDAL³;

¹University of Health Sciences, Prof. Dr. Cemil Tascioğlu City Hospital of Nuclear Medicine, Istanbul, TÜRKIYE, ²University of Health Sciences, Hamidiye Faculty of Nuclear Medicine, Istanbul, TÜRKIYE, ³University of Health Sciences, Prof. Dr. Cemil Tascioğlu City Hospital of Radiation Oncology, Istanbul, TÜRKIYE.

EP-0186

[18F]F-FAPI-74 PET for initial clinical staging in patients with pancreatic cancer : a prospective pilot study

J. Gil^{1,2}, W. Yun³, H. Choi^{1,2}, J. Paeng^{1,2}, K. Kang^{1,2}, J. Jang³, G. Cheon^{1,2};

¹Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF, ²Department of Nuclear Medicine, College of Medicine, Seoul National University, Seoul, KOREA, REPUBLIC OF, ³Department of Surgery, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0187

The prognostic value of 18F FDG PET/CT intra-tumoural metabolic heterogeneity in patients with esophageal squamous cell carcinoma treated with Concurrent Chemoradiotherapy or Definitive Chemoradiotherapy(dCRT)

Z. Zhu, X. Ma, Q. Xie, X. Yao;

The University of Science and Technology of China, Hefei, CHINA.

EP-0188

Diagnostic Performances Of [18f]F-Fdg Pet, Mri And Pet/Mri In Patients With Newly Diagnosed Pancreatic Adenocarcinoma

P. Bartoletti¹, G. Mango², S. Serafini³, R. Guastella⁴, C. Berto⁵, S. Da Pozzo⁶, M. Sitara¹, G. Fichera⁷, C. Giraudo¹, L. Evangelista¹;

¹Nuclear Medicine Unit, Department of Medicine DIMED, University of Padua, Padova, ITALY, ²Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY, ³General Surgery, Padua University Hospital, Padova, ITALY, ⁴General Surgery Università degli Studi di Padova, Padova, ITALY, ⁵Radiology Unit, Department of Medicine DIMED, University of Padua, Padova, ITALY, ⁶Radiology Unit, Azienda Ospedaliera di Padova, Padova, ITALY, ⁷Pediatric Radiology Unit, Padua University Hospital, Padova, ITALY.

EP-0189

Exploratory data on prostate-specific membrane antigen and vessels encapsulating tumour clusters in hepatocellular carcinomas: are two sides of the same coin?

R. Zanca^{1,2}, R. Akpınar³, L. Di Tommaso^{1,3}, F. Gelardi^{1,2}, M. Rodari², M. Sollini^{1,2};

¹Department of Biomedical Sciences, Humanitas University, Milan, ITALY, ²Nuclear Medicine, IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY, ³Pathology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, ITALY.

EP-0190

Ga-68 PSMA PET/CT Imaging Findings of Cholangiocellular Carcinoma

T. Kissa, Z. C. Balaban Genç, X. Niftaliyeva, N. Filizoglu, S. Kesim, K. Öksüzöğlü, F. Çağlıyan, S. Özgüven, F. Dede, T. Ones, H. T. Turoglu, T. Y. Erdil;

Marmara University Pendik Research and Training Hospital, Istanbul, TÜRKIYE.

EP-11

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B16 Neuroendocrine (Pancreatic and Others)

EP-0191

68Ga-DOTA-TATE in Cervicothoracic, Coeliac and Sacral Ganglia: sites of physiological uptake in the Era of total-body PET/CT

E. Triumbari¹, Y. Abdelhafez², D. Morland³, B. A. Spencer², A. Calabrò⁴, F. Sen², R. D. Badawi², M. Guindani⁵, L. Nardo²;

¹Nuclear Medicine Unit, TracerGlab, Rome, ITALY, ²Department of Radiology, UC Davis, Sacramento, CA, UNITED STATES OF AMERICA, ³Service de médecine nucléaire, Institut Godinot, Reims, FRANCE, ⁴Nuclear Medicine Department, University of Brescia and ASST Spedali Civili di Brescia, Brescia, ITALY, ⁵Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA.

EP-0192

The quantification for the treatment response evaluation of Metastatic Gastroenteropancreatic Neuroendocrine Tumors in Ga-68 DOTATATE PET/CT

Z. Koç¹, P. Özcan¹, E. Sezer², T. Kara³;

¹Mersin University Hospital Nuclear Medicine Dpt., Mersin, TÜRKIYE, ²Mersin University Hospital Oncology Dpt., Mersin, TÜRKIYE, ³Mersin University Hospital Pathology Dpt., Mersin, TÜRKIYE.

EP-0193

The additional value of SPECT/CT imaging to planar imaging in neuroendocrine tumors

A. Tsaroucha, N. Kapsoritakis, O. Bourgianni, G. Lamprakopoulos, M. Stathaki, E. Papadaki, S. Koukouraki; University Hospital of Heraklion, Heraklion, Crete, GREECE.

EP-0194

18F-AIF-NOTA-Octreotide PET/CT: Krenning's score and tumor burden influence by tumor volume and total lesion activity

M. González Martínez¹, A. Piana Bezaury¹, I. Pérez Díaz², M. Olarte Casas¹;

¹PET/CT unit, UNAM, Mexico City, MEXICO,

²UNAM, Mexico City, MEXICO.

EP-0195

Referral Patterns and Image Results of 2,249 [64Cu]Cu-DOTATATE PET/CT in a European Neuroendocrine Tumor Society Center of Excellence

M. Loft^{1,2}, E. A. Carlsen^{1,2}, C. B. Johnbeck^{1,2}, U. Knigge^{2,3}, M. Andreassen^{2,3}, S. W. Langer^{2,4,5}, H. H. Johannesen^{1,2}, J. Mortensen^{1,2,5}, L. H. Enevoldsen^{1,2}, P. Oturai^{1,2}, A. Kjaer^{1,2};

¹Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital – Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, DENMARK, ²European Neuroendocrine Tumor Society Center of Excellence at Copenhagen University Hospital – Rigshospitalet, Copenhagen, DENMARK, ³Departments of Clinical Endocrinology and Surgical Gastroenterology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, DENMARK, ⁴Department of Oncology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, DENMARK, ⁵Department of Clinical Medicine, University of Copenhagen, Copenhagen, DENMARK.

EP-0196
Impact on clinical management when using [18F] AIF-NOTA-octreotide instead of [68Ga]Ga-DOTA-SSA PET/CT in neuroendocrine tumor patients: preliminary results

H. Leupe¹, E. Pauwels¹, T. Vandamme^{2,3}, B. Van den Broeck⁴, W. Lybaert³, J. Dekervel⁵, J. Jaekers⁶, F. Cleeren⁷, J. Hofland⁸, A. Brouwers⁹, M. Koole¹, G. Bormans⁷, E. Van Cutsem⁵, K. Geboes¹⁰, C. Verslype⁵, S. Stroobants¹¹, C. M. Deroose¹;

¹Nuclear Medicine, University Hospitals Leuven & Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM, ²Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, BELGIUM, ³Oncology, NETwerk Antwerpen-Waasland CoE, Antwerp-Waasland, BELGIUM, ⁴Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM, ⁵Digestive Oncology, University Hospitals Leuven, Leuven, BELGIUM, ⁶Department of Visceral Surgery, University Hospitals KU Leuven, Leuven, BELGIUM, ⁷Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, BELGIUM, ⁸Department of Internal Medicine, Section of Endocrinology, ENETS Centre of Excellence Rotterdam, Erasmus MC Cancer Institute, Rotterdam, NETHERLANDS, ⁹University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS, ¹⁰Digestive Oncology, Department of Gastroenterology, Ghent University Hospital, Ghent, BELGIUM, ¹¹Nuclear Medicine, Antwerp University Hospital & Molecular Imaging and radiology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, BELGIUM.

EP-0197

Development of a Semi-Automatic Platform for Whole Body Tumor Segmentation and Radiomic Feature Extraction From 68Ga-DOTATATE PET/CT Using TriDFusion (3DF)

S. Krebs¹, D. Lafontaine, L. Bodej, M. E. Mayerhoefer, J. Humm, H. Schöder;

Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0198

The risk factors of pancreatic neuroendocrine tumor predicted by 18F-FDG and 68Ga-DOTANOC PET/CT before surgery.

J. Xu, S. Song;

Fudan University Shanghai Cancer Center, Shanghai, CHINA.

EP-0199

The use of 18F-DOPA PET/CT for the diagnosis of neuroendocrine tumors suspected or confirmed from unknown origin

A. Rodríguez Pajuelo, J. Cuenca Cuenca, M. Guerra Gómez, J. Jiménez-Hoyuela García;

Virgen del Rocío University Hospital, Seville, SPAIN.

EP-0200

Impact of Tumor-to-Background Ratio on Training of AI for Liver Metastasis Detection in Neuroendocrine Tumors

B. Schemmer;

Uniklinik Bonn, Bonn, GERMANY.

EP-0201

What is the utility of combined 68Ga-DOTATOC and 18F-FDG- PET/CT in the work-up of subjects with neuroendocrine tumors of unknown origin?

I. Bloise, S. Harsini, F. Benard, D. Wilson, J. M. Loree, P. Martineau;

BC Cancer, Vancouver, BC, CANADA.

EP-0202

[68Ga]Ga-DOTATOC PET radiomics supports lymph node metastases detection for accurate surgical planning of well-differentiated pancreatic neuroendocrine tumours patients

C. Bezzi^{1,2}, P. Mapelli^{1,2}, S. Ghezzi^{1,2}, F. Muffatti³, M. Schiavo Lena⁴, V. Andreasi³, C. Canevari³, P. Magnani², S. Partelli³, M. Falconi^{1,3}, A. Chiti^{1,2}, M. Picchio^{1,2};

¹Vita-Salute San Raffaele University, Milan, ITALY, ²Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ³Pancreatic Surgery Unit, Pancreas Translational & Clinical Research Centre, IRCCS San Raffaele Scientific Institute, Milan, ITALY, ⁴Pathology Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

EP-0203

Role of 68Ga-DOTANOC PET/CT in the assessment of Appendiceal Neuroendocrine Tumors

R. Goel, S. A. Shamim, N. Kumar, S. Rastogi, R. Kumar, C. Bal;

All India Institute of Medical Sciences, NEW DELHI, INDIA.

EP-0204

Clinical impact of [68Ga] Ga-DOTA-TOC PET/CT in the management of neuroendocrine tumors.

J. Villa Palacios, T. Aroui Luquin, D. Rivas-Navas, P. Guijarro-Caba, M. Muros De Fuentes;

Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0205

Utility of different semiquantitative parameters of [68Ga] Ga-DOTA-TOC PET/CT and their correlation with neuroendocrine tumors differentiation grade.

J. Villa Palacios, T. Aroui-Luquin, D. Rivas-Navas, M. Muros De Fuentes, R. Sanchez Sanchez;

Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0206

Quantification of 99mTc-EDDA/HYNIC-TOC SPECT/CT: a feasible alternative to 68Ga-DOTA-PET in patients with NET disease

P. Spiridon¹, A. Lazar¹, R. Maaz¹, J. Rabah¹, M. Mutuleanu^{1,2}, M. Gherghe^{1,2};

¹Nuclear Medicine Department, Institute of Oncology "Professor Doctor Alexandru Trestioreanu", Bucharest, ROMANIA, ²Nuclear Medicine Department, University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA.

EP-0207

Prognostic impact of Gallium-68 DOTANOC PET/CECT in metastatic well differentiated Gastro-entero-pancreatic Neuroendocrine Tumors (GEP NETs).

I. Dev, V. Rangarajan, A. Puranik, A. Agrawal, N. Purandare, S. Shah, S. Shrikhande, V. Chaudhari, S. Choudhury, S. Ghosh;

TATA MEMORIAL CENTRE, Mumbai, INDIA.

EP-0208

Role of 68Ga-DOTANOC PET/CT in the assessment of Lung Carcinoids

S. Shamim, R. Goel, N. Kumar, G. Arora, S. Rastogi, A. Goyal, R. Kumar, C. Bal;

AIIMS New Delhi, Delhi, INDIA.

EP-0209

Assessment of glucose metabolism in skeletal muscle and adipose tissue with the use of 2-[18F]FDG PET/CT in patients with ectopic adrenocorticotropin secretion

M. Opalinska¹, J. Kokoszka², E. Rzepka¹, K. Sitarz³, A. Sowa-Staszczak¹, A. Gillis-Januszewska¹, A. Hubalewska-Dydejczyk¹;

¹Jagiellonian University Medical College, Chair and Department of Endocrinology, Krakow, POLAND, ²Endocrinology, Oncologic Endocrinology and Nuclear Medicine Department, University Hospital in Krakow, Krakow, POLAND, ³University Hospital in Krakow, Krakow, POLAND.

EP-0210

The evaluation of kidney function using the Somatostatin (SSTR)-targeting radioligands 18F-SiFA-TATE, 68Ga-DOTATATE and 68Ga-DOTATOC in a theranostic setting

M. Tiling¹, A. Holzgreve¹, S. Kunte¹, G. Sheikh¹, M. Unterrainer^{2,1}, P. Bartenstein¹, A. Delker¹, L. Unterrainer¹;

¹Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, ²DIE RADIOLOGIE, Munich, GERMANY.

EP-0211

Spectrum of hyperuptake findings detected in PET/CT [68Ga]Ga-DOTA-TOC studies. Experience in our center

S. Bondia-Bescós, J. Vercher-Conejero, J. Martín-Marcuarta, A. Rodríguez-Gasen, J. Suils-Ramón, M. Perlaza-Jiménez, M. Pudas, B. Hervás-Sanz, J. Díaz-Moreno, M. Cortés-Romera;

Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital, Barcelona, SPAIN.

EP-0212

68Ga-DOTA peptides PET/CT radiomic parameters useful to differentiate para-physiological uptake in pancreatic uncinatene process from pancreatic NET.

F. Linguanti¹, E. M. Abenavoli², A. Lombardo¹, V. Briganti², F. Munga³, L. Antonuzzo⁴, D. Lavacchi⁴, L. Vaggelli², M. Matteini², R. Sciagra¹, V. Berti¹;

¹Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, ITALY, ²Department of Nuclear Medicine, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, ITALY, ³Department of Radiology, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, ITALY, ⁴Medical Oncology Unit, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, ITALY.

EP-0213

β-1600 Q.Clear Reconstruction Improves [68Ga]Ga-DOTANOC Digital PET/CT Image Quality

E. Fortunati¹, N. Bonazzi¹, M. Di Franco¹, L. Zanon², C. Mosconi^{3,4}, S. Civollani², D. Campana^{3,5}, C. Malizia⁶, V. Allegri², S. Fanti^{1,2}, V. Ambrosini^{1,2};

¹Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³DIMEC, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Radiology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁵Division of Medical Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁶PET Radiopharmacy Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0214

Comparison of 68Ga-DOTATATE PET/CT and 68Ga-DOTATATE PET/MR in Detection of Neuroendocrine Tumour Liver Metastasis

B. Demir¹, C. Soydal¹, M. Araz¹, M. H. Baltacioglu¹, D. Kuru Oz², N. O. Kucuk¹;

¹Ankara University School of Medicine Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Ankara University School of Medicine Department of Radiology, Ankara, TÜRKIYE.

EP-0215

[68Ga]Ga-DOTANOC and [18F]F-FDG PET/CT Tumour Burden Across 3-Grades Functional Scoring
E. Fortunati¹, N. Bonazzi¹, M. Di Franco¹, L. Zanon², C. Mosconi^{3,4}, D. Campana^{3,5}, C. Malizia⁶, E. Andriani⁶, V. Allegrini², S. Fantini^{1,2}, V. Ambrosini^{1,2};

¹Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³DIMEC, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁴Radiology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁵Division of Medical Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁶PET Radiopharmacy Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0216

Correlation Between Dual Tracer Imaging (68 Ga Dotanoc and 18 FDG PET) And Mib Index in WHO Grade 2 NET.

S. Kale, A. Puranik, N. Purandare, S. Shah, A. Agrawal, V. Rangarajan, S. Shrikhande, V. Ostwal, A. Ramaswamy, M. Bhandare, V. Chaudhari;
TATA MEMORIAL CENTRE, Mumbai, INDIA.

EP-12

e-Poster Area

**B: Imaging Clinical Studies -> B1
Oncological Imaging Clinical Study -> B17
Colorectal**

EP-0217

Differentiating subcentimeter lung metastasis in colorectal cancer patients by radiomics and deep learning approaches: a multicenter study
D. Ma;

Department of Colorectal Surgery, Zhejiang Cancer Hospital, Hangzhou, CHINA.

EP-0218

Correlation of 18F-FDG PET/CT Parameters Such As SUVmax, MTV and TLG with Histopathological Characteristics in Colorectal Cancer Patients

B. Ural, B. Okudan Tekin;
Ankara Bilkent City Hospital, Ankara, TÜRKIYE.

EP-13

e-Poster Area

**B: Imaging Clinical Studies -> B1
Oncological Imaging Clinical Study ->
B18a Prostate Staging**

EP-0219

PET/CT Imaging 2 Hours After Injection of [18F] PSMA-1007 Can Lead to Higher Staging of Prostate Cancer Than Imaging After 1 Hour

E. Hvittfeldt^{1,2}, U. Bitzen³, D. Minarik^{1,4}, J. Oddstig^{1,5}, B. Olsson^{2,1}, E. Trägårdh^{1,2};
¹Department of Translational Medicine, Wallenberg Centre for Molecular Medicine, Lund University, Malmö, SWEDEN, ²Department of Clinical Physiology and

Nuclear Medicine, Skåne University Hospital, Malmö, SWEDEN, ³Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund, SWEDEN, ⁴Department of Medical Physics, Skåne University Hospital, Malmö, SWEDEN, ⁵Department of Medical Physics, Skåne University Hospital, Lund, SWEDEN.

EP-0220

99mTc-PSMA-SPECT/CT in primary staging of high risk prostate cancer

K. Liepe¹, M. Baehr^{1,2}, T. M. Hoang³;
¹Klinikum Frankfurt (Oder), Frankfurt (Oder), GERMANY, ²Campus Virchow-Klinikum, Charité, Department of Diagnostic and Interventional Radiology, Berlin, GERMANY, ³Statistician, Düsseldorf, GERMANY.

EP-0221

Clinical Utility of 68Ga-PSMA PET/CT in Initial Staging of Patients with Prostate Cancer and Importance of Intraprostatic SUVmax Values

I. Rogic, A. Golubic, M. Zuvic, T. Smitran, N. Jukic, D. Huic;
University Hospital Centre Zagreb, Zagreb, CROATIA.

EP-0222

Head-to-head comparison of 68Ga-PSMA-11 with 68Ga-P137 in patients with suspected prostate cancer

T. Han, Z. Quan, M. Wang, X. Meng, M. Zhang, J. Ye, G. Li, J. Wang, F. Kang;
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

EP-0223

Comparison of 18F-Thretide PET/CT and multiparametric MRI for the detection of intermediate and high risk prostate cancer

J. Zang¹, Y. Yang¹, C. Wang¹, S. Chen¹, W. Miao¹, X. Chen², J. Zhang²;
¹Department of Nuclear Medicine, the First Affiliated Hospital, Fujian Medical University, Fuzhou, CHINA, ²Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.

EP-0224

The Relationship Of Lymph Node Distance And Disease Parameters In Prostate Cancer Ga-68 PSMA PET/CT Imaging

C. Aydin¹, B. Özdemir Günay², Ü. Korkmaz¹, F. Soyloğlu¹;
¹Trakya University, Edirne, TÜRKIYE, ²Edirne Sultan Murat I State Hospital, Nuclear Medicine Clinic, Edirne, TÜRKIYE.

EP-0225

The Relationship of Tumor SUVmax Value in 68Ga-PSMA PET/CT with Pathological Grade Group Grading System in Patients with Prostate Cancer

F. Demir, S. Karaçavuş, H. Gençer, A. Ozdal, Z. Erdogan, I. Ciftci, F. Cevik, N. Ozhan, H. İsci, M. Kaya;
Kayseri City Training and Research Hospital, Kayseri, TÜRKIYE.

EP-0226

Multimodality Approach with 68Ga-PSMA-11 PET/CT in Staging High-risk Prostate Cancer Patients Candidate to Radical Prostatectomy

G. Rovera¹, S. Grimaldi¹, M. Oderda², R. Passera¹, M. Falco¹, S. Dall'Armellina¹, P. Gontero², D. Deandrei¹;
¹Nuclear Medicine, Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, Turin, ITALY, ²Department of Surgical Sciences, Urology Unit, AOU Città della Salute e della Scienza di Torino, Molinette Hospital, University of Turin, Turin, ITALY.

EP-0227

Location-Based Detection of Low-Uptake Lymph Node Metastasis of Prostate Cancer in the Pelvis Using PSMA-PET/CT and Artificial Intelligence

B. Schemmer;
Uniklinik Bonn, Bonn, GERMANY.

EP-0228

Value of Ga-68 PSMA PET/CT in ISUP Grade 2 Prostate Cancer Patients

F. Aghazada, M. Demirbilek, O. Sahin, S. Asa, B. Onal, L. Kabasakal;
Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, TÜRKIYE.

EP-0229

Analytical performance validation of aPROMISE platform for prostate cancer tumor burden and index and dominant tumor assessment with 18F-DCFPyL PET/CT.

C. Lucas Lucas¹, A. M. García Vicente², L. García Zoghby², J. Pérez Beteta³, P. Borrelli⁴, M. Amo Salas⁵, A. Padilla Bermejo¹, M. N. Sicilia Pozo¹, M. Contreras Ameduri¹, M. Cruz Montijano², F. J. Pena Pardo¹, E. Noriega Álvarez¹, M. P. Talavera Rubio¹, V. M. Poblete García¹, Á. M. Soriano Castrejón²;
¹Nuclear Medicine Department. University General Hospital of Ciudad Real, Ciudad Real, SPAIN, ²Nuclear Medicine Department. University Hospital of Toledo, Toledo, SPAIN, ³Mathematical Oncology Laboratory. Castilla-La Mancha University, Ciudad Real, SPAIN, ⁴Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, SWEDEN, ⁵Mathematics Department. Castilla-La-Mancha University, Ciudad Real, SPAIN.

EP-0230

Contribution of 68Ga-PSMA-PET/CT to Risk Classification In Prostate Cancer With Gleason Score 6

Ö. Sahin, E. BEYHAN, Ö. E. FENERCİOĞLU, E. ARSLAN, T. F. ÇERMİK, N. ERGÜL;
University of Health Sciences, Istanbul Training and Research Hospital, Department of Nuclear Medicine, , Türkiye, Istanbul, TÜRKIYE.

EP-0231

Comparison of 68Ga-FAPI and 18F-PSMA PET/CT in the Evaluation of Ductal Adenocarcinoma of the Prostate

C. Liu, Q. Xie, T. Liu, Z. Li, C. Guo, Z. Yang;
Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, CHINA.

EP-0232

PSMA Immunohistochemistry Staining in Prostate Cancer Primary Lesion and Comparison with [68Ga] Ga-PSMA-PET/CT Findings

Z. Isik¹, G. Güner², M. Çağlar Tuncalı¹, M. Karcaaltincaba³, B. Akdoğan⁴, D. Akıncı³, M. Tuncel¹;
¹Hacettepe University, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Hacettepe University, Department of Pathology, Ankara, TÜRKIYE, ³Hacettepe University, Department of Radiology, Ankara, TÜRKIYE, ⁴Hacettepe University, Department of Urology, Ankara, TÜRKIYE.

EP-0233

Comparison of 68Ga-PSMA PET/MRI with PET and mpMRI in concise evaluation of primary prostate tumor and its prognostic value in detection of locally advanced prostate cancer

L. Uslu-Besli¹, B. Bakir², N. Urganci³, & Gürses³, S. Özle-Yıldız⁴, C. Demirdag⁵, K. Sönmezoglu¹, H. Sayman¹;
¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²Istanbul University, Istanbul Medical Faculty, Department of Radiology, Istanbul, TÜRKIYE, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Pathology, Istanbul, TÜRKIYE, ⁴Istanbul University, Istanbul Medical Faculty, Department of Biostatistics, Istanbul, TÜRKIYE, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Urology, Istanbul, TÜRKIYE.

EP-0234

Preliminary Clinical Study of a Novel Small-molecule PSMA Inhibitor 68Ga-SC691: Biodistribution, Dosimetry and Prospective Comparison with 68Ga-PSMA-11

J. Cao;
416 Hospital, China National Nuclear Corporation, Chengdu, CHINA.

EP-0235

PSMA PET/MR with parametric Patlak imaging to increase image contrast, better quantification and shorten examination times in patients with suspected prostate cancer.

M. Gammel, I. Rauscher, M. Eiber, S. van Marwick, S. Schachoff, R. Tauber, W. A. Weber, S. Nekolla;
TUM, Munich, GERMANY.

EP-0236

PSMA-PET and PCa: an exploratory analysis beyond the numerical definition of oligometastatic state

F. Mattana¹, L. Airò Farulla^{1,2}, G. Marvaso³, G. Corrao³, C. Lorubbio^{3,2}, M. G. Vincini³, M. Zaffaroni³, L. Muraglia¹, M. Colandrea¹, C. Fodor³, F. Ceci^{1,2}, B. A. Jereczek-Fossa^{3,2};
¹IEO European Institute of Oncology IRCCS, Nuclear Medicine Department, Milan, ITALY, ²Department of Oncology and Hemato-Oncology, University of Milan, ITALY, ³IEO European Institute of Oncology IRCCS, Department of Radiation Oncology, Milan, ITALY.

EP-0237

The spleen as a reference organ for PSMA expression evaluation according to PROMISE in Prostate cancer imaging with 18F-PSMA-1007 PET/CT: a critical approach

G. Arso¹, A. Georgiou², D. Katsampoukas², V. Mpalaris², S. Georga², E. Moralidis²;
¹3rd Department of Nuclear Medicine, Aristotle University of Thessaloniki School of Medicine, Papageorgiou Gen. Hospital, THESSALONIKI, GREECE,
²3rd Department of Nuclear Medicine, Aristotle University of Thessaloniki School of Medicine, Papageorgiou Gen. Hospital, Thessaloniki, GREECE.

EP-0238

Evaluation of imaging, clinical and pathological factors associated with 2-year biochemical recurrence in surgical patients with intermediate- to high-risk prostate cancer: a focus on 68GaPSMA PET and pelvic 3Tesla mpMRI

M. Celli¹, R. Gunelli², F. Ferroni¹, G. Feliciani¹, A. Sarnelli¹, P. Caroli¹, I. Marini¹, L. Fantini¹, V. Rossetti¹, U. De Giorgi¹, D. Barone¹, V. Di Iorio¹, F. Matteucci¹;
¹IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY, ²AUSL della Romagna – Presidio Ospedaliero Morgagni-Pierantoni, Forlì, ITALY.

EP-0239

PSMA PET/CT and local disease: a retrospective radiomic analysis based on a single center's experience

M. Monteiro¹, A. M. Ferreira¹, A. P. Moreira^{1,2}, R. Silva^{1,2}, G. Costa^{1,3};
¹CHUC, Coimbra, PORTUGAL, ²Instituto de Ciências Nucleares Aplicadas à Saúde, Coimbra, PORTUGAL, ³Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

EP-0240

PSG Score of Tubarial, Submandibular and Parotid Salivary Glands Utilizing 68Ga-PSMA-PET/CT-Scans of Prostate Cancer Patients

S. Al-Sadoon¹, F. Risheq², Z. Risheq², K. Faqeh²;
¹Nuclear Medicine PET/CT & Bone Density Center, Amman, JORDAN.

EP-14

e-Poster Area

**B: Imaging Clinical Studies -> B1
Oncological Imaging Clinical Study -> B18b Prostate BC Recurrence**

EP-0241

Therapeutic implications of 18F-PSMA PET/MRI in patients with prostate cancer and biochemical recurrence (PSA < 2 ng/ml) after prostatectomy

J. Garcia¹, A. Compte¹, M. Kauak¹, P. Bassa¹, T. Blanch¹, J. Pastor¹, E. Riera¹;
CETIR ASCIRES Grupo biomédico, Barcelona, SPAIN.

EP-0242

Clinical impact of 18F-DCFPyL PET/CT for clinical decision-making in biochemical recurrence of prostate cancer in our province.

Y. Santaella Guardiola¹, J. Rodríguez-Rubio Corona¹, M. Piñero Fernandez-Reyes¹, F. Cañete Sanchez¹, C. Quintana Bolaño¹, M. Pajares Vinardell¹;
Hospital Puerta del Mar, Cadiz, SPAIN.

P-0243

Evaluation of the Success of 18F-PSMA PET/CT in the Detection of Prostate Cancer Recurrence in Patients with Biochemical Recurrence

G. Sutcu¹, C. Soydal¹, M. Araz¹, Y. Urun², E. Suer³, S. Baltaci³, N. O. Kucuk¹;
¹Ankara University Medical School Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Ankara University Medical School Department of Medical Oncology, Ankara, TÜRKIYE, ³Ankara University Medical School Department of Urology, Ankara, TÜRKIYE.

EP-0244

Flare phenomenon of 99mTc-bone scintigraphy is a determinant of prognosis in patients with metastatic castration-resistant prostate cancer

X. Zhang¹, K. Nakajima², H. Horikoshi³, A. Mizokami⁴, K. Nishimoto⁵, K. Hashine⁶, H. Matsuyama⁷, S. Takahashi⁸, H. Wakabayashi¹, S. Kinuya¹;
¹Department of Nuclear Medicine, Kanazawa University, Kanazawa, Ishikawa, JAPAN, ²Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa, Ishikawa, JAPAN, ³Department of Diagnostic Radiology, Gunma Prefectural Cancer Center, Ota, JAPAN, ⁴Department of Urology, Kanazawa University, Kanazawa, Ishikawa, JAPAN, ⁵Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, JAPAN, ⁶Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, JAPAN, ⁷Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, JAPAN, ⁸Department of Urology, Nihon University School of Medicine, Tokyo, JAPAN.

EP-0245

Efficacy of 18-F-DCFPyL-PET/CT in the first biochemical recurrence of prostate cancer and its impact on therapeutic management

I. Obedkova¹, A. Prieto Soriano¹, L. Santamaria Chico¹, S. Guzmán Ortiz¹, K. Velasquez Diaz¹, P. Soares Meneses¹, M. Grajeda Gallardo¹, I. Garrido Solesio¹, M. Mitjavila Casanovas¹;
University Hospital Puerta de Hierro, Majadahonda, SPAIN.

EP-0246

Outcomes of [68Ga]Ga-PSMA-11 PET/CT in biochemical recurrence after brachytherapy

I. Próspero¹, G. Ferreira¹, J. C. Ferro¹, D. Barbosa¹, D. G. Silva¹, P. Leite Silva², S. Fontão de Castro¹, J. P. Teixeira¹, H. Duarte¹, I. Lucena Sampaio¹;
¹Department of Nuclear Medicine, Instituto Português de Oncologia do Porto, Porto, PORTUGAL, ²Cancer Epidemiology Group-Research Center, Department of Epidemiology, Instituto Português de Oncologia do Porto, Porto, PORTUGAL.

EP-0247

Impact of [18F]-DCFPyL (PSMA) PET/CT in the diagnostic and therapeutic impact in the biochemical recurrence of prostate cancer.

J. Fernández Fernández¹, E. Triviño-Ibáñez¹, D. Rivas-Navas¹, J. Villa-Palacios¹, A. Rodríguez-Fernández¹;
Virgen de las Nieves University Hospital, Granada, SPAIN.

EP-0248

Analysis of pathological findings in 18F-DCFPyL PSMA PET in recurrence of prostate cancer according to PSMA-RADS classification and E-PSMA overexpression score. Confirmation of results by pathological anatomy, biochemical response or imaging.

B. Hervás-Sanz¹, J. J. Robles-Barba¹, J. J. Martín-Marcuarta¹, S. Bondia-Bescós¹, M. Pudis¹, J. E. Romero-Herrera², G. Reynés-Llompart³, F. Ferrer-González⁴, J. F. Suárez-Novo⁵, M. Cortés-Romera¹;
¹Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ²Radiopharmaceutical Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ³Radiophysics Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ⁴Radiation Oncology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ⁵Urology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EP-0249

Comparison of Digital Versus Analog 68Ga-PSMA-11 PET/CT Performance in Hormone-sensitive Prostate Cancer Patients with Early Biochemical Recurrence or Persistence

G. Rovera¹, S. Grimaldi¹, S. Dall'Armellina¹, R. Passera¹, M. Oderda², P. Gontero², D. Deandrei¹;
¹Nuclear Medicine, Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, Turin, ITALY, ²Department of Surgical Sciences, Urology Unit, AOU Città della Salute e della Scienza di Torino, Molinette Hospital, University of Turin, Turin, ITALY.

EP-0250

Whole Body Tumour Burden On PET/CT With 18F-DCFPyL Obtained By aPROMISE Platform: Associations With Tumour Biology And PSA Kinetics In Patients With Biochemical Relapse Prostate Cancer.

L. García Zoghby¹, A. García Vicente¹, M. Amo-Salas², P. Borrell³, C. Lucas Lucas⁴, A. Padilla Bermejo⁴, N. Sicilia Pozo⁴, M. Contreras Ameduri⁴, M. Cruz Montijano¹, F. Pena Pardo⁴, E. Noriega Álvarez⁴, M. Talavera Rubio⁴, V. Poblete García⁴, Á. Soriano Castrejón¹;
¹University Hospital of Toledo, Toledo, SPAIN, ²Castilla-La Mancha University, Ciudad Real, SPAIN, ³Sahlgrenska University Hospital, Göteborg, SWEDEN, ⁴General University Hospital of Ciudad Real, Ciudad Real, SPAIN.

EP-0251

Influence of Gleason, ISUP grade, initial TNM, PSA values and kinetics on detection rate in prostate cancer recurrence by [18F]DCFPyL PSMA PET/CT

J. Martín-Marcuarta¹, J. Robles Barba¹, S. Bondia Bescos¹, E. Romero Herrera², G. Reynés Llompart³, J. Suárez Novo⁴, F. Ferrer Gonzalez⁵, S. Ruiz Llama⁶, M. Cortés Romera¹;
¹Department of MNU-PET/CT (IDI). Hospital Universitari de Bellvitge, Barcelona, SPAIN, ²Department of Radiopharmacy. Hospital Universitari de Bellvitge, Barcelona, SPAIN, ³Department of Radiophysics. ICO

Duran i Reynals, Barcelona, SPAIN, ⁴Department of Urology. Hospital Universitari de Bellvitge, Barcelona, SPAIN, ⁵Department of Radiotherapy. ICO Duran i Reynals, Barcelona, SPAIN, ⁶Department of Radiopharmacy. Hospital Germans Trias i Pujol, Barcelona, SPAIN.

EP-0252

Attitude and Management Change in Those Patients with Extrapelvic Findings in a PET-CT Study with PSMA

R. Bellviure-Meiro¹, M. Simó Perdigo¹, S. Menendez-Sanchez², C. Franco Monterroso¹, I. Navales Mateu¹, S. Asadurova¹, F. Velázquez¹, J. Echeverri Diaz¹, N. Calviño¹, S. Aguade-Bruix¹;
¹Hospital Universitari Vall d'Hebron, Barcelona, SPAIN, ²Clínica Universidad de Navarra, Pamplona, SPAIN.

EP-0253

Psma PET/CT Results and Effect on Treatment in Patients with Biochemical Recurrence After Radical Prostatectomy

K. Akçay¹, N. Selcuk¹, G. Beydagi¹, T. Toklu¹, E. Demirci¹, Ö. Sönmez¹, D. Karaçam¹, M. Yücel¹, E. Kaymak², O. Civi³, L. Kabasakal⁴;
¹yeditepe university, istanbul, TÜRKIYE, ²Istanbul Başakşehir Çam Sakura Hospital, istanbul, TÜRKIYE, ³istanbul oncology hospital, istanbul, TÜRKIYE, ⁴Istanbul University-Cerrahpaşa, istanbul, TÜRKIYE.

EP-0254

Serum values of prostate-specific antigen (PSA) and grade groups according to the International Society of Urological Pathology (ISUP grading), as determinants of [18F]DCFPyL PET/CT positivity in patients with biochemical recurrence of prostate cancer treated with radical prostatectomy.

A. Peñaherrera Cepeda¹, L. Díaz Gonzaga¹, J. Villanueva Curto¹, J. Badell Martínez¹, P. García-Talavera San Miguel¹, F. Gómez-Caminero López¹, E. Campaña Díaz¹, S. Rama Alonso¹, P. Tamayo Alonso¹;
Complejo asistencial universitario de Salamanca, Salamanca, SPAIN.

EP-0255

Usefulness of PET-MR with 18F-DCFPyL in the Diagnosis of Biochemical Recurrence in Prostate Cancer and its Therapeutic Implication

R. De Teresa¹, I. Plaza de las Heras¹, C. Field¹, L. García Cañamaque¹;
GRUPO HM HOSPITALES. UNIVERSIDAD SAN PABLO CEU, Madrid, SPAIN.

EP-0256

To evaluate the efficacy of F-18 PSMA -1007 PET/CT to diagnose biochemically recurrent Adenocarcinoma Prostate

A. Vyas¹, A. Tiwary Vyas²;
¹Max Superspeciality Hospital Vaishali, New Delhi, INDIA, ²Janakpuri Superspeciality Hospital, New Delhi, INDIA.

EP-0257

Prognostic Value of F-18 FDG PET/CT Metabolic Parameters in Prostate Cancer Patients

C. Soydal¹, M. H. Baltacioglu², M. Araz¹, B. Demir¹, N. O. Kucuk¹;
¹Ankara University Medical School, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Sbu Trabzon Kanuni Training and Research Hospital Department of Nuclear Medicine, Trabzon, TÜRKIYE.

EP-0258

Role of 68Ga/18F-PSMA PET/CT in the Secondary Staging of Prostate Cancer patients as a guide for clinicians

P. Mammucci, C. Ferrari, V. Lavelli, C. Battisti, N. C. Merenda, G. Rubini;
A.O.U. Policlinico di Bari, Bari, ITALY.

EP-15

e-Poster Area

**B: Imaging Clinical Studies -> B1
Oncological Imaging Clinical Study ->
B18c Prostate Other**

EP-0259

Dual time psma pet/ct with diuretics and contrast to detect prostate cancer pelvic metastases: is there a benefit?

T. Tognoli¹, M. R. F. Camacho², A. O. Santos¹, M. C. L. Lima¹, B. J. Amorim¹, U. Ferreira¹, E. Etchebehere¹;
¹State University of Campinas (UNICAMP), CAMPINAS-SP, BRAZIL, ²MND Campinas, CAMPINAS-SP, BRAZIL.

EP-0260

Ultrafast & Fast F18-PSMA 1007 PET/CT Acquisition in the Era of Digital PET/CT System; Single Institution Experience

A. Sadeq¹, Z. Alqallaf¹, I. Abdelrahman¹, M. Ibrahim¹, L. Ghadhanfer², F. Marafi¹;
¹Jaber AlAhmad center for Molecular Imaging, Shuwaikh medical area, KUWAIT, ²Faculty of Allied health sciences- Kuwait University, Jabriya, KUWAIT.

EP-0261

Multimodal Radiomics Features of periprostatic adipose tissue from 18F-PSMA-1007 PET/CT to predict Persistent Prostate-Specific Antigen

S. Bian;
the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, CHINA.

EP-0262

Association between blood-derived circulating-tumor DNA and ⁶⁸Ga-PSMA-HBED-CC PET/CT findings

K. Kluge^{1,2}, H. Einspieler¹, D. Haberl¹, C. Spielvogel^{1,2}, S. Stoiber^{3,2}, M. Hacker¹, L. Kenner^{3,2}, A. Haug^{1,2};
¹Medical University of Vienna - Dept. of Nuclear Medicine, Vienna, AUSTRIA, ²Medical University of Vienna - Christian Doppler Lab for Applied Metabolomics, Vienna, AUSTRIA, ³Medical University of Vienna - Dept. of Pathology, Vienna, AUSTRIA.

EP-0263

Evaluation of therapeutic response with 68Ga-prostate-specific membrane antigen (PSMA) PET/CT after androgen deprivation therapy in patients with prostate carcinoma

M. Dyankova^{1,2}, T. Stoeva¹, Z. Dancheva¹, S. Chausheva¹, T. Yordanova¹, B. Chaushev¹, A. Klisarova¹;
¹Medical University Varna "Prof. Dr. Paraskev Stoyanov", Department of Imaging Diagnostics, Interventional Radiology and Radiotherapy, Varna, BULGARIA, ²St. Marina University Hospital, Department of Nuclear Medicine, Varna, BULGARIA.

EP-0264

Comparing the Diagnostic Efficacy of 99m Tc-PSMA SPECT/CT Scanning After 75 Minutes and 4 Hours of Radiotracer Injection in Men with Prostate Cancer

A. Aghaee¹, A. Sahebkar¹, S. Soltani², H. Ghorbani³, K. Aryana¹, K. Sadri¹;
¹nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ²kidney transplantation research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ³kidney transplantation research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0265

Comparison of the 18F-PSMA-1007 and 18F-FAPI-42 PET/CT in the evaluation of prostate cancer and correlation between PSMA and FAPI uptake

X. Mu, M. Li, W. Fu;
Department of Nuclear medicine, Affiliated hospital of Guilin medical university, Guilin, CHINA.

EP-0266

Evaluating the diagnostic value of early static and delayed imaging of 68Ga-PSMA-11 PET/CT in detection of prostate bed recurrence and regional lymph node metastasis in prostate cancer patients

A. Aghaee, Z. Bakhshi, V. Roshan Ravan, K. Aryana, N. Norouzbeigi;
nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0267

Quantitative MRI parameters adds value in PSMA PET/MR for improving diagnostic specificity of Prostate Cancer with SUVmax<12

W. Ma, J. Wang, Z. Quan, F. Kang, J. Wang;
Fourth Military Medical University, Xi'an, CHINA.

EP-0268

68Ga-PSMA-PETCT for the evaluation of pulmonary nodules in patients with prostate cancer

G. Mateva, P. Bochev, N. Novoselska;
Acibadem CityClinic Mladost, Sofia, BULGARIA.

EP-0269

Optimizing PSMA Scintigraphy Imaging Protocols for Prostate Cancer in Resource Limited Settings

O. Kolade¹, A. Ayeni^{1,2}, J. Holness³, A. Brink¹, S. More¹;
¹University of Cape Town / Groote Schuur Hospital, Cape Town, SOUTH AFRICA, ²Klerksdorp/Tshepong Hospital Complex, Klerksdorp, SOUTH AFRICA, ³Stellenbosh University, Cape Town, SOUTH AFRICA.

EP-0270

AI18F-PSMA-617 PET Quantitative Analysis for Prostate Cancer Diagnosis: A Comprehensive Study

B. Liu¹, G. Hu², X. Wang², L. Huo², H. Ding¹, H. Zhang¹;
¹Tsinghua University, Beijing, CHINA, ²Peking Union Medical College Hospital, Beijing, CHINA.

EP-0271

The Effect of Folate on [68Ga]Ga-PSMA-11 Organ and Tumor Uptake: Predictions Using Physiologically Based Pharmacokinetic Modelling

H. Siebinga^{1,2}, J. J. M. A. Hendriks^{1,2}, A. D. R. Huitema^{2,3,4}, B. J. de Wit - van der Veen¹;
¹Department of Nuclear Medicine, NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS, ²Department of Pharmacy and Pharmacology, NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS, ³Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, NETHERLANDS, ⁴Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, NETHERLANDS.

EP-0272

PSMA PET/CT correlates with biochemical response in patients with prostate cancer undergoing High-Intensity Focused Ultrasound (HIFU) focal therapy

E. Lopci, G. Lughezzani, V. Fasulo, D. Maffei, A. Saita, P. Colombo, R. Hurl, K. Marzo, L. Leonardi, R. Peschiera, A. Benetti, S. Zandegiacomo, L. Pasini, J. Jandric, R. Zanca, P. Casale, M. Rodari, L. Balzarini, G. Guazzoni, N. Buffi, M. Lazzeri;
IRCCS - Humanitas Research Hospital, Rozzano MI, ITALY.

EP-0273

Guiding metastases-directed therapy with Prostate-Specific Membrane Antigen (PSMA) PET/CT improves the oncological outcome of oligometastatic prostate cancer patients

F. Lanfranchi¹, L. Belgioia¹, D. Albano², F. Dondi², F. Bertagna², E. Mataj³, F. Linguant⁴, E. M. Abenavoli⁵, L. Vaggelli⁶, B. Detti⁶, L. Urso⁷, N. Ortolan⁷, A. Malorgio⁸, M. Bartolomei⁷, A. Rizzo⁹, M. Racco⁹, A. Guarneri¹⁰, F. Garrou¹¹, S. Panareo¹², P. Ghedini¹², S. Morbelli¹, G. Sambuceti¹, M. Bauckneht¹;

¹Department of Health Sciences, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, ²Nuclear Medicine Department, Università degli Studi di Brescia and ASST Spedali Civili di Brescia, Brescia, ITALY, ³Department of Radiation Oncology, Università degli Studi di Brescia and ASST Spedali Civili di Brescia, Brescia, ITALY, ⁴Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, ITALY, ⁵Nuclear Medicine Division, Careggi University Hospital, Florence, ITALY, ⁶Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY, ⁷Nuclear Medicine Unit, Oncological Medical and Specialist Department, University Hospital of Ferrara, Ferrara, ITALY, ⁸Radiotherapy Unit, University Hospital of Ferrara, Ferrara, ITALY, ⁹Department of Nuclear Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, ITALY, ¹⁰Department of Radiotherapy, Candiolo Cancer Institute, FPO-IRCCS, Turin, ITALY, ¹¹Nuclear Medicine Unit, Department of Medical Sciences, AOU Città della Salute e della Scienza, University of Turin, Turin, ITALY, ¹²Nuclear Medicine Unit, Oncology and Haematology Department, University Hospital of Modena, Modena, ITALY.

EP-0274

Treatment response evaluation with PSMA-PET/CT imaging in patients with metastatic castration-resistant prostate cancer (mCRPC)

F. Kleiburg^{1,2}, L. F. De Geus-Oei^{1,2,3}, S. A. C. Luelmo², R. Spijkerman^{1,2}, F. A. J. Toonen⁴, F. Smit⁴, T. van der Hulle², L. Heijmen²;
¹University of Twente, Enschede, NETHERLANDS, ²Leiden University Medical Centre, Leiden, NETHERLANDS, ³Delft University of Technology, Delft, NETHERLANDS, ⁴Alrijne Hospital, Leiderdorp, NETHERLANDS.

EP-0275

Radium-223 response assessment and outcomes prediction using 68Ga-PSMA PET/CT: RECIP 1.0 vs PPP criteria

Q. Shagera, P. Flamen, C. Artigas;
Jules Bordet Institute, Université Libre de Bruxelles (ULB), Brussels, BELGIUM.

EP-0276

[68Ga]PSMA-11 PET/CT response in metastatic prostate cancer following systemic therapy

P. Aravind¹, T. D. Barwick^{2,1}, S. Dubash¹, M. J. Connor², H. Tam², F. A. Mauri¹, H. U. Ahmed^{1,2}, E. O. Aboagye¹;
¹Imperial College London, London, UNITED KINGDOM, ²Imperial College Hospital NHS TRUST, London, UNITED KINGDOM.

EP-0277

The use of clinical, laboratory, and imaging parameters to interpret bone focal uptakes in hormone-sensitive prostate cancer patients imaged with [18F]-PSMA-1007 PET/CT

F. D'Amico¹, A. Signori¹, D. Albano², M. Riondato³, F. Dondi², T. Di Raimondo¹, L. Sofia¹, F. Lanfranchi¹, C. Ghersi³, A. Democrito³, G. Fornarini⁴, C. Marini⁵, F. Bertagna², S. Morbelli¹, G. Sambuceti¹, M. Bauckneht¹;
¹Department of Health Sciences, University of Genoa, Genoa, ITALY, ²Nuclear Medicine, University of Brescia and ASST Spedali Civili Brescia, Brescia, ITALY, ³Nuclear Medicine Unit, IRCCS, Ospedale Policlinico San Martino, Genoa, ITALY, ⁴Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, ⁵CNR, Institute of Molecular Bioimaging and Physiology (IBFM), Genoa, ITALY.

EP-0278

Modified PROMISE Criteria for Standardized Interpretation of Gastrin Releasing Peptide Receptor (GRPR)-targeted PET

H. Duan, G. A. Davidzon, F. Moradi, T. Liang, H. Song, A. Iagaru;
Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

EP-0279

Consensus statements on Prostate Specific Membrane Antigen (PSMA)-Targeted Surgery - outcomes from an international multidisciplinary panel

F. van Leeuwen¹, A. Berrens², the PSMA-guided surgery panel, H. van der Poel³;
¹Leiden University Medical Center, Leiden, NETHERLANDS, ²NETHERLANDS cancer institute, Amsterdam, NETHERLANDS.

EP-0280

Evaluation of [18F]DCFPyL excretion in the saliva of patients with prostate cancer

B. Fernandes¹, J. Roy¹, F. Basuli², Y. McKinney¹, B. M. Warner³, E. Mena¹, L. Lindenberg¹, B. Turkbey¹, P. Choyke¹, F. I. Lin¹;

¹Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, UNITED STATES OF AMERICA, ²Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD, UNITED STATES OF AMERICA, ³National Institute of Dental and Craniofacial Research, National Institute of Health, Bethesda, MD, UNITED STATES OF AMERICA.

EP-0281

Clinical Application of 18F-Thretide PET/CT and Early PET/CT Scan in Prostate Cancer

X. Cheng^{1,2}, G. Hou^{1,2}, X. Wang^{1,2}, X. Chen^{3,4,5}, Y. Wang^{1,2}, V. Jakobsson^{3,4,5}, X. Shen^{1,2}, J. Zhang^{3,4,5}, R. Zheng^{1,2};

¹Department of Nuclear Medicine (PET-CT Center), National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA, ²Department of Nuclear Medicine (PET-CT Center), National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Langfang, CHINA, ³Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE, ⁴Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE, ⁵Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.

EP-0282

Dual tracer PET/CT with 68Ga-PSMA and 18F-FDG in patients with prostate cancer

Y. Zhang, M. Su;

Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0283

Improvement of Gleason Grading prediction in Prostate Cancer Stratification for Radical Prostatectomy: a Machine Learning-based Theronostic Multi-omics Study

J. Ning¹, C. P. Spielvogel^{1,2}, D. Haber¹, K. Trachtova¹, S. Stoiber¹, S. Rasul¹, V. Bystry¹, E. Gurnhofer¹, G. Timelthaler¹, L. Papp¹, M. Schleder¹, M. Hacker¹, A. Haug¹, L. Kenner¹;

¹Christian Doppler Lab for Applied Metabolomics, Medical University of Vienna, Vienna, AUSTRIA, ²JN and CPS shared the first authorship, Vienna, AUSTRIA.

EP-0284

Assessment of Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-Resistant Prostate Cancer

A. Gafita¹, L. Djaileb², I. Rauscher³, W. P. Fendler⁴, B. Hadaschik⁴, J. Czernin⁵, K. Herrmann⁴, S. P. Rowe¹, J. Calais⁶, M. Rettig⁶, M. Eiber³, M. Weber⁴, M. R. Benz⁶, A. Farolfi⁷;

¹Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA, ²University Grenoble Alpes, Grenoble, FRANCE, ³Technical University Munich, Munich, GERMANY, ⁴University Hospital Essen, Essen, GERMANY, ⁵University of California Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, ⁶University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, ⁷University of Bologna, Bologna, ITALY.

EP-0285

Association of Blood Count Parameters and Non-metastatic Bone Uptake at [18F]PSMA-1007 PET — Could Osteoporosis Be the Key to Unravel this Conundrum?

G. Ninatti¹, C. Pini¹, R. Camedda², F. Gelardi³, L. Antunovic⁴, C. Landoni^{1,5}, P. Mapelli⁴, M. Picchio^{6,4}, M. Sollini^{3,7}, A. Chiti^{6,4};

¹University of Milano Bicocca, Monza, ITALY, ²University of Rome Tor Vergata, Rome, ITALY, ³Humanitas University, Pieve Emanuele, ITALY, ⁴IRCCS San Raffaele Scientific Institute, Milan, ITALY, ⁵IRCCS-San Gerardo, Monza, ITALY, ⁶Vita-Salute San Raffaele University, Milan, ITALY, ⁷IRCCS Humanitas Research Hospital, Rozzano, ITALY.

EP-0286

The Impact of 18F-DCFPYL Specific Activity on Organ Uptake

G. Chausse¹, S. Plaha²;

¹McGill University, Montreal, QC, CANADA, ²University of British Columbia, Vancouver, BC, CANADA.

EP-0287

Can Ga-68 PSMA PET/CT Parameters Predict Progression in Hormone-Sensitive De Novo Metastatic Prostate Cancer

S. Aksu¹, B. B. Demirel¹, S. Gülbahar Ateş¹, Ö. Ateş², G. Uçmak¹;

¹Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, TÜRKIYE.

EP-0288

Reducing the frequency of prostate cancer biopsy by F18-rhPSMA7.3 PET/MR

T. Hekimsoy¹, S. Kleiner¹, M. Heck², K. Schwamborn³, M. Eiber¹, W. Weber¹;

¹Department of Nuclear Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, GERMANY, ²Department of Urology, Technical University of Munich, Klinikum rechts der Isar, Munich, GERMANY, ³Department of Pathology, Technical University of Munich, Klinikum rechts der Isar, Munich, GERMANY.

EP-16

e-Poster Area

**B: Imaging Clinical Studies -> B1
Oncological Imaging Clinical Study -> B19
Thyroid**

EP-0289

Prediction of Lymph Node Metastasis in Differentiated Thyroid Cancer Based on Radiomics Models: A Meta-analysis and Systematic Review

J. Mu, Y. Cao, X. Zhong, W. Diao, Z. Jia;

West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0290

Contribution of Neck Ultrasonography to Patient Management in Patients with Differentiated Thyroid Carcinoma with Excellent Response to Therapy

I. Hekimsoy¹, M. Guven², R. Tokac², G. Kavukcu³, A. Akgun²;

¹Department of Radiology, Torbalı State Hospital, Izmir, TÜRKIYE, ²Department of Nuclear Medicine, Ege University, Izmir, TÜRKIYE, ³Department of Radiology, Ege University, Izmir, TÜRKIYE.

EP-0291

Role of Thyroid Scintigraphy with pertechnetate in Congenital Hypothyroidism

A. Marques¹, J. Carvalho², F. Abreu¹;

¹Instituto de Medicina Nuclear da Faculdade de Medicina da Universidade de Lisboa, Lisboa, PORTUGAL, ²Centro Hospitalar de Lisboa Ocidental, Lisboa, PORTUGAL.

EP-0292

Semiquantitative analysis of 99mTc MIBI thyroid scan in patients with amiodarone induced thyrotoxicosis

L. Fischer^{1,2}, N. Girotto^{1,2}, T. Bogović Crnčić^{1,2}, M. Ilić Tomaš^{1,2}, S. Grbac-Ivanković^{1,2}, M. Mavrinac³;

¹Department of Nuclear Medicine, Faculty of Medicine, University of Rijeka, Rijeka, CROATIA, ²Clinical Department of Nuclear Medicine, Clinical Hospital Centre Rijeka, Rijeka, CROATIA, ³Department of Medical Informatics, Faculty of Medicine, University of Rijeka, Rijeka, CROATIA.

EP-0293

The prevalence of pre-thyroidectomy thyroid function test abnormalities among patients with differentiated thyroid carcinoma: A descriptive study

A. Aghaee, s. barashki, s. zakavi;

nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0294

Prognostic role of minimal extrathyroidal tumor extension (mETE) in the follow-up of patients with papillary carcinoma (PC) unaffected by other risk factors.

A. Marongiu, S. Nuvoli, S. Vargiu, P. Solinas, A. Spanu, G. Madeddu;

Unit of Nuclear Medicine, University of Sassari, viale S. Pietro 8 - 0700 Sassari, Italy, Sassari, ITALY.

EP-0295

68Ga FAPI-PET CT in patients with rising calcitonin after treatment of medullary thyroid carcinoma and negative conventional and nuclear imaging - pilot cases.

P. Bochev, G. Mateva, N. Novoselska;

Acibadem Cityclinic Mladost UMBAL, Sofia, BULGARIA.

EP-0296

The total volume of lung metastases from thyroid cancer based on infer artificial intelligence can predict abnormal lung function

M. Qi, R. Huang, S. Huang;

Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, CHINA.

EP-0297

SOP for cervical ultrasound cine loops on DTC follow-up

P. Seifert, M. P. Sopuschek, M. Freesmeyer;

Clinic of Nuclear Medicine, Jena, GERMANY.

EP-0298

[68Ga]Ga-PSMA-11 PET/CT in Thyroid Cancer - Preliminary Results

K. Zajkowska, M. Wojewódzka-Mirocha, P. Cegła, A. Sackiewicz, P. Ochman, J. Januszkiewicz-Caulier, A. Żyłka, M. Dedecjus;

Department of Oncological Endocrinology and Nuclear Medicine, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, POLAND.

EP-0299

Differentiated thyroid carcinoma: correlation between thyroglobulin, basal anti-thyroglobulin antibodies and post-ablative treatment study.

B. Hervás-Sanz, A. Rodríguez-Gasén, J. Suils-Ramon, M. P. Perlaza-Jiménez, M. Pudis, S. Bondia-Bescós, J. L. Díaz-Moreno, J. L. Vercher-Conejero, M. Cortés-Romera;

Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EP-0300

Does the duplication time of thyroglobulin have any use as a predictor factor on the detection of recurrence and or metastasis in the differentiated thyroid cancer in the 2-[18F]fluoro-2-deoxy-d-glucose PET/CT.

D. Rodriguez Oviedo, B. Manzarbeitia Arroba, M. Tagliatori Nogueira, M. Alvarez Moreno, C. Galindo, M. De La Rubia Marcos, M. Garcia Alonso, C. Paniagua Correa, C. Sandoval Moreno;

Hospital Universitario de Getafe, Madrid, SPAIN.

EP-0301

Comparative Study of [68Ga]Ga-DOTA-FAPI-04, [68Ga] Ga-DOTATATE and [18F] -DOPA in Imaging of Medullary Thyroid Carcinoma: A Case Series and 18F-DOPA in Imaging of Medullary Thyroid Carcinoma: A Case Series

G. dos Santos^{1,2}, A. Quagliata¹, E. Silvera^{1,2}, R. Castro¹, A. Banchoero¹, A. Damian¹, I. Cordero¹, K. Suanes¹, O. Alonso^{1,2}, E. Savio¹, P. Duarte¹, J. Gambini¹;

¹CUDIM, Uruguayan Center Of Molecular Imaging, Montevideo, URUGUAY, ²Hospital de Clínicas Dr. Manuel Quintelas, Montevideo, URUGUAY.

EP-0302

Correlation Between Clinical Characteristics And Effective Washout Time In Patients Treated With High Radioiodine Activities

C. Guerrero Calatayud, A. C. Marin, S. Prado Wohlwend, J. R. Cañón Sánchez, N. I. Orrego Castro, S. Montesinos González, A. M. Yepes Agudelo, P. Bello Arques;

Hospital La Fe, Valencia, Valencia, SPAIN.

EP-0303

Usefulness of 2-[18F]FDG PET/CT in indeterminate thyroid nodules (Bethesda III and IV) for risk stratification: do we still have to rely on FDG positivity? A retrospective monocentric experience
F. Serani¹, E. Tabacchi², L. Calderoni¹, G. Cuzzani¹, S. Chillotti³, S. Damiani⁴, S. Fantì⁵;
¹Nuclear Medicine, Alma Mater Studiorum -University of Bologna, Bologna, ITALY, ²Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Pathology Unit, Alma Mater Studiorum -University of Bologna, Bologna, ITALY, ⁴Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna-ITALY, Bologna, ITALY, ⁵Nuclear Medicine, Alma Mater Studiorum - University of Bologna, Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-17

e-Poster Area

**B: Imaging Clinical Studies -> B1
Oncological Imaging Clinical Study -> B20
Gynaecological**

EP-0304

Vulva lesions as characterized by F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
Z. Koç¹, P. Özcan¹, T. İlhan², S. Gökulu², Y. Karabulut³;
¹Mersin University Hospital Nuclear Medicine Dpt., Mersin, TÜRKIYE, ²Mersin University Hospital Gynecologic Oncology Dpt., Mersin, TÜRKIYE, ³Mersin University Hospital Pathology Dpt., Mersin, TÜRKIYE.

EP-0305

Comparison of the diagnostic efficacy between 68Ga-FAPI PET/CT and 18F-FDG PET/CT in gynecological malignancies: A Systemic Review and Meta-analysis
C. Zhao, L. Li;
West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0306

Prognostic value of semiquantitative parameters of 18F-FDG PET/CT in the staging of cervical cancer.
L. Rodríguez Díaz, C. Vigil Díaz, A. Laverde Mächler, J. Marañón González, S. Naranjo Sancho, M. Fernández Llana, M. Domínguez Grande, J. Suárez Fernández, N. Martín Fernández, F. González García;
Hospital Universitario Central de Asturias, Oviedo, SPAIN.

EP-0307

Development and External Testing of Integrating PET/MR Radiomics and Clinical Characteristics to Predict Lymphovascular Space Invasion in Endometrial Carcinoma: A Dual-Center Study
X. Li^{1,2}, T. Song^{1,2}, B. Cui^{1,2}, J. Li^{1,2}, J. Ma^{1,2}, H. Yang^{1,2}, Y. Wang³, H. Sun⁴, J. Lu^{1,2};
¹Department of Radiology and Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, CHINA, ²Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Capital Medical University, Beijing, CHINA, ³GE Healthcare China, Shanghai, CHINA, ⁴Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, CHINA.

EP-0308

Potential for time-synchronized PET/MRI with dual tracers of FDG and FES: Utility in the diagnostic capability to distinguish between benign and malignant endometrial lesions
J. Inukai-Inoue¹, M. Nogami^{2,3}, M. Tachibana¹, F. Zeng², K. Kubo², T. Kurimoto⁴, T. Tujikawa⁵, Y. Yoshida⁶, H. Okazawa³, T. Murakami^{1,2};
¹Department of Radiology, Kobe University Graduate School of Medicine, Kobe, JAPAN, ²Department of Radiology, Kobe University Hospital, Kobe, JAPAN, ³Division of Medical Imaging, Biomedical Imaging Research Center, University of Fukui, Fukui, JAPAN, ⁴GE Healthcare, Hino, JAPAN, ⁵Department of Radiology, Faculty of Medical Sciences, University of Fukui, Fukui, JAPAN, ⁶Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Fukui, JAPAN.

EP-0309

Comparing CECT, 18F-FDG PET and 68Ga-FAPI PET derived peritoneal carcinomatosis index (PCI) in primary ovarian cancers.
S. Singh, K. Verma, A. Singh;
Globe Healthcare, Lucknow, INDIA.

EP-0310

Investigation of the Effect of Hormonal Therapy on Endometrial FDG Uptake in Postmenopausal Women
R. Nakamoto, M. Yakami, T. Nobashi, H. Isoda, Y. Nakamoto;
Kyoto University Hospital, Kyoto, JAPAN.

EP-0311

Treatment response evaluation using FDG-PET/CT predicts survival in women with locally advanced cervical cancer
M. Markus¹, H. Sartor², M. Bjurberg³, E. Trägårdh¹;
¹Clinical Physiology and Nuclear Medicine, Malmö, SWEDEN, ²Radiology Diagnostics, Malmö, SWEDEN, ³Department of Hematology, Oncology and Radiation Physics, Malmö, SWEDEN.

EP-0312

MRI and 18F-FDG PET/CT interrelationship in the postradiotherapy cervical carcinoma early response assessment
S. Lucic^{1,2}, M. Spirovski^{1,2}, J. Licina^{1,2}, D. Stojanovic², A. Peter², M. A. Lucic^{1,2};
¹Medical Faculty, University of Novi Sad, Novi Sad, SERBIA, ²Oncology Institute of Vojvodina, Sremska Kamenica, SERBIA.

EP-0313

Utility of 18F FDG PET/CT in rare gynaecological malignancies
A. Nair S, V. Rangarajan, S. Shah, A. Agrawal, N. Purandare, A. Puranik, S. Choudhury;
Tata Memorial Hospital, Mumbai, INDIA.

EP-0314

Prognostic Role of F-18 FDG PET in Uterine Cervical Cancer Patients: 10 Years Experience
C. Soyda¹, M. H. Baltacioglu², M. Araz¹, S. Taskin³, N. O. Kucuk¹, U. F. Ortac³;
¹Ankara University Medical School, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Sbu Trabzon Kanuni Training and Research Hospital Department of Nuclear Medicine, Trabzon, TÜRKIYE, ³Ankara University Medical School, Department of Gynecology and Obstetrics, Ankara, TÜRKIYE.

EP-0315

Does Peritoneal Metastasis Evaluation with 18F-FDG PET/MRI Contribute to Prognosis Prediction in Patients with Ovarian Cancer
M. Baltacioglu¹, C. Soyda², M. Araz², D. Kuru Oz³, N. O. Kucuk²;
¹Sbu Trabzon Kanuni Training and Research Hospital Department of Nuclear Medicine, Trabzon, TÜRKIYE, ²Ankara University Medical School Department of Nuclear Medicine, Ankara, TÜRKIYE, ³Ankara University Medical School, Department of Radiology, Ankara, TÜRKIYE.

EP-0316

Role of Radiomics Applied to Baseline 18F-FDG PET/CT in Locally Advanced Cervical Carcinoma Patients Treated with Combined Chemoradiotherapy
G. Mathoux¹, L. Monaco², E. De Bernardi¹, G. Di Martino³, C. Crivellaro², F. Elisei², M. Musarra², L. Bazzano¹, C. Landoni^{1,2,4}, L. Guerra^{1,2,4}, C. Messa^{1,4};
¹Università degli Studi di Milano-Bicocca, Monza, ITALY, ²Nuclear Medicine Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, ITALY, ³UOC Gynaecology, Fondazione IRCCS San Gerardo dei Tintori, Monza, ITALY, ⁴Tecnomed Foundation, Monza, ITALY.

EP-0317

Potential of baseline and early response FDG-PET/MRI to predict radiotherapy outcome in uterine cervical squamous cell carcinoma - a pilot study
S. Strandberg¹, J. Jonsson¹, M. Zarei¹, K. Aglund¹, L. Blomqvist², K. Söderkvist¹, B. Zackrisson¹;
¹Department of Radiation sciences, Umea University, Umea, SWEDEN, ²Department of Molecular Medicine and Surgery, Karolinska Institute, Solna, SWEDEN.

EP-18

e-Poster Area

**B: Imaging Clinical Studies -> B1
Oncological Imaging Clinical Study -> B21
Lymphoma**

EP-0318

Metabolic tumour volume in Hodgkin lymphoma - a comparison between manual and AI-based analysis
M. Sadik¹, S. F. Barrington², J. Ulén³, O. Enqvist⁴, E. Trägårdh⁵, B. Saboury⁶, A. Lerberg Nielsen⁷, A. Loft Jakobsen⁸, J. Loaiza Gongora⁹, J. López-Urdaneta¹, R. Kumar¹⁰, L. Edenbrandt¹;
¹Molecular and Clinical Medicine, Gothenburg, SWEDEN, ²Clinical PET Centre, London, UNITED KINGDOM, ³Eigenvision AB, Malmö, SWEDEN, ⁴Eigenvision AB and Electrical Engineering, Malmö and Gothenburg, SWEDEN, ⁵Clinical Physiology and Nuclear Medicine, Malmö, SWEDEN, ⁶Radiology and Imaging Sciences,

Bethesda, MD, UNITED STATES OF AMERICA, ⁷Nuclear Medicine, Odense, DENMARK, ⁸Clinical Physiology, Copenhagen, DENMARK, ⁹Diagnostic Imaging, Oslo, NORWAY, ¹⁰Nuclear Medicine, Chandigarh, INDIA.

EP-0319

C-X-C Motif Chemokine Receptor 4-directed PET/CT provides improved Diagnostic Performance relative to [18F]FDG in Newly Diagnosed Patients with Marginal Zone Lymphoma
A. Kosmala¹, S. E. Serfling¹, S. Schneid¹, T. Higuchi^{1,2}, A. Weich³, C. Lapa⁴, P. E. Hartrampf¹, M. Raderer⁵, H. Einsele³, A. K. Buck¹, M. S. Topp³, J. Duell³, R. A. Werner^{1,6};
¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, JAPAN, ³Department of Internal Medicine II, University Hospital Würzburg, Würzburg, GERMANY, ⁴Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY, ⁵Department of Internal Medicine I, Medical University Vienna, Vienna, AUSTRIA, ⁶Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Sciences, Baltimore, MD, UNITED STATES OF AMERICA.

EP-0320

Development of prediction models for treatment response and prognosis in patients with diffuse large B-cell lymphoma based on 18F-FDG PET radiomics
Y. Zhou;
West China Hospital, Chengdu, CHINA.

EP-0321

Diagnostic performance of whole-body [18F] FDGPET/MRI with diffusion-weighted imaging for detecting bone marrow involvement in lymphomas
X. Chen, M. Wei, T. Yuan, B. Yu, N. Zhou, Z. Hua, Z. Yang, X. Wang;
Peking University Cancer Hospital & Institute, Beijing, CHINA.

EP-0322

A focus on the impact of spleen involvement in total metabolic tumor volume measurements in Diffuse Large B-Cell Lymphoma patients.
L. Rebaud^{1,2}, N. Capobianco³, K. Girum², A. Cottereau⁴, F. Morschhauser⁵, B. Spottiswoode⁶, I. Buvat²;
¹Siemens Healthcare SAS, Courbevoie, FRANCE, ²LITO laboratory, U1288 Inserm, Institut Curie, University Paris-Saclay, Orsay, FRANCE, ³Siemens Healthcare GmbH, Erlangen, GERMANY, ⁴Cochin University Hospital, AP-HP, Department of Nuclear Medicine, Paris, FRANCE, ⁵Service des Maladies du Sang, CHU Lille, Lille, FRANCE, ⁶Siemens Medical Solutions UNITED STATES OF AMERICA, Inc., Knoxville, TN, UNITED STATES OF AMERICA.

EP-0323

The Role Of Baseline 18F-FDG PET/CT Metrics And Radiomics Features In Predicting Primary Gastric Lymphoma Diagnosis
A. Calabro¹, D. Albano, F. Dondi, P. Bellini, A. Tucci, F. Bertagna;
ASST Spedali Civili of Brescia, University of Brescia, Brescia, ITALY.

EP-0324

18F-FDG PET/CT radiomics features and MYC protein expression predict progression in Diffuse Large B-cell Lymphoma

C. Cui, B. Li, X. Mu, Z. Wu;
SXMU, Tai Yuan, CHINA.

EP-0325

Prognostic value of baseline 18F-FDG PET/CT metabolic tumour volume and total lesion glycolysis in Diffuse Large B Cell Lymphoma patients

A. Doma^{1,2}, A. Studen^{3,4}, B. Jezeršek Novakovič^{1,2};
¹Ljubljana Oncology institute, Ljubljana, SLOVENIA, ²Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA, ³Experimental Particle Physics Department, Jožef Stefan Institute, Ljubljana, SLOVENIA, ⁴Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, SLOVENIA.

EP-0326

PET-Based Volumetric Biomarkers for Risk Stratification in Pediatric Hodgkin's Lymphoma

M. Dunaykin, M. Yadgarov, G. Shestopalov, K. Chaurasiya, E. Kireeva, Y. Likar;
Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow, RUSSIAN FEDERATION.

EP-0327

Prognostic value of interim FDG PET/CT in Extranodal Natural Killer/T-Cell Lymphoma, nasal type : comparison of Deauville scores, deltaSUVmax and qPET

W. Hou, R. Tian;
West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0328

Deep learning-based fully automatic segmentation of whole-body [18F]FDG PET/CT images from lymphoma patients: addition of CT data has poor impact on networks performance

C. S. Constantino^{1,2}, F. P. M. Oliveira¹, S. Leocádio¹, M. Silva¹, C. Oliveira¹, J. C. Castanheira¹, Â. Silva¹, S. Vaz¹, R. Teixeira¹, M. Neves¹, P. Lúcio¹, C. João¹, S. Vinga², D. C. Costa¹;
¹Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, PORTUGAL, ²INESC-ID, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, PORTUGAL.

EP-0329

Assessment of the metabolic volume of the tumor as a marker of response to therapy with CAR-T Cells in patients with B-cell non-Hodgkin lymphoma, our experience.

M. CASALLAS CEPEDA, J. Montalva Pastor, S. Salcedo, I. Gomez Fernandez, J. Alonso Farto;
Hospital General Universitario Gregorio Marañón, Madrid, SPAIN.

EP-0330

18F-FDG PET/CT Volumetric and Radiomic Features for lesions/patients' characterization in CAR-T therapy

E. Abenavoli¹, F. Linguanti¹, I. Cutini², L. Nassi³, B. Puccini³, M. Palazzo³, B. Sordì⁴, R. Saccardi², A. Vannucchi⁴, R. Sciagrà¹, V. Berti¹;
¹Nuclear Medicine Unit, Experimental and Clinical Biomedical Sciences Department "Mario Serio", AOU Careggi, Florence, Italy, Florence, ITALY, ²Department of Cellular Therapies and Transfusion Medicine, Careggi

University Hospital, Florence, ITALY, ³Hematology Department, Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY, ⁴Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, ITALY.

EP-0331

Is [18F]FDG PET/CT at one month of chimeric antigen receptor T-cell therapy (CAR-T) in lymphomas necessary in the early treatment response assessment?

P. Stefaneli Mormandi, C. Soldevila-Lozano, A. Caballero-Gonzalez, S. Abouzian Senhaji, P. Torres-Quintana, A. Fernández-León, R. Valverde-Jorge, M. Velasco-Nuño, J. Duch, V. Camacho, A. Flotats;
Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN.

EP-0332

Head-to-head comparison between 68Ga-Pentixafor and 18F-FDG PET/CT in diffuse large B cell lymphoma

P. Palanivelu, H. Goyal, D. Halanaik, P. Ganesan;
Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, INDIA.

EP-0333

18F-FDG PET/CT features as potent imaging biomarkers of efficacy and toxicity in large-B-cell lymphoma treated with CAR-T cell therapy

D. Leithner¹, J. R. Flynn¹, A. Mauguen¹, S. M. Devlin¹, T. Fei¹, B. S. Imber¹, H. Hubbeling¹, M. E. Mayerhoefer¹, D. Lafontaine¹, L. Michaud², M. Perales¹, H. Schöder¹, R. Shouval¹;
¹Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, ²Lausanne University Hospital, Lausanne, SWITZERLAND.

EP-0334

Effect of chemotherapy-related hepatic steatosis on liver 18F-FDG uptake in lymphoma patients

Y. Wang, M. Su, L. Li;
West China Hospital, Sichuan University, Chengdu City, CHINA.

EP-0335

Classical Hodgkin's Lymphoma: does baseline 18F-FDG PET/CT radiomics from the largest and hottest lesions add value to conventional prognostic models?

E. Triumbari^{1,2}, D. Morland³, R. Gatta⁴, A. Collarino⁴, E. Maiolo⁴, A. Cuccaro⁴, M. De Summa⁴, S. Chiesa⁴, L. Boldrini⁴, M. E. Mayerhoefer⁵, L. Nardo⁶, S. Hohaus⁴, S. Annunziata⁴;
¹Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, ITALY, ²Radiopharmacy Research Core Facility, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY, ³Service de médecine nucléaire, Institut Godinot and CReSTIC EA 3804, Université de Reims Champagne-Ardenne, Reims, FRANCE, ⁴Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, ITALY, ⁵Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, ⁶Department of Radiology, UC Davis, Sacramento, CA, UNITED STATES OF AMERICA.

EP-0336

Comparison of Low dose Vs standard dose 18F-FDG PET/CT in Lymphoma Patients using Conventional PET/CT Scanner

N. Kumar, J. Yadav, G. Arora, S. A. Shamim;
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0337

Do FDG PET metrics have a role for predicting the response to BeGeV therapeutic scheme in refractory Hodgkin lymphoma? A pilot study.

D. Pizzuto¹, N. Messina^{2,3}, E. Maiolo², F. D'Alò^{2,3}, S. Hohaus^{2,3}, S. Annunziata¹;
¹Nuclear Medicine Unit, GStEP Radiopharmacy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, ²Hematology Unit, Diagnostic Imaging, Radiation Oncology and Hematology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, ³Hematology Institute, University Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore, Rome, ITALY.

EP-0338

Normalization and 2-bit-quantization of FDG-PET using the Deauville Score for training an deep learning AI for lymphoma staging

B. Schemmer;
Uniklinik Bonn, Bonn, GERMANY.

EP-0339

Total metabolic tumor volume (TMTV) at baseline 18F-FDG PET/CT and Laboratory Prognostic Index (LAB-PI) as outcome predictors in Large B-Cell Lymphoma (LBCL).

L. García Belaústegui, S. Borwne, L. Sancho Rodríguez, R. Figueroa, F. Minguez, M. Canales, S. Huerga, V. Beteche-Antar, E. Pena, C. Grande, M. Garcia-Velloso;
Clínica Universidad de Navarra, Madrid, SPAIN.

EP-0340

Prognostic Value of Volumetric Parameters with 18F-FDG PET/TC in Follicular Lymphoma

P. Sarandeses¹, M. Poza¹, S. Pedraza¹, A. Medina Benito², A. Peter Seiffert², A. Jimenez², D. Vega¹, P. Zaragoza¹, S. Angiolillo¹, X. Guarnizo¹, S. Ruiz¹, A. Gomez¹, E. Martinez¹, A. Saviatto¹, A. Galiana¹, S. Barrio¹, M. Tabuenca¹;
¹HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, Madrid, SPAIN, ²Universidad Politécnica Madrid, Madrid, SPAIN.

EP-19

e-Poster Area

**B: Imaging Clinical Studies -> B1
Oncological Imaging Clinical Study -> B22
Other Hemato-Oncology**

EP-0341

18F-FDG PET/CT maybe not so helpless in detection leptomeningeal metastasis- a case report

T. Stoeva, M. Dyankova, S. Chausheva, T. Yordanova, Z. Dancheva, B. Chaushev, A. Klisarova;
UMHAT "Sveta Marina" EAD- Varna, Varna, BULGARIA.

EP-0342

18F-FDG PET/CT assessment of metabolic activity of the osteolytic lesions in patients with multiple myeloma after treatment for evaluation tumor vitality

T. Stoeva, Z. Dancheva, M. Dyankova, S. Chausheva, T. Yordanova, B. Chaushev, A. Klisarova;
UMHAT "Sveta Marina" EAD- Varna, Varna, BULGARIA.

EP-0343

18F-FDG PET/CT in unknown primary suspected of multiple myeloma

T. Stoeva, Z. Dancheva, M. Dyankova, T. Yordanova, S. Chausheva, B. Chaushev, A. Klisarova;
UMHAT "Sveta Marina" EAD- Varna, Varna, BULGARIA.

EP-0344

18F-FDG PET/CT assessment of metabolic activity of the osteolytic lesions in newly diagnosed multiple myeloma patients as predictive factor for overall survival

T. Stoeva, Z. Dancheva, M. Dyankova, T. Yordanova, S. Chausheva, B. Chaushev, A. Klisarova;
UMHAT "Sveta Marina" EAD- Varna, Varna, BULGARIA.

EP-0345

Impact of the Segmentation Method on the Correlation between Metabolic Tumor Volume and Total Circulating Tumor DNA

C. D. Ramos¹, G. Duffles¹, M. S. Takahashi¹, E. Napolitano², F. Lupinacci², L. Pereira², J. Maues¹, M. Chauffaille¹, I. Lorand-Metze¹;
¹University of Campinas, Campinas, BRAZIL, ²Laboratorio Fleury, Sao Paulo, BRAZIL.

EP-0346

End of treatment FDG PET CT in patients with Langerhans cell histiocytosis as a predictor of disease recurrence and survival.

P. Bochev¹, Z. Dancheva²;
¹Acibadem Cityclinic Mladost UMBAL, Sofia, BULGARIA, ²Medical University "Prof.Dr Paraskev Stoyanov", Varna, BULGARIA.

EP-0347

Unresolved Challenges in Functional Imaging of Multiple Myeloma: F-18 Fluorocholine PET/CT or F-18 FDG PET/CT? A Single Center Experience

G. KAYA¹, S. Akın², Y. Büyükaşık³, M. Tuncel¹, M. F. Bozkurt¹, P. Özgen Kıratlı¹;
¹Hacettepe University Medical School Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Hacettepe University Medical School Department of Medical Oncology, Ankara, TÜRKIYE, ³Hacettepe University Medical School Department of Hematology, Ankara, TÜRKIYE.

EP-0348

Prognostic utility of baseline 18F-FDG PET/CT in relapsed and refractory Multiple myeloma patients treated with T-cell redirecting bispecific antibodies.

F. MINGUEZ¹, V. Betech-Antar¹, L. Tamariz-Amador¹, A. Bronte Viedma¹, J. Rosales¹, J. Bastidas¹, C. von Gall², M. Romera¹, P. Echegoyen¹, F. Pareja del Rio¹, T. Cuenca¹, S. Menendez-Sanchez¹, L. García Belaustegui³, L. Sancho³, E. Guillen³, E. Prieto¹, R. Ramos³, J. Simon¹, M. Panizo¹, S. Huerga¹, J. San-Miguel¹, P. Rodriguez Otero¹, M. García-Velloso¹;

¹Clinica Universidad de Navarra, Pamplona, SPAIN, ²Siemens Healthineers, Molecular Imaging, Knoxville, TN, UNITED STATES OF AMERICA, ³Clinica Universidad de Navarra, Madrid, SPAIN.

EP-0349

Comparison of C-11 Methionine and F-18 FDG PET/CT findings in evaluation of Multiple Myeloma: First Türkiye Experience

E. Özkan¹, B. Demir¹, G. Cengiz Seva², M. Araz¹, C. Soydal¹, M. Beksac², N. O. Kucuk¹;

¹Ankara University School of Medicine Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Ankara University School of Medicine Department of Hematology, Ankara, TÜRKIYE.

EP-0350

Role of 18F-FDG PET/CT in patients with Castleman disease

R. Goel¹, N. Damle, Y. Dharmashaktu, C. Bal, M. Tripathi, R. Kumar, P. Kumar;

All India Institute of Medical Sciences (AIIMS), New Delhi, INDIA.

EP-0351

Talquetamab, a Novel Anti-Myeloma GPRC5DxCD3 Bispecific Antibody, is Associated with Increased Oropharyngeal FDG Uptake

J. Trak¹, T. Mouhieddine, G. Lancman, L. Sanchez, A. Chari, M. Ghesani;

Mount Sinai Hospital, New York, NY, UNITED STATES OF AMERICA.

EP-0352

A follow up of 30 patients with multiple myeloma confirmed: prognostic role of number of focal lesions and SUV max at diagnosis in 18F-FDG PET/CT

I. López Villar¹, V. Castillo Morales¹, I. Hernández Pérez¹, A. García Noblejas², S. Hernández Muñoz³, I. Salmerón Beliz³, J. Alonso Farto⁴, D. Zamudio⁴, N. Gómez de Leon³;

¹Princesa University Hospital, Nuclear Medicine Service, Madrid, SPAIN, ²Princesa University Hospital, Hematology Service, Madrid, SPAIN, ³Princesa University Hospital, Radiology Service, Madrid, SPAIN, ⁴Gregorio Marañón University Hospital, Nuclear Medicine Service, Madrid, SPAIN.

EP-0353

[11C]-Methionine as Novel Image Biomarker of Disease Activity in Newly Diagnosed Multiple Myeloma Patients - Comparison with [18F]-FDG

S. Serfling¹, M. Bittrich¹, A. K. Buck¹, T. Higuchi¹, S. Samnick¹, K. M. Kortüm¹, L. Rasche¹, H. Einsele¹, R. A. Werner¹, S. Knop²;

¹University Hospital Würzburg, Würzburg, GERMANY, ²Klinikum Nürnberg Nord, Nürnberg, GERMANY.

EP-0354

Multiple Myeloma: a comparison between 18F-FDG-PET/CT and 68Ga-PSMA-PET/CT

D. Bezzi¹, E. Zamagni², S. Fanti³, L. Vetrone¹, M. Talarico², C. Malizia³, C. Nanni²;

¹Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Seragnoli Institute of Hematology, Bologna University, Bologna, ITALY, ³Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0355

Sarcopenia and metabolic parameters of [18F]-FDG PET/CT in patients with multiple myeloma. Preliminary results.

A. Palomar-Muñoz¹, S. Hermosa-García^{2,3}, I. Sánchez-Rodríguez¹, Y. Benavente^{2,3}, J. A. Jorge-Novoa², V. Carrero-Vásquez¹, B. Hervás-Sanz¹, E. Garamundi-Grimalt⁴, G. Bustamante-Ramírez², E. Cabezudo-Pérez², M. Cortés-Romera¹, D. Casabonne^{2,3}, the IBERICAT/IMMAGE study collaborators;

¹Nuclear Medicine Department, Hospital Universitario Bellvitge, L'Hospitalet de Llobregat (Barcelona), SPAIN, ²Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat (Barcelona), SPAIN, ³Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, SPAIN, ⁴Pathological Anatomy Department, Hospital Universitario Bellvitge, L'Hospitalet de Llobregat (Barcelona), SPAIN, ⁵Hematology Department, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat (Barcelona), SPAIN, ⁶Hematology Department, Catalan Institute of Oncology (ICO) Hospital Sant Joan Despí Moisés Broggi, Sant Joan Despí (Barcelona), SPAIN.

EP-0356

[18F]- FDG PET/CT prognostic value in the assessment of multiple myeloma patients treated with CAR-T therapy

M. Tormo-Ratera¹, I. Zugasti², A. Oliver-Caldes², V. González-Calle³, V. Cabañas⁴, P. Rodríguez-Otero⁵, J. Reguera⁶, M. Mateos⁷, K. Quintero¹, S. Casanueva-Eliceiry¹, M. Cibeira⁸, A. Niñerola-Baizan¹, X. Tomas⁹, L. RosiñoP¹, P. Tamayo¹⁰, M. García-Velloso¹¹, C. Fernández de Larrea², X. Setoain¹;

¹Department of Nuclear Medicine, Hospital Clínic., Barcelona, SPAIN, ²Hospital Clínic. Institut d'Investigació Biomèdica August Pi i Sunyer., Barcelona, SPAIN, ³Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, SPAIN, ⁴Hospital Clínic Universitario Virgen de la Arrixaca, IMIB-Arrixaca, SPAIN, ⁵Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Pamplona, SPAIN, ⁶Hospital Universitario Virgen del Rocío, Sevilla, SPAIN, ⁷Hospital Universitario de Salamanca, Salamanca, SPAIN, ⁸Department of Hematology, Hospital Clínic., Barcelona, SPAIN, ⁹Department of Radiology, Hospital Clínic., Barcelona, SPAIN, ¹⁰Department of Nuclear Medicine, University Hospital of Salamanca, Salamanca, SPAIN, ¹¹Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, SPAIN.

EP-0357

Prognostic value of 18F-FDG PET/CT biomarkers in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy Preliminary results.

J. Cañadas Salazar¹, A. Martín Lopez, L. G. Díaz González, C. Montes fuentes, A. Martín García-Sancho, P. Tamayo Alonso;

Sacyl, Salamanca, SPAIN.

EP-20

e-Poster Area

**B: Imaging Clinical Studies -> B1
Oncological Imaging Clinical Study -> B23
Bone and Soft Tissues**

EP-0358

Dual time point [18F]FDG PET/CT can differentiate benign from malignant soft tissue tumors and outperforms the diagnostic performance of conventional PET/CT acquisition

P. D'Abadie¹, O. Gheysens, R. Lhomme, T. Kirchgessner, A. De Roo, T. Schubert;

Cliniques universitaires Saint Luc, Brussels, BELGIUM.

EP-0359

Prognostic Value of Pre-Treatment F-18 FDG PET/CT Parameters in Soft-Tissue Sarcomas

I. Ak Sivriköz¹, H. Deveci, E. Çiğin;

ESOGU School of Medicine Department of Nuclear Medicine, Eskisehir, TÜRKIYE.

EP-0360

Association of 'Hot Kidneys' on Bone Scintigraphy and Serum Ferritin Levels

I. Kuji¹, K. Watanabe¹, E. Ryuta¹, Y. Matsusaka¹, A. Seto¹, I. Matsunari²;

¹Department of Nuclear Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, JAPAN, ²Department of Nuclear Medicine, Saitama Medical University Hospital, Saitama Medical University, Moroyama, Saitama, JAPAN.

EP-0361

Prognostic value of metabolic parameters of 18F-FDG PET-CT in the staging of adult soft tissue sarcomas

A. Berardinelli¹, M. Meneses Navas¹, G. Cuesta Domingo¹, P. Nespral Torres¹, P. Romero Fernández¹, P. Dauden Oñate¹, P. Bascuñana¹, A. Crespo², M. Cabrera Martín¹;

¹Department of Nuclear Medicine, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Universidad Complutense, Madrid, SPAIN, ²Department of Radiology, Hospital Clínico San Carlos., Madrid, SPAIN.

EP-0362

Utility of metabolic indices in 18F-FDG-PETCT for prediction of presence, patterns and sites of metastases in patients with osteosarcoma

N. Kundu¹, S. Sagar, D. Khan, A. Roy, R. Goel, M. Y S, R. V, R. Kumar;

AIIMS New Delhi, Delhi, INDIA.

EP-0363

The Relationship Between Staging F-18 FDG PET/CT Parameters and Survival in Patients Diagnosed with Soft Tissue Sarcoma

N. Aydin¹, G. Mütevelizade, G. Gümüşer, E. Sayit Bilgin;

Celal Bayar University, Manisa, TÜRKIYE.

EP-0364

Additional diagnostic contribution of bone SPECT/CT in foot and ankle pathology

K. Bayardo¹, L. F. Portugal, F. Carrera, O. Alonso, R. Ferrando;

University of the Republic, Montevideo, URUGUAY.

EP-0365

Assessing the role of 18F-FDG PET-CT in the initial staging of soft tissue sarcomas: bone infiltration and distant metastasis

Y. Abadi Sedraoui¹, J. Cordero García, E. Ortiz Cruz, I. Barrientos Ruiz, J. Pozo Kreiling, C. Lancha Hernández, M. Coronado Poggio, S. Rizkallal Monzón, E. López Llobet, D. Monachello Araujo, L. Giraldo González, P. Portilla Merino, S. Rodado Marina, C. Escabias Del Pozo, L. Domínguez Gadea;

Hospital Universitario La Paz, Madrid, SPAIN.

EP-0366

Evaluation of F-18 FDG PET-CT based parameters in prediction of histopathological response to neoadjuvant chemotherapy in patients with Osteosarcoma

S. Maitra¹, N. Singh;

P.D. Hinduja National Hospital and MRC, Mumbai, INDIA.

EP-0367

Usefulness of SPECT/CT 99mTc MIBI for the evaluation of lesions suggestive of bone sarcomas.

F. Lemus Ramírez¹, A. López Méndez², D. Arguelles Pérez¹, D. Orendain Novoa¹;

¹Instituto Nacional De Rehabilitación Luis Guillermo Ibarra Ibarra, México, MEXICO, ²J&J, México, MEXICO.

EP-0368

18F-NaF PET/CT in diagnosis and response assessment to Radiofrequency Ablation (RFA) in Osteoid Osteoma patients

S. Shamim¹, N. Kumar, J. Pathak, G. Arora, S. Gamanagatti, S. Khan;

AIIMS New Delhi, Delhi, INDIA.

EP-21

e-Poster Area

**B: Imaging Clinical Studies -> B1
Oncological Imaging Clinical Study -> B24
Melanoma**

EP-0369

The value of 18F-FDG PET/MR in the metastasis and re-stage of melanoma after operation

F. Wang¹;

Hangzhou Universal Imaging diagnostic center, Hangzhou, CHINA.

EP-22

e-Poster Area

**B: Imaging Clinical Studies -> B1
Oncological Imaging Clinical Study -> B25
Any Other Malignant (including Primary of Unknown Origin)**

EP-0370

Utility of 68Ga FAPI 46 PET CT scan in oncology patients with indeterminate 18 FFDG PET CT findings- A single institute study
V. Malasani, s. dash, d. pendharkar, n. singhal, a. raj, m. mehndiratta, d. parwan, n. n. begum, a. tomar, a. javed; sarvodaya hospital and research center, faridabad, INDIA.

EP-0371

Comparison of Diagnostic Value between 18F-FDG PET/CT and Immunohistochemistry in Lymph Node Metastatic Cancer with Unknown Primary site
Y. Yu, S. Xu, X. Han; the First Affiliated Hospital, Zhengzhou, Zhengzhou, CHINA.

EP-0372

Diagnostic Efficacy of 68Ga-NY104 PET/CT in Patients With Clear Cell Renal Cell Carcinoma
W. Zhu, X. Li, Y. Zhang, L. Huo; Peking Union Medical College Hospital, Beijing, CHINA.

EP-0373

The added values of 18F-FAPI over 18F-FDG in patients with oncologic diseases for evaluation of malignant lesions and management of incidental pathologic uptake
X. Mu, M. Li, W. Fu; Department of Nuclear medicine, Affiliated hospital of Guilin medical university, Guilin, CHINA.

EP-0374

Using dual-time 18F-FAPI PET/CT to distinguishing the nature of lesion and avoid digestive pitfalls
X. Mu; Department of Nuclear medicine, Affiliated hospital of Guilin medical university, Guilin, CHINA.

EP-0375

Does Brown Adipose Tissue represent a double-edged sword with mixed effects?
W. Jalloul¹, D. Jalloul¹, R. Tibu², I. Grierosu^{1,2}, T. Ionescu¹, C. Stolniceanu^{1,2}, V. Ghizdovat^{1,2}, M. Moscalu¹, C. Stefanescu^{1,2}; ¹University of Medicine and Pharmacy U.M.F „Grigore T. Popa” Iasi, Romania, Iasi, ROMANIA, ²Nuclear Medicine Laboratory, County Emergency Hospital „Sf. Spiridon”, Iasi, ROMANIA.

EP-0376

Prognostic value of volumetric and metabolic 18F-FDG indices in patients with Merkel cell carcinoma: a multicentric retrospective study
M. Ricci¹, F. Zarrelli¹, B. Carabellese¹, A. Marzullo², M. Tudini³, B. Criscuoli⁴, G. A. Follacchio⁴, L. Travascio⁵, A. D. Di Nicola⁵, E. Giovannini⁶, F. Calabria⁷, M. Leporace⁷, A. Bagnato⁷, A. Cimin⁷; ¹Nuclear Medicine Unit, Cardarelli Hospital, Campobasso, ITALY, ²Nuclear Medicine Unit, St. Salvatore Hospital, L'Aquila, ITALY, ³Medical Oncology Unit, St. Salvatore Hospital, L'Aquila, ITALY, ⁴Nuclear Medicine Unit, Macerata Hospital, Macerata, ITALY, ⁵Nuclear Medicine Unit, P.O. Pescara, Pescara, ITALY, ⁶Nuclear Medicine Unit, S. Andrea Hospital, La Spezia, ITALY, ⁷Department of Nuclear Medicine and Theragnostics, “Mariano Santo” Hospital, Cosenza, ITALY.

EP-0377

68Ga-FAPI-04 PET/CT in Renal Cell Carcinoma: A Preliminary Study
C. Civan¹, S. Kuyumcu¹, D. Has Simsek¹, O. Sanli², Z. Ozkan¹, O. Hurdogan³, Y. Sanli¹; ¹Istanbul Faculty of Medicine, Nuclear Medicine Department, Istanbul, TÜRKIYE, ²Istanbul Faculty of Medicine, Urology Department, Istanbul, TÜRKIYE, ³Istanbul Faculty of Medicine, Pathology Department, Istanbul, TÜRKIYE.

EP-0378

68Ga-NY104 PET/CT helps discriminate metastatic clear cell renal cell carcinoma from post-surgical inflammation: compared with 18F-FDG
W. Zhu, X. Li, Y. Zhang, L. Huo; Peking Union Medical College Hospital, Beijing, CHINA.

EP-0379

A Rare Case of Adrenal Hemangioma with CT, MRI and Pathology Findings.
B. Karasah Erkek, A. Akgün, Y. Ertan, M. Harman; Ege University, Izmir, TÜRKIYE.

EP-0380

Comparison of 18F-FDG and 68Ga-FAPI PET/CT in the diagnosis of lung metastasis in different malignant tumors
Z. Yang; Fudan University Shanghai Cancer Center, Shanghai, CHINA.

EP-0381

Bone scan with technetium 99m-methyl diphosphonate, the missing link in the initial staging of muscle-invasive bladder carcinoma
A. Aghaee¹, S. Soltani², H. Ghorbani², H. Ghorbani¹, S. Zakavi¹, K. Aryana¹; ¹Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ²Kidney Transplantation Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0382

The Role of Integrin $\alpha v \beta 6$ -PET/CT for Patients with Different Cancer-Preliminary Clinical Experience
L. Li, Z. Xiao, D. Zeng, D. Xing, H. Wu, Y. Tian, C. Li, Y. He; Department of Nuclear Medicine, Zhongnan Hospital, Wuhan University, Wuhan, CHINA.

EP-0383

Tumor Uptake of a Bi-specific Antibody which Binds to CD137 and FAP is Shown Using 89[Zr]Zr-B1 765179 PET-imaging
M. Stavenga^{1,2}, M. C. Huisman^{3,2}, G. J. C. Zwezerijnen^{3,2}, J. J. Eertink^{1,2}, K. Ridler^{4,5}, Ö. Yalkinoglu⁶, H. Maas⁴, D. Radonjic⁷, J. Pasek⁸, D. J. Vugts^{3,2}, C. W. Menke-van der Houven van Oordt^{1,2}; ¹Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Medical Oncology, Amsterdam, NETHERLANDS, ²Cancer Center Amsterdam, research program, Amsterdam, NETHERLANDS, ³Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS, ⁴Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Translational Medicine & Clinical Pharmacology, Biberach, GERMANY, ⁵Invicor, A Konica Minolta Company, London, UNITED KINGDOM, ⁶Boehringer Ingelheim International GmbH,

Department of Translational Medicine & Clinical Pharmacology, Ingelheim am Rhein, GERMANY, ⁷Boehringer Ingelheim International GmbH, TA Oncology Medicine, Ingelheim am Rhein, GERMANY, ⁸Boehringer Ingelheim Pharmaceuticals, Early Clinical Operations, Ridgefield, CT, UNITED STATES OF AMERICA.

EP-0385

Diagnostic Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in the Evaluation of Carcinoma of Unknown Primary Against Computed Tomography; Experience of Single Centre
M. Numair Younis, U. B. Zahra, A. Shahid; Institute of Nuclear Medicine and Oncology-INMOL, Lahore, PAKISTAN.

EP-0386

The utility of PET/CT with 18F-FDG in the localization of unknown primary tumors and its correlation with anatomopathological findings: Experience of the University Hospital of Salamanca.
J. Badell¹, P. García-Talavera San Migue², F. Gómez-Caminero López¹, A. C. Peñaherrera Cepeda¹, E. Campaña Díaz¹, S. Rama Alonso¹, J. G. Villanueva Curto¹, L. G. Díaz González¹, P. Tamayo Alonso¹; ¹Hospital Clínico Universitario de Salamanca, Salamanca, SPAIN.

EP-0387

The relevance of 18FDG-PET/CT in the therapeutic assessment of recurrent leiomyosarcoma of the inferior vena cava
K. Ben Ahmed, M. Maaloul, H. Noomen, F. Chaltout, M. Ouachem, I. Jardak, S. Charfeddine, K. Chtourou, F. Guerhazi; Nuclear medicine department, Habib bourguiba hospital, Sfax, TUNISIA.

EP-0388

PSMA Theragnostic beyond prostate cancer. A monocentric prospective observational study on the diagnostic performance of PSMA PET/CT in patients with metastatic Renal Clear Cell Carcinoma
F. Serani¹, A. Farolfi², P. Castellucci², L. Vetrone¹, R. Mei², S. Fanti³; ¹Nuclear Medicine, Alma Mater Studiorum - University of Bologna, Bologna, ITALY, ²Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ³Nuclear Medicine, Alma Mater Studiorum - University of Bologna, Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-23

e-Poster Area

B: Imaging Clinical Studies -> B3 Other Oncological Clinical Study -> B31 Radioguided Surgery and Radiation Therapy Planning

EP-0389

Feasibility study about the intra-operative use of a novel PET/CT Specimen Imager in Prostate Cancer and Neuroendocrine Tumors
L. Muraglia¹, F. Mattana¹, L. Travaini¹, G. Musi², E. Bertani³, G. Renne⁴, E. Pisa⁴, M. Ferrari⁵, U. Fumagalli Romario³, O. De Cobelli², N. Fusco⁶, C. Francesco⁷; ¹Nuclear Medicine Division, European Institute of Oncology IRCCS, Milan, ITALY, ²Urology Division, European Institute of Oncology IRCCS; Oncology and Hemato-Oncology Department, University of Milan, Milan, ITALY, ³Digestive Surgery Division, European Institute of Oncology IRCCS, Milan, ITALY, ⁴Pathology Division, European Institute of Oncology IRCCS, Milan, ITALY, ⁵Medical Physics Unit, European Institute of Oncology IRCCS, Milan, ITALY, ⁶Pathology Division, European Institute of Oncology IRCCS; Oncology and Hemato-Oncology Department, University of Milan, Milan, ITALY, ⁷Nuclear Medicine Division, European Institute of Oncology IRCCS; Oncology and Hemato-Oncology Department, University of Milan, Milan, ITALY.

EP-0390

Preoperative Radioisotope-guided Localization of Non-palpable Pulmonary Nodules
M. Olajos, K. Park, Á. Ghimessy, K. Csende, M. Csaba, J. Andi, M. Téglás, L. Agócs, F. Rényi-Vámos, I. Sinkovics; National Institute Of Oncology, Budapest, HUNGARY.

EP-0391

Improving radical prostatectomy with intraoperative ex-vivo PSMA-PET/CT imaging
P. Frago Costa¹, C. Darr², A. Moraitis¹, T. Kah³, J. Engel⁴, M. Al-Nader², H. Henning³, J. Köllermann³, C. Kesch², U. Krafft², T. Maurer^{4,5}, D. Köhler⁶, S. Klutmann⁶, F. Falkenbach⁴, J. Kleesiek⁷, W. P. Fendler¹, K. Herrmann¹, B. Hadaschik²; ¹Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY, ²Department of Urology, University Hospital Essen, Essen, GERMANY, ³Institute of Pathology, University Hospital Frankfurt, Frankfurt, GERMANY, ⁴Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY, ⁵Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY, ⁶Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY, ⁷Institute of Artificial Intelligence in Medicine, University Hospital Essen, Essen, GERMANY.

EP-0393

Preoperative CT-guided radiolabeling of lung nodules with 99mTc-MAA and Video-Assisted or Robotic-Assisted Thorascopic Surgery: experience in our center since 2017.
C. Wakfe Corieh^{1,2}, E. Rodríguez Gallo^{1,2}, J. Sánchez Corral^{1,2}, N. Mimica Haasz^{1,2}, F. Moradiellos Díez^{1,2}, S. Amor Alonso^{1,2}, A. Maldonado Suarez^{1,2}; ¹Hospital Universitario Quirónsalud Madrid, Madrid, SPAIN, ²Universidad Europea, Madrid, SPAIN.

EP-0394

x2x2
E. Gromova¹, A. Smirnova¹, G. Kataeva², N. Plakhotina¹; ¹LDC MIBS, Saint-Petersburg, RUSSIAN FEDERATION, ²RRCRST, Saint-Petersburg, RUSSIAN FEDERATION.

EP-0395

Fast SPECT/CT confirmation of the preoperative location with ROLL: analysis of a 2-year single-centre real life experience

I. Lopo¹, E. Lima², A. Bitencourt², L. Santos², A. Tavares², P. Lapa^{1,3}, G. Costa^{1,3};

¹Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, ²A. C. Camargo Cancer Center, São Paulo, BRAZIL, ³Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

EP-0396

Intraoperative PET/CT Specimen Imaging for the Evaluation of Surgical Margins and Nodal Metastases in Prostate Cancer Patients Undergoing Robot-assisted PSMA-radioguided Surgery

G. Rovera¹, S. Grimaldi¹, M. Oderda², L. Delsedime³, D. D'Agate², F. Lavagno², A. Marquis², G. Marra², L. Molinaro³, P. Gontero², D. Deandrei¹;

¹Nuclear Medicine, Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, Turin, ITALY, ²Department of Surgical Sciences, Urology Unit, AOU Città della Salute e della Scienza di Torino, Molinette Hospital, University of Turin, Turin, ITALY, ³Department of Pathology, AOU Città della Salute e della Scienza di Torino, Molinette Hospital, University of Turin, Turin, ITALY.

EP-0397

DROP-IN robotic SPECT in sentinel lymph node prostate cancer patients

S. Azargoshasb¹, A. Berrens², L. J. Slof¹, E. M. K. Wit², P. J van Leeuwen², H. G. van der Poel², M. N. van Oosterom¹, F. W. B. van Leeuwen¹;

¹Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Cent, Leiden, NETHERLANDS, ²Department of Urology, NETHERLANDS Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.

EP-0398

IMPLEMENTATION OF IODINE-125 (125I) SEEDS MARKING IN NON-PALPABLE MALIGNANT BREAST LESIONS

M. Garcia Aragon, R. Zambrano Infantino, F. Sebastian Palacid, N. Alvarez Mena, A. Sainz Esteban, M. Alonso Rodriguez, M. Moral Cano, M. Gonzalez Soto, R. Ruano Perez;

Hospital Universitario Clínico Valladolid, Valladolid, SPAIN.

EP-0399

Minimally invasive radioguided parathyroidectomy: A descriptive report and correlation between variables of interest

M. Sanchez Torrente, R. Nieto Serrano, A. Martin Garcia, M. Gallego Marquez, J. Venero Chaparro, D. Becerra Garcia;

Hospital Universitario Clínico San Cecilio, Granada, SPAIN.

EP-0400

Lung nodule radioguided localization results.

M. Guiote Moreno¹, A. Lopez Cano¹, S. Castejón Echevarne¹, D. Tercero Garrido¹, R. Zurera Pareja², J. Vallejo Casas¹;

¹Hospital Universitario Reina Sofía, Cordoba, SPAIN, ²IMIBIC, Cordoba, SPAIN.

EP-0401

Diagnostic Value Of Salivary Gland Scintigraphy In Post-Radiation Xerostomia In Nasopharyngeal Carcinoma Patients: First Tunisian study

H. Rokbani¹, L. Zaabar^{1,2}, S. Zarraa^{3,2}, L. Kechaou³, M. El bess³, T. Ben Ghachem^{1,2}, C. Nasr^{4,2}, A. Mhiri^{1,2};

¹Nuclear Medicine departement, Salah Azaeiz Institute, tunis, TUNISIA, ²Faculté de Médecine de Tunis, Tunis, TUNISIA, ³Radiotherapy departement, Salah Azaeiz Institute, tunis, TUNISIA, ⁴Radiotherapy departement, Salah Azaeiz Institute, Tunis, TUNISIA.

EP-0402

Comparison of Radioactive Seed Localization and Radioguided Occult Lesion Localization in Surgical Success of Nonpalpable Breast Cancer

R. Sahin¹, M. Baykara Ulsan², E. S. Ata², M. B. Cengiz Gökmen³, N. Ergül¹, T. Aksoy¹, T. F. Çermik¹, E. Arslan¹;

¹University of Health Sciences, Istanbul Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²University of Health Sciences, Istanbul Training and Research Hospital, Department of Radiology, Istanbul, TÜRKIYE, ³University of Health Sciences, Istanbul Training and Research Hospital, Department of Surgery, Istanbul, TÜRKIYE.

EP-24

e-Poster Area

B: Imaging Clinical Studies -> B3 Other Oncological Clinical Study -> B32 Sentinel Node

EP-0403

SPECT/CT imaging and Sentinel lymphnode biopsy in early breast cancer in 150 patients -KMCH India experience.

K. Kamaleshwaran, E. Ramkumar;
Kovai Medical center and Hospital Limited (KMCH), Coimbatore, INDIA.

EP-0404

Unusual lymphatic drainage pathways detected by intradermal lymphoscintigraphy for sentinel lymph node biopsy in breast cancer.

G. Tartaglione¹, M. Pagan¹, F. P. Ieria¹, E. Covello², L. M. Marino Cosentino³, S. Di Filippo², S. Ghinassi³, R. Marsico³, L. Leone³, M. R. Limiti⁴, P. L. Bonatti^{2,3};

¹Cristo Re Hospital, Nuclear Medicine, Rome, ITALY, ²Santo Spirito Hospital, Breast Unit ASL Roma 1, Rome, ITALY, ³San Filippo Neri Hospital, Breast Unit ASL Roma 1, Rome, ITALY, ⁴Santo Spirito Hospital, Pathology, Breast Unit ASL Roma 1, Rome, ITALY.

EP-0405

Sentinel lymph node biopsy and axillary marking after neoadjuvant treatment in node-positive breast cancer patients

P. Guardia Jimena, A. Santos Bueno, Á. Rebollo Aguirre, E. Sánchez de Mora, A. Jiménez Heffernan;

Hospital Universitario Juan Ramón Jiménez, Huelva, SPAIN.

EP-0406

Local anaesthetic improves patient experience of breast and melanoma lymphoscintigraphy

K. Jewell, G. Kong, B. Emmerson, T. Akhurst, K. Moodie;
Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

EP-0407

Detection rates of sentinel lymph node biopsy (SLNB) in gynecological cancer. Our experience.

C. Ruiz Corbalán, A. De Agrela Serrao, A. Leiva Montejo, D. Cáceres Silva, M. Castellón Sanchez, L. Frutos Esteban, J. Navarro Fernandez, T. Rodriguez Locarno, A. Hernandez Martinez, L. Mohamed Salem, J. Contreras Gutierrez;

ARRIXACA, Murcia, SPAIN.

EP-0408

Radiation-free bimodal sentinel node procedure combining fluorescence and magnetic guidance and pre-operative resonance imaging in prostate cancer - A first in-human study

B. Michalik¹, S. Engels¹, M. C. Otterbach², M. N. van Oosterom³, M. Maurer², F. Wawroschek¹, A. Winter¹;

¹University Hospital for Urology, Klinikum Oldenburg, Carl von Ossietzky University Oldenburg, Oldenburg, GERMANY, ²University Institute for Diagnostic and Interventional Radiology, Klinikum Oldenburg, Carl von Ossietzky University Oldenburg, Oldenburg, GERMANY, ³Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS.

EP-0409

Validation of sentinel node biopsy in head and neck tumors at one single center. Our experience.

D. Rivas-Navas, J. Fernández-Fernández, E. Triviño-Ibáñez, C. Ramos-Font, R. Sánchez-Sánchez;

Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0410

Nodal staging in patients with penile cancer.

Correlation between [18F]FDG-PET/CT and sentinel node biopsy.

A. Piñeiro Donis, J. Fernández Fernández, E. Triviño Ibáñez, C. Ramos Font, R. Sánchez Sánchez;

Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0411

Investigation into the frequency of systemic tracer uptake when performing sentinel lymph node examinations

A. Carradus^{1,2}, M. Bradnam^{1,3}, J. Foster^{1,3}, A. Bolster^{1,2,3};

¹Department of Clinical Physics and Bioengineering, NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM, ²Nuclear Medicine, North East Sector Glasgow, NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM, ³College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UNITED KINGDOM.

EP-0412

Single Institution Study of Sentinel Lymph Node Detection in Cervical Cancer: Validating an Alternative to Pelvic Lymphadenectomy

D. Rombo¹, D. Fraga¹, M. Bernardino², I. Vitorino¹, E. Sousa¹, J. Aço¹, I. P. Carvalho¹, R. Sousa¹, A. F. Jorge², L. Salgado¹;

¹Serviço de Medicina Nuclear, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, PORTUGAL, ²Serviço de Ginecologia, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, PORTUGAL.

EP-0413

Prospective evaluation of SPECT/CT & intra-operative Gamma probe techniques for identification of sentinel lymph node (SLN) in early stage oral cancer

M. L. Narayan¹, P. Kaul², P. Singh³, T. Singha², M. Negi¹, P. K. Garg²;

¹All India Institute of Medical Sciences (A.I.I.M.S.), Rishikesh, India, INDIA, ²SGRR Institute of Medical Sciences and SMI Hospital, Dehradun, Uttarakhand, India, INDIA, ³All India Institute of Medical Sciences (A.I.I.M.S.), Bhubneshwar, Orissa, INDIA.

EP-0414

DROP-IN radioguided during robotic sentinel node procedures in bladder cancer

D. Rietbergen¹, M. N. van Oosterom¹, E. van Gennep¹, B. van Rhijn², H. G. van der Poel², F. W. B. van Leeuwen¹;

¹Leids Universitair Medisch Centrum (LUMC), Leiden, NETHERLANDS, ²NKI, Amsterdam, NETHERLANDS.

EP-0415

Lymphoscintigraphy patterns in recurrent breast cancer. Can they predict the outcome?

B. Pereira, P. Soeiro, A. Fernandes, A. Oliveira;

Centro Hospitalar Universitário de São João, Porto, PORTUGAL.

EP-0416

Lymphoscintigraphy in Breast Cancer. Is there a difference in primary versus recurrent disease?

B. Pereira, P. Soeiro, P. Dias, A. Oliveira, A. Fernandes;

Centro Hospitalar Universitário de São João, Porto, PORTUGAL.

EP-0417

Concordance between portable SPECT and conventional scintigraphy for detection of sentinel node in breast cancer

J. Orozco Cortés¹, Á. Esteban Hurtado², C. Siscar Gelo², M. Navas de la Cruz², L. Casas Calabuig², Á. Badenes Romero³, T. Mut Dolera², D. Reyes Ojeda¹, D. Balaguer Muñoz², P. Abreu Sánchez², P. Carcamo Ibarra¹, C. Plancha Mansanet², E. Caballero Calabuig²;

¹Hospital Clínico Universitario de Valencia, Valencia, SPAIN, ²Hospital Universitario Doctor Peset Valencia, Valencia, SPAIN, ³Hospital Universitario Joan XXIII Tarragona, Tarragona, SPAIN.

EP-0418

Is SPECT/CT useful in selective sentinel lymph node biopsy in melanoma in all primary lesion location?

P. Zaragoza Ballester, X. T. Guarnizo Poma, S. Angiolillo Grau, D. Vega Pérez, P. Sarandeses Fernández, Á. Galiana Morón, A. Saviatto Nardi, E. Martínez Albero, S. Ruiz Solís, M. Marín Ferrer, V. Godino Gulloteu, A. Gómez Grande, M. Tabuenca Mateo;

Hospital Universitario 12 De Octubre, Madrid, SPAIN.

EP-0419

Selective sentinel lymph node biopsy (SLNB) in early stages oral cavity cancer: a single center study

A. De Agrela Serrao, C. Ruiz Corbalan, A. M. Leiva Montejo, J. L. Navarro Fernández, M. Castellón Sanchez, T. E. Rodríguez Locarno, L. Frutos Esteban, A. C. Hernández Martínez, L. Mohamed Salem, D. R. Cáceres Silva, J. F. Contreras Gutierrez;

Hospital Clínico Universitario Virgen de Arrixaca, Murcia, SPAIN.

¹Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, ²A. C. Camargo Cancer Center, São Paulo, BRAZIL, ³Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

¹University of Health Sciences, Istanbul Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²University of Health Sciences, Istanbul Training and Research Hospital, Department of Radiology, Istanbul, TÜRKIYE, ³University of Health Sciences, Istanbul Training and Research Hospital, Department of Surgery, Istanbul, TÜRKIYE.

¹Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS.

¹Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, ²A. C. Camargo Cancer Center, São Paulo, BRAZIL, ³Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

¹University of Health Sciences, Istanbul Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE, ²University of Health Sciences, Istanbul Training and Research Hospital, Department of Radiology, Istanbul, TÜRKIYE, ³University of Health Sciences, Istanbul Training and Research Hospital, Department of Surgery, Istanbul, TÜRKIYE.

¹Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS.

¹Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, ²A. C. Camargo Cancer Center, São Paulo, BRAZIL, ³Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.

EP-0420

Sentinel Lymph Node Mapping For Endometrial Cancer: Results of the First Tunisian, Arab and African study.

L. Zaabar^{1,2}, H. Bouaziz^{2,3}, S. Sghaier⁴, G. Sahraoui^{5,2}, M. Slimane^{4,2}, M. Hechiche^{4,2}, K. Mrad^{5,2}, K. Raha^{4,2}, A. Mhiri^{1,2}; ¹Salah Azaeiz Institute, Nuclear Medicine departement, Tunis, TUNISIA, ²Faculté de Médecine de Tunis, Tunis, TUNISIA, ³Salah Azaeiz Institute, Surgical Department of Oncology, Tunis, TUNISIA, ⁴Salah Azaeiz Institute, Surgical Department of Oncology, Tunis, TUNISIA, ⁵Salah Azaeiz Institute, Pathological Anatomy Department, Tunis, TUNISIA.

EP-0421

Performance of 99mTc-albumin nanocolloid and indocyanine green as tracers in sentinel lymph node detection in cervical and endometrial cancer.
M. Grajeda Gallardo, A. Prieto Soriano, P. Meneses Soares, K. Velasquez Díaz, I. Garrido Solesio, L. Santamaria Chico, I. Obedkova, S. Guzmán Ortiz, M. Mitjavila Casanovas; Hospital Universitario Puerta de Hierro, Madrid, SPAIN.

EP-25

e-Poster Area

B: Imaging Clinical Studies -> B4 Cardiovascular Imaging Clinical Study -> B41 Perfusion

EP-0422

C-reactive protein and myocardial perfusion imaging

C. Sioka, A. Kekiopoulou, P. Kekiopoulos, A. Bechlioulis, A. Rammos, A. Papadopoulos, J. Al-Boucharali, S. Tsiouris, X. Xourgia, D. Dristiliaris, C. Katsouras; University Hospital of Ioannina, Ioannina, GREECE.

EP-0423

Atrial fibrillation is an independent predictor of the extent and severity of myocardial ischemia in myocardial perfusion imaging

C. Sioka, A. Bechlioulis, P. Zotou, S. Alexiou, A. Kekiopoulou, E. Gkika, P. Kekiopoulos, D. Dristiliaris, A. Rammos, L. Lakkas, K. Naka, L. Michalis, C. Katsouras; University Hospital of Ioannina, Ioannina, GREECE.

EP-0424

How did the COVID-19 pandemic affect SPECT myocardial perfusion scans? A single center experience

A. Aghaee, s. ataei nakhaei, e. askari, h. mohammadzadeh, h. roustae, f. karamian; nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0425

Stress Myocardial Perfusion Imaging (MPI) for Predicting Major Cardiac Events in Diabetic Women and Men

N. Fatima^{1,2}, S. Zaman³, A. Zaman⁴, J. Bano², M. u. Zaman^{5,2}; ¹Dept of Radiology Aga Khan University, Karachi, PAKISTAN, ²Dept of Nuclear Cardiology, Karachi Institute of Heart Diseases (KIHD), Karachi, PAKISTAN, ³Dr Ruth Pfau (CHK), Karachi, PAKISTAN, ⁴Dept of Medicine, Sunny Downstate Medical Centre, New

York, NY, UNITED STATES OF AMERICA, ⁵Dept of Radiology Aga Khan University, KARACHI, PAKISTAN.

EP-0426

Prognostic Value of Rest SPECT MPI Derived Left Ventricular Shape Indexes in Patients with Prediabetes

Y. Hu, Y. Zhao, R. Wang, L. Yang, Y. Li, Y. Wang, X. Diao, S. Li; Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, CHINA.

EP-0427

The Correlation Study between MPI and CAG in Risk Stratification of CAD Patients with Different Uric Acid Levels

Y. Chen¹, X. Liu¹, X. Li¹, M. Cai², S. Li³; ¹Shanxi Medical University, Tai Yuan, CHINA, ²Shanxi provincial People's Hospital & Fifth Clinical College of Shanxi Medical University Medicine, Tai Yuan, CHINA, ³The first hospital of Shanxi Medical University, Tai Yuan, CHINA.

EP-0428

Prognostic Value of Gated SPECT MPI Varied by Atherosclerotic Cardiovascular Disease Risk: A Retrospective Study

Y. Li, Y. Zhao, R. Wang, Y. Hu, Y. Wang, X. Diao, J. Zhang, S. Li; First Hospital of Shanxi Medical University, Taiyuan, CHINA.

EP-0429

Improving multi-pinhole cadmium zinc telluride myocardial perfusion imaging specificity without changing sensibility by using adapted prefilter parameters

F. Vauchot, A. Bourdon, M. Benkiran, J. Dubois; CHU Gui de Chaulliac, Montpellier, FRANCE.

EP-0430

Spherization Indexes by Rest SPECT Improves Risk Stratification in Patients with Non-obstructive Coronary Artery Disease

Y. Zhao, Y. Hu, P. Wu, Y. Li, S. Li; Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, CHINA.

EP-0431

Long-term Outcome of Patients after Radionuclide Myocardial Perfusion Imaging

J. Huang¹, K. Chien², Y. Wu³; ¹Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TAIWAN, ²Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, TAIWAN, ³Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, TAIWAN.

EP-0432

Comparison of Myocardial Perfusion Imaging Studies of Patients with Confirmed Coronary Artery Disease Performed on Traditional SPECT Gamma Camera and Dedicated Semiconductor Cardiac Gamma Camera

P. Cichocki¹, M. Blaszczyk¹, A. Aulich¹, Z. Adamczewski¹, A. Plachcinska²; ¹Nuclear Medicine Department, Medical University of Lodz, Lodz, POLAND, ²Department of Quality Control and Radiological Protection of the Medical University of Lodz, Lodz, POLAND.

EP-0433

Coronary Reserve assesement by means of routine standard perfusion SPECT (no first-pass): easy method to evaluate macro-angiopathy and microvascular lesions.

L. Philippe, C. Prunier-Aesch, Y. El Yaagoubi; Medecine Nucleaire Tourangelle, Chambray-les-Tours, FRANCE.

EP-0434

Clinical value of Tc-99m MIBI Myocardial Gated SPECT in children and adolescents presenting with exercise related chest pain

A. Alakbarli¹, M. A. Karacan¹, Y. Ozananar Sevinc², Y. Ceylan³, A. M. Argon¹, Z. Ozcan¹; ¹Ege University Hospital Nuclear Medicine, Izmir, TÜRKIYE, ²Bakircay University Cigli Regional Education Hospital, Izmir, TÜRKIYE, ³Usak University Hospital, Usak, TÜRKIYE.

EP-0435

Long-term prognostic value of semi-quantitative myocardial perfusion imaging in patients with homozygous familial hypercholesterolemia

J. Jiao, W. Dong, T. Mou, H. Mi, Y. Zhang; Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA.

EP-0436

The relationships between apolipoproteins and myocardial blood flow in patients with non-obstructive coronary artery disease

K. Zavadovsky, A. Maltseva, K. Kopeva, A. Mochula, O. Trubacheva, E. Grakova; Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.

EP-0437

Predictive Factors of Myocardial Perfusion SPECT Positivity using a CZT D SPECT Camera in 3594 Patients Referred For Myocardial Perfusion Imaging In one year.

M. Esnault¹, D. Legallois², P. Richard³, D. Agostini², M. Alain²; ¹Caen University, Caen, FRANCE, ²Caen University Hospital, Caen, FRANCE, ³Hospital privé Saint Martin, Caen, FRANCE.

EP-0438

Shorten Acquisition of Dynamic 11C-Acetate Cardiac PET/CT in Quantifying Pharmacokinetic Parameters

T. Gong¹, F. Shang¹, X. Tang¹, L. Huo², S. Liu¹; ¹School of Life Science, Beijing Institute of Technology, Beijing, CHINA, ²Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, CHINA.

EP-0439

Evaluation and related influencing factors of left ventricular systolic dyssynchrony after PCI in patients with acute myocardial infarction by gated myocardial perfusion imaging

J. Wang^{1,2}, Y. Wang^{1,2}; ¹The Third Affiliated Hospital of Soochow University, Changzhou, CHINA, ²Institute of Clinical Translation of Nuclear Medicine and Molecular Imaging, Soochow University, Changzhou, CHINA.

EP-0440

The Characteristics of Perfusion in Cardiac SPECT/CT of Suspected INOCA and Obstructive Coronary Artery Disease Patients.

M. Kalnina^{1,2}, B. Vitola^{3,4}, J. Kedrova¹, I. Mintale^{3,5}, A. Erglis^{3,2}; ¹Department of Radiology, Pauls Stradins Clinical University Hospital, Riga, LATVIA, ²Faculty of Medicine, University of Latvia, Riga, LATVIA, ³Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, Riga, LATVIA, ⁴Faculty of Medicine, Riga Stradins University, Riga, LATVIA, ⁵University of Latvia, Faculty of Medicine, Riga, LATVIA.

EP-0441

Comparison of Ejection Fraction Measurements with Novel Multi-pinhole Collimator on Triple-Nal-Detector SPECT and Conventional Dual-Nal-Detector Parallel-hole Collimator Technique

Á. Krizsán¹, K. Kukuls¹, L. Balazs², J. Kiss³, M. Alamin¹, V. Linczerne Bencze¹, S. Barna¹, I. Garai¹, J. Mester⁴, A. Forgacs¹; ¹ScanoMed Nuclear Medicine Centers, Debrecen, HUNGARY, ²Mediso Ltd., Budapest, HUNGARY, ³Medical Imaging Clinic Radiology, Clinical Center, University of Debrecen, Debrecen, HUNGARY, ⁴Universitätsklinikum Hamburg-Eppendorf, Hamburg, GERMANY.

EP-0442

Prognostic Value of Myocardial Blood Flow and Coronary Flow Reserve on Dynamic Myocardial SPECT

M. Havel, M. Kaminek, A. Klegova, L. Quinn, L. Henzlova, P. Koranda, V. Icova, G. Havlova; Department of Nuclear Medicine, University Hospital and Faculty of Medicine and Dentistry Palacký University, Olomouc, CZECH REPUBLIC.

EP-0443

Role of Myocardial Scintigraphy in Evaluating Patients in the Emergency Department

I. Gotuzzo¹, P. Ferro¹, R. Boni¹, P. Vai¹, R. H. J. A. Slart², P. A. Erba³; ¹Nuclear Medicine Department ASST Ospedale Papa Giovanni XXIII, Bergamo, ITALY, ²Medical Imaging Center, University Medical Center Groningen, Groningen, NETHERLANDS, ³Department of Medicine and Surgery, University of Milan Bicocca and Nuclear Medicine Department ASST Ospedale Papa Giovanni XXIII Bergamo, Bergamo, ITALY.

EP-0444

myocardial injury Assessment of SPECT MPI in fulminant and suspected myocarditis compared with CMR

J. Cui, S. Wang, Y. Ge; Henan Provincial People's Hospital Heart Center, Zhengzhou, CHINA.

EP-0445

Psychology of attendants/caregivers during the myocardial perfusion imaging of patients

C. Sioka, A. Bechlioulis, P. Giantsouli, Z. Panagiotou, S. Alexiou, P. Kekiopoulos, A. Kekiopoulou, A. Papadopoulos, L. Astrakas, P. Zotou, J. Zika, A. Arseniou, K. Pappas, C. Katsouras, P. Petrikis; University Hospital of Ioannina, Ioannina, GREECE.

EP-0446

The effect of Attenuation correction on myocardial blood flow and reserve measured by dynamic SPECT

A. Mochula, A. Maltseva, A. Cygikalo, O. Mochula, K. Zavadovsky;
Cardiology Research Institute, Tomsk NPMC,
Tomsk, RUSSIAN FEDERATION.

EP-0447

Transient ischemic dilatation and heart rate at stress and rest: Searching for a threshold of significance in patients with normal perfusion.

A. Alomar, A. Camarero, I. Blanco, N. Rudic, I. Saura, J. Cruz, A. Barrera, M. Ribelles, E. Goñi;
Hospital Universitario de Navarra (HUN), Pamplona, SPAIN.

EP-0448

The prognostic value of complex CMR and dynamic SPECT assessment in patient with acute myocardial infarction

A. Mochula, O. Mochula, E. Nalesnik, A. Maltseva, A. Sulejmanova, V. Ryabov, K. Zavadovsky;
Cardiology Research Institute, Tomsk NPMC,
Tomsk, RUSSIAN FEDERATION.

EP-0449

Attenuation correction in SPECT-Myocardial perfusion imaging: It can be corrected, but is it really useful?

S. Abhilash, S. Jeevan, P. Pradeep, S. Sarath, L. N. Manishi;
All India Institute of Medical Sciences, Rishikesh, INDIA.

EP-26

e-Poster Area

**B: Imaging Clinical Studies -> B4
Cardiovascular Imaging Clinical Study ->
B42 Metabolism and Innervation**

EP-0450

Automated absolute quantitation of cardiac sympathetic activity using convolutional neural network and 123I-MIBG SPECT/CT

S. Saito¹, K. Nakajima², L. Edenbrandt^{3,4}, M. Larsson⁵, O. Enqvist⁵, J. Ulén⁵, S. Kinuya¹;
¹Department of Nuclear Medicine, Kanazawa University, Kanazawa, JAPAN, ²Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa, JAPAN, ³Sahlgrenska University Hospital, Gothenburg, SWEDEN, ⁴University of Gothenburg, Gothenburg, SWEDEN, ⁵Eigenvision, Malmö, SWEDEN.

EP-0451

Long-term cardiac risk in recovered Covid-19 patients evaluated by 123I-mIBG

A. Liebich¹, G. Sheikh², B. Nittbaur¹, R. A. Bundschuh¹, M. Kircher¹, A. Dierks¹, P. Raake³, M. Rieger³, T. Higuchi⁴, C. Lapa¹, C. H. Pfof¹;
¹Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY, ²Department of Nuclear Medicine, LMU Munich, Munich, GERMANY, ³Cardiology, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY, ⁴Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, GERMANY.

EP-0452

The characteristic myocardial accumulation pattern in oncologic FDGPET/CT under long-term fasting is likely indicative of ischemic lesions

Y. Yashima¹, K. Takanam², K. Kiso², A. Masuda², M. Saito², Y. Toyama², Y. Maekawa², K. Takase², Y. Taniyama¹, T. Kamei¹;
¹Department of Surgery, Tohoku University Hospital, 1-1, Seiryō-cho, Aoba-Ku, Sendai, Miyagi, JAPAN, ²Department of Diagnostic Radiology, Tohoku University Hospital, 1-1, Seiryō-cho, Aoba-Ku, Sendai, Miyagi, JAPAN.

EP-0453

Combined Assessment of PET and CMR for Decision Making in patients with Coronary Artery Disease

X. Han, L. Wang, S. Song, W. Fang;
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CHINA.

EP-0454

Comparing the heart-to-mediastinum ratio of 123I-mIBG myocardial scintigraphy between a 2D image and a pseudo planar image converted from a 3D image acquired with a conventional and a ring CZT gamma camera

J. Hagerman¹, D. Minarik², R. Smith^{3,4}, E. Stormrud^{3,4}, S. Hall^{3,4}, A. Nahimi^{3,4}, O. Hansson^{3,4}, F. Hedeer^{1,5};
¹Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund/Malmö, SWEDEN, ²Radiation Physics, Skåne University Hospital, Lund/Malmö, SWEDEN, ³Clinical Memory Research Unit, Lund University, Malmö, SWEDEN, ⁴Memory Clinic, Skåne University Hospital, Malmö, SWEDEN, ⁵Clinical Physiology and Nuclear Medicine, Department of Clinical Sciences, Lund University, Lund, SWEDEN.

EP-0455

Prognostic Role of 123I-Mibg Cardiac Scintigraphy in Patients With Cardiac Transthyretin Amyloidosis (Attr)

F. Sebastián Palacín, B. Pérez López, R. Zambrano Infantino, M. García Aragón, N. Álvarez Mena, M. Alonso Rodríguez, J. Gómez Hidalgo, C. Gamazo Laherrán, R. Ruano Pérez;
Hospital Clínico Universitario Valladolid, Valladolid, SPAIN.

EP-27

e-Poster Area

**B: Imaging Clinical Studies -> B4
Cardiovascular Imaging Clinical Study ->
B43 Heart Failure (including Sarcoidosis and Amyloidosis)**

EP-0456

The proportion of hibernating myocardium in total perfusion defect predicts the reversal of ventricular remodeling and clinical outcomes in patients with HFrEF after CABG

Y. Lu, X. Zhang;
Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA.

EP-0457

Dynamic SPECT in heart failure with preserved ejection fraction: tips and tricks

K. Kopeva, A. Maltseva, A. Mochula, V. Shipulin, A. Gusakova, E. Grakova, K. Zavadovsky;
Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.

EP-0458

Left ventricle myocardial remodeling and coronary flow reserve in heart failure patients with non-obstructive coronary artery disease

K. Kopeva, A. Maltseva, A. Smogon, A. Mochula, V. Shipulin, K. Zavadovsky;
Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.

EP-0459

Diagnostic Value of Semi-Quantitative Parameters Obtained from [99mTc]Tc-PYP Bone Scintigraphy and SPECT/CT in Cardiac Amyloidosis

K. Kucuker, A. Aksu, B. Turgut;
Izmir Katip Celebi University, Atatürk Training and Research Hospital, Nuclear Medicine Department, Izmir, TÜRKIYE.

EP-0460

Prognostic value of right ventricular involvement in Transthyretin Cardiac amyloidosis: a quantitative 99mTc-DPD SPECT/CT study

M. Zhao¹, R. Calabretta², P. Binder², J. Yu², Z. Jiang², M. Hacker², X. Li²;
¹The Thrid Xiangya Hospital of Central South University, Changsha, CHINA, ²Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

EP-0461

Evaluation of left ventricular contractile function in patients with large perfusion defects: is gated MPI applicable?

V. Shipulin, S. Andreev, T. Shelkovnikova, V. M. Shipulin, A. Maslova, K. Zavadovsky;
Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.

EP-0462

Prediction value of left ventricular mechanical dyssynchrony indicators associated with super response to cardiac resynchronization therapy

T. Atabekov, A. Mishkina, R. Batalov, S. Sazonova, S. Krivolapov, V. Saushkin, M. Khlynin, Y. Varlamova, K. Zavadovsky, S. Popov;
Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.

EP-0463

Potential utility of SPECT/CT with 99mTc-Tektrotyd for imaging of post myocardial infarction inflammation

J. Ilyushenkova, S. Sazonova, A. Syrkina, A. Trusov, O. Mochula, A. Mishkina, V. Ryabov;
RI Cardiology, Tomsk, RUSSIAN FEDERATION.

EP-0464

99mTc-PYP Quantification Through SPECT/CT-Based Parameters in the Assessment of Cardiac Transthyretin Amyloidosis: Feasibility and Correlation with Semiquantitative Planar Indices

A. Lazar¹, M. Mutuleanu^{1,2}, A. Jercan³, S. Badelita³, D. Coriu^{3,2}, M. Gherghel^{1,2};
¹Institute of Oncology "Professor Doctor Alexandru Trestioreanu", Bucharest, ROMANIA, ²University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA, ³Fundeni Clinical Institute, Bucharest, ROMANIA.

EP-0465

Utility of SPECT/CT in 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis

B. Bardessi, P. Canales, J. Quintana, I. Díaz, C. Waeger, F. Aguilera, A. Hiplan, D. Jordan, N. Covarrubias, R. Jaimovich, K. Colorado;
Pontificia Universidad Católica de Chile, Santiago de Chile, CHILE.

EP-0466

Potential of glucose metabolic rate obtained from dynamic 18F-FDG PET/CT scan in differentiating cardiac sarcoidosis from physiological accumulation

M. Nagao¹, Y. Shirai¹, A. Yamamoto¹, K. Kaneko¹, A. Sakai¹, N. Komura², S. Sakai¹;
¹Tokyo Women's Medical University, Tokyo, JAPAN, ²Siemens Health Care, Tokyo, JAPAN.

EP-0467

Relationship between the distribution of diphosphonate uptake and changes in cardiac MRI in patients with transthyretin cardiac amyloidosis

L. Santamaría-Chico, K. Velásquez-Díaz, M. Mitjavila-Casanovas, P. Soares-Meneses, I. Obedkova, M. Grajeda-Gallardo, I. Garrido-Solesio, M. Pastrana-Ledesma, F. de Haro-del Moral;
Hospital Universitario Puerta de Hierro, Madrid, SPAIN.

EP-0468

Using reprojected planar images from 99mTc-labelled diphosphonate scintigraphy for visual scoring of transthyretin amyloidosis: validating a novel ring-configured cadmium zinc telluride gamma camera

I. Ceric Andelius^{1,2}, D. Minarik^{1,2}, R. Fridriksdóttir³, F. Hedeer^{3,4}, A. Stenvall^{1,4}, E. Trägårdh^{2,3}, J. Oddstig^{1,2};
¹Radiation Physics, Skåne University Hospital, Lund/Malmö, SWEDEN, ²Department of Translational Medicine and Wallenberg Centre of Molecular Medicine, Lund University, Malmö, SWEDEN, ³Department of Clinical Physiology and Nuclear Medicine, Lund/Malmö, SWEDEN, ⁴Department of Clinical Sciences, Lund University, Lund, SWEDEN.

EP-0469

Different extracardiac uptake, evidenced on 99mTc-HDP scintigraphy, in various types of cardiac amyloidosis

M. Starace¹, F. Cappelli², F. Peretto³, E. Costanzo⁴, R. Sciarra⁵, V. Berti¹;

¹Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy, florence, ITALY,

²Tuscan Regional Amyloid Centre, Careggi University Hospital, Florence, Italy, florence, ITALY, ³Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy, florence, ITALY, ⁴Department of Nuclear Medicine, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy, florence, ITALY,

⁵Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy, florence, ITALY.

EP-0470

The Relationship of Tc-99m Pyp Scintigraphy Parameters with Prognosis and Life Expectation in Cardiac Amyloidosis

Ü. Aksu¹, E. Akgün¹, S. G. Yaran¹, M. Ayer², A. Güler³, G. B. Güler³, A. Türkvatan⁴, M. Kaya¹, B. E. Akkas¹;

¹Başakşehir Çam and Sakura Hospital Clinic of Nuclear Medicine, Istanbul, TÜRKIYE, ²Başakşehir Çam and Sakura Hospital Clinic of Hematology, Istanbul, TÜRKIYE, ³Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Hospital Clinic of Cardiology, Istanbul, TÜRKIYE, ⁴Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Hospital Clinic of Radiology, Istanbul, TÜRKIYE.

EP-0471

Is there any relation between "Red flags" for cardiac amyloidosis, extracardiac uptake and the type of cardiac amyloidosis?

A. Roteta Unceta Barrenechea^{1,2}, F. Asensio Pérez³, G. Martínez Arias¹, D. Nogueira Souto¹, M. Parra Rina¹, T. Escalera Temprado¹, Y. Saker Diffalah¹, M. Delgado Castro¹, G. Guzmán Prudencio¹, L. Tardin Cardoso¹, P. Razola Alba¹, A. Andrés Gracia^{1,2};

¹UCMHMNA - Clinic Hospital "Lozano Blesa", Zaragoza, SPAIN, ²IIS-Aragon, Zaragoza, SPAIN, ³Universidad de Zaragoza, Zaragoza, SPAIN.

EP-0472

Is T-DM1 cardiotoxicity close monitoring relevant in palliative breast cancer patients? A single center experience using equilibrium radionuclide ventriculography (ERNV)

D. Silva¹, H. Duarte, P. Leite-Silva, J. F. Ferro, I. Próspero, D. Barbosa, S. F. Castro, G. Ferreira, J. P. Teixeira, I. L. Sampaio; Instituto Português de Oncologia do Porto Francisco Gentil, Porto, PORTUGAL.

EP-0473

Diagnostic Performance of Cardiac Magnetic Resonance and Cardiac Scintigraphy in patients with clinical suspicion of Transthyretin Cardiac Amyloidosis

M. Pudiš¹, P. C. Notta¹, L. Gràcia-Sánchez¹, I. E. Sánchez-Rodríguez¹, E. Claver-Garrido², C. Diez-López², J. González-Costello², V. Carrero-Vasquez¹, C. Martínez-Ramos¹, S. Bondía-Bescós¹, B. Hervás-Sanz¹, J. Díaz-Moreno¹, M. Cortés-Romera¹;

¹Nuclear Medicine - PET (IDI), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN, ²Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN.

EP-0474

Usefulness of semi-quantitative analysis in cardiac amyloidosis.

J. Venero Chaparro¹, M. Gallego Márquez, M. Sánchez Torrente, F. Garí Martínez, D. Guirado Llorente, M. Martínez-Valle Torres;

Hospital Clínico San Cecilio, Granada, SPAIN.

EP-0475

Ventricular Function Patterns In Ttr Cardiac Amyloidosis: Can We Select Patients For Resynchronization Therapies Using 99mTc-DPD Gspect?

F. Sebastián Palacid¹, B. Pérez López, M. García Aragón, R. Zambrano Infantino, N. Álvarez Mena, M. Alonso Rodríguez, J. Gómez Hidalgo, C. Gamazo Laherrán, R. Ruano Pérez;

Hospital Clínico Universitario Valladolid, Valladolid, SPAIN.

EP-28

e-Poster Area

B: Imaging Clinical Studies -> B4 Cardiovascular Imaging Clinical Study -> B44 Other Cardiovascular Imaging (including Plaque)

EP-0476

The Utility of Right Ventricular Myocardial Strain Ratio Estimated by Ammonia Positron Emission Tomography to Stratify the Risk for Coronary Artery Disease

A. Yamamoto¹, M. Nagao¹, M. Kawakubo², R. Nakao¹, Y. Matsuo¹, A. Sakai¹, M. Momose¹, K. Kaneko¹, K. Fukushima³, J. Yamaguchi¹, S. Sakai¹;

¹Tokyo Women's Medical University Hospital, Tokyo, JAPAN, ²Kyushu University, Fukuoka, JAPAN, ³Fukushima Medical University, Fukushima, JAPAN.

EP-0477

The relationships between quantitative CCTA and dynamic CZT SPECT in patients with non-obstructive coronary artery disease

K. Zavadovsky¹, A. Maltseva¹, R. Dorzhieva², A. Mochula¹, K. Kopeva¹, E. Grakova¹;

¹Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION, ²Siberian State Medical University of the Ministry of Health of the Russian Federation, Tomsk, RUSSIAN FEDERATION.

EP-0478

Prognostic value of coronary artery calcifications (CAC) applying a dedicated ECG-gated CT protocol using a hybrid gamma camera in combination with cardiac SPECT performed with a CZT scanner in patients during primary diagnosis of ischemic heart disease.

M. Chojnowska¹, A. Giżewska, A. Mazurek, M. Dziuk; Military Institute of Medicine - National Research Institute, Warsaw, POLAND.

EP-0479

Myocardial Extracellular Volume Fraction from Late Iodine Enhancement for Risk Stratification in Non-ischemic Heart Failure

J. Deng¹, D. Li^{1*};

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CHINA.

EP-0480

First-pass determination of thoracic aortic blood flow rate

V. Saushkin¹, Y. Varlamova, N. Ryumshina, A. Vrublevsky, D. Panfilov, B. Kozlov, S. Sazonova; Cardiology Research Institute, Tomsk NRM, Tomsk, RUSSIAN FEDERATION.

EP-0481

Unusual discovery of a lipomatous hypertrophy of interatrial septum causing hot spot on 18 fluorodeoxyglucose positron emission tomography: a case report

T. Ben Ghachem¹, M. Somai, I. Yeddes, I. Slim, A. Mhiri; Salah Azaiez Institute, Tunis, TUNISIA.

EP-29

e-Poster Area

B: Imaging Clinical Studies -> B5 Neurological Imaging Clinical Study -> B51 Neurodegeneration

EP-0482

Neuroimagen. Enfoque multimodal para la evaluación de pacientes con enfermedad de Alzheimer leve y terapia neuroprotectora.

Y. Peña Quián¹, L. Pérez², J. Batista¹, L. Torres¹, L. Rodríguez², T. Rodríguez²;

¹Centro de Isotopos, La Habana, CUBA, ²Center for Molecular Immunology, La Habana, CUBA, ³Hermanos Ameijeiras Hospital, La Habana, CUBA.

EP-30

e-Poster Area

B: Imaging Clinical Studies -> B6 Endocrinological Imaging Clinical Study -> B61 Endocrinology (including Thyroid Benign)

EP-0483

Screening of risk factors influencing the responsiveness of lung metastatic foci of differentiated thyroid cancer under 131I radiotherapies

W. Muyu¹, X. Liu², C. Liu³, S. Qin⁴, X. Lin¹, W. Shi⁵, Q. Ding³, X. Zhang³, P. Li¹;

¹Department of Nuclear Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA, ²Department of General Surgery, Xinqiao Hospital, Army Medical University, Chongqing, CHINA, ³School of Mathematical Sciences, Shanghai Jiao Tong University, Shanghai, CHINA, ⁴Department of Nuclear Medicine, Shanghai Tenth People's Hospital,

Tongji University School of Medicine University, Shanghai, CHINA, ⁵Department of Nuclear Medicine, Tianjin Medical University General Hospital, Shanghai, CHINA.

EP-0484

An exploratory study on pathologic molecular characteristics of sestamibi single positron emission computed tomography/computed tomography in predicting primary hyperparathyroidism

J. Yang¹, X. Su, J. Zhang, W. Weng, P. Zhou; the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

EP-0485

Graves' disease: do TRAb measurement help predicting thyroid radioiodine uptake?

I. Casimiro¹, G. Costa, R. Silva; Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL.

EP-0486

Does the hypothalamus-pituitary-adrenal axis play a role in the difference in treatment response to GLP-1 receptor agonists in type 2 diabetes?

S. Tokgöz¹, T. J. P. Jansen¹, R. Meijer², C. Frielink¹, C. J. Tack², B. E. de Galan^{2,3}, M. Gotthardt¹, M. Boss¹;

¹Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS, ²Department of Internal Medicine, Radboud University Medical Center, Nijmegen, NETHERLANDS, ³Department of Internal Medicine, Maastricht University Medical Center, CARIM School for cardiovascular diseases, Maastricht, NETHERLANDS.

EP-0487

68Ga-NODAGA-exendin4 PET-CT Imaging of Pancreatic Beta Cells: Preliminary Data in Type 1 Diabetic Patients and in Obese People

L. Ruffini¹, M. Scarlattei¹, G. Ladisa¹, S. Migliari¹, G. Baldari¹, V. Spigoni², R. Aldigeri², G. Cinquegrani², A. Dei Cas², R. Bonadonna²;

¹Nuclear Medicine Division, University Hospital of Parma, Parma, ITALY, ²Dept of Medicine & Surgery, University of Parma, Parma, ITALY.

EP-0488

Role of 68Ga DOTANOC PET/CT In Localisation of Culprit Ectopic ACTH Secreting Tumors

R. Kumar¹, S. Sagar, D. Khan, R. Khadgawat; All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0489

Short 4D 18F-Fluorocholine PET/CT for hyperparathyroidism: A new tool for hyper-functional parathyroid finding ?

A. CALLAUD¹, M. Bailly², G. Metrard²; ¹CHR, Orléans, FRANCE, ²CHRU Orléans, Orléans, FRANCE.

EP-0490

Detection of hyperfunctioning parathyroid glands using 18F-choline PET/CT in patients with negative or equivocal results of the complex 99mTcO4/99mTc-MIBI scintigraphy (including SPECT/CT)

P. Koranda¹, L. Quinn¹, M. Jenčo¹, J. Klacánek¹, M. Halenka², M. Mochňáková³, M. Kamínek¹;
¹Dept. of Nuclear Medicine, Univ. Hospital and Palacký University, Olomouc, Olomouc, CZECH REPUBLIC, ²Dept. of Internal Medicine III, Univ. Hospital and Palacký University, Olomouc, Olomouc, CZECH REPUBLIC, ³Dept. of Surgery II, Univ. Hospital and Palacký University, Olomouc, Olomouc, CZECH REPUBLIC.

EP-0491

[¹⁸F]Fluorocholine PET-CT in Preoperative Localization of Hyperfunctioning Parathyroid Glands: Continuing to Strengthen the Evidence

S. Casanueva Eliceiry^{1,2}, N. Sánchez Izquierdo^{2,1}, A. Niñerola-Baizán^{2,1}, M. Manyalich-Blasi^{1,3}, P. Domínguez-Garjito^{1,3}, M. Mora-Porta^{1,3}, F. Hanzu^{1,3}, M. Rodrigo-Calvo^{1,4}, S. Vidal-Sicart^{2,1}, O. Vidal-Pérez^{1,3}, D. Fuster-Pelfort^{2,1};
¹Hospital Clínic Barcelona, Barcelona, SPAIN, ²Instituto de diagnóstico por la imagen CDI, Barcelona, SPAIN, ³Instituto Clínic de Enfermedades Digestivas y Metabólicas (ICMDM), Barcelona, SPAIN, ⁴Centro de Diagnóstico Biomédico (CDB), Barcelona, SPAIN.

EP-0493

Diagnostic and Prognostic Value of [18F]F-DOPA PET/CT for Medullary Thyroid Cancer

S. Li, E. Rainer, S. Rasul, L. Hargitai, P. Riss, C. Scheuba, M. Hacker;
Medical University of Vienna, Vienna, AUSTRIA.

EP-0494

Correlation between SUVmax and analytical values in patients with primary hyperparathyroidism undergoing 18F-choline PET/CT

E. Rodríguez Gallo^{1,2}, C. Wakfie Corieh^{1,2}, A. Fernandez Alfonso^{1,2}, A. Álvarez Vázquez^{1,2}, E. Jodar Gimeno^{1,2}, B. Pérez-Arroyo^{1,2}, J. Martín Gil³, A. Maldonado^{1,2};
¹Hospital Universitario QuironSalud Madrid, Madrid, SPAIN, ²Universidad Europea, Madrid, SPAIN, ³Hospital Quirónsalud San José, Madrid, SPAIN.

EP-0495

Impact of digital [18F] Fluorocholine (FCH) PET/CT reconstruction technique on detection rate, reader confidence and agreement in localisation of parathyroid adenomas in persistent/ recurrent primary hyperparathyroidism

M. Naik, C. Ferguson, S. Lazic, A. Eccles, S. Khan, S. Khan, F. Palazzo, K. Houghton, T. D. Barwick;
Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

EP-0496

Utility of 18F-fluorocholine PET/CT in the management of primary hyperparathyroidism: our experience.

M. Sicilia Pozo¹, V. Poblete García¹, A. Padilla Bermejo¹, C. Lucas Lucas¹, M. Contreras Ameduri¹, L. García Zoghby², M. Cruz Montijano², F. J. Pena Pardo¹, M. P. Talavera Rubio¹, E. Noriega Álvarez¹, A. M. García Vicente², Á. Soriano Castrejón²;
¹Nuclear Medicine Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN, ²Nuclear Medicine Department, University General Hospital of Toledo, Toledo, SPAIN.

EP-0497

Role of 18F-DOPA PET/CT imaging in patients with Hyperinsulinemic Hypoglycemia(HI)

S. Sagar, N. A. Damle, D. Khan, P. Kumar, C. Bal, M. Tripathi, R. Sharma, V. Jain, M. Jana, N. Tandon;
AIIMS, Delhi, INDIA.

EP-0498

Efficacy of F-18 Fluorocholine PET/CT in detection of culprit lesions in normocalcemic & hypercalcemic primary hyperparathyroidism: Does it differ?

R. Wakankar, N. A. Damle, Y. Dharmashaktu, A. Khurana, P. Kumar, C. Bal, M. Tripathi, S. Agarwal, N. Tandon, R. Khadgawat;
AIIMS, New Delhi, INDIA.

EP-0499

Does myocardium and liver fractional uptake of circulating fatty acids change after consuming a meal in people with prediabetes?

J. Fernández Fernández¹, G. Sánchez-Delgado^{2,3,4}, S. Hogan-Lamarre^{4,5}, G. Richard⁴, F. Frisch⁴, S. Phoenix^{4,6}, M. Fortin^{3,4}, L. Bouffard⁴, C. Noll⁴, W. Mampuya⁴, B. Guérin^{4,6}, É. E. Turcotte^{4,6}, J. Hoeks⁷, P. Schrauwen⁷, A. C. Carpentier^{3,4}, D. P. Blondin^{4,8};
¹Department of Nuclear Medicine, Virgen de las Nieves University Hospital, Granada, SPAIN, ²Institute of Nutrition and Food Technology "Jose Mataix" and University Institute of Sports and Health, University of Granada, Granada, SPAIN, ³Department of Medicine, Division of Endocrinology, Université de Sherbrooke, Sherbrooke, QC, CANADA, ⁴Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Sherbrooke, QC, CANADA, ⁵Department of Pharmacology-Physiology, Université de Sherbrooke, Sherbrooke, QC, CANADA, ⁶Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, QC, CANADA, ⁷Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, NETHERLANDS, ⁸Department of Medicine, Division of Neurology, Université de Sherbrooke, Sherbrooke, QC, CANADA.

EP-0500

Incremental value of Tc-99m-sestamibi SPECT/CT in patients with positive planar scintigraphy in the detection of additional lesions in patients with Secondary/Tertiary hyperparathyroidism

R. Goel, N. A. Damle, Y. Dharmashaktu, C. Bal, P. Kumar, A. Kumar, Y. Gupta, R. Aphale, G. Puri, S. Chumber;
All India Institute of Medical Sciences (AIIMS), New Delhi, INDIA.

EP-0501

Predictive value of preoperative 18F-Fluorocholine PET/CT in bone mineral density improvement after parathyroidectomy in primary hyperparathyroidism.

S. Seyedinia¹, S. Mirshahvalad^{2,1}, T. Kiener¹, H. Kässmann¹, M. Beheshti¹, C. Pirich¹;
¹Division of Molecular Imaging & Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, AUSTRIA, ²Joint Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON, CANADA.

EP-0502

18F-Choline PET/CT in the detection of parathyroid adenomas hidden from conventional imaging techniques

E. López Llobet, C. Lancha Hernandez, L. Domínguez Gadea, J. Cordero García, S. Rizkallal Monzon, D. Monachello Araujo, Y. Abadi Sedraoui, L. Giraldo Gonzalez, P. Portilla Merino;
Hospital Universitario La Paz, Madrid, SPAIN.

EP-0503

PET/CT with 18F-choline in the study of primary hyperparathyroidism: evaluation of the technique, and correlation with histopathological and biochemical findings

E. Campaña Díaz, P. García-Talavera San Miguel, J. Alvarez Pérez, F. Gómez-Caminero López, C. Montes Fuentes, A. Peñaherrera Cepeda, J. Badell Martínez, S. Rama Alonso, M. Tamayo Alonso;
Hospital Universitario de Salamanca, Salamanca, SPAIN.

EP-0504

Role of [18F]F-choline PET/TC for presurgical identification of hyperfunctioning parathyroid glands in patients with primary hyperparathyroidism and inconclusive conventional imaging

P. Azpeitia Hernández, O. Ajuria Illarramendi, A. Martínez Lorca, P. Paredes Rodríguez, T. Navarro Martínez, U. Vera Schmülling, M. Gutiérrez Guerrero, M. Orduña Díez;
Hospital Universitario Ramón Y Cajal, Madrid, SPAIN.

EP-0505

Role of 99mTechnetium Sestamibi SPECT/CT in patients with negative planar scintigraphy in lesion localization in patients with hyperparathyroidism

Y. Dharmashaktu, N. A. Damle, R. Goel, C. Bal, P. Kumar, S. Chumber, G. Puri, R. Aphale;
All India Institute of Medical Sciences, Delhi, INDIA.

EP-0506

[18F]fluorocholine positron emission tomography/computed tomography characterization of benign thyroid nodules

K. Bajuk Studen^{1,2}, S. Rep¹, S. Gaberscek^{1,2}, K. Zaletel^{1,2}, E. Skorjanec Armic¹, L. Lezaic^{1,2};
¹University Medical Centre Ljubljana, Ljubljana, SLOVENIA, ²Medical Faculty, University of Ljubljana, Ljubljana, SLOVENIA.

EP-0507

Diagnostic Performance of C-X-C Motif Chemokine Receptor 4-directed PET/CT in Patients with Advanced Adrenocortical Carcinoma

W. Schlötelburg¹, A. Kosmala¹, P. E. Hartrampf¹, S. E. Serfling¹, A. Schirbel¹, M. Fassnacht², A. K. Buck¹, S. Hahner², R. A. Werner^{1,3};
¹Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, ²Division of Endocrinology and Diabetes, Department of Medicine I, University Hospital Würzburg, Würzburg, GERMANY, ³The Russel H Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, UNITED STATES OF AMERICA.

EP-0508

Minimally Invasive Radio-Guided Parathyroidectomy in Patients with Hyperparathyroidism: Experience at Our Center

N. Calviño, D. Villasboas-Roscolesi, M. De Bonilla-Candau, A. Ciscar, A. Martín del Rey, J. Echeverri-Díaz, S. Asadurova, F. Velazquez, R. Bellviure-Meiro, A. García-Burillo;
Hospital Universitario Vall de Hebron, Barcelona, SPAIN.

EP-0509

Diagnostic performance of 18FCH-PET/CT in Primary Hyperparathyroidism: semiquantitative analysis and correlation with biochemical data

C. Ferrari, F. Iuele, M. Frugis, P. Mammucci, C. Palumbo, A. Di Palo, G. Rubini;
Nuclear Medicine Department, University of Bari "Aldo Moro", Bari, Italy, Bari, ITALY.

EP-0510

Usefulness of 18F-Choline PET/CT in localizing hyperfunctioning parathyroid glands with negative 99mTc-MIBI scintigraphy and its correlation with pathological findings

I. Garrido Solesio, K. Velásquez Díaz, P. Meneses Soares, A. Grajeda Gallardo, I. Obedkova, L. Santamaría Chico, M. Mitjavila Casanovas, A. Prieto Soriano;
Hospital Universitario Puerta de Hierro, Madrid, SPAIN.

EP-31

e-Poster Area

B: Imaging Clinical Studies -> B7 Infection and Inflammation -> B71 Bone Infection and Inflammation

EP-0511

The study of non-infectious inflammatory diseases in paediatric patients: morpho-functional methods compared (18FDG-PET and 99mTc-WB Bone Scintigraphy vs STIR-MRI).

A. Monaci¹, A. Perrone², A. Tondo², F. Carra², T. Gian², C. Olianti¹;
¹University of Florence, Firenze, ITALY, ²University Hospital Meyer, Firenze, ITALY.

EP-32

e-Poster Area

B: Imaging Clinical Studies -> B7 Infection and Inflammation -> B72 Vasculitis and Endocarditis

EP-0512

Role of 18 Fluorodeoxyglucose positron emission tomography - computed tomography in the diagnosis of infective endocarditis : A report of 19 cases

O. Ben Elkilani, S. Mensi, G. Baazoug, Z. Missaoui, A. Ezzine, T. Dardouri, R. Sfar, K. Chatti; University Hospital Sahloul, Sousse, TUNISIA.

EP-0513

Takayasu's Disease - A Pathway To Diagnosis: Clinical Case Solved Using 18F-FDG PET/CT

P. Ilieva-Gabarska^{1,2,3}, Z. Dancheva³, R. Pencheva⁴, M. Slavova¹, L. Petrakiev¹, A. Antonov⁵, M. Dyankova^{6,3}, I. Vasilev⁷, T. Baltova⁷, Y. Todorova-Doneva⁸; ¹Nuclear medicine laboratory, Medical center "St. Marina - diagnostics and therapy", Pleven, BULGARIA, ²Department of Radiology and Radiotherapy, Medical university Pleven, Pleven, BULGARIA, ³Department of Imaging diagnostics, Interventional radiology and Radiotherapy, Medical university "Prof. Dr. Paraskev Stoyanov", Varna, BULGARIA, ⁴Rheumatology department, UMHAT "Dr Georgi Stranski", Pleven, BULGARIA, ⁵Department of haematology, University hospital "St. Marina - Pleven", Pleven, BULGARIA, ⁶Department of nuclear medicine and radionuclide therapy, UMHAT "St. Marina", Varna, BULGARIA, ⁷MBAL Avis Medica, Department of Radiology, Pleven, BULGARIA, ⁸ENT department, UMHAT "Dr Georgi Stranski", Pleven, BULGARIA.

EP-0514

Role of FDG PET-CT in Takayasu arteritis

Z. Missaoui, M. Noura, G. Baazoug, O. Ben Elkilani, K. Ayed, S. Raja, K. Chatti; University Hospital Center Sahloul, Sousse, TUNISIA.

EP-33

e-Poster Area

B: Imaging Clinical Studies -> B7 Infection and Inflammation -> B73 Other Infections and Inflammatory Diseases

EP-0515

FDG PET/CT response criteria in assessment of post Anti Koch's Treatment evaluation.

H. Rathore, N. R. Thaker, Bombay Hospital, Mumbai; Bombay Hospital And Medical Research Centre, Mumbai, INDIA.

EP-0516

Osteoarticular Inflammatory Activity Response To Tocilizumab In Patients With Refractory Polymyalgia Rheumatica: Contribution Of Semiquantitative Analysis Of [18F]FDG-PET/CT

I. Martínez-Rodríguez¹, D. Prieto-Peña², Á. Gutiérrez-González³, M. De Arcocha-Torres³, F. J. Gómez-de la Fuente¹, N. Martínez-Amador³, A. Sánchez-Salmón³, J. Jiménez-

Bonilla³, V. Mendi-Barcina³, A. Bota-Bota⁴, M. Pombo-López⁴, M. A. González-Gay², R. Quirce²;

¹Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN, ²Rheumatology Service. Marqués de Valdecilla University Hospital. Genetics and atherosclerosis research group on systemic inflammatory diseases (IDIVAL), Santander, SPAIN, ³Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN, ⁴Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander (España), SPAIN.

EP-0517

Comparative study of body fat distribution in naive people living with HIV (PLHIV) and after 48 weeks of antiretroviral therapies (ART) with Dolutegravir/lamivudine vs TAF/FTC/Bictegravir.

A. Piñeiro, C. Hidalgo Tenorio, E. Triviño Ibáñez, C. Ramos Font, R. Sánchez Sánchez; Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0518

18F-FDG PET/CT Imaging in Infectious Mononucleosis: Mimicking Lymphoma and Clinical Implications

N. Damle, J. Jaleel, S. Jain, A. Rasheed, V. Goenka, K. Gyanraj Sa, A. Khurana; All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0519

Real world comparison of radiopharmaceutical parameters and clinical utility in kit based and in house labelled 99m Tc Ubiquicidin as a infection imaging agent

D. Khan, S. Katala, N. A. Damle, C. Bal, S. Sagar, G. Arora, P. Kumar, M. Ansari, R. Kumar, H. Verma; AIIMS Delhi, Delhi, INDIA.

EP-34

e-Poster Area

B: Imaging Clinical Studies -> B8 Nephro-Urological Imaging Study -> B81 Nephro-Urology

EP-0520

Heterogeneity of PSMA Expression Assessed by 68Ga-PSMA-11 PET/CT in Patients with clear-cell renal cell carcinoma

M. Zhang; Department of Nuclear Medicine, Xijing Hospital, Xi'an, CHINA.

EP-0521

Dynamic characteristics of ureteral cancer with [11C]-choline total-body PET/CT

C. Liu¹, S. Wang², R. Wu³, Q. Xie¹, Y. Yang², Z. Yang¹; ¹Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, CHINA, ²Department of Urology, Peking University Cancer Hospital & Institute, Beijing, CHINA, ³Beijing United Imaging Research Institute of Intelligent Imaging, Beijing, CHINA.

EP-0522

Role of Tc99m SestaMIBI SPECT/CT in characterization of renal lesions - A prospective study

K. Agrawal, R. Emerson P, P. Nayak, S. Purkait, P. S. Patro, G. K. Parida; All India Institute of Medical Sciences (AIIMS), Bhubaneswar, INDIA.

EP-35

e-Poster Area

B: Imaging Clinical Studies -> B81 Nephro-Urology & B101 Other Clinical Studies

EP-0523

Are non-sampling methods useful for assessing GFR in a potential living kidney donor? A comparative study with the 3-sample method

M. A. Hernández Fructuoso, C. G. Franco Monterroso, B. Santos Montero, L. Garcia Lama, L. Rey Sánchez, V. Pascual Pascual, A. Garcia Burillo; Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

EP-0524

Assessing the Reliability of GFR Estimation with Lateral Kidney Centroid Depth of 99mTc-DTPA and 99mTc-MAG3 Renography

K. Thawinprawat; Siriraj Hospital, Bangkok, THAILAND.

EP-0525

Reproducibility of normal Gallbladder Ejection Fraction at 30 min by Biliary Scintigraphy for Diagnosis of Biliary Dyskinesia

M. A. Olarte, D. Cardosa-Cisneros, I. Soldevilla-Gallardo; American British Cowdray Medical Center, Mexico City, MEXICO.

EP-0526

75Se- Taurocholic acid in the study of Chronic Diarrhea. Our Experience

C. Paniagua Correa, L. Castillejos Rodríguez, A. Herrero Muñoz, D. Rodríguez Oviedo, C. Galindo Fernández, B. Manzarbeitia Arroba, M. Alvarez Moreno, A. Ortega Valle, C. Sandoval Moreno, M. De la Rubia Marcos, M. Tagliatori Nogueira, P. García Alonso; Hospital De Getafe, Getafe, SPAIN.

EP-0527

99mTc-DTPA肾脏动态成像评估成人患者双肾功能

X. Yan¹, Y. Ning¹, Y. Chen¹, M. Cai², S. Li³; ¹Shanxi Medical University, Tai Yuan, CHINA, ²Shanxi provincial People's Hospital & Fifth Clinical College of Shanxi Medical University, Tai Yuan, CHINA, ³The first hospital of Shanxi Medical University, Tai Yuan, CHINA.

EP-0528

V/P-SPECT detection of pulmonary thromboembolism in patients with respiratory infections: a diagnostic challenge?

I. C. Ferreira, R. T. Ferreira, J. G. Santos, A. I. Santos; Hospital Garcia de Orta, E.P.E., Almada, PORTUGAL.

EP-0529

Diagnostic Contribution of Volumetric Analysis of Lung Perfusion SPECT/CT in Location of Pulmonary Thromboembolism

N. Alvarez Mena, F. Sebastián Palacid, M. García Aragón, R. Zambrano Infantino, B. Pérez López, R. Ruano Pérez; Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

EP-0530

The prevalence of pulmonary thrombo-embolism in pregnancy guided clinically by maternal tachycardia

A. Alnabulsi¹, A. Ayeñi², S. Morel¹; ¹Division of Nuclear Medicine, Department of Radiation Medicine, University of Cape Town, Cape Town, SOUTH AFRICA, ²Division of Nuclear Medicine, Department of Radiation Medicine, University of Cape Town, Capetown, SOUTH AFRICA.

EP-0531

Are Planar Images In Pulmonary Perfusion Scintigraphy Sufficient For Positive Diagnosis Of Pulmonary Embolism In Pregnant Women?

L. Zaabar^{1,2}, K. Ben Amara³, T. Ben Ghachem^{1,2}, D. Ben Sellem^{1,2}, B. Letaief^{1,2}, A. Mhiri^{1,2}; ¹Salah Azaeiz Institute, Tunis, TUNISIA, ²Faculté de Médecine de Tunis, Tunis, TUNISIA, ³Health Ministry, Tunis, TUNISIA.

EP-0532

Hepatic [18F]FDG uptake in patients with obesity: a study on the effect of NAFLD

U. Ustinau, O. Kulterer, M. Krssak, I. Rausch, F. Kiefer, C. Philippe; Medical University of Vienna, Vienna, AUSTRIA.

EP-0533

Pre-treatment pituitary gland [18F]FDG uptake in oncological patients

C. A. Ruiz-Bedoya^{1,2}, S. F. Barrington^{1,3}, M. Yakubu¹, A. Hammers¹, G. J. R. Cook^{1,3}, M. Subesinghe^{1,3}; ¹King's College London & Guy's and St. Thomas' PET Centre, London, UNITED KINGDOM, ²Department of Imaging Chemistry & Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UNITED KINGDOM, ³Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, London, UNITED KINGDOM.

EP-0534

Relationship between the severity of vesicoureteral reflux and renal scarring in children. About 162 patients.

M. Habbache, Q. Naili, M. Abdi; Nuclear medicine Center or Blida, Algier, ALGERIA.

EP-36

e-Poster Area

C: Therapy Clinical Study -> C1 Oncological Therapy Clinical Study -> C11 Neuroendocrine Therapy

EP-0535

Actinium225 -DOTATATE peptide receptor radionuclide therapy (PRRT) as first line treatment in two cases of bowel Neuroendocrine tumors

K. Kamaleshwaran, E. Ramkumar;
Kovai Medical center and Hospital limited (KMCH), Coimbatore, INDIA.

EP-0536

Discovery of blood transcriptomic markers for response to [177Lu]Lu-DOTATATE in locally advanced or metastatic neuroendocrine neoplasms

S. Bae¹, H. Sung², H. Choi², H. Im³, M. Suh², J. Paeng², G. Cheon², K. Kang²;

¹Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, KOREA, REPUBLIC OF, ²Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF, ³Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, KOREA, REPUBLIC OF.

EP-0537

Long-term effects of peptide receptor radionuclide therapy (PRRT) used as a first-line treatment of GEP-NET - a single centre experience

M. Opalinska, K. Morawiec-Slawek, A. Kurzynska, A. Sowa-Staszczak, A. Hubalewska-Dydejczyk;
Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland, Krakow, POLAND.

EP-0538

Visual and Whole-Body Quantitative Analysis of 68-Ga-DOTATATE PET/CT to Predict Outcomes after 177Lu-DOTATATE

I. Sonni^{1,2}, M. Hotta^{1,3}, P. Thin¹, K. Nguyen¹, L. Gardner¹, L. Ciuca¹, A. Hayrapetian^{1,4}, M. P. Lewis^{1,5}, D. J. Lubin^{1,6}, M. Allen-Auerbach¹;

¹University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, ²Università Magna Graecia, Catanzaro, ITALY, ³National Center for Global Health and Medicine, Tokyo, JAPAN, ⁴University of South Alabama, Mobile, AL, UNITED STATES OF AMERICA, ⁵Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, UNITED STATES OF AMERICA, ⁶SUNY Upstate, Syracuse, NY, UNITED STATES OF AMERICA.

EP-0539

Therapy in Advanced Small Cell Lung Carcinoma - Investigating Outcome, Toxicity Profile and Prognostic Determinants

P. Hartrampf¹, A. Weich², F. Lutz¹, A. K. Buck¹, T. Higuchi¹, S. E. Serfling¹, Y. Zhi³, R. A. Werner¹;

¹Klinik und Poliklinik für Nuklearmedizin, Würzburg, GERMANY, ²Medizinische Klinik und Poliklinik II, Würzburg, GERMANY, ³Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen, Würzburg, GERMANY.

EP-0540

Impact of kidneys absorbed dose assessment during 177Lu-PRRT (peptide receptor radionuclide therapy) on patient management: examples from clinical experience

M. Ferrari, F. Botta, **C. Grana**, D. Alio, A. Barone, G. Castiglione Minischetti, S. Papi, I. Clerici, F. Ceci;
Istituto Europeo di Oncologia, Milano, ITALY.

EP-0541

Factors Predicting Response and Survival in Lutetium-177 DOTATATE Treatment of Neuroendocrine Tumours: Preliminary Results

Z. MAMMADKHANDLI¹, F. SOYLUOGLU¹, B. OZDEMIR GUNAY², C. AYDIN¹, U. KORKMAZ¹;

¹Trakya University, School of Medicine, Department of Nuclear Medicine, Edirne, TÜRKIYE, ²Sultan 1. Murat State Hospital, Clinic of Nuclear Medicine, Edirne, TÜRKIYE.

EP-0542

Impact of the SBVR 177Lu activity quantification method on organ and tumor dosimetry results after PRRT and on patient management

A. Chicheportiche, S. Raskin, Y. Krausz, J. Godefroy, S. Grozinsky-Glasberg, S. Ben-Haim;

Hadassah Ein Kerem Hospital, Jerusalem, ISRAEL.

EP-0543

Neoadjuvant PRRT with 90Y-DOTATOC: preliminary results from a monocentric prospective study

A. Barone¹, F. Mattana², L. L. Travaini², P. Rocca³, M. Colandrea², L. Gilardi², S. Fracassi², S. Papi³, I. Clerici³, M. E. Ferrari⁴, F. Botta⁴, E. Bertani⁵, F. Spada⁶, N. Fazio⁶, F. Ceci², C. M. Grana²;

¹Division of Nuclear Medicine, Istituto Europeo di Oncologia IRCCS, Milan, Italy, Milan, ITALY, ²Division of Nuclear Medicine, Istituto Europeo di Oncologia IRCCS, Milan, ITALY, ³Division of Pharmacy, Istituto Europeo di Oncologia IRCCS, Milan, ITALY, ⁴Medical Physics Unit, Istituto Europeo di Oncologia IRCCS, Milan, ITALY, ⁵Division of Digestive Surgery, Istituto Europeo di Oncologia IRCCS, Milan, ITALY, ⁶Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, Istituto Europeo di Oncologia IRCCS, Milan, ITALY.

EP-0544

Inflammatory markers as prognostic factor inTNE treated with 177Lu-DOTATATE

J. Villa Palacios, E. Triviño-Ibáñez, M. Muros de Fuentes, T. Aroui-Luquin, R. Sanchez-Sanchez;
Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0545

Kidneys functional volumes changes of patients undergoing 177Lu-DOTATATE treatment and the uncertainties measures in kidney dosimetry

J. Khan¹, T. Rydén², J. Svensson³, M. Van Essen⁴, P. Bernhardt⁵;

¹Department of Medical Radiation Sciences, Institute of Clinical Sciences, Gothenburg, SWEDEN, ²Department of Medical Physics and Biomedical Engineering (MFT), Sahlgrenska University Hospital, Gothenburg, SWEDEN, ³Department of Oncology, Institution of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN, ⁴Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, SWEDEN, ⁵Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN.

EP-0546

Evaluation of RadioLigand Therapy response in GEP-NETs: the role of 177Lu-Dotatate imaging

S. Valente¹, F. Linguanti¹, M. E. Abenavoli¹, L. Antonuzzo², V. Briganti³, D. Lavacchi⁴, M. Matteini³, F. Mungai⁵, R. Scigrà⁴, G. Simontacchi⁶, L. Vaggelli³, V. Berti¹;

¹Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134, Florence, ITALY, ²Clinical Oncology Unit,

Careggi University Hospital, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, ITALY, ³Department of Nuclear Medicine, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy, Florence, ITALY, ⁴Clinical Oncology Unit, Careggi University Hospital, Florence, Italy, Florence, ITALY, ⁵Department of Radiology, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134, Florence, Italy, Florence, ITALY, ⁶Radiation Oncology, Azienda Universitaria Ospedaliera Careggi, Florence, ITALY.

EP-0547

Efficacy of [177Lu]Lu-DOTA-TATE in metastatic neuroendocrine neoplasms of different locations: our experience.

M. Pudis¹, J. L. Vercher-Conejero¹, J. J. Martín-Marcuarta¹, A. Teule-Vega², S. Bondia-Bescós¹, B. Hervás-Sanz¹, A. Rodríguez-Gasén¹, J. Diaz-Moreno¹, M. Cortés-Romera¹;

¹Nuclear Medicine - PET (IDI), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN, ²Medical Oncology, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona, SPAIN.

EP-0548

Evaluation of the quality of life of patients with neuroendocrine tumors treated with Lutetium-177-DOTATATE

S. Asadurova, D. Villasboas, J. Hernando, F. Velazquez, R. Bellviure, J. Echeverri-Diaz, N. Calviño, A. García-Burillo;
Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

EP-0549

Radiomics analysis in 177Lu-DOTATATE therapy: Extracting new information from theranostic images

H. Abdollahi¹, X. Hou², J. Beauregard³, C. Uribe¹, A. Rahmim¹;

¹BC Cancer Research Institute, Vancouver, BC, CANADA, ²Department of Radiology, University of British Columbia, Vancouver, BC, CANADA, ³Cancer Research Centre and Department of Radiology and Nuclear Medicine, Université Laval, Quebec City, QC, CANADA.

EP-0550

Assessment of response to therapy and safety of 177Lu-DOTATATE in GEP-NET patients

M. Raddi, F. Di Gennaro, F. De Lauro, V. Porfidia, C. Maisto, G. Ventanieri, S. Melone, P. Gaballo, L. D'Ambrosio, S. Lastoria;

National Cancer Institute IRCCS Pascale, Naples, ITALY.

EP-0551

Evaluation of different infusion protocols and dosimetry assessment in patients undergoing peptide receptor radionuclide therapy with 177Lu-DOTATATE

A. Varallo¹, L. Piscopo¹, V. Gaudieri¹, S. Grasso¹, E. Zampella¹, C. Nappi¹, C. Oliviero², M. Italiano¹, F. Volpe¹, M. Falzarano¹, S. Clemente², A. Cuocolo¹, M. Klain¹;

¹Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, ITALY, ²Unit of Medical Physics and Radioprotection, University of Naples "Federico II", Naples, ITALY.

EP-37

e-Poster Area

**C: Therapy Clinical Study -> C1
Oncological Therapy Clinical Study -> C12
Prostate Cancer Therapy**

EP-0552

TheraP-based Selection Criteria Do Not result in a Survival Benefit When Compared With VISION Trial Criteria in Prostate Cancer Patients Scheduled for PSMA-targeted Radioligand Therapy

K. Michalski¹, A. Kosmala¹, R. A. Werner¹, S. Serfling¹, A. K. Seitz¹, C. Lapa², A. K. Buck¹, P. E. Hartrampf¹;

¹Universitätsklinikum Würzburg, Würzburg, GERMANY, ²Universitätsklinikum Augsburg, Augsburg, GERMANY.

EP-0553

The efficacy of prognostic factors derived from Ga68-PSMA PET-CT images in predicting treatment response and survival in patients with metastatic castration-resistant prostate cancer treated with Lu-177PSMA

M. Ofias¹, D. Has Simsek¹, Y. Sanli¹, S. Kuyumcu¹, E. Isik¹, S. Karadogan¹, M. Basaran², M. Ekenel¹, A. Mudun¹, Z. G. Ozkan¹;

¹Istanbul Faculty Of Medicine Department Of Nuclear Medicine, Istanbul, Türkiye, ²Istanbul University Institute Of Oncology, Department Of Medical Oncology, Istanbul, TÜRKIYE.

EP-0554

Dosimetric evaluation of 177Lu-PSMA-617 therapy: Feasibility of Single Time Point Imaging Protocol

S. Rezaei, E. Gharepapagh;
Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF.

EP-0555

Safety and Efficacy of re-treatment with Lutetium-177 PSMA Beyond Six Cycles in Patients with Castration-Resistant Prostate Cancer

E. Medhurst¹, R. Alipour², T. Akhurst², A. Azad³, J. P. Buteau¹, A. Cardin², B. Emmerson¹, M. B. Haskali⁴, G. Kong², L. Kostos³, P. Jackson¹, K. Raghava², A. Ravi Kumar², J. Saghebi², S. Sandhu³, L. Spain³, B. Tran³, M. S. Hofman¹;

¹Prostate Cancer Theranostics and Imaging Centre of Excellence; Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ²Department of Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ³Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, ⁴Radiopharmaceutical Production and Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA.

EP-0556

Can a cutoff be set for pre-treatment 68Ga-PSMA-11 PET/CT parameters to predict 177Lu-PSMA-I&T response and patient survival?

S. Mirshahvalad^{1,2}, R. Eisazadeh¹, G. Rendl¹, S. Gampenrieder³, G. Schweighofer-Zwinkl¹, H. Griessner⁴, C. Pirich¹, M. Beheshti¹;

¹Division of Molecular Imaging & Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, AUSTRIA, ²Joint Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON, CANADA, ³Division of Molecular Imaging & Theranostics, Department of Oncology, University Hospital, Paracelsus Medical University, Salzburg, AUSTRIA, ⁴Division of Molecular Imaging & Theranostics, Department of Urology, University Hospital, Paracelsus Medical University, Salzburg, AUSTRIA.

EP-0557

Clinical outcomes after treatment following the use of 18F-PSMA PET/CT scans in patients with recurrent prostate cancer

J. Rodriguez-Rubio Corona, F. Cañete Sánchez, Y. Santaella Guardiola, M. Piñero Fernandez-Reyes, C. Quintana Bolaño, M. Pajares Vinardell; Hospital Universitario Puerta del Mar, Cádiz, SPAIN.

EP-0558

The Tyr Phenomena: Hypo-calcemic Response in High Volume Treatment Responders to 177Lutetium PSMA Therapy

M. Swiha^{1,2}, S. Kumar³, M. Crumbaker¹, C. Harvey¹, S. Pathmanandavel¹, N. John^{1,4}, M. M. McDonald^{5,6}, R. Clifton-Bligh^{3,6}, A. Lee^{3,7,8}, P. Bastick⁹, W. Counter¹, A. Nguyen^{1,4}, L. Emmett^{1,4,5};

¹St Vincent's Hospital, Sydney, AUSTRALIA, ²Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, CANADA, ³Royal North Shore Hospital, Sydney, AUSTRALIA, ⁴St Vincent's Clinical School, University of New South Wales, Sydney, AUSTRALIA, ⁵Garvan Institute of Medical Research, Sydney, AUSTRALIA, ⁶School of Medical Science, Faculty of Medicine and Health, University of Sydney, Sydney, AUSTRALIA, ⁷Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, AUSTRALIA, ⁸Genesis Care, Sydney, AUSTRALIA, ⁹St George Hospital, Sydney, AUSTRALIA.

EP-0559

Evaluation of Radium-223 Dichloride in the Treatment of Castration-Resistant Prostate Adenocarcinoma with Symptomatic Bone Metastases

R. Maestre-Cutillas¹, A. M. Sanchez-Tornero², L. Baz-Sanz¹, G. Rubio-Fernández¹, L. Casas-Fernandez², M. Romero-Otero², J. A. Pérez-Iruela¹;

¹Hospital Universitario Ramon y Cajal, Madrid, SPAIN, ²Hospital Clínico Universitario de Valencia, Valencia, SPAIN.

EP-0560

Personalized [177Lu] Lutetium-PSMA therapy for patients with pre-treated castration-resistant prostate cancer: a single institution experience

J. Friedrich¹, W. Thaiss^{1,2,3}, F. Zengerling^{4,3}, V. Hechler⁴, M. Grunert^{5,1}, C. Bolenz^{4,3}, T. Wiegeler⁶, A. J. Beer^{1,3}, V. Prasad^{1,3};

¹Department of Nuclear Medicine, University Hospital Ulm, Ulm, GERMANY, ²Department of Diagnostic and Interventional Radiology, University Hospital Ulm, Ulm, GERMANY, ³Surgical Oncology Ulm, i2SOUL Consortium, Ulm, GERMANY, ⁴Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, GERMANY,

⁵Department of Nuclear Medicine, German Armed Forces Hospital, Ulm, GERMANY, ⁶Department of Radiation Oncology, University Hospital Ulm, Ulm, GERMANY.

EP-0561

No substantial subacute nephrotoxicity in patients with mCRPC treated with Lu-177 PSMA I&T regardless of mean absorbed kidney dose

M. Dotinga^{1,2}, E. C. Owers¹, E. J. Rijkhorst¹, D. M. V. de Vries-Huizing¹;

¹NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS, ²Leiden University Medical Center, Leiden, NETHERLANDS.

EP-0562

Prognostic Role Of 18F-Choline PET/CT Vs Bone Scintigraphy In Prostate Cancer Patients Treated With 223Ra-Dichloride.

L. García Zoghby¹, M. Cruz Montijano¹, A. García Vicente¹, M. Amo Salas², A. Padilla Bermejo³, C. Lucas Lucas³, N. Sicilia Pozo³, M. Contreras Ameduri³, F. Pena Pardo³, E. Noriega Álvarez³, M. Talavera Rubio³, V. Poblete García³, Á. Soriano Castrejón¹;

¹University Hospital of Toledo, Toledo, SPAIN, ²Castilla-La Mancha University, Ciudad Real, SPAIN, ³University General Hospital of Ciudad Real, Ciudad Real, SPAIN.

EP-0563

Evaluation of the clinical significance of parametric data of PSMA uptake in the prostate bed and its contribution to prognosis.

Z. Mammadkhanli¹, B. Ozdemir Gunay², E. Gokdemir¹, F. Ustun¹;

¹Trakya University, Faculty of Medicine, Department of Nuclear Medicine, Edirne, TÜRKIYE, ²Sultan 1. Murat State Hospital, Clinic of Nuclear Medicine, Edirne, TÜRKIYE.

EP-0564

Health-related quality of life in mCRPC patients receiving treatment with [177Lutetium] prostate specific membrane antigen targeted radioligand therapy

A. Karimzadeh¹, B. Feurecker², K. Knorr², M. Heck³, R. Tauber³, C. D'Alessandria², W. Weber², M. Eiber², I. Rauscher²;

¹Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY, ²Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, GERMANY, ³Department of Urology, School of Medicine, Technical University of Munich, Munich, GERMANY.

EP-0565

Safety and Efficacy of [177Lu]Lu-rhPSMA-10.1 Re-Challenge Therapy in Progressive mCRPC after [177Lu]Lu-PSMA I&T Therapy: Preliminary Results

A. Gäble¹, J. Enke¹, A. Amerein¹, O. Vierung¹, A. Rinscheid², M. Kircher¹, G. Wienand¹, C. Pfob¹, C. Lapa¹, A. Dierks¹, R. Bundschuh¹;

¹Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, GERMANY, ²Medical Physics and Radiation Protection, University Hospital Augsburg, Augsburg, GERMANY.

EP-0566

PSMA avidity-based recurrent patterns after 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer

S. Kwon^{1,2}, I. Rauscher¹, C. D'Alessandria¹, M. Eiber¹, W. Weber¹;

¹Rechts der Isar Medical Center, Technical University of Munich, Munich, GERMANY, ²Chonnam National University Medical School and Hwasun Hospital, Jeonnam, KOREA, REPUBLIC OF.

EP-0567

Effect of [223Ra]Radium dichloride on bone health

K. Krieger, A. Afshar-Oromieh, A. Rominger, S. Weidner; Inselspital Bern, Bern, SWITZERLAND.

EP-0568

First preliminary results on safety and efficacy of non carrier added (n.c.a.) 177Lutetium PSMA-I&T radioligand therapy, in a Single Institute

G. Limouris^{1,2}, M. Paphiti³, A. Manetou², A. Zafeirakis²;

¹Nuclear Medicine, Medical School, National and Kapodistrian University of Athens, Athens, GREECE, ²Nucl Med Dept, Army Share Fund Hospital of Athens, Athens, GREECE, ³Cyclotron Section, Pharmazac SA, Athens, GREECE.

EP-0569

Radium-223 dichloride ([223Ra]RaCl2) for metastatic Castration-Resistant Prostate Cancer (mCRPC): results of a real-world experience from a seven-year clinical practice

D. Barbosa, H. Duarte, J. Ferro, I. Próspero, D. Silva, S. Fontão de Castro, G. Ferreira, L. Violante, F. Lopes, I. Lucena Sampaio;

Portuguese Institute of Oncology, Oporto, PORTUGAL.

EP-0570

The Relationship Between F-18 FDG Avidity and Response to Lu-177 PSMA Therapy in Prostate Cancer Metastases

N. Coskun¹, M. Kartal², A. Erdogan², E. Ozdemir¹;

¹Ankara Bilkent City Hospital, Ankara Yildirim Beyazit University, Ankara, TÜRKIYE, ²Ankara Bilkent City Hospital, Ankara, TÜRKIYE.

EP-38

e-Poster Area

**C: Therapy Clinical Study -> C1
Oncological Therapy Clinical Study -> C13
Local Radionuclide Therapy (including Spheres)**

EP-0571

Correlation Of Y90-Absorbed Radiation Dose To Albi Scores In Liver Malignancies: Is It Safe Over 500 Gy Tumor Absorbed Dose With Voxel Based Dosimetric Approach?

E. Akgun;
University of Health Science Türkiye, Basaksehir Cam and Sakura City Hospital, Istanbul, TÜRKIYE.

EP-0572

Differences in PET/MRI and PET/CT post-therapy dosimetry in hepatocellular carcinoma (HCC) treated with yttrium-90 microspheres

K. Knesaurek, A. Abdelrahman, M. Ghesani; Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.

EP-0573

Predicting response in HCC selective internal radiation therapy with Y-90 microspheres using advanced PET/CT based dosimetry; LATAM and USA centers experience

D. Mena¹, I. Hume², R. García Monaco², C. Collaud², O. Peralta², A. Mollerach², P. Rodriguez², V. Jager², I. Arma², C. Cianciarelli², M. Chacon², V. Gonzalez², S. Sunagua², N. Pabstleben², K. Knešaurek³;

¹Nuclear Medicine World, CDMX, MEXICO, ²Hospital Italiano de Buenos Aires, Buenos Aires, ARGENTINA, ³Mount Sinai, NY, NY, UNITED STATES OF AMERICA.

EP-0574

Correlation of 90y Microsphere Dose Planned with Voxel-Based Dosimetry with Actual Absorbed Tumor Dose

A. Dere, E. Akgun, K. Bozkurt, B. Armutlu, B. E. Akkas, M. Kaya;

University of Health Sciences, Basaksehir Cam ve Sakura City Hospital, ISTANBUL, TÜRKIYE.

EP-0575

Development of a Topical Application Device for Non Melanoma Skin Cancer Therapy

M. Buonanno, M. Aurilio, A. Esposito, A. Morisco, R. De Marino, L. D'ambrosio, C. Maisto, V. Porfidia, S. Lastoria; IRCCS TUMORI FONDAZIONE G. PASCALE, Napoli, ITALY.

EP-0576

Is There Any Affect Of Tumor Location On Radioembolisation Treatment Response In Hepatocellular Carcinoma?

E. Akgun;

University of Health Science Türkiye, Basaksehir Cam and Sakura City Hospital, Istanbul, TÜRKIYE.

EP-0577

Factors Affecting Outcome in Hepatocellular Cancer Patients Treated with Selective Intra-arterial Radiomicrosphere Therapy

B. Soydas Turan¹, B. Volkan-Salanci², M. F. Bozkurt², G. Eldem³, E. Karabulut⁴, S. Yalcin⁵, F. Çay³, B. Peynircioğlu³, O. Ugur²;

¹Etilik City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TÜRKIYE, ³Hacettepe University Faculty of Medicine, Department of Interventional Radiology, Ankara, TÜRKIYE, ⁴Hacettepe University Faculty of Medicine, Department of Biostatistics, Ankara, TÜRKIYE, ⁵Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, TÜRKIYE.

EP-0578

A Case of Meningioma Applied Intraarterial Lu-177 DOTATATE

K. Mammadli, B. Karaşah Erkek, M. Parıldar, Ö. Şanlı; Ege University Faculty Of Medicine, Department Of Nuclear Medicine, Bornova, TÜRKIYE.

EP-0579

Hepatic transarterial radioembolization (TARE) with 90Yttrium glass microspheres for treatment of liver tumours: safety and survival outcomes.

A. De Agrela Serrao, A. M. Leiva Montejo, C. Ruiz Corbalan, M. Castellón Sanchez, J. L. Navarro Fernandez, T. E. Rodriguez Locarno, A. C. Hernández Martínez, L. Frutos Esteban, D. R. Cáceres Silva, L. Mohamed Salem, J. F. Contreras Gutierrez; Hospital Clínico Universitario Virgen de Arrixaca, Murcia, SPAIN.

EP-0580

Efficacy and safety of Y-90 radioembolization for colorectal cancer liver metastases.

J. Villa Palacios, E. Triviño-Ibáñez, E. González-Flores, P. Pardo-Moreno, A. Rodríguez-Fernández; Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0581

Factors impacting survival in colorectal liver metastases treated with Y-90 radioembolization.

J. Villa Palacios, E. Triviño-Ibáñez, J. Ciampi-Dopazo, E. González-Flores, A. Rodríguez-Fernández; Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EP-0582

Tumoricidal dosing approach with parenchymal sparing using voxel-based dosimetry in the Y90 glass microspheres treatment of liver lesions

C. Sin, B. E. Akkas, M. Kaya, E. Akgun; University of Health Sciences, Basaksehir Cam ve Sakura City Hospital, ISTANBUL, TÜRKIYE.

EP-0583

PET/CT-based Y-90 microsphere dosimetry to predict contralateral lobe hypertrophy after unilobar radioembolization in treatment-naive hepatocellular carcinoma

Y. Kang, J. Paeng; Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

EP-0584

The Role of Tumor FDG Metabolism and AFP Level in Predicting Treatment Response In HCC Patients Treated with 90Y Microspheres

G. Yilmaz, B. E. Akkas, M. Kaya, E. Akgün, Ö. Vural Topuz; University of Health Sciences Basaksehir Cam and Sakura City Hospital, İstanbul, TÜRKIYE.

EP-0585

Hepatic transarterial radioembolization with three different compounds: are there any survival-related biomarkers?

L. Asensio Valero, H. Rodriguez Parra, J. Orozco Cortes, C. Castillo Arias, L. Blanco Verdejo, A. Sanchez Tornero, M. Redal Peña, R. Díaz Expósito; Hospital Clínico de Valencia, Valencia, SPAIN.

EP-0586

Quantification of 99mTc-MAA for lung shunt estimation before 90Y radioembolization: comparison of three methods

E. Milan, D. Barbisan, G. Zambon, C. La Verde, P. Barzi, M. Sutto, S. Barbiero, F. Nistri, L. Vendramin; Ospedale Cà Foncello ULSS2, Treviso, ITALY.

EP-0587

Dose-response relationship for yttrium-90 resin microspheres in patients with liver metastases from colorectal carcinoma.

L. Sancho Rodriguez¹, C. Carballo Menayo², J. González-Martín², J. Bastidas Tamayo³, E. Guillén Valderrama¹, M. Rodríguez-Fraile³; ¹CLINICA UNIVERSIDAD DE NAVARRA, MADRID, SPAIN, ²Complejo Hospitalario Universitario Insular Materno Infantil de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, SPAIN, ³CLINICA UNIVERSIDAD DE NAVARRA, PAMPLONA, SPAIN.

EP-0588

Assessment of Similarity Between the Distributions of Tc-99m MAA Particles and Y-90 Resin Microspheres in Patients Receiving Transarterial Radioembolization for Liver Tumors

N. Coskun¹, A. Erdogan², M. Kartal², E. Ozdemir¹; ¹Ankara Bilkent City Hospital, Ankara Yildirim Beyazit University, Ankara, TÜRKIYE, ²Ankara Bilkent City Hospital, Ankara, TÜRKIYE.

EP-39

e-Poster Area

**C: Therapy Clinical Study -> C1
Oncological Therapy Clinical Study -> C14
Thyroid Therapy**

EP-0589

Association between successful adjuvant therapy and quantitative evaluation of radioactive iodine accumulation in the thyroid bed in patients with differentiated thyroid cancer

Y. Iizuka^{1,2}, T. Katagiri¹, R. Nakashima¹, M. Inoue¹, K. Nakamura¹, T. Mizowaki¹; ¹Kyoto University, Kyoto, JAPAN, ²Shizuoka City Shizuoka Hospital, Shizoka, JAPAN.

EP-0590

H. Wang, R. Tian; West China Hospital, Sichuan University, Chengdu, CHINA.

EP-0591

Follow-up Findings in the Group of Patients with Tall Cell Papillary Thyroid Cancer

B. Karasah Erkek, H. Sarıyıldız Gümüşgöz, R. Halit Tokaç, B. Sankaya, Y. Ertan, A. Akgün; Ege University, Izmir, TÜRKIYE.

EP-0592

Effectiveness of Empirical High-Dose I-131 Therapy in Patients with Differential Thyroid Cancer with Biochemical Incomplete Response

B. Kocabeyoglu¹, M. Guven¹, G. Kavukcu², A. Akgun¹; ¹Department of Nuclear Medicine, Ege University, Izmir, TÜRKIYE, ²Department of Radiology, Ege University, Izmir, TÜRKIYE.

EP-0593

The evaluation of the value of human recombinant thyrotropin administration for the patients with differentiated thyroid cancer during thyroid hormone withdrawal preparation for high dose radioiodine treatment.

J. Cha, W. Kang¹; Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, Seoul, KOREA, REPUBLIC OF.

EP-0594

Effectiveness of Iodine-131 therapy in patients with hyperthyroidism: The experience in the Nuclear Medicine Department of "Saints Anargyri" Cancer Hospital

S. Saranti, C. Altani, T. Karianos, K. Kouvelis, M. Bella, E. Taktikou; "Agiou Anargyroi" Cancer Hospital, Athens, GREECE.

EP-0595

Prognosis of Differentiated Thyroid Cancer after Reoperation

J. Cha, W. Kang, H. Cho; Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, Seoul, KOREA, REPUBLIC OF.

EP-0596

Aggressiveness and efficacy of 131I therapy in papillary thyroid cancer with peripheral nerve invasion: a propensity score matching study

X. Xiong; Zhujiang Hospital, Southern Medical University, Guangzhou, CHINA.

EP-0597

Quantitative analysis of residual thyroid gland radioactive counts and peripheral lymphocyte subsets before and after first radioactive iodine therapy in papillary thyroid carcinoma with Braf mutation

J. Zhang, H. Liu; First Hospital of Shanxi Medical University, Taiyuan, CHINA.

EP-0598

Development and validation of a lung metastasis-predicting Nomogram for intermediate- to high-risk differentiated thyroid carcinoma patients

F. Yu, J. Wang, W. Yang, Z. Yang, W. Ma; Xijing Hospital, Fourth Military Medical University, Xi'an, CHINA.

EP-0599

Second Neoplasms in Patients with Differentiated Thyroid Carcinomas (CDT) Treated With 131I (RAIT).

A. Peña, I. Vinagre Perez, M. Astudillo Sarmiento, R. Nuñez Muñoz, Y. Carreres Ortega, M. Muñoz del Diego, T. Ruiz Juan, S. Perez Fernandez, E. Rodeño Ortiz de Zarate; Hospital Universitario de Cruces, Barakaldo, SPAIN.

EP-0600

Radioiodine Avidity and Prognosis of Diffuse Sclerosing Subtype of Papillary Thyroid Cancer

C. Turkan¹, G. Güler², M. Tuncel¹; ¹Hacettepe University Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Hacettepe University Department of Pathology, Ankara, TÜRKIYE.

EP-0601

Analysis of hematological complications in patients with differentiated thyroid cancer

A. Savchenko; V. N. Karazin Kharkiv National University, Kharkiv, UKRAINE.

EP-0602

Comparison of Malignities Accompanying Thyroid Cancer According to RAI Treatment

D. Yüksel, M. Yücel, O. Yaylalı, T. Şengöz, A. Gültekin, F. S. Şimşek; Pamukkale Üniversitesi Tıp Fakültesi, Denizli, TÜRKIYE.

EP-0603

Prognostic Associations and Oncological Outcomes Regarding Intermediate Risk Differentiated Thyroid Cancer in Latin-American Population: A 13 Years Follow Up Retrospective Cohort

S. Gonzalez Rueda¹, A. Calderon Avila², J. Vargas Ahumada¹, P. Casanova Triviño¹, F. Garcia Perez¹, E. Gomez Argumosa¹; ¹Instituto Nacional de Cancerología, Tlalpan, Ciudad de México, MEXICO, ²Centro Medico Nacional S. XXI, Cuahutemoc, Ciudad de México, MEXICO.

EP-0604

Evaluation of the efficacy of treating Graves Disease with low doses of 131-iodine compared to high doses

B. Manzarbeitia Arroba, G. Guijarro de Armas, D. Rodriguez Oviedo, M. Alvarez Moreno, A. Ortega Valle, L. Castillejos Rodriguez, P. Garcia Alonso, C. Sandoval Moreno; Hospital Universitario de Getafe, Getafe, SPAIN.

EP-0605

Evaluation of the efficacy of treating Graves Disease with fixed doses of 131-iodine compared to calculated doses

B. Manzarbeitia Arroba, G. Guijarro de Armas, M. Alvarez Moreno, D. Rodriguez Oviedo, M. de la Rubia Marcos, A. Herrero Muñoz, C. Paniagua Correa, P. Garcia Alonso, C. Sandoval Moreno; Hospital Universitario de Getafe, Getafe, SPAIN.

EP-0606

Efficacy of empirical radioiodine therapy in patients with differentiated thyroid cancer and elevated serum thyroglobulin without evidence of structural disease

L. Piscopo¹, E. Zampella¹, C. Nappi¹, F. Volpe¹, V. Gaudieri¹, D. Bianco², F. Volpicelli¹, M. Falzarano¹, L. Pace³, A. Cuocolo¹, M. Klain¹; ¹Department of Advanced Biomedical Sciences, University Federico II, Napoli, ITALY, ²CIRA-Centro Italiano Ricerche Aerospaziali, Capua (CE), ITALY, ³Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, ITALY.

EP-40

e-Poster Area

**C: Therapy Clinical Study -> C1
Oncological Therapy Clinical Study -> C15
Other Oncological Treatments**

EP-0607

Occurrence of hematotoxic side effects during 90Y-FAPI-46 radioligand therapy (RLT) in patients with advanced metastatic tumor diseases

K. Pabst¹, R. Hamacher², H. Lanza fame³, I. A. Mavroeid², T. Bartel¹, M. Nader¹, S. Bauer², J. T. Siveke^{2,3,4}, M. Weber¹, D. Kersting¹, W. Jentzen¹, M. Ahrens⁵, K. Herrmann¹, W. P. Fendler¹, P. Fragoso-Costa¹;

¹Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, GERMANY, ²Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany, ³Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, GERMANY, ⁴Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, Partner Site Essen) and German Cancer Research Center, DKFZ, Heidelberg, GERMANY, ⁵Medical Clinic II, University Hospital Frankfurt, Frankfurt am Main, Germany, Frankfurt am Main, GERMANY.

EP-0608

Feasibility of high-dose targeted radiation with I131-apamistamab in patients with relapsed/refractory AML: Dosimetry and radiation safety experience from the phase 3 SIERRA trial

N. Pandit-Taskar¹, K. Prasad², L. Chen³, T. Senglaub⁴, M. Zgaljardic⁵, P. Brodin⁶, B. Serencsits⁷;

¹Molecular Imaging and Therapy, Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, ²University of Pennsylvania Health System, Philadelphia, PA, UNITED STATES OF AMERICA, ³Banner MD Anderson Cancer Center, Gilbert, AZ, UNITED STATES OF AMERICA, ⁴Medical College of Wisconsin, Milwaukee, WI, UNITED STATES OF AMERICA, ⁵Weill Cornell Medical Center, New York, NY, UNITED STATES OF AMERICA, ⁶Actinium Pharmaceuticals, Inc., New York, NY, UNITED STATES OF AMERICA, ⁷Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EP-0610

SSTR-directed Peptide Receptor Radionuclide Therapy in recurrent Meningioma

P. Hartrampf¹, M. Müller¹, S. E. Serfling¹, A. K. Buck¹, B. Polat², R. A. Werner¹;

¹Klinik und Poliklinik für Nuklearmedizin, Würzburg, GERMANY, ²Klinik und Poliklinik für Strahlentherapie, Würzburg, GERMANY.

EP-0611

Sequential treatment of High-risk Neuroblastoma combining I-131 MIBG high-dose and Topotecan. First experience

N. Orrego¹, S. Prado-Wohlwend, J. Balaguer-Guill, I. Torres-Espallardo, M. Part-Lopez, C. Guerrero-Calatayud, J. Cañón-Sánchez, S. Montesinos-Gonzalez, P. Bello-Arques; Hospital Universitari i Politècnic La Fe, Valencia, SPAIN.

EP-0612

New development Paradigm for Rare CNS cancers: Real World Data (RWD) Compared to Ongoing Safety and Feasibility Results from a Phase 1/2 Clinical Trial of 186RnL (Rhenium-186 Nanoliposome) (186Re) Obisbameda in Recurrent Glioma: The ReSPECT-GBM Trial

N. LaFrance¹, A. Brenner², J. Michalek², T. Patel³, A. Bao⁴, W. Phillips², M. Hedrick⁵, M. Moore⁵, J. Weinberg⁶, M. Youssef⁷, J. Floyd²;

¹Norman LaFrance, Austin, TX, UNITED STATES OF AMERICA, ²UT Health San Antonio, San Antonio, TX,

UNITED STATES OF AMERICA, ³UT Southwestern Medical Center, Dallas, TX, UNITED STATES OF AMERICA, ⁴Case Western Reserve University, Cleveland, OH, UNITED STATES OF AMERICA, ⁵PLUS Therapeutics, Austin, TX, UNITED STATES OF AMERICA, ⁶MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

EP-0613

Peptide Receptor Radionuclide Therapy In Advanced Refractory Meningiomas: Toxicity And Efficacy In A Long Term Follow Up

S. Severi¹, I. Grassi², A. Bongiovanni², A. Sarnelli², V. Di Iorio², N. Ranallo², F. Matteucci², I. Marini², E. Amadori², I. Azzali², N. Riva², L. Gurrieri², S. Nicolini², P. Caroli², M. Sansovini¹;

¹IRST IRCCS, Meldola, ITALY, ²IRST IRCCS, Forlì-Cesena, ITALY.

EP-0614

64CuCl2treatment: preliminary data on recurrent glioblastoma patients

D. Stanimirovic¹, D. Milakovic¹, J. Mijatovic¹, I. Rakita¹, G. Vuleta¹, M. Basile², S. Valentin²;

¹University Clinical Center of the Republic of Srpska, Banja Luka, BOSNIA AND HERZEGOVINA, ²A.C.O.M.-Advanced Center Oncology Macerata-S.R.L., Montecosaro (MC), ITALY.

EP-0615

Substantiation of an individual therapeutic dose of 153Sm-oxabiphor for the treatment of bone metastases

G. Grushka¹, L. Stadnyk², V. Bobrova²;

¹Kharkiv National Medical University, Kharkiv, UKRAINE, ²Grigorev Institute for Medical Radiology and Oncology, Kharkiv, UKRAINE.

EP-41

e-Poster Area

C: Therapy Clinical Study -> C2 Non-Oncological Treatments -> C21 Non-Oncological Treatments (including Thyroid Benign)

EP-0616

Radiosynoviorthesis of debilitating joints in haemophilia and rheumatoid arthritis : a local South East Asian hospital experience

K. Loke¹, W. Tay¹, L. T. Cheng², C. Ng¹, H. Low¹;

¹Singapore General Hospital, Singapore, SINGAPORE, ²National University Hospital Singapore, Singapore, SINGAPORE.

EP-0617

The Impact Role of High Specific activity of Radioactive Iodine 131I in Hyperthyroidism Response Rate

M. Al Rowaily¹, M. Al-Qahtani²;

¹KFSHRC & Alfaisal University, Riyadh, SAUDI ARABIA, ²KFSHRC, Riyadh, SAUDI ARABIA.

EP-0618

Plasma Volume Deficit estimation using Cr-51 labelled RBC in Acute Pancreatitis Patients

N. Kumar¹, S. Ballal, M. P. Yadav, M. Tripathi, C. Bal; All India Institute of Medical Sciences, New Delhi, India, New Delhi, INDIA.

EP-0619

Urinary Excretion Rate of I-131 During Treatment of Benign Thyroid Disease

U. Beguš¹, P. Tomšič², K. Bajuk Studen², E. Pirnat², S. Gaberšček², K. Zaletež²;

¹Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, SLOVENIA, ²Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA.

EP-0620

Quality of life after radioisotope synoviorthesis in patients with chronic inflammatory diseases refractory to conventional treatments.

J. Venero Chaparro¹, M. Sánchez Torrente, M. Gallego Márquez, F. Garí Martínez, D. Becerra García, M. Martínez-Valle Torres;

Hospital Clínico San Cecilio, Granada, SPAIN.

EP-0621

The most important problems of supervision over a patient qualified for knee synovectomy based on 10 years single-centre experience

M. Włodarczyk¹, Z. Adamczewski;

Nuclear Medicine Department, Central Clinical Hospital, Medical University of Lodz, Lodz, POLAND.

EP-0622

Treatment of Hidradenitis suppurativa (HS) - A pilot study : Can Nuclear Medicine therapy be the answer?

P. Gupta¹, K. K. Verma, R. Kumar;

AIIMS, New Delhi, INDIA.

EP-0623

Percutaneous Microwave thermoablation (PMWT) for dominant benign thyroid nodules(BTN): a two years single centre experience

B. Crisculi¹, C. Manni¹, G. Follacchio¹, F. Salvatori², C. Mincarelli², S. Alborino², F. Capocchetti¹;

¹Nuclear Medicine Unit, Macerata General Hospital, AST Macerata, ITALY, ²Interventional Radiology Unit, Macerata General Hospital, AST Macerata, ITALY.

EP-42

e-Poster Area

D: Technical Studies -> D1 Instrumentation -> D11 SPECT and SPECT/CT

EP-0624

SPECT Imaging Predictors of Social Anxiety Disorder Treatment Response: A New Way Forward

S. Rezaei¹, E. Gharepapagh; Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF.

EP-0625

Feasibility of an 123I-loflupane single photon emission tomography attenuation correction method with a deep convolutional neural network

Y. Sayawaki¹, T. Ueda¹, T. Tomimatsu¹, R. Nagaoka¹, K. Yamasita¹, S. Ito²;

¹Graduate school of Health Sciences, Kumamoto University, 4-24-1 Kuhonji Chuo-ku, Kumamoto-shi, Kumamoto-ken, JAPAN, ²Faculty of Life Sciences, Kumamoto University, 4-24-1 Kuhonji Chuo-ku, Kumamoto-shi, Kumamoto-ken, JAPAN.

EP-0626

Prognostic value of right ventricular dysfunction in chronic heart failure patients

A. Mishkina¹, T. Atabekov, S. Sazonova, S. Popov, K. Zavadovsky;

Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Tomsk, RUSSIAN FEDERATION.

EP-0627

Comparing myocardium perfusion imaging features between 3D and 2D general-purpose SPECT/CT systems

T. Noponen¹, L. Kääriä², R. Hirvilamm², M. Hakulinen³, M. Seppänen²;

¹Department of Clinical Physiology and Nuclear Medicine and Department of Medical Physics, Turku University Hospital, Turku, FINLAND, ²Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, FINLAND, ³Diagnostic Imaging Center, Kuopio University Hospital, Kuopio, FINLAND.

EP-0628

Use of SPECT-CT In The Combined SLNB Technique and Node Labeling with 125I Seeds in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.

M. Pérez Avila¹, M. Caballero Vivanco¹, F. González Asid¹, E. Córdoba Cañete¹, R. Sánchez Sánchez²;

¹Hospital Universitario Virgen de las Nieves, Granada, SPAIN, ²Hospital Universitario Virgen de las Nieves, Maracena, Granada, SPAIN.

EP-0629

PSF correction and Tc-99m quantitative performance of a disruptive CZT multiple-head SPECT-CT

A. Seret¹, C. Bernard²;

¹UNIVERSITY OF LIEGE, Liege, BELGIUM, ²CHU of LIEGE, Liege, BELGIUM.

EP-0630

Energy window narrowing or classical dual-energy window subtraction for scatter correction in a CZT multiple-head SPECT-CT

A. Seret¹, C. Bernard²;

¹UNIVERSITY OF LIEGE, Liege, BELGIUM, ²CHU of LIEGE, Liege, BELGIUM.

EP-0631

Small feature quantification in SPECT/CT - a focus on mandibular condyles

S. De Schepper^{1,2}, O. Lenssen³, G. Gnanasegaran⁴, T. Van den Wyngaert^{1,2}, J. C. Dickson⁵;

¹Department of Nuclear Medicine, Antwerp University Hospital, Edegem, BELGIUM, ²Faculty of Medicine and Health Sciences (MICA—IPPON), University of Antwerp, Wilrijk, BELGIUM, ³Department of Oral and Maxillofacial Surgery, ZNA Middelheim, Antwerp, BELGIUM, ⁴Department of Nuclear Medicine, Royal Free London NHS, London, UNITED KINGDOM, ⁵Institute of Nuclear Medicine, University College of London Hospitals NHS Foundation Trust, London, UNITED KINGDOM.

EP-0632

Reduction of the acquisition time and improvement of the dopaminergic imaging quality with CZT gamma camera. Comparison with conventional gamma cameras.

S. Asadurova, C. Lorenzo-Bosquet, S. Aguade, A. García-Burillo;
Hospital Universitari Vall d'Hebron, Barcelona, SPAIN.

EP-0633

The Art of Juggling: On the Influence of Sphere Positioning on Recovery Coefficients Determined Using an IEC-NEMA Phantom

J. Leube¹, J. Gustafsson², M. Lassmann¹, M. Salas Ramirez², J. Tran-Gia¹;

¹University Hospital Würzburg, Würzburg, GERMANY, ²Lund University, Lund, SWEDEN.

EP-0634

Objective Assessment of Gamma Camera's Intrinsic Resolution

P. Trindev¹, M. Dimcheva²;

¹Retired, 1233 Sofia, BULGARIA, ²Department of Nuclear Medicine, Sofia Cancer Center, Sofia, BULGARIA.

EP-0635

Calibration Factor and Recovery Coefficients for Lu-177 in a ring-shaped CZT gammacamera

A. Garcia, A. Seoane;

Vall d'Hebron Hospital Campus, Barcelona, SPAIN.

EP-0636

Reducing scan time for post-therapy [131I] NaI SPECT/CT scans and [99mTc]Tc-HDP bone scintigraphy SPECT

T. Ball, K. Sabanayagam, H. McMeekin, A. Haroon, M. Vadrucci, J. Buscombe, E. Nowosinska, M. Krishnamurthy; Barts Health NHS Trust, London, UNITED KINGDOM.

EP-43

e-Poster Area

D: Technical Studies -> D1 Instrumentation -> D12 PET/CT

EP-0637

The earlier 18F-FDG and 68Ga-DOTA-FAPI-04 dual-tracer total-body PET/CT scan timing: a feasibility study

Z. Zheng, Y. He, W. Mao, H. Yu, H. Wu, P. Hu, H. Shi; Zhongshan hospital, fudan university, Shanghai, CHINA.

EP-0638

Clinical evaluation of a head motion correction algorithm on PET/CT system

W. Yang¹, F. Kang¹, Z. Xie¹, G. Li¹, K. Guo¹, C. Xi², H. Liu², Y. Li², C. Sun², E. M. Revilla², Y. Zhao², D. Zhang², L. Shi², H. Yi², Y. Zhao², Y. Lu², J. Wang¹;

¹Department of Nuclear Medicine, Xijing hospital, Xi'an, CHINA, ²United Imaging Healthcare, Shanghai, CHINA.

EP-0639

18F-FDG PET/CT for evaluation of metastases in non-small cell lung cancer on the efficacy of immunotherapy

Y. Feng, P. Wang, Y. Chen, W. Dai;

Department of Nuclear Medicine, The First College of Clinical Medical Science, China Three Gorges University, Yichang city, CHINA.

EP-0640

PET imaging and quantification of small animals using a clinical SiPM-based camera

C. Desmots^{1,2}, C. Lasnon^{3,2}, C. Jaudet³, N. Aide²;

¹Caen University Hospital, Caen, FRANCE, ²Normandy University, UNICAEN, INSERM 1086 ANTICIPE, Caen, FRANCE, ³Comprehensive Cancer Centre F. Baclesse, Caen, FRANCE.

EP-0641

Value of 2-[18F]FDG-PET/CT in detecting immune-related adverse events in patients with malignant melanoma or non-small cell lung cancer: a systematic scoping review

S. Nadaraja¹, J. Helsing¹, M. Bezhad¹, L. H. Land², C. H. B. Ruhlmann², O. Gerke^{1,3}, M. G. Hildebrandt^{1,3,4};

¹Department of Nuclear Medicine, Odense University Hospital, Odense C, DENMARK, ²Department of Oncology, Odense University Hospital, Odense C, DENMARK, ³Department of Clinical Research, University of Southern Denmark, Odense C, DENMARK, ⁴Centre for Personalized Response Monitoring in Oncology (PREMIO), Odense University Hospital, Odense C, DENMARK.

EP-0642

Quantitative consistency assessment along the axial field of view of a total-body PET scanner

X. Meng¹, Y. Wu², F. Wang¹, Y. Song¹, R. Wu², N. Li¹, Z. Yang¹;

¹Peking University Cancer Hospital & Institute, Beijing, CHINA, ²Shanghai United Imaging Healthcare, Shanghai, CHINA.

EP-0643

68Ga-Pentixafor in Squamous Cell Carcinoma of the head and neck, a pilot study

B. Hadebe¹, L. Harry¹, L. Gabela¹, S. Masikane¹, M. Patel¹, P. Bipath¹, N. Cebekhulu¹, N. E. Nyakale², C. Aldous¹, M. M. Sathekge³, M. Voster¹;

¹University of KwaZulu Natal, Durban, SOUTH AFRICA, ²Sefako Makgatho Health Sciences University, Pretoria, SOUTH AFRICA, ³University of Pretoria, Durban, SOUTH AFRICA.

EP-0644

The asymmetry of tau deposition and its correlation with cerebral metabolic asymmetry in Alzheimer's disease

H. Lin, p. wu, c. zuo;

Department of Nuclear Medicine / PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA.

EP-0645

Characterizing the 5-Ring GE Discovery MI PET/CT Scanner Using AAPM TG-126 and Compare these Results with the NEMA NU 2-2012 Results

R. Almazrou¹, S. Alanazi¹, M. Alrabiah², R. Al-Fakhranee¹, O. Mawlawi³;

¹King Faisal Specialist Hospital and Research center, Riyadh, SAUDI ARABIA, ²GE HealthCare, Riyadh, SAUDI ARABIA, ³University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

EP-0646

Clinical solution to minimize mis-registration artifacts in PET/CT

T. Pan;

The University of Texas, Houston, TX, UNITED STATES OF AMERICA.

EP-0647

Physical and Clinical Optimization of Acquisition Durations on a Digital BGO High Sensitivity PET-CT System

Q. Maronnier, M. Terroir, T. Cassou-Mounat, A. Latgé, J. S. Texier, L. Vija, F. Courbon, O. Casselles;

Oncopole Claudius Regaud, Toulouse, FRANCE.

EP-0648

Quantitative Evaluation of Low-dose Whole-body Indirect Patlak Parametric Imaging with Deep Progressive Reconstruction

Q. Ye¹, C. Xi¹, H. Dai¹, H. Zeng¹, Y. Zhao¹, G. Li², F. Kang², J. Wang², Y. Lv¹, Y. Lu¹;

¹United Imaging Healthcare, Shanghai, CHINA, ²Xijing Hospital, Xi'an, CHINA.

EP-0649

Deep learning-based method for the reconstruction of high-quality 3D PET image from low-dose data

R. Guo^{1,2}, J. Wang³, Y. Miao^{1,2}, S. Xue⁴, Y. Zhang^{1,2}, K. Shi⁴, B. Li^{1,2}, G. Zheng³;

¹Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, ²Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Ruijin Center, Shanghai, CHINA, ³Institute of Medical Robotics, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China, Shanghai, CHINA, ⁴Department of Nuclear Medicine, University of Bern, Switzerland, Bern, SWITZERLAND.

EP-0650

Diffuse high uptake of 68Ga-FAPI in both kidneys helps with diagnosis of kidney diseases

X. Zhong¹, J. Cheng², M. Su², W. Zhang³;

¹Nuclear Medicine Department and Biomedical Big Data Center, West China Hospital of Sichuan University, Chengdu, CHINA, ²Nuclear Medicine Department, West China Hospital of Sichuan University, Chengdu, CHINA, ³Biomedical Big Data Center, West China Hospital of Sichuan University, Chengdu, CHINA.

EP-0651

Designing a 1-mm Resolution Brain-Dedicated PET System with a Hemispherical Detector Arrangement

T. Yamaya¹, E. Yoshida¹, G. Akamatsu¹, K. Narita^{2,1}, H. Tashima¹, Y. Iwao¹, M. Takahashi¹;

¹National Institutes for Quantum Science and Technology (QST), Chiba, JAPAN, ²Chiba University, Chiba, JAPAN.

EP-0652

68Ga -FAPI PET/CT Improves Detection Rates of Gastrointestinal Mucinous Adenocarcinoma or Signet Ring Cell Carcinoma: A Comparative Study with 18F-FDG

Y. Sun;

Fudan University, Shanghai Cancer center, Shanghai, CHINA.

EP-0653

Effect of Radiopharmaceutical Extravasation on the Accuracy of SUV Estimation in PET/CT

I. Znamenskiy^{1,2,3}, V. Volkov^{2,3}, A. Kondakov^{1,2}, M. Beregov³, D. Mosin^{1,2};

¹Petrovsky National Research Centre of Surgery, Moscow, RUSSIAN FEDERATION, ²Pirogov Russian National Research Medical University, Moscow, RUSSIAN FEDERATION, ³Federal center of brain research and neurotechnologies, Moscow, RUSSIAN FEDERATION.

EP-0654

Last generation digital PET: comparison of the performances of 5 vs. 6 rings systems and optimization of the overlap value

M. Bernardini¹, T. Mbaye¹, M. Alqabandi², F. Hyafil¹;

¹Hôpital Européen Georges Pompidou (HEGP), Paris, FRANCE, ²Nuclear Medicine Department, Faculty of Medicine, Kuwait University, Kuwait City, KUWAIT.

EP-0655

Influence of the CT-Energy on the Attenuation Correction of the PET/CT and the Impact on Small Bone Lesions

A. Haslauer, E. Solari, J. Brosch-Lenz, W. Weber, S. G. Nékolla;

Klinikum rechts der Isar, Technical University Munich, Munich, GERMANY.

EP-0656

PET digitization chain for Monte Carlo simulation in GATE

J. Salvadori¹, A. Merlet², B. Presles³, A. Etxebeste⁴, J. Vrigneaud³, D. Sarrut⁴;

¹Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg, FRANCE, ²Imagerie et Vision artificielle, ImViA EA 7535, Dijon, FRANCE, ³Institut de Chimie Moléculaire de l'Université de Bourgogne (ICMUB), UMR CNRS 6302, University of Burgundy, Dijon, FRANCE, ⁴Université de Lyon, CREATIS; CNRS UMR5220; Inserm U1044; INSA-Lyon; Université Lyon 1; Centre Leon Bérard, Lyon, FRANCE.

EP-0657

Sensitivity comparison of non-TOF and TOF PET/CT

L. Carnegie-Peake, J. Dickson, S. McQuaid;

University College London Hospital, London, UNITED KINGDOM.

EP-0658

Development and Validation of a Monte Carlo Simulation Workflow for a Total-Body PET Scanner
C. Pomranz^{1,2}, E. Elmoujarkach³, J. Cabello⁴, W. Lan⁵, M. Rafecas³, J. Mannheim^{1,6}, P. Linder⁵, A. Santangelo², C. la Fougère^{5,6}, B. Pichler^{1,6}, F. Schmidt^{1,5};
¹Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen, GERMANY, ²Institute for Astronomy and Astrophysics, Eberhard Karls University Tuebingen, Tuebingen, GERMANY, ³Institute of Medical Engineering, University of Lübeck, Lübeck, GERMANY, ⁴Siemens Medical Solutions UNITED STATES OF AMERICA, Inc., Knoxville, TN, UNITED STATES OF AMERICA, ⁵Department of Nuclear Medicine and Clinical Molecular Imaging, University hospital Tuebingen, Tuebingen, GERMANY, ⁶Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tuebingen, GERMANY.

EP-0659

Can SUVmax be used to predict the development of anatomical correspondence in bone uptakes detected by 18F-PSMA-1007-PET/CT?
L. Eklund, M. Anttinen, J. Vanhatalo, S. Malaspina, T. Noponen, J. Kempainen, P. Boström, M. Seppänen, O. Ettala;
University of Turku, Turku, FINLAND.

EP-0660

Measurement of NECR in a Long Axial Field of View Scanner using a Custom Humanoid Phantom covering the Full Axial Field
S. Holm, J. V. *Henriksen, T. L. Andersen, F. L. Andersen; Rigshospitalet, Copenhagen University Hospital, Copenhagen, DENMARK.

EP-0661

Feasibility study of Sub-minute acquisition with deep-learning reconstruction using 18F-FAPI Total-body PET/CT
E. Liu, L. Jiang;
Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, CHINA.

EP-0662

Effect of time-of-flight capabilities on noise in clinical PET-CT
S. McQuaid, L. Carnegie-Peake, J. C. Dickson; Institute of Nuclear Medicine, London, UNITED KINGDOM.

EP-44

e-Poster Area

D: Technical Studies -> D1 Instrumentation -> D13 PET/MR

EP-0663

Development of a low-cost protocol using standard equipment for the constant infusion administration of [18F]FDG in PET-MR
A. Cripps¹, J. Taylor^{1,2}, M. Singleton¹, D. Selvarajah^{1,2}, G. Armitage¹, A. Scott¹;
¹Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UNITED KINGDOM, ²University of Sheffield, Sheffield, UNITED KINGDOM.

EP-0664

Addressing PET Attenuation Correction Challenges for the ACR Accreditation of a Simultaneous PET/MR Scanner
H. Kulkarni¹, A. Samuels¹, T. Faasse¹, V. Sridhar², L. Hu², J. Botti¹;
¹BAMF Health, Grand Rapids, MI, UNITED STATES OF AMERICA, ²UIH America, Houston, TX, UNITED STATES OF AMERICA.

EP-45

e-Poster Area

D: Technical Studies -> D1 Instrumentation -> D15 Quality Control, Performance and Standardization

EP-0666

Coincidence distribution in 2-layer hemispheric PET geometries
K. Scheiff, A. Pashazadeh, C. Hoeschen; Otto-von-Guericke-University Magdeburg, Magdeburg, GERMANY.

EP-0667

MC Simulator Framework for Monolithic Scintillator Based PET and SPECT
J. Peter, L. P. Clemens;
German Cancer Research Center, Heidelberg, GERMANY.

EP-0668

The Situation of Nuclear Medicine in China: A Report of the First Official Nationwide Survey in 2021
H. Zhang¹, J. Zheng², N. Hu¹, Y. Liu¹, H. Jing¹, L. Huo¹;
¹Peking Union Medical College Hospital, Beijing, CHINA, ²Department of Radiology, University of Cambridge, Cambridge, UNITED KINGDOM.

EP-0669

Monte Carlo performance with impact of different crystal materials on sensitivity characteristic of preclinical PET scanner
Z. Karimi¹, P. Sheikhzadeh², M. Ay³;
¹Faculty of Physics, University of Isfahan, Isfahan, ISLAMIC REPUBLIC OF, ²Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Research Center for Molecular and Cellular Imaging (RCMCI), Advanced Medical Technologies and Equipment Institute (AMTEI), Tehran University of Medical Sciences (TUMS), Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0670

Determination of the Kernel with which to Smooth the CT for Air Fraction Correction in Lung PET/CT Studies
F. Leek^{1,2}, C. Anderson³, A. P. Robinson^{2,4,5}, R. M. Moss¹, B. F. Hutton¹, K. Thielemans¹;
¹University College London, London, UNITED KINGDOM, ²National Physical Laboratory, Teddington, UNITED KINGDOM, ³University College London Hospital NHS Foundation Trust, London, UNITED KINGDOM, ⁴The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM, ⁵University of Manchester, Manchester, UNITED KINGDOM.

EP-0671

Is It Reliable to Use NMQC-Toolkit as a Self-QC Software for Nuclear Medicine Departments?
N. KODALOGLU¹, G. Vura², N. C. Güldü³;
¹University of Health Sciences, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Radiation Oncology, ANKARA, TÜRKIYE, ²University of Health Sciences, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Nuclear Medicine, ANKARA, TÜRKIYE, ³University of Health Sciences, Ankara Bilkent City Hospital, Department of Nuclear Medicine, ANKARA, TÜRKIYE.

EP-0672

The Role of SPECT/CT NEMA NU2 Calibration in Quantitative Imaging
I. Irimescu^{1,2}, R. Maaz¹, A. Lazar¹, M. Mutuleanu^{1,3}, C. Petriou¹, M. Mihailescu², M. Gherghel^{1,3};
¹Institute of Oncology „Professor Doctor Alexandru Trestioreanu”, Bucharest, ROMANIA, ²Applied Sciences Doctoral School, Politehnica University, Bucharest, ROMANIA, ³„Carol Davila” University of Medicine and Pharmacy, Bucharest, ROMANIA.

EP-0673

Stability of Brain PET/CT Image Quantification for Imaging with a VR Headset
L. Raes^{1,2}, S. Bourgeois¹, A. Bracke¹, T. De Haan¹, H. Everaert^{1,2};
¹Universitair Ziekenhuis Brussel, Brussels, BELGIUM, ²Vrije Universiteit Brussel, Brussels, BELGIUM.

EP-46

e-Poster Area

D: Technical Studies -> D2 Data Analysis -> D21 Data Analysis in Neuro and Cardio

EP-0674

Parametric imaging of P-glycoprotein function at the blood-brain barrier using KE, brain-maps generated from dynamic [11C]metoclopramide PET data in rodents, monkeys, and humans
L. Breuil^{1,2}, M. El Biali³, D. Vodovar¹, S. Marie¹, S. Auvity^{1,2}, S. Goutal¹, S. Rodrigo¹, M. Bauer³, O. Langer^{3,4}, N. Tournier¹;
¹BioMaps, Laboratoire d'Imagerie Biomédicale Multimodale Paris-Saclay, Inserm, CNRS, CEA, Université Paris-Saclay, Orsay, France, Orsay, FRANCE, ²Inserm UMR-S1144, University of Paris Cité, 75006 Paris, France, Paris, FRANCE, ³Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria, Vienna, AUSTRIA, ⁴Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Austria, Vienna, AUSTRIA.

EP-0675

Coupling between Cortical Thickness and Glucose Metabolism in the Human Brain: a PET/MRI study
Q. Huang¹, Y. Yang², N. Qi², S. Ren¹, J. Wang¹, Y. Guan¹, J. Zhao², F. Xie¹;
¹Department of Nuclear Medicine & PET center Huashan Hospital Fudan University, Shanghai, CHINA, ²Department of Nuclear Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, CHINA.

EP-0676

Spinal Cord imaging by [11C]PIB PET/MRI: evaluation of drawing methods and reference region use in myelin uptake quantification of Healthy Volunteers and Multiple Sclerosis Patients
L. Zorante de Lucena, M. Sales Pitombeira, K. Repiso Campanholo, C. Alberto Buchpiguel, D. de Paula Faria; Centro de Medicina Nuclear do Hospital da Clínicas da Faculdade de Medicina da USP (CMN-HC-FMUSP), São Paulo, BRAZIL.

EP-0677

Quantification of Neuroinflammation using [18F] DPA714 PET in individuals with Long COVID
S. Golla¹, D. Visser¹, S. C. J. Verfaillie², E. M. Coomans¹, R. M. Rikken¹, E. van de Giessen¹, M. E. den Hollander¹, M. Yaqub¹, A. Verveen², F. Barkhof^{1,3}, J. Horn⁴, B. Koopman⁵, P. Schöber⁶, D. W. Koch², R. C. Schuit¹, A. D. Windhorst¹, M. Kassiou⁷, M. van Vugt⁸, H. Knoop², B. N. M. van Berckel¹, N. Tolboom⁹, R. Boellaard¹;
¹Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, NETHERLANDS, ²Department of Medical Psychology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, NETHERLANDS, ³Institute of Neurology and Healthcare Engineering, University College London, London, UNITED KINGDOM, ⁴Department of Intensive Care & Laboratory of Experimental Intensive Care and Anesthesiology (L-E-I-C-A), University of Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS, ⁵Pulmonary Medicine, OLVG, Amsterdam, NETHERLANDS, ⁶Department of Anaesthesiology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS, ⁷School of Chemistry, The University of Sydney, Sydney, AUSTRALIA, ⁸Department of Internal Medicine, University of Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS, ⁹Department of Radiology & Nuclear Medicine, University Medical Centre Utrecht, Utrecht, NETHERLANDS.

EP-0678

Florbetaben PET quantification strongly agrees with histopathological confirmation of amyloid-beta load and visual reads.
S. Bullich¹, J. Koikkalainen², A. Jovalekic¹, N. Roé-Vellvé¹, G. D. Kolinger¹, N. Koglin¹, A. W. Stephens¹, L. Thurfjell¹;
¹Life Molecular Imaging GmbH, Berlin, GERMANY, ²Combinostics Oy, Tampere, FINLAND.

EP-0679

Attenuation correction of cardiac PET with end-expiratory CT and average CT
K. Sander¹, T. Pan², A. Roby¹;
¹University of Texas Medical School, Houston, TX, UNITED STATES OF AMERICA, ²University of Texas at M. D. Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

EP-0680

“Enhancing Quantitative and Qualitative Analysis in Transthyretin Amyloid Cardiomyopathy Imaging: Preliminary Results from the iTAC IAEA Project”

P. Knoll¹, L. Torres Aroche², F. Mut³, G. Grossmann⁴, S. Orbal⁵, G. Agu⁶, S. Mirzaei⁶, I. de Souza Baptista⁴, D. Paez¹, A. Brink¹, M. Ljungberg⁷;

¹IAEA, Vienna, AUSTRIA, ²Nuclear medicine department, Centis, La Habana, CUBA, ³Servicio Medicina Nuclear, Hospital Italiano, Montevideo, URUGUAY, ⁴Hospital Moinhos de Vento, Porto Alegre, BRAZIL, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA, ⁶Department of Nuclear Medicine, Klinik Ottakring, Vienna, AUSTRIA, ⁷Lund University Skane University Hospital, Lund, SWEDEN.

EP-0681

A novel assisted workflow created to obtain cardiac semiquantitative indexes from 99mTc-DPD-scintigraphy and to correlate them with different etiologies of transthyretin-related cardiac amyloidosis.

S. E. Prisco¹, S. Mattoni¹, A. Paccagnella², F. Mattana³, M. F. Morrone^{4,5}, G. Della Gala⁴, M. Sguazzott⁶, S. Longhi⁶, G. Saturi⁶, S. Fanti^{1,7}, N. Galie⁶, L. Strigari⁴, R. Bonfiglioli⁷;

¹Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, ²Nuclear Medicine Unit, AUSL Romagna, Cesena, ITALY, ³IEO European Institute of Oncology IRCCS, Milano, ITALY, ⁴Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁵Specialization School in Medical Physics, University of Bologna, Bologna, ITALY, ⁶Cardiovascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ⁷Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-0682

Long-term prognostic value of automated measurements in nuclear cardiology: Comparisons with the expert reading scoring

G. Angelidis¹, V. Valotassiou¹, I. Tsougas¹, C. Tzavara¹, S. Giannakou¹, D. Psimadas¹, E. Theodorou¹, A. Ziaka¹, C. Ziangas¹, J. Skoularigis¹, F. Triposkiadis¹, P. Georgoulas¹; University of Thessaly, Larissa, GREECE.

EP-0683

Centiloid Calibration of a Commercial Amyloid Quantitation Software for different Fluorine-18 Radiotracers

R. Fahmi¹; Siemens Healthineers, Knoxville, TN, UNITED STATES OF AMERICA.

EP-0684

Comparison of MR arterial spin labelling regional Cerebral Blood Flow estimates to early amyloid PET measurements

J. Anton Rodriguez^{1,2}, J. C. Matthews³, L. A. Scott³, J. J. McFadden³, B. R. Dickie², K. Herholz², L. M. Parkes³; ¹The Christie NHS Foundation Trust and University of Manchester, Manchester, UNITED KINGDOM, ²Division of Informatics, Imaging and Data Sciences, MAHSC, University of Manchester, Manchester, UNITED KINGDOM, ³Division of Psychology, Communication and Human Neuroscience, Faculty of Biology, Medicine and Health-University of Manchester, Manchester, UNITED KINGDOM.

EP-0685

A ROI-based Quantitative Pipeline for [18F]-FDG PET Metabolism and pCASL Perfusion Joint Analysis: Validation on [18F]-FDG PET Data

V. Cerina¹, E. De Bernardi², C. Crivellaro³, S. Morzenti⁴, F. E. Pozzi¹, L. Jonghi Lavarini², V. Bigiogera², R. M. Moresco², G. Basso^{2,5};

¹PhD program in Neuroscience, Department of Medicine and Surgery, University of Milano Bicocca, Milano, ITALY, ²Department of Medicine and Surgery, University of Milano Bicocca, Milano, ITALY, ³Nuclear Medicine, Fondazione IRCCS San Gerardo dei Tintori, Monza, ITALY, ⁴Medical Physics, Fondazione IRCCS San Gerardo dei Tintori, Monza, ITALY, ⁵Neuroradiology, Fondazione IRCCS San Gerardo dei Tintori, Monza, ITALY.

EP-0686

Method evaluation for quantification of cerebral blood flow for [15O]-water PET/CT, a segmentation comparison between using ASPECTS method for simplified quantification to a 3D-volume based arterial atlas

A. Eriksson¹, J. Patrick Connelly¹, A. Gul Sherwani¹, L. Gridset¹, K. Angell¹, L. Gyland Mikalsen¹, C. Stokke¹, M. Stavrinou¹; Oslo Universityhospital, Oslo, NORWAY.

EP-47

e-Poster Area

D: Technical Studies -> D2 Data Analysis -> D22 Other Data Analysis

EP-0687

Comparison of Results Analysis for Isotopic Determination of Plasma Volume: a Prospective Study

M. Ragot¹, R. Charmelot¹, P. Orhon¹, B. Berton¹, A. Revy¹, M. Tempier¹, S. Levesque¹; Centre Jean Perrin, Clermont-Ferrand, FRANCE.

EP-0688

Discordance between 90Y PET/CT(MR)-estimated activity and dose calibrator measured administered activity: an international patient study in SIRT with resin and glass microspheres

T. Carlier¹, S. Gnesin², J. Mikell³, M. Conti⁴, J. Prior⁵, C. Bailly¹, M. Pérez Lago⁶, Y. Dewaraja⁷, T. Lima⁶;

¹University Hospital of Nantes, Nantes, FRANCE, ²Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, ³Department of Radiation Oncology, University of Michigan, Saint Louis, MI, UNITED STATES OF AMERICA, ⁴Siemens Medical Solutions UNITED STATES OF AMERICA, Inc, Knoxville, TN, UNITED STATES OF AMERICA, ⁵Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, ⁶Department of Radiology and Nuclear Medicine, Luzerner Kantonsspital and Faculty of Health Sciences and Medicine, University of Lucerne, Luzern, SWITZERLAND, ⁷Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA.

EP-0689

Using Different Dichotomisation Methods for Lesion Dissemination to Predict Survival Outcomes in Lymphoma Patients

X. Wong¹, L. Yong¹, Y. Chen^{2,3}, S. Liu^{1,3}, K. Lue¹;

¹Tzu Chi University of Science and Technology, Hualien, TAIWAN, ²Tzu Chi University, Hualien, TAIWAN, ³Hualien Tzu Chi Hospital, Hualien, TAIWAN.

EP-0690

Evaluation of Image Quality and Quantification with Various Scan Times on 64 Copper PET/CT Imaging: Phantom and Clinical study

F. Sadeghi¹, A. Monsef², P. Sheikhzadeh^{1,3};

¹Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN, UNITED STATES OF AMERICA, ³Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0691

Cluster Analysis in Binary Classification of Amyloid PET/MR Imaging with/without-Partial Volume Effect Correction

E. Balci¹, U. O. Akdemir¹, M. A. Topcuoglu², E. Saka², L. O. Atay¹;

¹Gazi University Medical Faculty Department of Nuclear Medicine, ANKARA, TÜRKIYE, ²Hacettepe University, Faculty of Medicine, Department of Neurology, ANKARA, TÜRKIYE.

EP-0692

Improving Efficiency of Simultaneous Dual-Tracer PET Imaging

Z. Li¹, V. Shah², S. L. M. Vio³, P. van Snick¹, G. Luurtsema¹, R. H. J. A. Slart¹, A. Lammertsma¹, C. Tsoumpas¹;

¹Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, ²Molecular Imaging, Siemens Medical Solutions UNITED STATES OF AMERICA, Inc., Knoxville, TN, UNITED STATES OF AMERICA, ³Department of Radiology and Nuclear medicine, Amsterdam University Medical Center, Amsterdam, NETHERLANDS.

EP-0693

Patlak graphical analysis: Net Influx Rate (Ki) obtained with a fully-automated Multiparametric PET Suite versus traditional Regional Plot

A. Capotosti¹, R. Moretti¹, M. De Summa², S. Taralli¹, E. Perrone^{1,3}, M. L. Calcagni^{1,3}, L. Indovina¹;

¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY, ²Medipass S.p.a. Servizio Integrativo PET/CT - Radiofarmacia, TracerGLab, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, ITALY, ³Università Cattolica del Sacro Cuore, Rome, ITALY.

EP-0694

PET imaging with somatostatin analogue (SomaKitTOC®) for assessment of neuroendocrine tumors: unknown physiological uptake, patient independent? Experience feedback

C. Provost¹, C. Schmitt¹, J. Fouque¹, O. Madar¹, L. Champion²;

¹Institut Curie, Radiopharmacology department, Saint Cloud, FRANCE, ²Institut Curie, Nuclear Medicine departement, Saint Cloud, FRANCE.

EP-0695

A fuzzy C-mean segmentation technique to estimate methodological uncertainties on time-activity curves in dynamic quantitative positron emission tomography studies

P. Laporte¹, J. Carrier^{1,2,3};

¹Département de Physique, Faculté des Arts et Sciences, Université de Montréal, Montréal, QC, CANADA, ²Institut de Génie Biomédical, Faculté de Médecine, Université de Montréal, Montréal, QC, CANADA, ³Département de radiologie, radio-oncologie et médecine nucléaire, Faculté de Médecine, Université de Montréal, Montréal, QC, CANADA.

EP-0696

Influence of normal database sample size on the development of new statistical image analysis software for bone SPECT imaging

Y. Yakushiji¹, K. Miwa², K. Wagatsuma^{1,3}, S. Fukuda¹, T. Yamao², Y. Kamitaka³, N. Miyaji², T. Hasegawa¹;

¹Kitasato University Graduate School of Medical Sciences, Kanagawa-ken, JAPAN, ²Fukushima Medical University, Fukushima-ken, JAPAN, ³Tokyo Metropolitan Institute of Gerontology, Tokyo-to, JAPAN.

EP-0697

The Management of Diabetic Patients During the Positron Emission Tomography Examination: the Experience of Sahloul University Hospital

A. Ben Naceur¹, A. Toumi¹, N. Ayachi¹, K. Chatti¹; Sahloul University Hospital, Sousse, TUNISIA.

EP-0698

Towards AI application with automatic subtraction to improve parathyroid adenomas detection

O. Boukhennoufa¹, L. Comas^{2,3}, E. Lajeune¹, C. Ungureanu², M. Soualhi¹, J. Nicod¹, N. Zerhouni¹, H. Boulahdour^{2,3};

¹Université de Franche-Comté, SUPMICROTECH, CNRS, institut FEMTO-ST, Besançon, FRANCE, ²Service de Médecine Nucléaire, CHU Besançon, Besançon, FRANCE, ³Université de Franche-Comté, LNI, F-25000, Besançon, FRANCE.

EP-0699

Evaluation of PalRe PET/CT segmentation software as cancerous lesion contouring tool in fully-automated annotation workflows for image-based research studies

D. Abler¹, M. Jreige², O. Michielin^{1,3}, N. Schaefer², J. O. Prior², A. Depeursinge^{4,2}, M. A. Cuendet^{1,5,6}, P. Blanc Durand⁷;

¹Department of Oncology, Precision Oncology Center, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, ²Nuclear Medicine and Molecular Imaging Department, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, ³Department of Oncology, Geneva University Hospital and University of Geneva, Geneva, SWITZERLAND, ⁴Institute of Informatics, School of Management, University of Applied Sciences Western Switzerland, Sierre, SWITZERLAND, ⁵Swiss Institute of Bioinformatics, University of Lausanne, Lausanne, SWITZERLAND, ⁶Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA, ⁷Nuclear Medicine Department, Henri-Mondor University Hospital, Créteil, FRANCE.

EP-0700

Pituitary Gland: Do We Really See It?
A. Macula^{1,2}, L. Airo³, S. Colombo Serra², M. Ali⁴, S. Papa⁴, G. Valbusa², A. Bifone¹, P. Gandolfo⁴;
¹Università di Torino, Torino, ITALY, ²Bracco Imaging S.p.a., Milano, ITALY, ³Università di Milano, Milano, ITALY, ⁴Centro Diagnostico Italiano, Milano, ITALY.

EP-0701

A statistical method to adapt a normal range for thyroid uptake measurements following replacement of a gamma camera
A. Gemmell^{1,2,3}, C. Brown^{1,2}, S. Ray³, S. Small^{1,2};
¹Nuclear Medicine, Gartnavel General Hospital, Glasgow, UNITED KINGDOM, ²Department of Clinical Physics & Bioengineering, Glasgow, UNITED KINGDOM, ³School of Mathematics & Statistics, University of Glasgow, Glasgow, UNITED KINGDOM.

EP-0702

Impact of using different SUV thresholds for delineating human brown adipose tissue volume with 18F-FDG PET-CT
Y. Garcia-Rivero, E. Rodríguez García, S. Beltrán Arenas, M. Pérez Gómez, C. Rodríguez García, Á. García Rodríguez, M. Ruiz Molina, G. Sánchez-Delgado;
Hospital Virgen De Las Nieves, Granada, SPAIN.

EP-0703

Parametric Images And KEi Index In A Small Kidneys Clearance Function Assessment
K. Filipczak, P. Cichocki, J. Kusmierek, A. Plachcinska, Z. Adamczewski;
Medical University of Lodz, Lodz, POLAND.

EP-0704

Standardized Uptake Values for SPECT-CT in Normal Lumbar Spine, using xSPECT Quant Bone Reconstruction
A. Duarte, D. Calado, N. do Canto, M. Correia, A. Figueiredo, S. Matos, B. Martins, C. Pinto, V. Sousa;
Hospital da Luz, Lisboa, PORTUGAL.

EP-0705

Relationship of 18F-FDG PET/CT metabolic parameters reduction during neoadjuvant chemotherapy to complete cytoreduction and pathologic response in primarily inoperable high-grade serous ovarian cancer.
L. Sancho Rodriguez¹, L. Sánchez Lorenzo¹, F. Boria Alegre¹, T. Iscar Galán¹, L. García Belaustegui¹, V. Carrasco Rubio¹, C. Beorlegui Arteta², M. Romera Caballo³, V. Betech Anta³, M. García Velloso³;
¹Clinica Universidad De Navarra, Madrid, SPAIN, ²Departamento de Salud. Gobierno de Navarra. Pamplona., Pamplona, SPAIN, ³Clinica Universidad De Navarra, Pamplona, SPAIN.

EP-0706

Is there any metabolic parameter of staging 18F-FDG-PET/CT related to the therapeutic strategy performed (primary cytoreduction vs. neoadjuvant chemotherapy and interval cytoreduction) in patients with high-grade serous ovarian cancer?
L. Sancho Rodriguez¹, L. Sánchez Lorenzo¹, F. Boria Alegre¹, T. Iscar Galán¹, L. García Belaustegui¹, E. eguillenv@unav.es¹, V. Carrasco Rubio¹, C. Beorlegui Arteta², M. Romera Caballo³, V. Betech Anta³, M. García Velloso³;
¹Clinica Universidad De Navarra, Madrid, SPAIN, ²Departamento De Salud. Gobierno De Navarra, Madrid, SPAIN, ³Clinica Universidad De Navarra, Pamplona, SPAIN.

EP-0707

Quantification parameters of 99mTc-MDP single-photon emission computed tomography/computed tomography in the diagnosis of active condylar hyperplasia.
M. Umar, D. Khan, S. Sagar, S. Ahmad Shamim, R. Kumar; Aiiims, Delhi, INDIA.

EP-0708

Normalizing SUV values by lean body mass effectively reflect patient weight and body composition variations improving SUVmax values determination in 18F-FDG PET-CT imaging.
A. Hurtado de Mendoza, M. Yaryes, C. Soza-Ried, H. Amaral;
Positronmed, Santiago, CHILE.

EP-0709

Current status and new trends in technetium-99m described through a patent analysis (2000-2022)
M. Riondato¹, D. Rigamonti², P. Martini³, C. Cittanti³, A. Boschi³, L. Uccelli³;
¹University Policlinic Hospital of Genoa, Genoa, ITALY, ²European and Italian Patent Attorney, Milan, ITALY, ³University of Ferrara, Ferrara, ITALY.

EP-0710

Building a Normative Database for [18F]-FDG imaging: Insights from a Japanese Screening Cohort S. Gutschmayer¹, T. Beyer¹, Z. Chen², T. Junichi³, S. Kinuya², L. Shiyam Sundar¹, S. Takeda³, H. Wakabayashi²;
¹Quantitative Imaging and Medical Physics (QIMP) Team, Medical University of Vienna, Vienna, AUSTRIA, ²Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN, ³PET Center, Kanazawa Advanced Medical Center, Kanazawa, JAPAN.

EP-48

e-Poster Area

D: Technical Studies -> D2 Data Analysis -> D23 Image Reconstruction

EP-0711

Validation for dual-gate motion correction techniques using ECG gating and data-driven respiratory motion correction for cardiac PET: A pilot study
K. Takanami¹, H. Odagiri², H. Watabe³, H. Kodama⁴, H. Kawakami⁵, A. Katsuki⁵, N. Uetake⁵, K. Takase¹;
¹Tohoku University Hospital, Sendai, JAPAN, ²Department of Diagnostic Image Analysis, Tohoku University Graduate School of Medicine, Sendai, JAPAN, ³Division

of Radiation Protection and Safety Control, Cyclotron and Radioisotope Center, Sendai, JAPAN, ⁴Department of Radiology, Tohoku University Hospital, Sendai, JAPAN, ⁵GE Healthcare Japan, Tokyo, JAPAN.

EP-0712

Determining the optimal reconstruction algorithm for FDG brain PET/CT images in BGO-based Whole body PET scanner
M. Asami¹, M. Ay¹, S. Farzanehfar², P. Ghafarian³, P. Sheikhzadeh²;
¹Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0713

Faster time-of-flight performance reduces effect of misregistration on myocardial uptake scores in cardiac PET-CT
M. Hylle¹, N. A. Bebbington², M. R. Pedersen³, H. D. Zacho¹;
¹Aalborg University Hospital, Aalborg, DENMARK, ²Siemens Healthcare A/S, Aarhus, DENMARK, ³Lillebaelt Hospital, Vejle, DENMARK.

EP-0714

Optimizing the Block Sequential Regularized Expectation Maximization (BSREM) Algorithm for 68Ga-PSMA PET-CT Imaging: Phantom and Clinical Study
F. Sadeghi^{1,2}, P. Sheikhzadeh^{1,3}, N. Kasraie⁴, S. Farzanehfar⁵, M. Abbasi³, Y. Salehi³, M. Ay^{1,2};
¹Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Department of Radiology, UT Southwestern Medical Center, Dallas, TX, UNITED STATES OF AMERICA.

EP-0715

Evaluation of advanced artificial intelligence-based PET image reconstruction (HYPER DPR) on brain PET/CT imaging
K. Miwa¹, M. Watanabe², M. Ishiguro², T. Yamao¹, N. Miyajiri¹, K. Hasegawa¹, A. Takenaka³, Y. Inui³, H. Toyama³;
¹Fukushima Medical University, Fukushima, JAPAN, ²Fujita Health University Hospital, Aichi, JAPAN, ³Fujita Health University School of Medicine, Aichi, JAPAN.

EP-0716

Impact of the 68Ga Source Model on Positron Range Simulations and 68Ga-specific PET Reconstructions
P. Gavriilidis^{1,2,3}, A. Marinus^{4,1}, F. M. Mottaghy^{5,1,2}, T. W. Deller⁶, F. P. Jansen⁶, M. Koole³, R. Wierds^{1,2};
¹Maastricht University Medical Center, Maastricht, NETHERLANDS, ²Maastricht University, Maastricht, NETHERLANDS, ³Katholieke Universiteit Leuven, Leuven, BELGIUM, ⁴Eindhoven University of Technology, Eindhoven, NETHERLANDS, ⁵RWTH University Hospital, Aachen, GERMANY, ⁶GE HealthCare, Waukesha, WI, UNITED STATES OF AMERICA.

EP-0717

Transforming a low-count nuclear medicine image into a high-count image using Dynamic Stochastic Resonance
A. Pandey, S. Kumar, P. D. Sharma, C. Patel, R. Kumar; All India Institute of Medical Sciences, New Delhi, INDIA.

EP-0718

Role of dynamic stochastic resonance in enhancing the contrast between the abnormal and no-abnormal tau uptake on reconstructed tau (F-18 ML-104) PET images
A. Pandey¹, J. Yadav², M. Tripathi¹;
¹All India Institute of Medical Sciences, New Delhi, INDIA, ²All India Institute of Medical Sciences, Faridabad, INDIA.

EP-0719

Comparative study of respiratory gating techniques on pulmonary 18F-FDG PET lesions
A. BORGES TAVARES¹, R. Amblard¹, F. Hugonnet², B. Paulmier², N. Garnier¹, R. Villeneuve¹, V. Nataf², F. Mocquot², M. Faraggi², B. Serrano¹;
¹Centre Hospitalier Princesse Grace - Medical Physics Department, Monaco, MONACO, ²Centre Hospitalier Princesse Grace - Nuclear Medicine Department, Monaco, MONACO.

EP-0720

Assessment of a new PET event-by-event image-based motion correction for brain imaging in amyloid and epilepsy on a multimodality PET-MR scanner
J. Anton Rodriguez^{1,2}, K. Herholz³, C. Oldfield¹, M. G. Spangler-Bickell⁴, T. W. Deller⁴, L. M. Parkes³, J. C. Matthews³;
¹The Christie NHS Foundation Trust, Manchester, UNITED KINGDOM, ²Division of Informatics, Imaging and Data Sciences, MAHSC, University of Manchester, Manchester, UNITED KINGDOM, ³Division of Psychology, Communication and Human Neuroscience, Faculty of Biology, Medicine and Health-University of Manchester, Manchester, UNITED KINGDOM, ⁴GE HealthCare, Waukesha, WI, UNITED STATES OF AMERICA.

EP-0721

Analysis of segmented single-photon emission computedtomography images acquired with and without a copper filter
S. Kheruka, N. Al Maymani, N. Al Makhmari, K. Al Riyami, R. Al Sukaiti, A. Jain, S. Usmani;
Department of Radiology & Nuclear Medicine, Sultan Qaboos Comprehensive Cancer Care and Research Center, Muscat, OMAN.

EP-0722

Advantages and opportunities of using an open-source reconstruction platform for SPECT quantification

S. Varzakis¹, A. Denis-Bacelar², D. Deidda², J. Dickson³, S. McQuaid³, K. Thielemans¹;
¹University College London, London, UNITED KINGDOM, ²National Physical Laboratory, London, UNITED KINGDOM, ³University College London Hospital, London, UNITED KINGDOM.

EP-49

e-Poster Area

D: Technical Studies -> D2 Data Analysis -> D24 Radiomics

EP-0723

Utility of delta radiomics for response evaluation in primary mediastinal large B-cell lymphoma

F. Yousefirizi¹, C. Gowdy², I. Klyuzhin³, K. Savage¹, C. Uribe¹, A. Rahmim³;
¹Bc Cancer, Vancouver, BC, CANADA, ²Bc Children's Hospital, Vancouver, BC, CANADA, ³Bc Cancer Research Institute, Vancouver, BC, CANADA.

EP-0724

Noninvasive diagnostic models based on CT scans for differentiating solitary pulmonary metastasis in colorectal cancer patients by artificial intelligence : a multicenter study

D. Ma;
Department of Colorectal Surgery, Zhejiang Cancer Hospital, Hangzhou, CHINA.

EP-0725

Bio-functional radiomics based machine learning for improving the accuracy of hypermetabolic lymph node metastasis in lung cancer

C. Ren;
Shanghai Proton and Heavy Ion Center, Shanghai, CHINA.

EP-0726

Multimodal Radiomic Analyses Allow IDH-Prediction in Glioma Patients at Initial Diagnosis

L. Kaiser¹, S. Quach², A. J. Zounek¹, A. Zatcepin¹, A. Holzgreve¹, A. Bollenbacher¹, L. Bartos¹, V. Ruf³, G. Böning¹, L. von Baumgarten², N. Thon², J. Herms³, M. J. Riemenschneider⁴, S. Stöcklein⁵, M. Brendel¹, R. Rupprecht⁶, J. Tonn², P. Bartenstein¹, S. Ziegler¹, N. L. Albert¹;
¹Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY, ²Department of Neurosurgery, University Hospital, LMU Munich, Munich, GERMANY, ³Center for Neuropathology and Prion Research, LMU Munich, Munich, GERMANY, ⁴Department of Neuropathology, University Hospital Regensburg, Regensburg, GERMANY, ⁵Department of Radiology, University Hospital, LMU Munich, Munich, GERMANY, ⁶Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, GERMANY.

EP-0727

Non-Invasive Pathological Gleason Score Prediction in Prostate Cancer Patients Using Machine Learning and 68Ga-PSMA PET/CT Radiomic Features

Z. Vosoughi¹, N. Hamzian², P. Geramifard³, H. Vosoughi⁴, F. Emami⁵, S. Faraji⁶, G. Hajianfar⁷, I. Shiri⁷, H. Zaidi⁷;
¹Department of Medical Physics, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, IRAN, ISLAMIC REPUBLIC OF, ²Department of Medical Physics, School of Medicine, Medical Physics department of Shahid Sadoughi University of Medical Sciences, Yazd, IRAN, ISLAMIC REPUBLIC OF, ³Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Nuclear Medicine Department, Razavi Hospital, Imam Reza International University, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ⁵Nuclear Medicine Department, Razavi Hospital, Imam Reza International University, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ⁶Department of Medical Physics, Mashhad University of Medical Science, Mashhad, IRAN, ISLAMIC REPUBLIC OF, ⁷Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, SWITZERLAND.

EP-0728

The value of 18F-FDG PET/MR radiomics features in predicting the pathological classification of rhabdomyosarcoma in children

Y. Xu;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EP-0729

Correlating 68Ga-PSMA PET/CT Imaging Features with PSA Variation for Castration-Resistant Prostate Cancer Patients

R. Eduardo^{1,2}, J. Badel³, D. Sarrut¹, E. Paquet³, A. Giraudet³;
¹Creatis, Lyon, FRANCE, ²Siemens Healthcare SAS, Paris, FRANCE, ³Centre Léon Berard, Lyon, FRANCE.

EP-0730

Prediction of pathological complete response in T-stage III rectal cancer using 18F-FDG PET texture features

S. Woo, J. Yang, H. Ju, K. Kim, A. Muath, S. Cho, U. Shin;
KIRAMS, Seoul, KOREA, REPUBLIC OF.

EP-0731

Reproducibility of CT radiomic features extracted from resampled images using various interpolation methods.

G. Mehta¹, A. Tripathi¹, S. Panchal^{1,2}, U. B. Sherkhane^{1,3}, N. Purandare^{1,2}, S. Mithun^{1,2,3}, A. K. Jha^{1,2}, V. Rangarajan^{1,2};
¹Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, INDIA, ²Homi Bhabha National Institute (HBN), Deemed University, Mumbai, INDIA, ³Department of Radiation Oncology (Maastr), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, 6229 ET Maastricht, NETHERLANDS.

EP-0732

A Comparative Study on Radiomics Pipelines for Histological Classification of Non-Small Cell Lung Cancer through [18F]FDG PET/CT

L. Wichert-Ana, L. Alexandre-Santos, A. C. Trevisan, L. R. Suzuki, F. A. Pitella, O. Y. Fukumori, M. Kato, P. M. Azevedo-Marques, M. Koenigkam-Santos;
Ribeirão Preto Medical School - University of São Paulo, Ribeirao Preto, BRAZIL.

EP-0733

Assessing PET andCMR radiomic featuresfor detectionof cardiac sarcoidosis

N. Mushari¹, G. Soultanidis², L. Duff³, M. G. Trivier^{2,4}, Z. A. Fayad², P. M. Robson², C. Tsoumpas^{1,2,5};
¹Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UNITED KINGDOM, ²BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA, ³Beatson Institute for Cancer Research, Glasgow, UNITED KINGDOM, ⁴Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA, ⁵Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, University of Groningen, Groningen, NETHERLANDS.

EP-0734

Role of Textural and Radiomic Analysis Parameters in Predicting Histopathological Parameters of the Tumour in Breast Cancer Patients.

M. Ravina, R. Kote, T. Lukose, R. K. Gupta, Y. Kashyap, D. Mohanty;
All India Institute of Medical Sciences, Raipur, Raipur, INDIA.

EP-0735

The Impact of Bayesian Penalized Likelihood (BPL) Reconstruction Algorithm With Various β -values on Radiomic Features Reproducibility: An [18F]FDG PET Phantom Study

Z. Valibeiglou¹, J. Pirayesh Islamian¹, Y. Soleymani², P. Sheikhzadeh^{3,4};
¹Department of Medical Physics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF, ²Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Department of Medical Physics and Biomedical Engineering, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0736

Can We Predict Future Relapsed Lymph Nodes on Staging PET/CT for Pediatric Hodgkin's Lymphoma?

N. C. M. Güldali¹, M. O. Kartal²;
¹University of Health Sciences, Ankara Bilkent City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE, ²Health Ministry of Türkiye Republic, Ankara Bilkent City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EP-50

e-Poster Area

D: Technical Studies -> D2 Data Analysis -> D25 Artificial Intelligence

EP-0737

The XGBoost algorithm combined with 18F-FDG PET/CT imaging in the differentiation between benign and malignant thyroid incidentalomas

J. Di¹, X. Ma¹, Z. Ge¹, Q. Xie¹, D. Kong¹, S. Liu¹, S. Lin², J. Ma³, H. Pei³, Y. Zhong⁴, W. Qu¹, X. Zheng¹;
¹Department of Nuclear Medicine Department, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CHINA, ²School of Computer Science and Engineering, Sun Yat-sen

University, Guangzhou, CHINA, ³The MOE Key Laboratory for Intelligent Networks and Network Security, Xi'an, CHINA, ⁴Department of Clinical Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CHINA.

EP-0738

Image quantitative parameters using deep learning-based denoising of ultra-fast whole-body [18F]FDG PET/CT are comparable to standard acquisitions

L. C. Silva¹, C. S. Constantino¹, M. Silva¹, F. P. M. Oliveira¹, R. Vigário², D. C. Costa¹;
¹Champalimaud Foundation, Lisbon, PORTUGAL, ²NOVA School of Science and Technology, Lisbon, PORTUGAL.

EP-0739

A pilot of study: Development of AI model to automatically segment the metastatic lesions on FDG-PET/CT in patients with differentiated thyroid cancer

Y. Li¹, K. Hirata^{1,2,3}, J. Takenaka^{1,2}, H. Endo¹, M. Tang¹, S. Watanabe^{1,2}, R. Kimura^{1,4}, K. Kudo^{1,3,4};
¹Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, JAPAN, ²Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, JAPAN, ³Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Sapporo, JAPAN, ⁴Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, JAPAN.

EP-0740

Predicting Sentinel Lymph Node Status by Using FDG-PET Imaging-Based Texture Analysis in Breast Cancer

K. Saglam, S. ASA, A. KIBAR, M. SAĞER, K. SÖNMEZOĞLU;
Istanbul University-Cerrahpasa Cerrahpasa Medical Faculty, Istanbul, TÜRKIYE.

EP-0741

Construction of a prognostic risk score model with multimodal features of18F-FDG PET/CT images of non-small cell lung cancer byfeatures fusing

X. Wang^{1,2}, X. Li^{1,2}, C. Cui^{1,2}, Z. Wu¹, Z. Wu³;
¹Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, CHINA, ²Collaborative Innovation Center for Molecular Imaging of Precision Medicine Shanxi Medical University, Taiyuan, Shanxi, CHINA, ³Collaborative Innovation Center for Molecular Imaging of Precision Medicine Shanxi Medical University, Taiyuan, Shanxi, CHINA.

EP-0742

Section-Based Regional Recognition of FDG PET/CT Images with Machine Learning

S. Asa, A. Kibar, S. E. Biyiklioglu, M. T. Bodur, S. Sager, K. Sonmezoglu;
Istanbul University Cerrahpasa, Istanbul, TÜRKIYE.

EP-0743

Assessing the Feasibility of Deep Learning-Based Attenuation Correction using Photon Emission Information in 18F-FDG PET Images for Dedicated Head and Neck PET Scanners

M. Shahrabaki Mofrad¹, A. Ghafari¹, A. Amiri Tehranizadeh², M. Ay¹, S. Farzenefar¹, P. Sheikhzadeh¹;
¹Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Mashhad University of Medical Science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-0744

A cascade AI-threshold system for volume segmentation and characterization of lung masses on 18F-FDG PET/CT

G. Savelli¹, E. Schiavon², M. Interlenghi², C. Bnà¹, C. Ferrari¹, M. Bonacina¹, C. Salvatore^{2,3}, I. Castiglioni⁴;
¹Fondazione Poliambulanza Istituto Ospedaliero, Brescia, ITALY, ²DeepTrace Technologies, Milan, ITALY, ³Department of Science, Technology and Society, Scuola Universitaria IUSS, Pavia, ITALY, ⁴Department of Physics, Università degli Studi di Milano-Bicocca, Milan, ITALY.

EP-0745

A New Thoracic CT and Lung Perfusion SPECT Dataset for Developing Analysis of the Lobar Lung Function Assessment

E. Amini^{1,2}, R. Klein^{1,3,4};
¹Ottawa Hospital Research Institute, Ottawa, ON, CANADA, ²Carleton University, Ottawa, ON, CANADA, ³The Ottawa Hospital Department of Nuclear Medicine, Ottawa, ON, CANADA, ⁴University of Ottawa Department of Medicine, Ottawa, ON, CANADA.

EP-0746

Deep-learning Model for Differentiation of Pediatric Bone Diseases by Bone Scintigraphy: A Feasibility Study

P. Yang¹, L. Jiang¹, Y. Xiang¹, J. Wei², Z. Zhao¹, H. Cai¹, Z. Yi², L. Li¹;
¹West China Hospital, Chengdu, CHINA, ²Sichuan University, Chengdu, CHINA.

EP-0747

Reliable and Precise Assessment of Liver Function with a Deep Learning Model-Based Workflow Using Hepatobiliary Scan

H. Sung¹, K. Cho¹, K. Kim¹, H. Choi^{1,2}, G. Cheon^{1,2};
¹Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF, ²Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-0748

ORCA - Optimized Registration through Conditional Adversarial networks for improved PET/CT co-registration using synthetic CT

Z. Chalampalakis¹, D. Iommi, I. Rausch, B. Geist, M. Hacker, T. Beyer, L. K. S. Sundar;
Medizinische Universität Wien, Vienna, AUSTRIA.

EP-0749

May Automated PET Lesion Detection Be Improved Focusing "AI-Brain" On Single Organs?

A. Macula^{1,2}, L. Airo³, S. Colombo Serra², M. Ali⁴, S. Papa⁴, G. Valbusa², A. Bifone¹, P. Gandolfo⁴;
¹Università di Torino, Torino, ITALY, ²Bracco Imaging S.p.a., Milano, ITALY, ³Università di Milano, Milano, ITALY, ⁴Centro Diagnostico Italiano, Milano, ITALY.

EP-0750

CT-free Total-body PET segmentation

C. Clement¹, S. Xue¹, Y. Mao², R. Guo², M. Viscione¹, A. Rominger¹, B. Li², K. Shi¹;
¹Inselspital Bern, Bern, SWITZERLAND, ²Ruijin Hospital, Shanghai, CHINA.

EP-0751

Convolutional neural networks for the prediction of changes in brain metabolism

E. Doering^{1,2}, T. Deusser³, M. C. Hönig^{1,4}, G. N. Bischoff⁴, T. van Eimeren¹, A. Drzezga^{1,4}, L. M. Ellingsen^{5,6};
¹University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Nuclear Medicine, Cologne, GERMANY, ²German Center for Neurodegenerative Diseases (DZNE), Bonn, GERMANY, ³Fraunhofer IAI, Bonn, GERMANY, ⁴Research Center Jülich, Institute of Neuroscience and Medicine - Molecular Organization of the Brain (INM-2), Jülich, GERMANY, ⁵Department of Electrical and Computer Engineering, University of Iceland, Reykjavik, ICELAND, ⁶Department of Electrical and Computer Engineering, The Johns Hopkins University, Baltimore, MD, UNITED STATES OF AMERICA.

EP-0752

A Feasibility Study of Attenuation and Scatter Correction in Whole-Body PET Imaging with 68Ga-Dotatate using Deep Learning: A Dual-Center Investigation

M. Sobhi¹, J. Pirayesh Islamian¹, N. Seyedi², M. Shahrehabaki Mofrad³, R. Samimi⁴, P. Sheikhzadeh⁵;
¹Department of Medical Physics Tabriz University of medical sci, Tabriz, IRAN, ISLAMIC REPUBLIC OF, ²Nursing and Midwifery Care Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Medical Physics and Biomedical Engineering Department, Medical Faculty, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁴Department of Medical Radiation Engineering, Shahid Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC OF, ⁵Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0753

Assessment of CNN Performance in Cases of Breast Cancer, Staging and Restaging- A Tumour Type Not Included in Algorithm Training

A. Nawwar^{1,2,3}, D. Darian⁴, J. Searle^{5,2}, T. Shimizu⁶, I. D. Lyburn^{7,2,8};
¹University Hospitals Bristol and Weston, NHS Foundation Trust, Bristol, UNITED KINGDOM, ²Cobalt Medical Charity, Cheltenham, UNITED KINGDOM, ³Faculty of Medicine, Cairo University, Cairo, EGYPT, ⁴Siemens Healthcare Ltd, Camberley, UNITED KINGDOM, ⁵Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire, UNITED KINGDOM, Cheltenham, UNITED KINGDOM, ⁶Siemens Medical Solutions UNITED STATES OF AMERICA, Inc., Chicago, IL, UNITED STATES OF AMERICA, ⁷Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire, UNITED KINGDOM, CHELTENHAM, UNITED KINGDOM, ⁸Cranfield Forensic Institute, Cranfield University, Wiltshire, UNITED KINGDOM.

EP-0754

Performance analysis of deep progressive learning denoising method vs conventional methods on low dose 18F-FDG whole body PET/CT scans with low counts/reduced time protocol

S. Singh¹, S. Nigam, R. Vajpayee;
Globe healthcare, Lucknow, INDIA.

EP-0755

Effects of CNN-based PET image denoising on image quality and lesion detectability

S. Gnesin¹, S. Medici¹, M. Jreige², M. Conti³, J. Schaefferkoetter³, J. O. Prior²;
¹Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne,

SWITZERLAND, ²Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, ³Siemens Medical Solutions UNITED STATES OF AMERICA, Knoxville, TN, UNITED STATES OF AMERICA.

EP-0756

Comparison of two artificial intelligence tools for anomaly detection and segmentation in 18F-FDG-PET/CT in a monocentric lung and breast cancers patient cohorts

M. Mechti¹, P. Blanc-Durand, E. Itti;
CHU Henri Mondor, PARIS, FRANCE.

EP-0757

Deep Learning for Automatic Prostate Segmentation On 18F-DCFPyL PET/CT In Prostate Cancer.

M. Cysouw¹, W. I. Luining, B. M. de Vries, D. E. Oprea-Lager, A. N. Vis, R. Boellaard;
Amsterdam UMC, Amsterdam, NETHERLANDS.

EP-0758

Assessment of a Deep Learning-Based Noise Reduction Algorithm on the Ultra-Fast Whole-Body Bone Tomoscintigraphies Recorded by a 360° CZT Camera

A. Bahloul^{1,2}, Y. Lamash³, N. Roth³, A. Dari¹, P. Marie^{1,2}, L. Imbert^{1,2};
¹CHRU-Nancy, Department of Nuclear Medicine, Nancy, FRANCE, ²Université de Lorraine, INSERM U1254, IADI, Nancy, FRANCE, ³Spectrum Dynamics Medical, Caesarea, ISRAEL

EP-0759

Automatically acquired tumour staging (T) in FDG-avid lung tumours aided by artificial intelligence.

P. Borrelli¹, M. Milà López², P. Fierro Alanis², M. Larsson³, R. Rossi Norrlund¹, R. Kaboteh¹, L. Edenbrandt^{1,4}, E. Trägårdh^{5,6};
¹Department of Clinical Physiology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, SWEDEN, ²Servicio Medicina Nuclear Hospital Universitario Joan XXIII de Tarragona, Tarragona, SPAIN, ³Eigenvision AB, Malmö, SWEDEN, ⁴Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN, ⁵Department of Translational Medicine and Wallenberg Center for Molecular Medicine, Lund University, Lund, SWEDEN, ⁶Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Malmö, SWEDEN.

EP-0760

Unsupervised and explainable phenotyping on multiparametric contrast enhanced MRI and dynamic 18F-FDOPA PET images of patients with glioma at initial diagnosis

T. Zaragori^{1,2}, A. Zinsz², M. Doyen^{1,2}, L. Imbert^{1,2}, J. Oster^{1,3}, A. Verger^{1,2};
¹Université de Lorraine, IADI, INSERM, UMR 1254, Vandoeuvre-lès-Nancy, FRANCE, ²Department of Nuclear Medicine & Nancyclotep Imaging Platform, CHRU-Nancy, Université de Lorraine, Vandoeuvre-lès-Nancy, FRANCE, ³CHRU Nancy, INSERM, CIC, Innovation Technologique, Université de Lorraine, Vandoeuvre-lès-Nancy, FRANCE.

EP-0761

Artificial intelligence Respiratory Gating in PET/CT Imaging: changes on MTV, TLG and SUVmax
P. Meneses Soares¹, A. Grajeda Gallardo, J. Mucientes Rasilla, R. Jimeno Permett, M. Mitjavila Casanovas;
HOSPITAL PUERTA DE HIERRO, MAJADAHONDA, SPAIN.

EP-51

e-Poster Area

D: Technical Studies -> D3 Radiation Protection -> D31 Radiation Exposure and Protection

EP-0762

Potential airborne releases of 68Ga and 177Lu: a method of preventive assessment
M. Marengo¹, S. Rubow²;
¹University of Bologna, Bologna, ITALY, ²University of Stellenbosch, Stellenbosch, SOUTH AFRICA.

EP-0763

CT dose reduction in hybrid PET/CT imaging
C. Pettinato¹, M. Schiavini, A. Castello, L. Florimonte, C. Canzi, F. Bardo, F. Buffoni, C. Colombo, V. Longari, E. Orunesu, M. Campoleoni, M. Castellani;
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, ITALY.

EP-0764

Ambient Dose Equivalent and Occupational Exposure for 177Lu-PSMA-I&T Radionuclide Therapy
Z. Hu¹, C. Liu², J. Liu², Z. Yang², R. Qiu¹;
¹Tsinghua University, Beijing, CHINA, ²Beijing Cancer Hospital, Beijing, CHINA.

EP-0765

Evaluation of staff exposure to ionising radiation in a PET/CT department
P. Archontakis^{1,2,3}, K. Silivridou², K. Maintas^{2,3}, D. Maintas^{2,3};
¹National and Kapodistrian University of Athens, Athens, GREECE, ²Iatriko Athinon, Athens, GREECE, ³Institute for Isotopic Studies, Athens, GREECE.

EP-0766

Beta radiation protection in Phosphorous-32 microparticles therapy. Tungsten or methacrylate shielding?
C. G. Franco Monterroso¹, B. Santos Montero, L. Rey Sánchez, L. García Lama, V. Pascual Pascual, M. A. Hernández Fructuoso;
Hospital Universitario Vall d'Hebron, Barcelona, SPAIN.

EP-0767

Study of yttrium-90 radiation attenuation using different types of shielding
L. Rey Sánchez¹, C. G. Franco Monterroso, B. Santos Montero, V. Pascual Pascual, L. García Lama, M. A. Hernández Fructuoso;
Hospital Universitario Vall d'hebron, Barcelona, SPAIN.

EP-0768

Evaluating the effectiveness of lead apron in a Nuclear Medicine (PET-CT) facility

A. Shaikh¹, R. Vatsa¹, V. Sawant¹, V. Rangarajan²;
¹Advanced Centre for Treatment, Research, and Education in Cancer, Navi Mumbai, INDIA,
²Tata Memorial Centre, Mumbai, INDIA.

EP-0769

A radiation exposure comparison between manual and automated setups during GALLIUM-68 peptide labelling

M. Costa^{1,2}, R. Parafita^{1,2}, A. Canudo^{1,2,2}, A. Capacho¹, F. Silva¹, H. Delgado^{1,2}, J. Correia^{1,2}, M. Correia^{1,2}, M. Silva^{1,2}, M. Andrade^{1,2}, M. Machado¹, P. Ferreira¹, P. H. Ferreira^{1,2}, R. Oliveira^{1,2}, S. Batanete^{1,2}, S. Teixeira^{1,2}, V. Vieira^{1,2}, F. Oliveira¹, D. Costa¹;
¹Champalimaud Foundation, Lisbon, PORTUGAL,
²Mercurius Health, Lisbon, PORTUGAL.

EP-0770

Typical values of quantities related to the patient dose from PET/CT in Bulgaria: first results

M. Sibinova¹, T. K. Todorova², A. R. Zagorska³;
¹Sofia University "St Kliment Ohridski", Sofia, BULGARIA,
²National center of radiobiology and radiation protection, Sofia, BULGARIA,
³Acibadem City Clinic University Hospital Tokuda, Sofia, BULGARIA.

EP-0771

Radiation Dose Reduction Strategy for SPECT/CT Bone Scan

M. Alezzi¹, O. Kotbi¹, G. Hammid¹, A. Fouda¹, Y. Zabarmawi²;
¹KING ABDULLAH MEDICAL CITY, Makkah, SAUDI ARABIA,
²Umm Al-qura University, Makkah, SAUDI ARABIA.

EP-0772

Radiation safety during 177-Lu labelling and therapy: experience in Bulgaria

A. Zagorska¹;
Acibadem City Clinic University Hospital Tokuda, Sofia, BULGARIA.

EP-52

e-Poster Area

D: Technical Studies -> D4 Dosimetry and Radiobiology -> D41 Preclinical Dosimetry and Radiobiology

EP-0773

Monte Carlo quantification damage by 64Cu incorporate in DNA

J. Carrasco¹, E. Padilla;
Instituto de Ciencias Nucleares, CDMX, MEXICO.

EP-0774

Evaluation of Repeatability of 177Lu Quantitative Imaging Using Monte Carlo Simulation

K. Ishikawa¹, C. Kubota¹, Y. Yasumoto¹, T. Sakashita², H. Daisaki¹;
¹Gunma Prefectural College of Health Sciences, Gunma, JAPAN,
²National Institutes for Quantum Science and Technology, Gunma, JAPAN.

EP-0775

Preclinical in vivo tumour dosimetry of a Lu-177-labelled ligand using a gamma probe

A. Klotsotyra¹, D. Arbuznikova^{1,2,3}, N. Steinacker^{1,2}, L. Domogalla^{1,2}, A. Eder^{1,2}, M. Mix¹;
¹Department of Nuclear Medicine, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY,
²Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), partner site Freiburg, Freiburg, Germany and German Cancer Research Center, Heidelberg, GERMANY,
³Department of Radiation Oncology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GERMANY.

EP-0776

Evaluation of the quantitative accuracy using Monte Carlo simulations in 177Lu imaging

C. Kubota¹, K. Ishikawa¹, Y. Yasumoto¹, T. Sakashita², H. Daisaki¹;
¹Gunma Prefectural College of Health Sciences, Gunma, JAPAN,
²National Institutes for Quantum Science and Technology, Gunma, JAPAN.

EP-53

e-Poster Area

D: Technical Studies -> D4 Dosimetry and Radiobiology -> D42 Clinical Dosimetry

EP-0777

IDAC-Dose 2.2. An internal dosimetry software for diagnostic nuclear medicine using the ICRP computational framework and calculation of the absorbed dose and effective dose to all 12 ICRP reference individuals

M. Andersson^{1,2}, K. Eckerman³, S. Mattsson²;
¹Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Gothenburg, SWEDEN,
²Medical Radiation Physics, Malmö, Malmö, SWEDEN,
³Center for Radiation Protection Knowledge, Oak Ridge National Laboratory, Oak Ridge, TN, UNITED STATES OF AMERICA.

EP-0778

IDAC-ALPHA: AN online ALPHA DOSIMETRY SOFTWARE FOR NORMAL ORGANS And TISSUES

M. Andersson^{1,2}, S. Mattsson²;
¹Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Göteborg, SWEDEN,
²Medical Radiation Physics, Malmö, Malmö, SWEDEN.

EP-0779

Dosimetric model for patients with renal failure undergoing dialysis during I-131 therapy for thyroid cancer

V. Nuttens¹, O. De Winter;
OLVZ, Aalst, BELGIUM.

EP-0780

Comparative analysis of positron-emitters for theranostic applications based on small bioconjugates

C. Morgat^{1,2}, U. Köster³, C. Champion⁴, P. Zanotti-Fregonara⁵, E. Hindi^{1,2,6};
¹Nuclear Medicine Department - University Hospital of Bordeaux, Bordeaux, FRANCE,
²University of Bordeaux, UMR CNRS 5287, INCIA, Bordeaux, FRANCE,
³Institut Laue Langevin, Grenoble, FRANCE,
⁴University of Bordeaux, CNRS, CEA, CELIA, UMR 5107, Talence, FRANCE,
⁵Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD, UNITED STATES OF AMERICA,
⁶Institut Universitaire de France, Paris, FRANCE.

EP-0781

Dosimetry and External Radiation Exposure in 177Lu-PSMA-617 Radioligand Therapy. The INT Pascale Experience

L. D'Ambrosio¹, V. Pirozzi Palmese, C. Maisto, R. de Marino, M. Aurilio, A. Morisco, V. Porfidia, C. Traino, R. De Migno, M. Raddi, F. De Lauro, F. Di Gennaro, S. Lastoria;
National Cancer Institute IRCCS Pascale, Naples, ITALY.

EP-0782

Partial volume correction on Lu-177 PSMA-617 parotid gland dosimetry

G. Mok¹, Z. Lu¹, G. Chen¹, Y. Liu¹, A. Afshar-Oromieh², A. Rominger², K. Shi²;
¹University of Macau, Taipa, MACAO,
²University of Bern, Bern, SWITZERLAND.

EP-0783

A new approach for individual dose monitoring in Molecular Radionuclide Therapy

R. Mirabelli¹, L. Campana¹, B. Cassano², F. Collamati³, R. Faccini¹, G. Iaccarino², C. Mancini Terracciano¹, S. Morganti³, F. Nicolanti¹, M. Pacilio⁴, A. Soriani², E. Solfaroli-Camillocchi⁵;
¹"Sapienza" - Università di Roma, Rome, ITALY,
²IRCCS Regina Elena National Cancer Institute, Rome, ITALY,
³National Institute of Nuclear Physics, Rome, ITALY,
⁴Azienda Ospedaliera-Universitaria Policlinico Umberto I, Rome, ITALY,
⁵Bambino Gesù Children's Hospital, Rome, ITALY.

EP-0784

131I and 177Lu Voxel Dosimetry: characterization, verification and preliminary patient results

E. Richetta¹, C. Valero, B. Elia, V. Pirro, M. Manfredi, R. Pellerito, M. Stasi;
Ordine Maurizio Hospital, Turin, ITALY.

EP-0785

True Single Time Point Dosimetry for [177Lu]Lu-PSMA targeted therapy - Is Haenscheid's method applicable?

J. Kurth¹, M. Heuschkel, B. Krause, S. M. Schwarzenböck;
Rostock University Medical Center, Rostock, GERMANY.

EP-0786

Accuracy of Few-Time-Point Dosimetry Using Non-Linear Mixed-Effects Modelling in Peptide-Receptor Radionuclide Therapy

R. Subangun¹, D. Hardiansyah¹, R. Ibrahim¹, B. Patrianasha¹, A. Beer², G. Glatting²;
¹Universitas Indonesia, Depok, INDONESIA,
²Ulm University, Ulm, GERMANY.

EP-0787

Validation of Pretherapeutic Dosimetry in Metastatic Thyroid Cancer Patient with Chronic Kidney Disease for I-131 Treatment

A. Al Jabri^{1,2}, J. Cooke³, S. Courne⁴, S. Ludgate⁵, M. Healy⁵;
¹Sultan Qaboos University, Muscat, OMAN,
²Trinity College Dublin, Dublin, IRELAND,
³Children's Health Ireland at Crumlin, Dublin, IRELAND,
⁴St Vincent's University Hospital, Dublin, IRELAND,
⁵St James's Hospital, Dublin, IRELAND.

EP-0788

A phantom study on I-124 digital PET/CT quantification performance for lesion dosimetry in (re)differentiated thyroid cancer

M. Dotinga^{1,2}, D. Vriens¹, L. F. de Geus-Oei^{1,3,4}, P. Dibbets-Schneider¹, M. K. Stam¹, M. Pool¹, F. Smit^{1,5}, E. Kapiteijn¹, F. H. P. van Velden¹;
¹Leiden University Medical Center, Leiden, NETHERLANDS,
²NETHERLANDS Cancer Institute, Amsterdam, NETHERLANDS,
³University of Twente, Enschede, NETHERLANDS,
⁴Technical University of Delft, Delft, NETHERLANDS,
⁵Alrijne Hospital, Leiderdorp, NETHERLANDS.

EP-0789

Comparison of bone marrow absorbed dose estimated using blood sampling and gamma camera methods for 177Lu labelled radiopharmaceuticals

G. Katre^{1,2}, T. Srichandan^{1,2}, A. Konuparamban¹, S. Ghag¹, A. Puranik¹, A. Agarwal¹, S. Mithun^{1,2,3}, A. Jha^{1,2}, V. Rangarajan^{1,2};
¹Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, INDIA,
²Homi Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA,
³Department of Radiation Oncology (Maastricht), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, NETHERLANDS.

EP-0790

Lu-177-PSMA Infusion vs Injection: No Difference in Dose Rates of Patients at the Time of Outpatient Discharge

V. Reijonen¹, K. Kiviluoto^{2,1}, V. Ahtiainen¹;
¹Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, FINLAND,
²HUS Pharmacy, Helsinki University Hospital, Helsinki, FINLAND.

EP-0791

Simplified Organ and Tumor Dosimetry for Lu-177-PSMA-I&T Radionuclide Therapy

W. Lehnert¹, L. Schatz, A. Karimzadeh, I. Apostolova, R. Buchert, S. Klutmann;
University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY.

EP-0792

Single time point tumour dosimetry after 177Lu-DOTATATE therapy

S. Ballout¹;
Cambridge University Hospital NHSFT, Cambridge, UNITED KINGDOM.

EP-0793

Role of lung density in voxel-based dosimetry of 90Y-TARE evaluated with Voxel S-Value (VSV) method and fast Monte Carlo simulation

R. Moretti¹, A. Capotosti¹, M. Vaccaro², C. d. Ribeiro², M. Nardini¹, G. Meffe¹, L. Placidi¹, L. Zagaria¹, M. De Risi¹, G. Perotti¹, L. Leccisotti¹, R. Iezzi¹, L. Indovina¹;
¹Fondazione Policlinico Universitario Agostino Gemelli, Rome, ITALY, ²Università Cattolica del Sacro Cuore, Rome, ITALY.

EP-0794

A Dosimetric Comparison of Radioembolization and External Beam Radiation Treatment For Liver Cancer

K. Wysoczynski, B. Mehadji, P. Park, S. Benedict, E. Roncali; University of California, Davis, Davis, CA, UNITED STATES OF AMERICA.

EP-0795

Impact of SPECT acquisition and reconstruction parameters in dosimetry of [177Lu]Lu-PSMA-617 and analogues

T. Lima, M. Gravinatti, A. Zander, H. Grünig, U. Bhure, M. Pérez Lago, K. Strobel; Luzerner Kantonsspital, Luzern, SWITZERLAND.

EP-0796

Commissioning and planning of treatment planning systems for Selective Internal Radiation Therapy

M. Santoro¹, G. Della Gala¹, G. Paolani¹, G. Rasoatsaranany², S. Strolin¹, L. Strigari¹;
¹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, ²International Centre for Theoretical Physics, Trieste, ITALY.

EP-0797

Effect of segmentation uncertainty on pre-therapeutic dosimetry of selective internal radiation therapy using Yttrium-90 Microsphere for hepatocellular carcinoma

A. Nautiyal, T. Melhuish, G. Lewis, S. Michopoulou; University Hospital Southampton, Southampton, UNITED KINGDOM.

EP-0798

Clinical dosimetry of patients treated with Capecitabine, Temozolomide and [177Lu]Lu-DOTA-TOC combined therapy.

A. Cichonski¹, J. B. Ćwikła², A. Kolańska-Ćwikła³, M. Kempńska-Wróbel¹;
¹National Centre for Nuclear Research, Warsaw, POLAND, ²Medical School, University of Warmia and Mazury, Olsztyn, POLAND, ³The Maria Skłodowska-Curie National Institute of Oncology, Warsaw, POLAND.

EP-0799

Voxel-level comparison of 99mTc-MAA SIRT planning SPECT-CT with 90Y-Microspheres post-therapy PET-CT

S. Heard, D. Gillett, R. Crawford, I. Harper, T. C. See, N. Shaida, L. Aloj; Cambridge University Hospitals NHS FT, Cambridge, UNITED KINGDOM.

EP-0800

Clinical experience of whole body and tumour dosimetry of 131-I-mIBG treatment for pediatric patients

I. Torres Espallardo^{1,2}, N. Orrego¹, M. Gándia-Ferrero², V. Cotanda³, C. Olivas¹, L. Martí-Bonmatí^{1,2}, P. Bello-Arques¹, J. Balaguer¹, S. Prado-Wohlwend¹;
¹Clinical Area of Medical Imaging, Valencia, SPAIN, ²Health Research Institute La Fe, Valencia, SPAIN, ³Fundacion IVO, Valencia, SPAIN.

EP-0801

DosePredict: An Open-source Software to Support Treatment Planning for Personalised Radiopharmaceutical Therapy

C. Gomes Ferreira¹, V. R. Warschun², J. Hu¹, S. Xue¹, L. Mercolli³, T. W. Vida², N. Navab², A. Afshar-Oromieh³, A. Rominger³, K. Shi¹;
¹University of Bern, Bern, SWITZERLAND, ²Technical University of Munich, Munich, GERMANY, ³Inselspital, Bern University Hospital, Bern, SWITZERLAND.

EP-54

e-Poster Area

D: Technical Studies -> D4 Dosimetry and Radiobiology -> D43 Clinical Radiobiology

EP-0802

Comparison of Administered Lu-177 and Ac-225 Activities of PSMA Treatments Against Metastatic Prostate Cancer: Radiobiological Factors

V. Ahtiainen^{1,2}, V. Reijonen¹, M. Tenhunen¹;
¹Helsinki University Hospital Comprehensive Cancer Centre, Helsinki, FINLAND, ²Helsinki University, Helsinki, FINLAND.

EP-55

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D51 New Radiopharmaceuticals - SPECT

EP-0803

Preparation of a 99mTc-labeled Bromobenzyl Ether Derivative Targeting PD-L1

W. Hongyong, C. Lu, Y. Liu, J. Wu, H. Wu, G. Han, P. Zou; Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, CHINA.

EP-0804

[113mIn]In-FAPI-46 radiolabeled complex: a new agent for SPECT imaging of FAP-expressing tumors

f. Bolourinovin¹, F. Badipa¹, s. zolghadri², h. yousefnia³;
¹PARS-ISOTOPE, karaj, IRAN, ISLAMIC REPUBLIC OF, ²Radiation Applications Research School, Nuclear Science and Technology Research Institute, P.O.Box: 11365-8486, Tehran-Iran, Tehran, IRAN, ISLAMIC REPUBLIC OF, ³Radiation Applications Research School, Nuclear Science and Technology Research Institute, P.O.Box: 11365-8486, Tehran-Iran, tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0805

First Experience with [195mPt]Cisplatin Imaging in Lung Cancer Patients

D. Hoogenkamp¹, E. A. Aalbersberg¹, K. van der Schilden², H. N. Hendrikse², M. P. J. Mooijer³, U. Funke³, B. D. Windhorst³, L. J. de Wit-van der Veen¹, M. M. G. Rossi¹, J. S. A. Belderbos¹, W. V. Vogel¹;
¹NETHERLANDS Cancer Institute (NKI-AVL), Amsterdam, NETHERLANDS, ²Nuclear Research and Consultancy Group (NRG), Petten, NETHERLANDS, ³Amsterdamumc (location VUmc), Amsterdam, NETHERLANDS.

EP-0806

Preparation and quality control of [113mIn]In-PEG4-BBN(7-14) as a new agent for SPECT imaging of GRPR-expressing tumors

s. zolghadri, F. Badipa, H. Yousefnia, B. Alirezapour, A. Bahrami-Samani, S. Shirvani-Arani, F. Bolouri-Novin; Nuclear Science and Technology Research Institute (NSTRI), Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0807

Preclinical evaluation of a novel PSMA-targeting radioligand [99mTc]Tc-BQ0413

E. Bezverkhniaia¹, P. Kanellopoulos¹, A. Abouzayed¹, M. Oroujeni¹, A. Vorobyeva², U. Rosenström¹, V. Tolmachev¹, A. Orlova¹;
¹Uppsala university, Uppsala, SWEDEN.

EP-56

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D52 New Radiopharmaceuticals - PET

EP-0808

Expanding the Versatility of F-18 Indirect Labeling: Optimizing the Synthesis of TDBFB Boronic Acid Derivatives for Indirect Labeling via Suzuki Coupling

Y. Yagi^{1,2,3}, H. Kimura², M. Ando¹, K. Kawaguchi¹, A. Sato¹, A. Shimizu¹, M. Fujimura¹, T. Higuchi^{3,4};
¹Kyoto college of Medical Science, Nantan, JAPAN, ²Kyoto Pharmaceutical University, Kyoto, JAPAN, ³University Hospital Würzburg, Würzburg, GERMANY, ⁴Okayama University, Okayama, JAPAN.

EP-0809

Automated One-Pot Synthesis of [18F]AIF-NOTA-Ubiquicidin[29-41] in Aqueous Solution with Preparative HPLC for Clinical PET/CT imaging

A. Meyer, C. Fischer, D. Hellwig; University Hospital, Regensburg, GERMANY.

EP-0810

Development of a 18F-PD-L1 radiotracer for cancer patient response to immunotherapy

M. Goodman, L. Chavan, W. Seo, H. Zecca, R. Voll, L. Birnbaum, J. Kelvin, E. Dreaden, N. Jui; Emory University, Atlanta, GA, UNITED STATES OF AMERICA.

EP-0811

rhTATE: A Radiohybrid Approach for 18F or 177LuLabelled Somatostatin Analogues Generating Chemically Identical Compounds

S. Deiser, V. König, S. Fenzl, T. Günther, N. Urtz-Urban, S. Inoue, A. Casini; Technical University Munich (TUM), Garching by Munich, GERMANY.

EP-0812

Phenolate-containing AAZTA-like chelators for 68Ga labelling. An in vitro and in vivo study.

L. Tei¹, J. Martinelli¹, M. Boccalon², A. Vagner³, D. Szikra⁴, G. Trencsenyi⁴, Z. Baranyai²;
¹Department of Science and Technological Innovation, University of Piemonte Orientale, Alessandria, ITALY, ²Bracco Research Centre, Bracco Imaging S.p.A., Colliere Giacosa, Via Ribes 5, ITALY, ITALY, ³Scanomed Ltd., Debrecen, Nagyerdei krt. 98, HUNGARY, ⁴Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, Nagyerdei krt. 98, HUNGARY.

EP-0813

Automated Synthesis Method To Produce The Pet Tracer [68ga]Ga-Fapi-46 For Clinical Applications: Development, Optimization And Validation

S. Migliari, G. Ladisa, M. Scarlattei, G. Baldari, L. Ruffini; Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Parma, ITALY.

EP-0814

Synthesis and Biological Evaluation of 18F-labelled Deuterated Tropane Derivatives as Dopamine Transporter Probes

Q. Hu¹, Z. Chen^{1,2,3}, Q. Li^{2,3}, J. Tang², Y. Fang², C. Liu², J. Liu^{1,2}, M. Qi^{2,4};
¹Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, CHINA, ²NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, CHINA, ³Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, School of Pharmacy, Xuzhou Medical University, Xuzhou, CHINA, ⁴School of Pharmaceutical Science, Inner Mongolia Medical University, Hohhot, CHINA.

EP-0815

18F-labeled TTCO-PSMA Conjugate as a novel PET agent for prostate cancer imaging

T. Zhang, Z. Zhang, G. Dong, L. Le, X. Ji, C. Peng, K. Li, X. Chen; Nanjing Medical University, Nanjing, CHINA.

EP-0816

A novel 68Ga-labeled spermine derivative probe for tumor imaging

K. Qin¹, D. Shi¹, H. Wang^{1,2,3}, S. Li^{1,2,3};
¹Shanxi Medical University, Taiyuan, Shanxi, CHINA, ²Shanxi Key Laboratory of Molecular Imaging, Taiyuan, Shanxi, CHINA, ³Collaborative Innovation Center for Molecular Imaging of Precision Medicine Shanxi Medical University, Taiyuan, Shanxi, CHINA.

EP-0817

Micro-PET Imaging Study of the Novel 68Ga-labeled PET Probe 68Ga-NOTAGA-Nap-Gal

Y. Xu¹, P. Zhou², Y. Wu², H. Wu¹, Y. Liu¹, H. Wang¹, P. Zou¹;
¹Jiangsu institute of Nuclear Medicine, Wuxi, CHINA, ²Nanjing Medical University, Nanjing, CHINA.

EP-0818

Atlas-Based Simulation for Pre-Estimation of Absorbed Dose in Critical Target Organs: A Study Using Monte Carlo Simulations with XCAT Phantoms and Real Patient Data in 68Ga-PSMA PET/CT

N. Vahidfar, M. Fallahpoor, S. Farzanefer; Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0819

Evaluation of Different Ranges of [18F]Fluoride for Production of [18F]F-FAPI-74

A. MORISCO, C. Maisto, R. de Marino, L. D'Ambrosio, E. Squame, M. Buonanno Recchimizuzo, A. Esposito, M. Aurilio, P. Gaballo, S. Lastoria; ISTITUTO NAZIONALE TUMORI - IRCCS - Fondazione G. Pascale, Napoli, ITALY.

EP-0820

Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin $\alpha v \beta 3$

K. Liu; Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, CHINA.

EP-0821

Initial clinical experience with 18F-JK-PSMA-7 PET-CT in evaluation of staging and biochemical recurrence of prostate carcinoma.

P. Chandra, S. Chinnappan, G. Chandran, C. L. Abraham; Zydus Hospital, Vadodara, INDIA.

EP-0822

Synthesis and Characterization of Zr/Mannose-Conjugated Indocyanine Green-Loaded Liposomes as Sentinel Lymph Node Multimodal Diagnostic Agents for PET/NIR Fluorescence Imaging

G. Kim^{1,2}, D. Jeong^{1,2}, H. Lee¹; ¹Dongnam Institute of Radiological and Medical Sciences (DIRAMS), Busan, KOREA, REPUBLIC OF, ²Dongguk University, Gyeongju, KOREA, REPUBLIC OF.

EP-0823

Biological Evaluation of Escherichia Coli Labeled with Zirconium-89 for the Development of Radiopharmaceuticals for Positron Emission Tomography

D. Jeong^{1,2}, G. Kim¹, E. Choi², S. Park², H. Lee¹, S. Kim²; ¹Dongnam Institute of Radiological and Medical Sciences (DIRAMS), Busan, KOREA, REPUBLIC OF, ²Dongguk University, Gyeongju, KOREA, REPUBLIC OF.

EP-0824

It's Twins!? 68Ga & 18F-labelled TriGalactan for Functional Liver Imaging

M. A. Zierke¹, K. Samadikhah², C. Rangger¹, M. Panzer³, A. Schmid², R. Haubner¹; ¹Nuclear Medicine, Innsbruck, AUSTRIA, ²Werner Siemens Imaging Center, Tübingen, GERMANY, ³Internal Medicine I, Innsbruck, AUSTRIA.

EP-0825

Model of Pharmacokinetic Based on Copper-64 Labeled DNA Bipyramid Nanostructure

P. Li, J. Li; Inner Mongolia Medical University, Hohhot, CHINA.

EP-0827

Radionuclide cisternography with PET/CT using Cu-64-DOTA

J. Greiser¹, S. Groeber¹, T. Weisheit¹, T. Niksch¹, C. Kuehnell¹, M. Schwab², R. Drescher¹, M. Freesmeyer¹; ¹Clinic of Nuclear Medicine, University Hospital, Jena, GERMANY, ²University Hospital, Clinic of Neurology, Jena, GERMANY.

EP-0828

11C-Labeled histamine derivatives for PET imaging

X. Shao, K. Mhanna, A. Brooks, J. Witek, D. Raffel, P. Scott; University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA.

EP-0829

Synthesis and Preclinical Evaluation of two novel 68Ga-labeled (R)-pyrrolidin-2-yl-boronic acid-based FAP-targeted tracers for Cancer Imaging with Positron Emission Tomography

S. Bendre, H. Kuo, H. Merken, Z. Zhang, J. Zeisler, N. Coplo, F. Bénard, K. Lin; BC Cancer Research Center, Vancouver, BC, CANADA.

EP-0830

[89Zr]Zr-desferrioxamine-B: A novel agent for PET imaging of Vibrio cholerae infection

H. Yousefnia, F. Mohammadpour-Ghazi, S. Zolghadri; Nuclear Science and Technology Research Institute (NSRTI), Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-0831

Preclinical evaluation of [18F]FEAO, a novel radiotracer for myocardial perfusion imaging in PET

M. Dziuk¹, E. Witkowska-Patena¹, S. Krajewski², J. Towpik², L. Steczek², K. Gotowicz², P. B. Kozanecki², J. Wlostowska², C. Kozanecki²; ¹Military Institute of Medicine National Research Institute, Warsaw, POLAND, ²Synektik Research, Warsaw, POLAND.

EP-0832

LANTana: A phase Ib study investigating epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]-DOTA-TATE in patients with metastatic neuroendocrine tumours

R. Sharma¹, S. R. Khan², M. Naik², T. D. Barwick³, E. O. Aboagye⁴; ¹Imperial college london, London, UNITED KINGDOM, ²Imperial college NHS Healthcare Trust, London, UNITED KINGDOM, ³Imperial College Healthcare NHS Trust London, London, UNITED KINGDOM, ⁴Imperial College London, London, UNITED KINGDOM.

EP-0833

Comparison of [68Ga]Ga-FAPI-46 PET/CT and [18F]FDG PET/CT hepatic tumors

F. Novruzov¹, E. Mehdi¹, N. Orucova², N. Aliyeva¹, R. Shukurov³, Z. Dadashov², F. Valla⁴, J. Aliyev⁵; ¹Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, Baku, AZERBAIJAN, ²Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, Baku, Azerbaijan, Baku, AZERBAIJAN, ³Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, Baku, Azerbaijan, Baku, Azerbaijan, Baku, AZERBAIJAN, ⁴Sofie, Totowa, NJ, UNITED STATES OF AMERICA, ⁵Azerbaijan National Centre of Oncology, Department of General Surgery, Baku, Azerbaijan, Baku, AZERBAIJAN.

EP-57

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D53 New Radiopharmaceuticals - Therapy

EP-0834

Radioimmunotherapy of experimental systemic mucormycosis in a murine model

J. Carvalho, M. E. Malo, K. J. H. Allen, C. Frank, Z. Xiao, R. Jiao, E. Dadachova; University of Saskatchewan, Saskatoon, SK, CANADA.

EP-0835

[123I]CC1: a Radiotheranostic Agent for PARP-expressing Cancer Imaging and Therapy

C. Chan, Z. Chen, M. Veal, G. Dias, G. Destro, M. Mosley, F. Guibbal, V. Gouverneur, B. Cornelissen; University of Oxford, Oxford, UNITED KINGDOM.

EP-0836

Theranostics approach to imaging and treating experimental melanoma with 203/212Pb-labeled antibodies to melanin

R. Jiao¹, K. J. H. Allen¹, M. Malokja782@mail.usask.ca¹, J. Wilson², B. J. B. Nelson², F. Wuest², E. Dadachova¹; ¹University of Saskatchewan, Saskatoon, SK, CANADA, ²University of Alberta, Edmonton, AB, CANADA.

EP-0837

Co-treatment with Trastuzumab Improved Therapy of HER2 expressing Xenografts with [177Lu]Lu-ABY-027 Affibody Molecule

Y. Liu¹, T. Xu¹, A. Vorobyeva¹, A. Loftenius², V. Bodenko³, A. Orlova¹, F. Y. Frejd², V. Tolmachev¹; ¹Uppsala University, Uppsala, SWEDEN, ²Affibody AB, Solna, SWEDEN, ³Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

EP-0838

Organotrifluoroborate Enhances Tumor Targeting of Fibroblast Activation Protein Inhibitors for Targeted Radionuclide Therapy

Y. Liu, M. Xu, J. Chen, X. Cui, Z. Liu; Peking University, Beijing, CHINA.

EP-0839

Development of anti-cancer radioimmunotherapy method targeting angiogenesis.

B. Park, J. Yoon, Y. An, S. Kim; Ajou University Hospital, Suwon, Gyeonggi-Do, KOREA, REPUBLIC OF.

EP-0840

Antimony-119, a promising Auger emitter for targeted radionuclide therapy to eradicate single tumor cells and tumor clusters

A. Larouze¹, M. Alcocer-Avila², C. Morgat¹, C. Champion¹, E. Hindie¹; ¹Université de Bordeaux, Bordeaux, FRANCE, ²Université de Lyon, Lyon, FRANCE.

EP-0841

A Nanodepot Incorporating 177Lu-Labeled Gold Nanoparticles is Ineffective for Treatment of 4T1 Tumours in Balb/c Mice Due to Low β -Particle Energy and Spatially Lower Doses and Shorter Dose Penetration

R. Liu¹, Z. Cai¹, E. Wong², Y. Lu², M. A. Winnik², R. M. Reilly^{1,3,4}; ¹Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, CANADA, ²Department of Chemistry, University of Toronto, Toronto, ON, CANADA, ³Department of Medical Imaging, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, CANADA, ⁴Joint Department of Medical Imaging and Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CANADA.

EP-0842

Radiation Nanomedicines for Local Treatment of Glioblastoma Multiforme - Epidermal Growth Factor Receptor-Targeted and Non-Targeted Gold Nanoparticles Labeled with the Auger Electron-Emitter, 197Hg

M. Brown¹, Z. Cai¹, S. Chen², V. Radchenko², W. Chung³, M. Winnik³, J. T. Rutka⁴, R. M. Reilly^{1,5}; ¹Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, CANADA, ²Life Sciences Division, TRIUMF, University of British Columbia, Vancouver, BC, CANADA, ³Department of Chemistry, University of Toronto, Toronto, ON, CANADA, ⁴Division of Neurosurgery, Hospital for Sick Children and Division of Neurosurgery, Department of Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, CANADA, ⁵Joint Department of Medical Imaging and Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CANADA.

EP-0843

Modification and Evaluation of EGFRVIII-Targeting Peptides for the Targeted Radiotherapy of Glioblastoma Multiforme

F. Schuderer^{1,2}, D. Werner³, M. Rassner³, C. Braun³, J. Galamba Correia⁴, A. Casini^{1,2}; ¹Chair of Medicinal and Bioinorganic Chemistry, Department of Chemistry, Technical University of Munich, Garching, GERMANY, ²Chair of Pharmaceutical Radiochemistry, Department of Chemistry, Technical University of Munich, Garching, GERMANY, ³Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig Maximilians University of Munich (LMU), Munich, GERMANY, ⁴Centro de Ciências e Tecnologias Nucleares and Departamento de Engenharia e Ciências Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, PORTUGAL.

EP-0844

Novel cMet Targeted Radiotheragnostics: Preclinical Development and Optimisation for Clinical Use

C. Portal¹, N. Swanwick¹, A. Prignon², A. Gibson¹; ¹Edinburgh Molecular Imaging Ltd., Edinburgh, UNITED KINGDOM, ²Laboratoire d'Imagerie Moléculaire Positronique (LIMP) UMS28 Small Animal Phenotyping, Sorbonne University, Paris, FRANCE.

EP-0845

Analysis of the effectiveness of 177Lu-Oxodotreotide in the treatment of neuroendocrine tumors sensitive to somatostatin receptors

Á. Alonso García¹, M. L. Bravo-Ferrer Moreno¹, A. Blesa Jiménez¹, M. A. Asensio Ruiz^{1,2}, M. T. Martínez Martínez^{1,2}; ¹Radiopharmacy Service, Virgen de la Arrixaca Hospital, Murcia, SPAIN, ²Instituto Murciano de Investigación Biosanitaria (IMIB)-Arrixaca, Murcia, SPAIN.

EP-58

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D54 New Biological Targets and Ligands

EP-0846

Targeting Regulatory T cells in experimental colon cancer with radioimmunotherapy.

Z. Xiao, R. Jiao, K. J. H. Allen, M. E. Malo, C. Frank, S. Giri, J. L. C. Carvalho, E. Dadachova; University of Saskatchewan, Saskatoon, SK, CANADA.

EP-0847

177Lu-PSMA treatment impacts on the full transcriptome of prostate cancer cells.

F. Amoroso¹, E. O'Neill¹, B. Cornelissen^{2,1}; ¹MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UNITED KINGDOM, ²Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS.

EP-0848

Molecular imaging based response monitoring of non-contact induction heating therapy on infected prosthetic joints

T. Buckle, M. M. Welling, D. D. D. Rietbergen, F. W. van Leeuwen, B. G. Pijls; Leiden University Medical Center, Leiden, NETHERLANDS.

EP-0849

Association Constant Determination of Macropa as Chelator for the Stable Complexation of Barium-131, Lanthanum-133 and Lutetium-177

M. Blei^{1,2}, B. Drobot³, J. Kretzschmar³, H. J. Pietzsch¹, K. Kopka^{1,2}, F. Reissig¹, C. Mamat^{1,2}; ¹Helmholtz-Zentrum Dresden-Rossendorf, Department of Radiopharmaceutical Cancer Research, Dresden, GERMANY, ²TU Dresden, Dresden, GERMANY, ³Helmholtz-Zentrum Dresden-Rossendorf, Department of Resource Ecology, Dresden, GERMANY.

EP-0850

Development and Characterization of Novel Peptide-Based Apelin Theranostic Probes for Glioblastoma

E. Besserer-Offroy^{1,2}, P. Jeanjean¹, F. Al Banaa¹, S. Kwock¹, E. Breault³, J. Fournier³, P. Sarret^{3,4}, D. A. Nathanson^{1,5}, J. Czernin^{1,5}, G. Carlucci^{1,5}, C. E. Mona^{1,5}; ¹David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, UNITED STATES OF AMERICA, ²Inserm U1086 - François Baclesse Comprehensive Cancer Centre, Caen, FRANCE, ³Faculty of Medicine and Health Sciences, Université

de Sherbrooke, Sherbrooke, QC, CANADA, ⁴Sherbrooke University Hospital - Research Centre, Sherbrooke, QC, CANADA, ⁵UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, UNITED STATES OF AMERICA.

EP-0851

PATO-Cy5, a bi-modal tracer for image-guided hepatobiliary surgery

D. Rietbergen, T. Buckle, M. P. van Meerbeek, L. J. Slof, M. van Oosterom, F. W. B. van Leeuwen; Leids Universitair Medisch Centrum (LUMC), Leiden, NETHERLANDS.

EP-59

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D55 Radiopharmacokinetics and Drug Development

EP-0852

Modifying Biodistribution of EpCAM-targeting DARPIn Ec1 by Fusion with Albumin Binding Domain (ABD): Effect of ABD Position

M. Oroujeni¹, A. Vorobyeva¹, A. Hani Binti Rosly¹, J. Garousi², Y. Liu¹, A. Schulga³, E. Konovalova⁴, A. Orlova¹, S. Deyev³, V. Tolmachev¹; ¹Uppsala University, Uppsala, SWEDEN, ²Royal Institute of Technology (KTH), Stockholm, SWEDEN, ³Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, ⁴Russian Academy of Sciences, Moscow, RUSSIAN FEDERATION.

EP-0853

Development of new bone-seeking radiolabeled compounds

K. Ogawa, K. Nishizawa, K. Mishiro, N. Effendi, T. Fuchigami, M. Munekane, H. Wakabayashi, S. Kinuya; Kanazawa University, Kanazawa, JAPAN.

EP-0854

Development of fluorinated α -methyl-3BPA derivatives for BNCT/PET theranostics

F. Hirano¹, N. Kondo¹, Y. Murata², A. Sudani², T. Temma¹; ¹Osaka Medical and Pharmaceutical University, Osaka, JAPAN, ²Stella Pharma Corporation, Osaka, JAPAN.

EP-0855

In Vivo Stability Evaluation of Astatobenzene Derivatives Having Neighboring Substituents

S. Hirata¹, K. Mishiro¹, K. Washiyama², T. Fuchigami¹, M. Munekane¹, K. Takahashi², Y. Arano³, S. Kinuya¹, K. Ogawa¹; ¹Kanazawa University, Kanazawa, JAPAN, ²Fukushima Medical University, Fukushima, JAPAN, ³Chiba University, Chiba, JAPAN.

EP-0856

Development of FAP-Targeted Inhibitors with Extended Blood Circulation

L. Feng¹, X. Zeng², J. Fang², H. Liu², X. Zhang³, D. Jiang¹, R. Zhuang²; ¹Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHINA, ²Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen,

CHINA, ³Department of Nuclear Medicine & Department of Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CHINA.

EP-0858

Method development for the analysis of 14C-acetaminophen by HPLC-MS

P. Chang, S. Fann; Institute of Nuclear Energy Research, Tao-Yuan, TAIWAN.

EP-0859

Radiolabeling and biodistribution evaluation of orally administered nanovaccines against enterotoxigenic Escherichia coli formed by vesicles of their outer membrane encapsulated in Gantrez[®]-mannosamine nanoparticles

G. Quincoces¹, M. Berzosa², F. Pareja¹, M. Collantes³, M. Ecaz³, R. Ramos-Membrive¹, J. Simón¹, V. Betech-Antar⁴, J. Rosales⁴, I. Peñuelas¹; ¹Radiopharmacy Unit. Nuclear Medicine Department. University Clinic of Navarra, Pamplona, SPAIN, ²Microbiology Department. University of Navarra, Pamplona, SPAIN, ³UNIMTRA. Nuclear Medicine Department. University Clinic of Navarra, Pamplona, SPAIN, ⁴Nuclear Medicine Department. University Clinic of Navarra, Pamplona, SPAIN.

EP-0860

Effects of DOTATATE on plasma protein-binding and tumour cell-uptake of 68Ga- and 177Lu-DOTATATE

L. Schneider, Y. Zhao, M. Zuhayra, U. Lützen; Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy UKSH, Kiel, GERMANY.

EP-0861

Evaluation of influence of albumin binding domain position on biodistribution of HER2-targeting DARPIn-DM1 drug conjugates using radiolabeling

A. Vorobyeva¹, T. Xu¹, Y. Liu¹, M. Oroujeni¹, A. Schulga^{2,3}, J. Garousi⁴, E. Konovalova², Y. Liao¹, A. Zikrileh¹, P. Kanellopoulos¹, O. Bragina^{5,3}, T. Gråslund⁴, A. Orlova¹, S. M. Deyev^{2,3}, V. Tolmachev¹; ¹Uppsala University, Uppsala, SWEDEN, ²ShemyakinOvchinnikov Institute of Bioorganic Chemistry, Moscow, RUSSIAN FEDERATION, ³Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION, ⁴Royal Institute of Technology (KTH), Stockholm, SWEDEN, ⁵Tomsk National Research Medical Center, Tomsk, RUSSIAN FEDERATION.

EP-0862

Preparation, double radiolabeling of Albumin Nanoparticles (HSA-NPs) with technetium-99m and gallium-67 and in vivo biodistribution studies using microSPECT/CT to accelerate their pharmaceutical development as nanovaccines

F. Pareja del Rio¹, E. van Brandwijk¹, J. A. Simon¹, A. Bronte¹, V. Betech-Antar¹, F. Minguez¹, M. Romera¹, J. J. Rosales¹, M. Collantes¹, R. Ramos², G. Quincoces¹, I. Peñuelas¹; ¹Nuclear Medicine Department. Clínica Universidad de Navarra, Pamplona, SPAIN, ²Nuclear Medicine Department. Clínica Universidad de Navarra, Madrid, SPAIN.

EP-0863

Pharmacological implications of molar activity of 225Ac-labeled PSMA targeting agents in prostate cancer tumor models.

R. Hernandez, A. Thickens, H. Comas Rojas, N. Clemons, A. Carston, Y. Medina Guevara, L. Lambert Lepesevich, A. Pinchuk; University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

EP-0864

In vitro stability of 99mTc-FITC-SFN for Oral Drug Delivery System

M. Asensio Ruiz^{1,2}, Á. Alonso García¹, M. Bravo-Ferrer Moreno¹, A. Blesa Jiménez¹, A. A. Lozano-Pérez^{2,3}, M. T. Martínez Martínez^{1,2}; ¹Radiopharmacy Service, Virgen de la Arrixaca Hospital, Murcia, SPAIN, ²Instituto Murciano de Investigación Biosanitaria (IMIB)-Arrixaca, Murcia, SPAIN, ³Departamento de Biotecnología Genómica y Mejora Vegetal, Instituto Murciano de Investigación y Desarrollo Agrario y Medioambiental, Murcia, SPAIN.

EP-0865

Development of new molecular drug delivery tools based on PET imaging : in vivo performance research of nucleic acid nanomaterials

Q. Xia; Department of Nuclear Medicine, School of Medicine, Shanghai Jiao Tong University, Shanghai, CHINA.

EP-0866

Preparation and in vitro evaluation of an anti-HER2 Affibody radiolabelled with Zr-89

D. Niculae^{1,2}, R. Leonte¹, R. Cornoiu¹, D. Cocioaba¹, L. Chilug¹, S. Baruta¹, B. Burghelae¹, L. Craciun¹, A. Popa¹, A. Necsoiu¹, D. Draganescu²; ¹Horia Hulubei National Institute for Physics and Nuclear Engineering, Bucharest (Magurele), ROMANIA, ²University of Medicine and Pharmacy Carol Davila, Bucharest, ROMANIA.

EP-0867

The Impact of Renal Uptake on 18F-DCFPyL Biodistribution

G. Chaussé¹, S. Plaha²; ¹McGill University, Montreal, QC, CANADA, ²University of British Columbia, Vancouver, BC, CANADA.

EP-60

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D56 Radionuclide Production

EP-0868

Preparation of Ga/Ni Solid Target for Cyclotron-produced 68Ge by Electrodeposition

Y. Shen; China Institute of Atomic Energy, Beijing, CHINA.

EP-0869

Developing Actinium-225 large-scale supply
S. Bertrand¹, S. Van den Berghel¹, W. Leysen², J. Mermans², S. Heinitz², D. Maertens¹, G. Scheveneels², C. Gameiro³, A. Cea², P. Vanwolleghe¹, M. Sprangers²;
¹Pantera, Mol, BELGIUM, ²Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM, ³Ion beam applications, Louvain-la-Neuve, BELGIUM.

EP-0870

CERAD, Center of Design and Synthesis of Radiopharmaceuticals for Molecular Targeting and 30 MeV cyclotron for medical isotope production in Poland
R. Mikolajczak, D. Pawlak, W. Wojdowska, I. Cieszykowska, T. Szyszko, P. Garnuszek;
National Centre for Nuclear research-POLATOM, Otwock, Poland, POLAND.

EP-0871

Cyclotron production of 68Ga with in-target dissolution
D. Szikra, V. Forgács;
University of Debrecen, Debrecen, HUNGARY.

EP-0872

Development of New Automated Methods for [18F]-NaF Productions using FDG synthesizer.
S. NGOKPOL, S. Kijprayoon, T. Saonam;
Bangkok hospital, Bangkok, THAILAND.

EP-0873

How Can Nuclear Physicians Mitigate the Patient's Fear of Medical Radiation Exposure? -Lessons Learned from Fukushima Dai-ichi Nuclear Power Plant Accident -
K. Ohno¹, M. Kajisako²;
¹Kyoto Collage of Medical Science, Kyoto Nantan, JAPAN, ²Kyoto University Hospital, Kyoto, JAPAN.

EP-0874

A low energy cyclotron, as an enabler for cancer diagnosis in emerging countries
J. Geets, E. Kral, J. Harray, V. Petry;
Ion Beam Applications SA, Louvain-La-Neuve, BELGIUM.

EP-61

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/Radiochemistry -> D57 Radiopharmaceutical Preparation and Quality Control

EP-0875

Radiosynthesis and Formulation of [18F]mFBG : The challenge of a clinical use radiopharmaceutical for a pediatric population
J. Fouque, L. Trump, B. Irumva, M. Steffann, E. Da Costa Branquinho, Q. Bruyer, C. Provost, O. Madar;
Institut Curie, Saint-Cloud, FRANCE.

EP-0876

Automated Production of 177Lu-Labelled Radiotracers Using Microfluidic Approach
S. Lahdenpohja¹, C. Piatkowski², L. Tanguy², B. Kuhnast¹;
¹Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Orsay, FRANCE, ²PMB Alcen, Peynier, FRANCE.

EP-0877

Comprehensive analysis of environmental monitoring data from the GMP radiopharmaceutical facility of the UMCG obtained between 2010-2022
H. Boersma¹, L. B. S. Bekhof², T. W. T. Poiesz², M. M. Woerdenbag¹, D. Giesen¹, H. T. Tholen¹, G. Luurtsema¹, M. N. Lub-de Hooge¹, H. J. Woerdenbag²;
¹University Medical Center Groningen, Groningen, NETHERLANDS, ²University of Groningen, Groningen, NETHERLANDS.

EP-0878

Fully Automated Radiosynthesis Quality Control and GMP Validation of [68Ga]Ga-PentixaFor for CXCR4 PET Imaging: First Taiwan Experience
M. Li¹, L. Hung¹, S. Yang¹, T. Lin¹, Y. Huang¹, W. Pa²;
¹Koo foundation Sun Yat-Sen Cancer Center, Taipei, TAIWAN, ²Advancharis Science and Research Co., Ltd, New Taipei City, TAIWAN.

EP-0879

Radiosynthesis of Theranostic FAP-2286: This Is the Way
M. Aurilio, C. Maisto, A. Esposito, V. Porfidia, M. Buonanno, R. de Marino, A. Morisco, E. Squame, S. Lastoria;
National Cancer Institute G. Pascale, Napoli, ITALY.

EP-0880

The Optimization of the Current ININ Method of Lu-177 DOTA-HYNIC-iPSMA
Y. Omar¹, Y. Atteya¹, N. Taha², M. AbdelKawi¹;
¹Misr Radiology Center, Cairo, EGYPT, ²Ain Shams University, Cairo, EGYPT.

EP-0881

Automated cassette-based synthesis of [18F] Fluoro-L-DOPA via Cu-mediated process for routine production in a GMP environment
N. Emmanuel, D. Goblet, G. Decoux, C. Gameiro;
IBA, Louvain-la-Neuve, BELGIUM.

EP-0882

The Use of a Mobile Clean Room for (Re)loading of a More Durable Sr-82/Rb-82 Generator
R. Claessens¹, J. C. Vink², K. Baggerman²;
¹Rubigen b.v, 's-Hertogenbosch, NETHERLANDS, ²Baggerman Farma Consult, Eindhoven, NETHERLANDS.

EP-0883

[68Ga]Ga-Pentixafor automatized synthesis using a new module: development and quality control before use in routine for CXCR4 PET imaging
T. Daniel, C. Balouzet Ravinet, J. Clerc, R. Batista, Y. Mouraef;
Hôpital Cochin, Assistance publique - Hôpitaux de Paris, Paris, FRANCE.

EP-0884

Formulation of a Kit for Preparing 89Zr-DFO-Pembrolizumab Injection Under Good Manufacturing Practices for Imaging the Uptake of Pembrolizumab into Brain Metastases in Patients with Lung Cancer by PET
S. Borlase¹, C. Chan¹, R. Reilly^{1,2};
¹Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, CANADA, ²Joint Department of Medical Imaging and Princess Margaret Cancer Centre, University Health Network, Toronto, ON, CANADA.

EP-0885

Investigation of the Radiolabelling Potential of the Aurora A Kinase Inhibitor Alisertib with Iodine-123 [123I]
E. Uygur¹, C. Sezgin¹, B. Y. Akdağ², T. Özbey², Y. Parlak¹, K. B. Karatay³, F. G. Gümüşer¹, F. Z. Biber Müftüler³;
¹Manisa Celal Bayar University, Manisa, TÜRKIYE, ²TENMAK, Ankara, TÜRKIYE, ³Ege University, İzmir, TÜRKIYE.

EP-0886

Radiolabeling of [225Ac]Ac-PSMA-617 vs [225Ac] Ac-DOTATATE: What Analogies? What Differences?
A. Esposito, M. Aurilio, M. Buonanno, A. Morisco, C. Maisto, L. D'Ambrosio, D. Di Martino, S. Lastoria;
IRCCS INT "Fondazione Pascale", Naples, ITALY.

EP-0887

Comparison of 111In and 201Tl Radiopharmaceutical Adsorption on Acrylic Phantoms
T. Inagaki¹, N. Fujita², R. Isobe¹, T. Nagahara¹, S. Abe², K. Kato¹;
¹Nagoya University Graduate School of Medicine, Nagoya, JAPAN, ²Department of Radiological Technology, Nagoya University Hospital, Nagoya, JAPAN.

EP-0888

Cassette-Based Sterility Testing of Radiopharmaceuticals: A Novel Approach to Ensuring Quality and Safety
M. Nousch¹, G. Reischl², R. Schulze³, K. Tautz⁴, D. Freitag-Steckl¹;
¹CUP Laboratorien Dr. Freitag GmbH, Radeberg, GERMANY, ²Universitätsklinikum Tübingen, Tübingen, GERMANY, ³Sächsisches Staatsministerium für Soziales und Gesellschaftlichen Zusammenhalt, Dresden, GERMANY, ⁴Eckert & Ziegler GmbH, Berlin, GERMANY.

EP-0889

Determination of Extractables and Leachables in Radiopharmaceuticals
M. Nousch¹, M. Janich¹, S. Becker², T. Otten², M. Zurbrugg², R. Schulze³;
¹CUP Laboratorien Dr. Freitag GmbH, Radeberg, GERMANY, ²Intertek (Schweiz) AG, Reinach, SWITZERLAND, ³Sächsisches Staatsministerium für Soziales und Gesellschaftlichen Zusammenhalt, Dresden, GERMANY.

EP-0890

Comparative analytical methods for testing residual solvents in quality control of PET radiopharmaceuticals
V. Mendi Barcina¹, M. De Arcocha Torres¹, Á. Gutiérrez González², I. Martínez Rodríguez², N. Martínez Amador², F. Gómez de la Fuente², A. Sánchez Salmón², J. Jiménez Bonilla², M. Pombo López², A. Bota Bota², R. Quirce Pisano²;
¹Radiopharmacy Unit, Nuclear Medicine Service Marqués de Valdecilla University Hospital. Molecular

Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN, ²Nuclear Medicine Service Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN.

EP-0891

Highly efficient, biocompatible radiolabeling method for in vivo cell tracking
R. Hernandez, A. Thickens, Z. Rosenkrans, L. Lambert-Lepesevich, J. Kink, E. Aluicio-Sarduy, A. Pinchuk, J. Engle;
University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

EP-0892

Comparative methods of labeling red blood cells
M. Crespi Busquets¹, J. Romero Herrera¹, S. Maymó Garrido¹, D. Rodríguez Puig¹, C. Munuera Sañudo¹, E. Pineda Fernández¹, M. Bueno Raspall¹, M. Cortés Romera²;
¹Radiopharmacy Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, SPAIN, ²Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN.

EP-0893

Automated Production Of [18F]UCB-J Using A Dibenzothiophenium Salt Precursor For Labelling
D. Pritchard, F. Sirindil, M. Glaser, R. Awais, F. Twyman, E. Eedan, K. Sander, E. Arstad;
University College London, London, UNITED KINGDOM.

EP-0894

Ga68-PSMA-11 : push it to the limit with prepurification
M. Debarge¹, A. Lombard¹, S. Journo¹, N. Veran¹, Q. Citerne¹, B. Demore^{2,1};
¹Nancy University Hospital, Vandoeuvre-lès-Nancy, FRANCE, ²Lorraine University, EA 4360 APEMAC, Nancy, FRANCE.

EP-0895

Initial experience on the cassette-based synthesis of 11C-Pittsburgh Compound-B
H. Gama Romero, F. Trejo-Ballado, E. Zamora-Romo, M. Mendoza-Figueroa, G. Tecuapetla-Chantes, U. Rabadán-Domínguez, G. Contreras-Castañón, A. Zárate-Morales, A. Flores-Moreno, M. Ávila-Rodríguez;
Unidad Radiofarmacia-Ciclotrón, Facultad de Medicina, Universidad Nacional Autónoma de México, MEXICO.

EP-0896

GMP Production of 89Zr-DFO-Pembrolizumab for Immuno-PET: predicting response in non-small lung cancer
I. Hrynchak¹, M. Silva¹, S. Silva², A. Fonseca¹, A. Falcão³, A. J. Abrunhosa^{1,3};
¹ICNAS Pharma Unipessoal, Lda, Coimbra, PORTUGAL, ²Pulmonology, Leiria Hospital Center, Leiria, PORTUGAL, ³CIBIT/ICNAS, Institute for Nuclear Science Applied to Health – University of Coimbra, Coimbra, PORTUGAL.

EP-0897

Optimizing of automated production of Gallium-68 radiolabeled clinical agents by cyclotron liquid target system
Y. Shimizu¹, K. Miyake², Y. Nakamoto²;
¹Kyoto University Hospital, Kyoto, JAPAN, ²Kyoto University Graduate School of Medicine, Kyoto, JAPAN.

EP-0898

Single center experience in the [18F]DPA-714 production using commercial disposable cassettes on AllinOne synthesizer

M. Riondato¹, A. Democrito¹, C. Ghersi¹, S. Grugni², M. Bauckneht¹, S. D. Morbelli¹, C. Marini³, G. Sambuceti¹; ¹University Policlinic Hospital of Genoa, Genoa, ITALY, ²Gamma Servizi srl, Borgherello Pavia, ITALY, ³CNR Institute of Molecular Bioimaging and Physiology (IBFM), Milan, ITALY.

EP-62

e-Poster Area

E: Other Studies -> E1 Case Reports

EP-0899

18F-FDG- PET/CT guided biopsy has an essential role in the diagnosis of primary extranodal diffuse large B-cell lymphoma of bone- a clinical case.

Z. Dancheva¹, S. Spasova, T. Stoeva, I. Kobakova, M. Dyankova, S. Chausheva, T. Yordanova, B. Chaushev, A. Klisarova, B. Balev; St Marina University Hospital, Varna, BULGARIA.

EP-0900

A rare finding in 18F-FDG PET/CT restaging - unilateral diaphragmatic crura increased uptake in patient with pneumonectomy - a Case report

T. Stoeva¹, T. Yordanova, M. Dyankova, S. Chausheva, Z. Dancheva, B. Chaushev, A. Klisarova; UMHAT "Sveta Marina" EAD- Varna, Varna, BULGARIA.

EP-0901

Osteomyelitis in patient with multiple myeloma- the invisible threat seen in 18F-FDG PET/CT

T. Stoeva¹, M. Dyankova, Z. Dancheva, T. Yordanova, S. Chausheva, B. Chaushev, A. Klisarova; UMHAT "Sveta Marina" EAD- Varna, Varna, BULGARIA.

EP-0902

18F-FDG PET/CT in a patient with two metachronous tumors and the possible diagnostic pitfalls

T. Stoeva¹, Z. Dancheva, M. Dyankova, S. Chausheva, T. Yordanova, B. Chaushev, A. Klisarova; UMHAT "Sveta Marina" EAD- Varna, Varna, BULGARIA.

EP-0903

A case report of abnormal bone imaging caused by bevacizumab

T. Yi¹, C. Yu; The Second Affiliated Hospital of Guilin Medical University, Guilin, CHINA.

EP-0904

Primary colorectal cancer with increased 68Ga-PSMA expression on PET/CT: incidental second malignancy in primary staging for prostate cancer (PC)

M. Dyankova^{1,2}, S. Chausheva¹, Z. Dancheva¹, T. Stoeva¹, T. Yordanova¹, B. Chaushev¹, A. Klisarova¹; ¹Medical University Varna "Prof. Dr. Paraskev Stoyanov", Department of Imaging Diagnostics, Interventional Radiology and Radiotherapy, Varna, BULGARIA, ²St. Marina University Hospital, Department of Nuclear Medicine, Varna, BULGARIA.

EP-0905

Unusual recurrence of secondary renal hyperparathyroidism caused by a ectopic undescended parathyroid adenoma: a case report

w. Weng¹; The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CHINA.

EP-0906

Incidental Paget bone disease as a potential pitfall in 18-F FDG PET/CT in melanoma patient

S. Moustafa¹; Assiut university hospital, Assiut university, EGYPT.

EP-0907

Pitfall In Tumor Assessment FDG-PET/CT Imaging In Hodgkin Lymphoma Due To Cocaine-Induced Nasal Inflammation

A. Jouglu¹, J. Alberini^{1,2,3}, B. Durand-Baillood¹, R. Ahond-Vionnet¹;

¹Department of Nuclear Medicine, Hôpital Pierre Bèregovoy, Nevers, FRANCE, ²Department of Nuclear Medicine, Centre Georges-François Leclerc, Dijon, FRANCE, ³ICMUB Laboratory, UMR CNRS 6302, University of Burgundy, Dijon, FRANCE.

EP-0908

Suspected Central Pontine Myelinolysis detected by 18F-FDG PET/CT in a patient with septic shock

L. Locantore¹, M. Cucca, E. Biggi, R. J. Egoue Mongoue, I. Ravelli, D. Riolo, M. Zuffante; Nuclear Medicine Unit, AOUI, Verona, ITALY.

EP-0909

FDG PET/CT in the Evaluation of Multi-systemic Involvement in Erdheim Chester Disease

M. Guven¹, M. Eroglu², A. Oral¹, C. Eraslan², Z. Ozcan¹; ¹Department of Nuclear Medicine, Ege University, Izmir, TÜRKIYE, ²Department of Radiology, Ege University, Izmir, TÜRKIYE.

EP-0910

Accidentally Detected Lung Masses as Carcinoma in 99mTc (V)-DMSA SPECT Imaging

E. Gharehpapagh¹, S. Rezaei¹, L. Namvar²; ¹Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF, ²Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF.

EP-0911

Unusual uptake of bone metastases in 99mTc-MAG3 dynamic renal scintigraphy

K. Aslaner¹, B. Arca, D. Has Simsek, F. Buyukkaya, Y. Sanli, S. Kuyumcu; Istanbul University, Istanbul, TÜRKIYE.

EP-0912

Contribution of SPECT-CT in the Differentiation of Ectopic Thyroid Tissue and Thyroglossal Duct Cyst

G. Deniz¹, E. G. Isik², D. Has Simsek², Y. Sanli², B. Arca², S. Kuyumcu²; ¹Istanbul University Istanbul Faculty of Medicine Nuclear Medicine Department, Istanbul, TÜRKIYE, Istanbul, TÜRKIYE, ²Istanbul University Istanbul Faculty of Medicine Nuclear Medicine Department, Istanbul, TÜRKIYE.

EP-0913

Case report: Pulmonary Langerhans cell histiocytosis (PLCH) - is it a challenge for 18F-FDG PET/CT?

M. Dyankova^{1,2}, T. Stoeva¹, Z. Dancheva¹, S. Chausheva¹, T. Yordanova¹, B. Chaushev¹, A. Klisarova¹; ¹Medical University Varna "Prof. Dr. Paraskev Stoyanov", Department of Imaging Diagnostics, Interventional Radiology and Radiotherapy, Varna, BULGARIA, ²St. Marina University Hospital, Department of Nuclear Medicine, Varna, BULGARIA.

EP-0914

Diagnostic pitfall in a PET/CT case of thyroid cancer with 18F-FDG multi-uptake

T. Yi¹, C. Yu; The Second Affiliated Hospital of Guilin Medical University, Guilin, CHINA.

EP-0915

Persistent bone focal uptake of 18F-PSMA-1007 in patient with prostate cancer and undetectable levels of PSA under hormone therapy

G. Bellettati¹, S. Pacella², A. Castello², E. Lopci³, L. Florimonte², M. Castellani²; ¹University of Milan, Milan, ITALY, ²Fondazione IRCCS Ca'Granda, Ospedale Maggiore Policlinico, Milan, ITALY, ³Humanitas Clinical and Research Hospital, Rozzano, ITALY.

EP-0916

Isolated limb perfusion (ILP) in a patient with myxoid liposarcoma (MLPS) of the lower extremity - case report

J. Peric¹, I. Žagar; Institute of Oncology Ljubljana, Ljubljana, SLOVENIA.

EP-0917

Phase analysis using CZT-SPECT for evaluating mechanical synchronization: a case report on Left bundle branch-optimized cardiac resynchronization therapy (LOT-CRT)

Q. Sun^{1,2}, S. Li³; ¹Department of Nuclear medicine, Shanxi Cardiovascular Hospital, Tai yuan, CHINA, ²Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Tai yuan, CHINA, ³Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Tai yuan, CHINA.

EP-0918

Study of joint infection in a Jehovah's Witness patient with 99mTc-Besilesomab

P. Guardia Jimena¹, A. Santos Bueno, E. Sánchez de Mora, C. Salgado Garcia, A. Jiménez Heffernan; Hospital Universitario Juan Ramón Jiménez, Huelva, SPAIN.

EP-0919

Perineural Spread Into Cerebello Pontine Angle, High Grade Salivary Duct Carcinoma Mimicking as Vestibular Schwannoma diagnosed on F18 FDG PET/CT - A Case report

A. Dixit¹; Rajiv Gandhi Cancer Institute And Research Centre, North West Delhi, INDIA.

EP-0920

SAPHO syndrome - a rare and challenging diagnosis on FDG PET/MRI

J. Foukal¹, T. Koprivova, H. Kašpárková; Fakultni nemocnice Brno, Brno, CZECH REPUBLIC.

EP-0921

Isolated splenic metastasis from colon cancer

S. Pacella¹, E. Farè², E. Collovà², L. Roncoroni², C. Migliorisi², A. Calcagno², M. Carletto², L. Maffioli³; ¹IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milano, ITALY, ²ASST Ovest Milanese-Ospedale Civile di Legnano, Legnano, ITALY, ³ASST Sette Laghi, Varese, ITALY.

EP-0922

The role of 2-[18F]FDG-PET/CT in a rare case of Nasal Cavity Melanoma

I. C. Ferreira¹, R. T. Ferreira¹, A. T. Xavier², S. Carmona¹, A. I. Santos¹; ¹Hospital Garcia de Orta, E.P.E., Almada, PORTUGAL, ²Centro Hospitalar Barreiro Montijo, E.P.E., Barreiro, PORTUGAL.

EP-0923

A Rare Coexistence of Rectal Adenocarcinoma and Primary Squamous Cell Carcinoma of the Thyroid: Emphasizing the Importance of FDG PET/CT Whole-Body Imaging

J. Yu¹, X. Cao, Y. Wang; The Fifth Affiliated Hospital of Sun Yat-sen University Department of Nuclear Medicine, Zhuhai, CHINA.

EP-0924

Gallbladder visualization, a false positive finding on 99mTc-labeled red blood cell

A. Leiva Montejo¹, A. De Agrela Serrao, D. Cáceres Silva, C. Ruiz Corbalán, T. Rodríguez Lorcano, J. Contreras Gutierrez, J. Navarro Fernández, L. Frutos Esteban, A. Hernandez Martinez, L. Mohamed Salem, M. Castellon Sánchez; Hospital Virgen de la Arrixaca, Murcia, SPAIN.

EP-0925

18F-FDG PET/CT identifying breast and pancreas metastases of Nasal Mucosal Melanoma

A. Leiva Montejo¹, C. Ruiz Corbalán, A. De Agrela Serrao, D. Cáceres Silva, J. Contreras Gutierrez, T. Rodríguez Lorcano, J. Navarro Fernández, L. Frutos Esteban, A. Hernandez Martinez, L. Mohamed Salem, M. Castellon Sánchez; Hospital Virgen de la Arrixaca, Murcia, SPAIN.

EP-0926

99mTc-labelled heat-Damaged Red Blood Cell scintigraphy in the study of unspecific nodular foci on CT - a case report

R. Silva¹, M. Silva, H. Martins, D. Leiro, A. Barbosa, L. Costa; Centro Hospitalar Universitário de Santo António, Porto, PORTUGAL.

EP-0927

Why Should We Look at the Thyroid Gland in Myocardial Perfusion Scintigraphy?

B. Pereira¹, P. Soeiro, A. Fernandes, A. Oliveira; Centro Hospitalar Universitário de São João, Porto, PORTUGAL.

EP-0928

Hyperparathyroidism Jaw Tumor Syndrome: A Case Report

E. Gharehpapagh¹, S. Rezaei; Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF.

EP-0929

PET/CT [18F]FDG Findings in Post-COVID-19 Syndrome with Cognitive Sequelae: A Case Report
L. Wichert-Ana, L. E. Lopes-Santos, D. L. Ferreira, A. C. Trevisan, L. Alexandre-Santos, M. P. Foss, M. Kato, F. B. Rodrigues, F. A. Pitella, O. Y. Fukumori, V. Tumas; *Ribeirão Preto Medical School - University of São Paulo, Ribeirão Preto, BRAZIL.*

EP-0930

A Rare Case of Bone Epithelioid Angiosarcoma In a Patient with History of Acute Myeloid Leukemia and Steroid-induced Osteonecrosis
D. Bucur, F. Paycha; *Hopital Lariboisiere, Paris, FRANCE.*

EP-0931

18F-FDG PET-CT in Merkel cell carcinoma: case report
A. Ciocan¹, L. Mititelu^{2,3}, C. Mazilu⁴, T. Mititelu^{2,3}, A. Mazilu⁵, D. Cuzino⁶, M. Oancea⁶, D. Zob⁷, D. Costache⁸, R. Mititelu^{2,4}; ¹Oncologic Institute "Prof. Dr. Alexandru Trestioreanu", Bucharest, ROMANIA, ²University of Medicine and Pharmacy "Dr. Carol Davila", Bucharest, ROMANIA, ³Institute of Military Medicine, Bucharest, ROMANIA, ⁴Clinic of Nuclear Medicine, Central University Emergency Military Hospital Bucharest, Bucharest, ROMANIA, ⁵Clinic of Endocrinology, Central University Emergency Military Hospital Bucharest, Bucharest, ROMANIA, ⁶Clinic of Radiology, Central University Emergency Military Hospital Bucharest, Bucharest, ROMANIA, ⁷Oncologic Institute "Prof. Dr. Alexandru Trestioreanu", Oncology department, Bucharest, ROMANIA, ⁸Clinic of Dermatology, Central University Emergency Military Hospital Bucharest, Bucharest, ROMANIA.

EP-0932

Pitfall in 68Ga PSMA PET/CT interpretation - Pathological Uptake in a Patient with Prostate Carcinoma and Pulmonary Tuberculosis
S. Fares¹, I. Rogić², D. Huić²; ¹General Hospital Varazdin, Varazdin, CROATIA, ²University Hospital Centre Zagreb, Zagreb, CROATIA.

EP-0933

Papillar Thyroid Carcinoma discovered on peritoneal carcinosis nodes : A case report of a 37-year-old woman
A. Bauduer, M. Krim, A. Latge, S. Zerdoud; *Oncopole, Toulouse, FRANCE.*

EP-0934

Recurrent Pituitary Adenoma ACTH-Secretant Detected Using 99mTc-EDDA/HYNIC-TOC - A Case Report
A. Bajenaru¹, C. Mazilu², M. Mititelu^{2,3}; ¹Nuclear Medicine Department, Oncology Institute „Prof. Dr. Alexandru Trestioreanu”, Bucharest, ROMANIA, ²Clinic of Nuclear Medicine, Central Emergency Military University Hospital "Dr. Carol Davila", Bucharest, ROMANIA, ³University of Medicine and Pharmacy "Dr. Carol Davila", Bucharest, ROMANIA.

EP-0935

Two examples of how 18F-FES-PET may assist oncologists in clinical dilemmas in breast cancer patients
S. Nogueira, F. A. B. Da Luz, V. Iacone, A. M. S. Petinatti, S. C. Lima, A. Osawa, L. Y. I. Yamaga; *Hospital Israelita Albert Einstein, São Paulo, BRAZIL.*

EP-0936

A rare case of bilateral seminal vesicle metastasis in carcinoid tumor of caecum
A. Kumar¹, G. Gunasekaran¹, N. Pandit²; ¹JIPMER, Puducherry, INDIA, ²JIPMER, Pondicherry, INDIA.

EP-0937

Different Pattern of Brain Metabolic Changes on 18F-FDG Brain PET in a Patient with Fronto-Temporal Lobar Degeneration: Case Report
A. Bajenaru¹, L. Mititelu^{2,3}, C. Mazilu⁴, D. Cuzino^{5,3}, C. Sirbu^{6,3}, M. Mititelu^{4,3}; ¹Nuclear Medicine Department, Oncology Institute „Prof. Dr. Alexandru Trestioreanu”, Bucharest, ROMANIA, ²Institute of Military Medicine, Bucharest, ROMANIA, ³University of Medicine and Pharmacy "Dr. Carol Davila", Bucharest, ROMANIA, ⁴Clinic of Nuclear Medicine, Central Emergency Military University Hospital "Dr. Carol Davila", Bucharest, ROMANIA, ⁵Clinic of Radiology, Central Emergency Military University Hospital "Dr. Carol Davila", Bucharest, ROMANIA, ⁶Clinic of Neurology, Central Emergency Military University Hospital "Dr. Carol Davila", Bucharest, ROMANIA.

EP-0938

Diagnosis of Erdheim-Chester disease by bone scintigraphy
A. Doumas¹, D. Boundas², P. Exadaktylou¹, E. Giannoula¹, A. Tsangaridi¹, G. Gerasimou¹, E. Papanastasiou¹, I. Iakovou¹; ¹Aristotle University, Thessaloniki, GREECE, ²Private Nuclear Medicine Centre, Ippokratis, Thessaloniki, GREECE.

EP-0939

Radiation-Associated Angiosarcoma After Breast Cancer detected on [18F]FDG PET/CT
M. Pudis¹, J. Suils-Ramón¹, I. Blazquez-Muñoz², F. X. Sanjuan-Garriga², A. Palomar-Muñoz¹, M. Cortés-Romera¹; ¹Nuclear Medicine - PET (IDI), Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, Barcelona, SPAIN, ²Anatomical Pathology Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, Barcelona, SPAIN.

EP-0940

A rare manifestation of multiple solitary extramedullary plasmacytomas
M. Dobrenic^{1,2}, J. Batinić¹; ¹Clinical Hospital Centre Zagreb, Zagreb, CROATIA, ²School of Medicine University of Zagreb, Zagreb, CROATIA.

EP-0941

PRRT for symptomatic paragangliomas and bilateral pheochromocytomas in an adult patient with a cyanotic heart condition
C. Burger¹, T. Moalosi¹, M. Mix², M. Conradie¹; ¹Stellenbosch University and Tygerberg Hospital, Cape Town, SOUTH AFRICA, ²Medical Center – University of Freiburg, Freiburg, GERMANY.

EP-0942

Nodal Migration of ruptured implant contents detected on [18F]FDG-PET/CT
M. Pudis, J. Suils-Ramón, A. Palomar-Muñoz, V. Carrero-Vasquez, C. Martínez-Ramos, S. Bondía-Bescós, B. Hervás-Sanz, J. Diaz-Moreno, M. Cortés-Romera; *Nuclear Medicine - PET (IDI), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN.*

EP-0943

Tumoral thrombosis of the inferior vena cava in a patient with multiple-relapsed adrenal cortical carcinoma
A. Mitoi¹, C. Mazilu¹, M. Oancea¹, M. Alexa¹, S. Serbanescu¹, A. Militaru¹, D. Craciun¹, A. Zaharia¹, M. Matei¹, R. Mititelu^{2,1}; ¹Central University Emergency Military Hospital, Bucharest, ROMANIA, ²University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA.

EP-0944

Aneurysmal Bone Cyst in a patient with McCune-Albright Syndrome
N. Aydin, G. Mütevelizade, G. Gümüşer, E. Sayıt Bilgin; *Celal Bayar University, Manisa, TÜRKIYE.*

EP-0945

Disseminated infection complicating acupuncture revealed by Gallium-67 scintigraphy
T. Chow; *Tuen Mun Hospital, Hong Kong, HONG KONG.*

EP-0946

Mitral annular calcification as a potential false positive for cardiac amyloidosis in [99mTc]Tc-DPD scintigraphy accurately identified by SPECT/CT - a case report
R. Nunes, V. Alves; *Centro Hospitalar Universitário de São João, Porto, PORTUGAL.*

EP-0947

Increased 68Ga-PSMA uptake in avascular necrosis of the hip
B. Okudan Tekin¹, B. Seven²; ¹Department of Nuclear Medicine, Ankara City Hospital, University of Health Sciences, Ankara, TÜRKIYE, ²Department of Nuclear Medicine, Sabuncuoğlu Şerefeddin Training and Research Hospital, Amasya, TÜRKIYE.

EP-0948

Pseudosarcomatous Periosteal Metastases of Lower Limbs Initially Misdiagnosed for Secondary Hypertrophic Osteoarthropathy then Properly Identified by [68Ga]Ga-PSMA PET/CT in a Patient Treated for Prostate Carcinoma
D. Filipan¹, P. Moreau², C. Thibault³, F. Montravers², F. Paycha⁴; ¹University Department of Oncology and Nuclear Medicine, Sestre Milosrdnice University Hospital Centre, Zagreb, CROATIA, ²Service de Médecine Nucléaire, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE, ³Service d'Oncologie Médicale, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE, ⁴Service de Médecine Nucléaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, FRANCE.

EP-0949

Retroperitoneal Fat-Containing Tumor. Tiptoeing between malignant and benign: A Case Report
M. Matei¹, A. Mitoi¹, S. Serbanescu¹, C. Mazilu¹, R. Mititelu^{1,2}; ¹Nuclear Medicine Department, Central University Emergency Military Hospital, Bucharest, ROMANIA, ²University of Medicine and Pharmacy Dr Carol Davila, Bucharest, ROMANIA.

EP-0950

Can PSMA based PET/CT scan be used in management of salivary gland neoplasms?
N. Ghesani, M. Posner, r. Kulkarni, M. Ghesani; *Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.*

EP-0951

A rare case of atypical lung carcinoid metastasis detected in the breast on 68Ga-DOTATATE PET/CT
B. Okudan Tekin¹, B. Seven², A. Albayrak³, A. Yıldırım¹; ¹Department of Nuclear Medicine, Ankara City Hospital, University of Health Sciences, Ankara, TÜRKIYE, ²Department of Nuclear Medicine, Sabuncuoğlu Şerefeddin Training and Research Hospital, Amasya, TÜRKIYE, ³Department of Pathology, Ankara City Hospital, University of Health Sciences, Ankara, TÜRKIYE.

EP-0952

18F-FDG PET-CT in Diagnosis and Staging of Lacrimal Gland Carcinoma: a Case Report
A. Militaru¹, A. C. Rosu², C. V. Mazilu¹, M. M. Matei¹, S. I. Serbanescu¹, M. G. Alexa¹, A. Mitoi¹, A. M. Zaharia¹, R. M. Mititelu^{1,3}; ¹Central University Emergency Military Hospital, Bucharest, Bucuresti, ROMANIA, ²Elias Emergency University Hospital, Bucuresti, ROMANIA, ³University of Medicine and Pharmacy "Carol Davila" Bucharest, Bucuresti, ROMANIA.

EP-0953

18F-FDG uptake in portal vein thrombosis: the upshot of IIIB-stage pulmonary adenocarcinoma and liver cirrhosis
M. Alexa¹, S. Serbanescu¹, A. Mitoi¹, C. Mazilu¹, M. Matei¹, M. Oancea¹, D. Craciun¹, R. Mititelu^{1,2}; ¹Central University Emergency Military Hospital, Bucharest, ROMANIA, ²University of Medicine and Pharmacy Carol Davila, Bucharest, ROMANIA.

EP-0954

Additional value of PET/MRI in diagnostic workflow of cognitive impairment
M. Pudis¹, M. Suarez-Piñera¹, S. Flores-Casapera^{1,2}, N. Vidal-Sarro³, L. Rodríguez-Bel¹, C. Martínez-Ramos¹, S. Bondía-Bescós¹, B. Hervás-Sanz⁴, M. Cortés-Romera¹; ¹Nuclear Medicine - PET (IDI), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN, ²Radiodiagnosics (IDI), Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, SPAIN, ³Anatomical Pathology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN, ⁴Nuclear Medicine - PET (IDI), Bellvitge University Hospital, Barcelona, SPAIN.

EP-0955

Pericardial mesothelioma: a case report.
B. Hervás-Sanz¹, P. C. Notta¹, L. M. Gràcia-Sánchez¹, L. Rodríguez-Bel¹, S. A. Bolívar-Cuevas², D. Castellón-Plaza², I. E. Sánchez-Rodríguez¹, M. Pudis¹, M. Cortés-Romera¹; ¹Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN, ²Diagnostic Radiology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EP-0956

Molecular Imaging Findings in Erdheim-Chester Disease-An Extremely Rare Multisystemic Disorder
A. Marcuseanu¹, A. Budau², D. Vasile¹, A. Lazar³, C. Sterea², M. Gherghe^{3,4};

¹National Institute of Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, ROMANIA, ²Central Military Emergency Hospital "Dr. Carol Davila", Bucharest, ROMANIA, ³Institute of Oncology "Prof. Dr. Alexandru Trestioreanu", Bucharest, ROMANIA, ⁴"Carol Davila" University of Medicine and Pharmacy, Bucharest, ROMANIA.

EP-0957

Assessment of False Positive PET/CT Pulmonary Lesions in Gastric Adenocarcinoma Staging

D. Craciun¹, C. Mazilu¹, A. Zaharia¹, A. Mitoi¹, R. Mititelu^{1,2};
¹Nuclear Medicine Department, Central University Emergency Military Hospital, Bucharest, ROMANIA, ²University of Medicine and Pharmacy Dr Carol Davila, Bucharest, ROMANIA.

EP-0958

Incidental detection of hydatid cyst on 18F-FDG PET/CT imaging

B. Okudan Tekin¹, B. Seven²;
¹Department of Nuclear Medicine, Ankara City Hospital, University of Health Sciences, Ankara, TÜRKIYE, ²Department of Nuclear Medicine, Sabuncuoğlu Şerefeddin Training and Research Hospital, Amasya, TÜRKIYE.

EP-0959

18F-FDG PET/CT findings in a patient with systemic lupus erythematosus

B. Okudan Tekin¹, B. Seven²;
¹Department of Nuclear Medicine, Ankara City Hospital, University of Health Sciences, Ankara, TÜRKIYE, ²Department of Nuclear Medicine, Sabuncuoğlu Şerefeddin Training and Research Hospital, Amasya, TÜRKIYE.

EP-0960

The importance of metabolic activity imaging in the evaluation of Central Nervous System Rosai-Dorfman Disease: A Case Report

M. Matei¹, C. Mateescu¹, A. Rosu², C. Mazilu¹, R. Mititelu^{1,3};
¹Nuclear Medicine Department, Central University Emergency Military Hospital, Bucharest, ROMANIA, ²University Hospital ELIAS, Bucharest, ROMANIA, ³University of Medicine and Pharmacy Dr Carol Davila, Bucharest, ROMANIA.

EP-0961

Functional change in a patient with neurological symptoms post-exercise disclosed by rest and stress cerebral blood flow perfusion imaging (99m)Tc-ECD SPECT

R. Moreira¹, R. Castro², D. S. Lobo¹, L. R. Sabioni¹, H. A. Guenka¹, I. Gottlieb¹;
¹Casa De Saude Sao Jose, Rio De Janeiro, BRAZIL, ²Ipanema Health Club, Rio De Janeiro, BRAZIL.

EP-0962

Radioguided occult lesion localization (ROLL) method in metastatic colorectal cancer - a case report

D. Silva, H. Duarte, I. Sousa, J. C. Ferro, I. Próspero, D. Barbosa, S. F. Castro, G. Ferreira, J. P. Teixeira, M. J. Sousa, P. Martins, I. L. Sampaio;
Instituto Português de Oncologia do Porto Francisco Gentil, Porto, PORTUGAL.

EP-0963

Brown tumours: an unmet need
B. Pereira, P. Soeiro, A. Fernandes, A. Oliveira;
Centro Hospitalar Universitário de São João, Porto, PORTUGAL.

EP-0964

The role of radio-guided surgery in choosing vascularized lymph nodes transfer microsurgery flap after breast cancer surgical treatment.

D. Rodriguez Oviedo, A. Maldonado Morillo, B. Manzarbeitia Arroba, M. Alvarez Moreno, M. Tagliatori Nogueira, M. De La Rubia Marcos, C. Sandoval Moreno, C. Galindo, M. Garcia Alonso, M. Castillejos Rodriguez;
Hospital Universitario de Getafe, Madrid, SPAIN.

EP-0965

Incidentaloma on [18F]FDG PET-CT breast cancer staging - a rare case of Schwannoma

B. Martins, P. Lopes, R. Veiga, C. Loewhental, J. L. Passos-Coelho;
Hospital da Luz, Lisboa, PORTUGAL.

EP-0966

Hepatic Artery Vasculitis: A rare presentation of single-organ vasculitis documented by 2-[18F]FDG PET/CT

R. T. Ferreira, I. C. Ferreira, F. Vinagre, S. Carmona, A. Prata, A. I. Santos;
Hospital Garcia de Orta, E. P. E., Almada, PORTUGAL.

EP-0967

18F-FDG PET/CT findings in a patient with renal angiomyolipoma

B. Okudan Tekin¹, A. S. Erdoğan¹, B. Seven²;
¹Department of Nuclear Medicine, Ankara City Hospital, University of Health Sciences, Ankara, TÜRKIYE, ²Department of Nuclear Medicine, Sabuncuoğlu Şerefeddin Training and Research Hospital, Amasya, TÜRKIYE.

EP-0968

Rare complication in the cholangiocarcinoma treatment - biliary bronchial fistula - localized with cholecintigraphy with SPECT/CT

P. Gadzicki, M. Nowak, A. Dyla, Z. Adamczewski;
Medical University of Lodz, Lodz, POLAND.

EP-0969

SPECT/CT Diagnosis of single adrenal metastasis of differentiated thyroid cancer

K. Bayardo, J. Naula, O. Alonso, R. Ferrando;
University of the Republic, Montevideo, URUGUAY.

EP-0970

Role of [18F]FDG PET/CT in the detection and differential diagnosis of peritoneal tuberculosis

S. Bondía-Bescós¹, V. Carrero-Vasquez¹, I. Sánchez-Rodríguez¹, A. Palomar-Muñoz¹, L. Gràcia-Sánchez¹, M. Pudis¹, B. Hervás-Sanz¹, J. Díaz-Moreno¹, M. Santin-Cerezales², X. Solanich-Moreno¹, M. Cortés-Romera¹;
¹Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital, Barcelona, SPAIN, ²Infeccious Diseases Department, Bellvitge University Hospital, Barcelona, SPAIN.

EP-0971

Dual-tracer PET/CT imaging to determine tumor heterogeneity in a patient with liver metastatic neuroendocrine neoplasm: A case report.

R. Moreira, I. Gottlieb, D. S. Lobo, H. A. Guenka;
Casa De Saude Sao Jose, Rio De Janeiro, BRAZIL.

EP-0972

18 FDG PET/CT imaging in anaplastic thyroid carcinoma : a case report

F. Chaltout, K. Ben Ahmed, M. Ouachem, T. Bint Mohamed, M. Maaloul, S. Charfeddine, K. Chtourou, F. Guermazi;
Department of Nuclear Medicine, Habib Bourguiba University Hospital of Sfax, Tunisia, Sfax, TUNISIA.

EP-0973

Sacroccygeal metastasis revealing a papillary carcinoma of the thyroid . A Case report

M. Bourouba;
Nuclear Medicine Clinique Fatema Al Azhar, Algiers, ALGERIA.

EP-0974

Gastric Empty and Esophagus Transit Scintigraphy Imaging of Long Term Tip 1 Diabetic Patient accidentally consuming Formic Acid

D. Yüksel, U. Moran, M. Yücel, S. Demirezen, A. Çelik;
Pamukkale Üniversitesi Tıp Fakültesi, Denizli, TÜRKIYE.

EP-0975

FDG PET/CT imaging in intra-abdominal round cell desmoplastic tumors: a case report

N. Abaouz, A. Guensi;
Department of Nuclear Medicine, University Hospital Ibn Rochd, Casablanca, MOROCCO.

EP-0976

Interest of FDG PET/CT Compared to Bone Scan in the Detection of Lytic Bone Metastasis in Breast Cancer

N. Abaouz, A. Guensi;
Department Of Nuclear Medicine, University Hospital Ibn Rochd, Casablanca, MOROCCO.

EP-0977

Unexpected 131I iodine scintigraphy finding

A. Aulich, B. Stefański, Z. Adamczewski;
Nuclear Medicine Department, Medical University of Lodz, Lodz, POLAND.

EP-0978

Incidental finding of pulmonary tumour in lung ventilation and perfusion SPECT: the importance of a combined low-dose CT scan

J. Carvalho, J. R. Duarte, A. Marques, F. Abreu, S. Pintão;
Centro Hospitalar de Lisboa Ocidental, Camaxide, PORTUGAL.

EP-0979

An adrenal nodule with very high 18F-FDG uptake

S. Fontão de Castro, J. Ferro, I. Próspero, D. Barbosa, D. Silva, L. Violante, G. Ferreira, I. Lucena e Sampaio;
Portuguese Institute of Oncology - Porto, Porto, PORTUGAL.

EP-0980

Detection of a right ventricle cardiac metastasis from lung adenocarcinoma in a 18F-FDG PET/CT study

S. Pacella¹, M. Mangano², L. Venegoni³, M. Cergnol³, A. Calcagno³, R. Ferrara⁴, C. Migliorisi³, M. Carletto³, L. Maffioli³;
¹IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milano, ITALY, ²ASST Valle Olona, Saronno, ITALY, ³ASST Ovest Milanese-Ospedale Civile di Legnano, Legnano, ITALY, ⁴ASST Ovest Milanese-Ospedale di Magenta, Magenta, ITALY, ⁵ASST Sette Laghi, Varese, ITALY.

EP-0981

Expect the unexpected- a rare case of incidentally detected recurrent bone invasive giant meningioma on F-18 FDG PET/CT, in a patient with stomach neoplasm

S. Chausheva, B. Chaushev, T. Stoeva, M. Dyankova, T. Yordanova, Z. Dancheva;
University Hospital St Marina Varna, Varna, BULGARIA.

EP-0982

99mTc-antigranulocyte antibody scintigraphy in mycosis fungoides

A. Velidaki, S. Episkopopoulou, I. Sevaslidou, N. Prosotsianiotis, E. Dagrakis, A. Kolindou;
Laiko General Hospital of Athens, Athens, GREECE.

EP-0983

Incidental increased Ga-68 FAPI Uptake in Calcified Meningioma

A. Namazova, A. Kibar, L. U. Beşli, O. E. Sahin, K. Sönmezoğlu;
Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Nuclear Medicine, ISTANBUL, TÜRKIYE.

EP-0984

Bilateral Warthin tumour with coexisting metastatic lung cancer: a rare case demonstrated by 2-[18F]FDG-PET/CT

I. C. Ferreira, R. T. Ferreira, I. Oliveira, A. I. Santos;
Hospital Garcia de Orta, E.P.E, Almada, PORTUGAL.

EP-0985

Brown tumors mimicking bone metastasis in a woman with a Parathyroid carcinoma. A Case report.

A. Genova¹, F. Porcaro¹, I. Annarumma¹, M. Prisco¹, L. Turchetta¹, A. Biasiucci², M. Catalano¹;
¹Nuclear Medicine Unit, AORN A. Cardarelli, Naples, NAPLES, ITALY, ²Histopathology Unit, AORN A. Cardarelli, Naples, NAPLES, ITALY.

EP-0986

An atypical aspect of bone scintigraphy in AL Amyloidosis

M. Bel lakhdar, H. Guerrouj, J. Rahali, I. Ghfir, N. Ben Raïs;
University mohamed V, Faculty of Medicine and Pharmacy, RABAT, MOROCCO.

EP-0987

Uncommon presentation of an aggressive tumor-FDG PET/CT clinching the diagnosis.

S. Sagar, D. Khan, N. A. Damle, M. Tripathi, M. Bhatt, Y. Gupta, N. Tandon;
AIIMS, Delhi, INDIA.

EP-0988

Basal Cell Carcinoma Transformation to Squamous Cell Carcinoma Following Systemic Treatment: Impressive PET/CT Images and Clinical Implications.

M. Pudis¹, P. C. Notta¹, B. Hervás-Sanz¹, J. R. Ferreras-Riera², M. Cortés-Romera¹;
¹Nuclear Medicine - PET (IDI), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN, ²Department of Dermatology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, SPAIN.

EP-0989

Case report: Soft Tissue Metastasis in Lung Cancer - The impact of 2-[18F]FDG PET/CT

R. T. Ferreira, I. C. Ferreira, I. Oliveira, D. Canário, S. Carmona, J. G. Santos, J. A. Sequeira, A. I. Santos; Hospital Garcia de Orta, E. P. E., Almada, PORTUGAL.

EP-0990

Evaluation of metabolic response with 18F-FDG PET-CT in advanced thymic adenocarcinoma

H. Noamen, K. Ben Ahmed, W. Amouri, T. Mohamed, I. Jardak, M. Maaloul, S. Charfeddine, K. Chtourou, F. Guerhazi; University hospital of Habib Bourguiba, Sfax, TUNISIA.

EP-0991

DLBCL mimicking infection on FDG PET/CT - resolving the conundrum

D. Khan, N. A. Damle, M. Tripathi, B. Pridhivi, P. Sethi, N. Wig, S. Sagar, A. Narayan; AIIMS Delhi, Delhi, INDIA.

EP-0992

Osteoblastoma like osteosarcoma - diagnostic challenge - a case report

N. Manevska¹, T. Makazlieva¹, S. Kostadinova Kunovska², S. Stojanoski¹, A. Gavrilovski³;

¹Institute of Pathophysiology and Nuclear medicine, Medical Faculty, University of Ss Cyril and Methodius, Skopje, NORTH MACEDONIA, ²Institute of Pathology, Medical Faculty, University of Ss Cyril and Methodius, Skopje, NORTH MACEDONIA, ³University Clinic for Orthopedic Surgery, Medical Faculty, University of Ss Cyril and Methodius, Skopje, NORTH MACEDONIA.

EP-0993

Contribution of whole-body bone scan coupled with SPECT/CT in the diagnosis of SAPHO syndrome: case report.

j. Charfi, S. Marwa, O. Ben Hamida, C. Mhiri, I. Slim, A. Mhiri; salah azaiez institute, tunis, TUNISIA.

EP-0994

Place of peritoneal scintigraphy in the diagnosis of pleuro-peritoneal communication: A case report.

K. Ayed, H. Charfi, M. Nouira, R. Sfar, K. Chatti; Nuclear Medicine Department, Sahloul Hospital, Sousse, TUNISIA.

EP-0995

Is Captopril renography with 99mTc-DTPA still of merit in renovascular hypertension? a case report

R. Belayouni, O. Ben Hamida, M. Ben Nasr, M. Somai, I. Slim, i. meddeb, I. Yeddes, A. Mhiri; Salah Azaiez Institute, Tunis, TUNISIA.

EP-63

e-Poster Area

E: Other Studies -> E3 Other Study (including Training, Projects)

EP-0996

Implementation of 3D digital SPECT/CT device for clinical workflow in myocardial perfusion imaging - a multidisciplinary collaborative project approach

J. Kaunisto, A. Keinänen, H. Gröhn, T. M. Laitinen, M. Hakulinen, S. Koponen, S. Halttunen, T. P. Laitinen; Kuopio University hospital, Kuopio, FINLAND.

EP-0997

Annual DXA Operator Audit - A single site experience

D. Teixeira Macarico, C. Reilly, A. Nicol; Nuclear Medicine Department, Queen Elizabeth University Hospital, Department of Physics and Bioengineering, NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM.

P-64

e-Poster Area

E: Other Studies -> E3 Other Study (including Training, Projects) -> Organisation and optimisation in nuclear medicine worldwide

EP-0998

University of Tor Vergata, Rome, Italy, contributes to the EU Horizon-2020 INCISIVE project for the development of Artificial Intelligence in Health Imaging

E. Triumbari¹, A. Kosvyra², T. Loncar-Turukalo³, A. Tzelepakis⁴, C. Barelle⁵, C. Symvoulidis⁶, S. Nabhani⁷, L. Zacharias⁷, G. Tsakou⁸, A. Chiaravalloti¹;

¹Nuclear Medicine Unit, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, ITALY, ²Aristotle University of Thessaloniki, Thessaloniki, GREECE, ³Faculty of Technical Sciences, University of Novi Sad, Novi Sad, SERBIA, ⁴Centre for Research & Technology Hellas, Hellas, GREECE, ⁵European Dynamics Luxembourg SA, Luxembourg, LUXEMBOURG, ⁶Telesto IOT solutions limited, Athens, GREECE, ⁷School of Life Sciences, Pharmacy and Chemistry, Kingston University London, Kingston, UNITED KINGDOM, ⁸Maggioli SPA, Greek site, Athens, GREECE.

EP-1000

NOAR COST Action: Advancing Targeted Alpha Therapy with Astatine-211 for Cancer Treatment

E. Janevik-Ivanovska¹, J. Gestin², E. Aneheim³, S. Lindgren³, J. Gaschet⁴, S. Palm⁵, D. Niculae⁶, P. Bouziotis⁷, M. Pruzynski⁸, P. Kolenc⁹, A. I. Jensen¹⁰, A. Abrunhosa¹¹, L. Navarro¹², H. Jensen¹³, R. Mikolajczak¹⁴, M. M. Herth¹⁵, M. Konijnenberg¹⁶, F. Guerard¹⁷;

¹University Goce Delcev Stip, Faculty of Medical Sciences, Stip, NORTH MACEDONIA, ²Université de Nantes, Inserm, CNRS, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes—Angers (CRCIINA)—UMR 1307, UMR 6075, *Action Chair of the COST Action CA19114, Network for Optimized Astatine labeled Radiopharmaceuticals (NOAR), 44007 Nantes Cedex 1, FRANCE, ³Department of Medical Radiation Sciences, Institute of Clinical Sciences, the Sahlgrenska Academy, University of Gothenburg; 413 45 Gothenburg, SWEDEN, ⁴Université de Nantes, CNRS, Inserm, CRCINA, 44000, Nantes, FRANCE, ⁵Department of Medical Radiation Sciences, Institute of Clinical Sciences, the Sahlgrenska Academy, University of Gothenburg; 413 45 Gothenburg, SWEDEN, ⁶Radiopharmaceutical Research Centre, Horia Hulubei National Institute for Physics and Nuclear

Engineering, 30 Reactorului Street, Măgurele, 077125 Ilfov, ROMANIA, ⁷Radiochemical Studies Laboratory, INRASTES, National Center for Scientific Research Demokritos, Aghia Paraskevi, 15341 Athens, GREECE, ⁸Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, POLAND, ⁹Department of Nuclear Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, SLOVENIA, ¹⁰Center for Nanomedicine and Theranostics (The Hevesy Laboratory), DTU Health Technology, Technical University of Denmark (DTU), Ørsteds Plads 345C, 2800 Lyngby, DENMARK, ¹¹ICNAS/CIBIT, Institute for Nuclear Sciences Applied to Health, University of Coimbra, Coimbra, PORTUGAL, ¹²Precirix, Brussels, BELGIUM, ¹³Cyclotron and PET unit KF-3982, Copenhagen University Hospital, Copenhagen, DENMARK, ¹⁴National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock-Swierk, POLAND, ¹⁵Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, DENMARK, ¹⁶Department of Radiology and Nuclear Medicine, Erasmus MC, 3000 CA Rotterdam, NETHERLANDS, ¹⁷Université de Nantes, Inserm, CNRS, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes—Angers (CRCIINA)—UMR 1307, UMR 6075, 44007 Nantes, FRANCE.

EP-1001

Appropriation of hybrid practices in oncological imaging: the situation of PET-CT in France from a management perspective.

R. Guignard^{1,2}, B. Geffroy², V. Fernandez³;

¹Clinique de Genolier, Genolier, SWITZERLAND, ²IMT Atlantique - LEMNA, Nantes, FRANCE, ³TELECOM Paris, Paris, FRANCE.

EP-1002

Novel approach for the technical implementation of radiowater studies for a pet/ct- scanner in hospital environment

M. Hakulinen¹, P. Poutiainen²;

¹Diagnostic Imaging Centre, Kuopio University Hospital, Kuopio, FINLAND, ²Cyclotron and radiopharmacy unit, Kuopio University Hospital, Kuopio, FINLAND.

EP-1003

Identifying the unique needs of transgender, non-binary and gender diverse patients in the nuclear medicine department

A. Cripps¹, J. Taylor^{1,2}, R. Salmon¹;

¹Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UNITED KINGDOM, ²University of Sheffield, Sheffield, UNITED KINGDOM.

EP-1004

Illuminating actionable practice to improve recall of medical information in nuclear medicine department

S. Ibba¹, P. Gandolfo¹, L. Airò Farulla², D. Zago¹, G. Fosci¹, S. Papa¹;

¹CDI Centro Diagnostico Italiano S.p.A., Milan, ITALY, ²University of Milan, Milan, ITALY.

EP-1005

Religion, beliefs and needs in thyroid cancer patients

E. Olariu, D. Picu; The Oncology Institute Cluj-Napoca, Cluj-Napoca, ROMANIA.

EP-1006

Performance Evaluation of the Incorporation of PET/CT Procedures in the SUS

B. Prates, L. Pozzo; Nuclear and Energy Research Institute, IPEN-CNEN/SP, São Paulo, BRAZIL.

EP-1007

Patient experience at the heart of the implementation of a PET/MRI system in our centre

J. Vercher-Conejero, M. Cortés-Romera, J. Martín Marcuartu, S. Millat Servent, I. Feliu Perez, C. Martínez Ramos, V. Carrero Vasquez, M. Pudis, S. Santamaria Lopez, I. Bonilla Aguilar, M. Fernandez Yuste; Bellvitge University Hospital, L'Hospitalet de Llobregat (Barcelona), SPAIN.

EP-1008

Knowledge, Attitude and Practice towards the Utility of Medical Radioisotopes for Diagnosis and Therapy of Disease used in Nepal

A. Gupta, P. Sah, S. Prasad, D. Baral; B.P. Koirala Institute of Health Sciences (BPKIHS), Dharan, NEPAL.

EP-1009

Cyclotron production of ultra-pure indium-111 radionuclide using gold-plated capsules in Iran

P. Ashtari^{1,2}, Y. Fazaeli³, G. Aslani¹, S. Feizi²;

¹Pars Isotope Co., Tehran, IRAN, ISLAMIC REPUBLIC OF, ²Nuclear Science & Technology Research Institute, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-1010

New method for synthesis of HMPAO compound and a novel method for purification of final product for Triple usage

M. Alizadeh, v. ghasemi, e. maleki, h. m. mehrabani, f. farajbakhsh, m. ghapanvari; parsisotope, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-1011

Comparison of diagnostic efficacy of 99mTc-MIBI SPECT/CT and ultrasonography for primary and secondary renal hyperparathyroidism

M. Jiang, W. Mei; Ningbo No.2 Hospital, Ningbo, CHINA.

EP-1012

ATTR Cardiac Amyloidosis and Carpal tunnel syndrome

S. Giourgouli, A. Kokkini-Paschou, V. Pantzou, M. Stathopoulou, J. Koutsikos; Henry Dunant Hospital Center, Athens, GREECE.

EP-1013

Monitoring Of Adverse Reactions Caused By [99m Tc] Tc-Mibi

G. Rubio-Fernández, R. Maestre-Cutillas, L. Baz-Sanz, L. Cebollada-Cameo, R. Castro-Velasco, C. Juan-Piriz, J. Pérez Iruela; Hospital Ramón y Cajal, Madrid, SPAIN.

EP-1014

Assessment of agreement between three creatinine-based GFR predicting equations and 99mTc-DTPA plasma clearance GFR in adult Caucasian patients : a single-center study
G. Arsos¹, D. Katsampoukas¹, A. Kalaitzoglou¹, E. Manou², E. Moralidis¹;

¹3rd Department of Nuclear Medicine, Aristotle University of Thessaloniki School of Medicine, Papageorgiou Gen. Hospital, Thessaloniki, GREECE, ²Nephrology Clinic, Papageorgiou Gen. Hospital, Thessaloniki, GREECE.

EP-1015

Development of a boronic acid targeting fluorescent sensor for evaluation of intracellular localization and quantification of blood concentration of boronoagents for BNCT

S. Takada^{1,2}, N. Kondo², T. Temma², M. Hagimori¹;
¹Laboratory of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien Kyubancho, Nishinomiya, Hyogo, JAPAN, ²Department of Biofunctional Analysis, Graduate School of Pharmaceutical Sciences, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, JAPAN.

EP-1016

Introducing a method for increasing yield and removing the harmful and toxic solvents during the synthesis process of Sestamibi and labeling it by 99mTc to investigate its applications in vascular imaging.

V. Ghasemi, m. alizadeh, h. m. mehrabani, e. maleki, m. ghapanvari, f. farajbaksh, E. Lohrasbi, J. Aghamohammadi;
parsiotope, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-65

e-Poster Area

Technologists e-Posters

EP-1017

Implementation of the new national directive to reduce radioactive waste disposal costs in nuclear medicine and radiometabolic therapy departments
M. Anelli¹, M. Nicoletto², A. Zambelli³, A. Di Nicola¹;

¹Azienda Sanitaria Locale di Pescara, Pescara, ITALY, ²Policlinico di Abano Terme, Abano Terme (PD), ITALY, ³Azienda Ospedaliera Universitaria di Padova, Padova, ITALY.

EP-1018

Usefulness of simplified respiratory motion freeze devise (IKI-TOMEHIRO-KUN) in myocardial perfusion SPECT

H. Ichikawa^{1,2}, T. Kato¹, H. Kondo³, T. Shibutani², H. Shimada¹, M. Onoguchi²;
¹Toyohashi Municipal Hospital, Toyohashi, JAPAN, ²Kanazawa university, Kanazawa, JAPAN, ³Nagoya University Hospital Department of Cardiology, Nagoya, JAPAN.

EP-1019

Does high Radiochemical purity obviate the need for a biodistribution whole body image in 68Ga-NOTA-UBI PET/CT?

S. Maurya, N. Damle, S. Ballal, A. Singhal, V. Tiwari, C. Bal, N. Singh, Y. Dharmashaktu, D. Khan, S. Sagar, A. Gawande;
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-1020

Evaluation of 68Ga-NOTA-Ubiqicidin (29-41) PET/CT with early and delayed imaging through qualitative and quantitative analysis.

N. Singh, N. Damle, S. Maurya, A. Singhal, S. Ballal, V. Tiwari, A. Gawande, P. Kumar, C. Bal, S. Sagar, J. Jaleel;
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-1021

The impact of multi-bed SPECT-CT misregistration on routine clinical service delivery

L. Wason, R. Williamson, J. Dixon, C. Reilly, A. Nicol;
NHS Greater Glasgow and Clyde, Glasgow, UNITED KINGDOM.

EP-1022

Image evaluation of different 99mTc/123I ratios for simultaneous dual-isotope myocardial SPECT using D-SPECT cardiac camera

T. Shibutani¹, M. Onoguchi¹, H. Yoneyama², T. Konishi², K. Nakajima²;
¹Department of Quantum Medical Technology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Ishikawa, JAPAN, ²Department of Radiological Technology, Kanazawa University Hospital, Kanazawa, Ishikawa, JAPAN, ³Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa, Ishikawa, JAPAN.

EP-1023

Assessing glomerular filtration rate through blood sampling via port and arm vein.

C. H. Led¹, L. J. Jeppesen¹, O. Gerke^{1,2}, S. Hvidsten¹, J. A. Simonsen^{1,2};
¹Department of Nuclear Medicine, Odense C, DENMARK, ²Department of Clinical Research, University of Southern Denmark, Odense, DENMARK.

EP-1024

Examination of optimum conditions for 99mTc brain perfusion SPECT using a new SZHRX collimator

T. Nishiyama¹, M. Onoguchi¹, T. Shibutani¹, A. H. Vija², F. Massanes², T. Shimizu², H. Yoneyama³, T. Konishi³, H. Mori⁴, K. Nakajima⁵;
¹Department of Quantum Medical Technology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, JAPAN, ²Siemens Medical Solutions UNITED STATES OF AMERICA, Inc., Hoffman Estates, IL, UNITED STATES OF AMERICA, ³Department of Radiological Technology, Kanazawa University Hospital, Kanazawa, JAPAN, ⁴Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN, ⁵Department of Functional Imaging and Artificial Intelligence, Kanazawa University, Kanazawa, JAPAN.

EP-1025

Inter- and intraobserver and the test-retest variability in bone density measurement in vertebral fracture assessment on DXA

S. Wongjarern, A. Willemsen, R. Slart;
UMCG, Groningen, NETHERLANDS.

EP-1026

The Advantages of using Nitrogen-13 Ammonia PET Imaging in Flow Quantification of Microvascular Diseases

G. Daigneault, M. Balu, M. Menelas;
CHUM, Montreal, QC, CANADA.

EP-1027

Investigation of volumetric measurements from gated myocardial perfusion Multi-Pinhole SPECT with shortening acquisition time

M. Alamin¹, S. Barna², V. Bencze Linczerné², K. Kukuts³, A. Oszlanszki³, J. Varga⁴, Á. Krizsán³, A. Forgács³, I. Gara²;
¹University of Debrecen, Debrecen, HUNGARY, ²University of Debrecen, Faculty of Medicine, Department of Medical Imaging, Division of Nuclear Medicine; Scanomed Nuclear Medicine Centres, Debrecen, HUNGARY, ³Scanomed Nuclear Medicine Centres, Debrecen, HUNGARY, ⁴University of Debrecen, Faculty of Medicine, Department of Medical Imaging, Division of Nuclear Medicine, Debrecen, HUNGARY.

EP-1028

Overall survival of patients undergoing transarterial radioembolization (TARE) and the influence of additional treatments, injected activity and mean dose to the tumor

S. Ialuna¹, N. Quartuccio¹, D. Scalisi², F. D'Amato³, M. R. Barcellona⁴, M. G. Bavetta⁴, G. Fusco⁴, E. Bronte⁵, E. Musso⁵, F. Bronte⁶, V. Picciotto⁴, A. Carroccio⁴, F. Verderame⁵, G. Malizia⁶, F. La Gattuta⁷, A. M. Moreci¹;
¹Nuclear Medicine Unit, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY, ²Health Physics Unit, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY, ³Unit of Interventional radiology, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY, ⁴Internal Medicine Unit, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY, ⁵Clinical Oncology Unit, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY, ⁶Gastroenterology Unit, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY, ⁷Interventional Radiology Unit, A.O.O.R. Villa Sofia Cervello, Palermo, ITALY.

EP-1029

Quantitative Parameters of 99mTc-PYP SPECT/CT Correlates with Left Ventricle Diastolic Dysfunction in Transthyretin Amyloid Cardiomyopathy, Not Myocardial Perfusion Reserve

Y. Chen¹, C. Ko¹, J. Cheng¹, A. Yu², C. Tsa², P. Tseng³, C. Chao⁴, M. Cheng¹, Y. Lin²;
¹Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, TAIWAN, ²Department of Internal Medicine, Division of Cardiology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, TAIWAN, ³Department of Internal Medicine, Division of Gastroenterology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, TAIWAN, ⁴Department of Neurology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, TAIWAN.

EP-1030

Optimization of Classical Pulmonary SPECT on a Revolutionary Camera

S. Hirs^{1,2}, A. E. Pedersen^{3,2}, H. Precht^{3,4,5}, S. Hess^{6,7,8}, R. Horvat^{6,7}, M. H. Vilstrup^{6,7}, P. L. Hansen^{2,4}, T. Q. Christensen^{2,9};
¹Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, DENMARK, ²Education of Radiography, UCL University College, Odense, DENMARK, ³Department of Radiology, Lillebaelt Hospital, University Hospitals of Southern Denmark, Kolding, DENMARK,

⁴Health Sciences Research Centre, UCL University College, Odense, DENMARK, ⁵Department of Regional Health, University of Southern Denmark, Odense, DENMARK, ⁶Department of Radiology and Nuclear Medicine, Hospital South West Jutland, Esbjerg, DENMARK, ⁷IRIS - Imaging Research Initiative Southwest, Esbjerg, DENMARK, ⁸Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, DENMARK, ⁹Department of Clinical Engineering, Region of Southern Denmark, Esbjerg, DENMARK.

EP-1031

Quantitative (FDG)PET/CT - How huge a small error can be

I. Pestean, A. Sabo, M. Cegan, M. Crisan, E. Barbus, D. Piciu;
Institute of Oncology, Cluj, ROMANIA.

EP-1032

Description amyloid PET (18F-Florbetaben) imaging protocol in patients with suspected Alzheimer's disease

M. Caballero Vivancos¹, M. Pérez Ávila¹, F. González Asid¹, E. Córdoba Cañete¹, R. Sánchez Sánchez²;
¹Hospital Universitario Virgen de las Nieves, Granada, SPAIN, ²Hospital Universitario Virgen de las Nieves, Maracena, Granada, SPAIN.

EP-1033

Evaluation of image quality according to the difference in acquisition methods(SS and CBM) between PET/CT manufacturers in the 68Ga study
E. Seo, J. Ryu;
Asan Medical Center, Seoul, KOREA, REPUBLIC OF.

EP-1034

99mTc Radiopharmaceuticals: Evaluation of Radiochemical Purities in the Last Two Years of Use
D. Di Martino, A. Prisco, F. Rescigno, M. Buonanno, V. Porfidia, A. Sposito, M. Aurilio, S. Lastoria;
Istituto Tumori G.Pascale, Napoli, ITALY.

EP-1035

How to optimize the synthesis of [177Lu]Lu-DOTATOC, from a simple manual operation
P. Christensen;
Aarhus University Hospital, Aarhus, DENMARK.

EP-1036

Impact of images reconstructed using Bayesian penalized likelihood on ability of [11C]MET-PET to differentiate malignant grades in brain gliomas
Y. Kamitaka^{1,2}, K. Wagatsuma^{1,3}, M. Inaji⁴, K. Ikemoto³, K. Miwa⁵, K. Ishii¹, M. Kobayashi²;

¹Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN, ²Division of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, JAPAN, ³Radiological Technology, Medical Engineering and Technology, School of Allied Health Sciences, Kitasato University, Kanagawa, JAPAN, ⁴Department of Neurosurgery, Tokyo Medical and Dental University, Tokyo, JAPAN, ⁵Department of Radiological Sciences, School of Health Sciences, Fukushima Medical University, Fukushima, JAPAN.

EP-1037


Nuclear Medicine
A. Alshehri, T. Wright, K. M. Prise, A. Cole;
Queens University Belfast, Belfast, UNITED KINGDOM.

12 SEPTEMBER, 2023
DOORS OPEN AT 19:00

EANM CLUBBING hosted by EARL

Featuring:
The Bad Powells

LOCATION: PALAIS WERTHEIM
CANOVAGASSE 1-5, 1010, VIENNA



Preparing for the New Era of Neuroimaging for Alzheimer's Disease



Satellite Symposium | Session 3 in Room F2
Sunday 10 September at 13:15-14:30

Chaired by Frederik Barkhof

Join our symposium on the cutting-edge advances in PET imaging in the new era of disease modification in Alzheimer's disease.

Program

Introduction

Role of PET imaging in the disease
modification era of Alzheimer's disease

Advances in AD PET biomarkers

PET tracers: Which, when, how, who?

Q&A

Summary

Faculty

Frederik Barkhof
Amsterdam UMC, The Netherlands
and University College London, UK

Silvia Morbelli
University of Genoa, Italy

Alexander Drzezga
University of Cologne, Germany

Lyduine Collij
Lund University, The Netherlands

All

Frederik Barkhof

Educational objectives

- Explain the critical role of PET imaging in the new era of disease modification of Alzheimer's disease
- Appraise the utility of current and emerging PET biomarkers in clinical practice
- Identify patterns from different PET tracers for a negative and positive AD brain and debate methods beyond binary amyloid PET interpretation

This activity is supported by an educational grant from Lilly.

 Springer Healthcare IME

SATELLITE SYMPOSIA

Sunday, September 10, 2023 13:15–14:45, Hall E2

Symposium by Monrol Nuclear Products:
PSMA radioligand therapy of prostate cancer in clinical practice



Chairperson: Dr. Derya Tilki

13:15–13:20	Welcome and Introduction Dr. Derya Tilki
13:20–13:35	Treatment Landscape of Advanced Prostate Cancer Maria De Santis
13:35–13:50	Importance of Next Generation Imaging in Prostate Cancer Management Ken Herrmann
13:50–14:05	Update of PSMA-Targeted Theranostics in Prostate Cancer Joe O'Sullivan
14:05–14:35	Case presentation Dr. Derya Tilki Multidisciplinary Panel Discussion Maria De Santis, Ken Herrmann, Joe O'Sullivan, Dr. Derya Tilki
14:35–14:45	Q&A

Sunday, September 10, 2023 (Available via Livestream and On Demand) 13:15–14:45, Hall F1

Symposium by TELIX:
Personalized Diagnostic in Urological Cancers:
the Promise of Nuclear Medicine



Chairperson: Prof. Stefano Fanti, Nuclear Medicine Unit,
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

	Focus on radiolabelled PSMA-PET/CT in Prostate cancer Prof. Stefano Fanti – Bologna, Italy Dr. Macarena Rodriguez Fraile – Pamplona, Spain
	Radiodiagnostic applied to Kidney and Bladder cancers Prof. Karolien Goffin – Leuven, Belgium
	The use of Artificial Intelligence in Prostate cancer management Dr Laszlo Papp – Vienna, Austria

Sunday, September 10, 2023 13:15–14:45, Hall F2

Springer Healthcare IME
(supported by an educational grant from Lilly)
Preparing for the new era of neuroimaging for Alzheimer's disease



Chairperson: Professor Frederik Barkhof (Amsterdam UMC,
The Netherlands and University College London, UK)

13:15–13:20	Introduction Frederik Barkhof
13:20–13:30	Role of PET imaging in the disease modification era of Alzheimer's disease Silvia Morbelli (University of Genoa, Italy)
13:30–13:45	Advances in AD PET biomarkers Alexander Drzezga (University of Cologne, Germany)
13:45–14:00	PET tracers: Which, when, how, who? Lyduine Collij (Lund University, The Netherlands)
14:00–14:45	Q&A (Audience and panel discussion)
14:20	Summary Frederik Barkhof

Sunday, September 10, 2023 (Available via Livestream and On Demand) 13:15–14:45, Hall K

Symposium by Pfizer:
Advancements in nuclear imaging
for the diagnosis of cardiac amyloidosis



Chairperson: Sharmila Dorbala

13:15–13:30	Introduction to cardiac amyloidosis: from recognition to treatment René Rettl
13:30–13:50	Using cardiac scintigraphy for non-invasive diagnosis of ATTR-CM Sharmila Dorbala
13:50–14:05	Sharing practical approaches to accurate diagnosis: a case-based study Olivier Gheysens
14:05–14:15	Q&A All faculty

Monday, September 11, 2023 13:15–14:45, Hall E2

Symposium by Spectrum Dynamics:
Reaching Higher Peaks in Digital SPECT Imaging



Join and hear VERITON-CT® and D-SPECT® users discuss how they are utilizing the latest groundbreaking technologies and how customers like you are finding their peak in digital SPECT imaging

Pr. Denis Agostini, MD, PhD. Head of Nuclear Medicine Department – University Hospital of Caen, CHU Caen, France
Dr. Miguel Ochoa Figueroa, MD, PhD. Specialist in Nuclear Medicine and Radiology – Linköping University Hospital, Sweden
Dr. Laetitia Imbert, PhD. Medical Physicist, Medical Physicist, Department of Nuclear Medicine – University Hospital of Nancy, CHRU Nancy, France
Pr. Antoine Verger, MD, PhD. Professor, Department of Nuclear Medicine – University Hospital of Nancy, CHRU Nancy, France

Monday, September 11, 2023 13:15–14:45, Hall C

Symposium by GE HealthCare:
Shaping the future with Total MI solutions



Chairperson: Mathias Goyen, Chief Medical Officer EMEA, GE HealthCare

13:15–13:20	Welcome and Introduction Mathias Goyen, Chief Medical Officer EMEA, GE HealthCare
13:20–13:40 (incl. 5 minutes Q&A)	Advancing Next Generation Radiotracers to Help Improve Patient Outcomes Paul Evans PhD, Head of Global R&D at GE HealthCare Regina Young, Head of Global Market Access at GE HealthCare
13:40–14:00 (incl. 5 minutes Q&A)	How Omni Legend delivers increased flexibility to clinical applications Prof. Mirosław Dziuk, Affidea PET/CT Centre, Warsaw, Poland
14:00–14:20 (incl. 5 minutes Q&A)	StarGuide™: the future of SPECT/CT is 3D Tommi Noponen, Medical Physicist, Adj. Prof., Turku University Hospital, Finland
14:20–14:40 (incl. 5 minutes Q&A)	Patient-centered Diagnostic Imaging and Adapting to Clinical Needs with SIGNA™ PET/MR Prof. Farshad Moradi, Stanford Health Care, USA

Monday, September 11, 2023 (Available via Livestream and On Demand) 13:15–14:45, Hall F1

Symposium by Siemens Healthineers:
Answering to clinical needs in molecular imaging



Chairperson: Matt Shah, Marketing Operations Head, Siemens Healthineers

Transitioning to next-generation SPECT/CT: radiographers share their experience
Juho Kuukasjärvi, Oulu University Hospital, Finland
Joni Granlund, Oulu University Hospital, Finland

PET/CT Imaging of connectome and inflammation
Univ.-Prof. Dr. M. Hacker, AKH Vienna, Austria

Monday, September 11, 2023 13:15–14:45, Hall F2

Symposium by Curium:
PYLCLARI® [Piflufolastat (¹⁸F)] now in Europe: Sharing current perspectives for the diagnosis of prostate cancer



Prof. Dr. Jeroen van Moorselaar Chairman, Department of Urology Amsterdam UMC, Amsterdam, Netherlands
Assoc. Prof. Dr. Daniela E. Oprea-Lager Department of Radiology and Nuclear Medicine Amsterdam UMC, Amsterdam, Netherlands
Assoc. Prof. Dr. Juan Antonio Vallejo Casas Department of Nuclear Medicine University Hospital Reina Sofía, Córdoba, Spain

Tuesday, September 12, 2023 (Available via Livestream and On Demand) 13:15–14:45, Hall K

Symposium by Novartis:
ADACAP Symposium at the EANM'23 World Meeting – Neuroendocrine tumour as an oncological entity



13:15–13:25	Welcome and introduction Dr Prakash Manoharan
13:25–13:35	General criteria for decision-making in patients with advanced GEP-NETS Dr Nicola Fazio
13:35–14:10	Medical Cases – Presentation and Panel Discussion Panel: Dr Nicola Fazio, Dr Jaume Capdevila
14:10–14:15	Close and thank you Dr Prakash Manoharan

Tuesday, September 12, 2023 13:15–14:45, Hall E2

Symposium by United Imaging:
Transforming Precision Medicine: Pioneering Breakthroughs in Long Axial FOV and Next-Generation PET Technologies



Join us on a clinical journey utilizing innovative Long Axial Field of View (FOV) and Next-Generation PET Technologies. Witness their transformative influence on patient care, drug discovery, and personalized theranostics, shaping the future of precision medicine for all.

Joniada Doraku – Medical Doctor of Department of Nuclear Medicine, Ospedale Sacro Cuore-Don Calabria Hospital
Hongcheng Shi – Director of the Department of Nuclear Medicine, Zhongshan Hospital, Fudan University
Jeffrey Yap – Director of the Center for Quantitative Cancer Imaging, Huntsman Cancer Institute
Li Huo – Director of the Department of Nuclear Medicine, Peking Union Medical College Hospital
Richard Carson – Professor of Biomedical Engineering and Radiology, Yale University

Tuesday, September 12, 2023 (Available via Livestream and On Demand) 13:15–14:45, Hall K

Symposium by Novartis:
ADACAP Symposium at the EANM'23 World Meeting –
Neuroendocrine tumour as an oncological entity



13:15–13:25	Welcome and introduction Dr Prakash Manoharan
13:25–13:35	General criteria for decision-making in patients with advanced GEP-NETS Dr Nicola Fazio
13:35–14:10	Medical Cases – Presentation and Panel Discussion Panel: Dr Nicola Fazio, Dr Jaume Capdevila
14:10–14:15	Close and thank you Dr Prakash Manoharan

Tuesday, September 12, 2023 13:15–14:45, Hall F2

Symposium by ABX GmbH:
Translation of ¹⁸F-PSMA-1007 from research to routine clinical use



Chairperson: Prof. Dr. med. Kambiz Rahbar – Klinik für Nuklearmedizin,
Universitätsklinikum Münster (UKM)

PSMA-ligands: Introduction, Biology and its clinical peers Univ.-Prof. Dr. med. Frederik L. Giesel – Klinik für Nuklearmedizin, Universitätsklinikum Düsseldorf (UKD)
Pitfalls and phenotypes: PSMA in- and outside prostate cancer Prof. Dr. Wolfgang Fendler – Klinik für Nuklearmedizin Essen
The advantages of low urinary clearance: what does the urologist gain from PSMA-imaging? Prof. Dr. med. Tobias Maurer, FEBU – Universitätsklinikum Hamburg-Eppendorf
PSMA-1007: From a phase 3 clinical study to routine use in France Prof. Dr. Pierre Olivier, Nuclear Medicine and Nancyclotep Molecular Imaging Platform, CHRU-Nancy, Université de Lorraine, Nancy, France
Biochemical Recurrence and PSMA Imaging: where are we today? Prof. Dr. med. Kambiz Rahbar – Klinik für Nuklearmedizin, Universitätsklinikum Münster (UKM)



Targeting cancer

As a leading biotech company, we are developing a new generation of targeted cancer treatments. With our innovative radiodiagnostics and therapeutics, we are shaping the theranostics of tomorrow.



www.itm-radiopharma.com



LIST OF EXHIBITORS (A - Z)

Exhibitor	Booth No.
A.C.O.M. Advanced Center Oncology Macerata S.r.l.	252
ABSCINT	248
ABX GmbH	220
CM ABX-CRO advanced pharmaceutical services	210
ACIC Machinery	219
CM Advanced Accelerator Applications Molecular Imaging	242
CM Novartis	318
Advanced Cyclotron Systems Inc.	251
CM Alliance Medical GmbH	406
Almedis Altmann GmbH	312
ArgonSoft	402
AtomVie Global Radiopharma Inc.	201
AWEX – Wallonia Export & Investment Agency	248
CM Blue Earth Diagnostics Ltd.	302
CM Boston Scientific International	231
Brightonix Imaging Inc	409
CM Bruker BioSpin, MOLECUBES, PMOD	319
BV Cyclotron	312
Chelatec SAS	205
CHEMATECH	208
CLERAD	212
CMR – Center of Molecular Research Corporation GmbH	202
CM COMECER SPA	305
Crystal Photonics GmbH	236
CUP Laboratorien Dr. Freitag GmbH / TRIMT GmbH	412
CM Curium	313
Cyclomedica Europe	410
DOSIsoft SA	213
DSD Pharma	312

ec2 Software Solutions	217
CM Eckert & Ziegler Isotope Products	240
CM Eckert & Ziegler Medical	240
EDL	307
EITA (European Isotopes Transport Association)	257
CM Eli Lilly	227
ELSE Solutions S.r.l.	234
Elysia-raytest GmbH	248
Epsilon	312
Evergreen Theragnostics, Inc.	204
for-med.nl customized medical accessories	312
Gamma Medical Technology	247
CM GE HealthCare	416
CM Hermes Medical Solutions	309
Hidex	207
Hoy Scandinavian	312
CM IBA SA	303
ImaginAb	408
Incepto Medical	250
Institute of Isotopes Co. Ltd.	314
Inter Medical Medizintechnik GmbH	253
INVIA Medical Imaging Solutions	237
Inviscan	258
Ionetix Corporation	308
Iotron Medical Inc	216
IRE ELiT	248
Isotope JSC	228
Isotopia Molecular Imaging Ltd.	215
ITEL Telecomunicazioni SRL	403
CM ITM Isotope Technologies Munich	417

Jiangsu Huayi Technology Co., Ltd.	255
Jubilant Radiopharma	411
LabLogic Systems Ltd., Hidex, Southern Scientific	207
CM Lemer Pax / Global Morpho Pharma	419
Ludlum Measurements	421
Lynax	254
CM Medi-Radiopharma Ltd.	317
CM Mediso Medical Imaging Systems	314, 315
MEDraysintell	248
MedTrace Pharma A/S	206
MIAS PHARMA	230a
MiE medical imaging electronics GmbH	413
CM MILabs B.V.	245
CM MIM Software Inc.	244
MNT Healthcare Services Inc.	218
MNT Kwint International BV	312
MNX Global Logistics	248
MOLECUBES	319
CM Monrol Nuclear Products Co./S.C. Monrol Europe SRL	311
MR Solutions Ltd.	246
Nuclear Medicine Europe eeg	211
Nuclear Shields BV	233
Nucleis	248
NUVIA Instruments GmbH	312
Oncidium Foundation	248
OncoBeta GmbH	226
ONCODESIGN SERVICES	209
CM OncoSil Medical Europe GmbH	235
Optimized Radiochemical Applications	404
CM Pars Isotope Co.	304
PBL Srl.	219
PentixaPharm GmbH	240
PI Medical Diagnostic Equipment B.V.	312
PMB-ALCEN	203
PMOD	319
CM POLATOM, Radioisotope Centre of National Centre for Nuclear Research	415
Positrono AG	222

QUBIO	224
RADIOPROTECH	243
Rotem GmbH	239
CM ROTOP Pharmaka GmbH	414
RQS Alexander Ruffani	256
Scannix	248
SCINTOMICS Molecular, att GmbH	249
CM SHINE Medical Technologies, LLC	238
CM Siemens Healthineers	418
CM Sirtex Medical Europe GmbH	301
Softway Medical	312
CM Spectrum Dynamics Medical	407
Southern Scientific	207
Sumitomo Heavy Industries, Ltd.	306
SYNTHRA GmbH	223
CM Telix Innovations	241
CM Tema Sinergie S.p.A.	316
CM Terumo Interventional Systems	405
TRASIS S.A.	225
TRISKEM INTERNATIONAL	230b
U.S. Department of Energy Isotope Program	320
CM United Imaging Healthcare	420
United Well	321
VANDERWILT techniques b.v.	312
vent-medis GmbH	230
CM Von Gahlen Nederland B.V.	310
Vortal	248
Voximetry	214
Wälischmiller Engineering GmbH	232
WIS – World Infinity Services	248
XEOS Medical NV	401

LIST OF EXHIBITORS (SORTED BY BOOTH NO.)

AtomVie Global Radiopharma Inc.	201
CMR – Center of Molecular Research Corporation GmbH	202
PMB-ALCEN	203
Evergreen Theragnostics, Inc.	204
Chelatec SAS	205
MedTrace Pharma A/S	206
Hidex	207
LabLogic Systems Ltd., Hidex, Southern Scientific	207
Southern Scientific	207
CHEMATECH	208
ONCODESIGN SERVICES	209
CM ABX-CRO advanced pharmaceutical services	210
Nuclear Medicine Europe eeg	211
CLERAD	212
DOSIsoft SA	213
Voximetry	214
Isotopia Molecular Imaging Ltd.	215
Iotron Medical Inc	216
ec2 Software Solutions	217
MNT Healthcare Services Inc.	218
ACIC Machinery	219
PBL Srl.	219
ABX GmbH	220
Positrigo AG	222
SYNTHRA GmbH	223
QUBIO	224
TRASIS S.A.	225
OncoBeta GmbH	226
CM Eli Lilly	227
Isotope JSC	228


vent-medis GmbH	230
MIAS PHARMA	230a
TRISKEM INTERNATIONAL	230b
CM Boston Scientific International	231
Wälischmiller Engeneering GmbH	232
Nuclear Shields BV	233
ELSE Solutions S.r.l.	234
CM OncoSil Medical Europe GmbH	235
Crystal Photonics GmbH	236
INVIA Medical Imaging Solutions	237
CM SHINE Medical Technologies, LLC	238
Rotem GmbH	239
CM Eckert & Ziegler Isotope Products	240
CM Eckert & Ziegler Medical	240
PentixaPharm GmbH	240
CM Telix Innovations	241
CM Advanced Accelerator Applications Molecular Imaging	242
RADIOPROTECH	243
CM MIM Software Inc.	244
CM MILabs B.V.	245
MR Solutions Ltd.	246
Gamma Medical Technology	247
AWEX – Wallonia Export & Investment Agency	248
Elysia-raytest GmbH	248
IRE ELiT	248
MEDDraysintell	248
MNX Global Logistics	248
Nucleis	248
Oncidium Foundation	248
Scannix	248

Vortal	248
WIS – World Infinity Services	248
ABSCINT	248
SCINTOMICS Molecular, att GmbH	249
Incepto Medical	250
Advanced Cyclotron Systems Inc.	251
A.C.O.M. Advanced Center Oncology Macerata S.r.l.	252
Inter Medical Medizintechnik GmbH	253
Lynax	254
Jiangsu Huayi Technology Co., Ltd.	255
RQS Alexander Ruffani	256
EITA (European Isotopes Transport Association)	257
Inviscan	258
CM Sirtex Medical Europe GmbH	301
CM Blue Earth Diagnostics Ltd.	302
CM IBA SA	303
CM Pars Isotope Co.	304
CM COMECER SPA	305
Sumitomo Heavy Industries, Ltd.	306
EDL	307
Ionetix Corporation	308
CM Hermes Medical Solutions	309
CM Von Gahlen Nederland B.V.	310
CM Monrol Nuclear Products Co./S.C. Monrol Europe SRL	311
Almedis Altmann GmbH	312
BV Cyclotron	312
DSD Pharma	312
Epsilon	312
for-med.nl customized medical accessories	312
Hoy Scandinavian	312
MNT Kwint International BV	312
NUVIA Instruments GmbH	312
PI Medical Diagnostic Equipment B.V.	312
Softway Medical	312
VANDERWILT techniques b.v.	312
CM Curium	313
Institute of Isotopes Co. Ltd.	314


CM Mediso Medical Imaging Systems	314, 315
CM Tema Sinergie S.p.A.	316
CM Medi-Radiopharma Ltd.	317
CM Novartis	318
CM Bruker BioSpin, MOLECUBES, PMOD	319
MOLECUBES	319
PMOD	319
U.S. Department of Energy Isotope Program	320
United Well	321
XEOS Medical NV	401
ArgonSoft	402
ITEL Telecomunicazioni SRL	403
Optimized Radiochemical Applications	404
CM Terumo Interventional Systems	405
CM Alliance Medical GmbH	406
CM Spectrum Dynamics Medical	407
ImaginAb	408
Brightonix Imaging Inc	409
Cyclomedica Europe	410
Jubilant Radiopharma	411
CUP Laboratorien Dr. Freitag GmbH / TRIMT GmbH	412
MiE medical imaging electronics GmbH	413
CM ROTOP Pharmaka GmbH	414
CM POLATOM, Radioisotope Centre of National Centre for Nuclear Research	415
CM GE HealthCare	416
CM ITM Isotope Technologies Munich	417
CM Siemens Healthineers	418
CM Lemer Pax / Global Morpho Pharma	419
CM United Imaging Healthcare	420
Ludlum Measurements	421

EXHIBITION HALLS


X4 – LEVEL 0



X3 – LEVEL -2



X2 – LEVEL -2



201	AtomVie Global Radiopharma Inc.
202	CMR – Center of Molecular Research Corporation GmbH
203	PMB-ALCEN
204	Evergreen Theragnostics, Inc.
205	Chelatec SAS
206	MedTrace Pharma A/S
207	Hidex
207	LabLogic Systems Ltd., Hidex, Southern Scientific
207	Southern Scientific
208	CHEMATECH
209	ONCODESIGN SERVICES
CM 210	ABX-CRO advanced pharmaceutical services
211	Nuclear Medicine Europe eeg
212	CLERAD
213	DOSISOFT SA
214	Voximetry
215	Isotopia Molecular Imaging Ltd.
216	Iotron Medical Inc
217	ec2 Software Solutions
218	MNT Healthcare Services Inc.
219	ACIC Machinery
219	PBL Srl.
220	ABX GmbH
222	Positrigo AG
223	SYNTHRA GmbH
224	QUBIO
225	TRASIS S.A.
226	OncoBeta GmbH
CM 227	Eli Lilly
228	Isotope JSC
230	vent-medis GmbH
230a	MIAS PHARMA

230b	TRISKEM INTERNATIONAL
CM 231	Boston Scientific International
232	Wältschmiller Engineering GmbH
233	Nuclear Shields BV
234	ELSE Solutions S.r.l.
CM 235	OncoSil Medical Europe GmbH
236	Crystal Photonics GmbH
237	INVIA Medical Imaging Solutions
CM 238	SHINE Medical Technologies, LLC
239	Rotem GmbH
CM 240	Eckert & Ziegler Isotope Products
CM 240	Eckert & Ziegler Medical
240	PentixaPharm GmbH
CM 241	Telix Innovations
CM 242	Advanced Accelerator Applications Molecular Imaging
243	RADIOPROTECH
CM 244	MIM Software Inc.
CM 245	MILabs B.V.
246	MR Solutions Ltd.
247	Gamma Medical Technology
248	AWEX – Wallonia Export & Investment Agency
248	Elysia-raytest GmbH
248	IRE ELiT
248	MEDDraysintell
248	MNX Global Logistics
248	Nucleis
248	Oncidium Foundation
248	Scannix
248	Vortal
248	WIS – World Infinity Services
248	ABSCINT
249	SCINTOMICS Molecular, att GmbH

250	Incepto Medical
251	Advanced Cyclotron Systems Inc.
252	A.C.O.M. Advanced Center Oncology Macerata S.r.l.
253	Inter Medical Medizintechnik GmbH
254	Lynax
255	Jiangsu Huayi Technology Co., Ltd.
256	RQS Alexander Ruffani
257	EITA (European Isotopes Transport Association)
258	Inviscan
CM 301	Sirtex Medical Europe GmbH
CM 302	Blue Earth Diagnostics Ltd.
CM 303	IBA SA
CM 304	Pars Isotope Co.
CM 305	COMECER SPA
306	Sumitomo Heavy Industries, Ltd.
307	EDL
308	Ionetix Corporation
CM 309	Hermes Medical Solutions
CM 310	Von Gahlen Nederland B.V.
CM 311	Monrol Nuclear Products Co./S.C. Monrol Europe SRL
312	Almedis Altmann GmbH
312	BV Cyclotron
312	DSD Pharma
312	Epsilon
312	for-med.nl customized medical accessories
312	Hoy Scandinavian
312	MNT Kwint International BV
312	NUVIA Instruments GmbH
312	PI Medical Diagnostic Equipment B.V.
312	Softway Medical
312	VANDERWILT techniques b.v.
CM 313	Curium

314	Institute of Isotopes Co. Ltd.
CM 314, 315	Mediso Medical Imaging Systems
CM 316	Tema Sinergie S.p.A.
CM 317	Medi-Radiopharma Ltd.
CM 318	Novartis
CM 319	Bruker BioSpin, MOLECUBES, PMOD
319	MOLECUBES
319	PMOD
320	U.S. Department of Energy Isotope Program
321	United Well
401	XEOS Medical NV
402	ArgonSoft
403	ITEL Telecomunicazioni SRL
404	Optimized Radiochemical Applications
CM 405	Terumo Interventional Systems
CM 406	Alliance Medical GmbH
CM 407	Spectrum Dynamics Medical
408	ImaginAb
409	Brightonix Imaging Inc
410	Cyclomedica Europe
411	Jubilant Radiopharma
412	CUP Laboratorien Dr. Freitag GmbH / TRIMT GmbH
413	MiE medical imaging electronics GmbH
CM 414	ROTOP Pharmaka GmbH
CM 415	POLATOM, Radioisotope Centre of National Centre for Nuclear Research
CM 416	GE HealthCare
CM 417	ITM Isotope Technologies Munich
CM 418	Siemens Healthineers
CM 419	Lerner Pax / Global Morpho Pharma
CM 420	United Imaging Healthcare
421	Ludlum Measurements

COMPANY PROFILES

A.C.O.M. Advanced Center Oncology Macerata S.r.l.

📍 Loc. Cavallino 39/A-B
62010 Montecosaro (MC), Italy

✉ amministrazione@acompet.it

🌐 <https://www.acompet.it>

ACOM SRL is a company operating in the nuclear medicine sector founded in 1999. Research is the driving force of the company, with 20 years of commitment and experience in the development of innovative radiopharmaceuticals to be included in the international market. The main area of interest and development is oncology, but the activities also involve neurodegenerative and cardiovascular diseases. The focus of the research is theranostic medicine, and in particular the development of Copper(64Cu)Chloride as a theranostic agent: a real integration of a diagnostic method with a specific therapeutic intervention. ACOM SRL is the first company in Europe to have brought in the market the radionuclide Copper-64 as a radiopharmaceutical precursor. ACOM SRL has recently obtained orphan designation in Europe for the treatment of glioblastoma with Copper(64Cu)Chloride. The professional skills of the team, the capacity to operate in critical contexts and an innovative approach demonstrated by constant investment in research and development, are just some of the distinctive features developed in these years of business. For any further information please visit our stand and our WEB page (www.acompet.it) where you can find the most updated information.

ABSCINT

📍 LegiaPark, Boulevard Patience et Beaujonc
3B - 4000 Liege, Belgium

✉ karine.clauwaert@abscint.com

🌐 <https://abscint.com>

ABSCINT is a clinical stage molecular imaging company developing in vivo diagnostics empowered by single-domain antibodies. Our name captures our essence, which is to address unmet medical needs with the development of unique antibodies (AB) providing superior performance in scintigraphy (SCINT). Our mission is to provide more precise, more specific, more convenient and safer diagnostics in the fields of oncology, cardiology and immunology.

ABX GmbH

📍 Heinrich-Gläser-Str. 10-14
01454 Radeberg, Germany

✉ info@abx.de

🌐 <http://abx.de>

ABX advanced biochemical compounds is a global frontrunner in radiopharmaceuticals, with a focus on positron emission tomography (PET) tracers. We develop and produce all compounds and components for any kind of radiotracer – from PET and SPECT precursors, PET reagent kits and cassettes, to complete radiopharmaceutical drug production in GMP environment. Based in Radeberg, Germany, and founded in 1997, our team of more than 350 employees is specialised in custom synthesis and manufacturing of precursors and peptides according to GMP for active pharmaceutical ingredients. Thanks to our expertise combined with bleeding edge equipment, we reach highest research, production, and quality standards. ABX is the only service provider of radiopharmaceutical production with a complete and independent supply chain – from precursor or peptide to excipients and sterile disposables.

ABX-CRO advanced pharmaceutical services

📍 Schössergasse 19
1067 Dresden, Germany

✉ info@abx-cro.com

🌐 <https://www.abx-cro.com>

Welcome to ABX-CRO!
ABX-CRO is an international CRO providing standard & specialised clinical and non-clinical studies, with emphasis on neuroscience, oncology and diagnostic imaging. With a unique translational medicine approach, we are happy to develop products from first non-clinical to late-stage multicentre human studies, or to support marketing authorisation. Our dedicated Molecular and Functional Imaging Core Lab provides comprehensive turn-key solutions covering all aspects of pre-clinical and clinical imaging and dosimetry. We provide solutions for radiolabelling, dosimetry, regulatory issues and the intricacies of functional imaging that are frequently seen as major obstacles in the conduct of oncology and imaging trials. Whether you represent a clinical trial site or want to find out how your project could benefit from our experience, come over and get an idea of our comprehensive services and expertise!

Advanced Accelerator Applications, a Novartis Company

📍 20 Rue Diesel
1630 Saint-Genis-Pouilly, France

✉ antonella.laudano@novartis.com

🌐 <https://www.novartis.com>

Advanced Accelerator Applications Molecular Imaging was set up in December 2022 as a separate business of Advanced Accelerator Applications, a Novartis Company, which was founded in 2002 as a spin-off of CERN, focused on developing and manufacturing targeted radioligand therapies and radioligands for Precision Imaging in Oncology. The Company is part of the Novartis group since 2018. We continue to carry on today the proud legacy of Diagnostic Imaging. Diagnostic Imaging uses targeted drugs containing radioactive particles for disease diagnosis and patient selection for therapies using Positron Emission Tomography (PET). Our mission is to help save lives through early precision diagnosis of sometimes rare diseases. In terms of diagnosis, Molecular Imaging is indeed a capable type of technology that is able to identify a disease in its early stages and determine, for example, the exact location of a tumor, often before symptoms appear or abnormalities can be detected with standard diagnostic tests. We can count on our efficient manufacturing capability, consisting of 12 production sites in 5 countries (with 2 under construction), an efficient transport network, reliable external partners and approximately 300 committed employees across Europe.

Advanced Cyclotron Systems Inc.

📍 150-7280 River Rd., V6X 1X5
Richmond, BC, Canada

✉ info@advancedcyclotron.com

🌐 <https://advancedcyclotron.com>

Advanced Cyclotron Systems, Inc. (ACSI) is a world leader in the design and manufacturing of cyclotron systems. With over 30 years of experience and more than 60 cyclotron systems installed, ACSI can provide a wide range of equipment and services worldwide. ACSI cyclotrons are used for the commercial production of PET and SPECT nuclides by internationally recognized companies and leading universities and research facilities. ACSI cyclotrons are designed, manufactured, and assembled in Richmond, Canada. ACSI offers a full spectrum of cyclotron systems ranging from PET cyclotrons to medium and high energy accelerators. All ACSI manufactured cyclotrons have variable energy and employ external ion source technology, offering the highest beam current output available on the market. The versatility, high beam current and exceptional quality of ACSI cyclotrons are some of the reasons why many of the world's most prestigious universities and research centres, as well as some of the most successful commercial radioisotope producers have chosen ACSI cyclotrons to meet their radioisotope production needs. For more information, please visit www.advancedcyclotron.com

Alliance Medical GmbH

📍 Westring 168
44575 Castrop-Rauxel, Germany

✉ nikki.polat@alliancemedical.eu

🌐 <http://www.alliancemedical.de>

Life Healthcare Europe, consisting of Life Molecular Imaging, Life Radiopharma and Life Alliance Medical is an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. These combined services allows physicians, pharma industry and academia greater access to established and innovative imaging agents for clinical trials and clinical routine.

ArgonSoft

📍 H-1133 Budapest, Váci út 76. Capital Square
1133 Budapest, Hungary

✉ info@argonsoft.hu

🌐 <https://www.argonsoft.hu/en>

ArgonSoft is a professional IT company in the high-end segment of the tailor-made software development business society. Since 2008 we have been successfully providing tailor-made software development services to our customers in the HealthCare sector and other areas as well. Our flagship product - ASIS.TO (www.asis.to) - is a highly flexible, state-of-the-art LIMS, designed for Radiopharmacy Labs and Cyclotron Facilities to make GMP compliant TRACER production more efficient. The SMART equipment integration functions enable a smooth, secure automated data transfer. Come to our booth to see a live demo! Our company has a strong nuclear medicine domain knowledge. Our end-to-end, iterative software development methodology complies with the GAMP5 guidelines and ensures high quality, customized results which helps our partners to achieve their business goals efficiently. These capabilities enable ArgonSoft to deliver high-end software products for You, like ASIS.TO. FURTHER SERVICES for HEALTHCARE COMPANIES:

- Digital Transformation Consultation
- Custom Software Development
- Integration Services

In 15+ years across 9 countries for over 30+ customers, we delivered 150+ successful projects.

AtomVie Global Radiopharma Inc.

📍 1280 Main Street West NRB-A316
L8S 4K1 Hamilton, Ontario, Canada

✉ info@atomvie.com

🌐 <https://www.atomvie.com>

AtomVie Global Radiopharma Inc. (AtomVie) is a global leading CDMO for the GMP manufacturing and global distribution of clinical and commercial radiopharmaceuticals. Building upon the expertise and high-quality services since 2008 from the Centre for Probe Development and Commercialization (CPDC), AtomVie offers the full range of scientific, technical, regulatory, quality, logistics and business expertise combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. AtomVie recently closed over \$90M Series A financing allowing it to complete the buildout and setup of its new 70,000 sq. ft. purpose-built, state-of-the-art facility. The new facility, set to open in late 2024, will offer expanded clinical and commercial manufacturing of radiopharmaceuticals for all level of throughput, scalable from low to high number of doses per batch. With its reliable logistic expertise, AtomVie currently serves international clients conducting studies in over 17 countries worldwide, improving patients' lives all over the globe.

AWEX – Wallonia Export & Investment Agency

📍 Place Sainctelette 2
1080 Brussels, Belgium

✉ lifesciences@awex.be

🌐 <https://www.awex.be/en>

The Wallonia Foreign Trade and Investment Agency, also known as AWEX, is Wallonia's - Region of Belgium - government agency in charge of foreign Trade and foreign investment. Wallonia is home to many nuclear medicine companies of various sizes, from SMEs to large companies, such as IBA and IRE, including spinoffs, suppliers and service providers. Our regional government supports the development of existing or newly established innovative activities with regard to R&D and production in the radiopharma and radiotherapy industry. AWEX is a one-stop shop for all foreign companies interested in setting up or expanding their business in Wallonia, as well as a partner for all Walloon companies wishing to develop their activities outside Belgium. If you're interested to know more, we will provide you with tailor-made information. Our partner BioWIN, the Health Cluster of Wallonia since 2006, encourages innovation and international development of Walloon actors active in this sector. BIOWIN connects some 250 key players: universities, research units and centers, R&D as well as manufacturing companies, incubators, capital providers, hospitals. To find out more about BioWIN's activities, please visit <https://biowin.org>.

Blue Earth Diagnostics Ltd.

📍 Magdalen Centre, Oxford Science Park
OX4 4GA, Oxford, United Kingdom

✉ contact@blueearthdx.com

🌐 <https://www.blueearthdiagnostics.com>

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is an international molecular imaging company on a growth trajectory to develop and commercialise innovative, well-differentiated diagnostic solutions that inform patient care and drive future therapies in cancer. Formed in 2014, the Company's success is driven by its management expertise, supported by a proven track record of rapid development and commercialisation of positron emission tomography radiopharmaceuticals. With a clinical focus in cancer, Blue Earth Diagnostics' expanding pipeline encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialisation of precision radiopharmaceuticals for potential use in diagnostic imaging and therapy.

Blue Earth Therapeutics Ltd

📍 Magdalen Centre, Oxford Science Park
OX4 4GA Oxford, United Kingdom

✉ contact@blueearthtx.com

🌐 <https://www.blueearththerapeutics.com>

Blue Earth Therapeutics Ltd is a clinical-stage radiopharmaceutical company dedicated to the advancement of next generation targeted radiotherapeutics to treat patients who have cancer. With proven leadership and therapeutic radiopharmaceutical expertise, Blue Earth Therapeutics has an emerging pipeline of precision targeted therapeutic radiopharmaceuticals, initially focused on prostate cancer with plans to expand into additional disease areas in oncology. Blue Earth Therapeutics is based in Oxford, UK. The company was formed in 2021 as a sister company to Blue Earth Diagnostics. Blue Earth Therapeutics is an indirect subsidiary of Bracco Imaging S.p.A., a world-leading diagnostic imaging provider.

Boston Scientific (BSCI)

📍 2 rue René Caudron
78960 Voisin-le-Bretonneux, France

✉ aliasgar.attarwala@bsci.com

🌐 <http://www.bostonscientific.eu>

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Interventional Oncology is giving medical teams powerful new options and patients new hopes. We believe this is just the beginning and are committed to working with you to change the fight against cancer. Boston Scientific's Selective Internal Radiation Therapy (SIRT) with TheraSphere™ is an intra-arterial directed therapy for hepatic malignancy where radioactive microspheres containing Yttrium-90 (90Y) are infused into the target liver arteries in order to treat the tumours. Simplicit90Y™ Personalised Dosimetry Software enables full potential of TheraSphere's personalization and precision in a simplified and time-efficient workflow. It provides confidence to physicians that each tumor gets the optimal radiation dose while preserving healthy tissue, ensuring safe and effective treatment for patients.

Bracco Imaging S.p.A.

📍 Via Egidio Folli 50
20134 Milan, Italy

✉ contact-us@bracco.com

🌐 <https://www.bracco.com>

Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures, and markets diagnostic imaging agents and solutions. It offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems, and dose-management software. In 2019 Bracco Imaging enriched its product portfolio by expanding the range of oncology nuclear imaging solutions in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting-edge biotechnology dedicated to advancing next-generation targeted radiotherapeutics to treat patients who have cancer.

Brightonix Imaging Inc

📍 #1705, SK V1 Tower, 25, Yeonmujang 5ga-gil,
Seongdong-gu, 4782 Seoul, South Korea

✉ info@brtnx.com

🌐 <https://www.brtnx.com/en>

Brightonix Imaging is a innovative healthcare company established with the goal to provide society with innovative biomedical imaging systems. We are currently offering preclinical PET systems and medical imaging AI solutions. - SimPET is the most compact and reliable MRI compatible SiPM PET insert for truly simultaneous PET/MRI studies in small animals. - BTXBrain is AI-powered automated quantification software for brain amyloid, tau, FDG, and DAT PET. It is designed with user-friendly interfaces for easy interactions and logically connected functions, and also provides a comprehensive report on brain PET tracer uptake. Brightonix Imaging is also developing the clinical PET scanner for brain, breast and extremity with support from Korea Medical Device Development Fund. Products: SimPET, BTXBrain, Pharos PET

BV Cyclotron

📍 Van der Boechorststraat 6A
1081 BT Amsterdam, Netherlands

✉ info@cyclotron.nl

🌐 <https://www.cyclotron.nl>

BV Cyclotron VU produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Strategically located in Amsterdam next to Amsterdam UMC we produce GMP-compliant medical isotopes in our state-of-the-art manufacturing facilities. Our long standing track record on supplying daily to the customers, our great expertise combined with strong collaborations makes us a reliable partner for hospitals, pharmaceutical companies and research centers all over the world.

Chelatec SAS

📍 1 rue Aronnax
44800 Saint-Herblain, France

✉ contact@chelatec.com

🌐 <https://www.chelatec.com>

Chelatec was founded in 2000 by seasoned scientists trained in the development of radiopharmaceuticals. Experts in the use of radioactive tracers, they decided to offer their knowledge in preclinical development of targeted radiotherapeutics to pharma and biotech. With state-of-the-art fully equipped laboratories for radiolabeling, radioanalyses, handling of cells and housing of animals, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, in vitro assays and in vivo investigations capabilities. Specializing in radiopharmaceutical R&D, Chelatec will provide you with information on your Investigational Medicinal Product to be part of the documentation package. All quality and non-clinical safety data required for translation of a radiopharmaceutical.

Our services cover/include:

- Bioconjugation
- Radioactive labeling
- Analytical controls (HPLC, iTLC/TLC, SDS-PAGE...)
- Stability studies (storage stability, plasma stability)
- In vitro assays (Binding affinity, IRF, internalization, cytotoxicity, autoradiography on tissue sections)
- In vivo investigations (Pharmacokinetics, biodistribution, efficacy, dosimetry)

CHEMATECH

📍 2 rue Pauline Kergomard
21000 DIJON, France

✉ info@chematech-mdt.com

🌐 <http://www.chematech-mdt.com>

CheMatech is a world-leading company specializing in the design and synthesis of bifunctional chelating agents such as DOTA, NOTA and NODAGA derivatives. These molecules are widely used for peptides or antibodies labeling with ^{67/68Ga}, ^{111In}, ^{64/67Cu}, ^{89Zr}, ... for PET/SPECT imaging, ^{177Lu}, ^{225Ac}, ^{212Pb}, ^{90Y}, ... for therapy. CheMatech offers a wide range of functionalized and protected chelating agents from milligrams to kilograms scale. CheMatech also realizes custom syntheses of chelators and provides cGMP services.

CLERAD

📍 184-186 boulevard Gustave Flaubert
63000 CLERMONT-FERRAND, France

✉ clerad@clerad.fr

🌐 <https://www.clerad.fr>

Since 2000, CLERAD has been a main leader in ionizing rays detection and more specifically in the medical field and the research of radio-labelled tissues, or radioguided surgery. Our goal: to provide the full range of diagnostic and treatment solutions for oncology in the operating room and in nuclear medicine from Sentinel Lymph node detection with our Gamma Supll probe, to Intraoperative Radiotherapy thanks to our latest innovation, the Papillon+.

CMR – Center of Molecular Research Corporation GmbH

📍 Bldg 638b – Cargo City South
60549 Frankfurt, Germany

✉ info@isotope-cmr.com

🌐 <https://isotope-cmr.com>

CMR (Center of Molecular Research) was founded in 2001 by the group of professional scientists in nuclear medicine and international economic relations spheres firstly, focusing on production and distributing of Oxygen-18 water with Isotopic Enrichment ≥ 98% and other medicine isotopes. After more than 20 years of development today CMR is a vertically constructed united group of companies having its representatives and offices in many countries of the world.

Nowadays CMR is not only one of the world's largest manufacturers of Oxygen-18 water but also the qualified supplier of a wide range of products including STABLE AND RADIOACTIVE ISOTOPES, PEPTIDES AND CHEMICAL KITS, which completely satisfy the needs of medicine centers and hospitals, scientists and technologists in isotopic fields.

Crystal Photonics GmbH

📍 Albert-Einstein-Straße 16
12489 Berlin, Germany

✉ ks@crystal-photonics.com

🌐 <http://www.crystal-photonics.com>

Crystal Photonics is engaged in Nuclear Medicine for highly qualified products of Molecular Imaging and intraoperative and transcutane sentinel lymph node localization (SLNE) since 25 years. The product range includes our excellent mini-USB Hand-Held-Gamma-Camera "CrystalCam", the surgical Gamma Probe System "Crystal Probe - automatic" with various kinds of cable and wireless probes. We are worldwide the first company, who is presenting complete autoclavable gamma probes without compromises!

Since this year is also available the very new detection system CrystalGuard for Isolated Limb Perfusion (ILP), as well as the very new CrystalAnalyzer for HPLC-investigation in coincidence mode for any PET-drugs are available. The 3D-free-hand-spect imaging system declipse®SPECT from our doughter company is also still in our portfolio.

Additionally, we present our very new mini-Laparoscopic gamma probe for robotic-assisted minimal-invasive surgeries, (Drop-in-Probe) special designed for the DaVinci robotic operation system. This probe was developed in the course of the new PSMA-technology for Prostate Cancer and has excellent medical-technical properties.

The product portfolio is completed by a large variety of miniaturized Gamma- and Beta-detectors for any kind of application, particularly for medical systems for the production of radioisotopes with high activities. For more information, please visit our websites: www.crystal-photonics.com

CUP Laboratorien Dr. Freitag GmbH

📍 Carl-Eschbach-Strasse 7
1454 Radeberg, Germany

✉ dfs@cup-freitag.de

🌐 <https://www.cup-freitag.de>

CUP Laboratorien Dr. Freitag GmbH, located in Radeberg, Germany, is a leading provider of GMP-compliant contract testing services for the radiopharmaceutical industry.

Our core competencies include sterility testing of radioactive pharmaceuticals and we are also experts in the analysis of Leachables and Extractables (E&L), identifying and quantifying potential impurities that may leach from manufacturing materials or packaging.

In addition to these services, CUP Laboratorien Dr. Freitag GmbH offers a wide range of testing options for medical radionuclides and precursors for radiopharmaceutical preparations. Our advanced analytical techniques and equipment enable us to accurately characterize and evaluate the purity and activity of these vital components, ensuring optimal performance and safety in radiopharmaceutical products.

We take pride in our commitment to quality and regulatory compliance. CUP Laboratorien Dr. Freitag GmbH has been inspected by the US Food and Drug Administration (FDA) and has earned GMP certification, demonstrating our adherence to the highest industry standards.

At CUP Laboratorien Dr. Freitag GmbH, we are driven by a passion for excellence in radiopharmaceutical testing and a commitment to supporting our clients in their quest to develop life-changing therapies. With our extensive experience, cutting-edge facilities, and unwavering dedication to quality, we are the trusted partner for radiopharmaceutical testing and quality assurance.

Curium

📍 63, avenue des Champs-Élysées
75008 Paris, France

✉ contactus@curiumpharma.com

🌐 <https://www.curiumpharma.com>

Curium is the world's largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.

With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for potentially life-threatening diseases to over 14 million patients annually. The name 'Curium' honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. The tagline 'Life Forward' represents our commitment to securing a brighter future for all those we serve: An enhanced quality of care for our patients. A trusted partner to our customers. A supportive employer to our valued team.

To learn more, visit www.curiumpharma.com

DOSIsoft SA

📍 45/47 Avenue Carnot
94230 Cachan, France

✉ info@dosisoft.com

🌐 <http://www.dosisoft.com>

Spin-off between Gustave Roussy & Institut Curie, DOSIsoft was founded in 2002. It develops patient-specific imaging and dosimetry software in Radiation Oncology & Nuclear Medicine to improve patient safety & treatment quality. 20 years of innovation and R&D investments have led to world leading software used in over 300 hospital centers in 60 countries.

PLANET® is a Patient-specific, multi-radionuclide (90Y/177Lu/131I/166Ho) dosimetry & theranostics platform. It comprises:

PLANET® Onco: Oncology software for Molecular Imaging (MI) & Radiotherapy. It helps to optimize disease diagnosis & therapy through registration, contouring, advanced quantification & patient response from multimodal imaging. Texture analysis for diagnosis, follow-up & radiomics is provided.

PLANET® Dose: Dosimetry software for Molecular RadioTherapy (MRT) providing multiple and integrated workflow for 90Y/177Lu/131I/166Ho dosimetry. It allows to personalize patient therapy through pre/post-implementation dosimetry, automatic structure propagation, calculation of residence time & comparison between treatment planning & validation control dose maps. Consolidation of multi-treatment stages is available.

DSD Pharma

📍 Schuhmeierstraße 24
1140 Purkersdorf, Austria

✉ office@dsd-pharma.com

🌐 <https://dsd-pharma.com>

DSD Pharma is a GDP certified distributor of radiopharmaceuticals and medical devices in the field of nuclear medicine and radiopharmacy, respectively, and ADR transportation based in Austria close to Vienna.

ec² Software Solutions

📍 3035 E. Patrick Lane, Suite 1
89120 Las Vegas, United States

✉ sales@ec2software.com

🌐 <http://www.ec2software.com>

ec² Software Solutions and our partner company, Numa LLC, are focused on developing and commercializing workflow and compatibility solutions for the molecular imaging community. Together, with over 60 years' experience, ec² and Numa provide innovative management solutions for cyclotrons, radiopharmacies, hot lab operations, drug manufacturers, multi-vendor connectivity, archiving and reporting. Our systems are presently installed in 6000 + facilities worldwide.

We provide Enterprise Solutions that secure ePHI patient data and consolidate installations all in a scalable architecture. The HL7 / DICOM Modality Worklist interfaces enhance scheduling and eliminate redundant data entry. NumaStatus can export patient dosimetry and dose information to the cameras, RIS/PACS or Dose Management system using DICOM secondary capture and Radiopharmaceutical Radiation Dose Structured Report (RRD SR). The HL7 export module and deliver dose information to the EMR and MAR.

Our online ordering (OLO) e-prescribing solutions are used by hundreds of commercial radiopharmacies and their customers in the U.S. and international markets. OLO eliminates transcription errors and enhances patient safety.

Eckert & Ziegler Isotope Products

📍 24937 Avenue Tibbitts
91355 Valencia, CA, United States

✉ nucmedsales@ezag.com

🌐 <https://sales.isotopeproducts.com>

Eckert and Ziegler Isotope Products (EZIP) offers a full range of Flood Sources, PET Sources, Specialized SPECT Sources and Multimodal Sources to meet the needs of the Nuclear Medicine community worldwide. EZIP is dedicated to serving the marketplace with high-value quality products safely constructed and delivered on time through a quality system founded on customer satisfaction, regulatory compliance and continuous improvement. With the inclusion of the Tecnonuclear portfolio, EZIP is now able to offer generators and radiolabeled cold kit compounds used in SPECT imaging. Please stop by to learn more about our products and the regions we can support.

Eckert & Ziegler Medical

📍 Robert-Roessle-Str.10
13125 Berlin, Germany

✉ marketing.medical@ezag.de

🌐 <https://medical.ezag.com/en>

Eckert & Ziegler Medical is one of two business segments of the Eckert & Ziegler Group, with headquarters in Berlin, Germany. With more than three decades of experience in the field, Medical represents the combined expertise in nuclear medicine, molecular imaging, radiation therapy and beyond, while always focusing customer success.

We complement our wide-ranging portfolio of innovative high-quality technical solutions with the provision of versatile services such as development and contract manufacturing. With our global network of GMP suites we offer fully licensed radioisotope labs, stable supply arrangements for almost all pharmaceutical radioisotopes, a state-of-the-art infrastructure including logistics, and a highly experienced staff that can be seconded to help with your preclinical and clinical projects.

As a one-stop-shop for all your radiopharmaceutical needs, using alpha, beta or gamma emitters, our products include everything from hot cell solutions to radiochemicals (e.g., Lu-177), radiopharmaceuticals (Yttriga, GalliaPharm®), radiosynthesis technology (Modular-Lab, KitLab) and radiochromatography equipment (e.g., AR-2000).

Contact as for GMP Suites, CDMO, CMC, GalliaPharm, Ac-225, Lu-177, Y-90, radioisotopes, hot cell solutions, IGG100, UniFill, SWB-15, rTLC, rHPLC, Flow-Count, Mini-Scan, MiniScanPRO, FlowCountPRO, IsoSeed and more.

EDL

📍 509 Av. de La Victoire du 8 Mai 1945
13130 Berre-L'Étang, France

✉ balart@edl.fr

🌐 <https://www.edl.fr>

Launched in 1994, EDL's software solutions have already attracted more than 600 medical imaging departments. EDL also publishes integrated applications covering all the modern needs of imaging services such as: RIS, PACS, DACS, VINA, Teleradiology, IA, Radiopharmacy and WEB portals.

EITA (European Isotopes Transport Association)

📍 c/o Vandelanotte Buro & Design Center,
Esplanade 1/85, 1020 Brussels, Belgium

✉ info@eita.org

🌐 <http://www.eita.org>

EITA is a non-profit association, which was founded in 1998 by European logistics providers trained, licensed and specialized in the handling and transport by Road, Air and Sea of radioactive isotopes, which are mainly used for medical purpose.

Mission

- Establishment of harmonized regulations and standards
Aiming for harmonized national and international regulations and legislations to guarantee the free market access in every state for the EITA members.
- Compliance with applicable regulations
To ensure all EITA member activities are carried out in full compliance with all applicable legal requirements.
- Safety, Security and traceability
To ensure safety and security and full traceability at all times during the complete supply chain.
- Quality
To ensure high quality of handling, packing and transport of radioactive isotopes in accordance with required standards.
- Competence centre
To provide a forum to exchange information and knowledge to increase awareness.

Eli Lilly

📍 Lilly Corporate Center
46285 Indianapolis, United States

✉ millerls@lilly.com

🌐 <https://www.lilly.com>

Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit lilly.com and lilly.com/newsroom or follow us on Facebook, Instagram, and LinkedIn.

ELSE Solutions S.r.l.

📍 Via Carlo Goldoni, 18
20090 Trezzano sul Naviglio (MI), Italy

✉ info@elsesolutions.com

🌐 <https://www.elsesolutions.com>

ELSE Solutions Srl is an Italian company founded in 1990 which boasts a long experience in the design and production of radiation detection systems, shielded manipulation systems and passthrough, automations, and plants for Nuclear Medicine, Radiopharmacy, Radiotherapy, and other applications in the Medical and Industrial fields. ELSE Solutions technologies are designed to meet the most advanced technology standards, safety, and environment care.

SmartEye Radiation Detection Platform is designed to be flexible, expandable, featuring PoE support, and is controlled by a Web based software, Shielded manipulation systems and passthrough are featuring fully encapsulated lead and PLC controlled ECO functions (auto standby) to reduce the electrical consumption, the patented automatic dispensing system is designed for zero loss of radioactivity and is certifying the prepared patient dose through a medical device dose calibrator, automations and plants are meeting the most updated international standards, PLC control is featuring advanced functions with User-Friendly remote interface, digital ovens for Radiotherapy masks are designed to work without water, significantly reducing preparation times and maximizing safety and hygiene of the process. ELSE Solutions' vision is to be an international reference for the design of innovative and state-of-art solutions in the Medical and Industrial fields.

Elysia-raytest Gmbh

📍 Rue du Sart-Tilman 375
B - 4031 Angleur, Belgium

✉ info@elysia-raytest.com

🌐 <https://www.elysia-raytest.com>

Elysia is a provider of hard- and software solutions for the full integrated quality control of your radio-pharmaceutical production. GINA X and SARA offer a user friendly and fully GMP compliant solution to your QC problems with BioTrax being our LIMS.

Radio-detectors are also used in TLC, HPLC and GC Radio-chromatography, Gamma Spectroscopy, Dose Calibration and well counting for the pharmaceutical, agrochemical and nuclear/PET industries.

Epsilon

📍 Erhatpasa Mahallesi 15.Sokak No.126/128
Atasehir, 3488 Istanbul, Türkiye

✉ info@epsilonsources.com

🌐 <http://www.epsilonsources.com>

ERS manufactures quality assurance sources that are compatible with the leading PET OEM manufacturers to provide high-quality products and customer satisfaction. For the calibration of PET, PET/CT, PET/MR & SPECT systems, 68Ge, 22Na, 57Co and 153Gd sources are used in different forms and activities depending on the system model. Customized sources in different forms and activities can be offered upon customer request by ERS.

Please contact your local distributor or ERS headquarters for product availability and additional information.

for-med.nl customized medical accessories

📍 Parallelweg zuid 33-02
5281 LB, Boxtel, Netherlands

✉ info@for-med.nl

🌐 <http://www.for-med.nl>

FOR-MED is a development and manufacturing company, specialized in customized medical accessories for radiology, nuclear medicine and radiotherapy. We are ISO13485 certified and able to make (custom) products with MDR/EUDAMED registration. Using state-of-the-art and innovative production methods we create a wide range of products for patient positioning and fixation, shielding and more. Furthermore, we offer a range of standard products for the clinical nuclear medicine practice, daily laboratory as well as research purposes. Typically, our customers are universities, hospitals and nuclear medicine departments, as well as radiopharmaceutical and imaging equipment companies. Our Products are available throughout Europe with our distributors, for more info visit www.for-med.nl or visit our booth at the EANM2023.

Gamma Medical Technology

📍 Friesdorfer Straße 194A
53175 Bonn, Germany

✉ info@gamma-mt.com

🌐 <http://www.gamma-mt.com>

Welcome to Gamma Medical Technology, a pioneering supplier of advanced gamma probes for Sentinel Lymph Node Biopsy (SLNB) and radio-guided surgery. Our objective is to transform cancer treatment with precision-focused surgical tools that elevate patient outcomes and streamline surgical processes.

Founded by a team of visionary medical experts and engineers, we are devoted to ongoing innovation, research, and development in radio-guided surgery. Our skilled team is dedicated to designing user-friendly gamma probes that meet the complex demands of modern surgical procedures.

Our flagship product, the CENNA-500W, exemplifies our commitment to quality and innovation. This next-gen gamma probe offers unmatched accuracy, sensitivity, and ease of use, enabling surgeons to confidently identify sentinel lymph nodes during SLNB. Its state-of-the-art design ensures precise gamma radiation detection, minimizing false-negative risks and reducing surgery times.

Gamma Medical Technology is renowned for quality, reliability, and exceptional customer support. We collaborate with surgeons and medical facilities worldwide, offering training, education, and ongoing assistance to optimize product use.

As we expand globally, we remain committed to our core values of innovation, excellence, and customer satisfaction. Discover the difference our products make in radio-guided surgery and join us in revolutionizing cancer treatment worldwide.

GE HealthCare

📍 283 rue de la miniere
78530 Buc, France

✉ maxime.teisseire@ge.com

🌐 <http://www.gehealthcare.co.uk>

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient's journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from prevention and screening, to diagnosis, treatment, therapy, and monitoring. We are an \$18 billion business with 51,000 employees working to create a world where healthcare has no limits.

Global Morpho Pharma

📍 72 rue de Lorraine ZA Erdre Active - Malabry,
BP 54201, 44242 La Chapelle-sur-Erdre, France

✉ sylvanie.guilloux@morphopharma.com

🌐 <https://morphopharma.com>

Global Morpho Pharma is a turnkey technology and service provider for the production and distribution of medical radioisotopes. We are developing innovative equipment and building efficient supply chains to enable our partners worldwide to manufacture nca Lu-177 and other radioisotopes of interest. We are dedicated to improving the accessibility of medical radioisotopes for the benefit of patients by providing convenient solutions to the rapidly expanding nuclear medicine ecosystem. Radioisotopes of interest : Lu-177, Tb-161, Ac-225
More information: <https://morphopharma.com/>

Hermes Medical Solutions AB

📍 Strandbergsgatan 16
112 51 Stockholm, Sweden

✉ info@hermesmedical.com

🌐 <https://www.hermesmedical.com>

Established in 1976 in Stockholm, Sweden, Hermes Medical Solutions continuously innovates to enable faster and more personalized diagnosis and therapies with its independent nuclear medicine and molecular imaging software. Hermes Medical Solutions was first to develop SPECT reconstruction software, first to develop dual-head whole body scanning, and first to introduce software for viewing fused images from different modalities. The HERMIA state-of-the-art, vendor-neutral software suite enables imaging professionals to streamline their workflows, and increase consistency and quality of clinical image review, whilst always keeping pace with the continual development of scanners, radiopharmaceuticals and imaging procedures in NM and MI. HERMIA harnesses the power of Artificial Intelligence and automation and combines it with the latest computing technology, to accelerate your workflow for all clinical scenarios in PET/ SPECT/CT/MR, onsite or remotely, regardless of scanner manufacturer. Our mission is to combine leadership in innovation for NM and MI software with customer-driven service. Our success lies in our close and longstanding collaboration with our customers to meet their software, support and service needs. HERMIA improves the quality of patient management and decision support for thousands of healthcare providers and their patients worldwide. Visit us at booth #309 and discover how HERMIA software can make a difference for your facility!

Hidex

📍 Lemminkäisenkatu 62
20520 Turku, Finland

✉ info@hidex.com

🌐 <https://hidex.com>

Hidex is a manufacturer of high-performance analysis equipment for life science research, radiation measurement, and nuclear medicine. As a world leader in detecting alpha, beta, and gamma emitters, Hidex offers optimized gamma counters for molecular imaging isotope energies. Our gamma counters are designed to streamline workflow, sample tracking, and ensure GxP compliance. Hidex liquid scintillation counters are used globally in the development and quality control of radiopharmaceuticals, utilizing isotopes such as Actinium, Radium, Thorium, Lutetium, Strontium, Yttrium, and more. At EANM, we are showcasing the following solutions: Automated gamma counting: The Hidex AMG, equipped with a NaI well detector and onboard sample balance, is ideal for metabolic studies, blood input function curves, Glucomerase filtration rate, and general nuclear medicine applications. PET radiochemistry: The Hidex Radiowater Generator is an online system for preparing Oxygen-15 H₂O infusions. With approximately 50 installations worldwide, Hidex is a pioneer in Oxygen-15 water technology. Liquid scintillation counting: Our Liquid scintillation counters 300SL and 600SL series are used by radiopharmaceutical production facilities for development and quality control of medical use isotopes, detection of impurities, contamination control with wipe tests as well as activity standardization. To learn more about our solutions, please book a meeting with our specialists or visit our booth

Hoy Scandinavian

📍 Jakob Møllersgård 4
9560 Hadsund, Denmark

✉ info@hoyscandinavian.dk

🌐 <https://www.hoyscandinavian.dk>

HOY Scandinavian was founded in 1991 as a supplier and distributor for Nuclear Medicine and radiochemistry department in Scandinavia. The "HOY Exclusive" product range was launched in 2006. The head office is located in Hadsund, Denmark, and all the HOY Exclusive product range are produced in Hadsund.

Today HOY Scandinavian is an international business that supplies products to nuclear medicine and oncology departments at hospitals and laboratories all over the world. We are known for supplying very high-quality products and are now a market leader in many markets – particularly in Scandinavia and Europe.

Our home market is primarily Denmark and Sweden. We are represented in other markets by a distributor network.

Products and activities

At HOY we develop and manufacture "Hoy Exclusive", an all in-house product design - offering quality products for radiation protection in nuclear medicine and PET departments.

The "HOY Exclusive" product portfolio has a modern timeless Scandinavian design, and offers maximum ergonomic comfort aligned to European standards.

Key products are:

- Vial glass Shields – Syringe Shielding – Syringe handling –
- Syringe Carrier and transports - Waste Contains – Tongs for Vials

IBA SA

📍 Chemin du Cyclotron 3
1348 Louvain la Neuve, Belgium

✉ elodie.vellut@iba-group.com

🌐 <https://www.iba-radiopharmasolutions.com>

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

ImaginAb

📍 423 Hindry Ave., Suite D
90301 Inglewood, United States

✉ info@imaginab.com

🌐 <http://www.imaginab.com>

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cystadiabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

INCEPTO MEDICAL

📍 10 Boulevard de Grenelle,
75015 Paris, France

✉ fanny.boutevin@incepto-medical.com

🌐 <https://incepto-medical.com>

We co-create with medical centers IA applications for radiology.

Healthcare professionals are now overwhelmed by the volume of patients and images. They need new tools. As safeguards of our Healthcare system, they need to be empowered and to participate in the AI production process. This is our mission through our co-creation projects.

We distribute the world's top applications via a unified platform.

Hundreds of start-ups have embarked on this adventure. They all want to produce AI to answer a specific clinical question. With our experience and our privileged relationship with the medical world, we support and integrate them on a dematerialized, secure, unique and simple platform.

We are building together the future of radiology: more reliable, faster, for more lives saved.

Incepto is this place at the crossroads of these paths: gathering solutions, market players and talents: Doctors, radiologists, researchers, data scientists, software developers, business developers, marketers and designers.

Saving Time, Saving Lives, Together.

Institute of Isotopes Co. Ltd.

📍 Konkoly-Thege Miklós u. 29-33.
1121 Budapest, Hungary

✉ commerce@izotop.hu

🌐 <https://www.izotop.hu>

Institute of Isotopes Co. Ltd. is on the frontline of radioisotope technology collaborating with long-term partners and customers. Over the years we have developed numerous products from diagnostic kits to radioactive sources for various radioactive applications. Our company provides varied and flexible services in this unique field. Our production complies with the highest quality standards: GMP, ISO9001, ISO13485, ISO14001 We are also engaged in product development projects and offer contract manufacturing, OEM services for our customers. Izotop looking forward to new products to widen our portfolio.

Fields of expertise:

- Radiopharmaceuticals, radiochemicals
- Immunoassay / In vitro products for human diagnosis and life science
- Synthesis / Radiosynthesis
- Radiation technique

Main products, services:

- Thyrotop I-131 sodium iodide hard capsules
- I-131 sodium iodide sterile solution
- I-131 MIBG injection for therapy and for diagnostic use
- Radiochemicals /I-125, I-131/
- Cold kits for Tc-^{99m}-labelling: DMSA, DTPA, PYRON, FYTON, MDP, TECHIDA, EC
- Sm-153-labelling MULTIBONE kit
- Ready to take part in R&D and manufacturing of active pharmaceutical ingredients, cold kits as well as investigational products for clinical trials.
- In Vitro diagnostics (RIA, IRMA, ELISA), Research Immunoassay kits;
- C-14 radiolabeled drug substances, GMP custom radiosynthesis;
- Radiation technique solutions for medical, research and industrial applications, Multipurpose irradiators

INVIA Medical Imaging Solutions

📍 3025 Boardwalk Drive, Suite 200
48108 Ann Arbor, United States

✉ info@inviasolutions.com

🌐 <http://www.inviasolutions.com>

INVIA develops advanced non-invasive nuclear cardiac imaging software for medical professionals to optimize patient care. Physicians use our software, 4DM, to accurately quantify, review, and report cardiac perfusion, function, and anatomy. Twenty-five camera, workstation, EMR and PACS partners provide 4DM integrated with their platform. The stand-alone version can be obtained from some of our partners or direct from INVIA. Originating at the University of Michigan more than twenty-five years ago, we developed 4DM with the patient in mind – enabling physicians around the world to make accurate interpretations. Visit us at INVIA booth to explore 4DM's latest features.

inviscan

📍 5 Rue Georges Guynemer
67120 Altorf (near Strasbourg), France

✉ info@inviscan.fr

🌐 <http://www.inviscan.fr>

Inviscan SAS is a high technology company located in France. inviscan develops and manufactures preclinical imaging systems used in medical research. Products of inviscan include PET/CT and CT systems for imaging rodents and larger animals (NHP), as well as novel MRI compatible PET technology. Inviscan is the original manufacturer of IRIS PET/CT systems and is the leading provider of preclinical PET/CT systems in a number of countries such as France and China. The systems are fully developed by inviscan and manufactured in France. Inviscan is a highly innovative company with several R&D programs on new technologies and applications. Inviscan is partner in several projects with high profile institutions including CNRS, INSERM, Helmholtz Institute in Germany, as well as CNR and University of Pisa in Italy.

lotron Medical Inc

📍 55 Madison Ave., Ste. 400
New Jersey, 7960 Morristown, United States

✉ enquiries@copper67.com

🌐 <http://www.copper67.com>

As the first commercial supplier of copper-67, lotron Medical is committed to improving the quality and accessibility of this radioisotope for the radiopharmaceutical community. Copper-67 is a proven and effective radioisotope for theranostics, particularly when paired with copper-64. The “perfect paring” of identical elements, differing only by isotope, delivers key advantages over other commonly used isotopes, including:

- Identical in-vivo behavior (imaging and therapy)
- Patient dose optimization (personalized medicine)
- Optimum half-life for small molecules
- Convenient off-site central manufacturing
- No reliance on nuclear reactors for production

Through our partnership with Canadian Isotope Innovation Corp., lotron Medical is supplying copper-67 to the US, Canada, and Europe, facilitating the development of next generation theranostics. For more information, please visit www.copper67.com.

IRE ELiT

📍 Avenue de l'Espérance, 1
B - 6220 Fleurus, Belgium

✉ marketing@ire.eu

🌐 <https://www.ire.eu/en>

IRE ELiT, the Institute for Radioelement innovation subsidiary, is a radiopharmaceutical company founded in 2010 to develop radiopharmaceutical drugs used in molecular imaging and therapy. Its main product is a Ge-68/Ga-68 generator, a simple and innovative PET imaging solution used, mainly, for NET tumors and recurrent prostate cancers.

Isotope JSC

📍 Pogodinskaya, 22
119435 Moscow, Russia

✉ isotop@isotop.ru

🌐 <http://www.isotop.ru/en>

Isotope JSC has been delivering radioactive and stable isotopes for all major applications for 65 years. Our production facilities are equipped with fission, cyclotron, electromagnetic and gas centrifuge technologies enabling the production of a broad product range for more than 750 clients from about 50 countries. We provide a wide variety of isotope-based products, including radiopharmaceuticals, medical generators, sealed radioactive sources, stable isotopes and raw material. Our isotope products are delivered by air, sea and land worldwide.

Isotopia Molecular Imaging Ltd.

📍 Alexander Yanai 39
4927735 Petach Tikva, Israel

✉ gbader@isotopia.co.il

🌐 <https://isotopia-global.com>

Isotopia aspired to be the world leader and innovative company in nuclear medicine by providing meaningful medical care for patients globally. Our flagship product, the radioisotope Lutetium-177 (both C.A and N.C.A), has attracted considerable attention and exhibited great promise in treating a variety of late-stage cancers, including metastatic prostate cancer and neuroendocrine tumours. Our production facilities include an advanced nuclear pharmacy that provides radionuclide-labeled compounds for PET/SPECT imaging, a cyclotron facility, and an aseptic manufacturing plant that also offers contract manufacturing services (CMO). Our customer services are available round the clock to provide thorough and meticulous guidance and support. Consistent and sustainable supply of Lutetium 177! Ensuring our services are efficiently available globally, we're establishing additional production facilities in Europe and North America. As we continue to take big strides towards becoming a prominent global supplier to the radiopharmaceutical industry, while maintaining the personal touch of a local partner, we remain focused on fulfilling the promise of nuclear medicine for advanced personalized cancer care.

ITEL Telecomunicazioni SRL

📍 Z.I. snc, Via Antonio Labriola
70037 Ruvo di Puglia BA, Italy

✉ itel@itelte.it

🌐 <https://itelpharma.com>

Itelpharma is a radiopharmaceutical company part of Italian healthcare company ITEL Group. It has been established as a GMP (Good Manufacturing Practice) certified pharmaceutical facility authorized by the Italian Drug Agency (AIFA). We produce radiopharmaceuticals for imaging diagnostics, which detect diseases in the fields of oncology, neurology and cardiology, with two production lines that can operate simultaneously. Itelpharma is recognized as one of the most trusted radiopharmaceutical manufacturers and suppliers. In addition to marketing our own radiopharmaceuticals, we are also contractors in the production and distribution of radiopharmaceuticals owned by other big pharmaceutical companies. At Itelpharma we have completely managed the design and implementation of our radiopharmaceutical production facility with two cyclotrons and an in-house microbiological laboratory. In over 10 years of activity, we have perfected our specializations and competences along with growing our full operations not only in manufacturing but also in research and radiopharmaceutical development. Above all, throughout this time, we have enhanced our scientific, technical, regulatory and commercial skills. We work in compliance with the best quality standards in microbiology and nuclear medicine, expanding and increasing the pipeline of molecular products and the services offer

ITM Isotope Technologies Munich SE

📍 Walther von Dyck Strasse 4
85748 Garching, Germany

✉ info@itm-radiopharma.com

🌐 <https://www.itm-radiopharma.com/home>

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.

Jiangsu Huayi Technology Co., Ltd.

📍 18 Fuyu Road, Haiyu Town
215522 Changshu City, China

✉ antony@huayi-isotopes.com

🌐 <http://www.huayitec.net>

Jiangsu Huayi Technology Co., Ltd. is a fully integrated provider of radiopharmaceuticals in China. We develop, manufacture, and distribute high-quality radiopharmaceutical products. CDMO services are offered to our global clients. We support projects from initial research phase to commercial production.

One of the divisions, Huayi Isotopes Co. (HIC), manufactures and distributes stable isotopes, PET and SPECT precursors, reagents kits, cassettes, and sterile vials etc. Products of HIC are supplied to clients around the world.

We are client-oriented and determined to build and foster long-term partnerships with our clients. Since the company was established in 2001, we have been dedicated to serving the nuclear medicine industry. Since 2014, we have been setting up nuclear medicine manufacturing sites strategically. Our integrated radiopharmaceutical manufacturing and distribution network will enable us to reach most of the patients in China. Follow us on LinkedIn, Twitter, Facebook, for the latest news

Products and Services

- Radiopharmaceuticals
- CDMO Services for Radiopharmaceuticals
- O-18 Water
- Total Solutions for PET Consumables
- Biochemicals
- Sterile Vials
- CMO Services (API, Reagents Kit & Cassettes, Fill/Finish)

Jubilant Radiopharma

📍 790 Township Line Road, Suite 325
19067 Yardley, United States

✉ jocelyn.polk@jubl.com

🌐 <http://www.jubilantradiopharma.com>

Jubilant Radiopharma is an industry leading radiopharmaceutical company committed to driving the value of cardiac PET as a vital imaging modality. We recognize the important role cardiac PET plays in evaluating cardiac physiology and function. We deliver better clinical outcomes as a result of our investment into our pipeline, infrastructure, and people—all of whom are driven by their uncompromised passion and dedication to the utility and sustainability of nuclear medicine. Jubilant Radiopharma is focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of "Improving Lives through Nuclear Medicine" on a global scale.

In the EEA, Jubilant partners with Cyclomedica to provide expanded access to next-generation PET products for enhanced diagnosis and management of patients with known or suspected coronary artery disease.

Jubilant is exhibiting alongside our Cyclomedica partner in Booth #401 at this year's EANM meeting. Please stop by our booth to learn more about the latest advancements in Cardiac PET imaging, and see how we can help you enhance your cardiac practice. For more information, please contact customer service at customerservice@jdi.jubl.com.

LabLogic Systems Ltd.

📍 Innovation House, 6 Europa View
S9 1XH Sheffield, United Kingdom

✉ solutions@lablogic.com

🌐 <https://lablogic.com>

LabLogic has over 35 years' experience of designing and manufacturing instruments and software for PET and Nuclear Medicine applications.

We will be showcasing our Tracer-QC system at EANM'23. Developed in conjunction with TraceAbility this instrument is already being seen as the future of PET QC. Certainly TraceAbility's years of experience in the PET industry, combined with LabLogic's expertise in software development, has created a unique instrument which can perform the essential PET QC tests with just 'single touch' operation and all in compliance with FDA 21 CFR Part 11 (Electronic Signatures) and Part 212 (GMP) regulations.

Our range of market leading products for PET and Nuclear Medicine applications also includes QC equipment such as r-TLC and r-HPLC instruments plus our single point of control radiochromatography software package – Laura for PET. The complete QC package is also available from LabLogic.

Furthermore we offer dedicated LIMS systems for PET and Nuclear medicine applications. PETra, a PET LIMS system designed to improve efficiency and compliance, SPECTra, a dedicated Radiopharmacy LIMS, and Orla, an online radiopharmaceutical order communication system.

Visit our booth #207 at the show to see demonstrations of the Tracer-QC and other products in our nuclear medicine range.

Lemer Pax

📍 72 rue de Lorraine, ZA Erdre Active - Malabry
BP 54201, 44242 La Chapelle-sur-Erdre, France

✉ contact@lemerpax.com

🌐 <https://www.lemerpax.com/en>

Worldwide leader in innovation in the radiation protection sector, Lemer Pax creates, designs, and engineers efficient radiation protection solutions for medical, research, industry, and nuclear applications.

With over 50 years of innovation, Lemer Pax exports all over the world, eco-aware and cutting edge of technology radiation protection products. Lemer Pax, protecting life, we strive for excellence to protect the most important thing: Life!

Medi-Radiopharma Ltd.

📍 Szamos u. 10-12.
2030 Érd, Hungary

✉ order@mediradiopharma.hu

🌐 <https://www.mediradiopharma.com>

Medi-Radiopharma (MRP) has more than 25 years of experience in developing, manufacturing, and supplying radiopharmaceutical products to customers around the globe. Our purpose is to serve the healthcare and improve patient outcomes through a wide portfolio of high-quality products. MRP specializes in the production and supply of generic in-vivo kits for Tc99m labelling used in nuclear medicine. By potentially enabling accurate early diagnosis and treatment of cancer, as well as heart, brain and bone diseases, our world-class products – registered in more than 80 countries worldwide - empower our customers with effective treatment and proven patient outcomes. We are also involved in the development of therapeutic radiopharmaceuticals. MRP holds valid Manufacturer's Authorization, Certificate of GMP Compliance of a Manufacturer, Wholesale Distribution Authorization, Certificate of GDP Compliance of a Wholesaler Distributor, GLP and ISO Certificate and relevant authorization for the manufacture and wholesale distribution of radiopharmaceuticals.

Mediso Ltd.

📍 Laborc u. 3.
1037 Budapest, Hungary

✉ sales@mediso.com

🌐 <https://mediso.com>

Mediso is a leading supplier of nuclear medicine hybrid imaging techniques for health care and research institutions of the world.

Mediso has a complete profile of development, manufacturing, selling and servicing of multi-modality molecular imaging systems. With over 30-year expertise and 1,350+ clinical installation Mediso offers solutions from imaging devices to evaluation and quantification software for both patient care and scientific research.

Besides a unique triple modality SPECT/CT/PET system, the AnyScan® TRIO family utilizes a triple head SPECT design and dedicated multi-pinhole collimation technology to achieve unparalleled sensitivity and quantitation accuracy especially for neuro- and cardiac imaging and for theranostic applications.

Mediso has a leader position in the preclinical nuclear imaging market with over 300 commissioned systems around the world. Beyond the market leading nanoScan® PET/CT and SPECT/CT, Mediso also offers standalone MRI and integrated PET/MRI systems based on a cryogen-free magnet with 3T or 7T field strength and a PET insert for simultaneous PET/MRI imaging.

Products are sold directly or through a distribution network in 100+ countries worldwide.

MEDraysintell

📍 Chemin du Cyclotron 6
B - 1348 Louvain-la-Neuve, Belgium

✉ peg@medraysintell.com

🌐 <https://www.medraysintell.com>

In Nuclear Medicine, we provide reports and directories with an exhaustive description and analysis of marketed radiopharmaceuticals, radiopharmaceuticals under clinical development, and radiopharmaceuticals under preclinical development, thru a description of about 970 products, together with a comprehensive profile of 380 companies active in nuclear medicine. Plus a complete review of the Cyclotrons used in Nuclear Medicine worldwide.

MedTrace Pharma A/S

📍 Agern Allé 5A
2970 Hørsholm, Denmark

✉ connect@medtrace.dk

🌐 <https://medtrace.dk>

MedTrace Pharma A/S is a development stage pharma and device company and an innovator in PET diagnostic imaging. The company is working on a solution to help healthcare professionals diagnose patients better and faster via ¹⁵O-water PET. Leading hospitals in the US, Europe and Japan are close partners.

In March 2022, MedTrace received FDA approval of the company's Investigational New Drug application and the approval to commence its RAPID-WATER-FLOW Phase 3 Clinical Trial to evaluate the use of ¹⁵O-water PET in diagnosing Coronary Artery Disease. Two months later, MedTrace announced that it had scanned the first subject. Meanwhile, the company is preparing for regulatory clearance in the EU.

Our solution consists of:

- 1) the P3 system, which is a point-of-care cGMP-compliant chemistry lab combining the process of manufacturing and injecting ¹⁵O-water into the patient.
- 2) the analytical software aQuant, which produces images combined with quantitative data of the PET scan.

At the same time, MedTrace is exploring clinical applications outside of cardiology and looking into research areas such as oncology and neurology. MedTrace, headquartered in Hørsholm, Denmark, and office in Minneapolis, US, is employing +35 people.

Brands: MedTrace Pharma, P3 System ¹⁵O-water system, aQuant cardiac analytical software

MIAS Pharma

📍 Stafford house, Suite 1, Strand Road
Portmarnock, D13 H525 Dublin, Ireland

✉ info@miaspharma.com

🌐 <https://miaspharma.com>

MIAS Pharma Ltd was set up in 2016 to enable Pharma / Bio-Pharma companies to manufacture and import products into the EU / EEA in a compliant manner, at optimal cost, with no significant investment in licence application activities or office / personnel costs.

MIAS Pharma delivers two main solutions:

1. A licensing framework to enable pharmaceutical importation and batch certification (required before each batch of a medicine can be made available in the EU/EEA marketplace)
2. Qualified Person (QP) services to oversee the release of investigational medicinal product for Clinical Trials and commercial product to the market.

MIAS Pharma also provide oversight of:

1. European Qualified Person (QP) services
2. Regulatory compliance of manufacturing activities
4. Regulatory compliance of Repackaging / Relabelling services
5. Regulatory compliance of Shipment and Transportation activities
6. Compliance with responsibilities as a Market Authorisation Holder (MAH)

MIAS operates in a hub and spoke model with a core group of MIAS employee being able to rely on a group of associated to flex up/down capacity depending on clients requirements.

MILabs B.V.

📍 Duwboot 7A,
3991CD Houten, Netherlands

✉ marketing@milabs.com

🌐 <https://www.milabs.com>

MILabs provides high-performance standalone and integrated SPECT, PET, CT, and, Optical Imaging systems for molecular imaging and in vivo imaging research. Our multimodal imaging technology with four-dimensional imaging capabilities enables researchers to improve diagnostics and therapy development through complementary, data-rich, co-registered images. Each modality by itself gives data beyond the capabilities of any other stand-alone system.

Our mission is to make molecular imaging clear. Through our continuous innovation and supportive service, the team at MILabs is dedicated to 'providing small details for big discoveries' for a wide range of imaging research programs. With over 100 installations worldwide, our fast-growing company collaborates with leading universities, hospitals, contract research organizations, and pharmaceutical companies. Our systems contribute significantly to developing new diagnostic solutions and therapies for diseases such as diabetes, cancer, and cardiac and neurodegenerative diseases. Explore how our cutting-edge preclinical imaging and technologies can accelerate research discoveries at www.milabs.com.

MIM Software Inc.

📍 25800 Science Park Dr., Ste 180
44122 Cleveland, United States

✉ info@mimsoftware.com

🌐 <http://www.mimsoftware.com>

MIM Software Inc. offers a comprehensive suite of applications that support Radiology and Nuclear Medicine's important role in cancer care. MIM Software products excel in Theranostics and emphasize the importance of quantitation, collaboration, and data management to provide physicians with crucial information to generate confident clinical guidance and inform effective treatments.

MIM Software drives your nuclear medicine workflow with comprehensive support for standard nuclear medicine studies, emerging radiotracers, neuro and cardiac imaging. MIM SurePlan™ offers tools to support the feasibility of molecular radiotherapy dosimetry and Y90 therapy within the busy Nuclear Medicine workflow. Quantitative images are needed to calculate accurate dosimetry, and MIM SPECTRA Quant™ provides a vendor-neutral SPECT reconstruction method that pairs dynamically with existing SPECT/CT cameras.

MIM Assistant® automates traditional clinical tasks and centralizes images and related data to a single repository. Flexible deployment options allow easy access to MIM Software from anywhere. The result is greater access to critical patient information in collaborative settings like tumor boards or for use in dictated reports.

MNT Healthcare Services Inc

📍 19 Mayıs Mah. Dr.Şevkey Bey Sk. No:5 Şişli
34360 İstanbul, Türkiye

✉ rita.lazo@mnt.com.tr

🌐 <http://www.mnt.com.tr>

Since 1990, MNT has been providing professional nuclear medicine and radiation oncology solutions to healthcare organizations. Currently, MNT operates 63 centers in Türkiye and 9 centers in Europe, offering specialized diagnostic and therapeutic services throughout all stages of nuclear medicine and radiation oncology.

With a dynamic and innovative approach, MNT is recognized as one of the most experienced healthcare service providers in the field. Its services reach patients in numerous NM and RT Centers within universities, state hospitals, and private hospitals. MNT also directly caters to cancer patients through its own branded centers, Neolife. Neolife is rapidly expanding its global presence and establishing itself as a formidable international brand. MNT operates 6 Neolife centers in Romania, 1 center in Moldova, and 2 centers in Bulgaria. Additionally, MNT is actively pursuing further projects in Africa, the Balkans, the Middle East, and Central Asia.

MNT adheres to the gold standards in medicine and leads in theragnostic applications. By utilizing cutting-edge technology, such as advanced imaging, molecular probes, and minimal radiation doses, MNT enables precise diagnosis and targeted therapies across its centers.

MNT ensures the smooth and timely completion of turn-key projects by offering the following services:

- Project Design and Installation
- Equipment Investment and Maintenance
- Personnel Recruitment
- Radiation Safety and Training
- Project Management

MNT Kwint International BV

📍 Suze Groenewegstraat 11
production: Industrieweg 6a waardenburg
4105EM Culemborg, Netherlands

✉ geert@mnt-int.com

🌐 <http://www.mnt-int.com>

Turnkey producer for complete Isotope facilities in hospitals & institutes, from GMP planning till realization for use of Mo-99 Tc Generator, I-131/ Ru-Kr or FDG- Ga68 facilities and also shielded accessories.

Turnkey producer for complete Therapy departments, including vacuum wastewater facilities. In 2019, Kwint International has successfully built and put into operation the world's biggest unit (28 therapy rooms); MNT International is the founding father of the so called 'golden standard' in hot labs for the labelling of isotopes. measurement equipment and GMP-Laboratory furniture according to the IAEA regulations combined in one product called "Ultra techneflow shielded Laminar downflow cabinet"; Training of Nuclear medical staff for all S.O.P.s (standard operating procedures) according rules/guidelines of the International Atomic Energy Agency (IAEA) and the European Association of Nuclear Medicine (EANM), including support at initial operation phase.

MNX Global Logistics

📍 Long Beach, CA (Corporate HQ) 5000 Airport
Plaza Drive, Suite 100
CA 90815 Long Beach, United States

✉ h.vandemaele@be-wis.com

🌐 <https://www.mnx.com>

MNX provides specialized time, temperature and security sensitive transportation and logistics services worldwide.

High standards, high value and high complexity: it's the nature of logistics for the life sciences and healthcare industries.

It takes precision, passion and partnership to transport your healthcare and medical packages around the world.

Our life sciences experience is as deep as our network is wide.

Monrol Nuclear Products Co./S.C. Monrol Europe SRL

📍 Rüzgarlıbahçe Mahallesi Çam Pınarı Sokak
No:3 D:10,11 Beykoz
34805 İstanbul, Türkiye

✉ monrol@monrol.com

🌐 <https://monrol.com.tr/en>

Monrol is one of the world's largest nuclear medicine companies leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals having headquarters in İstanbul. Monrol is distributing its world-class radiopharmaceutical products portfolio with excellence in global markets. Monrol is a CDMO, providing early development support to its customers as well as offering fully integrated services for today's nimble, lean, virtual companies effectively taking new product concepts into clinical trials, demonstrating proof of concept and going into first-in-human studies.

Monrol is committed to transform and improve patient journey in cancer treatment with its radiopharmaceutical products portfolio distributing to more than 60 countries around the globe. To learn more, visit www.monrol.com and LinkedIn.

MR Solutions Ltd.

📍 Ashbourne House, Old Portsmouth Road
GU3 1LR Guildford, United Kingdom

✉ richard.taylor@mrsolutions.com

🌐 <https://www.mrsolutions.com>

MR SOLUTIONS GROUP develops and manufactures innovative imaging solutions for the research industry. The company offers a large range of products for MR, CT, PET and SPECT. All scanners are interchangeable between each other for multi-modality imaging.

The company is the worldwide leader in high-field cryogen-free MR with its proprietary dry magnet technology. The MRS*DRYMAG product line delivers MR up to 9.4T and a bore size up to 42 cm. Advanced coils and software tools for pulse sequence programming are also available.

The magnet technology has exclusive features such as rotating the system to 90° and the ability to ramp the field of the magnet up and down within minutes. Helium lines and shielded rooms are not required, to keep installation costs extremely low. PET/MR imaging is possible up to 9.4T simultaneously. SPECT can be combined with PET/MR for a tri-modality imaging scanner. PET and SPECT scanners are based on our proprietary CLIP-ON technology. They are easily removable from the MR in minutes, and can be plugged straight onto the CT. This avoids the need for numerous scanners and large rooms. Several models of PET/SPECT/CT's are available: Benchtop, high resolution, and very large bore for 12 kg animals.

MR SOLUTIONS can refurbish and enhance all components from any MR.

MR Solutions holds prestigious Queen's awards, the innovation award from the Institute of Physics and is the winner in the global R&D 100 awards.

MR Solutions has offices across the world

Novartis

📍 Forum 1, Novartis Campus
CH-4002 Basel, Switzerland

✉ vida.niksic@novartis.com

🌐 <https://www.novartis.com>

Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About 108,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world.

Nuclear Medicine Europe eeg

📍 Avenue Louise 65
1050 Brussels, Belgium

✉ david.crunelle@nmeu.org

🌐 <https://nuclearmedicineeurope.eu>

Nuclear Medicine Europe (ex AIPES) represents many of the major pharmaceutical & Imaging equipment companies in the field of Nuclear Medicine in Europe. The combination of radiopharmaceuticals & state-of-the-art imaging permits noninvasive visualization of organs, function & structure within the body. Nuclear medicine is used in the diagnosis, management, treatment & prognosis of diseases across a broad range of medical specialties, such as oncology, cardiovascular & neurology to name a few, and as such is an integral part of patient care.

Nuclear Shields BV

📍 Akkervoortweg 29
5827 AP, Vortum-Mullem, Netherlands

✉ info@nuclear-shields.com

🌐 <http://www.nuclear-shields.com>

Nuclear Shields is a manufacturer of radiation shielding based in the Netherlands with more than 40 years of experience. The production facility is designed to meet the requirements of long term serial production and one-off custom projects. Lines of communication are short due to our small team of sales and engineering personnel. The focus on good and fast communication with the client helps us improve our services every day and makes sure the customer is satisfied.

Nuclear Shields is part of the Van Mullekom Group which was founded in The Netherlands in 1978. All factories share a common ground in engineering and radiation shielding that can be applied to many different industries, such as the healthcare, homeland security and nuclear industry. Nuclear Shields is a seller of a wide range of products regarding the shielding of radioactivity. Our products range from hot lab necessities and radiation shielding, to radiation detection and radiation cleanup solutions.

The In-House capabilities of the Van Mullekom Group range from prototyping to full assembly, which enables us to provide a wide range of solutions for a low price, high quality and with quick customer service. These in-house departments express our capability of manufacturing a wide product range, including the creation of custom-made solutions to fit your needs.

Nucleis

📍 Allée du Six-Août, 8
B - 4000 Liège, Belgium

✉ info@nucleis.eu

🌐 <https://nucleis.eu>

Nucleis is a radiopharmaceutical company manufacturing and distributing Radiopharmaceutical Drugs for Diagnostic and Therapy Monitoring.

Nucleis' portfolio presents Brand name drugs, IMP and CMO activities. This allows Nucleis to reach nuclear medicine services and (radio) pharmaceutical industry.

- GMP Certificate number BE/GMP/2022/114 for Human Medicinal Products
- GMP Certificate number BE/GMP/2022/115 for Human Investigational Medicinal Products
- MIA 1932 H
- MIA 1932 IMP

NUVIA Instruments GmbH

📍 Dornblüthstrasse 14 A
1277 Dresden, Germany

✉ kontakt@nuvia.com

🌐 <https://www.nuviatech-healthcare.com>

NUVIA Instruments GmbH is the new name of MED Nuklear-Medizintechnik Dresden GmbH and member of the NUVIA Group since 2014.

With 2 sites in Dresden and Dülmen, NUVIA Instruments GmbH designs and manufactures laboratory counters and radiation monitoring systems for nuclear medicine, PET-centres and therapy stations:

- Dose Calibrators
- Thyroid Uptake-Counters, Incorporation Counters, Well-Counters, Waste Water Counters
- Patient and Area Monitoring Systems
- Contamination Monitors (portable and hand-foot-clothing monitors)
- Waste and Release Monitors
- Laboratory Furniture (standard and customized)

About the NUVIA Group:

NUVIA is the nuclear branch of Soletanche Freyssinet, a subsidiary of Vinci Construction Group. Even though the NUVIA name was created in 2007, its history goes back to the beginning of the French and British nuclear industry. Today, with more than 30 years of experience and approx. 3,000 employees worldwide, the NUVIA Group offers engineering, services and products at all stages of a nuclear facility's lifecycle: design, construction, operations, maintenance, decommissioning. The NUVIATECH HEALTHCARE brand was created in 2017 to offer the Group's complete portfolio of instruments, systems and solutions for healthcare applications.

For more information about the NUVIA Group and its activities in the healthcare sector, you are welcome to visit us in The Pavilion!

Oncidium Foundation

📍 Av. Herrmann-Debroux, 40
B - 1160 Brussels, Belgium

✉ contact@oncidium-life.org

🌐 <https://www.oncidiumfoundation.org>

The Oncidium foundation is dedicated to support the development of radiotheranostics (RLT) for cancer care.

3 pillars:

- ACCESS through a wide network of ambassador experts and a worldwide map of therapy centers.
- EDUCATION & awareness are essential as it helps to bring a better understanding of the functioning & benefits of RLT.
- HOPE – The foundation is evaluating all possibilities to support clinical developments of efficient RLT & individual cases to reduce treatment overall costs in low-income countries. Come and meet us!

Oncobeta GmbH

📍 Schleißheimer Str. 91
85748 Garching bei München, Germany

✉ info@oncobeta.com

🌐 <https://www.oncobeta.com>

OncoBeta® GmbH with its headquarters located in Garching, near Munich, is a privately held medical device and radiochemical company specialized in the development and commercialization of state-of-the-art, innovative skin cancer therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified, TGA-Australia approved and certified by SAPHRA – South Africa. Furthermore, having the patient in focus, OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT® significantly improves outcomes and the quality of life of non-melanoma skin cancer patients.

ONCODESIGN SERVICES

📍 20 rue Jean Mazen
21000 Dijon, France

✉ contact@oncodesign-services.com

🌐 <https://www.oncodesign-services.com>

Oncodesign Services is a Contract research organization (CRO) specializing in drug discovery and preclinical services. From target identification to IND filing, the company contributes to the development of innovative therapies in oncology, inflammation and infectious diseases, with high medical needs.

Through integrated capabilities in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, in vivo/in vitro pharmacology, Oncodesign Services support the R&D programs of customers with a global footprint.

Based in Dijon, France, in the heart of the university and hospital cluster and within the Paris-Saclay cluster, Oncodesign Services has 230 employees in France, Canada and the United States.

OncoSil Medical Europe GmbH

📍 Suite 503, Level 5, 15 Blue Street
NSW 2060 North Sydney, Australia

✉ info@oncosil.com

🌐 <http://www.oncosil.com>

OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes for people living with cancer by utilising selective and targeted intratumoral placement of Phosphorous 32 (32P) Microparticles.

OncoSil™ is a single-use brachytherapy device that has received breakthrough device designation in the European Union, United Kingdom and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy.

OncoSil™ comprises of Phosphorous-32 (32P) Microparticles suspended in a specially formulated Diluent. The Microparticles are a permanent implant which contain Phosphorous-32 (32P), a pure beta-emitter radioisotope with a physical half-life of 14.27 days. In therapeutic use, 98% of the radiation is delivered within 81 days, which gives an absorbed dose equivalent to 100 Gy.

Pars Isotope Co.

📍 PARS ISOTOPE Co., No. 88, West 23rd St.,
Azadegan Blvd., South Sheikh Bahaie Ave.
1439955416 Tehran, Iran

✉ info@parsisotope.com

🌐 <https://parsisotope.com>

Pars Isotope Co. is the only producer and supplier of radiopharmaceuticals and radiopharmaceutical kits in Iran. Pars Isotope produces more than 50 different types of diagnostic (SPECT & PET) and therapeutic products in the field of nuclear medicine. Among our valuable products, we can mention Tc-99m and Ga-68 generators, which are known under the brand names of PARS-TEC II and PARS-GalluGen, respectively. Also, the variety of our radiopharmaceutical kits reaches more than 20 different types.

In order to improve the quality and quantity of medical products based on cGMP regulations, Pars Isotope participates in a project to implement new modern RRP, CKP and PET facilities in Iran. In addition, we focus on the following activities according to our profession and abilities:

- Production of more than 20 types of Tc-99m radiopharmaceutical kits.
- Production of 4 types of radionuclide generators to be used in PET & SPECT imaging.
- Production of new ready to use PET radiopharmaceuticals.
- Production of more than 22 ready to use theranostic, bone pain palliation and radio-synovectomy radiopharmaceuticals.
- Development and optimization of separation methods for different types of radioisotopes used in the production of radiopharmaceuticals.
- Development and optimization of advanced methodologies in the production of new radiopharmaceuticals.
- Production and development of industrial radioisotopes and radiation equipment used in various industries.

PBL Srl.

📍 Via Alessandro Volta, 8
43046 Rubbiano di Solignano, Italy

✉ annagiulia.bifani@pblsrl.it

🌐 <https://www.pbl.it>

PBL was born from an entrepreneurial investment started in 1979, when the first automation solutions for the beverage, chemical and pharmaceutical sectors were designed, built and installed.

The experience gained in over 40 years of technological research has allowed PBL to consolidate its position in the markets of interest, gaining the trust of new customers around the world.

PBL is investing in three main fields:

PHARMA DIVISION

We offer flexibility, innovation, technical expertise, and value on your investments for pharma, radio-pharma, and cosmetic custom solutions applied to primary and secondary packaging.

CONSUMER DIVISION

We design and supply filling and packaging lines for single-serve coffee pods. These lines can satisfy any client request and promptly react to the continuous market developments.

HEALTHCARE DIVISION

Our expertise in Artificial Intelligence and Deep Learning is offered to companies in need of dedicated industrial solutions based on innovative and efficient technologies.

PentixaPharm GmbH

📍 Bismarkstraße 13
97080 Würzburg, Germany

✉ info@pentixapharm.com

🌐 <https://pentixapharm.com>

PentixaPharm, an Eckert & Ziegler AG subsidiary, is developing the innovative theranostic pair PentixaFor and PentixaTher. These two peptide-based radiopharmaceuticals specifically target the CXCR4-receptor, which is overexpressed in many hematological diseases as well as various other indications.

The aim is to develop a specific diagnostic PET / CT tracer linked to Gallium-68, called PentixaFor for accurate identification and localization of CXCR4 overexpressing tumors. The therapeutic agent PentixaTher binds to the same receptor as the diagnostic agent but is linked to a stronger radiating nuclide (Yttrium-90). Therefore, PentixaTher has the potential to precisely destroy the targeted lesions. Both products are currently under clinical development.

PI Medical Diagnostic Equipment B.V.

📍 Forellenweg 7
4941 SJ, Raamsdonksveer, Netherlands

✉ info@pi-medical.nl

🌐 <http://www.pi-medical.nl>

PI Medical offers a wide range of instruments and accessories for the nuclear medicine market. The product range includes FDG dispensing systems, dose calibrators, contamination and radiation monitors, PET and SPECT phantoms, calibration sources and other QA devices, radiation shielding materials, Surgical equipment, Breast cancer localization products, patient positioning devices, etc.

PI Medical stands for high quality products and a high quality service.

With our own Service department, all highly trained and educated, we can provide the best service, support and advice to our end users.

Together with our partners, we can give you the best products and service for your needs.

PI Medical Diagnostic Equipment B.V. – a Medical Imaging Specialist !

PMB-ALCEN

📍 CD 56, Route des Michels, Lieu-dit
"La Corneirelle", 13790 Peynier, France

✉ contact@pmb-alcen.com

🌐 <https://www.pmb-alcen.com>

PMB is a human-sized company based in France, with a long-standing expertise in brazing dissimilar materials and specialized in the design and manufacture of complex assemblies and sub-assemblies (RF and beamline components, components

for X-ray tubes, ceramic-metal assemblies...), as well as particle accelerators and disruptive medical systems :

- iMiGiNE is an automated radiopharmaceutical production system for PET imaging and Theranostics. The system combines a cyclotron (iMiTRACE) with a robotized radiochemistry room (iMiLAB).
- iMiDEV is a Microfluidic Synthesizer designed for R&D and preclinical studies.

POLATOM, Radioisotope Centre of National Centre for Nuclear Research

📍 Andrzeja Sołtana 7
05-400 Otwock, Poland

✉ polatom@polatom.pl

🌐 <http://www.polatom.pl>

NCBJ Radioisotope Center POLATOM is a Polish producer and distributor of isotope preparations used in medicine, science, industry and environmental protection. It also conducts research and development works of an application nature and concern radiopharmacy, chemistry and nuclear technology as well as scientific disciplines such as radiochemistry, biochemistry, and immunology, resulting in development of our own products and technologies.

Our offer for nuclear medicine includes:

- ready-made radiopharmaceuticals, used in cancer therapy and in the treatment of benign thyroid diseases;
- technetium scintigraphy kits used in oncological diagnostics, intended for imaging of: kidneys, liver, bile ducts, spleen, heart, bones;
- labeling precursors;
- radionuclide generators ^{99m}Tc;
- accessories necessary in Departments of Nuclear Medicine;
- as well as various GMP and GMP compliant products and components for medical research.

NCBJ Radioisotope Center POLATOM holds the ISO 9001:2015 Quality System Certificate and the Internal Control System for trade in dual-use goods, as well as a Certificate confirming compliance with the GMP requirements. Moreover, in our Radioactivity Standards Laboratory, a management system compliant with the international standard ISO/IEC 17025:2018 has been implemented and maintained. Our RSL's technical competence – as a calibration laboratory – is confirmed by the accreditation certificate AP 120 granted by the Polish Center for Accreditation.

Positriago AG

📍 Technoparkstrasse 1
8005 Zurich, Switzerland

✉ info@positriago.com

🌐 <http://www.positriago.com>

Positriago is a pioneer in nuclear medical imaging technologies. Headquartered in Switzerland, the medical device company was founded in 2018. NeuroLF® - the company's first device - is an ultra-compact brain PET scanner which has applications in assessment of causes of dementias, such as Alzheimer's disease and other brain related disorders.

QUBIO

📍 Olmos 5, 2
15003 A Coruña, Spain

✉ manuel@qubiotech.com

🌐 <https://qubiotech.com>

At Qubiotech we develop software assisted by artificial intelligence for automatic and advanced neuroimaging analysis: Neurocloud, a CE marked tool for the quantification of biomarkers in neurodegenerative diseases, which quickly, accurately and efficiently helps the physician (radiologist, neurologist and nuclear medicine) in the diagnosis and monitoring of the patient providing a complete report of the results in a few minutes.

Neurocloud stands out for its experience of use and its clinically validated results (CE marked and FDA in progress) that help in the early diagnosis and follow-up of diseases such as Multiple Sclerosis, Epilepsy, Parkinson or Alzheimer.

Neurocloud's quantification allows moving from subjective assessments, which depend on the observer, to quantitative, reproducible assessments, and therefore members of the same team can reach the same results with certainty.

Qubiotech was born in the Neuroimaging Group of the University Hospital of Santiago de Compostela with the aim of bringing innovation in molecular image analysis to real clinical practice and also at a very low cost compared to the alternatives we had so far.

Welcome to Augmented Neuroimaging. Welcome to Qubiotech.

RADIOPROTECH

📍 12 chemin des Gorges
69570 Dardilly, France

✉ contact@radioprotech.com

🌐 <http://www.radioprotech.com>

Radiation protection equipment for Nuclear Medicine department. Designed and made in France. Our products range cover all radioprotection needs from the arrival of the radiopharmaceutical until its disposal.

Rotem GmbH

📍 Franz-Flemming-Str. 39A
4179 Leipzig, Germany

✉ info@rotem-eu.de

🌐 <https://rotem-medical.com>

Rotem, a longtime global leader in consumables for PET imaging, supplies cyclotrons around the world with complete packages for radiotracer production.

Our product range is centered on Oxygen-18 enriched water, plastic cassettes, precursors and complete reagent kits for various synthesis modules. All products are manufactured in compliance with cGMP requirements according to EU & PIC/S and are produced in our US FDA-inspected facility. Rotem's cGMP certified Mannose Triflate holds a certificate of suitability from the EDQM.

Production is supported by Rotem's in-house certified analytical laboratory which has a wide array of equipment and QC method development capabilities. Our highly skilled staff provides users with comprehensive technical and regulatory support as well as excellent customer service.

Rotem is particularly active in the design and production of consumables for radiotracers under development. These projects benefit from our interdisciplinary expertise, which is the result of many years of close collaboration with radiopharmaceutical companies worldwide.

Rotem GmbH in Leipzig serves customers in Europe, with local representatives in the U.K. and Ireland.

Other divisions in Rotem specialize in the development, production marketing and distribution of radiation detection monitoring equipment and decommissioning technology.

ROTOP Pharmaka GmbH

📍 Bautzner Landstraße 400
1328 Dresden, Germany

✉ j.neubert@rotop-pharmaka.de

🌐 <http://www.rotop-pharmaka.com>

With its many years of experience and its business location at the Helmholtz research site, ROTOP Pharmaka GmbH offers a modern pharmaceutical company with GMP compliant services.

Experience includes API/Cold Kit/Radiopharmaceutical development, cGMP manufacturing, marketing authorizations and worldwide distribution. ROTOP continuously expands its product portfolio by developing new products and entering new strategic partnerships. Furthermore, ROTOP offers a broad range of CDMO services. At every stage from the idea to your own product, we are happy to assist you with our broad knowledge and many years of experience. For more information about our products and services visit: www.rotop-pharmaka.com

RQS Alexander Ruffani

📍 Kantstrasse 15
1809 Heidenau, Germany

✉ info@rqs-ar.com

🌐 <http://www.rqs-ar.com>

RQS Alexander Ruffani was founded in 2017 and has years of experience in radiochemistry, radiopharmacy and analytical instrumentation.

A growing team of experienced and motivated professionals with expertise in synthesis development, radiochemistry, GMP-compliant production processes and chromatography instrumentation will help you find the best possible solution for your work application.

In 2020, RQS expanded to the USA and established Ruffani Quality Solutions, LLC. to provide timely and flexible local service. Our colleagues are specialized in the planning of production facilities as well as their construction, for this purpose they have been involved in several projects especially on the East Coast.

The team is ready to support you with all your requests and is looking forward to get in contact with you.

Thanks to deep experience in the various fields of nuclear medicine and radiochemistry, it is possible to offer a wide range of services of the highest quality.

- Support in laboratory planning, construction and commissioning
- Qualification, maintenance and repair of instruments for the production of (radio-) pharmaceuticals
- GMP documentation for radiopharmacy for quality management system
- Method development for various syntheses and quality control processes in radiopharmacy
- Validation of methods in production and quality control

Scannix

📍 Rue du Mont d'Orcq 3
B - 7503 Froyennes, Belgium

✉ info@scannix.com

🌐 <https://www.scannix.com>

Scannix is specialized in the development and sales of nuclear spectroscopy equipment and radioprotection systems. Scannix offers a wide range of measurement devices in order to maintain safety of staff, assess the health of nuclear facilities and safeguard the public and the environment.

SCINTOMICS Molecular, att GmbH

📍 Lindach 4
82256 Fürstfeldbruck, Germany

✉ info@sci-att.com

🌐 <https://sci-att.com>

Scintomics Molecular, Applied Theranostics Technologies (SCI-att), established in 2018, is a prominent and fast-growing player in the radiopharmaceutical industry. With a strategic focus on ensuring a consistent supply and comprehensive support for proprietary and innovative tracer technology and non-IP protected precursors, such as PSMA I&T and next-generation PSMA inhibitors like siPSMA-14 and SiFAlinTATE, SCI-att stands at the forefront of cutting-edge theranostics solutions.

As a subsidiary of Scintomics GmbH, SCI-att took over the prestigious GRP Module Series in 2020, further enhancing our capabilities and product offerings. We are dedicated to expanding our portfolio and providing our customers with an unparalleled portfolio of products and services. At SCI-att, we pride ourselves on delivering top-notch quality and exceptional customer support. We invite you to visit us at booth 249, where our knowledgeable team will be delighted to share information about our latest and exciting projects. Join us in shaping the future of theranostics as we look forward to welcoming you at our booth.

SHINE Medical Technologies, LLC

📍 3400 Innovation Court
53546 Janesville, United States

✉ lauratzakis@shinefusion.com

🌐 <http://www.shinefusion.com>

Based in Janesville, Wisconsin, SHINE Technologies is a next-generation fusion technology company, deploying safe, cost-effective and environmentally friendly systems for use in industrial imaging of components across aerospace, defense, transport, medicine, energy and more. SHINE's proprietary isotope production processes create both molybdenum-99 and n.c.a. lutetium-177, each of which are used in diagnostic and therapeutic medical procedures. SHINE is currently producing n.c.a. Lu-177, has a Drug Master File in place with the U.S. Food and Drug Administration and is rapidly scaling its production capabilities. It is also currently constructing a 43,000-square-foot facility that will be dedicated to producing fusion-based medical isotopes like Mo-99. SHINE plans to scale its fusion technology to recycle nuclear waste and to generate fusion power to deliver clean, abundant energy that could transform life on Earth. Learn more at www.shinefusion.com

Siemens Healthineers

📍 Henkestrasse 127.
91052 Erlangen, Germany

✉ maurice.koehr@siemens-healthineers.com

🌐 <https://www.siemens-healthineers.com/molecular-imaging>

At Siemens Healthineers, we pioneer breakthroughs in healthcare. For everyone. Everywhere. By constantly bringing breakthrough innovations to market, we enable healthcare professionals to deliver high-quality care, leading to the best possible outcome for patients. Our portfolio, spanning from in-vitro and in-vivo diagnostics to image-guided therapy and innovative cancer care, is crucial for clinical decision-making and treatment pathways. With our strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the biggest challenges in healthcare. We will continue to build on these strengths to help fight the world's most threatening diseases, improving the quality of outcomes, and enabling access to care. We are a team of 66,000 highly dedicated employees across more than 70 countries passionately pushing the boundaries of what's possible in healthcare to help improve people's lives around the world.

Sirtex Medical Europe GmbH

📍 Joseph-Schumpeter-Allee 33
53227 Bonn, Germany

✉ jean.le-scel@sirtex.com

🌐 <https://www.sirtex.com/eu>

Sirtex Medical is a global healthcare business with offices in the U.S., Australia, Germany and Singapore, working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. SIR-Spheres® Y-90 resin microspheres are a medical device used in selective internal radiation therapy (SIRT) for treatment of unresectable hepatocellular carcinoma (HCC) or unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

Softway Medical

📍 Arteparc - Batiment D
29 allée Saint-Jean, 13710 Fuveau, France

✉ mbenhammouda@softwaymedical.fr

🌐 <https://www.softwaymedical.fr>

Since 1998 NICESOFT develops innovative software solutions for Medical Imaging departments. We combine zero-footprint Web technology with a high specialization in Nuclear Medicine and Radiology to design applications that can be used in hospitals, private practices or even from home without any installation. Our VENUS product line provides a complete range of solutions, from online appointment booking to a full-Web Viewing & Processing Application Server. Thanks to its Web design, your images and reporting tools can be securely accessed from anywhere, making VENUS the ideal partner to develop teleradiology services. We are the leading RIS provider for Nuclear Medicine departments in France and have also equipped sites across Europe, the US, China and the Middle East. SOFTWAY MEDICAL is a leading cloud base provider of software and services for health institution in Europe. With more than 3,000 client institutions, we cover the entire range of healthcare services in the public and private hospital sectors, as well as in radiology and outpatient medicine, becoming the second largest European player in terms of market share in the EMR sector. Based on web technologies, the SOFTWAY MEDICAL group's solutions enable the entire patient care process to be managed and data to be shared securely between healthcare professionals.

Southern Scientific

📍 Scientific House, The Henfield Business Park
Shoreham Road, BN5 9SL Henfield,
United Kingdom

✉ info@southernscientific.co.uk

🌐 <https://www.southernscientific.co.uk>

Southern Scientific manufacture a range of probes and contamination monitors for medical applications, including the Care Wise C-Trak Apollo Gamma Probe System. This system provides accurate and precise detection of gamma radiation and is used during sentinel node biopsies in breast, melanoma and other types of cancer.

The C-Trak Apollo is the only system on the market allowing wireless or wired connectivity with the same probe. The well-known Omni Probe, provides an optimal balance between directionality and sensitivity. With the Apollo, surgeons can easily switch between wired and wireless eliminating any instrument downtime.

Southern Scientific will showcasing the C-Trak Apollo Gamma Probe System at EANM'23 alongside our range of contamination monitors which include the Radhound and Handhound.

The Radhound monitor is available with a wide range of probes suitable for detecting Alpha, Gamma and Beta isotopes.

The Handhound is a voice-activated hand monitor. All measurements are logged against a user and are easily downloaded to a USB.

Southern Scientific is also a distributor for the Capintec range of products, Digirad single head and cardiac cameras, and the MiE range of general purpose gamma cameras.

We are looking for distributors in certain countries. If you are interested, please visit booth #207 and speak to one of our team.

Spectrum Dynamics Medical Inc.

📍 Rue de Lausanne 31
1110 Morges, Switzerland

✉ info@spectrum-dynamics.com

🌐 <https://spectrum-dynamics.com>

Spectrum Dynamics is spearheading the transformation of Nuclear Medicine from analog to digital technology, enabling clinicians to provide superior healthcare services with improved image quality and efficiency at lower doses.

D-SPECT®: The world's first digital cardiac SPECT system based on Broadview Technology: swiveling CZT digital detectors. It is the platform for advanced applications such as TruCorr Attenuation Correction, TruFlow 3D dynamic SPECT imaging for Myocardial Flow Reserve (MFR) analysis, Simultaneous Dual Isotope Imaging (SDI). TruCorr: a deep learning application to generate attenuation corrected myocardial perfusion images. There is no need for additional CT transmission scan, as TruCorr utilizes the SPECT scan emission data.

VERITON-CT®: The world's first digital 360°CZT-based, ring-shaped gantry design SPECT/CT, with high-resolution 16 or 64 slice CT. It's 80cm wide bore accommodates patients of all sizes. VERITON features TruFlow 3D dynamic SPECT/CT imaging for SPECT MFR, bone, renal, and general studies. VERITON-CT continues to evolve with an energy range up to 400 KeV and multiple peak imaging, providing highest quality and quantitation-ready images.

SYNTHRA GmbH

📍 Albert-Einstein-Ring 21
22761 Hamburg, Germany

✉ info@synthra.com

🌐 <http://www.synthra.com>

Synthra – Desire and Passion for Radio Synthesizer
Synthra is a worldwide leading and specialized manufacturer of branded radio synthesizers and concentrates over 40 years of experiences in the field of targetry radiopharmaceutical production, quality control and lab automation. We are committed to automated production of molecular imaging tracers and continuously provide innovative solutions to facilitate and improve the production of tracers for Positron Emission Tomography (PET). Our portfolio comprises C-11, F-18, N-13, Ga-68, Lu-177, I-123, I-124, I-131 and other radioisotopes. It includes targets, radio synthesizers (including customized modules), quality control equipment, e.g. HPLC, spare parts and service.

Our radio synthesizers combine high performance and efficiency with high flexibility that enable the production of radiopharmaceuticals. All our synthesizer offers an fully automated self-cleaning system which is a far more ecofriendly and a time-efficient feature. Besides the attractive design, our software and synthesizers are highly user-friendly and meet the latest GMP regulations. Most commonly our modules offer an easy possibility to create own sequences for the synthesis of new radiopharmaceuticals.

In addition, we offer preventive maintenance contracts as well as full service contracts for each module and piece of QC equipment on demand. We are happy to welcome and meet you at our booth in hall X2.

Telix Innovations SA

📍 5 rue de Hermée
4040 Herstal, Belgium

✉ frederic.fantino@telixpharma.com

🌐 <https://telixpharma.com>

Telix is a global commercial-stage biopharmaceutical company focused on the development of therapeutic and diagnostic ("theranostic") radiopharmaceuticals, and a service provider in nuclear medicine, with its European headquarters located in Liège, Belgium.

Telix's targeted radiation imaging and therapy technologies have potential to transform the way clinicians can find and manage cancer and rare diseases, to inform treatment decisions and deliver personalised therapy in areas of major unmet medical need.

With more than 20 clinical studies underway worldwide (including partnered investigator-led studies), Telix's core pipeline is focused on prostate, kidney (renal), brain, and blood cancers as well as a range of hard to treat immunologic and rare diseases. Telix also has a growing research pipeline focused on novel targets and technologies.

Telix has received regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent (Illuccix®, TLX591-CDx, kit for the preparation of 68Ga-PSMA-11 injection) and is progressing marketing authorisation applications for TLX591-CDx in the European Union and the United Kingdom.

The company's manufacturing hub in Brussels South, Belgium, Telix Manufacturing Solutions, recently inaugurated, will deliver significant operational flexibility, R&D capabilities, and support commercial production requirements in Europe.

Terumo Interventional Systems

📍 Interleuvenlaan 40
3001 Leuven, Belgium

✉ sandrine.hocquel@terumo-europe.com

🌐 <http://www.terumo-europe.com>

Terumo is a global leader in medical technology and has been committed to „Contributing to Society through Healthcare“ for 100 years. Terumo Interventional Systems is working in partnership with Interventional Radiologists and Nuclear Medics within Interventional Oncology to ensure they have access to high quality tools for their patients. This partnership is based on Terumo's comprehensive range of access to therapeutic technology and services to support healthcare professionals with their patient needs.

QuiremSpheres™ Holmium-166 microspheres, QuiremScout™ Holmium-166 microspheres and Q-Suite™ imaging software make up. The Holmium Platform: three integrated products which aims to individualize SIRT at its full potential.

QuiremSpheres™ is the first Holmium-166 microsphere on the market which brings a wide range of benefits from higher dose rate, to optimized imaging capabilities.

QuiremSpheres™ are also the first SIRT microsphere to be designed with scout dose technology, QuiremScout™, which for the first time utilizes the same particle for the work up and the therapy, which aims to optimize patient selection and advance treatment planning using our Q-Suite™ imaging software. This CE-marked and in-house designed treatment planning software is also used for dose verification following the SIRT treatment to ensure you have delivered the dose you planned and will help to drive treatment efficacy and improve the outcomes for liver cancer patients.

TRASIS S.A.

📍 Rue Gilles Magnée 90 Maison
4430 Ans, Belgium

✉ info@trasis.com

🌐 <https://www.trasis.com/en>

At Trasis we are dedicated to helping the medical community access new radio-labelled therapeutic and diagnostic substances easily and faster.

To this end, we design, manufacture, sell and support high performance synthesizers (AllinOne and AllinOne mini), dose preparation equipment (Unidose and Quickfill dispensers), their shielding and accessories. We also develop customized synthetic methods and instruments. We can provide GMP Active Pharmaceutical Ingredients (API) and assist our customers with their regulatory affairs.

Our proven radiopharmaceutical expertise, coupled with our high-end instruments, allow us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorization.

TRIMT GmbH

📍 Carl-Eschebach-Straße 7
1454 Radeberg, Germany

✉ info@trimt.de

🌐 <http://www.trimt.de>

TRIMT GmbH was founded near Dresden, Germany in early 2021 and is dedicated to the development and commercialization of novel radiopharmaceuticals in molecular theranostics. The inventor-founded, science and data driven company, is managed and operated by experts with a strong scientific background, supported by an interdisciplinary board of advisors. Together with a consolidated network of academic and clinical collaborators and a top choice of industrial partners, TRIMT strives to exploit the full potential of a unique IP portfolio with a strategic, diversified selection of short- and long-term development goals.

The company's current focus is on a class of cellular biomarkers called integrins. There is compelling evidence that overexpression of the $\alpha\beta6$ integrin receptor is found in many cancers, such as PDAC, HNSCC and NSCLC, as well as in different kinds of fibrotic tissues, like in IPF, and is also involved in conditions like Long COVID. Ga-68-Trivehexin, the company's current lead compound, is a strong and selective ligand for this integrin subtype enabling detection of the aforementioned conditions by PET imaging and helping surgeons and oncologists to optimize treatments of their patients. The preclinical development of its therapeutic radiopharmaceutical companion exploiting the same mechanism has just been finished successfully and first clinical results are expected soon.

TrisKem International

📍 3 rue des Champs Geons
35170 Bruz, France

✉ contact@triskem.fr

🌐 <https://www.triskem-international.com>

TrisKem International develops, manufactures and commercializes highly selective resins for the separation and quality control of radionuclides such as Lu-177, Tb-161, Ga-67/8, Zr-89, Cu-61/4/7, Ac-225, Ge-68, Ti-44/5, Sc-43/4/7, Pb-212 and many other radionuclides for use in nuclear medicine – in diagnosis as well as in therapy.

Further to its range of resins TrisKem also develops and provides selective thin layer chromatography paper (i.e. DGA Sheets) for quality control of radionuclides and generator effluents (Ra-223, Ac-225, Pb-212, Ga-68,...) with respect to their radionuclidic purity, as well as for the control of presence of free radionuclides after labeling (i.e. CU Sheets).

TrisKem's resins are increasingly finding use in the production of radionuclides for radiopharmacy and are employed by leading radionuclide manufacturers worldwide.

Our R&D team is constantly working on the development of new resins and methods to help you with your separation needs. If you have a special separation need, need help with your method development, you are interested in participating in R&D projects or you are looking for a partner to commercialize a new technology you have developed, please do not hesitate to contact us!

U.S. Department of Energy Isotope Program (OAK Ridge)

📍 1000 Independence Ave., S.W.
20585-1615 Washington, DC, United States

✉ contact@isotopes.gov

🌐 <https://isotopes.gov>

The DOE Isotope Program supports the production and the development of production techniques of radioactive and stable isotopes that are in short supply for research and applications. Isotopes are high-priority commodities of strategic importance for the nation and are essential for energy, medical, and national security applications and for basic research; a goal of the program is to make critical isotopes more readily available to meet domestic U.S. needs.

The program also coordinates and supports isotope production at numerous universities, national laboratories, and commercial accelerator and reactor facilities throughout the nation to promote a reliable supply of domestic isotopes. The NIDC coordinates isotope production across these facilities and manages the business operations of the sale and distribution of isotopes.

United Well

📍 2nd Floor, No.1 Building, Lane#500
Furonghua Road, 201318 Shanghai, China

✉ monica.lee@unitedwell.com

🌐 <http://www.unitedwell.com>

United Well is a professional supplier of nuclear medicine products and services, dedicated to the management and layout of radiopharmaceuticals and their upstream and downstream industries, including the R&D, production, marketing and application of radiopharmaceuticals raw materials, medical isotopes, diagnostic and therapeutic radiopharmaceuticals, etc.

We tailor the overall solutions of nuclear medicine and radiopharmaceuticals for scientific and medical partners, including the solutions of accelerator production process of specific isotopes, a radiopharmaceutical solutions, modular laboratory supporting solutions, etc.

We provide services such as GLP or GMP site planning and construction, molecular imaging equipment and radiopharmaceutical production for relevant research institutions and enterprises. We also cooperate with them in accelerator operation and maintenance.

United Well has many years of practice and accumulation in the field of radiopharmaceuticals and nuclear medicine, and always focuses on the research and development of new products in the hope of mutually beneficial sharing and win-win cooperation with partners.

Von Gahlen Nederland B.V.

📍 Kelvinstraat 9
6902 PW, Zevenaar, Netherlands

✉ a.duiker@vongahlen.com

🌐 <http://www.vongahlen.com>

Von Gahlen designs and manufactures lead shielding products for the radiopharmacy and nuclear medicine industry. Our products range from transportation solutions to complete manufacturing lines, including automated dispensing systems. Since its founding over 5 decades ago, Von Gahlen has become a world leader in these industries. With our strong customer focus, we have managed to provide high quality products that meet or exceed industry standards and safety requirements. Von Gahlen hot cell installations may be found all over the world, including many of the largest turnkey installations in the field.

In our approach we not only focus on developing the best radiation-shielding lead products and solutions, but also on optimizing their lifecycle. We are your partner in the development of hot cells (also for special purposes) and complete laboratory facilities for nuclear medicine. We understand better than anyone the continuing need to guarantee long-lasting solutions, improve operational management and control costs.

Our team of professionals includes highly qualified technical designers as well as experienced manufacturing and installation personnel. Our modern factory is equipped with the latest computerized equipment. Von Gahlen is an ISO 9001 Certified Company. Our quality assurance program has been audited and approved by numerous customers. With Von Gahlen you can be assured of safe solutions, a reliable partnership and a lasting relationship.

Vortal

📍 44 Rue de le Belle Haie
B-1490 Court St Etienne, Belgium

✉ Info@Vortal.pro

🌐 <https://www.vortal.pro>

WHO WE ARE
Leader in reusable TYPE A certified transport system
OUR PRODUCTS
Transport system for liquid radio pharmaceuticals
Shielding material for radiopharma facilities
WHAT WE DO BETTER
TYPE A transport systems
Customized shielding for pharmaceutical environment
Automatic closure system for lead container
OUR MAIN REFERENCES
Advanced Acceleration Applications, Curium, IBA, IAEA, Siemens, Europet...

Voximetry

📍 8517 Excelsior Drive, Ste 207
53717 Madison, United States

✉ support@voximetry.com

🌐 <http://www.voximetry.com>

Voximetry is a software company committed to advancing Dosimetry-Guided Radiopharmaceutical Therapy (DG-RPT).

With Torch® we aim to improve patient outcomes by moving beyond population-based models and making it simpler for clinicians to develop patient-specific RPT treatment options.

As the industry accuracy leader, Torch® provides the only GPU-accelerated full Monte Carlo Dose Calculation, including voxel-level corrections for density. The result is an extremely accurate dose assessment in seconds.

Voximetry also offers a comprehensive range of Professional Services, with unmatched expertise and tools, which includes project management to expedite implementation, support for clinical trials, pre-clinical studies and research for clinics and research organizations.

Wälischmiller Engineering GmbH

📍 Schießstattweg 16
88677 Markdorf, Germany

✉ info@hwm.com

🌐 <http://www.hwm.com>

For over seventy years Wälischmiller has produced world-class innovative equipment for the nuclear industry. The company is certified according ISO 9001:2015, ISO 14001:2015, DIN ISO 45001:2018, KTA 1401, CEFRI-E and ATEX. Wälischmiller has a hard earned international reputation for performance, excellence in engineering and exceptional robotic hardware. In the most difficult and challenging nuclear environments, Wälischmiller has demonstrated the ability to bring solutions and success to many of the most difficult high-radiation remediation challenges.

Wälischmiller Engineering is a full range supplier and offers products reaching from simple tools to advanced solutions, such as universal grippers, mechanical telemanipulators for a wide range of applications (models A100 and A200), remote-controlled power manipulators from the A1000 series for handling heavy loads and the robot system TELBOT® with unique capabilities which includes unlimited rotation in all axes, no wiring inside or outside the TELBOT® arm, and unlimited fast and precise movement.

By choosing products of Wälischmiller Engineering, you choose products from a single source: engineering including product design and development, high manufacturing depth including single part assembly, all required specialised staff available within the company, installation at sites and worldwide service & maintenance.

WIS – World Infinity Services

📍 Rue de Hermée 255
B - 4040 Herstal, Belgium

✉ h.vandemaele@be-wis.com

🌐 <https://www.be-wis.com>

World Infinity Services is dedicated to the worldwide transport and logistics of radioactive materials and radiopharmaceutical products, including storage and import activities.

We are focused on providing a safe and secure, compliant and high-quality customer experience. In the frame of clinical studies, we provide worldwide door-to-door logistics, airfreight and charter services together with our dedicated partners.

XEOS Medical NV

📍 Ottergemsesteenweg-Zuid 808 b358
9000 Gent, Belgium

✉ info@xeos.care

🌐 <https://www.xeos.care>

XEOS wants to tackle the limitations of today's available imaging techniques applied in surgical oncology, by using the transformative power of molecular Imaging intra-operatively.

The AURA 10 is the first-ever PET-CT specimen imager for the operating room, offering surgeons and imaging specialists the sensitivity of PET imaging at submillimeter spatial resolution. Thanks to the AURA 10 mobile scanner, a specimen does no longer need to be transported to the radiology or pathology department during surgery. High-quality specimen images can now be obtained in the OR within 10 minutes after excision.

Founded in 2019 in Ghent, Belgium, XEOS is an expert in specimen imaging and focuses on improving outcomes in surgical oncology through innovations in intraoperative imaging. The XEOS team is passionate about expanding the use of molecular imaging to optimize clinical workflows and improve patient outcomes. The company has an admirable track record of in-house PET & CT design. XEOS is an ISO 13485 certified company.

CORPORATE MEMBERS

We gratefully acknowledge the support of the following companies (in alphabetical order):

	ABX-CRO advanced pharmaceutical services
	Advanced Accelerator Applications International
	Alliance Medical GmbH
	Blue Earth Diagnostics
	Boston Scientific International
	Bruker BioSpin, Preclinical Imaging Division
	Curium
	Comecer Group
	Eckert & Ziegler
	Eczacıbaşı-Monrol Nuclear Products Co.

	Eli Lilly
	GE HealthCare
	Hermes
	IBA
	ITM Isotope Technologies Munich SE
	Lemer Pax
	Mediso Medical Imaging Systems
	Medi-Radiopharma Ltd.
	MiLabs
	MIM Software

CORPORATE MEMBERS



Mirion Medical (Capintec)



National Centre for Nuclear Research Radioisotope Centre POLATOM



Oncosil



Pars Isotope



POINT Biopharma Inc.



ROTOP Pharmaka GmbH



Siemens Healthineers



Sirtex Medical Europe GmbH



SHINE Technologies LLC



Spectrum Dynamics Medical



Telix Pharmaceuticals



Tema Sinergie



Terumo



Von Gahlen



United Imaging Healthcare

USEFUL CONTACTS

SCIENTIFIC PROGRAMME

EANM Executive Office

Ms. Andrea Csismazia

Schmalzhofgasse 26,
1060 Vienna, Austria

Phone: +43 1 890 44 27

Fax: +43 1 890 44 27-9

E-mail: a.csismazia@eanm.org

Web: eanm23.eanm.org

INDUSTRY EXHIBITION

EANM Executive Office

Mr. Alexander Berger

Mr. Andreas Felser

(Congress Manager)

Schmalzhofgasse 26,

1060 Vienna, Austria

Phone: +43 1 890 44 27

Fax: +43 1 890 44 27-9

E-mail: a.berger@eanm.org

Web: eanm23.eanm.org

REGISTRATION

EANM Executive Office

Ms. Petra Neubauer

Schmalzhofgasse 26,

1060 Vienna, Austria

Phone: +43 1 890 44 27

Fax: +43 1 890 44 27-9

E-mail: registration@eanm.org

Web: eanm23.eanm.org

IMPRINT

PUBLISHER

European Association
of Nuclear Medicine

Schmalzhofgasse 26,
1060 Vienna, Austria

Phone: +43 1 890 44 27

Fax: +43 1 890 44 27-9

E-mail: office@eanm.org

Web: www.eanm.org

EDITORS

Valentina Garibotto,
EANM Congress Chair
2023-2025

Andreas Felser,
Andrea Csismazia,
EANM Executive Office

LAYOUT & DESIGN

Olga Dogadina,
Nikolaus Schmidt,
EANM Executive Office

CONTENT

No responsibility is taken for the
correctness of this information.
Information as per the time
publication, September 2023.

Reimagining Nuclear Medicine

Transforming patients' lives by leading innovation

Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through **technology leadership in R&D** and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About **108,000 people** of more than **140 nationalities** work together to bring Novartis products to nearly **800 million people** around the world.



**Rich
Oncology
Pipeline**

Targeting multiple
tumor types



Reimagining

Nuclear medicine by
developing drugs for targeted
radioligand therapy and
precision radioligand imaging



 **NOVARTIS**

Your trusted partner providing comprehensive products and services.

● Stable Isotopes
- Oxygen 18 Water

● Consumables for production
- Reagents Kits
- Cassettes
- Ancillaries

● CDMO Services for radiopharmaceuticals
- Drug development
- Registration
- Commercial production
- Logistics and distribution

● CRO Services
- Custom radiolabeling of drug candidates
- Preclinical ADME studies with imaging
- Pharmacokinetic and pharmacodynamic PET/SPECT studies
- Animal molecular imaging studies

GMP
Grade



Discover Our **GMP-grade** PSMA11 & PSMAI&T!

- Complete Compliance: Manufactured under GMP guidelines
- Higher Purity: Improve radiolabeling efficiency, get higher yields of product
- Net Peptide Guarantee: Make your radiolabeling more efficient, safe and consistent

International

+1 416 298 3366
Antony@huayi-isotopes.com

China

+86 512 52451806
sales@huayitec.net

www.huayitec.net

Follow us:   